{"744e10c31655b8bb868381fde6e0373e733199b2": [["IntroductionThe banking landscape has changed significantly over the last couple of decades and especially after the 2008 financial crisis.", [["banking landscape", "OBSERVATION", 16, 33]]], ["New regulations had an impact on many aspects of banking activity including: liquidity [1] , capital management [2] , profitability [3] , trade finance [4] , lending [5] , offbalance sheet activity [6] to name but a few.", [["capital management", "TREATMENT", 93, 111]]], ["Another area where there was a significant impact for many banks was in the volume and complexity of the new financial regulations and subsequent expansion of banks' compliance requirements [7] [8] [9] .IntroductionThe volume of regulatory reporting has increased significantly since the global financial crisis.", [["subsequent expansion of banks' compliance requirements", "TREATMENT", 135, 189], ["the global financial crisis", "PROBLEM", 284, 311], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["new", "OBSERVATION_MODIFIER", 105, 108], ["expansion", "OBSERVATION_MODIFIER", 146, 155], ["volume", "OBSERVATION_MODIFIER", 219, 225], ["increased", "OBSERVATION_MODIFIER", 254, 263], ["financial crisis", "OBSERVATION", 295, 311]]], ["Many regulated firms have found that reporting has become more complex and time consuming.", [["firms", "OBSERVATION", 15, 20], ["more complex", "OBSERVATION_MODIFIER", 58, 70]]], ["A large amount of reporting takes the form of firms submitting structured regulatory reports, while the number of ad hoc data requests has also grown.", [["large", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14]]], ["These intermittent requests can be particularly challenging and time consuming, since compliance with them can be very difficult to keep up-to-date [10] .IntroductionOne way to illustrate the huge growth in regulatory and compliance rules is to measure the time it would take, for example, to read the US banking centred regulations.", [["huge", "OBSERVATION_MODIFIER", 192, 196], ["growth", "OBSERVATION_MODIFIER", 197, 203]]], ["To view it differently, you would have been able to read through all of Shakespeare's works more than 115 times before you would be finished once with the US regulatory and compliance rules.IntroductionThere are further contrasts between reading lengthy literature works and reviewing regulatory rules.", [["the US regulatory", "TEST", 151, 168]]], ["Literature normally contains a static body of knowledge which do not require specialist training to understand and interpret the general content.", [["specialist training", "TREATMENT", 77, 96]]], ["Regulatory and compliance rules are dynamic in nature, since the ruleset gets updated and modified over time and requires professional training to interpret the meaning and intend.", [["professional training", "TREATMENT", 122, 143]]], ["The further problem for many banks is that reading and understanding regulations, in itself, does not guarantee that the rules gets implemented accurately and maintained over time.IntroductionThere are a significant cost and people impact involved with interpreting, implementing and complying with new regulations.", [["people", "ORGANISM", 225, 231], ["people", "SPECIES", 225, 231], ["significant", "OBSERVATION_MODIFIER", 204, 215]]], ["Regulations also reduce the chance that Central Banks have to bail out banks that are not playing by the rules.", [["Central Banks", "TREATMENT", 40, 53], ["Central Banks", "OBSERVATION", 40, 53]]], ["From a bank's perspective, being non-compliant, could result in reputational damage, a loss of investor confidence and imposed sanctions, which could lead to penalties, suspension of trading and the loss of its banking license [14, 15] .IntroductionOne recent development which could help with automating, streamlining and improving the management of regulatory requirements is called Regulatory Technology (RegTech) [16] .", [["loss of investor confidence", "DISEASE", 87, 114], ["reputational damage", "PROBLEM", 64, 83], ["a loss of investor confidence", "PROBLEM", 85, 114]]], ["Arner et al. [17] define RegTech as the contraction of the terms 'regulatory' and 'technology', which describes the use of technology, particularly Information Technology (IT), in the context of regulatory monitoring, reporting and compliance.", [["RegTech", "TREATMENT", 25, 32], ["regulatory monitoring", "TEST", 195, 216]]], ["RegTech has the ability to disrupt traditional Banking and Finance practises, since it can lead to a more robust and effective regulatory management process [19] .IntroductionFinancial regulations cover quite a wide spectrum of aspects including: reporting (e.g. capital and liquidity returns); transactional monitoring (e.g. Money Laundering and Fraud); client identity management (e.g. Know Your Client); risk management (e.g. scenario analysis and stress testing) and others [20] .", [["RegTech", "CHEMICAL", 0, 7], ["a more robust and effective regulatory management process", "PROBLEM", 99, 156], ["transactional monitoring", "TEST", 295, 319], ["risk management", "TREATMENT", 407, 422], ["scenario analysis", "TEST", 429, 446], ["stress testing", "TEST", 451, 465]]], ["In this capacity it works with all the business units to quantify the demand for these balance sheets resources and ensure that a sufficient supply is available [22] .", [["these balance sheets resources", "TREATMENT", 81, 111]]], ["A digital Treasury in banking is becoming more of a reality, with Hawser calling it the dawn of the Super Treasurer, with Artificial Intelligence turning Treasury into a sophisticated analytical centre [24] and Polak et al. [25] highlighting what can be expected from an Intelligent Finance and Treasury function going forward.IntroductionThe argument underpinning this article is that instead of duplicating RegTech implementation across the firm, it could be more optimal and efficient to integrate the regulatory management processes into the broader digital technology transformation plan of an intelligent Treasury department.", [["Artificial Intelligence turning", "TREATMENT", 122, 153], ["duplicating RegTech implementation", "TREATMENT", 397, 431], ["firm", "OBSERVATION", 443, 447]]], ["The research methodology will leverage work by Von Solms and Langerman [26] that used Design Science to develop a framework (i.e. artefact) called the Smart Digital Treasury Model (SDTM) to guide a Treasury's transition towards an intelligent analytical centre.", [["a Treasury's transition", "TREATMENT", 196, 219]]], ["The SDTM delivers improved strategic decision-making; however, the framework can potentially be expanded to also include regulatory management obligations.", [["regulatory management obligations", "TREATMENT", 121, 154], ["improved", "OBSERVATION_MODIFIER", 18, 26]]], ["The contribution of this research is that if an integrated approach can be established, it can lead to cost savings and other efficiencies, but crucially also enable better alignment of strategic decision-making and regulatory management practises.", [["cost savings and other efficiencies", "PROBLEM", 103, 138]]], ["This will ensure that prudential information conveyed to the Regulator is the exact same information used to drive commercial strategy formulation and monitored for management actions.IntroductionThe paper is structured as follows.", [["commercial strategy formulation", "TREATMENT", 115, 146], ["management actions", "TREATMENT", 165, 183]]], ["\"Overview of Regulatory Technology (RegTech)\" section provides an overview of RegTech, its target service areas and identifies the benefits this solution can deliver.", [["RegTech", "TREATMENT", 78, 85], ["this solution", "TREATMENT", 140, 153]]], ["\"Overview of digital technology utilisation in RegTech\" section reviews the different types of digital technologies available and their respective areas of application.", [["digital technologies", "TREATMENT", 95, 115]]], ["\"Treasury overview\" section provides an overview of a commercial bank's Treasury department and its evolving journey towards a 'smarter' management function.", [["a 'smarter' management", "TREATMENT", 125, 147]]], ["\"Banking Regulations and Treasury\" section considers the evolution of Regulations and the increasing regulatory obligations on Treasury.", [["Banking Regulations", "TREATMENT", 1, 20], ["Treasury\" section", "TREATMENT", 25, 42], ["Treasury", "TREATMENT", 127, 135]]], ["\"Smart Digital Treasury Model (SDTM)' section introduces the Smart Digital Treasury Model (SDTM) approach and explains how the framework can be used to integrate RegTech into an overarching digital transformation strategy.", [["Smart Digital Treasury Model (SDTM)' section", "TREATMENT", 1, 45], ["the Smart Digital Treasury Model (SDTM) approach", "TREATMENT", 57, 105]]], ["\"Integration of RegTech in a smart Treasury through using Robotic Process Automation (RPA)\" section explores one digital technology example, namely Robotic Process Automation to demonstrate how digitalisation can be used to streamline data processing and support more effective regulatory reporting.", [["RegTech", "TREATMENT", 16, 23], ["a smart Treasury", "TREATMENT", 27, 43], ["Robotic Process Automation", "TREATMENT", 58, 84]]], ["\"RegTech in the time of Corona\" section considers the advantages RegTech can offer financial organisations in unanticipated stress events-such as the market lockdown that occurred during 2020, due to the Coronavirus outbreak.Literature reviewFollowing the 2008 financial crisis, Bloomberg estimated that the biggest global banks have been fined over USD300bn in the period up to 2017 [27] .", [["Corona\" section", "TREATMENT", 24, 39], ["unanticipated stress events", "PROBLEM", 110, 137], ["the Coronavirus outbreak", "PROBLEM", 200, 224], ["Coronavirus", "OBSERVATION", 204, 215]]], ["According to Thompson Reuters in the period up to 2015, the volume of regulations has increased almost 5 times [28] .", [["increased", "OBSERVATION_MODIFIER", 86, 95]]], ["In order to manage the surge of regulations and compliance, banks have increased their workforce significantly, with knock-on effects on higher operating costs.Literature reviewCitigroup estimates that the biggest banking institutions have doubled the amount of people they employ to handle conformity and regulation.", [["people", "ORGANISM", 262, 268], ["people", "SPECIES", 262, 268]]], ["The Spanish bank BBVA reported that on average, financial institutions have 10 per cent to 15 per cent of their personnel dedicated to this area [29] .Literature reviewRegulations have not just impacted costs and the size of the workforce, but also impacted the shape of the balance sheet.", [["size", "OBSERVATION_MODIFIER", 217, 221]]], ["The paper also found that adjustment in the share of HQLA to total assets was entirely offset by an equal and opposite reduction in the share of short-term intra-financial loans, with the share of other assets remaining unaffected.", [["HQLA", "PROTEIN", 53, 57], ["equal", "OBSERVATION_MODIFIER", 100, 105], ["opposite", "OBSERVATION_MODIFIER", 110, 118], ["reduction", "OBSERVATION_MODIFIER", 119, 128]]], ["On the liability side, banks increased funding from more expensive stable non-bank and non-financial corporation deposits and decreased their reliance on less stable short-term wholesale and non-domestic funding.Literature reviewRegulatory changes had an effect across the board for most banks, who are struggling to manage the increased volume and complexity of the rules and governance obligations.", [["non-financial corporation deposits", "PROBLEM", 87, 121], ["Literature reviewRegulatory changes", "PROBLEM", 212, 247], ["the increased volume", "PROBLEM", 324, 344], ["increased", "OBSERVATION_MODIFIER", 328, 337], ["volume", "OBSERVATION", 338, 344]]], ["The challenges in the way of an efficient and costeffective regulatory reporting process are numerous, as highlighted by the Financial Service Authority (FSA) Digital Regulatory Reporting: Phase 2 Viability Assessment report [10] .", [["an efficient and costeffective regulatory reporting process", "PROBLEM", 29, 88]]], ["The top drivers identified in this report are inter alia: too many requirements; need for additional human resources; need to introduce/update IT systems; unclear/ vague requirements; redundant requirements; too many/ too frequent amendments.", [["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106], ["additional human resources", "TREATMENT", 90, 116], ["vague requirements", "PROBLEM", 164, 182], ["redundant requirements", "PROBLEM", 184, 206]]], ["Digital technology solutions can address many of these constraints and are one of the main factors why the FSA established this project.Literature reviewRegulatory Technology (RegTech) is an emerging application area that harnesses digital technology to make regulatory reporting, management and compliance easier.", [["Digital technology solutions", "TREATMENT", 0, 28]]], ["The problem is that RegTech can sometimes be an expensive technology, at least initially, to implement [31] , it does not operate efficiently in isolation, and the decision where the ownership should reside within the bank can sometimes be a problematic choice [32] .", [["RegTech", "SIMPLE_CHEMICAL", 20, 27]]], ["One of the reasons is the way the risk management and governance process is set up in most banks.Literature reviewIn the last decade or so, banks have built a governance model based on three lines of defence, in order to provide different layers of protection and oversight.", [["the risk management", "TREATMENT", 30, 49], ["governance process", "TREATMENT", 54, 72], ["a governance model", "TREATMENT", 157, 175]]], ["The second line of defence (2LOD) refers to the independent risk management and compliance functions that is responsible for oversight over the 1LOD and for designing and implementing the risk management framework.", [["the independent risk management", "TREATMENT", 44, 75], ["the risk management framework", "TREATMENT", 184, 213]]], ["The third line of defence (3LOD) typically refers to the audit function that verifies all actions and activity are within the defined control framework.", [["third", "OBSERVATION_MODIFIER", 4, 9], ["line", "OBSERVATION_MODIFIER", 10, 14]]], ["This creates a very strong and protective risk framework, but as pointed out by the Deloitte's 'Banking Regulatory outlook' [33] , this design set-up has the downside risk that it can lead to silo-driven development of capabilities and technology.Literature reviewFor RegTech to operate effectively and fit seamlessly into a bank, it needs to be integrated across the different lines of defence.", [["very strong", "OBSERVATION_MODIFIER", 15, 26], ["different lines", "OBSERVATION", 368, 383]]], ["If development is not holistically approached, there could be duplication and sub-optimal outcomes where the 1LOD will make decisions that are not always aligned with risk and reporting views generated by the 2LOD.Literature reviewA department in the bank that is very involved with frontoffice activity and first line defence, as well as regulatory measurement, monitoring and reporting, is the Treasury function.", [["duplication", "PROBLEM", 62, 73], ["duplication", "OBSERVATION", 62, 73]]], ["Since the financial crisis Treasury has grown significantly in strategic importance and has evoled to become the guardian of scarce balance sheet resources such as capital and liquidity [34] .Literature reviewLeveraging next-generation digital technologies can address many of the challenges Treasury face, namely streamlining data analysis; improving predictability of forecasts; creating operating efficiencies via automation; allowing real-time payments; and others.", [["streamlining data analysis", "TEST", 314, 340]]], ["Polak et al. [36] also highlight the importance of having a proper and well-defined approach to guide the evolution of the Treasury function from the current state to a more automated future state, where emphasis is placed on strategic activity rather than operational processing.Literature reviewTo this effect, Von Solms and Langerman [26] developed a framework called the Smart Digital Treasury Model (SDTM) that provides a well-defined digital roadmap that can help establish a smart Treasury function.", [["a proper and well-defined approach", "TREATMENT", 58, 92]]], ["This digitalisation approach can significantly improve the strategic management capabilities of a Treasury function and help a Treasurer to make an informed decision at the right time.Literature reviewThis intelligent Treasury mindset, which underpins the Smart Digital Treasury approach, can potentially be expanded to also include Regulatory management requirements through integrating RegTech developments within the digital transformation strategy of a smart Treasury department.", [["This digitalisation approach", "TREATMENT", 0, 28], ["Regulatory management requirements", "TREATMENT", 333, 367]]], ["This paper will consider this integration, the potential economies of scale it can offer and the combined benefits of aligning the strategic and regulatory management activities of a Treasury.", [["this integration", "TREATMENT", 25, 41], ["a Treasury", "TREATMENT", 181, 191]]], ["It is important to note that the focus is on a trans-national Treasury, meaning the logic is relevant to most jurisdictions and that the emphasis is on Treasury specific regulations and not the wider compliance requirements of the whole bank.Literature reviewThe next section will provide an overview of RegTech and how this emerging technology solution can be leveraged to resolve some of the challenges flowing from regulations.Overview of Regulatory Technology (RegTech)Many banks have struggled to find effective solutions to keep up with the increasing regulatory and compliance demands and additional costs.", [["this emerging technology solution", "TREATMENT", 320, 353], ["effective solutions", "TREATMENT", 507, 526], ["the increasing regulatory and compliance demands", "TREATMENT", 543, 591]]], ["These costs can be a significant burden as identified by the European Commission in their report 'Public Consultation on the Fitness Check on Supervisory Reporting', which estimated that most firms' regulatory reporting costs are around 1 per cent of total operating costs [37] .Overview of Regulatory Technology (RegTech)Regulatory Technology also called 'RegTech' has emerged as a potential lifeline to help firms ease this burden and boost their responsiveness to regulatory changes [38] .", [["this burden", "PROBLEM", 421, 432], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["burden", "OBSERVATION", 33, 39]]], ["This means the reconceptualisation of financial regulations through the fusing of Information Technology (IT) and especially digital technologies such as Artificial Intelligence, Cloud Computing, Big Data Analytics and others to deliver effective solutions for regulatory procedures like regulatory monitoring, compliance and reporting.", [["financial regulations", "TREATMENT", 38, 59], ["effective solutions", "TREATMENT", 237, 256], ["regulatory procedures", "TREATMENT", 261, 282], ["regulatory monitoring", "TEST", 288, 309]]], ["Johansson et al. [39] argue that RegTech is a required and necessary tool to keep up with compliance and regulatory changes.Overview of Regulatory Technology (RegTech)The feasibility of deploying RegTech arose from the overlapping progress in three different areas, namely increased financial and prudential expertise, technology improvements and higher volume of regulations [12] .", [["RegTech", "SIMPLE_CHEMICAL", 33, 40], ["increased", "OBSERVATION_MODIFIER", 273, 282]]], ["These different developments with RegTech residing at the heart are depicted in Fig. 1 .Overview of Regulatory Technology (RegTech)It is also important to understand how RegTech relates to Financial Technology (FinTech) developments.", [["heart", "ANATOMY", 58, 63], ["RegTech", "GENE_OR_GENE_PRODUCT", 34, 41], ["heart", "ORGAN", 58, 63], ["RegTech", "PROTEIN", 34, 41], ["RegTech", "TREATMENT", 34, 41], ["different", "OBSERVATION_MODIFIER", 6, 15], ["heart", "ANATOMY", 58, 63], ["Fig", "OBSERVATION_MODIFIER", 80, 83]]], ["In contrast, other authors such as Arner et al. [17] and Johansen [39] believe that although RegTech has its roots in FinTech, it should be considered as an independent sector, because it provides services for different groups not only the financial sector and has other recipients.", [["roots", "ANATOMY", 109, 114], ["RegTech", "CHEMICAL", 93, 100], ["RegTech", "GENE_OR_GENE_PRODUCT", 93, 100], ["roots", "ORGAN", 109, 114]]], ["The argument for separating the two industries is that FinTechs are changing the financial industry and becoming a challenger to traditional banking, while RegTech is being developed to assist all financial institutions (old or new) to deal with their regulatory obligations.Overview of Regulatory Technology (RegTech)RegTech has the ability to standardise, automate and speed up a lot of manual activities, which can make the Fig. 1 RegTech resides in the overlap of financial expertise, regulations and technology regulatory process more robust and economical.", [["FinTechs", "CHEMICAL", 55, 63], ["FinTechs", "SIMPLE_CHEMICAL", 55, 63], ["traditional banking", "TREATMENT", 129, 148]]], ["RegTech solutions offer enhanced characteristics [42] , inter alia:Technology Regulations\u2022 Agility-cluttered and interlinked data sets can be decoupled and organised through using more intelligent technologies; \u2022 Speed-reports can be configured and generated in a quicker turnaround time; \u2022 Integration-integrated approaches allow for shorter timeframes to generate operational solutions and get them up and running; and \u2022 Analytics-advanced analytic tools can intelligently process existing big data sets and unlock true value, e.g. improved insights and sourcing the same data for multiple purposes.Technology RegulationsRegTech is an exciting new technology development that is showing a lot of promise to make it easier and simpler for financial institutions to comply with ever-changing regulations, while reducing manual processes that cause errors and impact time and headcount.", [["RegTech solutions", "TREATMENT", 0, 17], ["operational solutions", "TREATMENT", 366, 387], ["big data sets", "TEST", 492, 505], ["unlock true value", "TEST", 510, 527]]], ["The next section looks at the main drivers influencing RegTech deployment and the type of service areas the technology is currently being applied to.Drivers of RegTech developments and key regulatory service areasPrior to the 2008 financial crisis, regulatory rules were significantly less onerous in terms of scope and complexity and were often managed by a small group of people on a non-dedicated and often quasi-manual basis.", [["people", "ORGANISM", 374, 380], ["people", "SPECIES", 374, 380], ["the technology", "TREATMENT", 104, 118]]], ["An example is the Sterling Stock Liquidity Regime, which enforced liquidity rules for the major sterling clearing banks in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 127, 129], ["the Sterling Stock Liquidity Regime", "TREATMENT", 14, 49]]], ["It required banks to hold a stock of Bank of England eligible assets to meet wholesale sterling outflows over the next 5 days and cover 5% of maturing retail deposits, withdrawable over the same period [30] and was often managed by the firm's Money Market Funding desk.", [["maturing retail deposits", "PROBLEM", 142, 166], ["retail deposits", "OBSERVATION", 151, 166]]], ["This is in marked contrast to the far more complex new liquidity standards introduced by the BASEL III Accord, like the Liquid Coverage Ratio (LCR) that measures all contingent cash outflows and liquidity stresses for on-and off-balance sheet exposures over a 30-day horizon.", [["new liquidity standards", "TREATMENT", 51, 74], ["the Liquid Coverage Ratio (LCR)", "TREATMENT", 116, 147], ["liquidity stresses", "PROBLEM", 195, 213], ["marked", "OBSERVATION_MODIFIER", 11, 17], ["new", "OBSERVATION_MODIFIER", 51, 54], ["liquidity", "OBSERVATION", 55, 64], ["cash outflows", "OBSERVATION", 177, 190]]], ["These drivers are described in more detail below:Significant amount of complex Regulatory change-Thomson Reuters [28] highlights that the volume of rules has increased manifold over the last couple of years making it difficult for financial firms to review and keep track of all the prudential changes.Ineffective legacy design set-up-the FSA report onDigital Reporting [10] found that many banks have fragmented and siloed Regulatory and Compliance functions and IT systems, often requiring a lot of manual intervention.", [["complex Regulatory change", "PROBLEM", 71, 96], ["manual intervention", "TREATMENT", 501, 520], ["increased", "OBSERVATION_MODIFIER", 158, 167], ["fragmented", "OBSERVATION", 402, 412]]], ["Enabling technology-certain digital technologies, such as Artificial Intelligence, have been around for a while, but due to recent growth in processing power and distributed computing have become a more feasible option [24] and [43] .Range of benefits-'Disrupting Finance: FinTech andStrategy in the 21st Century' edited by Lynn, Mooney, Rosati and Cummins [19] identifies a number of benefits for organisations including:Range of benefits-'Disrupting Finance: FinTech anda.", [["recent growth", "PROBLEM", 124, 137]]], ["Increased revenue-RegTech automation can increase competitiveness while increasing customer satisfaction and retention, through faster onboarding and completion of, for example, Know Your Client (KYC) and Anti-Money Laundering (AML) requirements. b.", [["AML", "DISEASE", 228, 231], ["AML", "CANCER", 228, 231], ["Anti-Money Laundering (AML) requirements", "TREATMENT", 205, 245]]], ["Reduced costs-can deliver streamlined and automated processes that reduce the number of people needed to manipulate data manually and check for errors, lowering the overall compliance cost. c.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["Reduced costs", "PROBLEM", 0, 13], ["errors", "PROBLEM", 144, 150]]], ["Efficiency and productivity gains-RegTech flexibility enable banks to adjust to regulatory volume and changes more efficiently and produce reports more frequently.", [["productivity gains", "PROBLEM", 15, 33], ["RegTech flexibility enable banks", "TREATMENT", 34, 66], ["regulatory volume", "TREATMENT", 80, 97]]], ["Reduced risk/improved governance-when banks can comply with regulations and the myriad of other compliance requirements more easily, they are less likely to suffer reputational damage, penalties, and fines from compliance missteps.Range of benefits-'Disrupting Finance: FinTech and5.", [["reputational damage", "PROBLEM", 164, 183], ["improved", "OBSERVATION_MODIFIER", 13, 21], ["governance", "OBSERVATION", 22, 32]]], ["Supervisory improvements-many regulators are also evaluating the benefits that RegTech can offer from a supervisory perspective, as described by Podder, Pisanu and Ghosh [16] .", [["RegTech", "SIMPLE_CHEMICAL", 79, 86]]], ["One example is that the large amount of regulatory reports submitted by banks to the Regulator needs to be reviewed and assessed, which often entails a cumbersome and slow process for the Regulator.", [["the Regulator", "TREATMENT", 184, 197], ["large", "OBSERVATION_MODIFIER", 24, 29], ["amount", "OBSERVATION_MODIFIER", 30, 36]]], ["Wider digital adoption-integration of RegTech within a firm-wide digital technology strategy can result in a more robust bank and deliver true economies of scale [44] .Range of benefits-'Disrupting Finance: FinTech andOne of the big considerations when evaluating where and how to deploy regulatory specific technology is that regulations are very broad in terms of scope and requirements and can differ between Regulators.", [["firm", "OBSERVATION_MODIFIER", 55, 59]]], ["This is to establish what type of digital technology would be most appropriate to address a specific problem.", [["a specific problem", "PROBLEM", 90, 108]]], ["The main targeted services areas include:Service area 1: regulatory reportingRegulatory reporting is the mandatory submission of data by banking and financial services firms to a Regulator, to establish transparency into their activity and ensure banks meet all the prescribed constraints.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Reporting in itself can cover a wide range of different financial disciplines including: financial reporting (e.g. FINREP); prudential reporting (e.g. BASEL III); transactional reporting (e.g. MiFID II).Service area 2: complianceRegulatory compliance entails meeting prudential rules as prescribed through specifications, policies, standards or laws and the steps taken to comply with all the relevant directives.", [["complianceRegulatory compliance entails", "TREATMENT", 219, 258]]], ["Due to the increasing number of regulations and need for operational transparency, organisations are increasingly adopting the use of consolidated and harmonised sets of compliance controls.", [["increasing", "OBSERVATION_MODIFIER", 11, 21], ["number", "OBSERVATION_MODIFIER", 22, 28]]], ["This approach is used to ensure that all necessary governance requirements can be met without the unnecessary duplication of effort and activity.Service area 3: transaction monitoringTransaction monitoring refers to the monitoring of customer transactions, including assessing historical and current customer information and interactions to provide a complete picture of customer activity.", [["the unnecessary duplication of effort", "TREATMENT", 94, 131], ["transaction monitoring", "TEST", 161, 183], ["Transaction monitoring", "TEST", 183, 205]]], ["This can include transfers, deposits and withdrawals.", [["withdrawals", "PROBLEM", 41, 52]]], ["It is a key mitigant against Anti-Money Laundering (AML).", [["AML", "ANATOMY", 52, 55], ["AML", "DISEASE", 52, 55], ["AML", "CANCER", 52, 55]]], ["This updated the UK's AML regime to incorporate international standards set by the Financial Action Task Force (FATF) and to transpose the EU's 5th Money Laundering Directive [45] .Service area 4: identity management and controlKnow Your Customer (KYC) is a standard in the financial industry that ensures investment advisors and banks have detailed information about their clients' identity, risk tolerance, investment knowledge and financial activity.", [["AML", "DISEASE", 22, 25], ["AML", "CANCER", 22, 25], ["'s AML regime", "TREATMENT", 19, 32]]], ["KYC protects both clients and financial institutions and typically involves requirements and policies such as risk management, customer acceptance policies, and transaction monitoring.Service area 5: risk managementRisk management includes the quantitative management of different risks across the firm and included scenario analysis, exposure computation and reporting of the exposures.Service area 5: risk managementThe management of these regulatory requirements puts ever increasing pressure on banks in terms of complexity, scope and frequency.", [["KYC", "CHEMICAL", 0, 3], ["transaction monitoring", "TEST", 161, 183], ["risk management", "TREATMENT", 200, 215], ["Risk management", "TREATMENT", 215, 230], ["the quantitative management", "TREATMENT", 240, 267], ["scenario analysis", "TEST", 316, 333], ["exposure computation", "TREATMENT", 335, 355], ["risk management", "TREATMENT", 403, 418], ["these regulatory requirements", "PROBLEM", 436, 465], ["increasing pressure on banks", "TREATMENT", 476, 504], ["firm", "OBSERVATION", 298, 302], ["pressure", "OBSERVATION_MODIFIER", 487, 495]]], ["Emerging digital technologies can play a key part to help with this increasing onerous regulatory management activity and demands.Service area 5: risk managementThe next section looks at the different available digital technologies and in what regulatory service areas they can be utilised, as part of RegTech application.Overview of digital technology utilisation in RegTechDigital technology solutions, for example, Artificial Intelligence have been around for many years, but it is only recently with the expansion in computing power and distributed processing that digital technology have become more viable from a cost perspective and practical to combine with data analytics.", [["this increasing onerous regulatory management", "TREATMENT", 63, 108], ["risk management", "TREATMENT", 146, 161], ["RegTech application", "TREATMENT", 302, 321], ["data analytics", "TEST", 666, 680]]], ["Many regulatory issues such as Money Laundering and Fraud tend to emerge from behaviours or transactions that are difficult to discover through traditional risk and control frameworks.Overview of digital technology utilisation in RegTech\u2022 Natural language processing (NPL)-this technology can support onerous regulatory compliance tasks that include scanning for revised or new regulations and modified risk reporting.", [["Many regulatory issues", "PROBLEM", 0, 22], ["scanning", "TEST", 350, 358]]], ["These algorithms can be automated to perform these functions continuously, share the impact with compliance process owners and also identify important decision-making drivers. \u2022 Robotic Process Automation (RPA)-RPA can deliver productivity and efficiency gains by automating nonvalue additive manual activities like data extraction, formatting and reconciliation tasks.", [["data extraction", "TREATMENT", 316, 331]]], ["When the risk reporting process is automated, it becomes easier to handle increased volume, higher granularity and various regulations across different jurisdictions. \u2022 Distributed ledger technology (DLT)-digitalisation of diverse RegTech-related processes can minimise the dependency on back-office personnel and departments.", [["increased volume", "PROBLEM", 74, 90], ["higher granularity", "PROBLEM", 92, 110], ["diverse RegTech", "PROBLEM", 223, 238], ["higher", "OBSERVATION_MODIFIER", 92, 98], ["granularity", "OBSERVATION", 99, 110]]], ["By replacing such traditional procedures with digital verifiable workflows, compliance and regulatory practices would be enhanced. \u2022 Artificial Intelligence (AI)-AI can assist with delivering a smarter and more efficient onboarding process of new clients, identify weaknesses in existing risk and control frameworks and help guide intelligent allocation of financial resources. \u2022 Cloud Computing (CC)-historically to integrate fragmented data systems in order to produce a real-time standardised view of risk information would have required a significant upfront IT investment and long lead time.", [["such traditional procedures", "TREATMENT", 13, 40], ["digital verifiable workflows", "TEST", 46, 74], ["regulatory practices", "TREATMENT", 91, 111], ["weaknesses in existing risk and control frameworks", "PROBLEM", 265, 315], ["financial resources", "TREATMENT", 357, 376], ["a significant upfront IT investment", "TREATMENT", 541, 576]]], ["CC can solve a number of these data and processing challenges more quickly and effectively.", [["CC", "CHEMICAL", 0, 2]]], ["A cloud platform allows businesses to scale as requirements change and it becomes easier to incorporate other data methodologies and analytics, such as Machine Learning and Big Data Analytics. \u2022 Machine Learning (ML)-can help with the back-testing of computational models and improve the predictability of the forecasting of cashflows. \u2022 Application programming interface (API)-the plug and play features of APIs can deliver better integration of fragmented activities and enable automated reporting to regulators.", [["the back-testing", "TEST", 231, 247], ["computational models", "TREATMENT", 251, 271], ["Application programming interface (API", "TREATMENT", 338, 376], ["the plug", "PROBLEM", 378, 386], ["plug", "OBSERVATION", 382, 386]]], ["Figure 2 illustrates potential application of these digital technologies across the different regulatory service areas, identified in \"Overview of Regulatory Technology (RegTech)\" section, that can enable RegTech solutions.", [["RegTech", "SIMPLE_CHEMICAL", 205, 212], ["these digital technologies", "TREATMENT", 46, 72]]], ["The application and combination of technologies are not definitive and can take many forms.", [["The application", "TREATMENT", 0, 15]]], ["This utilisation of digital technologies in isolation or in combination can transform the compliance and regulatory process, across the regulatory service areas by leveraging advanced analytics, intelligent algorithms and distributed processing power [46] .Overview of digital technology utilisation in RegTechGoing beyond its role in helping banks to comply and enforce regulation, RegTech can also deliver significant benefits for the Regulator [41] .", [["digital technologies", "TREATMENT", 20, 40], ["intelligent algorithms", "TEST", 195, 217], ["digital technology utilisation", "TREATMENT", 269, 299]]], ["The digital checks and balances RegTech can offer the Regulator is similar to fitting highperformance brakes on a racing car.", [["The digital checks", "TEST", 0, 18]]], ["Similarly, when it comes to observing regulations, RegTech can provide the confidence the markets need for commerce to move faster and to more rapidly adapt to disruption.Overview of digital technology utilisation in RegTechA core department within a bank that is very involved with the management and implementation of prudential regulations and compliance is the Treasury department.", [["RegTech", "PROTEIN", 51, 58], ["the management", "TREATMENT", 283, 297], ["prudential regulations", "TREATMENT", 320, 342]]], ["It is such an important area in a financial organisation that Hewlett [47] argues that a bank's Treasury should be positioned at the centre of strategic planning.Treasury overviewTreasury functions have existed in some form for centuries, but its role has changed significantly in the span of the last 30-40 years.", [["a bank's Treasury", "TREATMENT", 87, 104], ["strategic planning", "TREATMENT", 143, 161]]], ["At that time, Treasury activities were primarily centred around cash and working capital management.", [["working capital management", "TREATMENT", 73, 99]]], ["During this period, a number of authors researched the increasing importance of this management function highlighting various development aspects and focus areas within a Treasury.", [["this management function", "TREATMENT", 80, 104]]], ["Maphiri [49] identified the important role of Treasury in Cash Management and the stability of the financial organisation.", [["Maphiri", "CHEMICAL", 0, 7], ["Cash Management", "TREATMENT", 58, 73]]], ["Helliar and Dunne [51] studied the Control Mechanisms and processes in place (or lack of effective corporate governance) in Treasury departments, after the collapse of companies such as Barings and Enron.", [["Barings and Enron", "TREATMENT", 186, 203], ["collapse", "OBSERVATION", 156, 164]]], ["San-Jose et al. [52] explored the growing influence of Information Technology Systems on Finance and Treasury departments performance and identified the benefits, in terms of cost savings and improved decisionmaking.", [["cost savings", "TREATMENT", 175, 187]]], ["Polak [53] argued the need for centralising a bank Treasury function in the globalised world.Treasury overviewIn 2010, a comprehensive overview of Treasury practises was provided in 'Treasury Management: A Practitioners Guide' authored by Bragg [54] .", [["Polak", "CHEMICAL", 0, 5]]], ["It reaffirmed the importance of a Modern Treasury function and described all the main activities required in a 'best practise' Treasury.Treasury overviewThe world of banking in general and Treasury in specific, however, changed dramatically after the 2008 financial crisis.", [["a Modern Treasury function", "TREATMENT", 32, 58]]], ["The reason was due to Banking Supervisors issuing a range of new regulatory and compliance regulations to prevent another financial disaster.", [["new regulatory and compliance regulations", "TREATMENT", 61, 102]]], ["This required increased number of Treasury experts and specialised knowledge to implement the complex prudential rules and restructure the bank's balance sheet to conform to the new constraints.Treasury overviewThis forced the role and responsibility of a Treasury to undergo another major change in terms of scope and strategic importance, moving from a transactional manager to a balance sheet custodian [55] .", [["the complex prudential rules", "PROBLEM", 90, 118], ["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["Given the role of Treasury as the 'bank within the bank', as well as its impact and influence on the wider financial market stability [22] many Treasuries are exploring the utilisation of new technology to help them transition to a smarter analytical centre that can make more informed decisions in real-time.Treasury overviewThe concept of a smart Treasury function and the benefits of leveraging digital technologies have been identified by a number of authors in recent times.", [["a smart Treasury function", "PROBLEM", 341, 366], ["leveraging digital technologies", "TREATMENT", 387, 418]]], ["Hawser [24] argues that it is the dawn of the 'Super Treasurer' and that Artificial Intelligence can turn the Treasury function into a sophisticated analytic centre; while Meall [56] highlights the importance of digital technology as a Treasury survival strategy.Treasury overviewThe core argument of this paper is that there is merit in integrating digital technology developments in management areas such as Treasury to deliver improved strategic management practises as well as enhanced regulatory processes.", [["a Treasury survival strategy", "TREATMENT", 234, 262], ["management areas", "TREATMENT", 385, 401], ["strategic management practises", "TREATMENT", 439, 469]]], ["This alignment will ensure consistent decision-making between the bank's strategy and what is reported to the Regulator or the rules being complied to.", [["the bank's strategy", "TREATMENT", 62, 81]]], ["This integration idea will be explored in more detail in the next sections, by considering the impact of regulations on Treasury activities and then describing an approach how RegTech can be combined with the wider digital technology developments in Treasury.Banking Regulations and TreasuryBank regulations and rules have evolved significantly over the last couple of decades and especially since the 2008 financial crisis.", [["RegTech", "SIMPLE_CHEMICAL", 176, 183], ["Treasury activities", "TREATMENT", 120, 139], ["Banking Regulations", "TREATMENT", 259, 278], ["Treasury", "TREATMENT", 283, 291]]], ["Various new rulesets were published by regulators inter alia: Dodd-Frank Wall Street Reform and Consumer Act (Dodd Frank), Sarbanes-Oxley Act (SOX), Markets in Financial Instruments Directive (MiFID II); Basel accords (Basel III) and others.", [["Various new rulesets", "PROBLEM", 0, 20], ["new", "OBSERVATION_MODIFIER", 8, 11], ["Wall", "ANATOMY_MODIFIER", 73, 77]]], ["The Basel regulations are global standards that are set by the Basel Committee on Banking Supervision (BCBS) and are regulatory rules that set out a minimum requirement for aspects such as: bank capital adequacy, stress testing, market risk, leverage, liquidity risk and other types of risks impacting a bank's balance sheet viability.", [["stress testing", "TEST", 213, 227]]], ["The third version of the Basel Accords, namely Basel III, was developed in response to the deficiencies in the financial regulation revealed by the financial crisis of 2008.", [["the deficiencies", "PROBLEM", 87, 103]]], ["The updated and revised standards were intended to strengthen bank capital requirements, increase bank liquidity and decrease balance sheet leverage [57] .Banking Regulations and TreasuryBasel III expanded the Basel II rules in terms of measuring credit risk and the need for additional capital adequacy buffers, but it also introduced a range of new regulations.", [["increase bank liquidity", "TREATMENT", 89, 112], ["Banking Regulations", "TREATMENT", 155, 174], ["additional capital adequacy buffers", "TREATMENT", 276, 311]]], ["These included new metrics for measuring and monitoring inter alia: Liquidity risk [58] , i.e. Liquidity Coverage Ratio (LCR) and Net Stable Funding Ratio (NSFR and enforcing specific leverage limitations on the size of the balance sheet [59] .Banking Regulations and TreasuryThese expanded rules created a lot of new challenges for Treasuries and other banking functions to measure, monitor and manage the exposures, but especially to report these prudential numbers to the Regulator.", [["the balance sheet", "TEST", 220, 237], ["Banking Regulations", "TREATMENT", 244, 263], ["Treasury", "TREATMENT", 268, 276], ["Treasuries", "TREATMENT", 333, 343], ["Stable", "OBSERVATION_MODIFIER", 134, 140], ["new", "OBSERVATION_MODIFIER", 314, 317]]], ["In order to supervise the implementation and especially the adherence to these new rules, Central Banks required that commercial banks on a frequent and granular basis report their capital, liquidity and leverage and other exposures.Banking Regulations and TreasuryThe number and complexity of prudential reports have ballooned significantly over the last couple of years.", [["Banking Regulations", "TREATMENT", 233, 252], ["Treasury", "TREATMENT", 257, 265], ["Central", "OBSERVATION_MODIFIER", 90, 97], ["Banks", "OBSERVATION_MODIFIER", 98, 103], ["number", "OBSERVATION_MODIFIER", 269, 275], ["complexity", "OBSERVATION_MODIFIER", 280, 290], ["ballooned", "OBSERVATION_MODIFIER", 318, 327], ["significantly", "OBSERVATION_MODIFIER", 328, 341]]], ["And that excludes requirements from other Regulators like the European Central Bank (ECB) and Federal Reserve (FED) applicable to global banks which operate in multiple jurisdictions.Banking Regulations and TreasuryIn addition to daily risk management activities, the reporting of prudential numbers is a significant obligation for many areas in the bank including the Treasury function.", [["Federal Reserve (FED", "TREATMENT", 94, 114], ["Banking Regulations", "TREATMENT", 183, 202], ["Treasury", "TREATMENT", 207, 215], ["daily risk management", "TREATMENT", 230, 251], ["prudential numbers", "PROBLEM", 281, 299]]], ["Below is a couple of examples to illustrate the range of Treasury responsibilities and the additional complexity in light of the required regulations.Computing capital demand and supplyThe capital adequacy requirement and computation of risk weighted assets (RWA) in banks have changed significantly over the last couple of years, with the evolution of Basel I through Basel III.", [["capital demand", "OBSERVATION", 160, 174], ["capital", "OBSERVATION_MODIFIER", 189, 196]]], ["Treasury has to interact with all frontline businesses units that have RWA exposures, generated through taking credit risk, market risk, operational risk, counterparty risk, etc., in order to construct a holistic picture of the total bank-wide RWA demand.", [["RWA exposures", "PROBLEM", 71, 84], ["wide RWA demand", "TREATMENT", 239, 254]]], ["It also needs to work closely with the Finance department to model forecasted future impacts of RWAs and profitability to determine if the bank will have sufficient Equity and other capital sources to meet its minimum capital adequacy and additional capital buffer requirements.", [["additional capital buffer requirements", "TREATMENT", 239, 277]]], ["It is a very difficult and time-consuming process to consolidate fluctuating RWA demand, compute available capital supply and especially model the potential range of future outcomes.", [["fluctuating RWA demand", "PROBLEM", 65, 87]]], ["Given the fragmentation of different product systems, the process often involves manual interventions, which can be prone to errors and is difficult to duplicate for different What-If/Back-testing scenario analysis.Managing the Liquidity Coverage Ratio (LCR) and Net Stable Funding Ratio (NSFR)Prior to the financial crisis, there were no comprehensive global standard for liquidity management in place.", [["the fragmentation of different product systems", "PROBLEM", 6, 52], ["manual interventions", "TREATMENT", 81, 101], ["Back-testing scenario analysis", "TEST", 184, 214], ["the financial crisis", "PROBLEM", 303, 323], ["liquidity management", "TREATMENT", 373, 393], ["fragmentation", "OBSERVATION", 10, 23], ["Stable", "OBSERVATION_MODIFIER", 267, 273]]], ["This changed through the introduction of the LCR and NSFR regulations.", [["LCR", "DNA", 45, 48], ["NSFR", "DNA", 53, 57], ["the LCR", "TREATMENT", 41, 48], ["NSFR regulations", "TREATMENT", 53, 69]]], ["The LCR requires that a bank holds at least a 100% of High-Quality Liquid Assets (HQLA) against contingent liquidity outflows for both on-balance sheet and off-balance sheet exposures over a 30-day horizon.", [["LCR", "DNA", 4, 7], ["High-Quality Liquid Assets (HQLA)", "TREATMENT", 54, 87], ["contingent liquidity outflows", "PROBLEM", 96, 125]]], ["Both of these measures are complicated to compute and report given the need to first capture all notional cashflows over the 30-day or 1-year horizon and then apply the correct prudentially prescribed stress outflow weights.", [["cashflows", "CANCER", 106, 115], ["stress outflow weights", "PROBLEM", 201, 223], ["outflow weights", "OBSERVATION", 208, 223]]], ["What makes this activity even more demanding is that Regulators often expect banks to demonstrate the ability to produce these Liquidity reports daily.Structural product and equity hedgingA large portion of a bank's funding base originates from non-maturing deposits, which means the products have no definitive contractual maturity date, e.g. current accounts and common equity.", [["a bank's funding base", "TREATMENT", 207, 228], ["non-maturing deposits", "PROBLEM", 245, 266], ["equity", "OBSERVATION_MODIFIER", 174, 180], ["large", "OBSERVATION_MODIFIER", 190, 195], ["portion", "OBSERVATION_MODIFIER", 196, 203], ["non-maturing deposits", "OBSERVATION", 245, 266], ["no definitive", "UNCERTAINTY", 298, 311], ["contractual maturity", "OBSERVATION", 312, 332]]], ["These types of funding products share a couple of characteristics that can have a significant impact on a bank's net interest margin (NIM) stability.", [["a bank's net interest margin", "TREATMENT", 104, 132], ["funding", "OBSERVATION", 15, 22], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["impact", "OBSERVATION_MODIFIER", 94, 100]]], ["The first is that although this funding can contractually leave the bank within a day (either through client withdrawal or a credit loss) in practice, they remain stable for long periods of time.", [["stable", "OBSERVATION_MODIFIER", 163, 169]]], ["Secondly, the interest rate paid on these funds is close to zero, thereby equating to a long-term 0 percent fixed rate loan for the bank.", [["a long-term 0 percent fixed rate loan", "TREATMENT", 86, 123]]], ["This net interest rate position can create a significant fixed for floating interest rate exposure in the banking book.", [["This net interest rate position", "TREATMENT", 0, 31], ["significant", "OBSERVATION_MODIFIER", 45, 56]]], ["This can impact the bank's NIM stability, meaning if market rates go up, the bank's income increases, but if the market rates fall, income decreases.", [["the bank's NIM stability", "TREATMENT", 16, 40]]], ["Therefore, most banks execute a structural swap hedge to mitigate this exposure and thereby stabilise the net interest margin.", [["net", "OBSERVATION_MODIFIER", 106, 109], ["interest", "OBSERVATION_MODIFIER", 110, 118], ["margin", "OBSERVATION_MODIFIER", 119, 125]]], ["Since this hedging activity can significantly influence the bank's income (i.e. future profitability), regulators are very interested in the underlying assumptions and the models that underpin these decisions.Consequence of ineffective regulatory processesThese examples illustrate only a couple of the challenges that bank Treasuries face on a daily basis in managing and reporting bank risk positions.", [["ineffective regulatory processes", "PROBLEM", 224, 256]]], ["Incorrect reporting, bad systems or unexplained decisions can have significant impact on the bank's reputation and can often lead to penalties and fines.Consequence of ineffective regulatory processesAs an illustration, at the end of 2019 the Prudential Regulatory Authority (PRA) imposed a combined financial penalty on Citigroup Global Markets Limited (CGML), Citibank N.A. London branch (CBNA London) and Citibank Europe Plc UK branch (CEP UK) (together, Citi) of \u00a343.9 million for failings in relation to their internal controls and governance arrangements underpinning compliance with PRA regulatory reporting requirements.", [["the bank's reputation", "TREATMENT", 89, 110], ["ineffective regulatory processesAs", "PROBLEM", 168, 202], ["a combined financial penalty", "PROBLEM", 289, 317], ["failings", "PROBLEM", 485, 493], ["PRA regulatory reporting requirements", "TREATMENT", 590, 627], ["ineffective", "OBSERVATION_MODIFIER", 168, 179]]], ["This led to them failing to submit complete and accurate regulatory returns to the PRA [61] .", [["PRA", "GENE_OR_GENE_PRODUCT", 83, 86]]], ["In particular, the following items were highlighted:Consequence of ineffective regulatory processes\u2022 Citi failed to ensure that systems and controls supporting its UK regulatory reporting framework were designed, implemented and operating effectively; \u2022 Citi failed to allocate adequate human resources to ensure that CGML's liquidity returns were complete and accurate; \u2022 Citi's documentation of multiple aspects of its UK regulatory reporting control framework was inadequate given its size, complexity and systemic importance;Consequence of ineffective regulatory processes\u2022 CGML's approach to technical interpretations of reporting requirements was insufficiently robust given the complexity of those decisions and the impact they could have on the accuracy of the returns; and \u2022 Citi's oversight and governance in relation to regulatory reporting fell significantly below the standards expected of a systemically important institution.Integrating RegTech into a Treasury's digital transformationConsidering the Citi case [61] and other similar examples, there appears to be number of common themes and challenges to successfully managing regulatory demands including: fragmented data systems; manual time-consuming data manipulation/less time for strategic focus; real-Time reporting demand; interpretation of complex rules and regulations; effective governance and control around the process; and updating new regulations [10, 19, 62] .", [["Citi", "CHEMICAL", 101, 105], ["UK", "GENE_OR_GENE_PRODUCT", 164, 166], ["human", "ORGANISM", 287, 292], ["UK", "GENE_OR_GENE_PRODUCT", 421, 423], ["human", "SPECIES", 287, 292], ["human", "SPECIES", 287, 292], ["ineffective regulatory processes", "PROBLEM", 67, 99], ["Citi", "TREATMENT", 101, 105], ["CGML's liquidity", "TEST", 318, 334], ["Citi", "TEST", 373, 377], ["ineffective regulatory processes\u2022", "PROBLEM", 544, 577], ["fragmented data systems", "PROBLEM", 1173, 1196], ["size", "OBSERVATION_MODIFIER", 488, 492]]], ["RegTech systems can harness global data sets in a way that offers new and timely insight into regulatory processes, automating compliance and risk management tasks by pooling and aggregating data from a range of sources.", [["risk management tasks", "TREATMENT", 142, 163], ["aggregating data", "TEST", 179, 195]]], ["Often these data are too complex, too varied and too expensive, to review manually.Integrating RegTech into a Treasury's digital transformationHowever, to make these technologies an intrinsic part of the bank can be costly and time consuming, and not just during the implementation phase, but as part of the on-going maintenance.", [["a Treasury's digital transformation", "PROBLEM", 108, 143]]], ["It is therefore imperative that financial institutions have a sound understanding of the regulations they are required to follow, the processes that their business needs to put in place, and the most efficient method of implementing and enforcing these processes.Integrating RegTech into a Treasury's digital transformationAnother consideration is that RegTech cannot effectively be implemented and used on a stand-alone basis.", [["RegTech", "SIMPLE_CHEMICAL", 353, 360], ["a Treasury's digital transformation", "PROBLEM", 288, 323], ["a stand-alone basis", "TREATMENT", 407, 426]]], ["It needs to form part of an integrated deployment of digital technology in order to achieve true economies of scale.", [["digital technology", "TREATMENT", 53, 71]]], ["One solution is to incorporate RegTech into the digital transformation strategy of Treasury.", [["RegTech", "PROTEIN", 31, 38]]], ["The result would be that digital solutions could be leveraged to support both enhanced strategic management activity as well as better quality regulatory reporting.Integrating RegTech into a Treasury's digital transformationVon Solms and Langerman [26] developed a framework called a Smart Digital Treasury Model (SDTM) that provides a well-defined digital transformation plan for a Treasury to assess its digital maturity level and guide the effective adoption of digital technologies.", [["digital solutions", "TREATMENT", 25, 42], ["digital technologies", "TREATMENT", 465, 485]]], ["This framework can be expanded to include some of the regulatory management demands and thereby deliver an integrated and effective RegTech solution as part of the SDTM framework.", [["the regulatory management demands", "TREATMENT", 50, 83], ["an integrated and effective RegTech solution", "TREATMENT", 104, 148], ["the SDTM framework", "TREATMENT", 160, 178]]], ["The next section will introduce the framework and explore how it can be expanded to include the Regulatory Technology angle.Overview of the SDTMGiven the changing nature of Treasury and its increasing strategic management mandate, it is crucial to follow a well-defined framework to determine the current digital maturity and enable the transitioning to a more advanced digital user.", [["Treasury", "TREATMENT", 173, 181]]], ["The Smart Digital Treasury Model (SDTM) was developed for this purpose, to support and guide the evolution towards a next-generation smart Treasury [26] .", [["a next-generation smart Treasury", "TREATMENT", 115, 147]]], ["Figure 3 provides more insight into the underlying steps/ building blocks of the SDTM.Overview of the SDTMThe model comprises of 4 steps/building blocks, i.e.Overview of the SDTM\u2022 Step 1: Digital maturity assessment-measures the digital maturity of a Treasury against a specific set of criteria and scores the digitalisation level/readiness on a scale from none to expert, across key digital dimensions.", [["Digital maturity assessment", "TEST", 188, 215], ["the digitalisation level", "PROBLEM", 306, 330], ["a scale", "TEST", 344, 351]]], ["It then identifies and describes digital use cases for core Treasury activities and order these for further digitalisation development. \u2022 Step 2: Business case development and digital tool evaluation-digital use cases are mapped into the most appropriate digital technologies.", [["core Treasury activities", "TREATMENT", 55, 79], ["further digitalisation development", "TREATMENT", 100, 134], ["digital tool evaluation", "TEST", 176, 199]]], ["This is to ensure that the implementation will deliver the expected benefits and that Treasury successfully transition to a more digitally mature state. \u2022 Step 3: Digital road map of Technology implementation-this step articulates the implementation plan and development method (e.g. DevOps, Agile, Lean) to rollout the selected new digital technology. \u2022 Step 4: Management of new digital technology and risks-managing the changes and increased threats and risks arising from digitalisation in Treasury is an important consideration.", [["Technology implementation", "TREATMENT", 183, 208], ["development method", "TEST", 259, 277], ["new digital technology", "TREATMENT", 377, 399], ["the changes", "PROBLEM", 419, 430], ["increased threats", "PROBLEM", 435, 452], ["important consideration", "UNCERTAINTY", 509, 532]]], ["Digitalisation therefore requires a dedicated approach to identify and mitigate these potential risks.Expanding the SDTM to include regulatory processesThe SDTM which was originally designed to enhance strategic management activities within a Treasury department can be expanded to accommodate certain regulatory activities and services areas as well.", [["SDTM", "DNA", 116, 120], ["Expanding the SDTM", "PROBLEM", 102, 120], ["regulatory processes", "PROBLEM", 132, 152]]], ["This digital assessment and the construction of digital use cases of Treasury management activities can be expanded to also cover key Regulatory activities, for example, regulatory reporting.", [["This digital assessment", "TEST", 0, 23], ["Treasury management", "TREATMENT", 69, 88]]], ["Figure 4 shows how the spectrum of Treasury management activities and regulatory service areas can be combined to establish a comprehensive digital assessment picture.", [["Treasury management", "TREATMENT", 35, 54], ["a comprehensive digital assessment picture", "TEST", 124, 166]]], ["The rationale is that there is a large amount of communality and overlap in the way that underlying data are extracted and processed.", [["a large amount of communality", "PROBLEM", 31, 60], ["large", "OBSERVATION_MODIFIER", 33, 38], ["amount", "OBSERVATION_MODIFIER", 39, 45], ["communality", "OBSERVATION", 49, 60]]], ["Using an integrated approach will ensure future consistency between reporting views and strategic management views.Expanding the SDTM to include regulatory processesThe digital use cases covering the comprehensive set of Treasury activities can then be mapped into the most appropriate digital technologies (Step 2 of SDTM, see Fig. 4 ).", [["SDTM", "DNA", 129, 133], ["an integrated approach", "TREATMENT", 6, 28], ["reporting views", "TEST", 68, 83], ["strategic management views", "TEST", 88, 114], ["Expanding the SDTM", "PROBLEM", 115, 133], ["regulatory processes", "PROBLEM", 145, 165]]], ["This will ensure that RegTech is not developed on a standalone basis or that there is duplication of digital solutions across Treasury.", [["duplication of digital solutions across Treasury", "PROBLEM", 86, 134]]], ["The use of digital technology for regulatory purposes (RegTech) will also strengthen the collective business case justification to obtain senior management support for implementing these types of innovations within Treasury.", [["senior management support", "TREATMENT", 138, 163]]], ["Commercial metrics such as Return on Investment (ROI) will be significantly enhanced if digital technology solutionsDigital Maturity Assessment Business Cases and Digital Tools Digital Implementation Plan Management of Digital TechnologyTowards a next generation smart TreasuryDigital Maturity Assessment Business Cases and Digital Tools Digital Implementation Plan Management of Digital TechnologyStep 4 Step 1Digital Maturity Assessment Business Cases and Digital Tools Digital Implementation Plan Management of Digital TechnologyStep 2 S tep 3Fig.", [["digital technology solutions", "TREATMENT", 88, 116], ["Digital TechnologyStep 2 S tep 3Fig", "TREATMENT", 514, 549]]], ["3 Smart Digital Treasury Modelare leveraged for both management and regulatory-driven purposes.Fig.", [["both management", "TREATMENT", 48, 63], ["regulatory-driven purposes", "TREATMENT", 68, 94]]], ["Selected digital technology solutions can be embedded into core underlying bank systems for example: Big Data (BD) Analytics applied to Customer Product Systems will help to better understand customer behaviour; Machine Learning (ML) embedded within the Payments Systems can improve the Intraday Liquidity Risk management; and Robotic Process Automation (RPA) can be harnessed to automate data extraction from the Risk Management systems (see next section for more details).", [["Selected digital technology solutions", "TREATMENT", 0, 37], ["Customer Product Systems", "TREATMENT", 136, 160], ["the Intraday Liquidity Risk management", "TREATMENT", 283, 321], ["automate data extraction", "TREATMENT", 380, 404]]], ["Furthermore, Treasury can augment this smart information with additional digital analytics, e.g. Artificial Intelligence to drive subjective based strategic actions such as optimal allocation of financial resources such as capital and liquidity.Fig.", [["Artificial Intelligence", "TREATMENT", 97, 120], ["subjective based strategic actions", "TREATMENT", 130, 164], ["financial resources", "TREATMENT", 195, 214]]], ["3 Smart Digital Treasury ModelBy reducing the manual and time-consuming operational overhead involved with reporting activities, the Treasury's human resource requirement will also reduce.", [["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149]]], ["But rather than become obsolete these personnel can then be more efficiently be deployed to focus on subjective and strategic management activities, such as optimisation of the balance sheet and thereby deliver real bottom-line value for the bank.", [["strategic management activities", "TREATMENT", 116, 147], ["the balance sheet", "TREATMENT", 173, 190]]], ["They can also assist with the management of the additional risks and threats that can arise from the use of digital technology such cyber security; ensuring models are fair and unbiased; explainability of results, etc. (Step 4 of SDTM).Fig.", [["the management", "TREATMENT", 26, 40]]], ["3 Smart Digital Treasury ModelThe next section will focus in more detail on one specific digital technology, namely Robotic Process Automation (RPA) and how it can deliver improvements to the Treasury's management and regulatory reporting process through enabling automation.Integration of RegTech in a smart Treasury through using Robotic Process Automation (RPA)One of the most time-consuming operational activities in a Treasury is the extraction, formatting and reconciliation of data from various different source systems for management purposes and to feed the production of regulatory reports.", [["the Treasury's management", "TREATMENT", 188, 213], ["a smart Treasury", "TREATMENT", 301, 317], ["Robotic Process Automation", "TREATMENT", 332, 358], ["the extraction", "TREATMENT", 435, 449], ["management purposes", "TREATMENT", 531, 550]]], ["This is often a complex and manual intensive task since there is a dependency on diverse range of legacy systems (i.e. product, risk management, accounting, paymentFig.", [["a dependency", "PROBLEM", 65, 77], ["risk management", "TREATMENT", 128, 143]]], ["4Combining management and regulatory tasks into a holistic framework and trading systems) which is often not designed for the modern regulatory and management requirements.", [["4Combining management", "TREATMENT", 0, 21], ["management requirements", "TREATMENT", 148, 171]]], ["This type of process is inefficient and open to a number of risks and weaknesses, e.g. easy to make errors; difficult to duplicate and repeat on more a frequent basis; problematic to update if regulations change (i.e. data rules are hard-coded).", [["weaknesses", "PROBLEM", 70, 80]]], ["An innovative technology solution like RPA can significantly assist in streamlining and automating the reporting process [64] .", [["RPA", "PROTEIN", 39, 42], ["An innovative technology solution", "TREATMENT", 0, 33]]], ["RPA technology works very well in an environment which has the following characteristics: high level of manual calculation; electronic start and end points; high error rates; data intensive; repetitive in nature.", [["RPA", "PROTEIN", 0, 3], ["manual calculation", "TEST", 104, 122], ["high error rates", "PROBLEM", 157, 173]]], ["The first 2 or 3 steps in the process (i.e. data input, data output and reconciliation) share a lot of the above characteristics and tends to require minimal levels of subjective judgement.Fig.", [["data output", "TEST", 56, 67]]], ["4Ernst and Young estimates that there can be significant reduction of full time equivalent (FTE) personnel, if RPA technology is implemented to assist with data extraction, formatting and checking of correctness [64] .", [["RPA", "PROTEIN", 111, 114], ["data extraction", "TEST", 156, 171], ["significant", "OBSERVATION_MODIFIER", 45, 56], ["reduction", "OBSERVATION_MODIFIER", 57, 66]]], ["These human resources can then be deployed more optimally to focus on strategic and subject activities like assessing the underlying business and regulatory rules and interpreting the management information output of the various reports.", [["human", "ORGANISM", 6, 11], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11]]], ["The benefits of deploying RPA for Treasury regulatory activity include: automated systems can operate 24/7; it improves granularity and frequency of updates; it reduces FTE required; minimises error rates; it integrates relatively well within existing IT landscape; it can be trained by humans; and it leads to redeployment of Treasury staff to more strategic functions.", [["humans", "ORGANISM", 287, 293], ["RPA", "PROTEIN", 26, 29], ["humans", "SPECIES", 287, 293], ["humans", "SPECIES", 287, 293], ["minimises error rates", "PROBLEM", 183, 204]]], ["RPA is only one example of how a specific digital technology can help to automate operational activities within a Treasury.", [["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["RPA", "PROTEIN", 0, 3]]], ["It is not just a solution to automate manual and time-consuming operational activities, but also a powerful instrument to compute and interpret complicated forecasting results, identify unanticipated risks and crucially drive quicker and more intelligent regulatory assessments, during times of stress.", [["intelligent regulatory assessments", "TEST", 243, 277], ["stress", "PROBLEM", 295, 301]]], ["A practical example of where RegTech could provide valuable assistance in strategic decision-making and management of regulations, under a real-life stress event, is the recent Coronavirus (COVID 19) outbreak, which started in late 2019.", [["RegTech", "CHEMICAL", 29, 36], ["RegTech", "SIMPLE_CHEMICAL", 29, 36], ["the recent Coronavirus", "PROBLEM", 166, 188]]], ["It was a totally unforeseen risk, a once in a 100-year event, that had significant impacts on the financial markets and global economies.RegTech in the time of CoronaThe effects of lockdown restrictions to prevent the spreading of Corona has put increased pressure on the capital adequacy ratios of banks due to: increased credit losses; reduced opportunity to generate profit (i.e. retained earnings to bolster capital reserves); and higher capital requirements for risk measures such as value at risk, which includes the exceptionally higher market volatility.", [["RegTech", "TREATMENT", 137, 144], ["lockdown restrictions", "TREATMENT", 181, 202], ["increased pressure", "PROBLEM", 246, 264], ["increased credit losses", "PROBLEM", 313, 336], ["risk measures", "TREATMENT", 467, 480], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["impacts", "OBSERVATION", 83, 90], ["global", "OBSERVATION_MODIFIER", 120, 126], ["economies", "OBSERVATION", 127, 136], ["Corona", "ANATOMY_MODIFIER", 231, 237], ["increased", "OBSERVATION_MODIFIER", 246, 255], ["pressure", "OBSERVATION_MODIFIER", 256, 264], ["increased", "OBSERVATION_MODIFIER", 313, 322], ["credit losses", "OBSERVATION", 323, 336]]], ["It also influenced the funding and liquidity available to banks through a slowdown of money market activity and debt capital markets issuance opportunities and reduction in intra bank lending activity.RegTech in the time of CoronaIn order to reduce the impact on the financial markets, many central banks provided a variety of regulatory relieve packages.", [["a variety of regulatory relieve packages", "TREATMENT", 314, 354], ["reduction", "OBSERVATION_MODIFIER", 160, 169], ["intra bank", "OBSERVATION", 173, 183], ["central banks", "OBSERVATION", 291, 304]]], ["This ranged from injecting liquidity into the markets to allowing regulatory dispensations, e.g. lowering the Liquidity Coverage Ratio (LCR) requirement and/or allowing banks to dip into their additional capital buffers.", [["regulatory dispensations", "TREATMENT", 66, 90], ["the Liquidity Coverage Ratio (LCR) requirement", "TREATMENT", 106, 152]]], ["As illustration, the South African Reserve Bank (SARB) lowered the LCR requirement to 80% for the duration of the stress [65] and the Bank of England (BOE) allowed banks to offset increases in market risk capital, due to higher volatility in the value at risk calculation through a commensurate reduction in risks-not-in-VAR (RNIV) capital requirements [66] .RegTech in the time of CoronaThe issue is that although commercial banks might be allowed to temporarily dip into their liquidity and capital buffers, the expectation is that after a crisis they will revert back to the normal prescribed levels.", [["LCR", "DNA", 67, 70], ["the LCR requirement", "TREATMENT", 63, 82], ["higher volatility", "PROBLEM", 221, 238], ["a commensurate reduction", "TREATMENT", 280, 304], ["a crisis", "PROBLEM", 540, 548]]], ["In the absence of RegTech infrastructure, this can become a very difficult process to measure, monitor, manage and ensure future compliance.RegTech in the time of CoronaDigital technologies underpinning RegTech can play a key role in assessing the fluctuating regulatory metrics and crucially ensure the freed-up capital and liquidity are optimal deployed across the bank, i.e. diverted to areas where itDATA INPUTExtracting data from underlying systems and reading files email.DATA OUTPUT & QUALITYReformatting data, checking data quality and sending it out via distribution channelsRECONCILLIATIONInterpreting and combining data from systems and checking for correctnessBUSINESS RULESApplying business rules based on formalised principals and / or regulatory requirementsREPORTINGGenerating reports for strategic management and regulatory reporting is needed the most.", [["CoronaDigital technologies", "TREATMENT", 163, 189], ["DATA OUTPUT", "TEST", 478, 489], ["QUALITYReformatting data", "TEST", 492, 516], ["checking data quality", "TEST", 518, 539], ["combining data from systems", "TEST", 616, 643], ["correctness", "TEST", 661, 672], ["strategic management", "TREATMENT", 805, 825]]], ["For example, Big Data Analytics can be leveraged to analyse how customer behaviour will change under the unique stress event, e.g. how many clients will take up the loan repayment holiday offer and thereby impact the bank's profitability; Robotic Process Automation can allow for quicker generation of regulatory reports to assess the impact of liquidity and capital changes on key prudential metrics; and Artificial Intelligence can identify weaknesses in existing risk and control frameworks and help guide intelligent re-allocation of additional capital and liquidity resources to affected areas.REPORTINGThese are only a couple examples of the advantages that RegTech can offer in an unexpected market crisis.", [["RegTech", "SIMPLE_CHEMICAL", 664, 671], ["the bank's profitability", "TREATMENT", 213, 237], ["Robotic Process Automation", "TREATMENT", 239, 265], ["capital changes", "PROBLEM", 359, 374], ["weaknesses in existing risk and control frameworks", "PROBLEM", 443, 493], ["additional capital and liquidity resources", "TREATMENT", 538, 580]]], ["The point is that deployment of Regulatory Technology has many benefits, not just in business-as-usual operating times, but also as powerful and intelligent tool to manage changing regulatory requirements in unanticipated stress events, such as the Coronavirus outbreak.ConclusionThe banking landscape has changed significantly over the last couple of decades and especially after the 2008 financial crisis.", [["changing regulatory requirements", "PROBLEM", 172, 204], ["unanticipated stress events", "PROBLEM", 208, 235], ["the Coronavirus outbreak", "PROBLEM", 245, 269], ["Coronavirus", "OBSERVATION", 249, 260], ["banking landscape", "OBSERVATION", 284, 301]]], ["An area where significant impact was experienced for most banks is in the increase and complexity of new financial regulations and subsequent expansion of bank's compliance requirements.ConclusionThe volume and complexity of bank regulations have increased significantly over the last couple of years.", [["bank's compliance requirements", "TREATMENT", 155, 185], ["area", "OBSERVATION_MODIFIER", 3, 7], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["impact", "OBSERVATION", 26, 32], ["increase", "OBSERVATION_MODIFIER", 74, 82], ["new", "OBSERVATION_MODIFIER", 101, 104], ["financial regulations", "OBSERVATION", 105, 126], ["expansion", "OBSERVATION_MODIFIER", 142, 151], ["volume", "OBSERVATION_MODIFIER", 200, 206], ["complexity", "OBSERVATION_MODIFIER", 211, 221], ["bank regulations", "OBSERVATION", 225, 241], ["increased", "OBSERVATION_MODIFIER", 247, 256], ["significantly", "OBSERVATION_MODIFIER", 257, 270]]], ["This has put more pressure on banks to monitor and report a range of complex exposures and comply with all the different prudential requirements.ConclusionRegulatory Technology (RegTech) has emerged as a technology trend that can assist with the regulatory obligations of banks.", [["more pressure", "OBSERVATION_MODIFIER", 13, 26]]], ["RegTech makes use of Information Technology and digital technologies for enhancing regulatory procedures such as regulatory monitoring, compliance and reporting.", [["enhancing regulatory procedures", "TREATMENT", 73, 104], ["regulatory monitoring", "TEST", 113, 134]]], ["RegTech has emerged as a lifeline to help firms ease this burden and streamline labour-intensive and costly tasks.", [["RegTech", "CHEMICAL", 0, 7], ["this burden", "PROBLEM", 53, 64]]], ["RegTech solutions are aimed at making it easier and cheaper for financial institutions to comply with ever-changing regulations, without requiring manual processes that drive up errors, time and headcount.", [["RegTech solutions", "TREATMENT", 0, 17], ["financial institutions", "TREATMENT", 64, 86], ["manual processes", "TREATMENT", 147, 163]]], ["The problem is that digital technologies can be expensive and inefficient if deployed on a stand-alone basis.", [["digital technologies", "TREATMENT", 20, 40]]], ["In order to achieve efficiencies, it needs to be part of an integrated deployment of digital technology firm-wide to truly add value.", [["firm", "OBSERVATION", 104, 108]]], ["This paper explored how RegTech can be incorporated into the digital transformation strategy of a bank department such as Treasury.", [["RegTech", "SIMPLE_CHEMICAL", 24, 31]]], ["This would mean digital solutions could be leveraged to support both strategic Treasury management activity and regulatory reporting demands.", [["strategic Treasury management", "TREATMENT", 69, 98]]], ["This integration will truly create a smart Treasury function.ConclusionThe combined use of digital technology for management and regulatory purposes will also strengthen the collective business case formulation for implementing these kinds of innovations within Treasury.", [["digital technology", "TREATMENT", 91, 109], ["management", "TREATMENT", 114, 124], ["regulatory purposes", "TREATMENT", 129, 148]]], ["Measurements such as Return on Investment will be significantly boosted if digital technology solutions are leveraged for both management and regulatory-driven purposes.ConclusionRegulatory technologies have different advantages which could all help with delivering an improved and smarter regulatory management process.", [["digital technology solutions", "TREATMENT", 75, 103], ["both management", "TREATMENT", 122, 137], ["smarter regulatory management process", "TREATMENT", 282, 319]]], ["RPA can significantly reduce the operational and manual intensive process of data extraction and free up Treasury personnel to focus on more strategic and subjective management activities such as interpreting the reporting output and using the information to drive commercial decisions.ConclusionFurthermore, RegTech is not just beneficial in business as usual times, but can also provide a flexible and powerful tool to manage changing regulatory requirements in unanticipated stress events, such as during the Corona outbreak.", [["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["RPA", "PROTEIN", 0, 3], ["data extraction", "TREATMENT", 77, 92], ["subjective management activities", "TREATMENT", 155, 187], ["changing regulatory requirements", "PROBLEM", 428, 460], ["unanticipated stress events", "PROBLEM", 464, 491], ["the Corona outbreak", "PROBLEM", 508, 527]]]], "ba94dbb19b3a574e0f02dbd34b75c42359a52358": [["INTRODUCTIONSevere acute respiratory syndrome (SARS), a newly described infectious disease caused by the novel SARSassociated coronavirus (SARS-CoV), has become a major threat to public health globally.", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["infectious disease", "DISEASE", 72, 90], ["SARSassociated coronavirus", "DISEASE", 111, 137], ["SARS-CoV)", "DISEASE", 139, 148], ["SARSassociated coronavirus", "ORGANISM", 111, 137], ["SARS-CoV", "ORGANISM", 139, 147], ["SARSassociated coronavirus", "SPECIES", 111, 137], ["SARSassociated coronavirus", "SPECIES", 111, 137], ["SARS-CoV", "SPECIES", 139, 147], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a newly described infectious disease", "PROBLEM", 54, 90], ["the novel SARSassociated coronavirus", "PROBLEM", 101, 137], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["infectious", "OBSERVATION", 72, 82]]], ["1-4 SARS is highly contagious and has been aptly coined 'the first plague of the twenty-first century'.", [["SARS", "DISEASE", 4, 8], ["contagious", "OBSERVATION_MODIFIER", 19, 29]]], ["The disease is characterised by transmission in healthcare and household settings and through intriguing superspreading events which were pivotal in its global spread.", [["The disease", "PROBLEM", 0, 11], ["intriguing superspreading events", "PROBLEM", 94, 126], ["disease", "OBSERVATION", 4, 11], ["global", "OBSERVATION_MODIFIER", 153, 159], ["spread", "OBSERVATION_MODIFIER", 160, 166]]], ["[5] [6] [7] [8] [9] [10] [11] Superspreading events including a major hospital outbreak, in-flight transmission on board commercial PAEDIATRIC RESPIRATORY REVIEWS (2004) Summary Children are susceptible to infection by SARS-associated coronavirus (SARS-CoV) but the clinical picture of SARS is milder than in adults.", [["[5] [6] [7] [8] [9", "CHEMICAL", 0, 18], ["infection", "DISEASE", 206, 215], ["SARS-associated coronavirus", "DISEASE", 219, 246], ["SARS", "DISEASE", 248, 252], ["SARS", "DISEASE", 286, 290], ["[5] [6] [7] [8] [9] [10] [11", "SIMPLE_CHEMICAL", 0, 28], ["SARS-associated coronavirus", "ORGANISM", 219, 246], ["SARS-CoV", "ORGANISM", 248, 256], ["Children", "SPECIES", 178, 186], ["SARS-associated coronavirus", "SPECIES", 219, 246], ["SARS-CoV", "SPECIES", 248, 256], ["infection", "PROBLEM", 206, 215], ["SARS", "PROBLEM", 219, 223], ["coronavirus", "PROBLEM", 235, 246], ["SARS", "PROBLEM", 286, 290], ["infection", "OBSERVATION", 206, 215]]], ["Teenagers resemble adults in presentation and disease progression and may develop severe illness requiring intensive care and assisted ventilation.", [["illness", "DISEASE", 89, 96], ["disease progression", "PROBLEM", 46, 65], ["severe illness", "PROBLEM", 82, 96], ["intensive care", "TREATMENT", 107, 121], ["assisted ventilation", "TREATMENT", 126, 146], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["illness", "OBSERVATION", 89, 96]]], ["Fever, malaise, cough, coryza, chills or rigor, sputum production, headache, myalgia, leucopaenia, lymphopaenia, thrombocytopaenia, mildly prolonged activated partial thromboplastin times and elevated lactate dehydrogenase levels are common presenting features.", [["sputum", "ANATOMY", 48, 54], ["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 16, 21], ["coryza", "DISEASE", 23, 29], ["chills", "DISEASE", 31, 37], ["headache", "DISEASE", 67, 75], ["myalgia", "DISEASE", 77, 84], ["leucopaenia", "DISEASE", 86, 97], ["lymphopaenia", "DISEASE", 99, 111], ["thrombocytopaenia", "DISEASE", 113, 130], ["lactate", "CHEMICAL", 201, 208], ["lactate", "CHEMICAL", 201, 208], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 167, 181], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 201, 222], ["lactate dehydrogenase", "PROTEIN", 201, 222], ["Fever", "PROBLEM", 0, 5], ["malaise", "PROBLEM", 7, 14], ["cough", "PROBLEM", 16, 21], ["coryza", "PROBLEM", 23, 29], ["chills", "PROBLEM", 31, 37], ["rigor", "PROBLEM", 41, 46], ["sputum production", "PROBLEM", 48, 65], ["headache", "PROBLEM", 67, 75], ["myalgia", "PROBLEM", 77, 84], ["leucopaenia", "PROBLEM", 86, 97], ["lymphopaenia", "PROBLEM", 99, 111], ["thrombocytopaenia", "PROBLEM", 113, 130], ["mildly prolonged activated partial thromboplastin times", "PROBLEM", 132, 187], ["elevated lactate dehydrogenase levels", "PROBLEM", 192, 229], ["malaise", "OBSERVATION", 7, 14], ["cough", "OBSERVATION", 16, 21], ["chills", "OBSERVATION", 31, 37], ["sputum", "OBSERVATION", 48, 54], ["myalgia", "OBSERVATION", 77, 84], ["thrombocytopaenia", "OBSERVATION", 113, 130], ["mildly", "OBSERVATION_MODIFIER", 132, 138], ["prolonged", "OBSERVATION_MODIFIER", 139, 148], ["partial", "OBSERVATION_MODIFIER", 159, 166], ["thromboplastin times", "OBSERVATION", 167, 187]]], ["Radiographic findings are non-specific but highresolution computed tomography of the thorax in clinically suspected cases may be an early diagnostic aid when initial chest radiographs appear normal.", [["thorax", "ANATOMY", 85, 91], ["chest", "ANATOMY", 166, 171], ["thorax", "ORGAN", 85, 91], ["Radiographic findings", "TEST", 0, 21], ["highresolution computed tomography", "TEST", 43, 77], ["initial chest radiographs", "TEST", 158, 183], ["non-specific", "OBSERVATION_MODIFIER", 26, 38], ["thorax", "ANATOMY", 85, 91], ["chest", "ANATOMY", 166, 171], ["normal", "OBSERVATION", 191, 197]]], ["The improved reverse transcription-polymerase chain reaction (RT-PCR) assays are critical in the early diagnosis of SARS, with sensitivity approaching 80% in the first 3 days of illness when performed on nasopharyngeal aspirates, the preferred specimens.", [["nasopharyngeal aspirates", "ANATOMY", 204, 228], ["specimens", "ANATOMY", 244, 253], ["SARS", "DISEASE", 116, 120], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 204, 228], ["The improved reverse transcription-polymerase chain reaction", "PROBLEM", 0, 60], ["RT-PCR) assays", "TEST", 62, 76], ["SARS", "PROBLEM", 116, 120], ["sensitivity", "TEST", 127, 138], ["illness", "PROBLEM", 178, 185], ["nasopharyngeal aspirates", "TEST", 204, 228], ["nasopharyngeal", "ANATOMY", 204, 218], ["aspirates", "OBSERVATION", 219, 228]]], ["Absence of seroconversion to SARS-CoV beyond 28 days from disease onset generally excludes the diagnosis.", [["SARS", "DISEASE", 29, 33], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "SPECIES", 29, 37], ["seroconversion", "PROBLEM", 11, 25], ["SARS", "PROBLEM", 29, 33], ["CoV", "PROBLEM", 34, 37], ["disease onset", "PROBLEM", 58, 71], ["seroconversion", "OBSERVATION", 11, 25]]], ["The best treatment strategy for SARS among children remains to be determined.", [["SARS", "DISEASE", 32, 36], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["SARS", "PROBLEM", 32, 36]]], ["No case fatality has been reported in children and the short-to medium-term outcome appears to be good.", [["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46]]], ["The importance of continued monitoring for any long-term complications due to the disease or its empiric treatment, cannot be overemphasised. \u00df 2004 Elsevier Ltd.", [["continued monitoring", "TEST", 18, 38], ["any long-term complications", "PROBLEM", 43, 70], ["the disease", "PROBLEM", 78, 89], ["its empiric treatment", "TREATMENT", 93, 114], ["disease", "OBSERVATION", 82, 89]]], ["All rights reserved.INTRODUCTIONAbbreviations: SARS, severe acute respiratory syndrome; SARS-CoV, SARS-associated coronavirus; RSV, respiratory syncytial virus; ARDS, acute respiratory distress syndrome; CXR, chest radiograph; HRCT, high-resolution computed tomography; BOOP, bronchiolitis obliterans-organising pneumonia; NPA, nasopharyngeal aspirate; RT-PCR, reverse transcription-polymerase chain reaction; IFA, immunofluorescence assay; ELISA, enzyme-linked immunosorbant assay. *Correspondence to: C.W. Leung; E-mail: leungcw@ha.org.hk. airliners, transmission in a hotel and a large-scale community outbreak in a densely populated residential complex, primarily resulting from environmental contamination by a 'superspreader' with diarrhoea, were well described.", [["nasopharyngeal aspirate", "ANATOMY", 328, 351], ["SARS", "DISEASE", 47, 51], ["acute respiratory syndrome", "DISEASE", 60, 86], ["SARS-CoV", "DISEASE", 88, 96], ["SARS", "DISEASE", 98, 102], ["coronavirus", "DISEASE", 114, 125], ["RSV", "DISEASE", 127, 130], ["respiratory syncytial virus", "DISEASE", 132, 159], ["ARDS", "DISEASE", 161, 165], ["acute respiratory distress syndrome", "DISEASE", 167, 202], ["BOOP", "DISEASE", 270, 274], ["bronchiolitis obliterans", "DISEASE", 276, 300], ["pneumonia", "DISEASE", 312, 321], ["diarrhoea", "DISEASE", 737, 746], ["coronavirus", "ORGANISM", 114, 125], ["RSV", "ORGANISM", 127, 130], ["respiratory syncytial virus", "ORGANISM", 132, 159], ["coronavirus", "SPECIES", 114, 125], ["RSV", "SPECIES", 127, 130], ["respiratory syncytial virus", "SPECIES", 132, 159], ["SARS-CoV", "SPECIES", 88, 96], ["RSV", "SPECIES", 127, 130], ["respiratory syncytial virus", "SPECIES", 132, 159], ["SARS", "PROBLEM", 47, 51], ["severe acute respiratory syndrome", "PROBLEM", 53, 86], ["SARS", "PROBLEM", 88, 92], ["CoV", "PROBLEM", 93, 96], ["SARS", "PROBLEM", 98, 102], ["coronavirus", "PROBLEM", 114, 125], ["RSV", "PROBLEM", 127, 130], ["respiratory syncytial virus", "PROBLEM", 132, 159], ["ARDS", "PROBLEM", 161, 165], ["acute respiratory distress syndrome", "PROBLEM", 167, 202], ["CXR", "TEST", 204, 207], ["chest radiograph", "TEST", 209, 225], ["HRCT", "TEST", 227, 231], ["resolution computed tomography", "TEST", 238, 268], ["BOOP", "PROBLEM", 270, 274], ["bronchiolitis obliterans", "PROBLEM", 276, 300], ["pneumonia", "PROBLEM", 312, 321], ["NPA", "TEST", 323, 326], ["nasopharyngeal aspirate", "TEST", 328, 351], ["RT-PCR", "TEST", 353, 359], ["polymerase chain reaction", "PROBLEM", 383, 408], ["IFA", "TEST", 410, 413], ["immunofluorescence assay", "TEST", 415, 439], ["ELISA", "TEST", 441, 446], ["enzyme", "TEST", 448, 454], ["immunosorbant assay", "TEST", 462, 481], ["environmental contamination", "PROBLEM", 683, 710], ["diarrhoea", "PROBLEM", 737, 746], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86], ["respiratory syncytial", "ANATOMY", 132, 153], ["ARDS", "OBSERVATION", 161, 165], ["acute", "OBSERVATION_MODIFIER", 167, 172], ["respiratory distress", "OBSERVATION", 173, 193], ["chest", "ANATOMY", 209, 214], ["BOOP", "OBSERVATION", 270, 274], ["bronchiolitis obliterans", "OBSERVATION", 276, 300], ["pneumonia", "OBSERVATION", 312, 321], ["nasopharyngeal", "ANATOMY", 328, 342], ["large", "OBSERVATION_MODIFIER", 583, 588], ["densely", "OBSERVATION_MODIFIER", 619, 626], ["environmental contamination", "OBSERVATION", 683, 710]]], ["5, 6, [12] [13] [14] [15] The disease first started as a mysterious outbreak of atypical pneumonia in the Guangdong Province of southern China in November 2002.", [["5, 6, [12] [13] [14] [15", "CHEMICAL", 0, 24], ["pneumonia", "DISEASE", 89, 98], ["5, 6, [12] [13] [14] [15", "SIMPLE_CHEMICAL", 0, 24], ["The disease", "PROBLEM", 26, 37], ["atypical pneumonia", "PROBLEM", 80, 98], ["atypical", "OBSERVATION_MODIFIER", 80, 88], ["pneumonia", "OBSERVATION", 89, 98]]], ["By July 31, 2003, up to 29 countries and regions of the world had been affected by SARS.", [["SARS", "DISEASE", 83, 87]]], ["A worldwide total of 8098 cases of probable SARS, 1707 (21%) of these being healthcare workers and 774 deaths (9.6%) were recorded.", [["SARS", "DISEASE", 44, 48], ["deaths", "DISEASE", 103, 109], ["SARS", "PROBLEM", 44, 48], ["probable", "UNCERTAINTY", 35, 43]]], ["16 In Hong Kong, the toll was 1755 affected individuals, including 386 (22%) healthcare workers and 299 deaths (17%).", [["deaths", "DISEASE", 104, 110]]], ["16 The subsequent reemergence of the first six sporadic cases of SARS, two of which were probably laboratory-acquired, did not result in local transmission in Singapore, Taiwan and China.", [["SARS", "DISEASE", 65, 69], ["SARS", "PROBLEM", 65, 69]]], ["[17] [18] [19] [20] Children appeared to be less affected by the disease, with smaller case numbers and less severe illness reported.", [["illness", "DISEASE", 116, 123], ["[17] [18] [19] [20]", "SIMPLE_CHEMICAL", 0, 19], ["Children", "ORGANISM", 20, 28], ["Children", "SPECIES", 20, 28], ["less severe illness", "PROBLEM", 104, 123]]], ["[21] [22] [23] [24] All age groups are susceptible to SARS-CoV, which is new to humans.", [["SARS", "DISEASE", 54, 58], ["[21] [22] [23", "SIMPLE_CHEMICAL", 0, 13], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["SARS-CoV", "SPECIES", 54, 62], ["humans", "SPECIES", 80, 86], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["SARS", "OBSERVATION", 54, 58], ["new", "OBSERVATION_MODIFIER", 73, 76]]], ["However, rapid isolation of diseased adults, whose infectivity is lower in the first few days of illness, has contributed to reduced frequency of household exposure for children.", [["illness", "DISEASE", 97, 104], ["adults", "ORGANISM", 37, 43], ["children", "ORGANISM", 169, 177], ["children", "SPECIES", 169, 177], ["diseased adults", "PROBLEM", 28, 43], ["illness", "PROBLEM", 97, 104], ["rapid", "OBSERVATION_MODIFIER", 9, 14], ["isolation", "OBSERVATION_MODIFIER", 15, 24], ["diseased", "OBSERVATION", 28, 36], ["lower", "OBSERVATION_MODIFIER", 66, 71]]], ["The exact number of children affected by SARS worldwide is unknown as the age breakdown of reported cases was not available or incomplete for some of the affected countries (WHO SARS Surveillance Team, personal communication).", [["SARS", "DISEASE", 41, 45], ["SARS", "DISEASE", 178, 182], ["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28]]], ["It is estimated that children <18 years of age only accounted for about 5% of the total affected.", [["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29]]], ["There was no reported mortality in children (WHO SARS Surveillance Team, personal communication).INTRODUCTIONA total of 121 children aged <18 years were registered in the e-SARS database of the Hospital Authority of Hong Kong, accounting for 7% of all patients notified.", [["SARS", "DISEASE", 49, 53], ["children", "ORGANISM", 35, 43], ["children", "ORGANISM", 124, 132], ["patients", "ORGANISM", 252, 260], ["children", "SPECIES", 35, 43], ["children", "SPECIES", 124, 132], ["patients", "SPECIES", 252, 260], ["no", "UNCERTAINTY", 10, 12]]], ["The crude age-specific attack rate for children in Hong Kong was 8.9 per 100 000 persons <18 years of age.", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["persons", "SPECIES", 81, 88]]], ["Serologic confirmation of SARS was documented in 89 children (6.6 per 100 000 persons <18 years of age).", [["SARS", "DISEASE", 26, 30], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["persons", "SPECIES", 78, 85], ["Serologic confirmation", "TEST", 0, 22], ["SARS", "PROBLEM", 26, 30]]], ["Sixty-four children with clinical disease and seroconversion to SARS-CoV were managed in the authors' hospitals.", [["SARS", "DISEASE", 64, 68], ["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19], ["SARS-CoV", "SPECIES", 64, 72], ["clinical disease", "PROBLEM", 25, 41], ["seroconversion", "TREATMENT", 46, 60], ["CoV", "PROBLEM", 69, 72]]], ["The experience with this cohort of laboratory-confirmed patients forms the basis of the clinical information presented in this review.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["22, 23CLINICAL PICTURE Demographic characteristicsMost children reported worldwide were previously healthy and there was no sex predominance.", [["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["no", "UNCERTAINTY", 121, 123]]], ["Thirty-five (55%) of the 64 children managed by the authors were girls.", [["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36], ["girls", "SPECIES", 65, 70]]], ["The male to female ratio was 1:1.2.", [["female ratio", "TEST", 12, 24]]], ["The youngest patient was a 56-day-old premature infant, which is the youngest case reported to date.", [["patient", "ORGANISM", 13, 20], ["infant", "ORGANISM", 48, 54], ["patient", "SPECIES", 13, 20], ["infant", "SPECIES", 48, 54], ["premature infant", "PROBLEM", 38, 54]]], ["25 Comorbidity was only present in 5 children (8%) but none of them were immunocompromised.Epidemiologic linksAn epidemiologic link was available in the vast majority of children with SARS, which appeared to be the most important clue leading to diagnosis in an epidemic situation.", [["SARS", "DISEASE", 184, 188], ["children", "ORGANISM", 37, 45], ["children", "ORGANISM", 170, 178], ["children", "SPECIES", 37, 45], ["children", "SPECIES", 170, 178], ["immunocompromised", "PROBLEM", 73, 90], ["SARS", "PROBLEM", 184, 188], ["immunocompromised", "OBSERVATION", 73, 90]]], ["Worldwide, children were usually secondary household contacts of affected adults, some of whom were healthcare workers or international travellers returning from areas with local transmission of SARS.", [["SARS", "DISEASE", 195, 199], ["children", "ORGANISM", 11, 19], ["children", "SPECIES", 11, 19]]], ["Transmission among children or from children to adult contacts was uncommon.", [["children", "ORGANISM", 19, 27], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 19, 27], ["children", "SPECIES", 36, 44]]], ["About 60% of serologically confirmed children in Hong Kong were victims of a point source community outbreak due to environmental contamination.", [["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["environmental contamination", "PROBLEM", 116, 143]]], ["14 The actual proportion of children being secondary household contacts in the particular outbreak could not be determined given the short incubation period between exposure, either to a common environmental source or an index household member, and presentation.", [["children", "ORGANISM", 28, 36], ["children", "SPECIES", 28, 36]]], ["There is no published report on the differences in susceptibility and communicability between children and adults.", [["children", "ORGANISM", 94, 102], ["children", "SPECIES", 94, 102], ["no", "UNCERTAINTY", 9, 11]]], ["Any apparent difference might be related to different risks of exposure for the two age groups.Presenting features and clinical courseSARS is largely an atypical pneumonia with minimal or no extrapulmonary manifestation, apart from diarrhoea.", [["extrapulmonary", "ANATOMY", 191, 205], ["pneumonia", "DISEASE", 162, 171], ["diarrhoea", "DISEASE", 232, 241], ["Any apparent difference", "PROBLEM", 0, 23], ["an atypical pneumonia", "PROBLEM", 150, 171], ["extrapulmonary manifestation", "PROBLEM", 191, 219], ["diarrhoea", "PROBLEM", 232, 241], ["atypical", "OBSERVATION_MODIFIER", 153, 161], ["pneumonia", "OBSERVATION", 162, 171], ["minimal", "OBSERVATION_MODIFIER", 177, 184], ["no", "UNCERTAINTY", 188, 190], ["extrapulmonary", "ANATOMY", 191, 205], ["manifestation", "OBSERVATION", 206, 219], ["diarrhoea", "OBSERVATION", 232, 241]]], ["26 Cellular tropism of the SARS-CoV has been demonstrated primarily in pneumocytes and surface enterocytes of the small bowel.", [["pneumocytes", "ANATOMY", 71, 82], ["surface enterocytes", "ANATOMY", 87, 106], ["small bowel", "ANATOMY", 114, 125], ["SARS", "DISEASE", 27, 31], ["SARS-CoV", "ORGANISM", 27, 35], ["pneumocytes", "CELL", 71, 82], ["surface enterocytes", "CELLULAR_COMPONENT", 87, 106], ["bowel", "ORGAN", 120, 125], ["pneumocytes", "CELL_TYPE", 71, 82], ["SARS-CoV", "SPECIES", 27, 35], ["the SARS", "PROBLEM", 23, 31], ["CoV", "PROBLEM", 32, 35], ["Cellular tropism", "OBSERVATION", 3, 19], ["SARS", "OBSERVATION", 27, 31], ["pneumocytes", "OBSERVATION", 71, 82], ["surface enterocytes", "OBSERVATION", 87, 106], ["small bowel", "ANATOMY", 114, 125]]], ["27 The clinical presentation of SARS is nonspecific, with features overlapping those of atypical pneumonia caused by other respiratory pathogens such as influenza virus (including highly pathogenic avian influenza viruses), parainfluenza virus, adenovirus, respiratory syncytial virus (RSV), Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci and Legionella pneumophila.Presenting features and clinical courseThe clinical course of SARS in adult patients is well described and appears to follow a triphasic pattern.", [["SARS", "DISEASE", 32, 36], ["pneumonia", "DISEASE", 97, 106], ["influenza virus", "DISEASE", 153, 168], ["avian influenza viruses", "DISEASE", 198, 221], ["parainfluenza virus", "DISEASE", 224, 243], ["respiratory syncytial virus (RSV)", "DISEASE", 257, 290], ["Mycoplasma pneumoniae", "DISEASE", 292, 313], ["Chlamydia pneumoniae", "DISEASE", 315, 335], ["Chlamydia psittaci", "DISEASE", 337, 355], ["Legionella pneumophila", "DISEASE", 360, 382], ["SARS", "DISEASE", 445, 449], ["influenza virus", "ORGANISM", 153, 168], ["highly pathogenic", "ORGANISM", 180, 197], ["avian influenza viruses", "ORGANISM", 198, 221], ["parainfluenza virus", "ORGANISM", 224, 243], ["adenovirus,", "ORGANISM", 245, 256], ["respiratory syncytial virus", "ORGANISM", 257, 284], ["RSV", "ORGANISM", 286, 289], ["Mycoplasma pneumoniae", "ORGANISM", 292, 313], ["Chlamydia pneumoniae", "ORGANISM", 315, 335], ["Chlamydia psittaci", "ORGANISM", 337, 355], ["Legionella pneumophila", "ORGANISM", 360, 382], ["patients", "ORGANISM", 459, 467], ["influenza virus", "SPECIES", 153, 168], ["avian influenza viruses", "SPECIES", 198, 221], ["parainfluenza virus", "SPECIES", 224, 243], ["respiratory syncytial virus", "SPECIES", 257, 284], ["RSV", "SPECIES", 286, 289], ["Mycoplasma pneumoniae", "SPECIES", 292, 313], ["Chlamydia pneumoniae", "SPECIES", 315, 335], ["Chlamydia psittaci", "SPECIES", 337, 355], ["Legionella pneumophila", "SPECIES", 360, 382], ["patients", "SPECIES", 459, 467], ["influenza virus", "SPECIES", 153, 168], ["parainfluenza virus", "SPECIES", 224, 243], ["adenovirus", "SPECIES", 245, 255], ["respiratory syncytial virus", "SPECIES", 257, 284], ["RSV", "SPECIES", 286, 289], ["Mycoplasma pneumoniae", "SPECIES", 292, 313], ["Chlamydia pneumoniae", "SPECIES", 315, 335], ["Chlamydia psittaci", "SPECIES", 337, 355], ["Legionella pneumophila", "SPECIES", 360, 382], ["SARS", "PROBLEM", 32, 36], ["atypical pneumonia", "PROBLEM", 88, 106], ["other respiratory pathogens", "PROBLEM", 117, 144], ["influenza virus", "PROBLEM", 153, 168], ["highly pathogenic avian influenza viruses", "PROBLEM", 180, 221], ["parainfluenza virus", "PROBLEM", 224, 243], ["adenovirus", "PROBLEM", 245, 255], ["respiratory syncytial virus (RSV)", "PROBLEM", 257, 290], ["Mycoplasma pneumoniae", "PROBLEM", 292, 313], ["Chlamydia pneumoniae", "PROBLEM", 315, 335], ["Chlamydia psittaci", "PROBLEM", 337, 355], ["Legionella pneumophila", "PROBLEM", 360, 382], ["SARS", "PROBLEM", 445, 449], ["nonspecific", "OBSERVATION_MODIFIER", 40, 51], ["atypical", "OBSERVATION_MODIFIER", 88, 96], ["pneumonia", "OBSERVATION", 97, 106], ["respiratory pathogens", "OBSERVATION", 123, 144], ["influenza virus", "OBSERVATION", 153, 168], ["parainfluenza virus", "OBSERVATION", 224, 243], ["respiratory", "ANATOMY", 257, 268], ["syncytial virus", "OBSERVATION", 269, 284], ["Mycoplasma pneumoniae", "OBSERVATION", 292, 313], ["Chlamydia pneumoniae", "OBSERVATION", 315, 335], ["Chlamydia psittaci", "OBSERVATION", 337, 355], ["Legionella pneumophila", "OBSERVATION", 360, 382]]], ["6, [28] [29] [30] [31] [32] Following an incubation period of 2-10 days (mean 6.4 days, 95% CI 5.2 to 7.7), adults present with a prodrome characterised by high fever (temperature >38 8C), chills or rigor, malaise, headache, dizziness and myalgia.", [["fever", "DISEASE", 161, 166], ["chills", "DISEASE", 189, 195], ["headache", "DISEASE", 215, 223], ["dizziness", "DISEASE", 225, 234], ["myalgia", "DISEASE", 239, 246], ["[28] [29] [30] [31", "SIMPLE_CHEMICAL", 3, 21], ["CI", "TEST", 92, 94], ["a prodrome", "PROBLEM", 128, 138], ["high fever", "PROBLEM", 156, 166], ["temperature", "TEST", 168, 179], ["chills", "PROBLEM", 189, 195], ["rigor", "PROBLEM", 199, 204], ["malaise", "PROBLEM", 206, 213], ["headache", "PROBLEM", 215, 223], ["dizziness", "PROBLEM", 225, 234], ["myalgia", "PROBLEM", 239, 246], ["high", "OBSERVATION_MODIFIER", 156, 160], ["fever", "OBSERVATION", 161, 166], ["malaise", "OBSERVATION", 206, 213], ["myalgia", "OBSERVATION", 239, 246]]], ["Upper respiratory symptoms such as coryza and sore throat are mild and uncommon.", [["respiratory", "ANATOMY", 6, 17], ["sore throat", "ANATOMY", 46, 57], ["coryza", "DISEASE", 35, 41], ["sore throat", "DISEASE", 46, 57], ["throat", "ORGANISM_SUBDIVISION", 51, 57], ["Upper respiratory symptoms", "PROBLEM", 0, 26], ["coryza", "PROBLEM", 35, 41], ["sore throat", "PROBLEM", 46, 57], ["respiratory", "ANATOMY", 6, 17], ["symptoms", "OBSERVATION", 18, 26], ["sore throat", "ANATOMY", 46, 57], ["mild", "OBSERVATION_MODIFIER", 62, 66]]], ["Diarrhoea is a presenting feature in 6-20% of adult patients.", [["Diarrhoea", "DISEASE", 0, 9], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["Diarrhoea", "PROBLEM", 0, 9]]], ["6, 26, 30 After 2-7 days the disease progresses to involve the lower respiratory tract and a dry, non-productive cough or dyspnoea becomes prominent.", [["lower respiratory tract", "ANATOMY", 63, 86], ["cough", "DISEASE", 113, 118], ["dyspnoea", "DISEASE", 122, 130], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["the disease", "PROBLEM", 25, 36], ["the lower respiratory tract", "PROBLEM", 59, 86], ["a dry, non-productive cough", "PROBLEM", 91, 118], ["dyspnoea", "PROBLEM", 122, 130], ["disease", "OBSERVATION", 29, 36], ["lower", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86], ["non-productive", "OBSERVATION_MODIFIER", 98, 112], ["cough", "OBSERVATION", 113, 118], ["dyspnoea", "OBSERVATION", 122, 130], ["prominent", "OBSERVATION_MODIFIER", 139, 148]]], ["In 10-20% of cases, progression to acute respiratory distress syndrome (ARDS) necessitating intubation and assisted ventilation is observed.", [["respiratory", "ANATOMY", 41, 52], ["acute respiratory distress syndrome", "DISEASE", 35, 70], ["ARDS", "DISEASE", 72, 76], ["acute respiratory distress syndrome", "PROBLEM", 35, 70], ["ARDS", "PROBLEM", 72, 76], ["intubation", "TREATMENT", 92, 102], ["assisted ventilation", "TREATMENT", 107, 127], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory distress", "OBSERVATION", 41, 61], ["ARDS", "OBSERVATION", 72, 76]]], ["Mortality results primarily from respiratory failure and a significant proportion of patients recover from pulmonary destruction over an extended period.Presenting features and clinical courseSARS appears to run a less aggressive clinical course in children compared with adults.", [["respiratory", "ANATOMY", 33, 44], ["pulmonary", "ANATOMY", 107, 116], ["respiratory failure", "DISEASE", 33, 52], ["pulmonary destruction", "DISEASE", 107, 128], ["patients", "ORGANISM", 85, 93], ["pulmonary", "ORGAN", 107, 116], ["children", "ORGANISM", 249, 257], ["patients", "SPECIES", 85, 93], ["children", "SPECIES", 249, 257], ["respiratory failure", "PROBLEM", 33, 52], ["pulmonary destruction", "PROBLEM", 107, 128], ["respiratory failure", "OBSERVATION", 33, 52], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["pulmonary", "ANATOMY", 107, 116], ["destruction", "OBSERVATION", 117, 128]]], ["The severity of illness varies and the extent of asymptomatic infection is unknown, although it is believed to be uncommon.", [["illness", "DISEASE", 16, 23], ["infection", "DISEASE", 62, 71], ["illness varies", "PROBLEM", 16, 30], ["asymptomatic infection", "PROBLEM", 49, 71], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["illness", "OBSERVATION", 16, 23], ["asymptomatic", "OBSERVATION_MODIFIER", 49, 61], ["infection", "OBSERVATION", 62, 71], ["believed to be", "UNCERTAINTY", 99, 113], ["uncommon", "OBSERVATION", 114, 122]]], ["Children are usually hospitalised 3-4 days after the onset of symptoms.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 62, 70]]], ["In one paediatric case series, the mean duration of fever before admission was 3.7 AE 0.6 days (median 3, range 0-12).", [["fever", "DISEASE", 52, 57], ["fever", "PROBLEM", 52, 57]]], ["23 The most common presenting clinical features in children include fever, malaise, cough, coryza, chills or rigor, sputum production, headache and myalgia (Table 1) .", [["sputum", "ANATOMY", 116, 122], ["fever", "DISEASE", 68, 73], ["cough", "DISEASE", 84, 89], ["coryza", "DISEASE", 91, 97], ["chills", "DISEASE", 99, 105], ["sputum production", "DISEASE", 116, 133], ["headache", "DISEASE", 135, 143], ["myalgia", "DISEASE", 148, 155], ["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["fever", "PROBLEM", 68, 73], ["malaise", "PROBLEM", 75, 82], ["cough", "PROBLEM", 84, 89], ["coryza", "PROBLEM", 91, 97], ["chills", "PROBLEM", 99, 105], ["rigor", "PROBLEM", 109, 114], ["sputum production", "PROBLEM", 116, 133], ["headache", "PROBLEM", 135, 143], ["myalgia", "PROBLEM", 148, 155], ["most common", "OBSERVATION_MODIFIER", 7, 18], ["chills", "OBSERVATION", 99, 105]]], ["22, 23 Lethargy, poor feeding or anorexia, nausea, vomiting, diarrhoea, abdominal pain, sore throat, dyspnoea and dizziness are less commonly encountered.", [["abdominal", "ANATOMY", 72, 81], ["anorexia", "DISEASE", 33, 41], ["nausea", "DISEASE", 43, 49], ["vomiting", "DISEASE", 51, 59], ["diarrhoea", "DISEASE", 61, 70], ["abdominal pain", "DISEASE", 72, 86], ["sore throat", "DISEASE", 88, 99], ["dyspnoea", "DISEASE", 101, 109], ["dizziness", "DISEASE", 114, 123], ["abdominal", "ORGANISM_SUBDIVISION", 72, 81], ["Lethargy", "PROBLEM", 7, 15], ["poor feeding", "PROBLEM", 17, 29], ["anorexia", "PROBLEM", 33, 41], ["nausea", "PROBLEM", 43, 49], ["vomiting", "PROBLEM", 51, 59], ["diarrhoea", "PROBLEM", 61, 70], ["abdominal pain", "PROBLEM", 72, 86], ["sore throat", "PROBLEM", 88, 99], ["dyspnoea", "PROBLEM", 101, 109], ["dizziness", "PROBLEM", 114, 123], ["anorexia", "OBSERVATION", 33, 41], ["abdominal", "ANATOMY", 72, 81], ["pain", "OBSERVATION", 82, 86], ["sore throat", "ANATOMY", 88, 99], ["dyspnoea", "OBSERVATION", 101, 109], ["dizziness", "OBSERVATION", 114, 123]]], ["Less than 20% of children may pass loose to watery stools, but profuse diarrhoea is rare throughout the course of illness.", [["watery stools", "DISEASE", 44, 57], ["diarrhoea", "DISEASE", 71, 80], ["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25], ["loose to watery stools", "PROBLEM", 35, 57], ["profuse diarrhoea", "PROBLEM", 63, 80], ["illness", "PROBLEM", 114, 121], ["profuse", "OBSERVATION_MODIFIER", 63, 70], ["diarrhoea", "OBSERVATION", 71, 80]]], ["Blood and mucus in the stool, features suggestive of inflammatory enterocolitis, have not been reported.", [["Blood", "ANATOMY", 0, 5], ["mucus", "ANATOMY", 10, 15], ["stool", "ANATOMY", 23, 28], ["inflammatory enterocolitis", "DISEASE", 53, 79], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["mucus", "ORGANISM_SUBSTANCE", 10, 15], ["stool", "ORGANISM_SUBSTANCE", 23, 28], ["Blood and mucus in the stool", "TEST", 0, 28], ["inflammatory enterocolitis", "PROBLEM", 53, 79], ["mucus", "OBSERVATION", 10, 15], ["stool", "OBSERVATION", 23, 28], ["suggestive of", "UNCERTAINTY", 39, 52], ["inflammatory", "OBSERVATION_MODIFIER", 53, 65], ["enterocolitis", "OBSERVATION", 66, 79]]], ["Cough, predominantly unproductive in nature, is only found in just over half of the children at presentation.", [["Cough", "DISEASE", 0, 5], ["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["Cough", "PROBLEM", 0, 5], ["predominantly", "OBSERVATION_MODIFIER", 7, 20], ["unproductive", "OBSERVATION_MODIFIER", 21, 33]]], ["Definite physical signs of consolidation are hardly evident and crepitations (crackles) on chest auscultation are unusual despite prominent radiographic evidence of pulmonary infiltrates, even in patients who develop respiratory distress, hence the description of 'atypical' pneumonia.", [["chest", "ANATOMY", 91, 96], ["pulmonary", "ANATOMY", 165, 174], ["respiratory", "ANATOMY", 217, 228], ["pulmonary infiltrates", "DISEASE", 165, 186], ["respiratory distress", "DISEASE", 217, 237], ["pneumonia", "DISEASE", 275, 284], ["chest", "ORGAN", 91, 96], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 165, 186], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["consolidation", "PROBLEM", 27, 40], ["crepitations", "PROBLEM", 64, 76], ["crackles", "PROBLEM", 78, 86], ["chest auscultation", "TEST", 91, 109], ["pulmonary infiltrates", "PROBLEM", 165, 186], ["respiratory distress", "PROBLEM", 217, 237], ["'atypical' pneumonia", "PROBLEM", 264, 284], ["consolidation", "OBSERVATION", 27, 40], ["crackles", "OBSERVATION_MODIFIER", 78, 86], ["chest", "ANATOMY", 91, 96], ["prominent", "OBSERVATION_MODIFIER", 130, 139], ["evidence of", "UNCERTAINTY", 153, 164], ["pulmonary", "ANATOMY", 165, 174], ["infiltrates", "OBSERVATION", 175, 186], ["respiratory", "ANATOMY", 217, 228], ["distress", "OBSERVATION", 229, 237], ["atypical", "OBSERVATION_MODIFIER", 265, 273], ["pneumonia", "OBSERVATION", 275, 284]]], ["Lymphadenopathy, hepatosplenomegaly or clinical bleeding is absent.", [["Lymphadenopathy", "DISEASE", 0, 15], ["hepatosplenomegaly", "DISEASE", 17, 35], ["bleeding", "DISEASE", 48, 56], ["Lymphadenopathy", "PROBLEM", 0, 15], ["hepatosplenomegaly", "PROBLEM", 17, 35], ["clinical bleeding", "PROBLEM", 39, 56], ["hepatosplenomegaly", "OBSERVATION", 17, 35], ["bleeding", "OBSERVATION", 48, 56]]], ["Skin rash is an exceedingly rare manifestation.", [["Skin", "ANATOMY", 0, 4], ["Skin rash", "DISEASE", 0, 9], ["Skin", "ORGAN", 0, 4], ["Skin rash", "PROBLEM", 0, 9], ["rash", "OBSERVATION", 5, 9], ["exceedingly rare", "OBSERVATION_MODIFIER", 16, 32]]], ["22 Hypoxaemia is seldom noted at presentation and generally develops towards the end of the first week or the beginning of the second week of illness in severe cases.", [["Hypoxaemia", "DISEASE", 3, 13], ["illness", "DISEASE", 142, 149], ["Hypoxaemia", "PROBLEM", 3, 13], ["illness in severe cases", "PROBLEM", 142, 165], ["Hypoxaemia", "OBSERVATION", 3, 13]]], ["33 The youngest patient, however, presented with a cyanotic attack, dyspnoea, cough and hypothermia with subsequent development of fever.", [["cyanotic attack", "DISEASE", 51, 66], ["dyspnoea", "DISEASE", 68, 76], ["cough", "DISEASE", 78, 83], ["hypothermia", "DISEASE", 88, 99], ["fever", "DISEASE", 131, 136], ["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["a cyanotic attack", "PROBLEM", 49, 66], ["dyspnoea", "PROBLEM", 68, 76], ["cough", "PROBLEM", 78, 83], ["hypothermia", "PROBLEM", 88, 99], ["fever", "PROBLEM", 131, 136], ["cyanotic", "OBSERVATION", 51, 59], ["cough", "OBSERVATION", 78, 83], ["hypothermia", "OBSERVATION", 88, 99], ["fever", "OBSERVATION", 131, 136]]], ["25 Teenagers (aged >12 years) may resemble adults in presentation and disease progression.", [["disease progression", "PROBLEM", 70, 89]]], ["They tend to have more constitutional upsets and systemic symptoms of malaise, chills or rigor, headache, myalgia and dizziness are significantly more common ( Table 2) .", [["chills", "DISEASE", 79, 85], ["headache", "DISEASE", 96, 104], ["myalgia", "DISEASE", 106, 113], ["dizziness", "DISEASE", 118, 127], ["constitutional upsets", "PROBLEM", 23, 44], ["systemic symptoms", "PROBLEM", 49, 66], ["malaise", "PROBLEM", 70, 77], ["chills", "PROBLEM", 79, 85], ["rigor", "PROBLEM", 89, 94], ["headache", "PROBLEM", 96, 104], ["myalgia", "PROBLEM", 106, 113], ["dizziness", "PROBLEM", 118, 127], ["myalgia", "OBSERVATION", 106, 113]]], ["They appear sicker, have a greater need for oxygen therapy and other respiratory support and may require intensive care.", [["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["oxygen therapy", "TREATMENT", 44, 58], ["other respiratory support", "TREATMENT", 63, 88], ["intensive care", "TREATMENT", 105, 119], ["sicker", "OBSERVATION", 12, 18]]], ["33 Children 12 years of age generally have milder symptoms and coryza is significantly more common ( Table 2) .", [["coryza", "DISEASE", 63, 69], ["Children", "SPECIES", 3, 11], ["milder symptoms", "PROBLEM", 43, 58], ["coryza", "PROBLEM", 63, 69]]], ["They appear to run a milder and shorter clinical course.", [["a milder and shorter clinical course", "PROBLEM", 19, 55]]], ["The clinical picture is sometimes indistinguishable from other viral infections of the upper respiratory tract, thus posing a diagnostic challenge.Presenting features and clinical courseThe clinical course of SARS in the majority of children follows a biphasic pattern.", [["upper respiratory tract", "ANATOMY", 87, 110], ["viral infections of the upper respiratory tract", "DISEASE", 63, 110], ["SARS", "DISEASE", 209, 213], ["upper respiratory", "ORGANISM_SUBDIVISION", 87, 104], ["tract", "ORGANISM_SUBDIVISION", 105, 110], ["children", "ORGANISM", 233, 241], ["children", "SPECIES", 233, 241], ["other viral infections of the upper respiratory tract", "PROBLEM", 57, 110], ["a diagnostic challenge", "TEST", 124, 146], ["SARS", "PROBLEM", 209, 213], ["viral", "OBSERVATION_MODIFIER", 63, 68], ["infections", "OBSERVATION", 69, 79], ["upper", "ANATOMY_MODIFIER", 87, 92], ["respiratory tract", "ANATOMY", 93, 110]]], ["The phase of viral replication, which lasts for a few days, is characterised by an abrupt onset of fever and constitutional symptoms in association with an increase in body viral load.", [["body", "ANATOMY", 168, 172], ["fever", "DISEASE", 99, 104], ["body", "ORGANISM_SUBDIVISION", 168, 172], ["viral replication", "PROBLEM", 13, 30], ["fever", "PROBLEM", 99, 104], ["constitutional symptoms", "PROBLEM", 109, 132], ["an increase in body viral load", "PROBLEM", 153, 183], ["viral replication", "OBSERVATION", 13, 30], ["abrupt", "OBSERVATION_MODIFIER", 83, 89], ["fever", "OBSERVATION", 99, 104], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["body viral load", "OBSERVATION", 168, 183]]], ["34 The phase of immunopathologic damage is marked by the progression of pneumonia and hypoxaemia, when the body viral load declines and an exaggerated host immune response supervenes.", [["body", "ANATOMY", 107, 111], ["immunopathologic damage", "DISEASE", 16, 39], ["pneumonia", "DISEASE", 72, 81], ["hypoxaemia", "DISEASE", 86, 96], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["immunopathologic damage", "PROBLEM", 16, 39], ["pneumonia", "PROBLEM", 72, 81], ["hypoxaemia", "PROBLEM", 86, 96], ["the body viral load declines", "PROBLEM", 103, 131], ["an exaggerated host immune response supervenes", "PROBLEM", 136, 182], ["phase", "OBSERVATION_MODIFIER", 7, 12], ["immunopathologic", "OBSERVATION_MODIFIER", 16, 32], ["damage", "OBSERVATION", 33, 39], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["progression", "OBSERVATION_MODIFIER", 57, 68], ["pneumonia", "OBSERVATION", 72, 81], ["hypoxaemia", "OBSERVATION", 86, 96], ["exaggerated", "OBSERVATION_MODIFIER", 139, 150], ["host immune response", "OBSERVATION", 151, 171]]], ["35 The prodromal and pneumonic phases of the disease, however, may be less distinct in comparison with adult patients.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["The prodromal and pneumonic phases", "PROBLEM", 3, 37], ["the disease", "PROBLEM", 41, 52], ["prodromal", "OBSERVATION_MODIFIER", 7, 16], ["pneumonic", "OBSERVATION_MODIFIER", 21, 30], ["phases", "OBSERVATION_MODIFIER", 31, 37], ["disease", "OBSERVATION", 45, 52], ["may be", "UNCERTAINTY", 63, 69], ["less", "OBSERVATION_MODIFIER", 70, 74], ["distinct", "OBSERVATION_MODIFIER", 75, 83]]], ["Progression to ARDS, or the third phase as in adults, is only seen in a very small number of children, predominantly adolescents.", [["ARDS", "DISEASE", 15, 19], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["adolescents", "SPECIES", 117, 128], ["ARDS", "PROBLEM", 15, 19], ["ARDS", "OBSERVATION", 15, 19], ["small", "OBSERVATION_MODIFIER", 77, 82]]], ["The natural history of untreated SARS in both adults and children remains unclear.", [["SARS", "DISEASE", 33, 37], ["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65], ["untreated SARS", "PROBLEM", 23, 37]]], ["As most patients worldwide had received some form of empiric treatment in the form of antiviral agents with or without corticosteroids, the probability of spontaneous recovery could not be ascertained.", [["corticosteroids", "CHEMICAL", 119, 134], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["empiric treatment", "TREATMENT", 53, 70], ["antiviral agents", "TREATMENT", 86, 102], ["corticosteroids", "TREATMENT", 119, 134]]], ["Nevertheless, three children with mild disease had recovered on supportive therapy alone in the authors' cohort.", [["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["mild disease", "PROBLEM", 34, 46], ["supportive therapy", "TREATMENT", 64, 82], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["disease", "OBSERVATION", 39, 46]]], ["22, 23 Anecdotal reports of extrapulmonary manifestations of SARS, in the form of central nervous system dysfunction and probable viral hepatitis, have been described in adults.", [["extrapulmonary", "ANATOMY", 28, 42], ["central nervous system", "ANATOMY", 82, 104], ["SARS", "DISEASE", 61, 65], ["central nervous system dysfunction", "DISEASE", 82, 116], ["viral hepatitis", "DISEASE", 130, 145], ["central nervous system", "ANATOMICAL_SYSTEM", 82, 104], ["extrapulmonary manifestations", "PROBLEM", 28, 57], ["SARS", "PROBLEM", 61, 65], ["central nervous system dysfunction", "PROBLEM", 82, 116], ["viral hepatitis", "PROBLEM", 130, 145], ["extrapulmonary", "ANATOMY", 28, 42], ["SARS", "OBSERVATION", 61, 65], ["central", "ANATOMY_MODIFIER", 82, 89], ["nervous system", "ANATOMY", 90, 104], ["dysfunction", "OBSERVATION", 105, 116], ["probable", "UNCERTAINTY", 121, 129], ["viral hepatitis", "OBSERVATION", 130, 145]]], ["[36] [37] [38] Atypical presentation of SARS, in the form of non-specific febrile illness or febrile non-pneumonic respiratory illness, have been observed in both children and adults.", [["respiratory", "ANATOMY", 115, 126], ["SARS", "DISEASE", 40, 44], ["febrile illness", "DISEASE", 74, 89], ["respiratory illness", "DISEASE", 115, 134], ["children", "ORGANISM", 163, 171], ["children", "SPECIES", 163, 171], ["SARS", "PROBLEM", 40, 44], ["non-specific febrile illness", "PROBLEM", 61, 89], ["febrile non-pneumonic respiratory illness", "PROBLEM", 93, 134], ["non-specific", "OBSERVATION_MODIFIER", 61, 73], ["respiratory illness", "OBSERVATION", 115, 134]]], ["23, 39, 40 Such cases are likely to evade clinical detection in the absence of a definite contact history with patients with suspected or confirmed SARS.", [["SARS", "DISEASE", 148, 152], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["SARS", "PROBLEM", 148, 152]]], ["The full spectrum of clinical as well as subclinical illnesses caused by infection with SARS-CoV will unfold with further epidemiological studies and case reports.Radiologic featuresAs SARS is basically a pneumonic infection, chest radiograph (CXR) is therefore an essential diagnostic tool.", [["infection", "DISEASE", 73, 82], ["SARS", "DISEASE", 88, 92], ["SARS", "DISEASE", 185, 189], ["infection", "DISEASE", 215, 224], ["SARS-CoV", "ORGANISM", 88, 96], ["SARS-CoV", "SPECIES", 88, 96], ["subclinical illnesses", "PROBLEM", 41, 62], ["infection", "PROBLEM", 73, 82], ["SARS", "PROBLEM", 88, 92], ["further epidemiological studies", "TEST", 114, 145], ["Radiologic featuresAs SARS", "PROBLEM", 163, 189], ["a pneumonic infection", "PROBLEM", 203, 224], ["chest radiograph", "TEST", 226, 242], ["CXR", "TEST", 244, 247], ["infection", "OBSERVATION", 73, 82], ["pneumonic", "OBSERVATION_MODIFIER", 205, 214], ["infection", "OBSERVATION", 215, 224], ["chest", "ANATOMY", 226, 231]]], ["The principal radiographic abnormality of SARS in children is illdefined airspace shadowing, which presents as ground-glass opacities and/or unifocal, lobar or multifocal areas of consolidation.", [["lobar", "ANATOMY", 151, 156], ["SARS", "DISEASE", 42, 46], ["children", "ORGANISM", 50, 58], ["airspace", "MULTI-TISSUE_STRUCTURE", 73, 81], ["children", "SPECIES", 50, 58], ["The principal radiographic abnormality of SARS", "PROBLEM", 0, 46], ["illdefined airspace shadowing", "PROBLEM", 62, 91], ["ground-glass opacities", "PROBLEM", 111, 133], ["unifocal, lobar or multifocal areas of consolidation", "PROBLEM", 141, 193], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["radiographic", "OBSERVATION_MODIFIER", 14, 26], ["abnormality", "OBSERVATION", 27, 38], ["SARS", "OBSERVATION_MODIFIER", 42, 46], ["illdefined", "OBSERVATION_MODIFIER", 62, 72], ["airspace", "OBSERVATION_MODIFIER", 73, 81], ["shadowing", "OBSERVATION", 82, 91], ["ground", "OBSERVATION_MODIFIER", 111, 117], ["glass opacities", "OBSERVATION", 118, 133], ["unifocal", "OBSERVATION_MODIFIER", 141, 149], ["lobar", "OBSERVATION_MODIFIER", 151, 156], ["multifocal", "OBSERVATION_MODIFIER", 160, 170], ["areas", "OBSERVATION_MODIFIER", 171, 176], ["consolidation", "OBSERVATION", 180, 193]]], ["[21] [22] [23] [24] 41, 42 Unilateral focal opacity was reported as the most common finding in one paediatric case series and was evident in 86% of children at presentation (Fig. 1 ).", [["focal opacity", "DISEASE", 38, 51], ["[21] [22] [23] [24] 41", "SIMPLE_CHEMICAL", 0, 22], ["children", "ORGANISM", 148, 156], ["children", "SPECIES", 148, 156], ["Unilateral focal opacity", "PROBLEM", 27, 51], ["Unilateral", "OBSERVATION_MODIFIER", 27, 37], ["focal", "OBSERVATION_MODIFIER", 38, 43], ["opacity", "OBSERVATION", 44, 51], ["most common", "OBSERVATION_MODIFIER", 72, 83]]], ["22 In adults, regions of airspace disease predominate in the lower lobes but are also noted elsewhere.", [["airspace", "ANATOMY", 25, 33], ["lower lobes", "ANATOMY", 61, 72], ["airspace disease", "DISEASE", 25, 41], ["airspace", "MULTI-TISSUE_STRUCTURE", 25, 33], ["lower lobes", "ORGAN", 61, 72], ["airspace disease", "PROBLEM", 25, 41], ["regions", "OBSERVATION_MODIFIER", 14, 21], ["airspace", "ANATOMY_MODIFIER", 25, 33], ["disease", "OBSERVATION", 34, 41], ["lower lobes", "ANATOMY", 61, 72]]], ["6 There appears to be no predominant distribution pattern of consolidation in children.", [["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["consolidation", "PROBLEM", 61, 74], ["appears to be no", "UNCERTAINTY", 8, 24], ["predominant", "OBSERVATION_MODIFIER", 25, 36], ["distribution", "OBSERVATION_MODIFIER", 37, 49], ["pattern", "OBSERVATION_MODIFIER", 50, 57], ["consolidation", "OBSERVATION", 61, 74]]], ["[21] [22] [23] CXR opacities are most often peripheral or mixed central and peripheral in location.", [["[21] [22] [23] CXR", "SIMPLE_CHEMICAL", 0, 18], ["CXR opacities", "PROBLEM", 15, 28], ["opacities", "OBSERVATION", 19, 28], ["mixed", "OBSERVATION_MODIFIER", 58, 63], ["central", "OBSERVATION_MODIFIER", 64, 71], ["peripheral", "ANATOMY_MODIFIER", 76, 86]]], ["The lung opacities show a tendency to progress, with increase in size or involvement of multiple areas either unilaterally or bilaterally in moderate to severe cases.", [["lung opacities", "ANATOMY", 4, 18], ["lung opacities", "DISEASE", 4, 18], ["lung", "ORGAN", 4, 8], ["The lung opacities", "PROBLEM", 0, 18], ["moderate to severe cases", "PROBLEM", 141, 165], ["lung", "ANATOMY", 4, 8], ["opacities", "OBSERVATION", 9, 18], ["tendency", "OBSERVATION_MODIFIER", 26, 34], ["increase", "OBSERVATION_MODIFIER", 53, 61], ["size", "OBSERVATION_MODIFIER", 65, 69], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["areas", "OBSERVATION_MODIFIER", 97, 102], ["unilaterally", "ANATOMY_MODIFIER", 110, 122], ["bilaterally", "ANATOMY_MODIFIER", 126, 137], ["moderate", "OBSERVATION_MODIFIER", 141, 149], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["cases", "OBSERVATION", 160, 165]]], ["Rapid progression to unilateral multifocal or bilateral involvement, with reduction in lung volumes in the second week of illness, is typical in children who develop severe hypoxaemia (Fig. 2) .", [["lung", "ANATOMY", 87, 91], ["illness", "DISEASE", 122, 129], ["hypoxaemia", "DISEASE", 173, 183], ["lung", "ORGAN", 87, 91], ["children", "ORGANISM", 145, 153], ["children", "SPECIES", 145, 153], ["unilateral multifocal or bilateral involvement", "PROBLEM", 21, 67], ["reduction in lung volumes", "PROBLEM", 74, 99], ["illness", "PROBLEM", 122, 129], ["severe hypoxaemia (Fig", "PROBLEM", 166, 188], ["unilateral", "OBSERVATION_MODIFIER", 21, 31], ["multifocal", "OBSERVATION_MODIFIER", 32, 42], ["bilateral", "ANATOMY_MODIFIER", 46, 55], ["involvement", "OBSERVATION", 56, 67], ["reduction", "OBSERVATION_MODIFIER", 74, 83], ["lung", "ANATOMY", 87, 91], ["volumes", "OBSERVATION", 92, 99], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["hypoxaemia", "OBSERVATION", 173, 183]]], ["23 In the advanced stage of the disease, which only occurs in a very small number of children, widespread ground-glass opacities and diffuse patchy consolidations are seen, likely representing progression to ARDS.Radiologic featuresPneumonic changes may not be apparent at presentation as mildly symptomatic individuals may be identified early in the prodromal period through contact tracing of patients diagnosed with SARS.", [["ARDS", "DISEASE", 208, 212], ["SARS", "DISEASE", 419, 423], ["children", "ORGANISM", 85, 93], ["patients", "ORGANISM", 395, 403], ["children", "SPECIES", 85, 93], ["patients", "SPECIES", 395, 403], ["the disease", "PROBLEM", 28, 39], ["widespread ground-glass opacities", "PROBLEM", 95, 128], ["diffuse patchy consolidations", "PROBLEM", 133, 162], ["ARDS", "PROBLEM", 208, 212], ["Radiologic features", "TEST", 213, 232], ["Pneumonic changes", "PROBLEM", 232, 249], ["mildly symptomatic individuals", "PROBLEM", 289, 319], ["contact tracing", "TEST", 376, 391], ["SARS", "PROBLEM", 419, 423], ["advanced stage", "OBSERVATION_MODIFIER", 10, 24], ["disease", "OBSERVATION", 32, 39], ["very", "OBSERVATION_MODIFIER", 64, 68], ["small", "OBSERVATION_MODIFIER", 69, 74], ["number", "OBSERVATION_MODIFIER", 75, 81], ["widespread", "OBSERVATION_MODIFIER", 95, 105], ["ground-glass opacities", "OBSERVATION", 106, 128], ["diffuse", "OBSERVATION_MODIFIER", 133, 140], ["patchy", "OBSERVATION_MODIFIER", 141, 147], ["consolidations", "OBSERVATION", 148, 162], ["likely representing", "UNCERTAINTY", 173, 192], ["progression", "OBSERVATION_MODIFIER", 193, 204], ["ARDS", "OBSERVATION", 208, 212], ["may not be apparent", "UNCERTAINTY", 250, 269], ["mildly", "OBSERVATION_MODIFIER", 289, 295], ["symptomatic", "OBSERVATION", 296, 307], ["may be", "UNCERTAINTY", 320, 326]]], ["Repeat CXR examination, as guided by failure of resolution of symptoms or change in clinical condition, will clarify the picture by revealing new pulmonary infiltrates as the disease progresses.", [["pulmonary", "ANATOMY", 146, 155], ["pulmonary", "ORGAN", 146, 155], ["Repeat CXR examination", "TEST", 0, 22], ["symptoms", "PROBLEM", 62, 70], ["change in clinical condition", "PROBLEM", 74, 102], ["new pulmonary infiltrates", "PROBLEM", 142, 167], ["the disease progresses", "PROBLEM", 171, 193], ["change", "OBSERVATION_MODIFIER", 74, 80], ["new", "OBSERVATION_MODIFIER", 142, 145], ["pulmonary", "ANATOMY", 146, 155], ["infiltrates", "OBSERVATION", 156, 167], ["disease", "OBSERVATION", 175, 182]]], ["Frequent monitoring of CXR changes has the additional benefit of detecting early radiographic deterioration in many patients, heralding clinical deterioration.", [["patients", "ORGANISM", 116, 124], ["CXR", "PROTEIN", 23, 26], ["patients", "SPECIES", 116, 124], ["Frequent monitoring of CXR changes", "TEST", 0, 34], ["early radiographic deterioration", "PROBLEM", 75, 107], ["heralding clinical deterioration", "PROBLEM", 126, 158]]], ["Radiographic resolution, on the other hand, generally lags behind clinical improvement.", [["Radiographic resolution", "TEST", 0, 23], ["resolution", "OBSERVATION_MODIFIER", 13, 23]]], ["Complete resolution of the airspace opacities can take more than a month in the most severely affected children.", [["airspace opacities", "ANATOMY", 27, 45], ["opacities", "DISEASE", 36, 45], ["airspace", "PATHOLOGICAL_FORMATION", 27, 35], ["children", "ORGANISM", 103, 111], ["children", "SPECIES", 103, 111], ["the airspace opacities", "PROBLEM", 23, 45], ["resolution", "OBSERVATION_MODIFIER", 9, 19], ["airspace", "ANATOMY_MODIFIER", 27, 35], ["opacities", "OBSERVATION", 36, 45]]], ["23 No preliminary evidence of pulmonary fibrosis, bronchial wall thickening, bronchiectasis or lung volume loss was observed on follow-up in one paediatric case series.", [["pulmonary", "ANATOMY", 30, 39], ["bronchial wall", "ANATOMY", 50, 64], ["lung", "ANATOMY", 95, 99], ["pulmonary fibrosis", "DISEASE", 30, 48], ["bronchiectasis", "DISEASE", 77, 91], ["lung volume loss", "DISEASE", 95, 111], ["pulmonary", "ORGAN", 30, 39], ["bronchial wall", "MULTI-TISSUE_STRUCTURE", 50, 64], ["lung", "ORGAN", 95, 99], ["pulmonary fibrosis", "PROBLEM", 30, 48], ["bronchial wall thickening", "PROBLEM", 50, 75], ["bronchiectasis", "PROBLEM", 77, 91], ["lung volume loss", "PROBLEM", 95, 111], ["No preliminary evidence of", "UNCERTAINTY", 3, 29], ["pulmonary", "ANATOMY", 30, 39], ["fibrosis", "OBSERVATION", 40, 48], ["bronchial", "ANATOMY", 50, 59], ["wall", "ANATOMY_MODIFIER", 60, 64], ["thickening", "OBSERVATION", 65, 75], ["bronchiectasis", "OBSERVATION", 77, 91], ["lung", "ANATOMY", 95, 99], ["volume loss", "OBSERVATION", 100, 111]]], ["23 Viral pneumonias tend to show reticulo-nodularity as well as a symmetrical perihilar peribronchial pattern of infiltration which is sometimes marked by hilar adenopathy.", [["hilar adenopathy", "ANATOMY", 155, 171], ["Viral pneumonias", "DISEASE", 3, 19], ["reticulo-nodularity", "DISEASE", 33, 52], ["adenopathy", "DISEASE", 161, 171], ["hilar adenopathy", "CANCER", 155, 171], ["Viral pneumonias", "PROBLEM", 3, 19], ["reticulo-nodularity", "PROBLEM", 33, 52], ["a symmetrical perihilar peribronchial pattern of infiltration", "PROBLEM", 64, 125], ["hilar adenopathy", "PROBLEM", 155, 171], ["pneumonias", "OBSERVATION", 9, 19], ["reticulo", "OBSERVATION_MODIFIER", 33, 41], ["nodularity", "OBSERVATION", 42, 52], ["symmetrical", "OBSERVATION_MODIFIER", 66, 77], ["perihilar", "ANATOMY_MODIFIER", 78, 87], ["peribronchial", "ANATOMY_MODIFIER", 88, 101], ["infiltration", "OBSERVATION", 113, 125], ["marked", "OBSERVATION_MODIFIER", 145, 151], ["hilar", "ANATOMY", 155, 160], ["adenopathy", "OBSERVATION", 161, 171]]], ["43 In contrast to pneumonias caused by other respiratory pathogens, the CXR of children with SARS shows no evidence of interstitial disease, hilar adenopathy, mediastinal widening, significant pleural effusion, cavitation, abscess formation, pneumatocele, pneumothorax or pneumomediastinum.", [["interstitial", "ANATOMY", 119, 131], ["hilar adenopathy", "ANATOMY", 141, 157], ["mediastinal", "ANATOMY", 159, 170], ["pleural", "ANATOMY", 193, 200], ["abscess", "ANATOMY", 223, 230], ["pneumatocele", "ANATOMY", 242, 254], ["pneumonias", "DISEASE", 18, 28], ["SARS", "DISEASE", 93, 97], ["interstitial disease", "DISEASE", 119, 139], ["adenopathy", "DISEASE", 147, 157], ["pleural effusion", "DISEASE", 193, 209], ["cavitation", "DISEASE", 211, 221], ["abscess", "DISEASE", 223, 230], ["pneumatocele", "DISEASE", 242, 254], ["pneumothorax", "DISEASE", 256, 268], ["pneumomediastinum", "DISEASE", 272, 289], ["children", "ORGANISM", 79, 87], ["hilar adenopathy", "PATHOLOGICAL_FORMATION", 141, 157], ["pleural", "PATHOLOGICAL_FORMATION", 193, 200], ["abscess", "PATHOLOGICAL_FORMATION", 223, 230], ["children", "SPECIES", 79, 87], ["pneumonias", "PROBLEM", 18, 28], ["other respiratory pathogens", "PROBLEM", 39, 66], ["the CXR", "TEST", 68, 75], ["SARS", "PROBLEM", 93, 97], ["interstitial disease", "PROBLEM", 119, 139], ["hilar adenopathy", "PROBLEM", 141, 157], ["mediastinal widening", "PROBLEM", 159, 179], ["significant pleural effusion", "PROBLEM", 181, 209], ["cavitation", "PROBLEM", 211, 221], ["abscess formation", "PROBLEM", 223, 240], ["pneumatocele", "PROBLEM", 242, 254], ["pneumothorax", "PROBLEM", 256, 268], ["pneumomediastinum", "PROBLEM", 272, 289], ["pneumonias", "OBSERVATION", 18, 28], ["respiratory pathogens", "OBSERVATION", 45, 66], ["no evidence of", "UNCERTAINTY", 104, 118], ["interstitial", "ANATOMY_MODIFIER", 119, 131], ["disease", "OBSERVATION", 132, 139], ["hilar", "ANATOMY", 141, 146], ["adenopathy", "OBSERVATION", 147, 157], ["mediastinal", "ANATOMY", 159, 170], ["widening", "OBSERVATION", 171, 179], ["significant", "OBSERVATION_MODIFIER", 181, 192], ["pleural", "ANATOMY", 193, 200], ["effusion", "OBSERVATION", 201, 209], ["cavitation", "OBSERVATION_MODIFIER", 211, 221], ["abscess", "OBSERVATION", 223, 230], ["pneumatocele", "OBSERVATION", 242, 254], ["pneumothorax", "OBSERVATION", 256, 268], ["pneumomediastinum", "OBSERVATION", 272, 289]]], ["[21] [22] [23] [24] 41, 42 Nevertheless, the radiographic features of SARS in children are non-specific.", [["SARS", "DISEASE", 70, 74], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["SARS", "PROBLEM", 70, 74], ["non-specific", "OBSERVATION_MODIFIER", 91, 103]]], ["Radiological differentiation of SARS from other commonly encountered childhood respiratory illnesses causing airspace disease can be difficult.", [["respiratory", "ANATOMY", 79, 90], ["airspace", "ANATOMY", 109, 117], ["SARS", "DISEASE", 32, 36], ["respiratory illnesses", "DISEASE", 79, 100], ["airspace disease", "DISEASE", 109, 125], ["airspace", "MULTI-TISSUE_STRUCTURE", 109, 117], ["SARS", "PROBLEM", 32, 36], ["childhood respiratory illnesses", "PROBLEM", 69, 100], ["airspace disease", "PROBLEM", 109, 125], ["SARS", "OBSERVATION", 32, 36], ["respiratory illnesses", "OBSERVATION", 79, 100], ["airspace disease", "OBSERVATION", 109, 125]]], ["41 High-resolution computed tomography (HRCT) of the chest has been used as an early diagnostic tool in clinically suspected children with initial negative or equivocal chest radiographs.", [["chest", "ANATOMY", 53, 58], ["chest", "ANATOMY", 169, 174], ["chest", "ORGAN", 53, 58], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 125, 133], ["High-resolution computed tomography (HRCT) of the chest", "TEST", 3, 58], ["equivocal chest radiographs", "TEST", 159, 186], ["chest", "ANATOMY", 53, 58], ["chest", "ANATOMY", 169, 174]]], ["[21] [22] [23] [24] 41 HRCT findings may include groundglass opacification, unifocal or multifocal consolidation in subpleural, peripheral or central regions and interlobular septal and intralobular interstitial thickening (Fig. 3) .", [["subpleural", "ANATOMY", 116, 126], ["central regions", "ANATOMY", 142, 157], ["interlobular septal", "ANATOMY", 162, 181], ["intralobular interstitial", "ANATOMY", 186, 211], ["[21] [22] [23] [24] 41", "SIMPLE_CHEMICAL", 0, 22], ["subpleural", "MULTI-TISSUE_STRUCTURE", 116, 126], ["interlobular septal", "TISSUE", 162, 181], ["intralobular interstitial", "TISSUE", 186, 211], ["HRCT findings", "TEST", 23, 36], ["groundglass opacification", "PROBLEM", 49, 74], ["multifocal consolidation in subpleural, peripheral or central regions", "PROBLEM", 88, 157], ["interlobular septal and intralobular interstitial thickening", "PROBLEM", 162, 222], ["may include", "UNCERTAINTY", 37, 48], ["groundglass opacification", "OBSERVATION", 49, 74], ["unifocal", "OBSERVATION_MODIFIER", 76, 84], ["multifocal", "OBSERVATION_MODIFIER", 88, 98], ["consolidation", "OBSERVATION", 99, 112], ["subpleural", "ANATOMY_MODIFIER", 116, 126], ["peripheral", "ANATOMY_MODIFIER", 128, 138], ["central", "ANATOMY_MODIFIER", 142, 149], ["regions", "ANATOMY_MODIFIER", 150, 157], ["interlobular", "ANATOMY_MODIFIER", 162, 174], ["septal", "ANATOMY_MODIFIER", 175, 181], ["intralobular", "ANATOMY_MODIFIER", 186, 198], ["interstitial", "ANATOMY_MODIFIER", 199, 211], ["thickening", "OBSERVATION", 212, 222]]], ["The characteristic peripheral alveolar opacities are reminiscent of bronchiolitis obliterans-organising pneumonia (BOOP).", [["peripheral alveolar opacities", "ANATOMY", 19, 48], ["peripheral alveolar opacities", "DISEASE", 19, 48], ["bronchiolitis obliterans", "DISEASE", 68, 92], ["pneumonia", "DISEASE", 104, 113], ["BOOP", "DISEASE", 115, 119], ["peripheral alveolar", "MULTI-TISSUE_STRUCTURE", 19, 38], ["The characteristic peripheral alveolar opacities", "PROBLEM", 0, 48], ["bronchiolitis obliterans", "PROBLEM", 68, 92], ["organising pneumonia", "PROBLEM", 93, 113], ["BOOP", "PROBLEM", 115, 119], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["alveolar", "ANATOMY_MODIFIER", 30, 38], ["opacities", "OBSERVATION", 39, 48], ["reminiscent of", "UNCERTAINTY", 53, 67], ["bronchiolitis obliterans", "OBSERVATION", 68, 92], ["pneumonia", "OBSERVATION", 104, 113], ["BOOP", "OBSERVATION", 115, 119]]], ["6, 21, 44 In general, HRCT is sensitive in detecting more extensive airspace consolidation and ground-glass attenuation than CXR.", [["airspace", "ANATOMY", 68, 76], ["airspace", "MULTI-TISSUE_STRUCTURE", 68, 76], ["CXR", "PROTEIN", 125, 128], ["HRCT", "TEST", 22, 26], ["more extensive airspace consolidation", "PROBLEM", 53, 90], ["ground-glass attenuation", "PROBLEM", 95, 119], ["CXR", "TEST", 125, 128], ["extensive", "OBSERVATION_MODIFIER", 58, 67], ["airspace", "OBSERVATION_MODIFIER", 68, 76], ["consolidation", "OBSERVATION", 77, 90], ["ground", "OBSERVATION_MODIFIER", 95, 101], ["glass attenuation", "OBSERVATION", 102, 119]]], ["The investigation is particularly useful when lung parenchymal abnormalities are minimal early in the course of illness, or being obscured by the diaphragm and the cardiac silhouette.", [["lung parenchymal", "ANATOMY", 46, 62], ["diaphragm", "ANATOMY", 146, 155], ["cardiac", "ANATOMY", 164, 171], ["lung parenchymal abnormalities", "DISEASE", 46, 76], ["illness", "DISEASE", 112, 119], ["lung parenchymal", "MULTI-TISSUE_STRUCTURE", 46, 62], ["diaphragm", "ORGAN", 146, 155], ["cardiac", "ORGAN", 164, 171], ["The investigation", "TEST", 0, 17], ["lung parenchymal abnormalities", "PROBLEM", 46, 76], ["illness", "PROBLEM", 112, 119], ["lung", "ANATOMY", 46, 50], ["parenchymal", "ANATOMY_MODIFIER", 51, 62], ["abnormalities", "OBSERVATION", 63, 76], ["minimal", "OBSERVATION_MODIFIER", 81, 88], ["early", "OBSERVATION_MODIFIER", 89, 94], ["illness", "OBSERVATION", 112, 119], ["diaphragm", "ANATOMY", 146, 155], ["cardiac", "ANATOMY", 164, 171], ["silhouette", "ANATOMY_MODIFIER", 172, 182]]], ["The utility of chest HRCT lies in the early confirmation of airspace disease in radiographically inapparent cases with a strong contact history and clinical features highly suspicious of SARS, thus allowing prompt isolation and monitoring for clinical and radiological deterioration.Laboratory featuresThe haematological and biochemical abnormalities of SARS in children are neither diagnostic nor specific.", [["airspace", "ANATOMY", 60, 68], ["airspace disease", "DISEASE", 60, 76], ["SARS", "DISEASE", 187, 191], ["SARS", "DISEASE", 354, 358], ["chest", "ORGAN", 15, 20], ["airspace", "MULTI-TISSUE_STRUCTURE", 60, 68], ["children", "ORGANISM", 362, 370], ["children", "SPECIES", 362, 370], ["chest HRCT", "TEST", 15, 25], ["airspace disease", "PROBLEM", 60, 76], ["SARS", "PROBLEM", 187, 191], ["prompt isolation", "TEST", 207, 223], ["monitoring", "TEST", 228, 238], ["clinical and radiological deterioration", "PROBLEM", 243, 282], ["Laboratory features", "TEST", 283, 302], ["The haematological and biochemical abnormalities of SARS", "PROBLEM", 302, 358], ["chest", "ANATOMY", 15, 20], ["airspace disease", "OBSERVATION", 60, 76]]], ["Like adults, the most consistent haematological finding is lymphopaenia, which is present in about 70% of children at presentation and about 90% during the course of illness.", [["lymphopaenia", "DISEASE", 59, 71], ["illness", "DISEASE", 166, 173], ["lymphopaenia", "CANCER", 59, 71], ["children", "ORGANISM", 106, 114], ["children", "SPECIES", 106, 114], ["lymphopaenia", "PROBLEM", 59, 71], ["illness", "PROBLEM", 166, 173], ["lymphopaenia", "OBSERVATION", 59, 71]]], ["22, 23 Depletion of lymphocytes may be secondary to the direct cytopathic effect of the virus, cytokine-mediated apoptosis, lymphocyte margination due to increased cortisol secretion from activation of the hypothalamic-pituitary-adrenal axis or the administration of high-dose glucocorticoids, which have a profound lympholytic effect, especially on T lymphocytes.", [["lymphocytes", "ANATOMY", 20, 31], ["lymphocyte", "ANATOMY", 124, 134], ["T lymphocytes", "ANATOMY", 350, 363], ["cortisol", "CHEMICAL", 164, 172], ["glucocorticoids", "CHEMICAL", 277, 292], ["cortisol", "CHEMICAL", 164, 172], ["lymphocytes", "CELL", 20, 31], ["lymphocyte", "CELL", 124, 134], ["cortisol", "SIMPLE_CHEMICAL", 164, 172], ["pituitary", "ORGAN", 219, 228], ["adrenal", "ORGAN", 229, 236], ["glucocorticoids", "SIMPLE_CHEMICAL", 277, 292], ["T lymphocytes", "CELL", 350, 363], ["lymphocytes", "CELL_TYPE", 20, 31], ["cytokine", "PROTEIN", 95, 103], ["T lymphocytes", "CELL_TYPE", 350, 363], ["lymphocytes", "TREATMENT", 20, 31], ["the direct cytopathic effect", "PROBLEM", 52, 80], ["the virus", "PROBLEM", 84, 93], ["cytokine-mediated apoptosis", "PROBLEM", 95, 122], ["lymphocyte margination", "PROBLEM", 124, 146], ["increased cortisol secretion", "PROBLEM", 154, 182], ["the hypothalamic-pituitary-adrenal axis", "PROBLEM", 202, 241], ["high-dose glucocorticoids", "TREATMENT", 267, 292], ["a profound lympholytic effect", "PROBLEM", 305, 334], ["lymphocyte margination", "OBSERVATION", 124, 146], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["cortisol secretion", "OBSERVATION", 164, 182], ["pituitary", "ANATOMY", 219, 228], ["adrenal axis", "ANATOMY", 229, 241], ["profound", "OBSERVATION_MODIFIER", 307, 315], ["lympholytic effect", "OBSERVATION", 316, 334]]], ["[45] [46] [47] Other haematological abnormalities such as leucopaenia, thrombocytopaenia and mildly prolonged activated partial thromboplastin times are observed in about 30% of children.", [["haematological abnormalities", "DISEASE", 21, 49], ["leucopaenia", "DISEASE", 58, 69], ["thrombocytopaenia", "DISEASE", 71, 88], ["[45] [46] [47]", "SIMPLE_CHEMICAL", 0, 14], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 128, 142], ["children", "ORGANISM", 178, 186], ["children", "SPECIES", 178, 186], ["Other haematological abnormalities", "PROBLEM", 15, 49], ["leucopaenia", "PROBLEM", 58, 69], ["thrombocytopaenia", "PROBLEM", 71, 88], ["mildly prolonged activated partial thromboplastin times", "PROBLEM", 93, 148], ["thrombocytopaenia", "OBSERVATION", 71, 88], ["mildly", "OBSERVATION_MODIFIER", 93, 99], ["prolonged", "OBSERVATION_MODIFIER", 100, 109], ["partial thromboplastin", "OBSERVATION", 120, 142]]], ["Anaemia is rarely found at presentation and is only detected in <5% of children.", [["Anaemia", "DISEASE", 0, 7], ["children", "ORGANISM", 71, 79], ["children", "SPECIES", 71, 79], ["Anaemia", "PROBLEM", 0, 7]]], ["22, 23 Unlike adults, a significant drop in the haemoglobin level during the course of illness that necessitates discontinuation of empiric antiviral therapy, namely ribavirin, has not been observed.", [["illness", "DISEASE", 87, 94], ["ribavirin", "CHEMICAL", 166, 175], ["ribavirin", "CHEMICAL", 166, 175], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 48, 59], ["ribavirin", "SIMPLE_CHEMICAL", 166, 175], ["a significant drop in the haemoglobin level", "PROBLEM", 22, 65], ["illness", "PROBLEM", 87, 94], ["empiric antiviral therapy", "TREATMENT", 132, 157], ["ribavirin", "TREATMENT", 166, 175], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["drop", "OBSERVATION_MODIFIER", 36, 40]]], ["[22] [23] [24] Reactive thrombocytosis on recovery from SARS is significantly more common in children 12 years of age.", [["thrombocytosis", "DISEASE", 24, 38], ["SARS", "DISEASE", 56, 60], ["[22] [23] [24] Reactive", "SIMPLE_CHEMICAL", 0, 23], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["Reactive thrombocytosis", "PROBLEM", 15, 38], ["Reactive", "OBSERVATION_MODIFIER", 15, 23], ["thrombocytosis", "OBSERVATION", 24, 38]]], ["23 This phenomenon is sometimes observed in children recovering from systemic viral infections and is probably not related to the use of corticosteroids.", [["systemic viral infections", "DISEASE", 69, 94], ["corticosteroids", "CHEMICAL", 137, 152], ["children", "ORGANISM", 44, 52], ["corticosteroids", "SIMPLE_CHEMICAL", 137, 152], ["children", "SPECIES", 44, 52], ["systemic viral infections", "PROBLEM", 69, 94], ["corticosteroids", "TREATMENT", 137, 152], ["systemic", "OBSERVATION_MODIFIER", 69, 77], ["viral infections", "OBSERVATION", 78, 94], ["probably not related to", "UNCERTAINTY", 102, 125]]], ["Despite an abnormal clotting profile with elevated D-dimer levels and the detection of lupus anticoagulants in a small number of children, bleeding events or thrombotic complications have not been reported.", [["lupus anticoagulants", "DISEASE", 87, 107], ["bleeding", "DISEASE", 139, 147], ["thrombotic complications", "DISEASE", 158, 182], ["D-dimer", "GENE_OR_GENE_PRODUCT", 51, 58], ["children", "ORGANISM", 129, 137], ["D-dimer", "PROTEIN", 51, 58], ["children", "SPECIES", 129, 137], ["an abnormal clotting profile", "PROBLEM", 8, 36], ["elevated D-dimer levels", "PROBLEM", 42, 65], ["lupus anticoagulants", "TREATMENT", 87, 107], ["bleeding events", "PROBLEM", 139, 154], ["thrombotic complications", "PROBLEM", 158, 182], ["abnormal", "OBSERVATION_MODIFIER", 11, 19], ["clotting", "OBSERVATION", 20, 28], ["lupus anticoagulants", "OBSERVATION", 87, 107], ["small", "OBSERVATION_MODIFIER", 113, 118], ["thrombotic", "OBSERVATION", 158, 168]]], ["22, 48 The most common biochemical abnormality in children with SARS is an elevated lactate dehydrogenase level, which is present in about 50% at presentation and about 70% during the course of illness.", [["SARS", "DISEASE", 64, 68], ["lactate", "CHEMICAL", 84, 91], ["illness", "DISEASE", 194, 201], ["lactate", "CHEMICAL", 84, 91], ["children", "ORGANISM", 50, 58], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 84, 105], ["lactate dehydrogenase", "PROTEIN", 84, 105], ["children", "SPECIES", 50, 58], ["The most common biochemical abnormality", "PROBLEM", 7, 46], ["SARS", "PROBLEM", 64, 68], ["an elevated lactate dehydrogenase level", "PROBLEM", 72, 111], ["illness", "PROBLEM", 194, 201], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["abnormality", "OBSERVATION", 35, 46], ["elevated", "OBSERVATION_MODIFIER", 75, 83], ["lactate dehydrogenase", "OBSERVATION", 84, 105]]], ["Elevated alanine aminotransferase levels are seen in <20% of children at presentation and <50% during the course of illness.", [["alanine", "CHEMICAL", 9, 16], ["illness", "DISEASE", 116, 123], ["alanine", "CHEMICAL", 9, 16], ["alanine", "AMINO_ACID", 9, 16], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 17, 33], ["children", "ORGANISM", 61, 69], ["children", "SPECIES", 61, 69], ["Elevated alanine aminotransferase levels", "PROBLEM", 0, 40], ["illness", "PROBLEM", 116, 123], ["alanine aminotransferase", "OBSERVATION", 9, 33]]], ["Elevation of creatine kinase levels vary from 10% to 40% between case series.", [["creatine", "CHEMICAL", 13, 21], ["creatine", "CHEMICAL", 13, 21], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 13, 28], ["creatine kinase", "PROTEIN", 13, 28], ["Elevation of creatine kinase levels", "TEST", 0, 35], ["case series", "TEST", 65, 76], ["creatine kinase", "OBSERVATION", 13, 28]]], ["22, 23 Teenage patients tend to have more derangement of laboratory parameters and they may take longer to resolve.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["laboratory parameters", "TEST", 57, 78]]], ["22 Similar to human infection with avian influenza A H5N1 virus, cytokine dysregulation is believed to be pivotal in the immunopathogenesis of SARS among adults and children.", [["human infection", "DISEASE", 14, 29], ["SARS", "DISEASE", 143, 147], ["human", "ORGANISM", 14, 19], ["avian influenza A H5N1 virus", "ORGANISM", 35, 63], ["children", "ORGANISM", 165, 173], ["cytokine", "PROTEIN", 65, 73], ["human", "SPECIES", 14, 19], ["avian influenza", "SPECIES", 35, 50], ["A H5N1 virus", "SPECIES", 51, 63], ["children", "SPECIES", 165, 173], ["human", "SPECIES", 14, 19], ["A H5N1 virus", "SPECIES", 51, 63], ["human infection", "PROBLEM", 14, 29], ["avian influenza A H5N1 virus", "PROBLEM", 35, 63], ["cytokine dysregulation", "PROBLEM", 65, 87], ["infection", "OBSERVATION", 20, 29], ["believed to be", "UNCERTAINTY", 91, 105]]], ["Serial monitoring of the plasma inflammatory cytokine profile using flow cytometry in a cohort of eight paediatric patients suggests that the caspase-1-dependent pathway in infected macrophages is selectively activated, as reflected by substantial elevation of circulating interleukin-1b levels.", [["plasma", "ANATOMY", 25, 31], ["macrophages", "ANATOMY", 182, 193], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["patients", "ORGANISM", 115, 123], ["caspase-1", "GENE_OR_GENE_PRODUCT", 142, 151], ["macrophages", "CELL", 182, 193], ["interleukin-1b", "GENE_OR_GENE_PRODUCT", 273, 287], ["plasma inflammatory cytokine", "PROTEIN", 25, 53], ["caspase-1", "PROTEIN", 142, 151], ["infected macrophages", "CELL_TYPE", 173, 193], ["interleukin", "PROTEIN", 273, 284], ["patients", "SPECIES", 115, 123], ["Serial monitoring", "TEST", 0, 17], ["the plasma inflammatory cytokine profile", "TEST", 21, 61], ["flow cytometry", "TEST", 68, 82], ["the caspase", "TEST", 138, 149], ["infected macrophages", "PROBLEM", 173, 193], ["substantial elevation of circulating interleukin-1b levels", "PROBLEM", 236, 294], ["infected macrophages", "OBSERVATION", 173, 193], ["substantial", "OBSERVATION_MODIFIER", 236, 247], ["elevation", "OBSERVATION_MODIFIER", 248, 257]]], ["49 Conversely, interleukin-6 and tumour necrosis factor-a levels, which are markedly increased in human infection with avian influenza A H5N1 virus, are not overtly elevated throughout the course of illness.", [["necrosis", "DISEASE", 40, 48], ["infection", "DISEASE", 104, 113], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 15, 28], ["tumour necrosis factor-a", "GENE_OR_GENE_PRODUCT", 33, 57], ["human", "ORGANISM", 98, 103], ["avian influenza A H5N1 virus", "ORGANISM", 119, 147], ["interleukin-6", "PROTEIN", 15, 28], ["tumour necrosis factor", "PROTEIN", 33, 55], ["human", "SPECIES", 98, 103], ["avian influenza", "SPECIES", 119, 134], ["A H5N1 virus", "SPECIES", 135, 147], ["human", "SPECIES", 98, 103], ["A H5N1 virus", "SPECIES", 135, 147], ["interleukin", "TEST", 15, 26], ["tumour necrosis factor", "PROBLEM", 33, 55], ["a levels", "TEST", 56, 64], ["human infection", "PROBLEM", 98, 113], ["avian influenza A H5N1 virus", "PROBLEM", 119, 147], ["overtly elevated", "PROBLEM", 157, 173], ["illness", "PROBLEM", 199, 206], ["tumour", "OBSERVATION_MODIFIER", 33, 39], ["necrosis", "OBSERVATION", 40, 48], ["markedly", "OBSERVATION_MODIFIER", 76, 84], ["increased", "OBSERVATION_MODIFIER", 85, 94], ["human", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 104, 113], ["elevated", "OBSERVATION_MODIFIER", 165, 173]]], ["50, 51 The predominant activation of the Th1 immune response facilitates viral clearance and may explain the rapid recovery of children.DIAGNOSISAs SARS is a newly emerging infectious disease with unknown aetiology initially, the initial case definitions of suspected and probable SARS promulgated by the World Health Organization were meant for surveillance and were necessarily broadly inclusive and non-specific.", [["SARS", "DISEASE", 148, 152], ["infectious disease", "DISEASE", 173, 191], ["SARS", "DISEASE", 281, 285], ["Th1", "GENE_OR_GENE_PRODUCT", 41, 44], ["children", "ORGANISM", 127, 135], ["children", "SPECIES", 127, 135], ["viral clearance", "TEST", 73, 88], ["a newly emerging infectious disease", "PROBLEM", 156, 191], ["SARS", "PROBLEM", 281, 285], ["surveillance", "TEST", 346, 358], ["predominant", "OBSERVATION_MODIFIER", 11, 22], ["activation", "OBSERVATION", 23, 33], ["Th1 immune", "OBSERVATION", 41, 51], ["rapid", "OBSERVATION_MODIFIER", 109, 114], ["non-specific", "OBSERVATION_MODIFIER", 402, 414]]], ["Patients were categorised based on clinical, radiologic and epidemiologic features and after exclusion of alternative diagnoses.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["The original WHO surveillance case definitions for SARS required that lower respiratory symptoms of cough, short-ness of breath or difficulty breathing were present.", [["respiratory", "ANATOMY", 76, 87], ["SARS", "DISEASE", 51, 55], ["cough", "DISEASE", 100, 105], ["SARS", "PROBLEM", 51, 55], ["lower respiratory symptoms", "PROBLEM", 70, 96], ["cough", "PROBLEM", 100, 105], ["short-ness of breath", "PROBLEM", 107, 127], ["difficulty breathing", "PROBLEM", 131, 151]]], ["Applying this would have missed many children who do not present with the above symptoms.", [["children", "ORGANISM", 37, 45], ["children", "SPECIES", 37, 45], ["the above symptoms", "PROBLEM", 70, 88]]], ["The lack of sensitivity and specificity of the initial WHO case definitions have generated uncertainty in individual case management at the point of care.", [["individual case management", "TREATMENT", 106, 132]]], ["24, 52 With more understanding of the disease and identification of a novel coronavirus as the causative agent, the case definitions of SARS were revised on May 1, 2003.", [["coronavirus", "DISEASE", 76, 87], ["SARS", "DISEASE", 136, 140], ["coronavirus", "ORGANISM", 76, 87], ["the disease", "PROBLEM", 34, 45], ["a novel coronavirus", "PROBLEM", 68, 87], ["SARS", "PROBLEM", 136, 140]]], ["53 As the clinical and radiologic features were non-specific, much emphasis was placed on the identification of an epidemiologic link to suggest the diagnosis.", [["non-specific", "OBSERVATION_MODIFIER", 48, 60]]], ["The vast majority of patients in the last epidemic had a clear history of exposure, either to patients suspected of or diagnosed with SARS, or to a setting where recent local transmission was occurring.", [["SARS", "DISEASE", 134, 138], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 94, 102], ["SARS", "PROBLEM", 134, 138], ["recent local transmission", "PROBLEM", 162, 187], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17]]], ["54 Nevertheless, careful epidemiologic history taking remains essential in the diagnostic work-up and early implementation of appropriate infection control measures in suspected patients.", [["infection", "DISEASE", 138, 147], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["appropriate infection control measures", "TREATMENT", 126, 164], ["infection", "OBSERVATION", 138, 147]]], ["Important questions to ask in the 'peace time' include: (1) history of recent travel to pre-viously SARS-affected areas or areas with an increased likelihood of animal to human transmission of SARS-CoV infection; (2) close contact with a suspected SARS patient;DIAGNOSIS(3) history of recent hospitalisation or contact with a healthcare facility; (4) individuals who are either healthcare workers or laboratory workers with potential exposure to SARS patients or live SARS-CoV; and (5) link to a cluster of cases of unexplained respiratory illness in the community.DIAGNOSISMicrobiological investigations are the cornerstones for the confirmation of SARS.", [["respiratory", "ANATOMY", 528, 539], ["SARS", "DISEASE", 100, 104], ["SARS-CoV infection", "DISEASE", 193, 211], ["SARS", "DISEASE", 248, 252], ["SARS", "DISEASE", 446, 450], ["SARS", "DISEASE", 468, 472], ["respiratory illness", "DISEASE", 528, 547], ["SARS", "DISEASE", 650, 654], ["human", "ORGANISM", 171, 176], ["SARS-CoV", "ORGANISM", 193, 201], ["patient", "ORGANISM", 253, 260], ["patients", "ORGANISM", 451, 459], ["CoV", "ORGANISM", 473, 476], ["human", "SPECIES", 171, 176], ["patient", "SPECIES", 253, 260], ["patients", "SPECIES", 451, 459], ["human", "SPECIES", 171, 176], ["SARS-CoV", "SPECIES", 193, 201], ["SARS-CoV", "SPECIES", 468, 476], ["pre-viously SARS", "PROBLEM", 88, 104], ["affected areas", "PROBLEM", 105, 119], ["SARS", "PROBLEM", 193, 197], ["CoV infection", "PROBLEM", 198, 211], ["unexplained respiratory illness", "PROBLEM", 516, 547], ["DIAGNOSISMicrobiological investigations", "TEST", 565, 604], ["the confirmation", "TEST", 630, 646], ["SARS", "PROBLEM", 650, 654], ["increased", "OBSERVATION_MODIFIER", 137, 146], ["infection", "OBSERVATION", 202, 211], ["respiratory illness", "OBSERVATION", 528, 547]]], ["The diagnostic work-up should include tests for pathogens which cause communityacquired pneumonia in children.", [["pneumonia", "DISEASE", 88, 97], ["children", "ORGANISM", 101, 109], ["children", "SPECIES", 101, 109], ["tests", "TEST", 38, 43], ["pathogens", "PROBLEM", 48, 57], ["communityacquired pneumonia", "PROBLEM", 70, 97], ["pneumonia", "OBSERVATION", 88, 97]]], ["23 A blood culture is also needed.", [["blood", "ANATOMY", 5, 10], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["A blood culture", "TEST", 3, 18]]], ["For children with productive cough who are old enough to produce a reliable specimen, sputum for bacterial culture should be performed.", [["specimen", "ANATOMY", 76, 84], ["sputum", "ANATOMY", 86, 92], ["cough", "DISEASE", 29, 34], ["children", "ORGANISM", 4, 12], ["sputum", "ORGANISM_SUBSTANCE", 86, 92], ["children", "SPECIES", 4, 12], ["productive cough", "PROBLEM", 18, 34], ["sputum", "TEST", 86, 92], ["bacterial culture", "TEST", 97, 114]]], ["Nasopharyngeal aspirate (NPA) should be saved for rapid antigen detection of influenza A and B, RSV, adenovirus and parainfluenza types 1, 2 and 3, using direct immunofluorescence assays.", [["Nasopharyngeal aspirate", "ANATOMY", 0, 23], ["influenza A and B", "DISEASE", 77, 94], ["Nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 23], ["NPA", "CANCER", 25, 28], ["influenza A", "ORGANISM", 77, 88], ["B", "GENE_OR_GENE_PRODUCT", 93, 94], ["RSV", "ORGANISM", 96, 99], ["adenovirus", "ORGANISM", 101, 111], ["parainfluenza types 1", "ORGANISM", 116, 137], ["3", "GENE_OR_GENE_PRODUCT", 145, 146], ["parainfluenza", "SPECIES", 116, 129], ["RSV", "SPECIES", 96, 99], ["adenovirus", "SPECIES", 101, 111], ["Nasopharyngeal aspirate", "TEST", 0, 23], ["rapid antigen detection", "TEST", 50, 73], ["influenza", "PROBLEM", 77, 86], ["RSV", "PROBLEM", 96, 99], ["adenovirus", "PROBLEM", 101, 111], ["parainfluenza types", "TEST", 116, 135], ["direct immunofluorescence assays", "TEST", 154, 186], ["aspirate", "OBSERVATION", 15, 23]]], ["Urine samples may be tested for Legionella pneumophila and Streptococcus pneumoniae antigens.", [["Urine samples", "ANATOMY", 0, 13], ["Urine samples", "ORGANISM_SUBSTANCE", 0, 13], ["Legionella pneumophila", "ORGANISM", 32, 54], ["Streptococcus pneumoniae", "ORGANISM", 59, 83], ["Streptococcus pneumoniae antigens", "PROTEIN", 59, 92], ["Legionella pneumophila", "SPECIES", 32, 54], ["Streptococcus pneumoniae", "SPECIES", 59, 83], ["Legionella pneumophila", "SPECIES", 32, 54], ["Streptococcus pneumoniae", "SPECIES", 59, 83], ["Urine samples", "TEST", 0, 13], ["Legionella pneumophila", "PROBLEM", 32, 54], ["Streptococcus pneumoniae antigens", "PROBLEM", 59, 92], ["Streptococcus pneumoniae", "OBSERVATION", 59, 83]]], ["NPA specimens should also be inoculated into different cell lines for isolation of respiratory viruses.", [["NPA specimens", "ANATOMY", 0, 13], ["cell lines", "ANATOMY", 55, 65], ["respiratory viruses", "DISEASE", 83, 102], ["NPA", "CHEMICAL", 0, 3], ["NPA specimens", "CANCER", 0, 13], ["cell lines", "CELL", 55, 65], ["cell lines", "CELL_LINE", 55, 65], ["NPA specimens", "TEST", 0, 13], ["different cell lines", "TREATMENT", 45, 65], ["respiratory viruses", "PROBLEM", 83, 102], ["cell lines", "OBSERVATION", 55, 65], ["respiratory viruses", "OBSERVATION", 83, 102]]], ["Serologic studies should include Mycoplasma pneumoniae IgM and paired acute and convalescent sera for IgG against Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia psittaci, Legionella pneumophila, influenza A and B, RSV, adenovirus and parainfluenza types 1, 2 and 3.", [["sera", "ANATOMY", 93, 97], ["Mycoplasma pneumoniae", "DISEASE", 114, 135], ["Chlamydia pneumoniae", "DISEASE", 137, 157], ["Chlamydia psittaci", "DISEASE", 159, 177], ["Legionella pneumophila", "DISEASE", 179, 201], ["influenza A and B", "DISEASE", 203, 220], ["parainfluenza", "DISEASE", 242, 255], ["Mycoplasma pneumoniae", "ORGANISM", 33, 54], ["IgM", "ORGANISM", 55, 58], ["sera", "ORGANISM_SUBSTANCE", 93, 97], ["IgG", "GENE_OR_GENE_PRODUCT", 102, 105], ["Mycoplasma pneumoniae", "ORGANISM", 114, 135], ["Chlamydia pneumoniae", "ORGANISM", 137, 157], ["Chlamydia psittaci", "ORGANISM", 159, 177], ["Legionella pneumophila", "ORGANISM", 179, 201], ["influenza A", "ORGANISM", 203, 214], ["B", "GENE_OR_GENE_PRODUCT", 219, 220], ["RSV", "ORGANISM", 222, 225], ["adenovirus", "ORGANISM", 227, 237], ["parainfluenza types 1", "ORGANISM", 242, 263], ["3", "GENE_OR_GENE_PRODUCT", 271, 272], ["Mycoplasma pneumoniae IgM", "PROTEIN", 33, 58], ["IgG", "PROTEIN", 102, 105], ["Mycoplasma pneumoniae", "SPECIES", 33, 54], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["Chlamydia pneumoniae", "SPECIES", 137, 157], ["Chlamydia psittaci", "SPECIES", 159, 177], ["Legionella pneumophila", "SPECIES", 179, 201], ["RSV", "SPECIES", 222, 225], ["parainfluenza", "SPECIES", 242, 255], ["Mycoplasma pneumoniae", "SPECIES", 33, 54], ["Mycoplasma pneumoniae", "SPECIES", 114, 135], ["Chlamydia pneumoniae", "SPECIES", 137, 157], ["Chlamydia psittaci", "SPECIES", 159, 177], ["Legionella pneumophila", "SPECIES", 179, 201], ["RSV", "SPECIES", 222, 225], ["Serologic studies", "TEST", 0, 17], ["Mycoplasma pneumoniae IgM", "PROBLEM", 33, 58], ["paired acute", "PROBLEM", 63, 75], ["convalescent sera", "TEST", 80, 97], ["IgG", "TEST", 102, 105], ["Mycoplasma pneumoniae", "PROBLEM", 114, 135], ["Chlamydia pneumoniae", "PROBLEM", 137, 157], ["Chlamydia psittaci", "PROBLEM", 159, 177], ["Legionella pneumophila", "PROBLEM", 179, 201], ["influenza", "PROBLEM", 203, 212], ["RSV", "PROBLEM", 222, 225], ["adenovirus", "PROBLEM", 227, 237], ["parainfluenza types", "PROBLEM", 242, 261], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["RSV", "ANATOMY", 222, 225]]], ["Specific tests for the detection of SARS-CoV include: (1) molecular or nucleic acid amplification test using reverse transcription-polymer-ase chain reaction (RT-PCR); (2) antibody tests; and (3) cell culture.", [["cell", "ANATOMY", 196, 200], ["SARS", "DISEASE", 36, 40], ["nucleic acid", "CHEMICAL", 71, 83], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["cell", "CELL", 196, 200], ["SARS-CoV", "SPECIES", 36, 44], ["Specific tests", "TEST", 0, 14], ["the detection", "TEST", 19, 32], ["SARS", "PROBLEM", 36, 40], ["nucleic acid amplification test", "TEST", 71, 102], ["reverse transcription", "TEST", 109, 130], ["polymer", "TEST", 131, 138], ["chain reaction", "PROBLEM", 143, 157], ["RT-PCR", "TEST", 159, 165], ["antibody tests", "TEST", 172, 186], ["cell culture", "TEST", 196, 208]]], ["55RT-PCRIn view of the high transmissibility of SARS in hospitals, laboratory confirmation of the diagnosis early in the course of illness is vital to allow for the best utilisation of the limited isolation and cohorting facilities in most hospitals.", [["SARS", "DISEASE", 48, 52], ["laboratory confirmation", "TEST", 67, 90], ["illness", "PROBLEM", 131, 138]]], ["Rapid diagnosis with RT-PCR tests targeting specific segments of the SARS-CoV genome, primarily the polymerase gene, were used extensively during the last epidemic.", [["SARS-CoV", "ORGANISM", 69, 77], ["SARS-CoV genome", "DNA", 69, 84], ["polymerase gene", "DNA", 100, 115], ["SARS-CoV", "SPECIES", 69, 77], ["RT-PCR tests", "TEST", 21, 33], ["the SARS", "PROBLEM", 65, 73], ["CoV genome", "TREATMENT", 74, 84], ["CoV genome", "OBSERVATION", 74, 84]]], ["[1] [2] [3] [56] [57] [58] [59] The method can be applied to nasopharyngeal aspirates, nose and throat swabs, saliva, sputum, endotracheal aspirates, bronchoalveolar lavage, stool, urine, plasma and serum.", [["nasopharyngeal aspirates", "ANATOMY", 61, 85], ["nose", "ANATOMY", 87, 91], ["throat swabs", "ANATOMY", 96, 108], ["saliva", "ANATOMY", 110, 116], ["sputum", "ANATOMY", 118, 124], ["endotracheal aspirates", "ANATOMY", 126, 148], ["bronchoalveolar lavage", "ANATOMY", 150, 172], ["stool", "ANATOMY", 174, 179], ["urine", "ANATOMY", 181, 186], ["plasma", "ANATOMY", 188, 194], ["serum", "ANATOMY", 199, 204], ["[1] [2] [3] [56] [57] [58] [59]", "SIMPLE_CHEMICAL", 0, 31], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 61, 85], ["nose", "ORGANISM_SUBDIVISION", 87, 91], ["throat swabs", "ORGANISM_SUBSTANCE", 96, 108], ["saliva", "ORGANISM_SUBSTANCE", 110, 116], ["sputum", "ORGANISM_SUBSTANCE", 118, 124], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 126, 148], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 150, 172], ["stool", "ORGANISM_SUBSTANCE", 174, 179], ["urine", "ORGANISM_SUBSTANCE", 181, 186], ["plasma", "ORGANISM_SUBSTANCE", 188, 194], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["The method", "TREATMENT", 32, 42], ["nasopharyngeal aspirates", "TEST", 61, 85], ["nose and throat swabs", "TEST", 87, 108], ["saliva, sputum", "TEST", 110, 124], ["endotracheal aspirates", "TEST", 126, 148], ["bronchoalveolar lavage", "TEST", 150, 172], ["stool, urine, plasma and serum", "TEST", 174, 204], ["nasopharyngeal", "ANATOMY", 61, 75], ["aspirates", "OBSERVATION", 76, 85], ["nose", "ANATOMY", 87, 91], ["throat", "ANATOMY", 96, 102], ["endotracheal", "ANATOMY", 126, 138], ["bronchoalveolar lavage", "OBSERVATION", 150, 172]]], ["Nasopharyngeal aspirates, combined nose and throat swabs and stool are the most commonly used.RT-PCRExperience in Hong Kong and Toronto suggests that the first generation conventional RT-PCR assays in use at the time of the initial outbreak lacked sufficient sensitivity to clinically rule out SARS.", [["Nasopharyngeal aspirates", "ANATOMY", 0, 24], ["nose", "ANATOMY", 35, 39], ["throat swabs", "ANATOMY", 44, 56], ["stool", "ANATOMY", 61, 66], ["SARS", "DISEASE", 294, 298], ["Nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 0, 24], ["nose", "ORGANISM_SUBDIVISION", 35, 39], ["throat swabs", "ORGANISM_SUBSTANCE", 44, 56], ["stool", "ORGANISM_SUBSTANCE", 61, 66], ["Nasopharyngeal aspirates", "TEST", 0, 24], ["combined nose and throat swabs", "TEST", 26, 56], ["PCR assays", "TEST", 187, 197], ["SARS", "PROBLEM", 294, 298], ["aspirates", "OBSERVATION", 15, 24], ["nose", "ANATOMY", 35, 39], ["throat", "ANATOMY", 44, 50], ["stool", "OBSERVATION", 61, 66]]], ["1, 60 Despite initial optimism, the test has a sensitivity of 30% in NPA, 28% in combined nose and throat swabs and 20% in stool in the first 5 days of illness.", [["nose", "ANATOMY", 90, 94], ["throat swabs", "ANATOMY", 99, 111], ["stool", "ANATOMY", 123, 128], ["NPA", "CANCER", 69, 72], ["nose", "ORGANISM_SUBDIVISION", 90, 94], ["stool", "ORGANISM_SUBSTANCE", 123, 128], ["the test", "TEST", 32, 40], ["a sensitivity", "TEST", 45, 58], ["NPA", "TEST", 69, 72], ["throat swabs", "TEST", 99, 111], ["illness", "PROBLEM", 152, 159], ["nose", "ANATOMY", 90, 94], ["throat swabs", "ANATOMY", 99, 111]]], ["61 It only reaches a maximum sensitivity of 60% when performed on upper respiratory specimens collected between days 9 to 11 from onset of fever (Government Virus Unit, Public Health Laboratory Centre, Hong Kong Special Administrative Region.", [["upper respiratory specimens", "ANATOMY", 66, 93], ["fever", "DISEASE", 139, 144], ["a maximum sensitivity", "TEST", 19, 40], ["upper respiratory specimens", "TEST", 66, 93], ["fever", "PROBLEM", 139, 144]]], ["Data on file), where day 10 coincides with the maximum viral load in NPA specimens as CLINICAL PICTURE, DIAGNOSIS, TREATMENT AND OUTCOME OF SARS IN CHILDREN 281Clinical definition of SARSA person with a history of: Fever (!38 8C) AND One or more symptoms of lower respiratory tract illness (cough, difficulty breathing, shortness of breath) AND Radiographic evidence of lung infiltrates consistent with pneumonia or RDS OR autopsy findings consistent with the pathology of pneumonia or RDS without an identifiable cause AND No alternative diagnosis can fully explain the illness Laboratory definition of SARS A person with symptoms and signs that are clinically suggestive of SARS AND with positive laboratory findings for SARS-CoV based on one or more of the following diagnostic criteria: (a) PCR positive for SARS-CoV using a validated method from: At least two different clinical specimens (e.g. nasopharyngeal and stool) OR The same clinical specimen collected on two or more occasions during the course of the illness (e.g. sequential nasopharyngeal aspirates) OR Two different assays or repeat PCR using a new RNA extract from the original clinical sample on each occasion of testing (b) Seroconversion by ELISA or IFA Negative antibody test on acute serum followed by positive antibody test on convalescent phase serum tested in parallel OR Four-fold or greater rise in antibody titre between acute and convalescent phase sera tested in parallel (c) Virus isolation Isolation in cell culture of SARS-CoV from any specimen AND PCR confirmation using a validated method measured in adult patients.", [["NPA specimens", "ANATOMY", 69, 82], ["lower respiratory tract", "ANATOMY", 258, 281], ["lung", "ANATOMY", 370, 374], ["specimens", "ANATOMY", 884, 893], ["nasopharyngeal", "ANATOMY", 900, 914], ["specimen", "ANATOMY", 947, 955], ["nasopharyngeal aspirates", "ANATOMY", 1041, 1065], ["sample", "ANATOMY", 1156, 1162], ["serum", "ANATOMY", 1258, 1263], ["serum", "ANATOMY", 1321, 1326], ["sera", "ANATOMY", 1430, 1434], ["cell", "ANATOMY", 1487, 1491], ["specimen", "ANATOMY", 1521, 1529], ["Fever", "DISEASE", 215, 220], ["lower respiratory tract illness", "DISEASE", 258, 289], ["cough", "DISEASE", 291, 296], ["shortness of breath", "DISEASE", 320, 339], ["pneumonia", "DISEASE", 403, 412], ["RDS", "DISEASE", 416, 419], ["pneumonia", "DISEASE", 473, 482], ["RDS", "DISEASE", 486, 489], ["SARS", "DISEASE", 604, 608], ["SARS", "DISEASE", 676, 680], ["SARS", "DISEASE", 723, 727], ["SARS", "DISEASE", 812, 816], ["illness", "DISEASE", 1016, 1023], ["lower", "ORGANISM_SUBDIVISION", 258, 263], ["respiratory tract", "ORGANISM_SUBDIVISION", 264, 281], ["lung", "ORGAN", 370, 374], ["SARS-CoV", "ORGANISM", 723, 731], ["nasopharyngeal", "CANCER", 900, 914], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 1041, 1065], ["serum", "ORGANISM_SUBSTANCE", 1258, 1263], ["serum", "ORGANISM_SUBSTANCE", 1321, 1326], ["sera", "ORGANISM_SUBSTANCE", 1430, 1434], ["cell", "CELL", 1487, 1491], ["SARS-CoV", "ORGANISM", 1503, 1511], ["patients", "ORGANISM", 1594, 1602], ["person", "SPECIES", 189, 195], ["person", "SPECIES", 611, 617], ["patients", "SPECIES", 1594, 1602], ["SARS-CoV", "SPECIES", 723, 731], ["SARS-CoV", "SPECIES", 812, 820], ["SARS-CoV", "SPECIES", 1503, 1511], ["the maximum viral load", "TEST", 43, 65], ["NPA specimens", "TEST", 69, 82], ["Fever", "PROBLEM", 215, 220], ["lower respiratory tract illness", "PROBLEM", 258, 289], ["cough", "PROBLEM", 291, 296], ["difficulty breathing", "PROBLEM", 298, 318], ["shortness of breath", "PROBLEM", 320, 339], ["lung infiltrates", "PROBLEM", 370, 386], ["pneumonia", "PROBLEM", 403, 412], ["RDS", "PROBLEM", 416, 419], ["autopsy findings", "PROBLEM", 423, 439], ["pneumonia", "PROBLEM", 473, 482], ["RDS", "PROBLEM", 486, 489], ["the illness", "PROBLEM", 567, 578], ["symptoms", "PROBLEM", 623, 631], ["signs", "PROBLEM", 636, 641], ["SARS", "PROBLEM", 676, 680], ["positive laboratory findings", "PROBLEM", 690, 718], ["SARS", "PROBLEM", 723, 727], ["CoV", "PROBLEM", 728, 731], ["a) PCR", "TEST", 792, 798], ["SARS", "PROBLEM", 812, 816], ["CoV", "PROBLEM", 817, 820], ["the illness", "PROBLEM", 1012, 1023], ["sequential nasopharyngeal aspirates", "TEST", 1030, 1065], ["Two different assays", "TEST", 1070, 1090], ["repeat PCR", "TEST", 1094, 1104], ["a new RNA extract", "PROBLEM", 1111, 1128], ["testing", "TEST", 1183, 1190], ["Seroconversion", "TEST", 1195, 1209], ["ELISA", "TEST", 1213, 1218], ["IFA", "TEST", 1222, 1225], ["antibody test", "TEST", 1235, 1248], ["acute serum", "TEST", 1252, 1263], ["positive antibody test", "PROBLEM", 1276, 1298], ["convalescent phase serum", "TEST", 1302, 1326], ["greater rise in antibody titre", "PROBLEM", 1362, 1392], ["convalescent phase sera", "TEST", 1411, 1434], ["parallel (c) Virus isolation Isolation", "PROBLEM", 1445, 1483], ["cell culture", "TEST", 1487, 1499], ["SARS", "PROBLEM", 1503, 1507], ["any specimen", "TEST", 1517, 1529], ["PCR confirmation", "TEST", 1534, 1550], ["a validated method", "TEST", 1557, 1575], ["lower", "ANATOMY_MODIFIER", 258, 263], ["respiratory tract", "ANATOMY", 264, 281], ["evidence of", "UNCERTAINTY", 358, 369], ["lung", "ANATOMY", 370, 374], ["infiltrates", "OBSERVATION", 375, 386], ["consistent with", "UNCERTAINTY", 387, 402], ["pneumonia", "OBSERVATION", 403, 412], ["RDS", "OBSERVATION", 416, 419], ["consistent with", "UNCERTAINTY", 440, 455], ["pneumonia", "OBSERVATION", 473, 482], ["RDS", "OBSERVATION", 486, 489], ["nasopharyngeal", "ANATOMY", 900, 914], ["antibody titre", "OBSERVATION", 1378, 1392]]], ["35 The low viral load in the upper respiratory tract in the initial few days of illness poses a diagnostic challenge.", [["upper respiratory tract", "ANATOMY", 29, 52], ["illness", "DISEASE", 80, 87], ["upper respiratory", "ORGANISM_SUBDIVISION", 29, 46], ["tract", "ORGANISM_SUBDIVISION", 47, 52], ["The low viral load in the upper respiratory tract", "PROBLEM", 3, 52], ["illness", "PROBLEM", 80, 87], ["a diagnostic challenge", "TEST", 94, 116], ["low viral load", "OBSERVATION", 7, 21], ["upper", "ANATOMY_MODIFIER", 29, 34], ["respiratory tract", "ANATOMY", 35, 52]]], ["The lower respiratory tract as the primary target of SARS-CoV infection is the probable explanation.", [["lower respiratory tract", "ANATOMY", 4, 27], ["SARS-CoV infection", "DISEASE", 53, 71], ["lower", "ORGANISM_SUBDIVISION", 4, 9], ["respiratory tract", "ORGANISM_SUBDIVISION", 10, 27], ["SARS-CoV", "ORGANISM", 53, 61], ["SARS-CoV", "SPECIES", 53, 61], ["The lower respiratory tract", "PROBLEM", 0, 27], ["SARS", "PROBLEM", 53, 57], ["CoV infection", "PROBLEM", 58, 71], ["lower", "ANATOMY_MODIFIER", 4, 9], ["respiratory tract", "ANATOMY", 10, 27], ["CoV", "OBSERVATION_MODIFIER", 58, 61], ["infection", "OBSERVATION", 62, 71], ["probable explanation", "UNCERTAINTY", 79, 99]]], ["Sputum specimens appear to have a higher diagnostic yield but productive cough is uncommon in SARS patients in the early phase of illness and sputum is difficult to obtain in children.", [["Sputum specimens", "ANATOMY", 0, 16], ["sputum", "ANATOMY", 142, 148], ["cough", "DISEASE", 73, 78], ["SARS", "DISEASE", 94, 98], ["illness", "DISEASE", 130, 137], ["Sputum specimens", "CANCER", 0, 16], ["patients", "ORGANISM", 99, 107], ["children", "ORGANISM", 175, 183], ["patients", "SPECIES", 99, 107], ["children", "SPECIES", 175, 183], ["Sputum specimens", "TEST", 0, 16], ["a higher diagnostic yield", "PROBLEM", 32, 57], ["productive cough", "PROBLEM", 62, 78], ["illness", "PROBLEM", 130, 137], ["sputum", "PROBLEM", 142, 148], ["productive", "OBSERVATION_MODIFIER", 62, 72], ["cough", "OBSERVATION", 73, 78], ["early phase", "OBSERVATION_MODIFIER", 115, 126]]], ["The overall diagnostic yield in the second week of illness increases to >80% when stool specimens are also examined, with stool yielding better results than respiratory specimens.", [["stool specimens", "ANATOMY", 82, 97], ["respiratory specimens", "ANATOMY", 157, 178], ["stool", "ORGANISM_SUBSTANCE", 122, 127], ["illness", "PROBLEM", 51, 58], ["stool specimens", "TEST", 82, 97], ["respiratory specimens", "TEST", 157, 178]]], ["61Improved RNA extractionImproving RNA extraction from the specimen can markedly improve the sensitivity of conventional RT-PCR assays.", [["specimen", "ANATOMY", 59, 67], ["RNA extractionImproving RNA extraction", "TREATMENT", 11, 49], ["conventional RT-PCR assays", "TEST", 108, 134]]], ["When a modified RNA extraction protocol is combined with an optimised real-time RT-PCR assay, a sensitivity of 80% and specificity of 100% can now be achieved in the first 3 days of illness, using NPA as the preferred specimen.", [["specimen", "ANATOMY", 218, 226], ["NPA", "CHEMICAL", 197, 200], ["NPA", "CHEMICAL", 197, 200], ["a modified RNA extraction protocol", "TREATMENT", 5, 39], ["a sensitivity", "TEST", 94, 107], ["specificity", "TEST", 119, 130], ["illness", "PROBLEM", 182, 189], ["NPA", "TREATMENT", 197, 200]]], ["57 A recently described real-time nested PCR assay performed on throat swabs is capable of detecting <10 copies of viral genome per reaction and achieves a much shorter turn-around time than conventional nested RT-PCR.", [["throat swabs", "ANATOMY", 64, 76], ["viral genome", "DNA", 115, 127], ["nested PCR assay", "TEST", 34, 50], ["throat swabs", "TEST", 64, 76], ["viral genome per reaction", "PROBLEM", 115, 140], ["conventional nested RT-PCR", "TREATMENT", 191, 217], ["viral genome", "OBSERVATION", 115, 127]]], ["62 The technique of real-time RT-PCR has also been applied to plasma and serum samples.", [["plasma", "ANATOMY", 62, 68], ["serum samples", "ANATOMY", 73, 86], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["serum samples", "ORGANISM_SUBSTANCE", 73, 86], ["real-time RT-PCR", "TREATMENT", 20, 36], ["plasma and serum samples", "TEST", 62, 86]]], ["It has been shown that 50% of plasma and 78% of serum samples are positive for SARS-CoV RNA during the first week of illness in adult SARS patients.", [["plasma", "ANATOMY", 30, 36], ["serum samples", "ANATOMY", 48, 61], ["SARS", "DISEASE", 134, 138], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["serum samples", "ORGANISM_SUBSTANCE", 48, 61], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["patients", "ORGANISM", 139, 147], ["SARS-CoV RNA", "RNA", 79, 91], ["patients", "SPECIES", 139, 147], ["SARS-CoV", "SPECIES", 79, 87], ["plasma", "TEST", 30, 36], ["serum samples", "TEST", 48, 61], ["SARS", "PROBLEM", 79, 83], ["CoV RNA", "PROBLEM", 84, 91], ["illness", "PROBLEM", 117, 124]]], ["63 A detection rate of 87.5-100% obtained in the plasma of eight paediatric patients within the first week of illness similarly suggests that plasma SARS-CoV RNA quantification is a very sensitive and potentially useful early diagnostic tool.", [["plasma", "ANATOMY", 49, 55], ["plasma", "ANATOMY", 142, 148], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["patients", "ORGANISM", 76, 84], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["plasma SARS-CoV RNA", "RNA", 142, 161], ["patients", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 149, 157], ["A detection rate", "TEST", 3, 19], ["illness", "PROBLEM", 110, 117], ["plasma SARS", "TEST", 142, 153], ["CoV RNA quantification", "TEST", 154, 176]]], ["34 The potential advantages of realtime RT-PCR include an increase in sensitivity, reduction in analytical time, reduction of risk of carry over contamination and availability of quantitative result for disease monitoring and prognostic purposes.", [["realtime RT-PCR", "TREATMENT", 31, 46], ["an increase in sensitivity", "PROBLEM", 55, 81], ["disease monitoring", "TEST", 203, 221], ["prognostic purposes", "TEST", 226, 245], ["increase", "OBSERVATION_MODIFIER", 58, 66]]], ["63 Interestingly, despite a milder clinical course in paediatric patients, no significant differences in plasma viral loads are observed in plasma samples taken from paediatric and adult SARS patients within the first week of admission and at day 7 after fever onset.", [["plasma", "ANATOMY", 105, 111], ["plasma samples", "ANATOMY", 140, 154], ["SARS", "DISEASE", 187, 191], ["fever", "DISEASE", 255, 260], ["patients", "ORGANISM", 65, 73], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["plasma samples", "ORGANISM_SUBSTANCE", 140, 154], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 192, 200], ["significant differences in plasma viral loads", "PROBLEM", 78, 123], ["plasma samples", "TEST", 140, 154], ["fever onset", "PROBLEM", 255, 266], ["no", "UNCERTAINTY", 75, 77], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["viral loads", "OBSERVATION", 112, 123]]], ["34 Obtaining an NPA specimen has been regarded by some as a hazardous procedure posing significant risk to the operator, although it is the best specimen for the rapid diagnosis of SARS and the exclusion of other pathogens in the early phase of illness.", [["NPA specimen", "ANATOMY", 16, 28], ["specimen", "ANATOMY", 145, 153], ["SARS", "DISEASE", 181, 185], ["NPA specimen", "CANCER", 16, 28], ["an NPA specimen", "TEST", 13, 28], ["a hazardous procedure", "TREATMENT", 58, 79], ["SARS", "PROBLEM", 181, 185], ["other pathogens", "PROBLEM", 207, 222], ["illness", "PROBLEM", 245, 252], ["early phase", "OBSERVATION_MODIFIER", 230, 241]]], ["To obviate the need for the protection of healthcare workers, an ingenious method for self-obtaining nasopharyngeal specimens through conjunctiva-upper respiratory tract irrigation (CURTI) has been described as an alternative.", [["nasopharyngeal specimens", "ANATOMY", 101, 125], ["conjunctiva", "ANATOMY", 134, 145], ["upper respiratory tract", "ANATOMY", 146, 169], ["nasopharyngeal specimens", "MULTI-TISSUE_STRUCTURE", 101, 125], ["conjunctiva", "ORGAN", 134, 145], ["upper respiratory", "ORGANISM_SUBDIVISION", 146, 163], ["tract", "ORGANISM_SUBDIVISION", 164, 169], ["nasopharyngeal specimens", "TEST", 101, 125], ["conjunctiva", "TREATMENT", 134, 145], ["upper respiratory tract irrigation", "TREATMENT", 146, 180], ["upper", "ANATOMY_MODIFIER", 146, 151], ["respiratory tract", "ANATOMY", 152, 169]]], ["64SerologyThe lack of serologic evidence of prior SARS-CoV infection in humans suggests that the virus has only recently entered the human population, presumably from an animal reservoir in southern China.", [["64Serology", "CHEMICAL", 0, 10], ["SARS-CoV infection", "DISEASE", 50, 68], ["SARS-CoV", "ORGANISM", 50, 58], ["humans", "ORGANISM", 72, 78], ["human", "ORGANISM", 133, 138], ["humans", "SPECIES", 72, 78], ["human", "SPECIES", 133, 138], ["SARS-CoV", "SPECIES", 50, 58], ["humans", "SPECIES", 72, 78], ["human", "SPECIES", 133, 138], ["prior SARS", "PROBLEM", 44, 54], ["CoV infection", "PROBLEM", 55, 68], ["the virus", "PROBLEM", 93, 102], ["an animal reservoir", "TREATMENT", 167, 186], ["SARS", "OBSERVATION", 50, 54], ["CoV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68], ["virus", "OBSERVATION", 97, 102], ["animal", "OBSERVATION_MODIFIER", 170, 176], ["reservoir", "OBSERVATION_MODIFIER", 177, 186]]], ["65, 66 Specific IgM and IgG antibodies appear in response to SARS-CoV infection, with their levels changing during the course of the infection.", [["SARS-CoV infection", "DISEASE", 61, 79], ["infection", "DISEASE", 133, 142], ["IgM", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 24, 38], ["SARS-CoV", "ORGANISM", 61, 69], ["IgM", "PROTEIN", 16, 19], ["IgG antibodies", "PROTEIN", 24, 38], ["SARS-CoV", "SPECIES", 61, 69], ["Specific IgM", "TEST", 7, 19], ["IgG antibodies", "TEST", 24, 38], ["SARS", "PROBLEM", 61, 65], ["CoV infection", "PROBLEM", 66, 79], ["their levels", "PROBLEM", 86, 98], ["the infection", "PROBLEM", 129, 142], ["CoV", "OBSERVATION_MODIFIER", 66, 69], ["infection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 133, 142]]], ["Serum antibody testing by immunofluorescence assay (IFA) or enzymelinked immunosorbant assay (ELISA) have been developed to diagnose SARS.", [["Serum", "ANATOMY", 0, 5], ["SARS", "DISEASE", 133, 137], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum antibody", "PROTEIN", 0, 14], ["Serum antibody testing", "TEST", 0, 22], ["immunofluorescence assay", "TEST", 26, 50], ["IFA", "TEST", 52, 55], ["enzymelinked immunosorbant assay", "TEST", 60, 92], ["ELISA", "TEST", 94, 99]]], ["1, 3, 35, 67 The IFA test detects IgM and IgG antibodies and yields positive results in 16% and 55% of cases, respectively, after 10 days of illness.", [["IgM", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 42, 56], ["IgM", "PROTEIN", 34, 37], ["IgG antibodies", "PROTEIN", 42, 56], ["The IFA test", "TEST", 13, 25], ["IgM", "TEST", 34, 37], ["IgG antibodies", "TEST", 42, 56], ["illness", "PROBLEM", 141, 148]]], ["Both are detectable in 91% of IFA tests by 25 days.", [["IFA tests", "TEST", 30, 39], ["detectable", "OBSERVATION_MODIFIER", 9, 19]]], ["68 An indirect immunofluorescence test for IgG antibody provides a sensitivity and specificity of 100%.", [["IgG antibody", "PROTEIN", 43, 55], ["An indirect immunofluorescence test", "TEST", 3, 38], ["IgG antibody", "TEST", 43, 55], ["a sensitivity", "TEST", 65, 78], ["specificity", "TEST", 83, 94]]], ["67 The ELISA test detects a mixture of serum IgM and IgG antibodies, 80% and 85% respectively being positive by the second week.", [["serum", "ANATOMY", 39, 44], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["IgM", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["serum IgM", "PROTEIN", 39, 48], ["IgG antibodies", "PROTEIN", 53, 67], ["The ELISA test", "TEST", 3, 17], ["serum IgM", "TEST", 39, 48], ["IgG antibodies", "TEST", 53, 67]]], ["Detection rate for both is 100% by week 3.", [["Detection rate", "TEST", 0, 14]]], ["The decay curves suggest that IgM seropositivity is lost by about 12 weeks, while IgG titres peak at 4 weeks and remain elevated until 12 weeks.", [["IgM", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgG", "GENE_OR_GENE_PRODUCT", 82, 85], ["IgM", "PROTEIN", 30, 33], ["IgG", "PROTEIN", 82, 85], ["The decay curves", "TEST", 0, 16], ["IgM seropositivity", "PROBLEM", 30, 48], ["IgG titres", "TEST", 82, 92], ["IgM seropositivity", "OBSERVATION", 30, 48]]], ["69 The antibody response is usually negative until 10 days from onset of symptoms.", [["The antibody response", "TEST", 3, 24], ["symptoms", "PROBLEM", 73, 81]]], ["By day 28, seroconversion is demonstrated in 93% of SARS patients despite corticosteroid therapy.", [["SARS", "DISEASE", 52, 56], ["patients", "ORGANISM", 57, 65], ["corticosteroid", "SIMPLE_CHEMICAL", 74, 88], ["patients", "SPECIES", 57, 65], ["seroconversion", "TREATMENT", 11, 25], ["SARS", "PROBLEM", 52, 56], ["corticosteroid therapy", "TREATMENT", 74, 96], ["corticosteroid therapy", "OBSERVATION", 74, 96]]], ["35 Seroconversion from negative to positive or a !four-fold rise in IgG antibody titres indicates recent infection.", [["infection", "DISEASE", 105, 114], ["IgG", "GENE_OR_GENE_PRODUCT", 68, 71], ["IgG antibody", "PROTEIN", 68, 80], ["Seroconversion", "TEST", 3, 17], ["four-fold rise", "TEST", 50, 64], ["IgG antibody titres", "TEST", 68, 87], ["recent infection", "PROBLEM", 98, 114], ["-fold", "OBSERVATION_MODIFIER", 54, 59], ["rise", "OBSERVATION_MODIFIER", 60, 64], ["IgG antibody titres", "OBSERVATION", 68, 87], ["infection", "OBSERVATION", 105, 114]]], ["No detection of antibody in serum obtained >28 days from onset of illness indicates an absence of SARS-CoV infection and is the only laboratory method for excluding the diagnosis.", [["serum", "ANATOMY", 28, 33], ["illness", "DISEASE", 66, 73], ["SARS-CoV infection", "DISEASE", 98, 116], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["SARS-CoV", "ORGANISM", 98, 106], ["SARS-CoV", "SPECIES", 98, 106], ["antibody in serum", "TEST", 16, 33], ["illness", "PROBLEM", 66, 73], ["SARS", "PROBLEM", 98, 102], ["CoV infection", "PROBLEM", 103, 116], ["antibody", "OBSERVATION", 16, 24], ["infection", "OBSERVATION", 107, 116]]], ["70, 71 Serologic testing appears to be the best method for confirming SARS, with positive rates ranging from 93% to 99%.", [["SARS", "DISEASE", 70, 74], ["Serologic testing", "TEST", 7, 24], ["SARS", "PROBLEM", 70, 74], ["positive rates", "TEST", 81, 95]]], ["35, 52, 61 IgM or other antibody assays have not been successful in closing the diagnostic window within the first week of illness.", [["IgM", "GENE_OR_GENE_PRODUCT", 11, 14], ["IgM", "PROTEIN", 11, 14], ["IgM", "TEST", 11, 14], ["other antibody assays", "TEST", 18, 39], ["illness", "PROBLEM", 123, 130]]], ["65 Even if some patients seroconvert early, the utility of serology is confined to retrospective diagnosis given the generally long lag time to seroconversion.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["serology", "TEST", 59, 67], ["seroconversion", "PROBLEM", 144, 158]]], ["IgG usually remains detectable after resolution of the illness but the duration of persisting protective neutralising antibodies and their boosting response remain unknown.Viral cultureSARS-CoV can be isolated from respiratory secretions, blood or stool by inoculating cell cultures and growing the virus.", [["respiratory secretions", "ANATOMY", 215, 237], ["blood", "ANATOMY", 239, 244], ["stool", "ANATOMY", 248, 253], ["cell cultures", "ANATOMY", 269, 282], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["Viral", "ORGANISM", 172, 177], ["cultureSARS-CoV", "GENE_OR_GENE_PRODUCT", 178, 193], ["respiratory secretions", "ORGANISM_SUBSTANCE", 215, 237], ["blood", "ORGANISM_SUBSTANCE", 239, 244], ["stool", "ORGANISM_SUBSTANCE", 248, 253], ["cell cultures", "CELL", 269, 282], ["IgG", "PROTEIN", 0, 3], ["neutralising antibodies", "PROTEIN", 105, 128], ["Viral cultureSARS-CoV", "SPECIES", 172, 193], ["IgG", "TEST", 0, 3], ["the illness", "PROBLEM", 51, 62], ["persisting protective neutralising antibodies", "TREATMENT", 83, 128], ["Viral cultureSARS", "TEST", 172, 189], ["CoV", "PROBLEM", 190, 193], ["respiratory secretions", "PROBLEM", 215, 237], ["blood or stool by inoculating cell cultures", "TEST", 239, 282], ["the virus", "PROBLEM", 295, 304], ["stool", "ANATOMY", 248, 253]]], ["Vero E6 cells and fetal rhesus monkey kidney cells are suitable to support the viral growth, with the cytopathic effect demonstrable by 2-6 and 2-4 days respectively after inoculation.", [["Vero E6 cells", "ANATOMY", 0, 13], ["fetal", "ANATOMY", 18, 23], ["kidney cells", "ANATOMY", 38, 50], ["Vero E6 cells", "CELL", 0, 13], ["rhesus", "ORGANISM", 24, 30], ["monkey", "ORGANISM", 31, 37], ["kidney cells", "CELL", 38, 50], ["Vero E6 cells", "CELL_LINE", 0, 13], ["fetal rhesus monkey kidney cells", "CELL_TYPE", 18, 50], ["rhesus monkey", "SPECIES", 24, 37], ["Vero E6", "SPECIES", 0, 7], ["rhesus monkey", "SPECIES", 24, 37], ["Vero E6 cells", "TREATMENT", 0, 13], ["fetal rhesus monkey kidney cells", "TREATMENT", 18, 50], ["the viral growth", "PROBLEM", 75, 91], ["the cytopathic effect", "PROBLEM", 98, 119], ["inoculation", "PROBLEM", 172, 183], ["E6 cells", "OBSERVATION", 5, 13], ["viral growth", "OBSERVATION", 79, 91], ["cytopathic", "OBSERVATION_MODIFIER", 102, 112]]], ["[1] [2] [3] The cultured virus must be identified as SARS-CoV with further tests, primarily RT-PCR assays.", [["virus", "ORGANISM", 25, 30], ["SARS-CoV", "ORGANISM", 53, 61], ["SARS-CoV", "SPECIES", 53, 61], ["The cultured virus", "PROBLEM", 12, 30], ["SARS", "PROBLEM", 53, 57], ["further tests", "TEST", 67, 80], ["RT-PCR assays", "TEST", 92, 105]]], ["61 The major limitation of viral culture in SARS is its very low sensitivity.", [["SARS", "DISEASE", 44, 48], ["viral culture", "TEST", 27, 40], ["SARS", "PROBLEM", 44, 48], ["very low sensitivity", "PROBLEM", 56, 76], ["major", "OBSERVATION_MODIFIER", 7, 12], ["limitation", "OBSERVATION_MODIFIER", 13, 23], ["viral culture", "OBSERVATION", 27, 40]]], ["In one paediatric series, the virus was only successfully isolated from NPA cultures in 16% of children.", [["NPA cultures", "ANATOMY", 72, 84], ["NPA cultures", "CELL", 72, 84], ["children", "ORGANISM", 95, 103], ["NPA cultures", "CELL_LINE", 72, 84], ["children", "SPECIES", 95, 103], ["the virus", "PROBLEM", 26, 35], ["NPA cultures", "TEST", 72, 84]]], ["23 Negative cell culture results, like negative RT-PCR results, do not exclude SARS infection.", [["cell", "ANATOMY", 12, 16], ["SARS infection", "DISEASE", 79, 93], ["cell", "CELL", 12, 16], ["cell culture", "TEST", 12, 24], ["RT-PCR", "TEST", 48, 54], ["SARS infection", "PROBLEM", 79, 93], ["infection", "OBSERVATION", 84, 93]]], ["Cell culture is also a very demanding test and primary virus isolation takes too long to be meaningful for early diagnosis.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell culture", "TEST", 0, 12], ["a very demanding test", "PROBLEM", 21, 42], ["primary virus isolation", "PROBLEM", 47, 70]]], ["Furthermore, amplification of the viable virus is associated with a potential biohazard, necessitating biosafety level three containment.", [["the viable virus", "PROBLEM", 30, 46], ["a potential biohazard", "TREATMENT", 66, 87], ["biosafety level three containment", "TREATMENT", 103, 136], ["virus", "OBSERVATION", 41, 46]]], ["Culture-based diagnostic techniques are unlikely to be widely available but with the exception of animal inoculation, it is the only way to show the existence of viable SARS-CoV.", [["SARS", "DISEASE", 169, 173], ["SARS-CoV", "ORGANISM", 169, 177], ["SARS-CoV", "SPECIES", 169, 177], ["Culture", "TEST", 0, 7], ["diagnostic techniques", "TEST", 14, 35], ["animal inoculation", "PROBLEM", 98, 116], ["inoculation", "OBSERVATION", 105, 116], ["viable", "OBSERVATION_MODIFIER", 162, 168], ["SARS", "OBSERVATION", 169, 173]]], ["4, 72 The usual 'gold standard' of microbiological diagnosis, namely the isolation of the pathogen, has limited application in SARS.TREATMENTDuring the global outbreak of SARS, it was understandable that treatment was empiric, given the explosive epidemic of a life-threatening infection in multiple countries before the viral agent was even identified.", [["SARS", "DISEASE", 127, 131], ["SARS", "DISEASE", 171, 175], ["infection", "DISEASE", 278, 287], ["microbiological diagnosis", "TEST", 35, 60], ["the pathogen", "PROBLEM", 86, 98], ["SARS", "PROBLEM", 171, 175], ["treatment", "TREATMENT", 204, 213], ["empiric", "TREATMENT", 218, 225], ["a life-threatening infection", "PROBLEM", 259, 287], ["the viral agent", "TREATMENT", 317, 332], ["global", "OBSERVATION_MODIFIER", 152, 158], ["outbreak", "OBSERVATION_MODIFIER", 159, 167], ["infection", "OBSERVATION", 278, 287]]], ["Time for planning, let alone conducting, a well-designed prospective clinical trial to assess the efficacy of any treatment regimen was simply not there.TREATMENTA proposed regimen consisting of antibiotics, ribavirin and corticosteroids was based on initial anecdotal successes in 2 outbreak studies in adult patients.", [["ribavirin", "CHEMICAL", 208, 217], ["ribavirin", "CHEMICAL", 208, 217], ["corticosteroids", "CHEMICAL", 222, 237], ["ribavirin", "SIMPLE_CHEMICAL", 208, 217], ["corticosteroids", "SIMPLE_CHEMICAL", 222, 237], ["patients", "ORGANISM", 310, 318], ["patients", "SPECIES", 310, 318], ["any treatment regimen", "TREATMENT", 110, 131], ["TREATMENTA proposed regimen", "TREATMENT", 153, 180], ["antibiotics", "TREATMENT", 195, 206], ["ribavirin", "TREATMENT", 208, 217], ["corticosteroids", "TREATMENT", 222, 237]]], ["6, 28 Subsequently, a standard treatment protocol was developed by a group of physicians in Hong Kong, which included (1) antibiotics for treatment of community-acquired pneumonia caused by usual and by atypical pathogens, (2) ribavirin as a broad-spectrum antiviral agent targeting the presumed viral etiology of SARS, and (3) immunomodulating agents in the form of glucocorticoids.", [["pneumonia", "DISEASE", 170, 179], ["ribavirin", "CHEMICAL", 227, 236], ["SARS", "DISEASE", 314, 318], ["glucocorticoids", "CHEMICAL", 367, 382], ["ribavirin", "CHEMICAL", 227, 236], ["ribavirin", "SIMPLE_CHEMICAL", 227, 236], ["glucocorticoids", "SIMPLE_CHEMICAL", 367, 382], ["a standard treatment protocol", "TREATMENT", 20, 49], ["antibiotics", "TREATMENT", 122, 133], ["treatment", "TREATMENT", 138, 147], ["community-acquired pneumonia", "PROBLEM", 151, 179], ["atypical pathogens", "PROBLEM", 203, 221], ["ribavirin", "TREATMENT", 227, 236], ["a broad-spectrum antiviral agent", "TREATMENT", 240, 272], ["SARS", "PROBLEM", 314, 318], ["immunomodulating agents", "TREATMENT", 328, 351], ["glucocorticoids", "TREATMENT", 367, 382], ["pneumonia", "OBSERVATION", 170, 179], ["atypical", "OBSERVATION_MODIFIER", 203, 211], ["pathogens", "OBSERVATION", 212, 221], ["presumed", "UNCERTAINTY", 287, 295], ["viral", "OBSERVATION_MODIFIER", 296, 301], ["glucocorticoids", "OBSERVATION", 367, 382]]], ["73 A similar regimen in children consisting of antibiotics and ribavirin, with or without corticosteroids, was used.", [["ribavirin", "CHEMICAL", 63, 72], ["ribavirin", "CHEMICAL", 63, 72], ["children", "ORGANISM", 24, 32], ["ribavirin", "SIMPLE_CHEMICAL", 63, 72], ["children", "SPECIES", 24, 32], ["A similar regimen", "TREATMENT", 3, 20], ["antibiotics", "TREATMENT", 47, 58], ["ribavirin", "TREATMENT", 63, 72], ["corticosteroids", "TREATMENT", 90, 105]]], ["21, 74, 75 In adult patients, the high incidence of deranged liver function, leucopaenia, severe lymphopaenia, thrombocytopaenia and progression to ARDS suggests severe systemic inflammatory damage induced by SARS-CoV.", [["liver", "ANATOMY", 61, 66], ["deranged liver function", "DISEASE", 52, 75], ["leucopaenia", "DISEASE", 77, 88], ["lymphopaenia", "DISEASE", 97, 109], ["thrombocytopaenia", "DISEASE", 111, 128], ["ARDS", "DISEASE", 148, 152], ["inflammatory damage", "DISEASE", 178, 197], ["SARS", "DISEASE", 209, 213], ["patients", "ORGANISM", 20, 28], ["liver", "ORGAN", 61, 66], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 209, 217], ["patients", "SPECIES", 20, 28], ["SARS-CoV", "SPECIES", 209, 217], ["deranged liver function", "PROBLEM", 52, 75], ["leucopaenia", "PROBLEM", 77, 88], ["severe lymphopaenia", "PROBLEM", 90, 109], ["thrombocytopaenia", "PROBLEM", 111, 128], ["ARDS", "PROBLEM", 148, 152], ["severe systemic inflammatory damage", "PROBLEM", 162, 197], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["liver", "ANATOMY", 61, 66], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["lymphopaenia", "OBSERVATION", 97, 109], ["thrombocytopaenia", "OBSERVATION", 111, 128], ["ARDS", "OBSERVATION", 148, 152], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["systemic", "OBSERVATION_MODIFIER", 169, 177], ["inflammatory", "OBSERVATION", 178, 190]]], ["1 The pathogenesis of the infection is postulated as an over-exuberant immunopathological reaction or a ''cytokine storm'' resulting from unrestricted viral replication during the early stages of the disease.", [["infection", "DISEASE", 26, 35], ["cytokine", "PROTEIN", 106, 114], ["the infection", "PROBLEM", 22, 35], ["exuberant immunopathological reaction", "PROBLEM", 61, 98], ["a ''cytokine storm''", "PROBLEM", 102, 122], ["unrestricted viral replication", "TREATMENT", 138, 168], ["the disease", "PROBLEM", 196, 207], ["infection", "OBSERVATION", 26, 35], ["exuberant", "OBSERVATION_MODIFIER", 61, 70], ["immunopathological", "OBSERVATION", 71, 89], ["viral replication", "OBSERVATION", 151, 168], ["disease", "OBSERVATION", 200, 207]]], ["Findings consistent with cytokine dysregulation are the radiological changes of multifocal, flitting, BOOP-like features with progression to ARDS, the histological changes of macrophage infiltration and diffuse alveolar damage and the dramatic clinical and radiologic improvement with high-dose corticosteroid therapy.", [["macrophage", "ANATOMY", 175, 185], ["alveolar", "ANATOMY", 211, 219], ["BOOP", "DISEASE", 102, 106], ["ARDS", "DISEASE", 141, 145], ["alveolar damage", "DISEASE", 211, 226], ["macrophage", "CELL", 175, 185], ["alveolar", "MULTI-TISSUE_STRUCTURE", 211, 219], ["corticosteroid", "SIMPLE_CHEMICAL", 295, 309], ["cytokine", "PROTEIN", 25, 33], ["cytokine dysregulation", "PROBLEM", 25, 47], ["multifocal, flitting", "PROBLEM", 80, 100], ["BOOP", "PROBLEM", 102, 106], ["ARDS", "PROBLEM", 141, 145], ["macrophage infiltration", "PROBLEM", 175, 198], ["diffuse alveolar damage", "PROBLEM", 203, 226], ["high-dose corticosteroid therapy", "TREATMENT", 285, 317], ["consistent with", "UNCERTAINTY", 9, 24], ["cytokine dysregulation", "OBSERVATION", 25, 47], ["multifocal", "OBSERVATION_MODIFIER", 80, 90], ["BOOP", "OBSERVATION", 102, 106], ["progression", "OBSERVATION_MODIFIER", 126, 137], ["ARDS", "OBSERVATION", 141, 145], ["macrophage infiltration", "OBSERVATION", 175, 198], ["diffuse", "OBSERVATION_MODIFIER", 203, 210], ["alveolar damage", "OBSERVATION", 211, 226], ["dramatic", "OBSERVATION_MODIFIER", 235, 243]]], ["1, 76 The viral load in SARS followed an inverted V pattern, with progressive fall in viral shedding after day 10-15, correlating with seroconversion.", [["SARS", "DISEASE", 24, 28], ["The viral load", "TEST", 6, 20], ["SARS", "PROBLEM", 24, 28], ["an inverted V pattern", "PROBLEM", 38, 59], ["progressive fall in viral shedding", "PROBLEM", 66, 100], ["seroconversion", "PROBLEM", 135, 149], ["viral load", "OBSERVATION", 10, 20], ["inverted V pattern", "OBSERVATION", 41, 59], ["progressive", "OBSERVATION_MODIFIER", 66, 77], ["fall", "OBSERVATION", 78, 82], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["seroconversion", "OBSERVATION", 135, 149]]], ["35 The logical approach to preventing severe disease is to restrict viral replication and to modulate inappropriate immunological responses.", [["The logical approach", "TREATMENT", 3, 23], ["severe disease", "PROBLEM", 38, 52], ["viral replication", "TREATMENT", 68, 85], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["disease", "OBSERVATION", 45, 52]]], ["In principle, antiviral agent should be prescribed first during the phase of active viral replication, followed by an immunomodulator if the former fails and the patient is affected by immune hyperactivation.TREATMENTThe use of ribavirin in adults and children has been reported by groups of investigators worldwide.", [["ribavirin", "CHEMICAL", 228, 237], ["ribavirin", "CHEMICAL", 228, 237], ["patient", "ORGANISM", 162, 169], ["ribavirin", "SIMPLE_CHEMICAL", 228, 237], ["children", "ORGANISM", 252, 260], ["patient", "SPECIES", 162, 169], ["children", "SPECIES", 252, 260], ["antiviral agent", "TREATMENT", 14, 29], ["active viral replication", "TREATMENT", 77, 101], ["an immunomodulator", "TREATMENT", 115, 133], ["immune hyperactivation", "PROBLEM", 185, 207], ["TREATMENT", "TREATMENT", 208, 217], ["ribavirin", "TREATMENT", 228, 237], ["viral replication", "OBSERVATION", 84, 101], ["immune hyperactivation", "OBSERVATION", 185, 207], ["ribavirin", "OBSERVATION", 228, 237]]], ["1, 6, [21] [22] [23] [24] [28] [29] [30] 35, [77] [78] [79] [80] [81] [82] Ribavirin was empirically chosen in SARS because of its broad-spectrum of activities against DNA and RNA viruses.", [["1, 6, [21] [22] [23] [24] [28] [29] [30] 35, [77] [78] [79] [80] [81] [82", "CHEMICAL", 0, 73], ["Ribavirin", "CHEMICAL", 75, 84], ["SARS", "DISEASE", 111, 115], ["1, 6, [21] [22] [23] [24] [28] [29] [30] 35", "CHEMICAL", 0, 43], ["[77] [78] [79] [80] [81] [82] Ribavirin", "CHEMICAL", 45, 84], ["[21] [22] [23] [24] [28] [29] [30] 35", "SIMPLE_CHEMICAL", 6, 43], ["[77] [78] [79] [80] [81] [82] Ribavirin", "SIMPLE_CHEMICAL", 45, 84], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["Ribavirin", "TREATMENT", 75, 84], ["DNA", "PROBLEM", 168, 171], ["RNA viruses", "PROBLEM", 176, 187]]], ["Ribavirin was also known to be effective in the treatment of fulminant murine hepatitis, which is caused by an animal coronavirus.", [["Ribavirin", "CHEMICAL", 0, 9], ["fulminant murine hepatitis", "DISEASE", 61, 87], ["Ribavirin", "CHEMICAL", 0, 9], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["murine", "ORGANISM", 71, 77], ["murine", "SPECIES", 71, 77], ["coronavirus", "SPECIES", 118, 129], ["Ribavirin", "TREATMENT", 0, 9], ["fulminant murine hepatitis", "PROBLEM", 61, 87], ["an animal coronavirus", "PROBLEM", 108, 129], ["fulminant murine hepatitis", "OBSERVATION", 61, 87], ["animal coronavirus", "OBSERVATION", 111, 129]]], ["In the murine hepatitis model, ribavirin exerted an immunomodulatory effect by decreasing the release of proinflammatory cytokines from the macrophages and switching the immune response from a Th 2 to a Th 1 response.", [["macrophages", "ANATOMY", 140, 151], ["hepatitis", "DISEASE", 14, 23], ["ribavirin", "CHEMICAL", 31, 40], ["ribavirin", "CHEMICAL", 31, 40], ["murine", "ORGANISM", 7, 13], ["ribavirin", "SIMPLE_CHEMICAL", 31, 40], ["macrophages", "CELL", 140, 151], ["Th 2", "GENE_OR_GENE_PRODUCT", 193, 197], ["Th 1", "GENE_OR_GENE_PRODUCT", 203, 207], ["proinflammatory cytokines", "PROTEIN", 105, 130], ["macrophages", "CELL_TYPE", 140, 151], ["murine", "SPECIES", 7, 13], ["the murine hepatitis model", "TREATMENT", 3, 29], ["ribavirin", "TREATMENT", 31, 40], ["proinflammatory cytokines", "PROBLEM", 105, 130], ["the macrophages", "PROBLEM", 136, 151], ["hepatitis", "OBSERVATION", 14, 23], ["immunomodulatory effect", "OBSERVATION", 52, 75], ["proinflammatory cytokines", "OBSERVATION", 105, 130], ["macrophages", "OBSERVATION", 140, 151]]], ["83, 84 However, it was later learnt that ribavirin demonstrated no or minimal activity against SARS-CoV isolates in vitro.", [["ribavirin", "CHEMICAL", 41, 50], ["SARS", "DISEASE", 95, 99], ["ribavirin", "CHEMICAL", 41, 50], ["ribavirin", "SIMPLE_CHEMICAL", 41, 50], ["SARS-CoV", "ORGANISM", 95, 103], ["SARS-CoV", "SPECIES", 95, 103], ["ribavirin", "TREATMENT", 41, 50], ["SARS", "PROBLEM", 95, 99], ["CoV isolates", "TEST", 100, 112]]], ["85, 86 In vitro testing indicated that ribavirin failed to inhibit replication or cell to cell spread at low drug concentrations.", [["cell", "ANATOMY", 82, 86], ["cell", "ANATOMY", 90, 94], ["ribavirin", "CHEMICAL", 39, 48], ["ribavirin", "CHEMICAL", 39, 48], ["ribavirin", "SIMPLE_CHEMICAL", 39, 48], ["cell", "CELL", 82, 86], ["cell", "CELL", 90, 94], ["vitro testing", "TEST", 10, 23], ["ribavirin", "TREATMENT", 39, 48], ["cell to cell spread", "PROBLEM", 82, 101], ["ribavirin", "OBSERVATION", 39, 48]]], ["87 Although inhibitory activity was demonstrated at high drug concentrations, the resultant cytotoxic effects were undesirable.", [["high drug concentrations", "PROBLEM", 52, 76], ["the resultant cytotoxic effects", "PROBLEM", 78, 109], ["cytotoxic effects", "OBSERVATION", 92, 109]]], ["88 It appeared that due to the low activity of ribavirin in vitro, inhibitory concentrations might not be achieved clinically without causing significant toxicity.TREATMENTInvestigators in Canada have generally used ribavirin at a higher dosage similar to that recommended for treatment of several viral haemorrhagic fever syndromes and have observed severe adverse events in adult patients.", [["ribavirin", "CHEMICAL", 47, 56], ["toxicity", "DISEASE", 154, 162], ["ribavirin", "CHEMICAL", 216, 225], ["viral haemorrhagic fever", "DISEASE", 298, 322], ["ribavirin", "CHEMICAL", 47, 56], ["ribavirin", "CHEMICAL", 216, 225], ["ribavirin", "SIMPLE_CHEMICAL", 47, 56], ["ribavirin", "SIMPLE_CHEMICAL", 216, 225], ["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 382, 390], ["ribavirin", "TREATMENT", 47, 56], ["inhibitory concentrations", "TREATMENT", 67, 92], ["significant toxicity", "PROBLEM", 142, 162], ["TREATMENTInvestigators", "TREATMENT", 163, 185], ["ribavirin", "TREATMENT", 216, 225], ["a higher dosage", "TREATMENT", 229, 244], ["treatment", "TREATMENT", 277, 286], ["several viral haemorrhagic fever syndromes", "PROBLEM", 290, 332], ["severe adverse events", "PROBLEM", 351, 372], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["toxicity", "OBSERVATION", 154, 162], ["viral", "OBSERVATION_MODIFIER", 298, 303], ["haemorrhagic", "OBSERVATION_MODIFIER", 304, 316], ["severe", "OBSERVATION_MODIFIER", 351, 357]]], ["Booth et al. reported that 40% of patients had elevated hepatic transaminase levels, 14% had sinus bradycardia, 76% had haemolysis with haemoglobin levels declining by at least 2g/ dL in 49% and that 18% had to discontinue treatment.", [["hepatic", "ANATOMY", 56, 63], ["sinus", "ANATOMY", 93, 98], ["sinus bradycardia", "DISEASE", 93, 110], ["haemolysis", "DISEASE", 120, 130], ["patients", "ORGANISM", 34, 42], ["hepatic", "ORGAN", 56, 63], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 136, 147], ["patients", "SPECIES", 34, 42], ["elevated hepatic transaminase levels", "PROBLEM", 47, 83], ["sinus bradycardia", "PROBLEM", 93, 110], ["haemolysis", "PROBLEM", 120, 130], ["haemoglobin levels", "TEST", 136, 154], ["treatment", "TREATMENT", 223, 232], ["elevated", "OBSERVATION", 47, 55], ["hepatic", "ANATOMY", 56, 63], ["transaminase levels", "OBSERVATION", 64, 83]]], ["30 Knowles et al. reported that 61%, 58% and 46% of 110 patients had haemolytic anemia, hypocalcemia and hypomagnesaemia, respectively.", [["haemolytic anemia", "DISEASE", 69, 86], ["hypocalcemia", "DISEASE", 88, 100], ["hypomagnesaemia", "DISEASE", 105, 120], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["haemolytic anemia", "PROBLEM", 69, 86], ["hypocalcemia", "PROBLEM", 88, 100], ["hypomagnesaemia", "PROBLEM", 105, 120], ["haemolytic", "OBSERVATION_MODIFIER", 69, 79], ["anemia", "OBSERVATION", 80, 86], ["hypocalcemia", "OBSERVATION", 88, 100], ["hypomagnesaemia", "OBSERVATION", 105, 120]]], ["89 Children appear to tolerate ribavirin much better than their adult counterparts.", [["ribavirin", "CHEMICAL", 31, 40], ["ribavirin", "CHEMICAL", 31, 40], ["Children", "ORGANISM", 3, 11], ["Children", "SPECIES", 3, 11], ["ribavirin", "TREATMENT", 31, 40], ["ribavirin", "OBSERVATION", 31, 40]]], ["[21] [22] [23] [24] Solid clinical data to demonstrate the efficacy of ribavirin is lacking.", [["ribavirin", "CHEMICAL", 71, 80], ["ribavirin", "CHEMICAL", 71, 80], ["[21] [22] [23", "SIMPLE_CHEMICAL", 0, 13], ["ribavirin", "SIMPLE_CHEMICAL", 71, 80], ["Solid clinical data", "TEST", 20, 39], ["ribavirin", "TREATMENT", 71, 80], ["ribavirin", "OBSERVATION", 71, 80]]], ["The limited data suggest that, at least in adults, dosages of about 2g/d might be effective while not causing severe adverse reactions.", [["severe adverse reactions", "PROBLEM", 110, 134]]], ["Such doses should be considered for further studies.", [["further studies", "TEST", 36, 51]]], ["85 The only randomised controlled trial involving the use of ribavirin in the treatment of SARS was conducted in China by Zhao et al. The open-label study failed to demonstrate any efficacy and led the investigators to conclude that ribavirin, given at 400-600 mg/d, was less effective than early and aggressive use of corticosteroids combined with non-invasive ventilatory support.", [["ribavirin", "CHEMICAL", 61, 70], ["SARS", "DISEASE", 91, 95], ["ribavirin", "CHEMICAL", 233, 242], ["ribavirin", "CHEMICAL", 61, 70], ["ribavirin", "CHEMICAL", 233, 242], ["corticosteroids", "CHEMICAL", 319, 334], ["ribavirin", "SIMPLE_CHEMICAL", 61, 70], ["ribavirin", "SIMPLE_CHEMICAL", 233, 242], ["corticosteroids", "SIMPLE_CHEMICAL", 319, 334], ["ribavirin", "TREATMENT", 61, 70], ["SARS", "PROBLEM", 91, 95], ["The open-label study", "TEST", 134, 154], ["ribavirin", "TREATMENT", 233, 242], ["corticosteroids", "TREATMENT", 319, 334], ["non-invasive ventilatory support", "TREATMENT", 349, 381], ["ventilatory support", "OBSERVATION", 362, 381]]], ["77 Non-randomised studies of corticosteroids have been reported in both adults and children with seemingly favourable outcomes in terms of clinical and radiologic improvements, suggesting that the combined use of ribavirin and corticosteroids might be effective.", [["corticosteroids", "CHEMICAL", 29, 44], ["ribavirin", "CHEMICAL", 213, 222], ["corticosteroids", "CHEMICAL", 227, 242], ["corticosteroids", "CHEMICAL", 29, 44], ["ribavirin", "CHEMICAL", 213, 222], ["corticosteroids", "CHEMICAL", 227, 242], ["children", "ORGANISM", 83, 91], ["ribavirin", "SIMPLE_CHEMICAL", 213, 222], ["corticosteroids", "SIMPLE_CHEMICAL", 227, 242], ["children", "SPECIES", 83, 91], ["Non-randomised studies", "TEST", 3, 25], ["corticosteroids", "TREATMENT", 29, 44], ["ribavirin", "TREATMENT", 213, 222], ["corticosteroids", "TREATMENT", 227, 242]]], ["1, 6, [21] [22] [23] 28, 33, 35, 73, 82, 90, 91 Other reports on the combined regimen were inconclusive or failed to demonstrate obvious benefit.", [["[21] [22] [23", "SIMPLE_CHEMICAL", 6, 19], ["the combined regimen", "TREATMENT", 65, 85]]], ["30, 78, 79 In the paediatric series reported by Leung et al., 95% and 84% of the 44 children with laboratory-confirmed SARS were treated with ribavirin and corticosteroids respectively, without significant adverse events and all patients recovered.", [["SARS", "DISEASE", 119, 123], ["ribavirin", "CHEMICAL", 142, 151], ["ribavirin", "CHEMICAL", 142, 151], ["corticosteroids", "CHEMICAL", 156, 171], ["children", "ORGANISM", 84, 92], ["ribavirin", "SIMPLE_CHEMICAL", 142, 151], ["patients", "ORGANISM", 229, 237], ["children", "SPECIES", 84, 92], ["patients", "SPECIES", 229, 237], ["SARS", "PROBLEM", 119, 123], ["ribavirin", "TREATMENT", 142, 151], ["corticosteroids", "TREATMENT", 156, 171], ["significant adverse events", "PROBLEM", 194, 220]]], ["23 In the series reported by Chiu et al., 95% and 62% of the 21 children received ribavirin and corticosteroids, respectively and achieved similar outcomes.", [["ribavirin", "CHEMICAL", 82, 91], ["ribavirin", "CHEMICAL", 82, 91], ["corticosteroids", "CHEMICAL", 96, 111], ["children", "ORGANISM", 64, 72], ["ribavirin", "SIMPLE_CHEMICAL", 82, 91], ["children", "SPECIES", 64, 72], ["ribavirin", "TREATMENT", 82, 91], ["corticosteroids", "TREATMENT", 96, 111]]], ["22 All were subsequently confirmed by seroconversion to SARS-CoV after the report was published.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV", "ORGANISM", 56, 64], ["SARS-CoV", "SPECIES", 56, 64]]], ["Bitnun et al. reported the use of ribavirin without corticosteroids in 10 children with probable SARS but virologic confirmation was lacking.", [["ribavirin", "CHEMICAL", 34, 43], ["SARS", "DISEASE", 97, 101], ["ribavirin", "CHEMICAL", 34, 43], ["corticosteroids", "CHEMICAL", 52, 67], ["ribavirin", "SIMPLE_CHEMICAL", 34, 43], ["children", "ORGANISM", 74, 82], ["children", "SPECIES", 74, 82], ["ribavirin", "TREATMENT", 34, 43], ["corticosteroids", "TREATMENT", 52, 67], ["SARS", "PROBLEM", 97, 101], ["virologic confirmation", "TEST", 106, 128]]], ["24 In contrast, Zeng et al. treated 33 children with Chinese traditional medicine and antibiotics with good results.", [["children", "ORGANISM", 39, 47], ["children", "SPECIES", 39, 47], ["Chinese traditional medicine", "TREATMENT", 53, 81], ["antibiotics", "TREATMENT", 86, 97]]], ["Only 10 of the children had an epidemiologic link to SARS, however, and virologic data were not available.", [["SARS", "DISEASE", 53, 57], ["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["virologic data", "TEST", 72, 86]]], ["92 The use of corticosteroids in viral infections is controversial and is potentially hazardous.", [["corticosteroids", "CHEMICAL", 14, 29], ["viral infections", "DISEASE", 33, 49], ["corticosteroids", "CHEMICAL", 14, 29], ["corticosteroids", "TREATMENT", 14, 29], ["viral infections", "PROBLEM", 33, 49], ["corticosteroids", "OBSERVATION", 14, 29], ["viral infections", "OBSERVATION", 33, 49], ["hazardous", "OBSERVATION_MODIFIER", 86, 95]]], ["As an immunosuppressive agent, corticosteroids might promote viral replication, enhance infectivity and possibly cause a rebound of infection.", [["corticosteroids", "CHEMICAL", 31, 46], ["infection", "DISEASE", 132, 141], ["corticosteroids", "CHEMICAL", 31, 46], ["corticosteroids", "SIMPLE_CHEMICAL", 31, 46], ["an immunosuppressive agent", "TREATMENT", 3, 29], ["corticosteroids", "TREATMENT", 31, 46], ["viral replication", "TREATMENT", 61, 78], ["enhance infectivity", "PROBLEM", 80, 99], ["a rebound of infection", "PROBLEM", 119, 141], ["viral replication", "OBSERVATION", 61, 78], ["rebound", "OBSERVATION_MODIFIER", 121, 128], ["infection", "OBSERVATION", 132, 141]]], ["It is known that in acute viral respiratory infections, early-response cytokines such as tumour necrosis factor, interleukin-1 and interleukin-6 mediate lung injury.", [["respiratory", "ANATOMY", 32, 43], ["lung", "ANATOMY", 153, 157], ["viral respiratory infections", "DISEASE", 26, 54], ["necrosis", "DISEASE", 96, 104], ["lung injury", "DISEASE", 153, 164], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 89, 111], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 113, 126], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 131, 144], ["lung", "ORGAN", 153, 157], ["cytokines", "PROTEIN", 71, 80], ["tumour necrosis factor", "PROTEIN", 89, 111], ["interleukin-1", "PROTEIN", 113, 126], ["interleukin-6", "PROTEIN", 131, 144], ["acute viral respiratory infections", "PROBLEM", 20, 54], ["early-response cytokines", "PROBLEM", 56, 80], ["tumour necrosis factor", "PROBLEM", 89, 111], ["interleukin", "TEST", 113, 124], ["interleukin-6 mediate lung injury", "PROBLEM", 131, 164], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["respiratory infections", "OBSERVATION", 32, 54], ["response cytokines", "OBSERVATION", 62, 80], ["tumour necrosis", "OBSERVATION", 89, 104], ["lung", "ANATOMY", 153, 157], ["injury", "OBSERVATION", 158, 164]]], ["The rationale for using corticosteroids is to suppress the ''cytokine storm'' which is thought to be the main factor accounting for the progression of disease.", [["corticosteroids", "CHEMICAL", 24, 39], ["cytokine", "PROTEIN", 61, 69], ["corticosteroids", "TREATMENT", 24, 39], ["disease", "PROBLEM", 151, 158], ["thought to be", "UNCERTAINTY", 87, 100], ["main", "OBSERVATION_MODIFIER", 105, 109], ["progression", "OBSERVATION_MODIFIER", 136, 147], ["disease", "OBSERVATION", 151, 158]]], ["But using corticosteroids with possibly ineffective antiviral therapy in patients with viral pneumonitis can be hazardous.", [["viral pneumonitis", "DISEASE", 87, 104], ["corticosteroids", "CHEMICAL", 10, 25], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["corticosteroids", "TREATMENT", 10, 25], ["ineffective antiviral therapy", "TREATMENT", 40, 69], ["viral pneumonitis", "PROBLEM", 87, 104], ["possibly", "UNCERTAINTY", 31, 39], ["ineffective", "OBSERVATION_MODIFIER", 40, 51], ["antiviral therapy", "OBSERVATION", 52, 69], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["pneumonitis", "OBSERVATION", 93, 104]]], ["93 Despite the initial success of corticosteroids in the treatment of SARS, the report of an adult patient whose clinical course was complicated by fatal aspergillosis was disturbing and had even led others to recommend close laboratory monitoring for aspergillosis in SARS patients receiving corticosteroids.", [["corticosteroids", "CHEMICAL", 34, 49], ["SARS", "DISEASE", 70, 74], ["aspergillosis", "DISEASE", 154, 167], ["aspergillosis", "DISEASE", 252, 265], ["SARS", "DISEASE", 269, 273], ["corticosteroids", "CHEMICAL", 34, 49], ["corticosteroids", "CHEMICAL", 293, 308], ["patient", "ORGANISM", 99, 106], ["patients", "ORGANISM", 274, 282], ["patient", "SPECIES", 99, 106], ["patients", "SPECIES", 274, 282], ["corticosteroids", "TREATMENT", 34, 49], ["SARS", "PROBLEM", 70, 74], ["fatal aspergillosis", "PROBLEM", 148, 167], ["close laboratory monitoring", "TEST", 220, 247], ["aspergillosis", "PROBLEM", 252, 265], ["SARS", "PROBLEM", 269, 273], ["corticosteroids", "TREATMENT", 293, 308], ["fatal", "OBSERVATION_MODIFIER", 148, 153], ["aspergillosis", "OBSERVATION", 154, 167], ["aspergillosis", "OBSERVATION", 252, 265]]], ["94, 95 In retrospect, we do not think that ribavirin alone has any significant effect in halting disease progression and corticosteroids are probably unnecessary for children who do not develop moderate to severe hypoxaemia.", [["ribavirin", "CHEMICAL", 43, 52], ["hypoxaemia", "DISEASE", 213, 223], ["ribavirin", "CHEMICAL", 43, 52], ["corticosteroids", "CHEMICAL", 121, 136], ["ribavirin", "SIMPLE_CHEMICAL", 43, 52], ["corticosteroids", "SIMPLE_CHEMICAL", 121, 136], ["children", "ORGANISM", 166, 174], ["children", "SPECIES", 166, 174], ["ribavirin", "TREATMENT", 43, 52], ["halting disease progression", "PROBLEM", 89, 116], ["corticosteroids", "TREATMENT", 121, 136], ["moderate to severe hypoxaemia", "PROBLEM", 194, 223], ["ribavirin", "OBSERVATION", 43, 52], ["moderate", "OBSERVATION_MODIFIER", 194, 202], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["hypoxaemia", "OBSERVATION", 213, 223]]], ["In our experience, as with others, corticosteroids may be life saving in patients who are threatened by impending acute respiratory failure.", [["respiratory", "ANATOMY", 120, 131], ["acute respiratory failure", "DISEASE", 114, 139], ["corticosteroids", "CHEMICAL", 35, 50], ["corticosteroids", "SIMPLE_CHEMICAL", 35, 50], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["corticosteroids", "TREATMENT", 35, 50], ["impending acute respiratory failure", "PROBLEM", 104, 139], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory failure", "OBSERVATION", 120, 139]]], ["We cannot categorically recommend this treatment strategy in view of the small number of children treated and the lack of objective evidence from a controlled trial.", [["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["this treatment strategy", "TREATMENT", 34, 57], ["a controlled trial", "TREATMENT", 146, 164], ["small", "OBSERVATION_MODIFIER", 73, 78]]], ["The place of corticosteroids in the rescue therapy of patients who have clearly experienced failure of supportive care remains to be determined.TREATMENTNo evidence-based therapeutic approach for SARS exists although more than 30 papers have been published internationally that mention antiviral treatment.", [["corticosteroids", "CHEMICAL", 13, 28], ["SARS", "DISEASE", 196, 200], ["corticosteroids", "CHEMICAL", 13, 28], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["corticosteroids", "TREATMENT", 13, 28], ["the rescue therapy", "TREATMENT", 32, 50], ["supportive care", "TREATMENT", 103, 118], ["SARS", "PROBLEM", 196, 200], ["antiviral treatment", "TREATMENT", 286, 305], ["corticosteroids", "OBSERVATION", 13, 28], ["antiviral treatment", "OBSERVATION", 286, 305]]], ["Various other antiviral and immunomodulating agents have been used in adult patients with preliminary success.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Various other antiviral", "TREATMENT", 0, 23], ["immunomodulating agents", "TREATMENT", 28, 51], ["antiviral", "OBSERVATION", 14, 23]]], ["These include the use of lopinavir / ritonavir in combination with ribavirin and corticosteroids, interferon a plus corticosteroids and convalescent plasma from patients.", [["plasma", "ANATOMY", 149, 155], ["lopinavir / ritonavir", "CHEMICAL", 25, 46], ["ribavirin", "CHEMICAL", 67, 76], ["lopinavir", "CHEMICAL", 25, 34], ["ritonavir", "CHEMICAL", 37, 46], ["ribavirin", "CHEMICAL", 67, 76], ["corticosteroids", "CHEMICAL", 81, 96], ["lopinavir", "SIMPLE_CHEMICAL", 25, 34], ["ritonavir", "SIMPLE_CHEMICAL", 37, 46], ["ribavirin", "SIMPLE_CHEMICAL", 67, 76], ["corticosteroids", "SIMPLE_CHEMICAL", 81, 96], ["corticosteroids", "SIMPLE_CHEMICAL", 116, 131], ["plasma", "ORGANISM_SUBSTANCE", 149, 155], ["patients", "ORGANISM", 161, 169], ["interferon", "PROTEIN", 98, 108], ["patients", "SPECIES", 161, 169], ["lopinavir", "TREATMENT", 25, 34], ["ritonavir", "TREATMENT", 37, 46], ["ribavirin", "TREATMENT", 67, 76], ["corticosteroids", "TREATMENT", 81, 96], ["interferon a plus corticosteroids", "TREATMENT", 98, 131], ["convalescent plasma", "TREATMENT", 136, 155]]], ["[96] [97] [98] [99] Their true role in the treatment of children is unknown.TREATMENTKnowledge generated by detailed bioinformatic analysis of the SARS-CoV genome can be harnessed to identify possible targets for antiviral therapy, such as enzymatic proteins of the viral replicase-transcriptase complex.", [["children", "ORGANISM", 56, 64], ["SARS-CoV", "ORGANISM", 147, 155], ["replicase-transcriptase complex", "GENE_OR_GENE_PRODUCT", 272, 303], ["SARS-CoV genome", "DNA", 147, 162], ["enzymatic proteins", "PROTEIN", 240, 258], ["viral replicase-transcriptase complex", "PROTEIN", 266, 303], ["children", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 147, 155], ["the SARS", "PROBLEM", 143, 151], ["CoV genome", "PROBLEM", 152, 162], ["antiviral therapy", "TREATMENT", 213, 230], ["enzymatic proteins", "TREATMENT", 240, 258], ["the viral replicase", "TREATMENT", 262, 281], ["viral replicase", "OBSERVATION", 266, 281]]], ["This approach has been reviewed by Davidson and Siddell who concluded that the most economical and effective way to contain the virus would be the therapeutic use of antiviral agents to block viral entry to target cells or to inhibit intracellular viral replication.", [["cells", "ANATOMY", 214, 219], ["intracellular", "ANATOMY", 234, 247], ["cells", "CELL", 214, 219], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 234, 247], ["target cells", "CELL_TYPE", 207, 219], ["the virus", "PROBLEM", 124, 133], ["antiviral agents", "TREATMENT", 166, 182], ["intracellular viral replication", "TREATMENT", 234, 265], ["viral replication", "OBSERVATION", 248, 265]]], ["100 In vitro studies have highlighted the antiviral potential of several compounds, including recombinant human interferon b-1a, interferon b-1b, glycyrrhizin, human monoclonal antibody against the spike protein of SARS-CoV and small interfering RNA.", [["interferon b-1b", "CHEMICAL", 129, 144], ["glycyrrhizin", "CHEMICAL", 146, 158], ["glycyrrhizin", "CHEMICAL", 146, 158], ["human", "ORGANISM", 106, 111], ["interferon b-1a", "GENE_OR_GENE_PRODUCT", 112, 127], ["interferon b-1b", "GENE_OR_GENE_PRODUCT", 129, 144], ["glycyrrhizin", "SIMPLE_CHEMICAL", 146, 158], ["human", "ORGANISM", 160, 165], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 215, 223], ["recombinant human interferon b-1a, interferon b-1b, glycyrrhizin, human monoclonal antibody", "PROTEIN", 94, 185], ["spike protein", "PROTEIN", 198, 211], ["SARS-CoV and small interfering RNA", "RNA", 215, 249], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 160, 165], ["SARS-CoV", "SPECIES", 215, 223], ["vitro studies", "TEST", 7, 20], ["recombinant human interferon b", "TREATMENT", 94, 124], ["interferon b", "TREATMENT", 129, 141], ["glycyrrhizin", "TREATMENT", 146, 158], ["human monoclonal antibody", "TREATMENT", 160, 185], ["SARS", "PROBLEM", 215, 219], ["CoV", "PROBLEM", 220, 223], ["small interfering RNA", "PROBLEM", 228, 249], ["small", "OBSERVATION_MODIFIER", 228, 233], ["interfering RNA", "OBSERVATION", 234, 249]]], ["[101] [102] [103] [104] [105] With more understanding of the pathogenesis as well as the clinical course of the disease, treatment will evolve.", [["the pathogenesis", "PROBLEM", 57, 73], ["the disease", "PROBLEM", 108, 119], ["treatment", "TREATMENT", 121, 130], ["disease", "OBSERVATION", 112, 119]]], ["The best treatment for SARS in adults and children remains unknown.", [["SARS", "DISEASE", 23, 27], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["SARS", "PROBLEM", 23, 27]]], ["Time is now on our side to plan for clinical trials should the disease re-emerge.", [["clinical trials", "TREATMENT", 36, 51], ["the disease re-emerge", "PROBLEM", 59, 80]]], ["With increased vigilance, rapid detection and effective infection control measures, outbreaks of SARS seem less likely.", [["infection", "DISEASE", 56, 65], ["SARS", "DISEASE", 97, 101], ["increased vigilance", "PROBLEM", 5, 24], ["rapid detection", "TEST", 26, 41], ["effective infection control measures", "TREATMENT", 46, 82], ["SARS", "PROBLEM", 97, 101], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["vigilance", "OBSERVATION", 15, 24], ["effective", "OBSERVATION_MODIFIER", 46, 55], ["infection", "OBSERVATION", 56, 65]]], ["It might never be possible, therefore, to recruit a sufficient number of patients to complete the trials and give us an early answer.PROGNOSISIn adults, the risk factors for severe illness are advanced age, high initial absolute neutrophil counts, low platelet counts, high initial or peak lactate dehydrogenase levels and positive RT-PCR results for NPA specimens.", [["neutrophil", "ANATOMY", 229, 239], ["platelet", "ANATOMY", 252, 260], ["NPA specimens", "ANATOMY", 351, 364], ["illness", "DISEASE", 181, 188], ["lactate", "CHEMICAL", 290, 297], ["lactate", "CHEMICAL", 290, 297], ["patients", "ORGANISM", 73, 81], ["neutrophil", "CELL", 229, 239], ["platelet", "CELL", 252, 260], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 290, 311], ["lactate dehydrogenase", "PROTEIN", 290, 311], ["patients", "SPECIES", 73, 81], ["severe illness", "PROBLEM", 174, 188], ["high initial absolute neutrophil counts", "PROBLEM", 207, 246], ["low platelet counts", "PROBLEM", 248, 267], ["high initial or peak lactate dehydrogenase levels", "PROBLEM", 269, 318], ["NPA specimens", "TEST", 351, 364], ["might never be possible", "UNCERTAINTY", 3, 26], ["absolute neutrophil counts", "OBSERVATION", 220, 246], ["low platelet counts", "OBSERVATION_MODIFIER", 248, 267]]], ["6, [106] [107] [108] [109] Only one paediatric series has identified risk factors for severe illness in terms of requirements for oxygen and intensive care.", [["illness", "DISEASE", 93, 100], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "CHEMICAL", 130, 136], ["oxygen", "SIMPLE_CHEMICAL", 130, 136], ["severe illness", "PROBLEM", 86, 100], ["oxygen", "TREATMENT", 130, 136], ["intensive care", "TREATMENT", 141, 155], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["illness", "OBSERVATION", 93, 100]]], ["These include a sore throat, a high neutrophil count at presentation, and peak neutrophilia.", [["neutrophil", "ANATOMY", 36, 46], ["sore throat", "DISEASE", 16, 27], ["neutrophilia", "DISEASE", 79, 91], ["neutrophil", "CELL", 36, 46], ["a sore throat", "PROBLEM", 14, 27], ["a high neutrophil count", "PROBLEM", 29, 52], ["peak neutrophilia", "PROBLEM", 74, 91], ["high neutrophil count", "OBSERVATION_MODIFIER", 31, 52], ["peak neutrophilia", "OBSERVATION", 74, 91]]], ["The finding of sore throat as an independent risk factor is intriguing but may be incidental, given the small number of patients.", [["sore throat", "ANATOMY", 15, 26], ["sore throat", "DISEASE", 15, 26], ["sore throat", "ORGANISM_SUBDIVISION", 15, 26], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["sore throat", "PROBLEM", 15, 26], ["an independent risk factor", "PROBLEM", 30, 56], ["sore throat", "ANATOMY", 15, 26], ["may be", "UNCERTAINTY", 75, 81], ["small", "OBSERVATION_MODIFIER", 104, 109]]], ["No association between the presence of sore throat and the detection of SARS-CoV by RT-PCR or culture in NPA specimens, which might correlate with higher viral load, could be demonstrated.", [["NPA specimens", "ANATOMY", 105, 118], ["sore throat", "DISEASE", 39, 50], ["SARS", "DISEASE", 72, 76], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 72, 80], ["NPA specimens", "CANCER", 105, 118], ["SARS-CoV", "SPECIES", 72, 80], ["sore throat", "PROBLEM", 39, 50], ["the detection", "TEST", 55, 68], ["SARS", "PROBLEM", 72, 76], ["CoV by RT-PCR", "TEST", 77, 90], ["culture in NPA specimens", "TEST", 94, 118], ["higher viral load", "PROBLEM", 147, 164], ["sore", "OBSERVATION", 39, 43], ["viral load", "OBSERVATION", 154, 164]]], ["23OUTCOMEThe short-term outcome of SARS among children is good in comparison to adults.", [["SARS", "DISEASE", 35, 39], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["short-term", "OBSERVATION_MODIFIER", 13, 23]]], ["The need for intensive care and mechanical ventilation was up to 23.2% and 13.8% respectively in adults.", [["intensive care", "TREATMENT", 13, 27], ["mechanical ventilation", "TREATMENT", 32, 54]]], ["6 Chiu et al. reported that 9.5% of children required oxygen supplementation and none required assisted ventilation.", [["oxygen", "CHEMICAL", 54, 60], ["oxygen", "CHEMICAL", 54, 60], ["children", "ORGANISM", 36, 44], ["oxygen", "SIMPLE_CHEMICAL", 54, 60], ["children", "SPECIES", 36, 44], ["oxygen supplementation", "TREATMENT", 54, 76], ["assisted ventilation", "TREATMENT", 95, 115]]], ["22 Leung et al. reported an oxygen requirement in 20.5% and assisted ventilatory support in 6.8% of children.", [["oxygen", "CHEMICAL", 28, 34], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["children", "ORGANISM", 100, 108], ["children", "SPECIES", 100, 108], ["an oxygen requirement", "PROBLEM", 25, 46], ["assisted ventilatory support", "TREATMENT", 60, 88], ["et al", "OBSERVATION", 9, 14], ["oxygen requirement", "OBSERVATION", 28, 46]]], ["23 The figures for oxygen requirement and assisted ventilation in the two paediatric series combined are 17% and 5%, respectively.OUTCOMEDiffuse thinning and shedding of hair was observed in 41.5% of children in one series, generally at 2-3 months after disease onset.", [["hair", "ANATOMY", 170, 174], ["oxygen", "CHEMICAL", 19, 25], ["oxygen", "CHEMICAL", 19, 25], ["oxygen", "SIMPLE_CHEMICAL", 19, 25], ["hair", "ORGAN", 170, 174], ["children", "ORGANISM", 200, 208], ["children", "SPECIES", 200, 208], ["oxygen requirement", "PROBLEM", 19, 37], ["assisted ventilation", "TREATMENT", 42, 62], ["disease onset", "PROBLEM", 254, 267], ["oxygen requirement", "OBSERVATION", 19, 37]]], ["This is consistent with acute telogen effluvium secondary to febrile systemic illness, critical care or severe psychologic stress in life-threatening situations.", [["febrile systemic illness", "DISEASE", 61, 85], ["acute telogen effluvium", "PROBLEM", 24, 47], ["febrile systemic illness", "PROBLEM", 61, 85], ["severe psychologic stress in life-threatening situations", "PROBLEM", 104, 160], ["consistent with", "UNCERTAINTY", 8, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["telogen", "OBSERVATION", 30, 37], ["febrile", "OBSERVATION_MODIFIER", 61, 68], ["systemic", "OBSERVATION_MODIFIER", 69, 77], ["illness", "OBSERVATION", 78, 85], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["23 Li et al. examined the radiologic and pulmonary function outcomes of 47 children, 6 months after diagnosis and detected mild radiologic abnormalities with HRCT and in pulmonary function testing in 34% and 10.5% respectively.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 170, 179], ["pulmonary", "ORGAN", 41, 50], ["children", "ORGANISM", 75, 83], ["pulmonary", "ORGAN", 170, 179], ["children", "SPECIES", 75, 83], ["mild radiologic abnormalities", "PROBLEM", 123, 152], ["HRCT", "TEST", 158, 162], ["pulmonary function testing", "TEST", 170, 196], ["pulmonary", "ANATOMY", 41, 50], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["pulmonary", "ANATOMY", 170, 179]]], ["110 However, all children were asymptomatic and had normal clinical examination, premorbid HRCT and pulmonary function test results were not available for comparison.", [["pulmonary", "ANATOMY", 100, 109], ["children", "ORGANISM", 17, 25], ["pulmonary", "ORGAN", 100, 109], ["children", "SPECIES", 17, 25], ["premorbid HRCT", "TEST", 81, 95], ["pulmonary function test", "TEST", 100, 123], ["pulmonary", "ANATOMY", 100, 109]]], ["In contrast, some adult patients have devel-oped pulmonary fibrosis despite recovery from the primary illness.", [["pulmonary", "ANATOMY", 49, 58], ["fibrosis", "DISEASE", 59, 67], ["primary illness", "DISEASE", 94, 109], ["patients", "ORGANISM", 24, 32], ["pulmonary", "ORGAN", 49, 58], ["patients", "SPECIES", 24, 32], ["pulmonary fibrosis", "PROBLEM", 49, 67], ["the primary illness", "PROBLEM", 90, 109], ["pulmonary", "ANATOMY", 49, 58], ["fibrosis", "OBSERVATION", 59, 67]]], ["111 The psychological impact of separation, isolation in an intimidating hospital environment, bereavement and family disintegration following the death of close adult family members in children who recovered from SARS are immense.", [["death", "DISEASE", 147, 152], ["SARS", "DISEASE", 214, 218], ["children", "ORGANISM", 186, 194], ["children", "SPECIES", 186, 194], ["separation", "TREATMENT", 32, 42], ["isolation", "TREATMENT", 44, 53]]], ["However, children appear to be more resilient than adults in psychological adjustment to SARS and serious psychological sequelae were not evident 3 months after discharge.", [["SARS", "DISEASE", 89, 93], ["children", "ORGANISM", 9, 17], ["children", "SPECIES", 9, 17], ["SARS", "PROBLEM", 89, 93], ["serious psychological sequelae", "PROBLEM", 98, 128]]], ["23 Continued monitoring for delayed onset of psychological problems in children is essential.OUTCOMEChildren who have recovered from the acute illness should be monitored for the possibility of continued viral shedding and the development of pulmonary sequelae and postviral complications (e.g. chronic fatigue), as well as for any long-term complications of high-dose corticosteroid therapy.CONCLUSIONChildren are susceptible to infection by SARS-CoV.", [["pulmonary", "ANATOMY", 242, 251], ["acute illness", "DISEASE", 137, 150], ["pulmonary sequelae", "DISEASE", 242, 260], ["chronic fatigue", "DISEASE", 295, 310], ["infection", "DISEASE", 430, 439], ["SARS", "DISEASE", 443, 447], ["children", "ORGANISM", 71, 79], ["pulmonary", "ORGAN", 242, 251], ["SARS-CoV", "ORGANISM", 443, 451], ["children", "SPECIES", 71, 79], ["SARS-CoV", "SPECIES", 443, 451], ["psychological problems", "PROBLEM", 45, 67], ["the acute illness", "PROBLEM", 133, 150], ["continued viral shedding", "PROBLEM", 194, 218], ["pulmonary sequelae", "PROBLEM", 242, 260], ["postviral complications", "PROBLEM", 265, 288], ["chronic fatigue)", "PROBLEM", 295, 311], ["any long-term complications", "PROBLEM", 328, 355], ["high-dose corticosteroid therapy.CONCLUSIONChildren", "TREATMENT", 359, 410], ["infection", "PROBLEM", 430, 439], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["illness", "OBSERVATION", 143, 150], ["pulmonary", "ANATOMY", 242, 251], ["sequelae", "OBSERVATION", 252, 260], ["infection", "OBSERVATION", 430, 439]]], ["Despite the milder clinical picture, the good short-to medium-term outcome and the availability of reliable early diagnostic techniques, treatment remains controversial.", [["the milder clinical picture", "PROBLEM", 8, 35], ["treatment", "TREATMENT", 137, 146]]], ["The long-term outcome of SARS in children remains unknown.", [["SARS", "DISEASE", 25, 29], ["children", "ORGANISM", 33, 41], ["children", "SPECIES", 33, 41], ["SARS", "PROBLEM", 25, 29], ["long-term", "OBSERVATION_MODIFIER", 4, 13]]], ["There are still enormous gaps in our knowledge about SARS.", [["SARS", "DISEASE", 53, 57], ["enormous", "OBSERVATION_MODIFIER", 16, 24], ["gaps", "OBSERVATION", 25, 29]]], ["Much work needs to be done, urgently.PRACTICE POINTSSARS is largely an atypical pneumonia with minimal or no extrapulmonary manifestation apart from diarrhoea.", [["extrapulmonary", "ANATOMY", 109, 123], ["pneumonia", "DISEASE", 80, 89], ["diarrhoea", "DISEASE", 149, 158], ["an atypical pneumonia", "PROBLEM", 68, 89], ["extrapulmonary manifestation", "PROBLEM", 109, 137], ["diarrhoea", "PROBLEM", 149, 158], ["atypical", "OBSERVATION_MODIFIER", 71, 79], ["pneumonia", "OBSERVATION", 80, 89], ["minimal", "OBSERVATION_MODIFIER", 95, 102], ["no", "UNCERTAINTY", 106, 108], ["extrapulmonary", "ANATOMY", 109, 123], ["manifestation", "OBSERVATION", 124, 137], ["diarrhoea", "OBSERVATION", 149, 158]]], ["The clinical picture of SARS is milder in children but teenagers may develop severe illness resembling adults.", [["SARS", "DISEASE", 24, 28], ["illness", "DISEASE", 84, 91], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["SARS", "PROBLEM", 24, 28], ["severe illness", "PROBLEM", 77, 91]]], ["The clinical, radiologic and laboratory features of SARS are non-specific.", [["SARS", "DISEASE", 52, 56], ["SARS", "PROBLEM", 52, 56], ["non-specific", "OBSERVATION_MODIFIER", 61, 73]]], ["Refined RT-PCR assays can achieve a sensitivity of 80% in the early diagnosis of SARS in the first 3 days of illness.", [["SARS", "DISEASE", 81, 85], ["Refined RT-PCR assays", "TEST", 0, 21], ["a sensitivity", "TEST", 34, 47], ["SARS", "PROBLEM", 81, 85], ["illness", "PROBLEM", 109, 116]]], ["NPA specimens are the preferred specimens for RT-PCR assays in the first week of illness.", [["NPA specimens", "ANATOMY", 0, 13], ["specimens", "ANATOMY", 32, 41], ["NPA", "CHEMICAL", 0, 3], ["NPA specimens", "CANCER", 0, 13], ["NPA specimens", "TEST", 0, 13], ["RT-PCR assays", "TEST", 46, 59], ["illness", "PROBLEM", 81, 88]]], ["Both NPA and stool specimens should be tested in the second week.", [["stool specimens", "ANATOMY", 13, 28], ["NPA", "CHEMICAL", 5, 8], ["NPA", "CHEMICAL", 5, 8], ["NPA", "SIMPLE_CHEMICAL", 5, 8], ["stool specimens", "ORGANISM_SUBSTANCE", 13, 28], ["Both NPA and stool specimens", "TEST", 0, 28]]], ["A negative RT-PCR result cannot exclude the diagnosis.", [["A negative RT-PCR", "TEST", 0, 17]]], ["Absence of seroconversion beyond 28 days from disease onset generally excludes the diagnosis.", [["seroconversion", "PROBLEM", 11, 25], ["disease onset", "PROBLEM", 46, 59], ["seroconversion", "OBSERVATION", 11, 25]]], ["Apart from supportive treatment, including oxygen therapy and assisted ventilation, other treatment modalities remain unproven.RESEARCH DIRECTIONSMolecular biology of SARS-CoV and mechanisms of its genome expression.", [["oxygen", "CHEMICAL", 43, 49], ["SARS", "DISEASE", 167, 171], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["SARS-CoV", "ORGANISM", 167, 175], ["SARS-CoV", "SPECIES", 167, 175], ["supportive treatment", "TREATMENT", 11, 31], ["oxygen therapy", "TREATMENT", 43, 57], ["assisted ventilation", "TREATMENT", 62, 82], ["other treatment modalities", "TREATMENT", 84, 110], ["SARS", "PROBLEM", 167, 171], ["supportive", "OBSERVATION_MODIFIER", 11, 21], ["treatment", "OBSERVATION", 22, 31], ["oxygen therapy", "OBSERVATION", 43, 57], ["genome expression", "OBSERVATION", 198, 215]]], ["Pathogenesis of SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 16, 34], ["SARS-CoV", "ORGANISM", 16, 24], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV infection", "PROBLEM", 21, 34], ["SARS", "OBSERVATION", 16, 20], ["CoV", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34]]], ["Natural history and full spectrum of SARS-CoV infection.", [["SARS-CoV infection", "DISEASE", 37, 55], ["SARS-CoV", "ORGANISM", 37, 45], ["SARS-CoV", "SPECIES", 37, 45], ["SARS", "PROBLEM", 37, 41], ["CoV infection", "PROBLEM", 42, 55], ["CoV", "ANATOMY", 42, 45], ["infection", "OBSERVATION", 46, 55]]], ["Novel therapy and vaccine.", [["Novel therapy", "TREATMENT", 0, 13], ["vaccine", "TREATMENT", 18, 25]]], ["Longitudinal follow-up for long-term outcome and persistence of protective immunity to reinfection.", [["reinfection", "DISEASE", 87, 98], ["reinfection", "PROBLEM", 87, 98], ["reinfection", "OBSERVATION", 87, 98]]]], "74cc88c60223c1e334877357fbba94f693f0e126": [["INTRODUCTIONInflammation has been historically considered as an obligatory marker of arterial disease.INTRODUCTIONCholesterol itself is an inflammatory mediator, being a crystalline product (1) and, by its physical presence, activating NLRP3 (NOD-, LRR-and pyrin domain-containing 3), a general mediator of arterial tissue inflammation (2) .", [["arterial", "ANATOMY", 85, 93], ["arterial tissue", "ANATOMY", 307, 322], ["arterial disease", "DISEASE", 85, 101], ["INTRODUCTIONCholesterol", "CHEMICAL", 102, 125], ["inflammation", "DISEASE", 323, 335], ["INTRODUCTIONCholesterol", "CHEMICAL", 102, 125], ["arterial", "MULTI-TISSUE_STRUCTURE", 85, 93], ["INTRODUCTIONCholesterol", "SIMPLE_CHEMICAL", 102, 125], ["NLRP3", "GENE_OR_GENE_PRODUCT", 236, 241], ["NOD", "GENE_OR_GENE_PRODUCT", 243, 246], ["LRR", "GENE_OR_GENE_PRODUCT", 249, 252], ["pyrin domain-containing 3", "GENE_OR_GENE_PRODUCT", 257, 282], ["arterial tissue", "TISSUE", 307, 322], ["NLRP3", "PROTEIN", 236, 241], ["NOD", "PROTEIN", 243, 246], ["LRR", "PROTEIN", 249, 252], ["pyrin domain-containing 3", "PROTEIN", 257, 282], ["arterial disease", "PROBLEM", 85, 101], ["a crystalline product", "TREATMENT", 168, 189], ["LRR", "TEST", 249, 252], ["pyrin domain", "TREATMENT", 257, 269], ["arterial tissue inflammation", "PROBLEM", 307, 335], ["arterial", "ANATOMY", 85, 93], ["disease", "OBSERVATION", 94, 101], ["inflammatory", "OBSERVATION_MODIFIER", 139, 151], ["arterial tissue", "ANATOMY", 307, 322], ["inflammation", "OBSERVATION", 323, 335]]], ["NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated activation of the interleukin-1\u03b2 (IL-1\u03b2) family of cytokines, thus inducing an inflammatory pyroptotic cell death (3) .", [["cell", "ANATOMY", 182, 186], ["NLRP3", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase 1", "GENE_OR_GENE_PRODUCT", 60, 69], ["interleukin-1\u03b2", "GENE_OR_GENE_PRODUCT", 97, 111], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 113, 118], ["cell", "CELL", 182, 186], ["NLRP3", "PROTEIN", 0, 5], ["caspase 1", "PROTEIN", 60, 69], ["interleukin-1\u03b2 (IL-1\u03b2) family", "PROTEIN", 97, 126], ["cytokines", "PROTEIN", 130, 139], ["NLRP3", "TREATMENT", 0, 5], ["an inflammasome", "PROBLEM", 32, 47], ["caspase", "TREATMENT", 60, 67], ["the interleukin", "TEST", 93, 108], ["cytokines", "PROBLEM", 130, 139], ["an inflammatory pyroptotic cell death", "PROBLEM", 155, 192], ["inflammasome", "OBSERVATION", 35, 47], ["inflammatory", "OBSERVATION_MODIFIER", 158, 170], ["pyroptotic cell death", "OBSERVATION", 171, 192]]], ["This molecular mechanism is the final development of the seminal idea by Ross and Glomset, who postulated endothelial injury as the inducer of cell proliferation and expansion of smooth muscle cells (SMCs) (4, 5) .", [["seminal", "ANATOMY", 57, 64], ["endothelial", "ANATOMY", 106, 117], ["cell", "ANATOMY", 143, 147], ["smooth muscle cells", "ANATOMY", 179, 198], ["SMCs", "ANATOMY", 200, 204], ["endothelial injury", "DISEASE", 106, 124], ["seminal", "ORGANISM_SUBSTANCE", 57, 64], ["endothelial", "TISSUE", 106, 117], ["cell", "CELL", 143, 147], ["smooth muscle cells", "CELL", 179, 198], ["SMCs", "CELL", 200, 204], ["smooth muscle cells", "CELL_TYPE", 179, 198], ["SMCs", "CELL_TYPE", 200, 204], ["endothelial injury", "PROBLEM", 106, 124], ["cell proliferation", "PROBLEM", 143, 161], ["expansion of smooth muscle cells", "PROBLEM", 166, 198], ["seminal", "ANATOMY", 57, 64], ["Ross", "OBSERVATION", 73, 77], ["endothelial", "ANATOMY", 106, 117], ["injury", "OBSERVATION", 118, 124], ["cell proliferation", "OBSERVATION", 143, 161], ["expansion", "OBSERVATION_MODIFIER", 166, 175], ["smooth muscle cells", "OBSERVATION", 179, 198]]], ["The association between local inflammation, elevated levels of low-density lipoproteins (LDL) and noxious life habits brought forward the concept of structural lipoprotein changes allowing aggregation and/or oxidation (6) .INTRODUCTIONThe presently established role of enhanced myelopoiesis in the development of arterial inflammatory changes and the identification of newer mediators from both inflammatory and immune systems can provide novel mechanisms underlying the development of arterial disease.INTRODUCTIONAs a lipid-driven inflammatory disease, a balance of proinflammatory and inflammationresolving mechanisms are responsible for the final outcomes (7) .", [["arterial", "ANATOMY", 313, 321], ["arterial", "ANATOMY", 486, 494], ["inflammation", "DISEASE", 30, 42], ["arterial disease", "DISEASE", 486, 502], ["LDL", "SIMPLE_CHEMICAL", 89, 92], ["lipoprotein", "SIMPLE_CHEMICAL", 160, 171], ["arterial", "MULTI-TISSUE_STRUCTURE", 313, 321], ["arterial", "MULTI-TISSUE_STRUCTURE", 486, 494], ["lipid", "SIMPLE_CHEMICAL", 520, 525], ["low-density lipoproteins", "PROTEIN", 63, 87], ["LDL", "PROTEIN", 89, 92], ["local inflammation", "PROBLEM", 24, 42], ["elevated levels of low-density lipoproteins", "PROBLEM", 44, 87], ["noxious life habits", "PROBLEM", 98, 117], ["structural lipoprotein changes", "PROBLEM", 149, 179], ["enhanced myelopoiesis", "PROBLEM", 269, 290], ["arterial inflammatory changes", "PROBLEM", 313, 342], ["newer mediators", "PROBLEM", 369, 384], ["both inflammatory and immune systems", "PROBLEM", 390, 426], ["arterial disease", "PROBLEM", 486, 502], ["inflammatory disease", "PROBLEM", 533, 553], ["proinflammatory and inflammationresolving mechanisms", "PROBLEM", 568, 620], ["local", "OBSERVATION_MODIFIER", 24, 29], ["inflammation", "OBSERVATION", 30, 42], ["elevated", "OBSERVATION_MODIFIER", 44, 52], ["levels", "OBSERVATION_MODIFIER", 53, 59], ["low-density lipoproteins", "OBSERVATION_MODIFIER", 63, 87], ["lipoprotein", "OBSERVATION", 160, 171], ["enhanced", "OBSERVATION_MODIFIER", 269, 277], ["myelopoiesis", "OBSERVATION", 278, 290], ["arterial", "ANATOMY", 313, 321], ["inflammatory", "OBSERVATION", 322, 334], ["inflammatory", "OBSERVATION", 395, 407], ["arterial", "ANATOMY", 486, 494], ["disease", "OBSERVATION", 495, 502], ["inflammatory disease", "OBSERVATION", 533, 553], ["proinflammatory", "OBSERVATION_MODIFIER", 568, 583]]], ["While bone marrow (BM) and spleen were not considered to play a significant role in atheroma formation, it is now well established that BM is responsible for the enhanced myelopoiesis, allowing recruitment of inflammatory cells, particularly monocytes, to the arterial intima (8, 9) .", [["bone marrow", "ANATOMY", 6, 17], ["BM", "ANATOMY", 19, 21], ["spleen", "ANATOMY", 27, 33], ["atheroma", "ANATOMY", 84, 92], ["BM", "ANATOMY", 136, 138], ["inflammatory cells", "ANATOMY", 209, 227], ["monocytes", "ANATOMY", 242, 251], ["arterial intima", "ANATOMY", 260, 275], ["atheroma", "DISEASE", 84, 92], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 6, 17], ["BM", "TISSUE", 19, 21], ["spleen", "ORGAN", 27, 33], ["atheroma", "PATHOLOGICAL_FORMATION", 84, 92], ["BM", "CELL", 136, 138], ["inflammatory cells", "CELL", 209, 227], ["monocytes", "CELL", 242, 251], ["arterial intima", "MULTI-TISSUE_STRUCTURE", 260, 275], ["inflammatory cells", "CELL_TYPE", 209, 227], ["monocytes", "CELL_TYPE", 242, 251], ["atheroma formation", "PROBLEM", 84, 102], ["the enhanced myelopoiesis", "PROBLEM", 158, 183], ["inflammatory cells", "PROBLEM", 209, 227], ["monocytes", "TEST", 242, 251], ["bone marrow", "ANATOMY", 6, 17], ["spleen", "ANATOMY", 27, 33], ["not considered", "UNCERTAINTY", 39, 53], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["atheroma", "OBSERVATION", 84, 92], ["BM", "OBSERVATION", 136, 138], ["responsible for", "UNCERTAINTY", 142, 157], ["enhanced", "OBSERVATION_MODIFIER", 162, 170], ["myelopoiesis", "OBSERVATION", 171, 183], ["inflammatory cells", "OBSERVATION", 209, 227], ["arterial", "ANATOMY_MODIFIER", 260, 268], ["intima", "ANATOMY", 269, 275]]], ["The rise of hematopoietic and progenitor cells (HSPCs) occurring after myocardial infarction (MI) (10) can well explain the increased growth of plaques and the associated higher protease activity.", [["hematopoietic", "ANATOMY", 12, 25], ["progenitor cells", "ANATOMY", 30, 46], ["HSPCs", "ANATOMY", 48, 53], ["myocardial", "ANATOMY", 71, 81], ["plaques", "ANATOMY", 144, 151], ["myocardial infarction", "DISEASE", 71, 92], ["MI", "DISEASE", 94, 96], ["plaques", "DISEASE", 144, 151], ["hematopoietic", "CELL", 12, 25], ["progenitor cells", "CELL", 30, 46], ["HSPCs", "CELL", 48, 53], ["myocardial", "MULTI-TISSUE_STRUCTURE", 71, 81], ["plaques", "PATHOLOGICAL_FORMATION", 144, 151], ["hematopoietic and progenitor cells", "CELL_TYPE", 12, 46], ["HSPCs", "CELL_TYPE", 48, 53], ["protease", "PROTEIN", 178, 186], ["hematopoietic and progenitor cells", "PROBLEM", 12, 46], ["myocardial infarction", "PROBLEM", 71, 92], ["MI", "PROBLEM", 94, 96], ["the increased growth of plaques", "PROBLEM", 120, 151], ["the associated higher protease activity", "PROBLEM", 156, 195], ["rise", "OBSERVATION_MODIFIER", 4, 8], ["hematopoietic", "ANATOMY", 12, 25], ["progenitor cells", "OBSERVATION", 30, 46], ["myocardial", "ANATOMY", 71, 81], ["infarction", "OBSERVATION", 82, 92], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["growth", "OBSERVATION_MODIFIER", 134, 140], ["plaques", "OBSERVATION", 144, 151], ["higher", "OBSERVATION_MODIFIER", 171, 177], ["protease activity", "OBSERVATION", 178, 195]]], ["Clonal hematopoiesis (CH), in addition to eliciting effects through inflammatory mediators, reduces the epigenetic modifier enzyme ten-eleven translocation 2 (TET2) raising atherosclerotic risk (11) .", [["atherosclerotic", "DISEASE", 173, 188], ["ten-eleven translocation 2", "GENE_OR_GENE_PRODUCT", 131, 157], ["TET2", "GENE_OR_GENE_PRODUCT", 159, 163], ["inflammatory mediators", "PROTEIN", 68, 90], ["epigenetic modifier enzyme", "PROTEIN", 104, 130], ["Clonal hematopoiesis (CH)", "PROBLEM", 0, 25], ["inflammatory mediators", "PROBLEM", 68, 90], ["the epigenetic modifier enzyme ten-eleven translocation", "PROBLEM", 100, 155], ["atherosclerotic risk", "PROBLEM", 173, 193], ["hematopoiesis", "OBSERVATION", 7, 20], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80], ["atherosclerotic", "OBSERVATION_MODIFIER", 173, 188]]], ["TET2 deficient cells, when clonally expanded, markedly increase plaque size and NLRP3 inflammasome mediated IL-1\uf062 secretion (12) .", [["cells", "ANATOMY", 15, 20], ["plaque", "ANATOMY", 64, 70], ["TET2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 15, 20], ["plaque", "PATHOLOGICAL_FORMATION", 64, 70], ["NLRP3", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-1\uf062", "GENE_OR_GENE_PRODUCT", 108, 113], ["TET2 deficient cells", "CELL_LINE", 0, 20], ["NLRP3", "PROTEIN", 80, 85], ["TET2 deficient cells", "PROBLEM", 0, 20], ["markedly increase plaque size", "PROBLEM", 46, 75], ["NLRP3 inflammasome", "TEST", 80, 98], ["deficient cells", "OBSERVATION", 5, 20], ["clonally", "OBSERVATION_MODIFIER", 27, 35], ["expanded", "OBSERVATION_MODIFIER", 36, 44], ["markedly", "OBSERVATION_MODIFIER", 46, 54], ["increase", "OBSERVATION_MODIFIER", 55, 63], ["plaque", "OBSERVATION_MODIFIER", 64, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["NLRP3 inflammasome", "OBSERVATION", 80, 98]]], ["Further, toll like receptors, in particular Toll-like receptor 4 (TLR4) (13) by interacting with myeloid differentiation factor-88 (MyD88) can lead to cellular signaling, resulting in hematopoietic and stromal cell development (14) .", [["cellular", "ANATOMY", 151, 159], ["hematopoietic", "ANATOMY", 184, 197], ["stromal cell", "ANATOMY", 202, 214], ["toll like receptors", "GENE_OR_GENE_PRODUCT", 9, 28], ["Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 44, 64], ["TLR4", "GENE_OR_GENE_PRODUCT", 66, 70], ["myeloid differentiation factor-88", "GENE_OR_GENE_PRODUCT", 97, 130], ["MyD88", "GENE_OR_GENE_PRODUCT", 132, 137], ["cellular", "CELL", 151, 159], ["hematopoietic", "CELL", 184, 197], ["stromal cell", "CELL", 202, 214], ["toll like receptors", "PROTEIN", 9, 28], ["TLR4", "PROTEIN", 66, 70], ["myeloid differentiation factor-88", "PROTEIN", 97, 130], ["MyD88", "PROTEIN", 132, 137], ["myeloid differentiation factor", "TEST", 97, 127], ["cellular signaling", "PROBLEM", 151, 169], ["hematopoietic and stromal cell development", "PROBLEM", 184, 226], ["hematopoietic", "ANATOMY", 184, 197], ["stromal cell", "OBSERVATION", 202, 214]]], ["Hypercholesterolemia causes HSPCs to proliferate, leading to leukocytosis and enhanced atherosclerosis both in animal models and humans (15).", [["HSPCs", "ANATOMY", 28, 33], ["Hypercholesterolemia", "DISEASE", 0, 20], ["leukocytosis", "DISEASE", 61, 73], ["atherosclerosis", "DISEASE", 87, 102], ["HSPCs", "CELL", 28, 33], ["humans", "ORGANISM", 129, 135], ["HSPCs", "CELL_TYPE", 28, 33], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["Hypercholesterolemia", "PROBLEM", 0, 20], ["HSPCs to proliferate", "PROBLEM", 28, 48], ["leukocytosis", "PROBLEM", 61, 73], ["enhanced atherosclerosis", "PROBLEM", 78, 102], ["leukocytosis", "OBSERVATION", 61, 73], ["enhanced", "OBSERVATION_MODIFIER", 78, 86], ["atherosclerosis", "OBSERVATION", 87, 102]]], ["Hematopoietic cells are also characterized by the Akt (protein kinase B) pathway, i.e. a serine/threonine-specific protein kinase playing multiple roles in processes, such as glucose metabolism, apoptosis, cell migration and proliferation, with three isoforms, Akt1, Akt2 and Akt3.INTRODUCTIONLoss of Akt1 in apo E -/mice leads to severe atherosclerosis (18), whereas loss of Akt1 and Akt2 in hematopoietic cells (Akt3 only ) provides arterial protection.", [["Hematopoietic cells", "ANATOMY", 0, 19], ["cell", "ANATOMY", 206, 210], ["hematopoietic cells", "ANATOMY", 393, 412], ["arterial", "ANATOMY", 435, 443], ["glucose", "CHEMICAL", 175, 182], ["atherosclerosis", "DISEASE", 338, 353], ["serine", "CHEMICAL", 89, 95], ["threonine", "CHEMICAL", 96, 105], ["glucose", "CHEMICAL", 175, 182], ["Hematopoietic cells", "CELL", 0, 19], ["Akt", "GENE_OR_GENE_PRODUCT", 50, 53], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 55, 71], ["threonine", "AMINO_ACID", 96, 105], ["glucose", "SIMPLE_CHEMICAL", 175, 182], ["cell", "CELL", 206, 210], ["Akt1", "GENE_OR_GENE_PRODUCT", 261, 265], ["Akt2", "GENE_OR_GENE_PRODUCT", 267, 271], ["Akt3", "GENE_OR_GENE_PRODUCT", 276, 280], ["Akt1", "GENE_OR_GENE_PRODUCT", 301, 305], ["apo E", "GENE_OR_GENE_PRODUCT", 309, 314], ["Akt1", "GENE_OR_GENE_PRODUCT", 376, 380], ["Akt2", "GENE_OR_GENE_PRODUCT", 385, 389], ["hematopoietic cells", "CELL", 393, 412], ["Akt3", "GENE_OR_GENE_PRODUCT", 414, 418], ["arterial", "MULTI-TISSUE_STRUCTURE", 435, 443], ["Hematopoietic cells", "CELL_TYPE", 0, 19], ["Akt", "PROTEIN", 50, 53], ["protein kinase B", "PROTEIN", 55, 71], ["serine/threonine-specific protein kinase", "PROTEIN", 89, 129], ["Akt1", "PROTEIN", 261, 265], ["Akt2", "PROTEIN", 267, 271], ["Akt3", "PROTEIN", 276, 280], ["Akt1", "PROTEIN", 301, 305], ["apo E", "PROTEIN", 309, 314], ["Akt1", "PROTEIN", 376, 380], ["Akt2", "PROTEIN", 385, 389], ["hematopoietic cells", "CELL_TYPE", 393, 412], ["Akt3", "PROTEIN", 414, 418], ["mice", "SPECIES", 317, 321], ["Hematopoietic cells", "PROBLEM", 0, 19], ["a serine/threonine", "TEST", 87, 105], ["glucose metabolism", "TEST", 175, 193], ["apoptosis", "PROBLEM", 195, 204], ["cell migration", "PROBLEM", 206, 220], ["proliferation", "TEST", 225, 238], ["Akt1 in apo E", "TREATMENT", 301, 314], ["severe atherosclerosis", "PROBLEM", 331, 353], ["loss of Akt1 and Akt2 in hematopoietic cells", "PROBLEM", 368, 412], ["arterial protection", "TREATMENT", 435, 454], ["cell migration", "OBSERVATION", 206, 220], ["severe", "OBSERVATION_MODIFIER", 331, 337], ["atherosclerosis", "OBSERVATION", 338, 353], ["hematopoietic cells", "OBSERVATION", 393, 412], ["arterial", "ANATOMY", 435, 443]]], ["The presence of only the Akt1 isoform is detrimental for the viability of monocytes/macrophages, eventually leading to the development of smaller atherosclerotic lesions.INTRODUCTIONLDL-associated inflammatory changes may thus be linked to enhanced hematopoiesis although the role of TET2 mutations has not been confirmed in all studies (19) but also to direct activities such as: a) enhanced cholesterol crystal deposition, raising the vascular inflammasome NLRP3; b) rise of different T lymphocyte subtypes leading to plaque proliferation and potential rupture (20); c) development of tissue inflammatory changes, mainly linked to raised cytokines and hsCRP.INTRODUCTIONA link between the first two mechanisms, i.e. direct inflammatory effects and T cell proliferation, has been provided by the identification of a novel regulator i.e. the NLRC5 (NLRF family CARD Domain Containing 5) previously known as a major regulator of innate immunity (21).", [["monocytes", "ANATOMY", 74, 83], ["macrophages", "ANATOMY", 84, 95], ["atherosclerotic lesions", "ANATOMY", 146, 169], ["vascular", "ANATOMY", 437, 445], ["T lymphocyte", "ANATOMY", 487, 499], ["plaque", "ANATOMY", 520, 526], ["tissue", "ANATOMY", 587, 593], ["T cell", "ANATOMY", 750, 756], ["atherosclerotic", "DISEASE", 146, 161], ["cholesterol", "CHEMICAL", 393, 404], ["plaque", "DISEASE", 520, 526], ["rupture", "DISEASE", 555, 562], ["cholesterol", "CHEMICAL", 393, 404], ["Akt1", "GENE_OR_GENE_PRODUCT", 25, 29], ["monocytes", "CELL", 74, 83], ["macrophages", "CELL", 84, 95], ["atherosclerotic lesions", "PATHOLOGICAL_FORMATION", 146, 169], ["TET2", "GENE_OR_GENE_PRODUCT", 284, 288], ["cholesterol", "SIMPLE_CHEMICAL", 393, 404], ["vascular", "MULTI-TISSUE_STRUCTURE", 437, 445], ["NLRP3", "GENE_OR_GENE_PRODUCT", 459, 464], ["T lymphocyte", "CELL", 487, 499], ["plaque", "PATHOLOGICAL_FORMATION", 520, 526], ["tissue", "TISSUE", 587, 593], ["T cell", "CELL", 750, 756], ["NLRC5", "GENE_OR_GENE_PRODUCT", 842, 847], ["NLRF family CARD Domain Containing 5", "GENE_OR_GENE_PRODUCT", 849, 885], ["Akt1 isoform", "PROTEIN", 25, 37], ["monocytes", "CELL_TYPE", 74, 83], ["macrophages", "CELL_TYPE", 84, 95], ["TET2", "PROTEIN", 284, 288], ["vascular inflammasome NLRP3", "PROTEIN", 437, 464], ["T lymphocyte subtypes", "CELL_TYPE", 487, 508], ["cytokines", "PROTEIN", 640, 649], ["hsCRP.INTRODUCTIONA", "PROTEIN", 654, 673], ["NLRC5", "PROTEIN", 842, 847], ["NLRF family CARD Domain Containing 5", "PROTEIN", 849, 885], ["monocytes/macrophages", "PROBLEM", 74, 95], ["smaller atherosclerotic lesions", "PROBLEM", 138, 169], ["associated inflammatory changes", "PROBLEM", 186, 217], ["enhanced hematopoiesis", "PROBLEM", 240, 262], ["TET2 mutations", "PROBLEM", 284, 298], ["a) enhanced cholesterol crystal deposition", "PROBLEM", 381, 423], ["the vascular inflammasome NLRP3", "PROBLEM", 433, 464], ["different T lymphocyte subtypes", "PROBLEM", 477, 508], ["plaque proliferation", "PROBLEM", 520, 540], ["potential rupture", "PROBLEM", 545, 562], ["tissue inflammatory changes", "PROBLEM", 587, 614], ["raised cytokines", "PROBLEM", 633, 649], ["direct inflammatory effects", "PROBLEM", 718, 745], ["T cell proliferation", "PROBLEM", 750, 770], ["a novel regulator", "TREATMENT", 815, 832], ["the NLRC5 (NLRF family CARD Domain Containing", "TREATMENT", 838, 883], ["Akt1 isoform", "OBSERVATION", 25, 37], ["monocytes", "OBSERVATION", 74, 83], ["macrophages", "OBSERVATION", 84, 95], ["smaller", "OBSERVATION_MODIFIER", 138, 145], ["atherosclerotic", "OBSERVATION_MODIFIER", 146, 161], ["lesions", "OBSERVATION", 162, 169], ["inflammatory", "OBSERVATION", 197, 209], ["hematopoiesis", "OBSERVATION", 249, 262], ["vascular", "ANATOMY", 437, 445], ["lymphocyte subtypes", "OBSERVATION", 489, 508], ["plaque", "OBSERVATION_MODIFIER", 520, 526], ["proliferation", "OBSERVATION", 527, 540], ["rupture", "OBSERVATION", 555, 562], ["tissue", "ANATOMY", 587, 593], ["inflammatory", "OBSERVATION", 594, 606], ["inflammatory", "OBSERVATION_MODIFIER", 725, 737], ["cell proliferation", "OBSERVATION", 752, 770]]], ["NLRC5 has an essential role in determining vascular intimal hyperplasia (22) and NLRC5 knock-out (Nlrc5 -/ ) mice exhibit more severe intimal hyperplasia compared to wild-type mice after carotid ligation.", [["vascular intimal hyperplasia", "ANATOMY", 43, 71], ["intimal", "ANATOMY", 134, 141], ["carotid", "ANATOMY", 187, 194], ["intimal hyperplasia", "DISEASE", 134, 153], ["NLRC5", "GENE_OR_GENE_PRODUCT", 0, 5], ["vascular intimal", "TISSUE", 43, 59], ["NLRC5", "GENE_OR_GENE_PRODUCT", 81, 86], ["Nlrc5 -/ )", "GENE_OR_GENE_PRODUCT", 98, 108], ["intimal hyperplasia", "PATHOLOGICAL_FORMATION", 134, 153], ["mice", "ORGANISM", 176, 180], ["carotid", "MULTI-TISSUE_STRUCTURE", 187, 194], ["NLRC5", "PROTEIN", 0, 5], ["Nlrc5", "PROTEIN", 98, 103], ["mice", "SPECIES", 109, 113], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 176, 180], ["vascular intimal hyperplasia", "PROBLEM", 43, 71], ["NLRC5 knock", "TEST", 81, 92], ["more severe intimal hyperplasia", "PROBLEM", 122, 153], ["carotid ligation", "TREATMENT", 187, 203], ["essential", "OBSERVATION_MODIFIER", 13, 22], ["vascular intimal", "ANATOMY", 43, 59], ["hyperplasia", "OBSERVATION", 60, 71], ["more", "OBSERVATION_MODIFIER", 122, 126], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["intimal", "OBSERVATION_MODIFIER", 134, 141], ["hyperplasia", "OBSERVATION", 142, 153], ["carotid", "ANATOMY", 187, 194], ["ligation", "OBSERVATION", 195, 203]]], ["Finally, a potential regulator of the proinflammatory signaling from neutrophils is the dimeric S100 A8/A9, a proinflammatory alarmin, highly expressed in neutrophils and rapidly released into the circulation after myocardial ischemia (28).", [["neutrophils", "ANATOMY", 69, 80], ["neutrophils", "ANATOMY", 155, 166], ["myocardial", "ANATOMY", 215, 225], ["myocardial ischemia", "DISEASE", 215, 234], ["neutrophils", "CELL", 69, 80], ["S100 A8", "GENE_OR_GENE_PRODUCT", 96, 103], ["A9", "GENE_OR_GENE_PRODUCT", 104, 106], ["alarmin", "GENE_OR_GENE_PRODUCT", 126, 133], ["neutrophils", "CELL", 155, 166], ["myocardial", "MULTI-TISSUE_STRUCTURE", 215, 225], ["neutrophils", "CELL_TYPE", 69, 80], ["dimeric S100 A8", "PROTEIN", 88, 103], ["A9", "PROTEIN", 104, 106], ["proinflammatory alarmin", "PROTEIN", 110, 133], ["neutrophils", "CELL_TYPE", 155, 166], ["a proinflammatory alarmin", "TEST", 108, 133], ["neutrophils", "TEST", 155, 166], ["myocardial ischemia", "PROBLEM", 215, 234], ["circulation", "ANATOMY_MODIFIER", 197, 208], ["myocardial", "ANATOMY", 215, 225], ["ischemia", "OBSERVATION", 226, 234]]], ["This potent activator of the receptor of advanced glycation end products (29) was found to be associated with reduced ventricular ejection fraction one-year after the MI (30), with a raised incidence of hospitalizations for heart failure.INTRODUCTIONIn view of the diversified tissue responses to inflammatory stimuli and the need for a better understanding of diagnostic procedures and possible therapeutic approaches, the aim of this review article is manifold.", [["ventricular", "ANATOMY", 118, 129], ["heart", "ANATOMY", 224, 229], ["tissue", "ANATOMY", 277, 283], ["MI", "DISEASE", 167, 169], ["heart failure", "DISEASE", 224, 237], ["ventricular", "MULTI-TISSUE_STRUCTURE", 118, 129], ["heart", "ORGAN", 224, 229], ["tissue", "TISSUE", 277, 283], ["advanced glycation end products", "TREATMENT", 41, 72], ["reduced ventricular ejection fraction", "PROBLEM", 110, 147], ["the MI", "PROBLEM", 163, 169], ["heart failure", "PROBLEM", 224, 237], ["inflammatory stimuli", "TEST", 297, 317], ["diagnostic procedures", "TEST", 361, 382], ["therapeutic approaches", "TREATMENT", 396, 418], ["ventricular", "ANATOMY", 118, 129], ["ejection fraction", "OBSERVATION", 130, 147], ["heart", "ANATOMY", 224, 229], ["failure", "OBSERVATION", 230, 237], ["inflammatory", "OBSERVATION_MODIFIER", 297, 309]]], ["It will examine present day evidence of the most appropriate diagnostic approaches and will evaluate in detail the pharmacological strategies, examining the possible antiinflammatory profile of drugs of major use in cardiovascular prevention.", [["cardiovascular", "ANATOMY", 216, 230], ["cardiovascular", "ANATOMICAL_SYSTEM", 216, 230], ["drugs", "TREATMENT", 194, 199], ["cardiovascular prevention", "TREATMENT", 216, 241]]], ["This in-depth scrutiny will lead at times to apparent discrepancies between efficacy on a major therapeutic target and presence or absence of anti-inflammatory activity.", [["anti-inflammatory activity", "PROBLEM", 142, 168], ["anti-inflammatory activity", "OBSERVATION", 142, 168]]], ["These observations may be of crucial value in the selection of the most appropriate therapeutic agent.Clinical evaluation of inflammation-associated cardiovascular riskThe need for an easier access to the evaluation of cardiovascular (CV) risk associated to inflammation has led to the wide use of C-reactive protein (CRP), a mediator well known in the monitoring of systemic inflammatory diseases, such as rheumatoid arthritis and other articular J o u r n a l P r e -p r o o f disorders.", [["cardiovascular", "ANATOMY", 149, 163], ["cardiovascular", "ANATOMY", 219, 233], ["articular", "ANATOMY", 438, 447], ["inflammation", "DISEASE", 125, 137], ["cardiovascular (CV) risk", "DISEASE", 219, 243], ["inflammation", "DISEASE", 258, 270], ["inflammatory diseases", "DISEASE", 376, 397], ["rheumatoid arthritis", "DISEASE", 407, 427], ["cardiovascular", "ANATOMICAL_SYSTEM", 219, 233], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 298, 316], ["CRP", "GENE_OR_GENE_PRODUCT", 318, 321], ["C-reactive protein", "PROTEIN", 298, 316], ["CRP", "PROTEIN", 318, 321], ["Clinical evaluation", "TEST", 102, 121], ["inflammation", "PROBLEM", 125, 137], ["cardiovascular risk", "PROBLEM", 149, 168], ["the evaluation", "TEST", 201, 215], ["cardiovascular (CV) risk", "PROBLEM", 219, 243], ["inflammation", "PROBLEM", 258, 270], ["C-reactive protein", "TEST", 298, 316], ["CRP", "TEST", 318, 321], ["systemic inflammatory diseases", "PROBLEM", 367, 397], ["rheumatoid arthritis", "PROBLEM", 407, 427], ["disorders", "PROBLEM", 479, 488], ["inflammation", "OBSERVATION", 125, 137], ["cardiovascular risk", "OBSERVATION", 149, 168], ["cardiovascular", "ANATOMY", 219, 233], ["inflammation", "OBSERVATION", 258, 270], ["systemic", "OBSERVATION_MODIFIER", 367, 375], ["inflammatory", "OBSERVATION", 376, 388], ["rheumatoid arthritis", "OBSERVATION", 407, 427], ["articular", "ANATOMY", 438, 447]]], ["CRP is a member of the short pentraxin family, expression being stimulated by proinflammatory cytokines, i.e. in particular IL-6, but also IL-1\uf062\uf02c TNF\uf061 and others (31) .", [["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["pentraxin", "GENE_OR_GENE_PRODUCT", 29, 38], ["IL-6", "GENE_OR_GENE_PRODUCT", 124, 128], ["IL-1", "GENE_OR_GENE_PRODUCT", 139, 143], ["TNF", "GENE_OR_GENE_PRODUCT", 146, 149], ["CRP", "PROTEIN", 0, 3], ["pentraxin family", "PROTEIN", 29, 45], ["proinflammatory cytokines", "PROTEIN", 78, 103], ["IL-6", "PROTEIN", 124, 128], ["IL", "PROTEIN", 139, 141], ["TNF", "PROTEIN", 146, 149], ["CRP", "TEST", 0, 3], ["proinflammatory cytokines", "TEST", 78, 103]]], ["CRP binds microbial polysaccharides and ligands on damaged cells.", [["cells", "ANATOMY", 59, 64], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 59, 64], ["CRP", "PROTEIN", 0, 3], ["damaged cells", "CELL_TYPE", 51, 64], ["CRP binds microbial polysaccharides", "PROBLEM", 0, 35], ["ligands on damaged cells", "PROBLEM", 40, 64], ["microbial polysaccharides", "OBSERVATION", 10, 35], ["ligands", "OBSERVATION_MODIFIER", 40, 47], ["damaged cells", "OBSERVATION", 51, 64]]], ["This leads to activation of the classical complement mediated pathway, thus removing damaged or apoptotic cells, in turn activating monocytes (32) .Clinical evaluation of inflammation-associated cardiovascular riskWhile there is general agreement that CRP is a relevant risk biomarker for CVD (33, 34) , there has been no consensus on a causative role.", [["cells", "ANATOMY", 106, 111], ["monocytes", "ANATOMY", 132, 141], ["cardiovascular", "ANATOMY", 195, 209], ["inflammation", "DISEASE", 171, 183], ["CVD", "DISEASE", 289, 292], ["cells", "CELL", 106, 111], ["monocytes", "CELL", 132, 141], ["CRP", "GENE_OR_GENE_PRODUCT", 252, 255], ["apoptotic cells", "CELL_TYPE", 96, 111], ["monocytes", "CELL_TYPE", 132, 141], ["CRP", "PROTEIN", 252, 255], ["damaged or apoptotic cells", "PROBLEM", 85, 111], ["monocytes", "TEST", 132, 141], ["Clinical evaluation", "TEST", 148, 167], ["inflammation", "PROBLEM", 171, 183], ["CRP", "TEST", 252, 255], ["CVD", "PROBLEM", 289, 292], ["apoptotic cells", "OBSERVATION", 96, 111], ["inflammation", "OBSERVATION", 171, 183], ["no", "UNCERTAINTY", 319, 321]]], ["Mendelian randomization studies failed to prove a causal link between genetic variants of CRP affecting protein level and risk of coronary heart disease (35) , in contrast to the case of IL-6 (36), with, however, impractical diagnostic application due to a short half-life and circadian variations (37) .", [["coronary", "ANATOMY", 130, 138], ["heart", "ANATOMY", 139, 144], ["coronary heart disease", "DISEASE", 130, 152], ["CRP", "GENE_OR_GENE_PRODUCT", 90, 93], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 130, 144], ["IL-6", "GENE_OR_GENE_PRODUCT", 187, 191], ["CRP", "PROTEIN", 90, 93], ["IL", "PROTEIN", 187, 189], ["Mendelian randomization studies", "TEST", 0, 31], ["CRP affecting protein level", "PROBLEM", 90, 117], ["coronary heart disease", "PROBLEM", 130, 152], ["coronary heart", "ANATOMY", 130, 144], ["disease", "OBSERVATION", 145, 152]]], ["The same conclusion applies to IL-1\u03b2, since there is no available technology allowing a reliable measurement.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-1\u03b2", "PROTEIN", 31, 36], ["a reliable measurement", "TEST", 86, 108]]], ["The difficulty in determining these cytokines contrasts with the commercially robust and standardized high-sensitivity (hs)CRP immunoassay.Clinical evaluation of inflammation-associated cardiovascular riskThe association of plaque morphology/tendency to rupture with hsCRP levels has been evaluated by appropriate studies (38) .", [["cardiovascular", "ANATOMY", 186, 200], ["plaque", "ANATOMY", 224, 230], ["inflammation", "DISEASE", 162, 174], ["rupture", "DISEASE", 254, 261], ["CRP", "GENE_OR_GENE_PRODUCT", 123, 126], ["plaque", "PATHOLOGICAL_FORMATION", 224, 230], ["hsCRP", "GENE_OR_GENE_PRODUCT", 267, 272], ["cytokines", "PROTEIN", 36, 45], ["CRP", "PROTEIN", 123, 126], ["hsCRP", "PROTEIN", 267, 272], ["CRP immunoassay", "TEST", 123, 138], ["Clinical evaluation", "TEST", 139, 158], ["inflammation", "PROBLEM", 162, 174], ["cardiovascular risk", "PROBLEM", 186, 205], ["plaque morphology", "PROBLEM", 224, 241], ["rupture", "PROBLEM", 254, 261], ["hsCRP levels", "TEST", 267, 279], ["appropriate studies", "TEST", 302, 321], ["inflammation", "OBSERVATION", 162, 174], ["cardiovascular risk", "OBSERVATION", 186, 205], ["plaque", "OBSERVATION", 224, 230], ["rupture", "OBSERVATION", 254, 261]]], ["The prognostic value of hsCRP in post-acute coronary syndrome (ACS) patients on optimal medical treatment was found to be weak (39) .", [["coronary", "ANATOMY", 44, 52], ["post-acute coronary syndrome", "DISEASE", 33, 61], ["ACS", "DISEASE", 63, 66], ["hsCRP", "GENE_OR_GENE_PRODUCT", 24, 29], ["coronary", "MULTI-TISSUE_STRUCTURE", 44, 52], ["patients", "ORGANISM", 68, 76], ["hsCRP", "PROTEIN", 24, 29], ["patients", "SPECIES", 68, 76], ["hsCRP", "TEST", 24, 29], ["post-acute coronary syndrome", "PROBLEM", 33, 61], ["optimal medical treatment", "TREATMENT", 80, 105], ["coronary", "ANATOMY", 44, 52]]], ["A higher sensitivity was found in a cross-sectional study (40) , indicating significant correlations with the dynamic changes in plaque structure.", [["plaque", "ANATOMY", 129, 135], ["plaque", "PATHOLOGICAL_FORMATION", 129, 135], ["A higher sensitivity", "PROBLEM", 0, 20], ["a cross-sectional study", "TEST", 34, 57], ["the dynamic changes in plaque structure", "PROBLEM", 106, 145], ["higher", "OBSERVATION_MODIFIER", 2, 8], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["plaque", "OBSERVATION", 129, 135]]], ["In the small IBIS Study a reduction of necrotic core volume with lower hsCRP, not LDL-C, was described (41) .", [["necrotic core", "ANATOMY", 39, 52], ["necrotic", "DISEASE", 39, 47], ["necrotic core", "TISSUE", 39, 52], ["hsCRP", "GENE_OR_GENE_PRODUCT", 71, 76], ["LDL-C", "GENE_OR_GENE_PRODUCT", 82, 87], ["hsCRP", "PROTEIN", 71, 76], ["LDL", "PROTEIN", 82, 85], ["necrotic core volume", "PROBLEM", 39, 59], ["lower hsCRP", "PROBLEM", 65, 76], ["LDL", "TEST", 82, 85], ["small", "OBSERVATION_MODIFIER", 7, 12], ["IBIS", "OBSERVATION", 13, 17], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["necrotic", "OBSERVATION_MODIFIER", 39, 47], ["core", "OBSERVATION_MODIFIER", 48, 52], ["volume", "OBSERVATION_MODIFIER", 53, 59], ["lower hsCRP", "OBSERVATION_MODIFIER", 65, 76]]], ["In a more extensive visual histology study, after 12 month-rosuvastatin treatment, the reduction of hsCRP showed highly significant positive correlations with necrotic core and dense calcium volumes and negative correlations with fibrous and fibrofatty plaque volumes, not with LDL-cholesterol changes (42) .Clinical evaluation of inflammation-associated cardiovascular riskThere is thus as present a high interest in evaluating risk of CV disease (CVD) and other diseases in individuals with low LDL-C (43), a frequent finding in coronary patients, associated with an increased risk of all-cause mortality (44) .", [["necrotic core", "ANATOMY", 159, 172], ["fibrous", "ANATOMY", 230, 237], ["fibrofatty plaque", "ANATOMY", 242, 259], ["cardiovascular", "ANATOMY", 355, 369], ["coronary", "ANATOMY", 531, 539], ["rosuvastatin", "CHEMICAL", 59, 71], ["necrotic", "DISEASE", 159, 167], ["calcium", "CHEMICAL", 183, 190], ["cholesterol", "CHEMICAL", 282, 293], ["inflammation", "DISEASE", 331, 343], ["CV disease", "DISEASE", 437, 447], ["CVD", "DISEASE", 449, 452], ["rosuvastatin", "CHEMICAL", 59, 71], ["calcium", "CHEMICAL", 183, 190], ["cholesterol", "CHEMICAL", 282, 293], ["rosuvastatin", "SIMPLE_CHEMICAL", 59, 71], ["hsCRP", "GENE_OR_GENE_PRODUCT", 100, 105], ["calcium", "SIMPLE_CHEMICAL", 183, 190], ["fibrous", "TISSUE", 230, 237], ["fibrofatty plaque", "PATHOLOGICAL_FORMATION", 242, 259], ["LDL-cholesterol", "SIMPLE_CHEMICAL", 278, 293], ["LDL-C", "GENE_OR_GENE_PRODUCT", 497, 502], ["patients", "ORGANISM", 540, 548], ["hsCRP", "PROTEIN", 100, 105], ["LDL", "PROTEIN", 278, 281], ["LDL", "PROTEIN", 497, 500], ["patients", "SPECIES", 540, 548], ["extensive visual histology study", "TEST", 10, 42], ["rosuvastatin treatment", "TREATMENT", 59, 81], ["the reduction of hsCRP", "TEST", 83, 105], ["necrotic core and dense calcium volumes", "PROBLEM", 159, 198], ["fibrous and fibrofatty plaque volumes", "PROBLEM", 230, 267], ["LDL", "TEST", 278, 281], ["Clinical evaluation", "TEST", 308, 327], ["inflammation", "PROBLEM", 331, 343], ["CV disease", "PROBLEM", 437, 447], ["CVD", "PROBLEM", 449, 452], ["other diseases in individuals", "PROBLEM", 458, 487], ["low LDL-C", "PROBLEM", 493, 502], ["necrotic", "OBSERVATION_MODIFIER", 159, 167], ["dense", "OBSERVATION_MODIFIER", 177, 182], ["calcium volumes", "OBSERVATION", 183, 198], ["fibrous", "OBSERVATION_MODIFIER", 230, 237], ["fibrofatty", "OBSERVATION_MODIFIER", 242, 252], ["plaque", "OBSERVATION", 253, 259], ["inflammation", "OBSERVATION", 331, 343], ["CV disease", "OBSERVATION", 437, 447], ["coronary", "ANATOMY", 531, 539], ["increased", "OBSERVATION_MODIFIER", 569, 578]]], ["Low LDL-C may be a chance finding in random series of individuals or it may be dependent upon mutations in proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like 3, microsomal triglyceride transfer protein or apolipoprotein (apo) B (45) .Clinical evaluation of inflammation-associated cardiovascular riskIn order to assess the critical value of LDL-C vs hsCRP, a crucial study was that by Penson et al on Reasons for Geographical and Racial Differences in Stroke (REGARDS) (46) .", [["cardiovascular", "ANATOMY", 303, 317], ["inflammation", "DISEASE", 279, 291], ["Stroke", "DISEASE", 474, 480], ["triglyceride", "CHEMICAL", 194, 206], ["LDL-C", "GENE_OR_GENE_PRODUCT", 4, 9], ["individuals", "ORGANISM", 54, 65], ["proprotein convertase subtilisin/kexin type 9", "GENE_OR_GENE_PRODUCT", 107, 152], ["PCSK9", "GENE_OR_GENE_PRODUCT", 154, 159], ["angiopoietin-like 3", "GENE_OR_GENE_PRODUCT", 162, 181], ["microsomal triglyceride transfer protein", "GENE_OR_GENE_PRODUCT", 183, 223], ["apolipoprotein (apo) B", "GENE_OR_GENE_PRODUCT", 227, 249], ["LDL-C", "SIMPLE_CHEMICAL", 363, 368], ["hsCRP", "GENE_OR_GENE_PRODUCT", 372, 377], ["LDL", "PROTEIN", 4, 7], ["proprotein convertase subtilisin/kexin type 9", "PROTEIN", 107, 152], ["PCSK9", "PROTEIN", 154, 159], ["angiopoietin", "PROTEIN", 162, 174], ["microsomal triglyceride transfer protein", "PROTEIN", 183, 223], ["apolipoprotein (apo) B", "PROTEIN", 227, 249], ["LDL", "PROTEIN", 363, 366], ["hsCRP", "PROTEIN", 372, 377], ["Low LDL", "PROBLEM", 0, 7], ["dependent upon mutations", "PROBLEM", 79, 103], ["proprotein convertase subtilisin/kexin type", "TEST", 107, 150], ["angiopoietin", "TEST", 162, 174], ["microsomal triglyceride transfer protein", "TEST", 183, 223], ["Clinical evaluation", "TEST", 256, 275], ["inflammation", "PROBLEM", 279, 291], ["LDL", "TEST", 363, 366], ["hsCRP", "PROBLEM", 372, 377], ["a crucial study", "TEST", 379, 394], ["Stroke", "PROBLEM", 474, 480], ["inflammation", "OBSERVATION", 279, 291], ["Stroke", "OBSERVATION", 474, 480]]], ["In this, the relationship between low LDL-C (<70 mg/dL) compared to >70 mg/dl and hsCRP < 2 compared with \uf0b32 mg/L was evaluated.", [["LDL-C", "GENE_OR_GENE_PRODUCT", 38, 43], ["LDL", "PROTEIN", 38, 41], ["hsCRP", "TEST", 82, 87]]], ["The Authors concluded that participants with high LDL-C and low hsCRP have a lower risk of stroke, CHD and CHD deaths compared to those in the same LDL-C category but with high hsCRP.J o u r n a l P r e -p r o o fParticipants with high hsCRP (\uf0b3 2 mg/L) and low LDL-C (<70mg/dL) did not show any additional risk reduction but a significant rise of all-cause mortality (46) .", [["stroke", "DISEASE", 91, 97], ["CHD", "DISEASE", 99, 102], ["CHD", "DISEASE", 107, 110], ["deaths", "DISEASE", 111, 117], ["LDL-C", "GENE_OR_GENE_PRODUCT", 50, 55], ["hsCRP", "GENE_OR_GENE_PRODUCT", 64, 69], ["LDL-C", "SIMPLE_CHEMICAL", 148, 153], ["hsCRP", "GENE_OR_GENE_PRODUCT", 236, 241], ["LDL-C", "SIMPLE_CHEMICAL", 261, 266], ["LDL", "PROTEIN", 50, 53], ["hsCRP", "PROTEIN", 64, 69], ["LDL", "PROTEIN", 148, 151], ["hsCRP", "PROTEIN", 177, 182], ["hsCRP", "PROTEIN", 236, 241], ["LDL", "PROTEIN", 261, 264], ["participants", "SPECIES", 27, 39], ["high LDL-C", "PROBLEM", 45, 55], ["low hsCRP", "PROBLEM", 60, 69], ["stroke", "PROBLEM", 91, 97], ["CHD", "PROBLEM", 99, 102], ["CHD deaths", "PROBLEM", 107, 117], ["high hsCRP", "PROBLEM", 172, 182], ["fParticipants", "PROBLEM", 212, 225], ["high hsCRP", "PROBLEM", 231, 241], ["low LDL", "TEST", 257, 264], ["any additional risk reduction", "PROBLEM", 291, 320], ["stroke", "OBSERVATION", 91, 97], ["significant", "OBSERVATION_MODIFIER", 327, 338], ["rise", "OBSERVATION_MODIFIER", 339, 343]]], ["These findings are in line with those more recently provided by Guedenay et al evaluating residual inflammatory risk (RIR) in 3,013 patients undergoing percutaneous intervention with low baseline LDL-C (\uf0a3 70 mg/dL) (47) and serial hsCRP assessments.", [["percutaneous", "ANATOMY", 152, 164], ["patients", "ORGANISM", 132, 140], ["LDL-C", "SIMPLE_CHEMICAL", 196, 201], ["LDL", "PROTEIN", 196, 199], ["hsCRP", "PROTEIN", 231, 236], ["patients", "SPECIES", 132, 140], ["residual inflammatory risk", "PROBLEM", 90, 116], ["percutaneous intervention", "TREATMENT", 152, 177], ["LDL", "TEST", 196, 199], ["C", "TEST", 200, 201], ["serial hsCRP assessments", "TEST", 224, 248], ["residual", "OBSERVATION_MODIFIER", 90, 98], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["They were characterized as persistent low RIR, attenuated RIR (first high then low hsCRP), increased RIR (first low then high hsCRP), or persistent high RIR.", [["hsCRP", "GENE_OR_GENE_PRODUCT", 126, 131], ["RIR", "PROTEIN", 58, 61], ["hsCRP", "PROTEIN", 83, 88], ["RIR", "PROTEIN", 101, 104], ["hsCRP", "PROTEIN", 126, 131], ["RIR", "PROTEIN", 153, 156], ["persistent low RIR", "PROBLEM", 27, 45], ["attenuated RIR", "PROBLEM", 47, 61], ["low hsCRP", "PROBLEM", 79, 88], ["increased RIR", "PROBLEM", 91, 104], ["persistent high RIR", "PROBLEM", 137, 156], ["persistent", "OBSERVATION_MODIFIER", 27, 37], ["low RIR", "OBSERVATION_MODIFIER", 38, 45], ["increased", "OBSERVATION_MODIFIER", 91, 100], ["persistent", "OBSERVATION_MODIFIER", 137, 147], ["high RIR", "OBSERVATION", 148, 156]]], ["There was a stepwise raised incidence rate of major adverse cardiac and cerebrovascular accidents in these four risk categories within one year of the second hsCRP measurement.Drug approaches to the inflammatory cardiovascular residual riskA number of drug approaches have been guided by knowledge of the inflammatory basis of CVD ( Table 1) .", [["cardiac", "ANATOMY", 60, 67], ["cerebrovascular", "ANATOMY", 72, 87], ["cardiovascular", "ANATOMY", 212, 226], ["adverse cardiac and cerebrovascular accidents", "DISEASE", 52, 97], ["CVD", "DISEASE", 327, 330], ["cardiac", "ORGAN", 60, 67], ["cerebrovascular", "ANATOMICAL_SYSTEM", 72, 87], ["hsCRP", "PROTEIN", 158, 163], ["major adverse cardiac and cerebrovascular accidents", "PROBLEM", 46, 97], ["the second hsCRP measurement", "TEST", 147, 175], ["Drug approaches", "TREATMENT", 176, 191], ["the inflammatory cardiovascular residual riskA", "PROBLEM", 195, 241], ["drug approaches", "TREATMENT", 252, 267], ["cerebrovascular", "ANATOMY", 72, 87], ["inflammatory", "OBSERVATION_MODIFIER", 199, 211], ["inflammatory", "OBSERVATION_MODIFIER", 305, 317]]], ["The CV preventive activity of the most widely used inhibitor of cyclooxygenase (COX)-1 antagonist, aspirin, has not been recently supported by a number of large controlled intervention studies (48, 49) , although possibly the drug may be effective in individuals homozygous for the soluble guanylate cyclase (sGC) gene variant GUCY1A3 risk(G) allele (50) .", [["aspirin", "CHEMICAL", 99, 106], ["aspirin", "CHEMICAL", 99, 106], ["guanylate", "CHEMICAL", 290, 299], ["cyclooxygenase (COX)-1 antagonist", "GENE_OR_GENE_PRODUCT", 64, 97], ["aspirin", "SIMPLE_CHEMICAL", 99, 106], ["guanylate cyclase", "GENE_OR_GENE_PRODUCT", 290, 307], ["sGC", "GENE_OR_GENE_PRODUCT", 309, 312], ["GUCY1A3 risk(G)", "GENE_OR_GENE_PRODUCT", 327, 342], ["soluble guanylate cyclase (sGC) gene", "DNA", 282, 318], ["cyclooxygenase (COX)", "TREATMENT", 64, 84], ["aspirin", "TREATMENT", 99, 106], ["the soluble guanylate cyclase", "PROBLEM", 278, 307]]], ["Selective COX-2 inhibitors have led to CV harm, in particular rofecoxib, although the later large PRECISION study comparing celecoxib with ibuprofen and naproxen in over 27,000 subjects with arthritis did not identify a clear CV harm (51) .", [["rofecoxib", "CHEMICAL", 62, 71], ["celecoxib", "CHEMICAL", 124, 133], ["ibuprofen", "CHEMICAL", 139, 148], ["naproxen", "CHEMICAL", 153, 161], ["arthritis", "DISEASE", 191, 200], ["rofecoxib", "CHEMICAL", 62, 71], ["celecoxib", "CHEMICAL", 124, 133], ["ibuprofen", "CHEMICAL", 139, 148], ["naproxen", "CHEMICAL", 153, 161], ["COX-2", "GENE_OR_GENE_PRODUCT", 10, 15], ["rofecoxib", "SIMPLE_CHEMICAL", 62, 71], ["celecoxib", "SIMPLE_CHEMICAL", 124, 133], ["ibuprofen", "SIMPLE_CHEMICAL", 139, 148], ["naproxen", "SIMPLE_CHEMICAL", 153, 161], ["COX", "PROTEIN", 10, 13], ["Selective COX-2 inhibitors", "TREATMENT", 0, 26], ["CV harm", "PROBLEM", 39, 46], ["celecoxib", "TREATMENT", 124, 133], ["ibuprofen", "TREATMENT", 139, 148], ["naproxen", "TREATMENT", 153, 161], ["arthritis", "PROBLEM", 191, 200], ["arthritis", "OBSERVATION", 191, 200]]], ["In a follow-up study celecoxib proved actually safer than ibuprofen and naproxen when given with aspirin (52) but there was no evidence of CV benefit.Drug approaches to the inflammatory cardiovascular residual riskAside from the COX-inhibitors, agents modulating pathways in downstream response to injury, i.e. secretory and lipoprotein associated phospholipase A2 (53), P-selectin (54) and the IL-1 \uf062\uf020selective inhibitor anakinra (55) , all failed to provide evidence of potential activity on CV endpoints.Drug approaches to the inflammatory cardiovascular residual riskThe CANTOS trial with the anti-IL-1-\uf062\uf020 monoclonal antibody canakinumab (56) , enrolled patients with previous MI and hsCRP \uf0b3 2 mg/L and provided a proof-of-concept for the hypothesis of residual inflammatory risk.", [["cardiovascular", "ANATOMY", 186, 200], ["cardiovascular", "ANATOMY", 543, 557], ["celecoxib", "CHEMICAL", 21, 30], ["ibuprofen", "CHEMICAL", 58, 67], ["naproxen", "CHEMICAL", 72, 80], ["aspirin", "CHEMICAL", 97, 104], ["anakinra", "CHEMICAL", 422, 430], ["canakinumab", "CHEMICAL", 630, 641], ["MI", "DISEASE", 681, 683], ["celecoxib", "CHEMICAL", 21, 30], ["ibuprofen", "CHEMICAL", 58, 67], ["naproxen", "CHEMICAL", 72, 80], ["aspirin", "CHEMICAL", 97, 104], ["celecoxib", "SIMPLE_CHEMICAL", 21, 30], ["ibuprofen", "SIMPLE_CHEMICAL", 58, 67], ["naproxen", "SIMPLE_CHEMICAL", 72, 80], ["aspirin", "SIMPLE_CHEMICAL", 97, 104], ["COX", "GENE_OR_GENE_PRODUCT", 229, 232], ["lipoprotein", "SIMPLE_CHEMICAL", 325, 336], ["phospholipase A2", "GENE_OR_GENE_PRODUCT", 348, 364], ["P-selectin", "GENE_OR_GENE_PRODUCT", 371, 381], ["IL-1", "GENE_OR_GENE_PRODUCT", 395, 399], ["anakinra", "SIMPLE_CHEMICAL", 422, 430], ["anti-IL-1", "GENE_OR_GENE_PRODUCT", 597, 606], ["patients", "ORGANISM", 658, 666], ["COX", "PROTEIN", 229, 232], ["phospholipase A2", "PROTEIN", 348, 364], ["selectin", "PROTEIN", 373, 381], ["hsCRP", "PROTEIN", 688, 693], ["patients", "SPECIES", 658, 666], ["celecoxib", "TREATMENT", 21, 30], ["ibuprofen", "TREATMENT", 58, 67], ["naproxen", "TREATMENT", 72, 80], ["aspirin", "TREATMENT", 97, 104], ["CV benefit", "PROBLEM", 139, 149], ["Drug approaches", "TREATMENT", 150, 165], ["the inflammatory cardiovascular residual riskAside", "PROBLEM", 169, 219], ["the COX-inhibitors", "TREATMENT", 225, 243], ["agents modulating pathways", "TREATMENT", 245, 271], ["injury", "PROBLEM", 298, 304], ["secretory and lipoprotein associated phospholipase A2", "TEST", 311, 364], ["selectin", "TEST", 373, 381], ["the IL-1 \uf062\uf020selective inhibitor anakinra", "TREATMENT", 391, 430], ["potential activity on CV endpoints", "PROBLEM", 472, 506], ["Drug approaches", "TREATMENT", 507, 522], ["the inflammatory cardiovascular residual risk", "PROBLEM", 526, 571], ["The CANTOS trial", "TEST", 571, 587], ["the anti-IL", "TEST", 593, 604], ["\uf062\uf020 monoclonal antibody canakinumab", "TREATMENT", 607, 641], ["previous MI", "PROBLEM", 672, 683], ["hsCRP \uf0b3", "TREATMENT", 688, 695], ["residual inflammatory risk", "PROBLEM", 757, 783], ["no evidence of", "UNCERTAINTY", 124, 138], ["inflammatory", "OBSERVATION_MODIFIER", 173, 185], ["inflammatory", "OBSERVATION_MODIFIER", 530, 542], ["residual", "OBSERVATION_MODIFIER", 757, 765], ["inflammatory risk", "OBSERVATION", 766, 783]]], ["Canakinumab reduced hsCRP by 35% and did not affect, at any dose, LDL-C, HDL-C and TG levels (57) .", [["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["hsCRP", "GENE_OR_GENE_PRODUCT", 20, 25], ["LDL-C", "SIMPLE_CHEMICAL", 66, 71], ["HDL-C", "SIMPLE_CHEMICAL", 73, 78], ["TG", "SIMPLE_CHEMICAL", 83, 85], ["hsCRP", "PROTEIN", 20, 25], ["LDL", "PROTEIN", 66, 69], ["HDL", "PROTEIN", 73, 76], ["Canakinumab reduced hsCRP", "PROBLEM", 0, 25], ["LDL", "TEST", 66, 69], ["C", "TEST", 70, 71], ["HDL", "TEST", 73, 76], ["TG levels", "TEST", 83, 92]]], ["After a median follow-up of 3. in the incidence of new-onset diabetes was found.", [["diabetes", "DISEASE", 61, 69], ["new-onset diabetes", "PROBLEM", 51, 69], ["new", "OBSERVATION_MODIFIER", 51, 54], ["onset", "OBSERVATION_MODIFIER", 55, 60], ["diabetes", "OBSERVATION", 61, 69]]], ["Canakinumab reduced MACE rates to a similar extent in patients with or without diabetes (59) and was associated with a significant reduction in deaths from lung cancer (60) .", [["lung cancer", "ANATOMY", 156, 167], ["Canakinumab", "CHEMICAL", 0, 11], ["diabetes", "DISEASE", 79, 87], ["deaths", "DISEASE", 144, 150], ["lung cancer", "DISEASE", 156, 167], ["Canakinumab", "CHEMICAL", 0, 11], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["patients", "ORGANISM", 54, 62], ["lung cancer", "CANCER", 156, 167], ["patients", "SPECIES", 54, 62], ["Canakinumab reduced MACE rates", "PROBLEM", 0, 30], ["diabetes", "PROBLEM", 79, 87], ["a significant reduction in deaths", "PROBLEM", 117, 150], ["lung cancer", "PROBLEM", 156, 167], ["similar extent", "OBSERVATION_MODIFIER", 36, 50], ["significant", "OBSERVATION_MODIFIER", 119, 130], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["lung", "ANATOMY", 156, 160], ["cancer", "OBSERVATION", 161, 167]]], ["Deaths from infection were instead significantly raised.Drug approaches to the inflammatory cardiovascular residual riskAmong patients on canakinumab, those achieving on-treatment hsCRP \uf0a3 2 mg/L had a higher benefit in terms of reduction of major CV events (HR: 0.75; 95% CI: 0.66-0.85), CV mortality (HR: 0.69; 95% CI: 0.56-0.85) and all-cause mortality (HR: 0.69; 95% CI: 0.58-0.81) regardless of canakinumab dose (Figure 1 ) (61) .", [["cardiovascular", "ANATOMY", 92, 106], ["infection", "DISEASE", 12, 21], ["canakinumab", "CHEMICAL", 138, 149], ["canakinumab", "CHEMICAL", 399, 410], ["canakinumab", "CHEMICAL", 138, 149], ["canakinumab", "CHEMICAL", 399, 410], ["patients", "ORGANISM", 126, 134], ["canakinumab", "SIMPLE_CHEMICAL", 138, 149], ["canakinumab", "SIMPLE_CHEMICAL", 399, 410], ["hsCRP", "PROTEIN", 180, 185], ["patients", "SPECIES", 126, 134], ["infection", "PROBLEM", 12, 21], ["the inflammatory cardiovascular residual riskAmong", "PROBLEM", 75, 125], ["canakinumab", "TREATMENT", 138, 149], ["treatment hsCRP", "TREATMENT", 170, 185], ["major CV events", "PROBLEM", 241, 256], ["HR", "TEST", 258, 260], ["CI", "TEST", 272, 274], ["CV mortality", "TEST", 288, 300], ["HR", "TEST", 302, 304], ["CI", "TEST", 316, 318], ["HR", "TEST", 356, 358], ["CI", "TEST", 370, 372], ["canakinumab dose", "TREATMENT", 399, 415], ["infection", "OBSERVATION", 12, 21], ["inflammatory", "OBSERVATION_MODIFIER", 79, 91]]], ["Reaching this hsCRP threshold translated into a 5-year NNT estimate of 16 for MI, stroke, coronary revascularization or all-cause death.", [["coronary", "ANATOMY", 90, 98], ["MI", "DISEASE", 78, 80], ["stroke", "DISEASE", 82, 88], ["death", "DISEASE", 130, 135], ["hsCRP", "GENE_OR_GENE_PRODUCT", 14, 19], ["coronary", "MULTI-TISSUE_STRUCTURE", 90, 98], ["hsCRP", "PROTEIN", 14, 19], ["this hsCRP threshold", "PROBLEM", 9, 29], ["MI", "PROBLEM", 78, 80], ["stroke", "PROBLEM", 82, 88], ["coronary revascularization", "TREATMENT", 90, 116], ["death", "PROBLEM", 130, 135], ["stroke", "OBSERVATION", 82, 88], ["coronary", "ANATOMY", 90, 98], ["revascularization", "OBSERVATION", 99, 116]]], ["For participants who did not achieve on-treatment hsCRP < 2mg/dL the 5-year NNT estimate was 57 (61) .", [["hsCRP", "PROTEIN", 50, 55], ["participants", "SPECIES", 4, 16], ["hsCRP", "TEST", 50, 55]]], ["Among chronic kidney disease patients, canakinumab reduced the risk of MACEs by 18% with the highest benefit for those achieving on-treatment hsCRP levels below 2 mg/L (-32%) (62) .", [["kidney", "ANATOMY", 14, 20], ["chronic kidney disease", "DISEASE", 6, 28], ["canakinumab", "CHEMICAL", 39, 50], ["MACEs", "DISEASE", 71, 76], ["canakinumab", "CHEMICAL", 39, 50], ["kidney", "ORGAN", 14, 20], ["patients", "ORGANISM", 29, 37], ["canakinumab", "SIMPLE_CHEMICAL", 39, 50], ["hsCRP", "PROTEIN", 142, 147], ["patients", "SPECIES", 29, 37], ["Among chronic kidney disease", "PROBLEM", 0, 28], ["canakinumab", "TREATMENT", 39, 50], ["MACEs", "TEST", 71, 76], ["hsCRP levels", "TEST", 142, 154], ["chronic", "OBSERVATION_MODIFIER", 6, 13], ["kidney", "ANATOMY", 14, 20], ["disease", "OBSERVATION", 21, 28]]], ["Canakinumab reduced in a dose dependent manner the composite of hospitalizations for heart failure or heart failure-related mortality: HR= 1.00 (50 mg, reference value), 0.88 (150 mg) and 0.78 (300 mg) (62) .Drug approaches to the inflammatory cardiovascular residual riskA further trial investigating efficacy of anti-inflammatory treatments in coronary patients was the Cardiovascular Inflammation Reduction Trial (CIRT), was designed to evaluate the effects of low dose methotrexate (15-20 mg per week) vs placebo.", [["heart", "ANATOMY", 85, 90], ["heart", "ANATOMY", 102, 107], ["cardiovascular", "ANATOMY", 244, 258], ["coronary", "ANATOMY", 346, 354], ["Cardiovascular", "ANATOMY", 372, 386], ["Canakinumab", "CHEMICAL", 0, 11], ["heart failure", "DISEASE", 85, 98], ["heart failure", "DISEASE", 102, 115], ["Cardiovascular Inflammation", "DISEASE", 372, 399], ["methotrexate", "CHEMICAL", 473, 485], ["Canakinumab", "CHEMICAL", 0, 11], ["methotrexate", "CHEMICAL", 473, 485], ["Canakinumab", "SIMPLE_CHEMICAL", 0, 11], ["heart", "ORGAN", 85, 90], ["heart", "ORGAN", 102, 107], ["coronary", "MULTI-TISSUE_STRUCTURE", 346, 354], ["patients", "ORGANISM", 355, 363], ["methotrexate", "SIMPLE_CHEMICAL", 473, 485], ["patients", "SPECIES", 355, 363], ["Canakinumab", "TREATMENT", 0, 11], ["a dose dependent manner", "TREATMENT", 23, 46], ["heart failure", "PROBLEM", 85, 98], ["heart failure", "PROBLEM", 102, 115], ["HR", "TEST", 135, 137], ["Drug approaches", "TREATMENT", 208, 223], ["the inflammatory cardiovascular residual riskA", "PROBLEM", 227, 273], ["anti-inflammatory treatments", "TREATMENT", 314, 342], ["the Cardiovascular Inflammation Reduction Trial (CIRT)", "TREATMENT", 368, 422], ["low dose methotrexate", "TREATMENT", 464, 485], ["placebo", "TREATMENT", 509, 516], ["heart", "ANATOMY", 85, 90], ["failure", "OBSERVATION", 91, 98], ["heart", "ANATOMY", 102, 107], ["failure", "OBSERVATION", 108, 115], ["inflammatory", "OBSERVATION_MODIFIER", 231, 243], ["anti-inflammatory", "OBSERVATION_MODIFIER", 314, 331], ["coronary", "ANATOMY", 346, 354]]], ["Patients had to have, in addition to prior MI or multivessel coronary disease, either type 2 diabetes or the metabolic syndrome.", [["coronary", "ANATOMY", 61, 69], ["MI", "DISEASE", 43, 45], ["multivessel coronary disease", "DISEASE", 49, 77], ["type 2 diabetes", "DISEASE", 86, 101], ["metabolic syndrome", "DISEASE", 109, 127], ["Patients", "ORGANISM", 0, 8], ["coronary", "MULTI-TISSUE_STRUCTURE", 61, 69], ["Patients", "SPECIES", 0, 8], ["prior MI", "PROBLEM", 37, 45], ["multivessel coronary disease", "PROBLEM", 49, 77], ["type 2 diabetes", "PROBLEM", 86, 101], ["the metabolic syndrome", "PROBLEM", 105, 127], ["multivessel", "OBSERVATION", 49, 60], ["coronary", "ANATOMY", 61, 69], ["disease", "OBSERVATION", 70, 77], ["diabetes", "OBSERVATION", 93, 101], ["metabolic syndrome", "OBSERVATION", 109, 127]]], ["The trial was stopped since methotrexate did not result in the lowering of IL-1\uf062\uf02c\uf020IL-6 or hsCRP vs placebo.", [["methotrexate", "CHEMICAL", 28, 40], ["methotrexate", "CHEMICAL", 28, 40], ["methotrexate", "SIMPLE_CHEMICAL", 28, 40], ["IL-1\uf062\uf02c", "GENE_OR_GENE_PRODUCT", 75, 81], ["IL-6", "GENE_OR_GENE_PRODUCT", 82, 86], ["hsCRP", "GENE_OR_GENE_PRODUCT", 90, 95], ["IL", "PROTEIN", 75, 77], ["hsCRP", "PROTEIN", 90, 95], ["methotrexate", "TREATMENT", 28, 40], ["IL", "TEST", 75, 77], ["hsCRP", "PROBLEM", 90, 95], ["placebo", "TREATMENT", 99, 106]]], ["The primary endpoint occurred in 201 patients in the methotrexate and 207 in the placebo group (HR 0.96, 95% CI 0.79 to 1.16).", [["methotrexate", "CHEMICAL", 53, 65], ["methotrexate", "CHEMICAL", 53, 65], ["patients", "ORGANISM", 37, 45], ["methotrexate", "SIMPLE_CHEMICAL", 53, 65], ["patients", "SPECIES", 37, 45], ["the methotrexate", "TREATMENT", 49, 65], ["HR", "TEST", 96, 98], ["CI", "TEST", 109, 111]]], ["Methotrexate treatment was associated with raised liver enzymes, reduction in leukocytes and hematocrit and a higher incidence of non-basal cell skin cancer vs placebo (63) .", [["liver", "ANATOMY", 50, 55], ["leukocytes", "ANATOMY", 78, 88], ["non-basal cell skin cancer", "ANATOMY", 130, 156], ["Methotrexate", "CHEMICAL", 0, 12], ["non-basal cell skin cancer", "DISEASE", 130, 156], ["Methotrexate", "CHEMICAL", 0, 12], ["Methotrexate", "SIMPLE_CHEMICAL", 0, 12], ["liver", "ORGAN", 50, 55], ["leukocytes", "CELL", 78, 88], ["non-basal cell skin cancer", "CANCER", 130, 156], ["liver enzymes", "PROTEIN", 50, 63], ["leukocytes", "CELL_TYPE", 78, 88], ["Methotrexate treatment", "TREATMENT", 0, 22], ["raised liver enzymes", "PROBLEM", 43, 63], ["reduction in leukocytes", "PROBLEM", 65, 88], ["hematocrit", "TEST", 93, 103], ["non-basal cell skin cancer", "PROBLEM", 130, 156], ["liver", "ANATOMY", 50, 55], ["reduction", "OBSERVATION_MODIFIER", 65, 74], ["leukocytes", "OBSERVATION", 78, 88], ["hematocrit", "OBSERVATION_MODIFIER", 93, 103], ["higher", "OBSERVATION_MODIFIER", 110, 116], ["non-basal cell", "OBSERVATION", 130, 144], ["skin", "ANATOMY", 145, 149], ["cancer", "OBSERVATION", 150, 156]]], ["The different patient selection may explain the divergent results: in the CANTOS study patients were selected based on elevated hsCRP levels, whereas CIRT included patients with relatively normal inflammatory biomarkers (hsCRP= 1.6 mg/L), poorly modified by treatment (64) .Drug approaches to the inflammatory cardiovascular residual riskColchicine, of general use in the treatment of gouty attacks and pericarditis, by inhibiting neutrophil motility and with marked anti-inflammatory effects, particularly in reducing local cytokine production (65) , and improving endothelial function (66) was the object of a large outcome trial, the Colchicine Cardiovascular Outcomes Trial (COLCOT).", [["cardiovascular", "ANATOMY", 310, 324], ["neutrophil", "ANATOMY", 431, 441], ["endothelial", "ANATOMY", 566, 577], ["Cardiovascular", "ANATOMY", 648, 662], ["riskColchicine", "CHEMICAL", 334, 348], ["gouty attacks", "DISEASE", 385, 398], ["pericarditis", "DISEASE", 403, 415], ["Colchicine", "CHEMICAL", 637, 647], ["riskColchicine", "CHEMICAL", 334, 348], ["Colchicine", "CHEMICAL", 637, 647], ["patient", "ORGANISM", 14, 21], ["patients", "ORGANISM", 87, 95], ["hsCRP", "GENE_OR_GENE_PRODUCT", 128, 133], ["patients", "ORGANISM", 164, 172], ["riskColchicine", "SIMPLE_CHEMICAL", 334, 348], ["neutrophil", "CELL", 431, 441], ["endothelial", "CELL", 566, 577], ["Colchicine", "SIMPLE_CHEMICAL", 637, 647], ["hsCRP", "PROTEIN", 128, 133], ["hsCRP", "PROTEIN", 221, 226], ["cytokine", "PROTEIN", 525, 533], ["patient", "SPECIES", 14, 21], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 164, 172], ["the CANTOS study", "TEST", 70, 86], ["elevated hsCRP levels", "PROBLEM", 119, 140], ["hsCRP", "TEST", 221, 226], ["the inflammatory cardiovascular residual riskColchicine", "PROBLEM", 293, 348], ["gouty attacks", "PROBLEM", 385, 398], ["pericarditis", "PROBLEM", 403, 415], ["neutrophil motility", "PROBLEM", 431, 450], ["marked anti-inflammatory effects", "PROBLEM", 460, 492], ["the Colchicine Cardiovascular Outcomes Trial (COLCOT)", "TREATMENT", 633, 686], ["inflammatory", "OBSERVATION_MODIFIER", 196, 208], ["inflammatory", "OBSERVATION_MODIFIER", 297, 309], ["gouty", "OBSERVATION", 385, 390], ["pericarditis", "OBSERVATION", 403, 415], ["neutrophil motility", "OBSERVATION", 431, 450], ["marked", "OBSERVATION_MODIFIER", 460, 466], ["anti-inflammatory effects", "OBSERVATION", 467, 492]]], ["This examined the effects of low dose colchicine (0.5 mg/day) or placebo on CV events in 4,745 patients with ACS on optimal medical treatment, randomized within 30 days of the event (67) .", [["colchicine", "CHEMICAL", 38, 48], ["ACS", "DISEASE", 109, 112], ["colchicine", "CHEMICAL", 38, 48], ["colchicine", "SIMPLE_CHEMICAL", 38, 48], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["low dose colchicine", "TREATMENT", 29, 48], ["placebo", "TREATMENT", 65, 72], ["ACS", "PROBLEM", 109, 112], ["optimal medical treatment", "TREATMENT", 116, 141]]], ["The primary end-point occurred in 5.5% of patients given colchicine vs 7.5% in the placebo group (HR 0.77; 95% CI 0.62-0.96) (68).", [["colchicine", "CHEMICAL", 57, 67], ["colchicine", "CHEMICAL", 57, 67], ["patients", "ORGANISM", 42, 50], ["colchicine", "SIMPLE_CHEMICAL", 57, 67], ["patients", "SPECIES", 42, 50], ["colchicine", "TREATMENT", 57, 67], ["HR", "TEST", 98, 100], ["CI", "TEST", 111, 113]]], ["The effect was predominantly driven by lower risk of angina and stroke, without a significant effect on death J o u r n a l P r e -p r o o f from CV causes or MI incidence.", [["angina", "DISEASE", 53, 59], ["stroke", "DISEASE", 64, 70], ["death", "DISEASE", 104, 109], ["MI", "DISEASE", 159, 161], ["angina", "PROBLEM", 53, 59], ["stroke", "PROBLEM", 64, 70], ["a significant effect on death", "PROBLEM", 80, 109], ["CV causes", "PROBLEM", 146, 155], ["MI incidence", "PROBLEM", 159, 171], ["angina", "OBSERVATION", 53, 59], ["stroke", "OBSERVATION", 64, 70]]], ["No changes in hsCRP were detected, thus casting doubt on the postulated anti-inflammatory protective mechanism (69) .", [["hsCRP", "GENE_OR_GENE_PRODUCT", 14, 19], ["hsCRP", "PROTEIN", 14, 19], ["changes in hsCRP", "PROBLEM", 3, 19]]], ["A number of other inflammation antagonists including those targeting L-6 or TNF-\uf061\uf020 have been also tested without success.", [["inflammation", "DISEASE", 18, 30], ["L-6", "GENE_OR_GENE_PRODUCT", 69, 72], ["TNF-\uf061\uf020", "GENE_OR_GENE_PRODUCT", 76, 82], ["L-6", "PROTEIN", 69, 72], ["TNF", "PROTEIN", 76, 79], ["other inflammation antagonists", "TREATMENT", 12, 42], ["TNF", "TREATMENT", 76, 79], ["inflammation", "OBSERVATION", 18, 30]]], ["TNF-\uf061\uf020(etanercept) and IL-6 blockade (tociluzumab) tend to increase pro-atherogenic apo B containing lipoproteins (70, 71) .Drug approaches to the inflammatory cardiovascular residual riskA protective role of HDL in reducing plaque inflammation has been finally described recently (72) in diabetic mice, reporting a promoted atherosclerosis regression by raising HDL levels, a benefit linked to suppressed hyperglycemia-induced hematopoiesis, monocytosis and neutrophilia.Drug approaches to the inflammatory cardiovascular residual riskThe improvement in cholesterol efflux from bone marrow progenitors led to a suppression of proliferation as well as to polarization of plaque macrophages to the atherosclerosis-resolving M2.Statins.The beneficial effect of statins on coronary events is generally assumed to be linked to their hypocholesterolemic properties (73) .", [["cardiovascular", "ANATOMY", 160, 174], ["plaque", "ANATOMY", 225, 231], ["cardiovascular", "ANATOMY", 508, 522], ["bone marrow progenitors", "ANATOMY", 579, 602], ["plaque macrophages", "ANATOMY", 671, 689], ["coronary", "ANATOMY", 770, 778], ["etanercept", "CHEMICAL", 7, 17], ["tociluzumab", "CHEMICAL", 38, 49], ["plaque inflammation", "DISEASE", 225, 244], ["diabetic", "DISEASE", 289, 297], ["atherosclerosis", "DISEASE", 325, 340], ["hyperglycemia", "DISEASE", 406, 419], ["hematopoiesis", "DISEASE", 428, 441], ["monocytosis", "DISEASE", 443, 454], ["neutrophilia", "DISEASE", 459, 471], ["cholesterol", "CHEMICAL", 555, 566], ["atherosclerosis", "DISEASE", 697, 712], ["Statins", "CHEMICAL", 726, 733], ["statins", "CHEMICAL", 759, 766], ["tociluzumab", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 555, 566], ["Statins", "CHEMICAL", 726, 733], ["statins", "CHEMICAL", 759, 766], ["TNF-\uf061\uf020", "GENE_OR_GENE_PRODUCT", 0, 6], ["etanercept", "SIMPLE_CHEMICAL", 7, 17], ["IL-6", "GENE_OR_GENE_PRODUCT", 23, 27], ["tociluzumab", "SIMPLE_CHEMICAL", 38, 49], ["apo B", "GENE_OR_GENE_PRODUCT", 84, 89], ["cardiovascular", "ANATOMICAL_SYSTEM", 160, 174], ["HDL", "SIMPLE_CHEMICAL", 209, 212], ["plaque", "PATHOLOGICAL_FORMATION", 225, 231], ["mice", "ORGANISM", 298, 302], ["HDL", "SIMPLE_CHEMICAL", 363, 366], ["cholesterol", "SIMPLE_CHEMICAL", 555, 566], ["bone marrow progenitors", "CELL", 579, 602], ["plaque macrophages", "CELL", 671, 689], ["statins", "SIMPLE_CHEMICAL", 759, 766], ["coronary", "MULTI-TISSUE_STRUCTURE", 770, 778], ["TNF", "PROTEIN", 0, 3], ["pro-atherogenic apo B", "PROTEIN", 68, 89], ["lipoproteins", "PROTEIN", 101, 113], ["HDL", "PROTEIN", 209, 212], ["HDL", "PROTEIN", 363, 366], ["bone marrow progenitors", "CELL_TYPE", 579, 602], ["plaque macrophages", "CELL_TYPE", 671, 689], ["mice", "SPECIES", 298, 302], ["mice", "SPECIES", 298, 302], ["TNF", "TEST", 0, 3], ["etanercept", "TREATMENT", 7, 17], ["IL-6 blockade", "TREATMENT", 23, 36], ["Drug approaches", "TREATMENT", 124, 139], ["the inflammatory cardiovascular residual riskA", "PROBLEM", 143, 189], ["HDL", "TREATMENT", 209, 212], ["reducing plaque inflammation", "PROBLEM", 216, 244], ["a promoted atherosclerosis regression", "PROBLEM", 314, 351], ["HDL levels", "TEST", 363, 373], ["suppressed hyperglycemia", "PROBLEM", 395, 419], ["induced hematopoiesis", "PROBLEM", 420, 441], ["monocytosis", "PROBLEM", 443, 454], ["neutrophilia", "PROBLEM", 459, 471], ["Drug approaches", "TREATMENT", 472, 487], ["the inflammatory cardiovascular residual risk", "PROBLEM", 491, 536], ["cholesterol efflux", "PROBLEM", 555, 573], ["bone marrow progenitors", "PROBLEM", 579, 602], ["proliferation", "PROBLEM", 627, 640], ["plaque macrophages", "PROBLEM", 671, 689], ["the atherosclerosis", "PROBLEM", 693, 712], ["M2", "PROBLEM", 723, 725], ["Statins", "TREATMENT", 726, 733], ["statins", "TREATMENT", 759, 766], ["coronary events", "PROBLEM", 770, 785], ["lipoproteins", "ANATOMY", 101, 113], ["inflammatory", "OBSERVATION_MODIFIER", 147, 159], ["HDL", "OBSERVATION_MODIFIER", 209, 212], ["plaque", "OBSERVATION", 225, 231], ["atherosclerosis", "OBSERVATION", 325, 340], ["hematopoiesis", "OBSERVATION", 428, 441], ["monocytosis", "OBSERVATION_MODIFIER", 443, 454], ["neutrophilia", "OBSERVATION", 459, 471], ["inflammatory", "OBSERVATION_MODIFIER", 495, 507], ["improvement", "OBSERVATION_MODIFIER", 540, 551], ["cholesterol efflux", "OBSERVATION", 555, 573], ["bone", "ANATOMY", 579, 583], ["marrow progenitors", "OBSERVATION", 584, 602], ["proliferation", "OBSERVATION", 627, 640], ["plaque", "OBSERVATION_MODIFIER", 671, 677], ["macrophages", "OBSERVATION", 678, 689], ["atherosclerosis", "OBSERVATION", 697, 712], ["resolving", "OBSERVATION_MODIFIER", 713, 722], ["M2", "OBSERVATION_MODIFIER", 723, 725], ["coronary", "ANATOMY", 770, 778]]], ["Since mevalonic acid is the precursor of numerous metabolites, inhibition of HMG-CoA reductase potentially results in pleiotropic effects (74) .Statins.However, statins can decrease the number of LDL particles infiltrating the vessel wall and thus potentially reducing CRP.", [["vessel wall", "ANATOMY", 227, 238], ["mevalonic acid", "CHEMICAL", 6, 20], ["Statins", "CHEMICAL", 144, 151], ["statins", "CHEMICAL", 161, 168], ["mevalonic acid", "CHEMICAL", 6, 20], ["HMG-CoA", "CHEMICAL", 77, 84], ["Statins", "CHEMICAL", 144, 151], ["statins", "CHEMICAL", 161, 168], ["mevalonic acid", "SIMPLE_CHEMICAL", 6, 20], ["HMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 77, 94], ["statins", "SIMPLE_CHEMICAL", 161, 168], ["LDL", "SIMPLE_CHEMICAL", 196, 199], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 227, 238], ["CRP", "GENE_OR_GENE_PRODUCT", 269, 272], ["HMG-CoA reductase", "PROTEIN", 77, 94], ["CRP", "PROTEIN", 269, 272], ["mevalonic acid", "TREATMENT", 6, 20], ["HMG-CoA reductase", "TREATMENT", 77, 94], ["Statins", "TREATMENT", 144, 151], ["statins", "TREATMENT", 161, 168], ["CRP", "TEST", 269, 272], ["CoA", "ANATOMY", 81, 84], ["LDL particles", "OBSERVATION", 196, 209], ["vessel", "ANATOMY", 227, 233], ["wall", "ANATOMY_MODIFIER", 234, 238], ["potentially", "UNCERTAINTY", 248, 259], ["reducing", "OBSERVATION_MODIFIER", 260, 268], ["CRP", "OBSERVATION_MODIFIER", 269, 272]]], ["Statins do indeed display significant anti-inflammatory effects and this has led to some non-lipid indications, e.g. the treatment of periodontal inflammation associated with reduced carotid inflammation (75) .Statins.The role of hsCRP reduction in the large number of statin trials has been the object of a prior review article (76) and data are thus summarized in (78) (79) (80) (81) .", [["periodontal", "ANATOMY", 134, 145], ["carotid", "ANATOMY", 183, 190], ["Statins", "CHEMICAL", 0, 7], ["periodontal inflammation", "DISEASE", 134, 158], ["reduced carotid inflammation", "DISEASE", 175, 203], ["Statins", "CHEMICAL", 210, 217], ["statin", "CHEMICAL", 269, 275], ["Statins", "CHEMICAL", 0, 7], ["Statins", "CHEMICAL", 210, 217], ["carotid", "MULTI-TISSUE_STRUCTURE", 183, 190], ["hsCRP", "GENE_OR_GENE_PRODUCT", 230, 235], ["hsCRP", "PROTEIN", 230, 235], ["Statins", "TREATMENT", 0, 7], ["significant anti-inflammatory effects", "PROBLEM", 26, 63], ["periodontal inflammation", "PROBLEM", 134, 158], ["reduced carotid inflammation", "PROBLEM", 175, 203], ["Statins", "TREATMENT", 210, 217], ["hsCRP reduction", "TREATMENT", 230, 245], ["statin trials", "TREATMENT", 269, 282], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["anti-inflammatory", "OBSERVATION", 38, 55], ["periodontal", "ANATOMY", 134, 145], ["inflammation", "OBSERVATION", 146, 158], ["reduced", "OBSERVATION_MODIFIER", 175, 182], ["carotid", "ANATOMY", 183, 190], ["inflammation", "OBSERVATION", 191, 203], ["large", "OBSERVATION_MODIFIER", 253, 258], ["number", "OBSERVATION_MODIFIER", 259, 265]]], ["In all these, the largest benefit was found in patients achieving LDL-C < 70 mg/dL and hsCRP < 2 mg/L (82).", [["patients", "ORGANISM", 47, 55], ["LDL-C", "SIMPLE_CHEMICAL", 66, 71], ["hsCRP", "GENE_OR_GENE_PRODUCT", 87, 92], ["LDL", "PROTEIN", 66, 69], ["hsCRP", "PROTEIN", 87, 92], ["patients", "SPECIES", 47, 55], ["LDL", "TEST", 66, 69], ["hsCRP", "TEST", 87, 92], ["largest", "OBSERVATION_MODIFIER", 18, 25]]], ["This was confirmed in the primary prevention JUPITER trial on 18,000 patients with median LDL-C 108 mg/dL and elevated hsCRP (> 2.0 mg/L) (83) , where the largest reduction in CV events (-65%), occurred upon achieving both LDL-C < 70 mg/dL and hsCRP < 2 mg/dL (84) .", [["patients", "ORGANISM", 69, 77], ["LDL-C", "SIMPLE_CHEMICAL", 90, 95], ["hsCRP", "GENE_OR_GENE_PRODUCT", 119, 124], ["LDL-C", "SIMPLE_CHEMICAL", 223, 228], ["hsCRP", "GENE_OR_GENE_PRODUCT", 244, 249], ["LDL", "PROTEIN", 90, 93], ["hsCRP", "PROTEIN", 119, 124], ["LDL", "PROTEIN", 223, 226], ["hsCRP", "PROTEIN", 244, 249], ["patients", "SPECIES", 69, 77], ["median LDL", "TEST", 83, 93], ["elevated hsCRP", "PROBLEM", 110, 124], ["the largest reduction", "PROBLEM", 151, 172], ["CV events", "PROBLEM", 176, 185], ["LDL", "TEST", 223, 226], ["hsCRP", "TEST", 244, 249], ["largest", "OBSERVATION_MODIFIER", 155, 162], ["reduction", "OBSERVATION_MODIFIER", 163, 172]]], ["When added to statins, it leads to an incremental lowering of LDL-C levels and improved cardiovascular outcomes (86) .Statins.In a study on rabbits on a high fat diet and atherosclerosis, ezetimibe led to both reduced progression of atheromas and plaque stabilization.", [["cardiovascular", "ANATOMY", 88, 102], ["atheromas", "ANATOMY", 233, 242], ["plaque", "ANATOMY", 247, 253], ["statins", "CHEMICAL", 14, 21], ["Statins", "CHEMICAL", 118, 125], ["atherosclerosis", "DISEASE", 171, 186], ["ezetimibe", "CHEMICAL", 188, 197], ["atheromas", "DISEASE", 233, 242], ["plaque", "DISEASE", 247, 253], ["statins", "CHEMICAL", 14, 21], ["Statins", "CHEMICAL", 118, 125], ["ezetimibe", "CHEMICAL", 188, 197], ["LDL-C", "SIMPLE_CHEMICAL", 62, 67], ["cardiovascular", "ANATOMICAL_SYSTEM", 88, 102], ["rabbits", "ORGANISM", 140, 147], ["fat", "TISSUE", 158, 161], ["ezetimibe", "SIMPLE_CHEMICAL", 188, 197], ["atheromas", "CANCER", 233, 242], ["plaque", "PATHOLOGICAL_FORMATION", 247, 253], ["LDL", "PROTEIN", 62, 65], ["rabbits", "SPECIES", 140, 147], ["rabbits", "SPECIES", 140, 147], ["statins", "TREATMENT", 14, 21], ["an incremental lowering of LDL", "TREATMENT", 35, 65], ["C levels", "TEST", 66, 74], ["Statins", "TREATMENT", 118, 125], ["a study", "TEST", 129, 136], ["a high fat diet", "TREATMENT", 151, 166], ["atherosclerosis", "PROBLEM", 171, 186], ["ezetimibe", "TREATMENT", 188, 197], ["atheromas", "PROBLEM", 233, 242], ["plaque stabilization", "TREATMENT", 247, 267], ["atherosclerosis", "OBSERVATION", 171, 186], ["reduced", "OBSERVATION_MODIFIER", 210, 217], ["progression", "OBSERVATION_MODIFIER", 218, 229], ["atheromas", "OBSERVATION", 233, 242], ["plaque", "OBSERVATION", 247, 253]]], ["CRP levels were significantly reduced with no further reduction occurring by the addition of simvastatin (87) .", [["simvastatin", "CHEMICAL", 93, 104], ["simvastatin", "CHEMICAL", 93, 104], ["CRP", "GENE_OR_GENE_PRODUCT", 0, 3], ["simvastatin", "SIMPLE_CHEMICAL", 93, 104], ["CRP", "PROTEIN", 0, 3], ["CRP levels", "TEST", 0, 10], ["further reduction", "TREATMENT", 46, 63], ["simvastatin", "TREATMENT", 93, 104]]], ["Clinical studies did not fully confirm this conclusion, i.e. a pooled analysis of trials in hypercholesterolemic patients showed no significant hsCRP changes.", [["hypercholesterolemic", "DISEASE", 92, 112], ["patients", "ORGANISM", 113, 121], ["hsCRP", "GENE_OR_GENE_PRODUCT", 144, 149], ["hsCRP", "PROTEIN", 144, 149], ["patients", "SPECIES", 113, 121], ["Clinical studies", "TEST", 0, 16], ["a pooled analysis", "TEST", 61, 78], ["significant hsCRP changes", "PROBLEM", 132, 157], ["no", "UNCERTAINTY", 129, 131], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["hsCRP", "OBSERVATION", 144, 149]]], ["Conversely, when ezetimibe was added to baseline statin therapy, a -10% reduction of hsCRP was observed (88) .", [["ezetimibe", "CHEMICAL", 17, 26], ["statin", "CHEMICAL", 49, 55], ["ezetimibe", "CHEMICAL", 17, 26], ["statin", "CHEMICAL", 49, 55], ["ezetimibe", "SIMPLE_CHEMICAL", 17, 26], ["statin", "SIMPLE_CHEMICAL", 49, 55], ["hsCRP", "GENE_OR_GENE_PRODUCT", 85, 90], ["hsCRP", "PROTEIN", 85, 90], ["ezetimibe", "TREATMENT", 17, 26], ["baseline statin therapy", "TREATMENT", 40, 63], ["hsCRP", "TEST", 85, 90]]], ["In the recent IMPROVE-IT trial, adding ezetimibe to simvastatin gave a further 20% and 14% reduction of LDL-C and hsCRP, respectively (89) .", [["ezetimibe", "CHEMICAL", 39, 48], ["simvastatin", "CHEMICAL", 52, 63], ["ezetimibe", "CHEMICAL", 39, 48], ["simvastatin", "CHEMICAL", 52, 63], ["ezetimibe", "SIMPLE_CHEMICAL", 39, 48], ["simvastatin", "SIMPLE_CHEMICAL", 52, 63], ["LDL-C", "GENE_OR_GENE_PRODUCT", 104, 109], ["hsCRP", "GENE_OR_GENE_PRODUCT", 114, 119], ["LDL", "PROTEIN", 104, 107], ["hsCRP", "PROTEIN", 114, 119], ["ezetimibe", "TREATMENT", 39, 48], ["simvastatin", "TREATMENT", 52, 63], ["LDL", "TEST", 104, 107], ["hsCRP", "TEST", 114, 119]]], ["In chronic kidney disease patients (SHARP trial), the combination simvastatin/ezetimibe resulted in a 35% reduction of LDL-C vs placebo and a 21% reduction of hsCRP (90) ( Table 2 ).Bempedoic acid.This prodrug, targeting ATP-citrate lyase (ACL), is primarily responsible for the production of extra-mitochondrial acetyl-CoA (91), the carbon precursor for cholesterol and fatty acid biosynthesis.", [["kidney", "ANATOMY", 11, 17], ["chronic kidney disease", "DISEASE", 3, 25], ["simvastatin", "CHEMICAL", 66, 77], ["ezetimibe", "CHEMICAL", 78, 87], ["LDL-C", "CHEMICAL", 119, 124], ["Bempedoic acid", "CHEMICAL", 182, 196], ["ATP-citrate", "CHEMICAL", 221, 232], ["acetyl-CoA", "CHEMICAL", 313, 323], ["cholesterol", "CHEMICAL", 355, 366], ["fatty acid", "CHEMICAL", 371, 381], ["simvastatin", "CHEMICAL", 66, 77], ["ezetimibe", "CHEMICAL", 78, 87], ["Bempedoic acid", "CHEMICAL", 182, 196], ["ATP", "CHEMICAL", 221, 224], ["citrate", "CHEMICAL", 225, 232], ["acetyl-CoA", "CHEMICAL", 313, 323], ["carbon", "CHEMICAL", 334, 340], ["cholesterol", "CHEMICAL", 355, 366], ["fatty acid", "CHEMICAL", 371, 381], ["kidney", "ORGAN", 11, 17], ["patients", "ORGANISM", 26, 34], ["simvastatin", "SIMPLE_CHEMICAL", 66, 77], ["ezetimibe", "SIMPLE_CHEMICAL", 78, 87], ["LDL-C", "SIMPLE_CHEMICAL", 119, 124], ["hsCRP", "GENE_OR_GENE_PRODUCT", 159, 164], ["Bempedoic acid", "SIMPLE_CHEMICAL", 182, 196], ["ATP-citrate lyase", "GENE_OR_GENE_PRODUCT", 221, 238], ["ACL", "GENE_OR_GENE_PRODUCT", 240, 243], ["extra-mitochondrial acetyl-CoA (91)", "SIMPLE_CHEMICAL", 293, 328], ["carbon", "SIMPLE_CHEMICAL", 334, 340], ["cholesterol", "SIMPLE_CHEMICAL", 355, 366], ["fatty acid", "SIMPLE_CHEMICAL", 371, 381], ["LDL", "PROTEIN", 119, 122], ["hsCRP", "PROTEIN", 159, 164], ["ATP-citrate lyase", "PROTEIN", 221, 238], ["ACL", "PROTEIN", 240, 243], ["patients", "SPECIES", 26, 34], ["chronic kidney disease", "PROBLEM", 3, 25], ["the combination simvastatin", "TREATMENT", 50, 77], ["ezetimibe", "TREATMENT", 78, 87], ["LDL", "TEST", 119, 122], ["placebo", "TREATMENT", 128, 135], ["a 21% reduction of", "TREATMENT", 140, 158], ["hsCRP", "TEST", 159, 164], ["Bempedoic acid", "TREATMENT", 182, 196], ["This prodrug", "TREATMENT", 197, 209], ["ATP-citrate lyase", "TREATMENT", 221, 238], ["the carbon precursor", "TEST", 330, 350], ["cholesterol", "TEST", 355, 366], ["fatty acid biosynthesis", "TREATMENT", 371, 394], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["kidney", "ANATOMY", 11, 17], ["disease", "OBSERVATION", 18, 25], ["fatty acid", "OBSERVATION", 371, 381]]], ["Bempedoic acid is metabolized to the active form only in the liver, not in muscle.Bempedoic acid.Phase 3 studies have indicated a stable LDL-C reduction in the range of 25-35%, additional to that of statins, with minimal muscular side effects.", [["liver", "ANATOMY", 61, 66], ["muscle", "ANATOMY", 75, 81], ["muscular", "ANATOMY", 221, 229], ["Bempedoic acid", "CHEMICAL", 0, 14], ["Bempedoic acid", "CHEMICAL", 82, 96], ["statins", "CHEMICAL", 199, 206], ["Bempedoic acid", "CHEMICAL", 0, 14], ["Bempedoic acid", "CHEMICAL", 82, 96], ["statins", "CHEMICAL", 199, 206], ["Bempedoic acid", "SIMPLE_CHEMICAL", 0, 14], ["liver", "ORGAN", 61, 66], ["muscle", "ORGAN", 75, 81], ["Bempedoic acid", "SIMPLE_CHEMICAL", 82, 96], ["LDL-C", "SIMPLE_CHEMICAL", 137, 142], ["LDL", "PROTEIN", 137, 140], ["Bempedoic acid", "TEST", 0, 14], ["Bempedoic acid", "TREATMENT", 82, 96], ["Phase 3 studies", "TEST", 97, 112], ["LDL", "TEST", 137, 140], ["C reduction", "TREATMENT", 141, 152], ["statins", "TREATMENT", 199, 206], ["minimal muscular side effects", "PROBLEM", 213, 242], ["active", "OBSERVATION", 37, 43], ["liver", "ANATOMY", 61, 66], ["not in", "UNCERTAINTY", 68, 74], ["muscle", "ANATOMY", 75, 81], ["stable", "OBSERVATION_MODIFIER", 130, 136], ["LDL", "OBSERVATION", 137, 140], ["reduction", "OBSERVATION_MODIFIER", 143, 152]]], ["Clinical studies have consistently shown a marked hsCRP lowering activity, the highest efficacy being reported in diabetics (92) , i.e. -41%.", [["hsCRP", "GENE_OR_GENE_PRODUCT", 50, 55], ["hsCRP", "PROTEIN", 50, 55], ["Clinical studies", "TEST", 0, 16], ["a marked hsCRP lowering activity", "PROBLEM", 41, 73], ["diabetics", "TEST", 114, 123], ["marked", "OBSERVATION_MODIFIER", 43, 49], ["hsCRP", "OBSERVATION_MODIFIER", 50, 55], ["lowering", "OBSERVATION_MODIFIER", 56, 64], ["activity", "OBSERVATION_MODIFIER", 65, 73]]], ["In the CLEAR Tranquility trial on statin intolerant patients, bempedoic acid (180 mg) added to background lipid-modifying therapy reduced LDL-C and hsCRP by -28.5% and -31%, respectively (93).Bempedoic acid.In the CLEAR Serenity trial (94) , enrolling patients with LDL-C of at least 70 mg/dL despite maximum tolerated statin therapy, bempedoic acid treatment resulted in greater LDL-C lowering vs placebo both at week 12 (difference, -18.1%) and 24 (difference, -16.1%).", [["statin", "CHEMICAL", 34, 40], ["bempedoic acid", "CHEMICAL", 62, 76], ["Bempedoic acid", "CHEMICAL", 192, 206], ["statin", "CHEMICAL", 319, 325], ["bempedoic acid", "CHEMICAL", 335, 349], ["statin", "CHEMICAL", 34, 40], ["bempedoic acid", "CHEMICAL", 62, 76], ["Bempedoic acid", "CHEMICAL", 192, 206], ["bempedoic acid", "CHEMICAL", 335, 349], ["statin", "SIMPLE_CHEMICAL", 34, 40], ["patients", "ORGANISM", 52, 60], ["bempedoic acid", "SIMPLE_CHEMICAL", 62, 76], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["LDL-C", "SIMPLE_CHEMICAL", 138, 143], ["hsCRP", "GENE_OR_GENE_PRODUCT", 148, 153], ["Bempedoic acid", "SIMPLE_CHEMICAL", 192, 206], ["patients", "ORGANISM", 252, 260], ["LDL-C", "SIMPLE_CHEMICAL", 266, 271], ["bempedoic acid", "SIMPLE_CHEMICAL", 335, 349], ["LDL-C", "SIMPLE_CHEMICAL", 380, 385], ["LDL", "PROTEIN", 138, 141], ["hsCRP", "PROTEIN", 148, 153], ["LDL", "PROTEIN", 266, 269], ["LDL", "PROTEIN", 380, 383], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 252, 260], ["statin intolerant", "TREATMENT", 34, 51], ["bempedoic acid", "TREATMENT", 62, 76], ["background lipid", "TREATMENT", 95, 111], ["modifying therapy", "TREATMENT", 112, 129], ["LDL", "TEST", 138, 141], ["C", "TEST", 142, 143], ["hsCRP", "TEST", 148, 153], ["Bempedoic acid", "TREATMENT", 192, 206], ["LDL", "TEST", 266, 269], ["statin therapy", "TREATMENT", 319, 333], ["bempedoic acid treatment", "TREATMENT", 335, 359], ["LDL", "TEST", 380, 383], ["placebo", "TREATMENT", 398, 405]]], ["Relative to hsCRP the difference was -13.3% and -11.9% at weeks 12 and 24, respectively (95) ( Table 2) .Bempedoic acid.Combination of bempedoic acid with ezetimibe dramatically reduced LDL-C up to -41%.Bempedoic acid.Bempedoic acid plus ezetimibe reduced hsCRP by 35.1% compared to a rise of 21.6% in the placebo group and an 8.2% reduction with ezetimibe, given as a monotherapy (96) .", [["Bempedoic acid", "CHEMICAL", 105, 119], ["bempedoic acid", "CHEMICAL", 135, 149], ["ezetimibe", "CHEMICAL", 155, 164], ["Bempedoic acid", "CHEMICAL", 203, 217], ["Bempedoic acid", "CHEMICAL", 218, 232], ["ezetimibe", "CHEMICAL", 238, 247], ["ezetimibe", "CHEMICAL", 347, 356], ["Bempedoic acid", "CHEMICAL", 105, 119], ["bempedoic acid", "CHEMICAL", 135, 149], ["ezetimibe", "CHEMICAL", 155, 164], ["Bempedoic acid", "CHEMICAL", 203, 217], ["Bempedoic acid", "CHEMICAL", 218, 232], ["ezetimibe", "CHEMICAL", 238, 247], ["ezetimibe", "CHEMICAL", 347, 356], ["hsCRP", "GENE_OR_GENE_PRODUCT", 12, 17], ["Bempedoic acid", "SIMPLE_CHEMICAL", 105, 119], ["bempedoic acid", "SIMPLE_CHEMICAL", 135, 149], ["ezetimibe", "SIMPLE_CHEMICAL", 155, 164], ["LDL-C", "GENE_OR_GENE_PRODUCT", 186, 191], ["Bempedoic acid", "SIMPLE_CHEMICAL", 203, 217], ["Bempedoic acid", "SIMPLE_CHEMICAL", 218, 232], ["ezetimibe", "SIMPLE_CHEMICAL", 238, 247], ["hsCRP", "GENE_OR_GENE_PRODUCT", 256, 261], ["ezetimibe", "SIMPLE_CHEMICAL", 347, 356], ["hsCRP", "PROTEIN", 12, 17], ["LDL", "PROTEIN", 186, 189], ["hsCRP", "PROTEIN", 256, 261], ["hsCRP", "TEST", 12, 17], ["Bempedoic acid", "TREATMENT", 105, 119], ["bempedoic acid", "TREATMENT", 135, 149], ["ezetimibe", "TREATMENT", 155, 164], ["LDL", "TEST", 186, 189], ["C", "TEST", 190, 191], ["Bempedoic acid", "TREATMENT", 203, 217], ["Bempedoic acid", "TEST", 218, 232], ["ezetimibe", "TREATMENT", 238, 247], ["hsCRP", "TEST", 256, 261], ["an 8.2% reduction", "TREATMENT", 324, 341], ["ezetimibe", "TREATMENT", 347, 356], ["a monotherapy", "TREATMENT", 367, 380]]], ["The combination therapy was not superior to bempedoic acid alone, probably due to the considerable hsCRP lowering achieved in monotherapy (-31.9%).", [["bempedoic acid", "CHEMICAL", 44, 58], ["bempedoic acid", "CHEMICAL", 44, 58], ["bempedoic acid", "SIMPLE_CHEMICAL", 44, 58], ["hsCRP", "GENE_OR_GENE_PRODUCT", 99, 104], ["hsCRP", "PROTEIN", 99, 104], ["The combination therapy", "TREATMENT", 0, 23], ["the considerable hsCRP lowering", "PROBLEM", 82, 113], ["monotherapy", "TREATMENT", 126, 137]]], ["In each treatment group, baseline levels of hsCRP were 3.1 mg/L J o u r n a l P r e -p r o o f (bempedoic acid + ezetimibe), 2.9 mg/L (bempedoic acid), 2.8 mg/L (ezetimibe), and 3.0 mg/L (placebo) (96, 97) ( Table 2 ).Bempedoic acid.In the CLEAR Wisdom trial, enrolling patients with atherosclerotic cardiovascular diseases (ASCVD), heterozygous familial hypercholesterolemia, or both, on optimal statin treatment, bempedoic acid was superior to placebo in reducing hsCRP: -18.7% vs -9.4% with a median difference of -8.7%. hsCRP baseline levels were 1.61 (mg/L) in the bempedoic and 1.88 (mg/L) in the placebo group.", [["cardiovascular", "ANATOMY", 300, 314], ["bempedoic acid", "CHEMICAL", 96, 110], ["ezetimibe", "CHEMICAL", 113, 122], ["bempedoic acid", "CHEMICAL", 135, 149], ["ezetimibe", "CHEMICAL", 162, 171], ["Bempedoic acid", "CHEMICAL", 218, 232], ["atherosclerotic cardiovascular diseases", "DISEASE", 284, 323], ["ASCVD", "DISEASE", 325, 330], ["familial hypercholesterolemia", "DISEASE", 346, 375], ["statin", "CHEMICAL", 397, 403], ["bempedoic acid", "CHEMICAL", 415, 429], ["bempedoic", "CHEMICAL", 570, 579], ["bempedoic acid", "CHEMICAL", 96, 110], ["ezetimibe", "CHEMICAL", 113, 122], ["bempedoic acid", "CHEMICAL", 135, 149], ["ezetimibe", "CHEMICAL", 162, 171], ["Bempedoic acid", "CHEMICAL", 218, 232], ["statin", "CHEMICAL", 397, 403], ["bempedoic acid", "CHEMICAL", 415, 429], ["hsCRP", "GENE_OR_GENE_PRODUCT", 44, 49], ["bempedoic acid", "SIMPLE_CHEMICAL", 96, 110], ["ezetimibe", "SIMPLE_CHEMICAL", 113, 122], ["bempedoic acid", "SIMPLE_CHEMICAL", 135, 149], ["ezetimibe", "SIMPLE_CHEMICAL", 162, 171], ["Bempedoic acid", "SIMPLE_CHEMICAL", 218, 232], ["patients", "ORGANISM", 270, 278], ["cardiovascular", "MULTI-TISSUE_STRUCTURE", 300, 314], ["bempedoic acid", "SIMPLE_CHEMICAL", 415, 429], ["hsCRP", "GENE_OR_GENE_PRODUCT", 466, 471], ["hsCRP", "GENE_OR_GENE_PRODUCT", 524, 529], ["hsCRP", "PROTEIN", 44, 49], ["hsCRP", "PROTEIN", 466, 471], ["hsCRP", "PROTEIN", 524, 529], ["patients", "SPECIES", 270, 278], ["baseline levels", "TEST", 25, 40], ["hsCRP", "TEST", 44, 49], ["a l P r e -p r o o f", "TREATMENT", 74, 94], ["bempedoic acid", "TREATMENT", 96, 110], ["ezetimibe", "TREATMENT", 113, 122], ["bempedoic acid)", "TREATMENT", 135, 150], ["ezetimibe", "TREATMENT", 162, 171], ["Bempedoic acid", "TREATMENT", 218, 232], ["atherosclerotic cardiovascular diseases (ASCVD)", "PROBLEM", 284, 331], ["heterozygous familial hypercholesterolemia", "PROBLEM", 333, 375], ["optimal statin treatment", "TREATMENT", 389, 413], ["bempedoic acid", "TREATMENT", 415, 429], ["hsCRP", "TEST", 466, 471], ["vs", "TEST", 480, 482], ["a median difference", "TEST", 494, 513], ["hsCRP baseline levels", "TEST", 524, 545], ["the bempedoic", "TEST", 566, 579], ["CLEAR", "OBSERVATION_MODIFIER", 240, 245], ["Wisdom", "OBSERVATION", 246, 252], ["atherosclerotic", "OBSERVATION_MODIFIER", 284, 299], ["cardiovascular", "ANATOMY", 300, 314], ["diseases", "OBSERVATION", 315, 323], ["familial", "OBSERVATION_MODIFIER", 346, 354], ["hypercholesterolemia", "OBSERVATION", 355, 375]]], ["After 12 weeks, a statistically difference was achieved (-17.4%) (98) ( Table 2) .Nicotinic acid.Nicotinic acid (niacin or vitamin B3), at pharmacological doses, i.e. about 1-2 g/day exerts a powerful antilipolytic activity, reducing free fatty acid (FFA) release from the adipose tissue to the liver, where triglycerides (TG) re-synthesis occurs (99) .", [["adipose tissue", "ANATOMY", 273, 287], ["liver", "ANATOMY", 295, 300], ["Nicotinic acid", "CHEMICAL", 82, 96], ["Nicotinic acid", "CHEMICAL", 97, 111], ["niacin", "CHEMICAL", 113, 119], ["vitamin B3", "CHEMICAL", 123, 133], ["fatty acid", "CHEMICAL", 239, 249], ["FFA", "CHEMICAL", 251, 254], ["triglycerides", "CHEMICAL", 308, 321], ["Nicotinic acid", "CHEMICAL", 82, 96], ["Nicotinic acid", "CHEMICAL", 97, 111], ["niacin", "CHEMICAL", 113, 119], ["vitamin B3", "CHEMICAL", 123, 133], ["fatty acid", "CHEMICAL", 239, 249], ["triglycerides", "CHEMICAL", 308, 321], ["Nicotinic acid", "SIMPLE_CHEMICAL", 82, 96], ["Nicotinic acid", "SIMPLE_CHEMICAL", 97, 111], ["niacin", "SIMPLE_CHEMICAL", 113, 119], ["vitamin B3", "SIMPLE_CHEMICAL", 123, 133], ["free fatty acid", "SIMPLE_CHEMICAL", 234, 249], ["FFA", "SIMPLE_CHEMICAL", 251, 254], ["adipose tissue", "TISSUE", 273, 287], ["liver", "ORGAN", 295, 300], ["triglycerides", "SIMPLE_CHEMICAL", 308, 321], ["TG", "SIMPLE_CHEMICAL", 323, 325], ["Nicotinic acid", "TREATMENT", 82, 96], ["Nicotinic acid", "TREATMENT", 97, 111], ["niacin", "TREATMENT", 113, 119], ["vitamin B3)", "TREATMENT", 123, 134], ["reducing free fatty acid (FFA)", "TREATMENT", 225, 255], ["triglycerides", "TEST", 308, 321], ["liver", "ANATOMY", 295, 300]]], ["Some Authors believe that nicotinic acid, similar to fibrates, may exert a moderate stimulation of peroxisomal proliferation as a PPAR\u03b1 agonist (100) .", [["peroxisomal", "ANATOMY", 99, 110], ["nicotinic acid", "CHEMICAL", 26, 40], ["fibrates", "CHEMICAL", 53, 61], ["nicotinic acid", "CHEMICAL", 26, 40], ["nicotinic acid", "SIMPLE_CHEMICAL", 26, 40], ["fibrates", "SIMPLE_CHEMICAL", 53, 61], ["peroxisomal", "CELLULAR_COMPONENT", 99, 110], ["PPAR\u03b1", "GENE_OR_GENE_PRODUCT", 130, 135], ["nicotinic acid", "PROBLEM", 26, 40], ["fibrates", "TREATMENT", 53, 61], ["a moderate stimulation of peroxisomal proliferation", "PROBLEM", 73, 124], ["moderate", "OBSERVATION_MODIFIER", 75, 83], ["peroxisomal proliferation", "OBSERVATION", 99, 124]]], ["In this way nicotinic acid may activate lipoprotein lipase reducing TG, to a lesser extent LDL-C, and raising HDL-C levels (101) .Nicotinic acid.The profile of nicotinic acid, particularly the significant positive impact on HDL-C levels, has led to large placebo controlled studies in ASCVD patients (102, 103) given extended release nicotinic acid.", [["nicotinic acid", "CHEMICAL", 12, 26], ["TG", "DISEASE", 68, 70], ["Nicotinic acid", "CHEMICAL", 130, 144], ["nicotinic acid", "CHEMICAL", 160, 174], ["ASCVD", "DISEASE", 285, 290], ["nicotinic acid", "CHEMICAL", 334, 348], ["nicotinic acid", "CHEMICAL", 12, 26], ["Nicotinic acid", "CHEMICAL", 130, 144], ["nicotinic acid", "CHEMICAL", 160, 174], ["nicotinic acid", "CHEMICAL", 334, 348], ["nicotinic acid", "SIMPLE_CHEMICAL", 12, 26], ["lipoprotein lipase", "GENE_OR_GENE_PRODUCT", 40, 58], ["TG", "SIMPLE_CHEMICAL", 68, 70], ["LDL-C", "SIMPLE_CHEMICAL", 91, 96], ["HDL-C", "SIMPLE_CHEMICAL", 110, 115], ["Nicotinic acid", "SIMPLE_CHEMICAL", 130, 144], ["nicotinic acid", "SIMPLE_CHEMICAL", 160, 174], ["HDL-C", "SIMPLE_CHEMICAL", 224, 229], ["patients", "ORGANISM", 291, 299], ["nicotinic acid", "SIMPLE_CHEMICAL", 334, 348], ["lipoprotein lipase", "PROTEIN", 40, 58], ["LDL", "PROTEIN", 91, 94], ["HDL", "PROTEIN", 110, 113], ["HDL", "PROTEIN", 224, 227], ["patients", "SPECIES", 291, 299], ["nicotinic acid", "TREATMENT", 12, 26], ["lipoprotein lipase", "TEST", 40, 58], ["TG", "TEST", 68, 70], ["LDL", "TEST", 91, 94], ["HDL", "TEST", 110, 113], ["C levels", "TEST", 114, 122], ["Nicotinic acid", "TREATMENT", 130, 144], ["nicotinic acid", "TEST", 160, 174], ["the significant positive impact", "PROBLEM", 189, 220], ["HDL", "TEST", 224, 227], ["large placebo controlled studies", "PROBLEM", 249, 281], ["extended release nicotinic acid", "TREATMENT", 317, 348], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["positive", "OBSERVATION", 205, 213], ["large", "OBSERVATION_MODIFIER", 249, 254]]], ["These studies did not result in a significant reduction of major coronary events.", [["coronary", "ANATOMY", 65, 73], ["coronary", "MULTI-TISSUE_STRUCTURE", 65, 73], ["These studies", "TEST", 0, 13], ["major coronary events", "PROBLEM", 59, 80], ["coronary", "ANATOMY", 65, 73]]], ["In metabolic syndrome (104), nicotinic acid reduced hsCRP by -40% (from 2.7\uf0b10.55 to 1.7\uf0b10.25 mg/L), and similar, albeit lesser reductions, were noted for TNF-\u03b1, Plasminogen activator inhibitor-1 (probably reflecting the reduction of TGs) and IL-7, not IL-6.", [["metabolic syndrome", "DISEASE", 3, 21], ["nicotinic acid", "CHEMICAL", 29, 43], ["nicotinic acid", "CHEMICAL", 29, 43], ["nicotinic acid", "SIMPLE_CHEMICAL", 29, 43], ["hsCRP", "GENE_OR_GENE_PRODUCT", 52, 57], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 154, 159], ["Plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 161, 194], ["TGs", "SIMPLE_CHEMICAL", 233, 236], ["IL-7", "GENE_OR_GENE_PRODUCT", 242, 246], ["IL-6", "GENE_OR_GENE_PRODUCT", 252, 256], ["hsCRP", "PROTEIN", 52, 57], ["TNF", "PROTEIN", 154, 157], ["Plasminogen activator inhibitor-1", "PROTEIN", 161, 194], ["TGs", "PROTEIN", 233, 236], ["IL-7", "PROTEIN", 242, 246], ["IL-6", "PROTEIN", 252, 256], ["metabolic syndrome", "PROBLEM", 3, 21], ["nicotinic acid", "TEST", 29, 43], ["hsCRP", "TEST", 52, 57], ["TNF", "TEST", 154, 157], ["Plasminogen activator inhibitor", "TREATMENT", 161, 192], ["TGs", "TEST", 233, 236], ["IL", "TEST", 242, 244], ["metabolic syndrome", "OBSERVATION", 3, 21]]], ["In a comparative evaluation of nicotinic acid and fenofibrate, the former was more effective at lowering hsCRP, though fenofibrate led to a more beneficial lipoprotein profile (105) ( Table 2) .Fibrates.These activators of the PPAR\uf061 system have not shown clear effects on hsCRP.", [["nicotinic acid", "CHEMICAL", 31, 45], ["fenofibrate", "CHEMICAL", 50, 61], ["fenofibrate", "CHEMICAL", 119, 130], ["nicotinic acid", "CHEMICAL", 31, 45], ["fenofibrate", "CHEMICAL", 50, 61], ["fenofibrate", "CHEMICAL", 119, 130], ["nicotinic acid", "SIMPLE_CHEMICAL", 31, 45], ["fenofibrate", "SIMPLE_CHEMICAL", 50, 61], ["hsCRP", "GENE_OR_GENE_PRODUCT", 105, 110], ["fenofibrate", "SIMPLE_CHEMICAL", 119, 130], ["PPAR\uf061", "GENE_OR_GENE_PRODUCT", 227, 232], ["hsCRP", "GENE_OR_GENE_PRODUCT", 272, 277], ["hsCRP", "PROTEIN", 105, 110], ["PPAR", "PROTEIN", 227, 231], ["hsCRP", "PROTEIN", 272, 277], ["a comparative evaluation", "TEST", 3, 27], ["nicotinic acid", "TREATMENT", 31, 45], ["fenofibrate", "TREATMENT", 50, 61], ["fenofibrate", "TREATMENT", 119, 130], ["Fibrates", "TREATMENT", 194, 202], ["hsCRP", "TEST", 272, 277], ["PPAR", "ANATOMY", 227, 231], ["clear", "OBSERVATION", 255, 260]]], ["A 5-year treatment with fenofibrate significantly reduced LDL-C (14.2%) but not hsCRP (+ 0.8 mg/L) (106), a finding similar to the data described in a sub-analysis of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial in type 2 diabetics (107).", [["fenofibrate", "CHEMICAL", 24, 35], ["Fenofibrate", "CHEMICAL", 178, 189], ["Diabetes", "DISEASE", 225, 233], ["type 2 diabetics", "DISEASE", 244, 260], ["fenofibrate", "CHEMICAL", 24, 35], ["Fenofibrate", "CHEMICAL", 178, 189], ["fenofibrate", "SIMPLE_CHEMICAL", 24, 35], ["LDL-C", "SIMPLE_CHEMICAL", 58, 63], ["hsCRP", "SIMPLE_CHEMICAL", 80, 85], ["Fenofibrate", "SIMPLE_CHEMICAL", 178, 189], ["LDL", "PROTEIN", 58, 61], ["hsCRP", "PROTEIN", 80, 85], ["fenofibrate", "TREATMENT", 24, 35], ["LDL", "TEST", 58, 61], ["C", "TEST", 62, 63], ["hsCRP", "TEST", 80, 85], ["the FIELD (Fenofibrate Intervention", "TREATMENT", 167, 202], ["Diabetes", "PROBLEM", 225, 233]]], ["In patients with mixed dyslipidemia, rosuvastatin (40 mg), rosuvastatin (10 mg) plus fenofibrate (200 mg) or rosuvastatin (10 mg) plus omega 3 (2 g) led to 53%, 28% and 23% reduction in hsCRP, respectively, vs baseline (108).", [["dyslipidemia", "DISEASE", 23, 35], ["rosuvastatin", "CHEMICAL", 37, 49], ["rosuvastatin", "CHEMICAL", 59, 71], ["fenofibrate", "CHEMICAL", 85, 96], ["rosuvastatin", "CHEMICAL", 109, 121], ["rosuvastatin", "CHEMICAL", 37, 49], ["rosuvastatin", "CHEMICAL", 59, 71], ["fenofibrate", "CHEMICAL", 85, 96], ["rosuvastatin", "CHEMICAL", 109, 121], ["patients", "ORGANISM", 3, 11], ["rosuvastatin", "SIMPLE_CHEMICAL", 37, 49], ["rosuvastatin", "SIMPLE_CHEMICAL", 59, 71], ["fenofibrate", "SIMPLE_CHEMICAL", 85, 96], ["rosuvastatin", "SIMPLE_CHEMICAL", 109, 121], ["hsCRP", "GENE_OR_GENE_PRODUCT", 186, 191], ["hsCRP", "PROTEIN", 186, 191], ["patients", "SPECIES", 3, 11], ["mixed dyslipidemia", "PROBLEM", 17, 35], ["rosuvastatin", "TREATMENT", 37, 49], ["rosuvastatin", "TREATMENT", 59, 71], ["fenofibrate", "TREATMENT", 85, 96], ["rosuvastatin", "TREATMENT", 109, 121], ["dyslipidemia", "OBSERVATION", 23, 35]]], ["In patients with the metabolic syndrome, however, a highly significant hsCRP reduction of 49.5% was reported (109) .Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists.", [["metabolic syndrome", "DISEASE", 21, 39], ["patients", "ORGANISM", 3, 11], ["hsCRP", "GENE_OR_GENE_PRODUCT", 71, 76], ["Proprotein convertase subtilisin/kexin 9", "GENE_OR_GENE_PRODUCT", 116, 156], ["PCSK9", "GENE_OR_GENE_PRODUCT", 158, 163], ["hsCRP", "PROTEIN", 71, 76], ["Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "PROTEIN", 116, 176], ["patients", "SPECIES", 3, 11], ["the metabolic syndrome", "PROBLEM", 17, 39], ["a highly significant hsCRP reduction", "PROBLEM", 50, 86], ["Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "TREATMENT", 116, 176], ["metabolic syndrome", "OBSERVATION", 21, 39]]], ["PCSK9 is a liver-secreted plasmaprotein that regulates the number of cell-surface LDL receptors, thus inhibiting LDL uptake (110, 111) .", [["liver", "ANATOMY", 11, 16], ["cell", "ANATOMY", 69, 73], ["surface", "ANATOMY", 74, 81], ["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["liver", "ORGAN", 11, 16], ["plasmaprotein", "GENE_OR_GENE_PRODUCT", 26, 39], ["cell", "CELL", 69, 73], ["LDL", "GENE_OR_GENE_PRODUCT", 82, 85], ["LDL", "SIMPLE_CHEMICAL", 113, 116], ["PCSK9", "PROTEIN", 0, 5], ["liver-secreted plasmaprotein", "PROTEIN", 11, 39], ["cell-surface LDL receptors", "PROTEIN", 69, 95], ["LDL", "PROTEIN", 113, 116], ["PCSK9", "TEST", 0, 5], ["LDL uptake", "TEST", 113, 123], ["liver", "ANATOMY", 11, 16], ["secreted plasmaprotein", "OBSERVATION", 17, 39], ["LDL uptake", "OBSERVATION", 113, 123]]], ["Two fully human mAbs, alirocumab and evolocumab, have been approved for human use in August 2015, whereas bococizumab has been discontinued in November 2016 (112) .", [["alirocumab", "CHEMICAL", 22, 32], ["evolocumab", "CHEMICAL", 37, 47], ["bococizumab", "CHEMICAL", 106, 117], ["alirocumab", "CHEMICAL", 22, 32], ["evolocumab", "CHEMICAL", 37, 47], ["bococizumab", "CHEMICAL", 106, 117], ["human", "ORGANISM", 10, 15], ["alirocumab", "SIMPLE_CHEMICAL", 22, 32], ["evolocumab", "SIMPLE_CHEMICAL", 37, 47], ["human", "ORGANISM", 72, 77], ["bococizumab", "SIMPLE_CHEMICAL", 106, 117], ["human mAbs", "PROTEIN", 10, 20], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 72, 77], ["Two fully human mAbs", "TREATMENT", 0, 20], ["alirocumab", "TREATMENT", 22, 32], ["evolocumab", "TREATMENT", 37, 47]]], ["Other approaches to inhibit PCSK9 are being developed, including small molecule inhibitors, antisense oligonucleotides, RNA interference therapies (inclisiran) and a vaccine (113, 114) .Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists.", [["inclisiran", "CHEMICAL", 148, 158], ["PCSK9", "GENE_OR_GENE_PRODUCT", 28, 33], ["Proprotein convertase subtilisin/kexin 9", "GENE_OR_GENE_PRODUCT", 186, 226], ["PCSK9", "GENE_OR_GENE_PRODUCT", 228, 233], ["PCSK9", "PROTEIN", 28, 33], ["Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "PROTEIN", 186, 246], ["PCSK9", "TREATMENT", 28, 33], ["small molecule inhibitors", "TREATMENT", 65, 90], ["antisense oligonucleotides", "TREATMENT", 92, 118], ["RNA interference therapies", "TREATMENT", 120, 146], ["a vaccine", "TREATMENT", 164, 173], ["Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "TREATMENT", 186, 246]]], ["PCSK9 is a liver-secreted plasmaRaised PCSK9 liver expression is positively linked to TNF-\u03b1 and interferon \uf067 levels (115, 116) ], but no clear relationship has been observed between PCSK9 levels and hsCRP.", [["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 45, 50], ["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["liver", "ORGAN", 11, 16], ["PCSK9", "GENE_OR_GENE_PRODUCT", 39, 44], ["liver", "ORGAN", 45, 50], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 86, 91], ["interferon \uf067", "GENE_OR_GENE_PRODUCT", 96, 108], ["PCSK9", "GENE_OR_GENE_PRODUCT", 182, 187], ["hsCRP", "GENE_OR_GENE_PRODUCT", 199, 204], ["PCSK9", "PROTEIN", 0, 5], ["PCSK9", "PROTEIN", 39, 44], ["TNF", "PROTEIN", 86, 89], ["interferon", "PROTEIN", 96, 106], ["PCSK9", "PROTEIN", 182, 187], ["hsCRP", "PROTEIN", 199, 204], ["PCSK9", "TEST", 0, 5], ["a liver", "TEST", 9, 16], ["TNF", "TEST", 86, 89], ["interferon \uf067 levels", "TEST", 96, 115], ["PCSK9 levels", "TEST", 182, 194], ["hsCRP", "TEST", 199, 204], ["liver", "ANATOMY", 11, 16]]], ["This supports the observation that PCSK9 antagonists do not exert a significant anti-inflammatory activity.", [["PCSK9", "GENE_OR_GENE_PRODUCT", 35, 40], ["PCSK9", "PROTEIN", 35, 40], ["PCSK9 antagonists", "TREATMENT", 35, 52], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["anti-inflammatory activity", "OBSERVATION", 80, 106]]], ["As previously reviewed by our group (117), although there is no impact on hsCRP, the application of this biomarker identifies patients with a high CV risk achieving better ASCVD prevention after PCSK9Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists.", [["ASCVD", "DISEASE", 172, 177], ["hsCRP", "GENE_OR_GENE_PRODUCT", 74, 79], ["patients", "ORGANISM", 126, 134], ["PCSK9Proprotein convertase subtilisin/kexin 9", "GENE_OR_GENE_PRODUCT", 195, 240], ["PCSK9", "GENE_OR_GENE_PRODUCT", 242, 247], ["hsCRP", "PROTEIN", 74, 79], ["PCSK9Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "PROTEIN", 195, 260], ["patients", "SPECIES", 126, 134], ["hsCRP", "TEST", 74, 79], ["this biomarker", "TEST", 100, 114], ["a high CV risk", "PROBLEM", 140, 154], ["better ASCVD prevention", "TREATMENT", 165, 188], ["PCSK9Proprotein convertase subtilisin/kexin 9 (PCSK9) antagonists", "TREATMENT", 195, 260], ["no", "UNCERTAINTY", 61, 63]]], ["PCSK9 is a liver-secreted plasmainhibition.", [["liver", "ANATOMY", 11, 16], ["PCSK9", "GENE_OR_GENE_PRODUCT", 0, 5], ["liver", "ORGAN", 11, 16], ["PCSK9", "PROTEIN", 0, 5], ["PCSK9", "TEST", 0, 5], ["liver", "ANATOMY", 11, 16]]], ["In the FOURIER study, even in patients with extremely low levels of LDL-C, there was a stepwise risk increment according to baseline hsCRP: +9% (<1 mg/L), +10.8% (1-3 mg/L) and +13.1% (>3mg/L) (118) .", [["patients", "ORGANISM", 30, 38], ["LDL-C", "SIMPLE_CHEMICAL", 68, 73], ["hsCRP", "GENE_OR_GENE_PRODUCT", 133, 138], ["LDL", "PROTEIN", 68, 71], ["patients", "SPECIES", 30, 38], ["the FOURIER study", "TEST", 3, 20], ["extremely low levels of LDL-C", "PROBLEM", 44, 73], ["hsCRP", "TEST", 133, 138]]], ["The ODYSSEY OUTCOMES with alirocumab showed no absolute changes for hsCRP although baseline hsCRP levels did identify subjects at higher risk (119) .", [["alirocumab", "CHEMICAL", 26, 36], ["alirocumab", "CHEMICAL", 26, 36], ["alirocumab", "SIMPLE_CHEMICAL", 26, 36], ["hsCRP", "GENE_OR_GENE_PRODUCT", 68, 73], ["hsCRP", "GENE_OR_GENE_PRODUCT", 92, 97], ["hsCRP", "PROTEIN", 68, 73], ["hsCRP", "PROTEIN", 92, 97], ["alirocumab", "TREATMENT", 26, 36], ["absolute changes", "PROBLEM", 47, 63], ["hsCRP", "TEST", 68, 73], ["baseline hsCRP levels", "TEST", 83, 104], ["no", "UNCERTAINTY", 44, 46]]], ["The debate on whether or not LDL-C and hsCRP are inseparable risk markers of risk was addressed in a post hoc analysis of the SPIRE-1 and -2 (Studies of PCSK9 Inhibition and the Reduction of Vascular Events) trials, with bococizumab.", [["Vascular", "ANATOMY", 191, 199], ["bococizumab", "CHEMICAL", 221, 232], ["bococizumab", "CHEMICAL", 221, 232], ["LDL-C", "SIMPLE_CHEMICAL", 29, 34], ["hsCRP", "GENE_OR_GENE_PRODUCT", 39, 44], ["PCSK9", "GENE_OR_GENE_PRODUCT", 153, 158], ["Vascular", "MULTI-TISSUE_STRUCTURE", 191, 199], ["bococizumab", "SIMPLE_CHEMICAL", 221, 232], ["LDL", "PROTEIN", 29, 32], ["hsCRP", "PROTEIN", 39, 44], ["PCSK9", "PROTEIN", 153, 158], ["LDL", "TEST", 29, 32], ["C", "PROBLEM", 33, 34], ["hsCRP", "PROBLEM", 39, 44], ["a post hoc analysis", "TEST", 99, 118], ["the SPIRE", "TEST", 122, 131], ["PCSK9 Inhibition", "TREATMENT", 153, 169], ["bococizumab", "TREATMENT", 221, 232], ["Vascular", "ANATOMY", 191, 199]]], ["This latter led to a dramatic reduction in LDL-C, but when patients were stratified according to on-treatment hsCRP levels, i.e. <1 (reference value), 1-3, and >3 mg/L , HRs were 1, 1.16 (95%CI 0.81-1.66) and 1.62 (95%CI 1.14-2.30) (120) ( Table 3) .Lomitapide.This powerful inhibitor of the microsomal transfer protein (MTP) system was developed for the treatment of homozygous type II patients.", [["Lomitapide", "CHEMICAL", 250, 260], ["Lomitapide", "CHEMICAL", 250, 260], ["LDL-C", "SIMPLE_CHEMICAL", 43, 48], ["patients", "ORGANISM", 59, 67], ["hsCRP", "GENE_OR_GENE_PRODUCT", 110, 115], ["Lomitapide", "SIMPLE_CHEMICAL", 250, 260], ["microsomal transfer protein", "GENE_OR_GENE_PRODUCT", 292, 319], ["MTP", "GENE_OR_GENE_PRODUCT", 321, 324], ["patients", "ORGANISM", 387, 395], ["LDL", "PROTEIN", 43, 46], ["hsCRP", "PROTEIN", 110, 115], ["microsomal transfer protein", "PROTEIN", 292, 319], ["MTP", "PROTEIN", 321, 324], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 387, 395], ["a dramatic reduction in LDL-C", "PROBLEM", 19, 48], ["hsCRP levels", "TEST", 110, 122], ["HRs", "TEST", 170, 173], ["CI", "TEST", 191, 193], ["CI", "TEST", 218, 220], ["Lomitapide", "TREATMENT", 250, 260], ["This powerful inhibitor", "TREATMENT", 261, 284], ["the microsomal transfer protein (MTP) system", "TREATMENT", 288, 332], ["homozygous type II patients", "PROBLEM", 368, 395], ["dramatic", "OBSERVATION_MODIFIER", 21, 29], ["reduction", "OBSERVATION_MODIFIER", 30, 39]]], ["While clinical studies have not been addressed to the evaluation of inflammatory/anti-inflammatory markers, of special interest is the very long study on efficacy/safety in homozygous patients (121) .", [["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["clinical studies", "TEST", 6, 22], ["the evaluation", "TEST", 50, 64], ["inflammatory/anti-inflammatory markers", "PROBLEM", 68, 106], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80]]], ["In addition to a very effective LDL-C reduction (-45.5%), the evaluation of data after 246 weeks of treatment reported a moderate rise in liver fat (from 0.7 to 10.2%) and, most interestingly, a progressive reduction of hsCRP, with a dramatic change, i.e. -60% from baseline to week 24.", [["liver fat", "ANATOMY", 138, 147], ["LDL-C", "SIMPLE_CHEMICAL", 32, 37], ["liver fat", "TISSUE", 138, 147], ["hsCRP", "GENE_OR_GENE_PRODUCT", 220, 225], ["LDL", "PROTEIN", 32, 35], ["hsCRP", "PROTEIN", 220, 225], ["C reduction", "TREATMENT", 36, 47], ["the evaluation of data", "TEST", 58, 80], ["treatment", "TREATMENT", 100, 109], ["a moderate rise in liver fat", "PROBLEM", 119, 147], ["a progressive reduction of hsCRP", "PROBLEM", 193, 225], ["a dramatic change", "PROBLEM", 232, 249], ["moderate", "OBSERVATION_MODIFIER", 121, 129], ["rise", "OBSERVATION_MODIFIER", 130, 134], ["liver fat", "ANATOMY", 138, 147], ["progressive", "OBSERVATION_MODIFIER", 195, 206], ["reduction", "OBSERVATION_MODIFIER", 207, 216], ["hsCRP", "OBSERVATION", 220, 225], ["dramatic", "OBSERVATION_MODIFIER", 234, 242], ["change", "OBSERVATION_MODIFIER", 243, 249]]], ["This finding, certainly of high clinical interest, may be also linked to the drug's activity on the human ether-a-go-go-related gene (hERG) channel currents, observed only at high concentrations (>1.7 \u00b5M).", [["ether", "CHEMICAL", 106, 111], ["human", "ORGANISM", 100, 105], ["ether", "SIMPLE_CHEMICAL", 106, 111], ["hERG", "DNA", 134, 138], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105]]], ["These are epigenetic readers that bind acetylated lysines on histone tails transcription factors via bromodomains (BD 1 and 2) (122) .", [["lysines", "CHEMICAL", 50, 57], ["histone tails transcription factors", "GENE_OR_GENE_PRODUCT", 61, 96], ["BD 1", "GENE_OR_GENE_PRODUCT", 115, 119], ["histone tails", "PROTEIN", 61, 74], ["transcription factors", "PROTEIN", 75, 96], ["bind acetylated lysines", "TREATMENT", 34, 57], ["histone tails transcription", "TREATMENT", 61, 88], ["BD", "TEST", 115, 117], ["acetylated lysines", "OBSERVATION", 39, 57]]], ["BET proteins play a role as molecular scaffolds between acetylation dependent binding sites and transcriptional machinery.", [["BET", "GENE_OR_GENE_PRODUCT", 0, 3], ["BET proteins", "PROTEIN", 0, 12], ["acetylation dependent binding sites", "PROTEIN", 56, 91], ["BET proteins", "TREATMENT", 0, 12], ["molecular scaffolds", "TREATMENT", 28, 47], ["acetylation dependent binding sites", "TREATMENT", 56, 91], ["transcriptional machinery", "TREATMENT", 96, 121]]], ["Interest in this pathway has been raised after the observation that thienotriazolodiazepines, reportedly increasing plasma levels of apo AI and macrophage reverse cholesterol transport in mice (123) , inhibit the BET proteins (BRTD, BRD2, BRD3 and BRD4), this being apparently the main molecular mechanism for the apo AI change.Lomitapide.In view of the non-optimal activity of the thienotriazolodiazepines, affecting essentially all BET associated proteins, a compound that has entered clinical trial is apabetalone, preferentially targeting BRD4 and the bromodomain BD2 (124) .", [["plasma", "ANATOMY", 116, 122], ["macrophage", "ANATOMY", 144, 154], ["thienotriazolodiazepines", "CHEMICAL", 68, 92], ["cholesterol", "CHEMICAL", 163, 174], ["Lomitapide", "CHEMICAL", 328, 338], ["thienotriazolodiazepines", "CHEMICAL", 382, 406], ["apabetalone", "CHEMICAL", 505, 516], ["thienotriazolodiazepines", "CHEMICAL", 68, 92], ["cholesterol", "CHEMICAL", 163, 174], ["Lomitapide", "CHEMICAL", 328, 338], ["thienotriazolodiazepines", "CHEMICAL", 382, 406], ["apabetalone", "CHEMICAL", 505, 516], ["thienotriazolodiazepines", "SIMPLE_CHEMICAL", 68, 92], ["plasma", "ORGANISM_SUBSTANCE", 116, 122], ["apo AI", "GENE_OR_GENE_PRODUCT", 133, 139], ["macrophage", "CELL", 144, 154], ["cholesterol", "SIMPLE_CHEMICAL", 163, 174], ["mice", "ORGANISM", 188, 192], ["BET", "GENE_OR_GENE_PRODUCT", 213, 216], ["BRTD", "GENE_OR_GENE_PRODUCT", 227, 231], ["BRD2", "GENE_OR_GENE_PRODUCT", 233, 237], ["BRD3", "GENE_OR_GENE_PRODUCT", 239, 243], ["BRD4", "GENE_OR_GENE_PRODUCT", 248, 252], ["apo", "GENE_OR_GENE_PRODUCT", 314, 317], ["Lomitapide", "SIMPLE_CHEMICAL", 328, 338], ["thienotriazolodiazepines", "SIMPLE_CHEMICAL", 382, 406], ["BET", "GENE_OR_GENE_PRODUCT", 434, 437], ["apabetalone", "SIMPLE_CHEMICAL", 505, 516], ["BRD4", "GENE_OR_GENE_PRODUCT", 543, 547], ["apo AI", "PROTEIN", 133, 139], ["BET proteins", "PROTEIN", 213, 225], ["BRTD", "PROTEIN", 227, 231], ["BRD2", "PROTEIN", 233, 237], ["BRD3", "PROTEIN", 239, 243], ["BRD4", "PROTEIN", 248, 252], ["BET associated proteins", "PROTEIN", 434, 457], ["BRD4", "PROTEIN", 543, 547], ["bromodomain BD2 (124)", "PROTEIN", 556, 577], ["mice", "SPECIES", 188, 192], ["thienotriazolodiazepines", "TREATMENT", 68, 92], ["apo AI", "PROBLEM", 133, 139], ["macrophage reverse cholesterol transport", "TREATMENT", 144, 184], ["the BET proteins", "PROBLEM", 209, 225], ["BRTD", "PROBLEM", 227, 231], ["BRD2", "PROBLEM", 233, 237], ["the apo AI change", "PROBLEM", 310, 327], ["Lomitapide", "TREATMENT", 328, 338], ["the thienotriazolodiazepines", "TREATMENT", 378, 406], ["apabetalone", "TREATMENT", 505, 516], ["the bromodomain BD2", "TEST", 552, 571]]], ["Apabetalone (RVX208) has been shown to raise HDL-C from 3.2 to 8.3%, particularly the larger HDL particles in humans (125) .Lomitapide.Besides the HDL-C raising capacity, apabetalone is able to reduce factors and pathways associated with vascular calcification, i.e. by inhibiting extracellular calcium deposition and reducing differentiation markers in coronary artery vascular SMCs in osteogenic conditions (126) .", [["vascular", "ANATOMY", 238, 246], ["extracellular", "ANATOMY", 281, 294], ["coronary artery vascular SMCs", "ANATOMY", 354, 383], ["Apabetalone", "CHEMICAL", 0, 11], ["RVX208", "CHEMICAL", 13, 19], ["apabetalone", "CHEMICAL", 171, 182], ["vascular calcification", "DISEASE", 238, 260], ["calcium", "CHEMICAL", 295, 302], ["Apabetalone", "CHEMICAL", 0, 11], ["RVX208", "CHEMICAL", 13, 19], ["apabetalone", "CHEMICAL", 171, 182], ["calcium", "CHEMICAL", 295, 302], ["Apabetalone", "SIMPLE_CHEMICAL", 0, 11], ["RVX208", "SIMPLE_CHEMICAL", 13, 19], ["HDL-C", "SIMPLE_CHEMICAL", 45, 50], ["HDL", "SIMPLE_CHEMICAL", 93, 96], ["humans", "ORGANISM", 110, 116], ["HDL-C", "SIMPLE_CHEMICAL", 147, 152], ["apabetalone", "SIMPLE_CHEMICAL", 171, 182], ["vascular", "MULTI-TISSUE_STRUCTURE", 238, 246], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 281, 294], ["calcium", "SIMPLE_CHEMICAL", 295, 302], ["coronary artery vascular SMCs", "CELL", 354, 383], ["HDL", "PROTEIN", 45, 48], ["coronary artery vascular SMCs", "CELL_TYPE", 354, 383], ["humans", "SPECIES", 110, 116], ["humans", "SPECIES", 110, 116], ["Apabetalone", "TREATMENT", 0, 11], ["HDL", "TEST", 45, 48], [".Lomitapide", "TREATMENT", 123, 134], ["the HDL", "TEST", 143, 150], ["C raising capacity", "PROBLEM", 151, 169], ["apabetalone", "TREATMENT", 171, 182], ["vascular calcification", "PROBLEM", 238, 260], ["extracellular calcium deposition", "PROBLEM", 281, 313], ["vascular", "ANATOMY", 238, 246], ["calcification", "OBSERVATION", 247, 260], ["calcium deposition", "OBSERVATION", 295, 313], ["coronary artery", "ANATOMY", 354, 369], ["vascular SMCs", "ANATOMY", 370, 383], ["osteogenic conditions", "OBSERVATION", 387, 408]]], ["The mechanism of reduced calcification of VSMCs appears to be a true epigenetic mechanism involving BDR4.", [["VSMCs", "ANATOMY", 42, 47], ["calcification", "DISEASE", 25, 38], ["VSMCs", "CELL", 42, 47], ["BDR4", "GENE_OR_GENE_PRODUCT", 100, 104], ["VSMCs", "CELL_TYPE", 42, 47], ["BDR4", "PROTEIN", 100, 104], ["reduced calcification of VSMCs", "PROBLEM", 17, 47], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["calcification", "OBSERVATION", 25, 38], ["VSMCs", "ANATOMY", 42, 47], ["appears to be", "UNCERTAINTY", 48, 61]]], ["Apabetalone also appeared to reduce alkaline phosphatase (ALP) levels and also hsCRP, the two being correlated, although reduced ALP predicted CV risk independent of hsCRP, thus possibly providing a novel mechanism of CV protection (127) .Lomitapide.While the numerous early studies on the CV preventive activity of apabetalone had failed to provide convincing evidence of significant effectiveness (128), a pooled analysis of these studies (129) had shown, in contrast, a close to 40% reduction of events following drug treatment.", [["Apabetalone", "CHEMICAL", 0, 11], ["Lomitapide", "CHEMICAL", 239, 249], ["apabetalone", "CHEMICAL", 316, 327], ["Apabetalone", "CHEMICAL", 0, 11], ["Lomitapide", "CHEMICAL", 239, 249], ["apabetalone", "CHEMICAL", 316, 327], ["Apabetalone", "SIMPLE_CHEMICAL", 0, 11], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 36, 56], ["ALP", "GENE_OR_GENE_PRODUCT", 58, 61], ["hsCRP", "GENE_OR_GENE_PRODUCT", 79, 84], ["ALP", "GENE_OR_GENE_PRODUCT", 129, 132], ["hsCRP", "GENE_OR_GENE_PRODUCT", 166, 171], ["Lomitapide", "SIMPLE_CHEMICAL", 239, 249], ["apabetalone", "SIMPLE_CHEMICAL", 316, 327], ["alkaline phosphatase", "PROTEIN", 36, 56], ["ALP", "PROTEIN", 58, 61], ["hsCRP", "PROTEIN", 79, 84], ["ALP", "PROTEIN", 129, 132], ["hsCRP", "PROTEIN", 166, 171], ["Apabetalone", "TREATMENT", 0, 11], ["alkaline phosphatase", "TEST", 36, 56], ["ALP) levels", "TEST", 58, 69], ["hsCRP", "TEST", 79, 84], ["reduced ALP", "PROBLEM", 121, 132], ["hsCRP", "TEST", 166, 171], ["CV protection", "TREATMENT", 218, 231], ["Lomitapide", "TREATMENT", 239, 249], ["apabetalone", "TREATMENT", 316, 327], ["significant effectiveness", "PROBLEM", 373, 398], ["a pooled analysis", "TEST", 406, 423], ["these studies", "TEST", 427, 440], ["drug treatment", "TREATMENT", 516, 530], ["significant", "OBSERVATION_MODIFIER", 373, 384]]], ["This encouraged planning a secondary prevention trial in type 2 diabetics with low HDL-C (<40 mg/dL in males and <45 mg/dL in females) on optimal lipid-lowering therapy.", [["HDL-C", "SIMPLE_CHEMICAL", 83, 88], ["lipid", "SIMPLE_CHEMICAL", 146, 151], ["HDL", "PROTEIN", 83, 86], ["a secondary prevention trial", "TREATMENT", 25, 53], ["type 2 diabetics", "PROBLEM", 57, 73], ["low HDL", "TREATMENT", 79, 86], ["optimal lipid", "TREATMENT", 138, 151], ["lowering therapy", "TREATMENT", 152, 168]]], ["They were randomized to apabetalone (100 mg b.i.d.) or a matching placebo (130) .", [["apabetalone", "CHEMICAL", 24, 35], ["apabetalone", "CHEMICAL", 24, 35], ["apabetalone", "SIMPLE_CHEMICAL", 24, 35], ["apabetalone", "TREATMENT", 24, 35], ["a matching placebo", "TREATMENT", 55, 73]]], ["After a median follow-up of 26.5 months, there were no statistically significant differences in LDL-C levels, hsCRP and HbA1c.", [["LDL-C", "SIMPLE_CHEMICAL", 96, 101], ["hsCRP", "GENE_OR_GENE_PRODUCT", 110, 115], ["LDL", "PROTEIN", 96, 99], ["hsCRP", "PROTEIN", 110, 115], ["LDL", "TEST", 96, 99], ["hsCRP", "TEST", 110, 115], ["HbA1c", "TEST", 120, 125], ["no", "UNCERTAINTY", 52, 54]]], ["At week 24, mean HDL-C levels rose from a mean of 33 mg/dL to 38.0 mg/dL with apabetalone and to 36.6 mg/dL J o u r n a l P r e -p r o o f with placebo (131) .", [["apabetalone", "CHEMICAL", 78, 89], ["apabetalone", "CHEMICAL", 78, 89], ["HDL-C", "SIMPLE_CHEMICAL", 17, 22], ["apabetalone", "SIMPLE_CHEMICAL", 78, 89], ["HDL", "PROTEIN", 17, 20], ["mean HDL", "TEST", 12, 20], ["C levels", "TEST", 21, 29], ["apabetalone", "TREATMENT", 78, 89], ["placebo", "TREATMENT", 144, 151]]], ["An interesting opening for apabetalone is the recently described potential activity of BRD2 and BRD4 inhibitors on SARS-CoV-2, by way of an interaction with transmembrane protein E of the virus (132).Hypertension and inflammationRecent developments in the understanding of CV risk associated to hypertension have pointed out the role of novel actors in the regulation of immune phenomena.", [["apabetalone", "CHEMICAL", 27, 38], ["Hypertension", "DISEASE", 200, 212], ["hypertension", "DISEASE", 295, 307], ["apabetalone", "CHEMICAL", 27, 38], ["apabetalone", "SIMPLE_CHEMICAL", 27, 38], ["BRD2", "SIMPLE_CHEMICAL", 87, 91], ["BRD4", "SIMPLE_CHEMICAL", 96, 100], ["SARS-CoV-2", "ORGANISM", 115, 125], ["transmembrane protein E", "GENE_OR_GENE_PRODUCT", 157, 180], ["BRD2", "PROTEIN", 87, 91], ["transmembrane protein E", "PROTEIN", 157, 180], ["apabetalone", "TREATMENT", 27, 38], ["BRD2", "TREATMENT", 87, 91], ["BRD4 inhibitors", "TREATMENT", 96, 111], ["the virus", "PROBLEM", 184, 193], ["Hypertension", "PROBLEM", 200, 212], ["inflammationRecent developments", "PROBLEM", 217, 248], ["CV risk", "PROBLEM", 273, 280], ["hypertension", "PROBLEM", 295, 307], ["immune phenomena", "PROBLEM", 371, 387], ["hypertension", "OBSERVATION", 295, 307], ["immune phenomena", "OBSERVATION", 371, 387]]], ["Aside from the classical Th1 and Th2 cells, regulatory T-cells (Tregs) and Th17 have shown differential plasticities, indicating that in particular Tregs appear to attenuate hypertension target organ damage, whereas Th17 cells may exacerbate damage.", [["Th2 cells", "ANATOMY", 33, 42], ["regulatory T-cells", "ANATOMY", 44, 62], ["Tregs", "ANATOMY", 64, 69], ["Tregs", "ANATOMY", 148, 153], ["organ", "ANATOMY", 194, 199], ["Th17 cells", "ANATOMY", 216, 226], ["hypertension", "DISEASE", 174, 186], ["organ damage", "DISEASE", 194, 206], ["Th1", "CELL", 25, 28], ["Th2 cells", "CELL", 33, 42], ["regulatory T-cells", "CELL", 44, 62], ["Tregs", "CELL", 64, 69], ["Th17", "CELL", 75, 79], ["Tregs", "CELL", 148, 153], ["organ", "ORGAN", 194, 199], ["Th17 cells", "CELL", 216, 226], ["Th1 and Th2 cells", "CELL_TYPE", 25, 42], ["regulatory T-cells", "CELL_TYPE", 44, 62], ["Tregs", "CELL_TYPE", 64, 69], ["Th17", "CELL_TYPE", 75, 79], ["Tregs", "CELL_TYPE", 148, 153], ["Th17 cells", "CELL_TYPE", 216, 226], ["Th17", "TEST", 75, 79], ["differential plasticities", "PROBLEM", 91, 116], ["hypertension target organ damage", "PROBLEM", 174, 206], ["Th17 cells", "PROBLEM", 216, 226], ["damage", "PROBLEM", 242, 248], ["Th1", "OBSERVATION", 25, 28], ["Th2 cells", "OBSERVATION", 33, 42], ["differential", "OBSERVATION_MODIFIER", 91, 103], ["plasticities", "OBSERVATION", 104, 116], ["hypertension", "OBSERVATION", 174, 186], ["Th17 cells", "OBSERVATION", 216, 226]]], ["Tregs are characterized by the ability to suppress inflammatory signaling of immune and non-immune cells (133) and may reduce target organ damage in hypertensive models, possibly by way of IL-10 and TGF\u03b2 mediated immunosuppression (134) .", [["Tregs", "ANATOMY", 0, 5], ["cells", "ANATOMY", 99, 104], ["organ", "ANATOMY", 133, 138], ["organ damage", "DISEASE", 133, 145], ["hypertensive", "DISEASE", 149, 161], ["Tregs", "CELL", 0, 5], ["immune", "CELL", 77, 83], ["non-immune cells", "CELL", 88, 104], ["organ", "ORGAN", 133, 138], ["IL-10", "GENE_OR_GENE_PRODUCT", 189, 194], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 199, 203], ["Tregs", "CELL_TYPE", 0, 5], ["immune and non-immune cells", "CELL_TYPE", 77, 104], ["IL", "PROTEIN", 189, 191], ["TGF\u03b2", "PROTEIN", 199, 203], ["inflammatory signaling of immune and non-immune cells", "PROBLEM", 51, 104], ["target organ damage in hypertensive models", "PROBLEM", 126, 168], ["IL", "TEST", 189, 191], ["TGF\u03b2 mediated immunosuppression", "TREATMENT", 199, 230], ["damage", "OBSERVATION", 139, 145]]], ["Th17 cells are instead characterized by the expression of transcription factor retinoic acid-related orphan receptor (ROR)\u03b3 together with the production of IL-17.", [["Th17 cells", "ANATOMY", 0, 10], ["Th17 cells", "CELL", 0, 10], ["retinoic acid-related orphan receptor", "GENE_OR_GENE_PRODUCT", 79, 116], ["ROR)\u03b3", "GENE_OR_GENE_PRODUCT", 118, 123], ["IL-17", "GENE_OR_GENE_PRODUCT", 156, 161], ["Th17 cells", "CELL_TYPE", 0, 10], ["transcription factor", "PROTEIN", 58, 78], ["retinoic acid-related orphan receptor (ROR)\u03b3", "PROTEIN", 79, 123], ["IL-17", "PROTEIN", 156, 161], ["Th17 cells", "TREATMENT", 0, 10]]], ["This exacerbates tissue damage in hypertensives (135) .", [["tissue", "ANATOMY", 17, 23], ["tissue damage", "DISEASE", 17, 30], ["hypertensives", "DISEASE", 34, 47], ["tissue", "TISSUE", 17, 23], ["This exacerbates tissue damage in hypertensives", "PROBLEM", 0, 47], ["tissue", "OBSERVATION_MODIFIER", 17, 23], ["damage", "OBSERVATION", 24, 30]]], ["Tregs have been implicated in hypertension protection experienced by females, displaying, among others, a larger percentage of infiltrating T-cells in female spontaneously hypertensive rats, compared to males (136) .Hypertension and inflammationInflammatory pathways and mediators are used by immune cells to drive high blood pressure (BP) and end-organ damage.", [["Tregs", "ANATOMY", 0, 5], ["infiltrating T-cells", "ANATOMY", 127, 147], ["immune cells", "ANATOMY", 293, 305], ["blood", "ANATOMY", 320, 325], ["organ", "ANATOMY", 348, 353], ["hypertension", "DISEASE", 30, 42], ["hypertensive", "DISEASE", 172, 184], ["Hypertension", "DISEASE", 216, 228], ["inflammation", "DISEASE", 233, 245], ["Tregs", "CELL", 0, 5], ["T-cells", "CELL", 140, 147], ["rats", "ORGANISM", 185, 189], ["immune cells", "CELL", 293, 305], ["blood", "ORGANISM_SUBSTANCE", 320, 325], ["organ", "ORGAN", 348, 353], ["Tregs", "CELL_TYPE", 0, 5], ["infiltrating T-cells", "CELL_TYPE", 127, 147], ["immune cells", "CELL_TYPE", 293, 305], ["rats", "SPECIES", 185, 189], ["hypertension protection", "TREATMENT", 30, 53], ["spontaneously hypertensive rats", "PROBLEM", 158, 189], ["Hypertension", "PROBLEM", 216, 228], ["inflammationInflammatory pathways", "PROBLEM", 233, 266], ["immune cells", "PROBLEM", 293, 305], ["high blood pressure", "TEST", 315, 334], ["BP", "TEST", 336, 338], ["end-organ damage", "PROBLEM", 344, 360], ["hypertension", "OBSERVATION", 30, 42], ["infiltrating", "OBSERVATION", 127, 139], ["inflammation", "OBSERVATION_MODIFIER", 233, 245], ["Inflammatory", "OBSERVATION_MODIFIER", 245, 257], ["organ", "ANATOMY", 348, 353], ["damage", "OBSERVATION", 354, 360]]], ["Activation of immune cells and recruitment to a target organ leads to production of cytokines and chemokines that determine local inflammatory responses.Hypertension and inflammationInflammatory cytokines and chemokines involved in hypertension are TNF-\u03b1, IL-17, MCP-1, and IL-6 (137).", [["immune cells", "ANATOMY", 14, 26], ["organ", "ANATOMY", 55, 60], ["Hypertension", "DISEASE", 153, 165], ["inflammation", "DISEASE", 170, 182], ["hypertension", "DISEASE", 232, 244], ["immune cells", "CELL", 14, 26], ["organ", "ORGAN", 55, 60], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 249, 254], ["IL-17", "GENE_OR_GENE_PRODUCT", 256, 261], ["MCP-1", "GENE_OR_GENE_PRODUCT", 263, 268], ["IL-6", "GENE_OR_GENE_PRODUCT", 274, 278], ["immune cells", "CELL_TYPE", 14, 26], ["cytokines", "PROTEIN", 84, 93], ["chemokines", "PROTEIN", 98, 108], ["Inflammatory cytokines", "PROTEIN", 182, 204], ["chemokines", "PROTEIN", 209, 219], ["TNF", "PROTEIN", 249, 252], ["MCP", "PROTEIN", 263, 266], ["immune cells", "PROBLEM", 14, 26], ["recruitment", "TREATMENT", 31, 42], ["cytokines and chemokines", "TREATMENT", 84, 108], ["Hypertension", "PROBLEM", 153, 165], ["inflammationInflammatory cytokines", "PROBLEM", 170, 204], ["chemokines", "PROBLEM", 209, 219], ["hypertension", "PROBLEM", 232, 244], ["TNF", "TEST", 249, 252], ["IL", "TEST", 256, 258], ["MCP", "TEST", 263, 266], ["IL", "TEST", 274, 276], ["immune cells", "OBSERVATION", 14, 26], ["inflammation", "OBSERVATION_MODIFIER", 170, 182], ["Inflammatory", "OBSERVATION_MODIFIER", 182, 194], ["hypertension", "OBSERVATION", 232, 244]]], ["Two TNF-\u03b1 receptors have been described: TNFR1 and TNFR2 (138) .", [["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 4, 19], ["TNFR1", "GENE_OR_GENE_PRODUCT", 41, 46], ["TNFR2", "GENE_OR_GENE_PRODUCT", 51, 56], ["TNF-\u03b1 receptors", "PROTEIN", 4, 19], ["TNFR1", "PROTEIN", 41, 46], ["TNFR2", "PROTEIN", 51, 56], ["Two TNF-\u03b1 receptors", "TEST", 0, 19], ["TNFR2", "TEST", 51, 56]]], ["In humans, high serum TNFR1 levels strongly correlate with hypertension associated diseases, e.g. end-stage renal disease and type 2 diabetes (139) .", [["serum", "ANATOMY", 16, 21], ["renal", "ANATOMY", 108, 113], ["hypertension", "DISEASE", 59, 71], ["end-stage renal disease", "DISEASE", 98, 121], ["type 2 diabetes", "DISEASE", 126, 141], ["humans", "ORGANISM", 3, 9], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["TNFR1", "GENE_OR_GENE_PRODUCT", 22, 27], ["renal", "ORGAN", 108, 113], ["TNFR1", "PROTEIN", 22, 27], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["high serum TNFR1 levels", "TEST", 11, 34], ["hypertension associated diseases", "PROBLEM", 59, 91], ["end-stage renal disease", "PROBLEM", 98, 121], ["type 2 diabetes", "PROBLEM", 126, 141], ["hypertension", "OBSERVATION", 59, 71], ["stage", "OBSERVATION_MODIFIER", 102, 107], ["renal", "ANATOMY", 108, 113], ["disease", "OBSERVATION", 114, 121], ["diabetes", "OBSERVATION", 133, 141]]], ["There are, however, reports indicating that genetic deletion of TNFR1 leads to increased BP in response to angiotensin (Ang) II (140) .", [["angiotensin", "CHEMICAL", 107, 118], ["Ang) II", "CHEMICAL", 120, 127], ["TNFR1", "GENE_OR_GENE_PRODUCT", 64, 69], ["BP", "SIMPLE_CHEMICAL", 89, 91], ["angiotensin (Ang) II", "GENE_OR_GENE_PRODUCT", 107, 127], ["TNFR1", "PROTEIN", 64, 69], ["BP", "PROTEIN", 89, 91], ["genetic deletion of TNFR1", "PROBLEM", 44, 69], ["increased BP", "PROBLEM", 79, 91], ["angiotensin (Ang", "TREATMENT", 107, 123]]], ["The epidemiological Malmo Diet and Cancer Study investigated the association of TNFR1 and TNFR2 in middle-aged individuals and reported that both were associated with an increased risk of intracerebral hemorrhage (ICH), suggesting that TNF mediated inflammation may lead to vascular changes preceding ICH (141) .Angiotensin converting enzyme (ACE)-inhibitors.They exert a significant anti-inflammatory activity at the vascular level.", [["intracerebral", "ANATOMY", 188, 201], ["vascular", "ANATOMY", 274, 282], ["vascular", "ANATOMY", 418, 426], ["Cancer", "DISEASE", 35, 41], ["intracerebral hemorrhage", "DISEASE", 188, 212], ["ICH", "DISEASE", 214, 217], ["inflammation", "DISEASE", 249, 261], ["ICH", "DISEASE", 301, 304], ["Angiotensin", "CHEMICAL", 312, 323], ["Cancer", "CANCER", 35, 41], ["TNFR1", "GENE_OR_GENE_PRODUCT", 80, 85], ["TNFR2", "GENE_OR_GENE_PRODUCT", 90, 95], ["individuals", "ORGANISM", 111, 122], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["TNF", "GENE_OR_GENE_PRODUCT", 236, 239], ["vascular", "MULTI-TISSUE_STRUCTURE", 274, 282], ["Angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 312, 341], ["ACE", "GENE_OR_GENE_PRODUCT", 343, 346], ["vascular", "MULTI-TISSUE_STRUCTURE", 418, 426], ["TNFR1", "PROTEIN", 80, 85], ["TNFR2", "PROTEIN", 90, 95], ["TNF", "PROTEIN", 236, 239], ["Angiotensin converting enzyme", "PROTEIN", 312, 341], ["ACE", "PROTEIN", 343, 346], ["Cancer Study", "TEST", 35, 47], ["TNFR1", "TEST", 80, 85], ["TNFR2", "TEST", 90, 95], ["intracerebral hemorrhage", "PROBLEM", 188, 212], ["ICH", "PROBLEM", 214, 217], ["TNF mediated inflammation", "PROBLEM", 236, 261], ["vascular changes preceding ICH", "PROBLEM", 274, 304], ["Angiotensin converting enzyme (ACE)", "TREATMENT", 312, 347], ["inhibitors", "TREATMENT", 348, 358], ["middle", "ANATOMY_MODIFIER", 99, 105], ["increased", "OBSERVATION_MODIFIER", 170, 179], ["intracerebral", "ANATOMY", 188, 201], ["hemorrhage", "OBSERVATION", 202, 212], ["inflammation", "OBSERVATION", 249, 261], ["vascular", "ANATOMY", 274, 282], ["significant", "OBSERVATION_MODIFIER", 372, 383], ["anti-inflammatory activity", "OBSERVATION", 384, 410], ["vascular", "ANATOMY", 418, 426]]], ["AngII treatment in rodents elevates BP and VCAM-1; chemokines such as monocyte chemotactic protein-1 (MCP-1) and macrophage-colony stimulating factor (M-CSF) are up-regulated in the aortas of Ang II-treated mice.", [["aortas", "ANATOMY", 182, 188], ["AngII", "CHEMICAL", 0, 5], ["Ang II", "CHEMICAL", 192, 198], ["AngII", "SIMPLE_CHEMICAL", 0, 5], ["rodents", "ORGANISM", 19, 26], ["BP", "SIMPLE_CHEMICAL", 36, 38], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 43, 49], ["monocyte chemotactic protein-1", "GENE_OR_GENE_PRODUCT", 70, 100], ["MCP-1", "GENE_OR_GENE_PRODUCT", 102, 107], ["macrophage-colony stimulating factor", "GENE_OR_GENE_PRODUCT", 113, 149], ["M-CSF", "GENE_OR_GENE_PRODUCT", 151, 156], ["aortas", "MULTI-TISSUE_STRUCTURE", 182, 188], ["Ang II", "GENE_OR_GENE_PRODUCT", 192, 198], ["mice", "ORGANISM", 207, 211], ["BP", "PROTEIN", 36, 38], ["VCAM", "PROTEIN", 43, 47], ["chemokines", "PROTEIN", 51, 61], ["monocyte chemotactic protein-1 (MCP-1", "PROTEIN", 70, 107], ["macrophage-colony stimulating factor", "PROTEIN", 113, 149], ["CSF", "PROTEIN", 153, 156], ["Ang II", "PROTEIN", 192, 198], ["mice", "SPECIES", 207, 211], ["mice", "SPECIES", 207, 211], ["AngII treatment", "TREATMENT", 0, 15], ["BP", "TEST", 36, 38], ["VCAM", "TEST", 43, 47], ["chemokines", "TEST", 51, 61], ["monocyte chemotactic protein", "TEST", 70, 98], ["MCP", "TEST", 102, 105], ["macrophage", "TEST", 113, 123], ["colony stimulating factor", "TEST", 124, 149], ["macrophage", "ANATOMY", 113, 123], ["aortas", "ANATOMY", 182, 188]]], ["In these animals, enalapril treatment reduces atherosclerosis, but in particular, vascular inflammation, by markedly reducing elevated chemokine levels (143) .", [["vascular", "ANATOMY", 82, 90], ["enalapril", "CHEMICAL", 18, 27], ["atherosclerosis", "DISEASE", 46, 61], ["inflammation", "DISEASE", 91, 103], ["enalapril", "CHEMICAL", 18, 27], ["enalapril", "SIMPLE_CHEMICAL", 18, 27], ["vascular", "MULTI-TISSUE_STRUCTURE", 82, 90], ["chemokine", "PROTEIN", 135, 144], ["enalapril treatment", "TREATMENT", 18, 37], ["atherosclerosis", "PROBLEM", 46, 61], ["vascular inflammation", "PROBLEM", 82, 103], ["markedly reducing elevated chemokine levels", "PROBLEM", 108, 151], ["atherosclerosis", "OBSERVATION", 46, 61], ["vascular", "ANATOMY", 82, 90], ["inflammation", "OBSERVATION", 91, 103]]], ["A direct clinical comparison of a major ACE-inhibitor, ramipril, with the angiotensin receptor blocker telmisartan, in type 2 diabetics, showed that both exerted a similar antiinflammatory activity, as evaluated from a fall of hsCRP (144) .", [["ramipril", "CHEMICAL", 55, 63], ["angiotensin", "CHEMICAL", 74, 85], ["telmisartan", "CHEMICAL", 103, 114], ["ramipril", "CHEMICAL", 55, 63], ["telmisartan", "CHEMICAL", 103, 114], ["ACE", "GENE_OR_GENE_PRODUCT", 40, 43], ["ramipril", "SIMPLE_CHEMICAL", 55, 63], ["telmisartan", "SIMPLE_CHEMICAL", 103, 114], ["hsCRP", "GENE_OR_GENE_PRODUCT", 227, 232], ["hsCRP", "PROTEIN", 227, 232], ["a major ACE-inhibitor", "TREATMENT", 32, 53], ["ramipril", "TREATMENT", 55, 63], ["the angiotensin receptor blocker telmisartan", "TREATMENT", 70, 114], ["type 2 diabetics", "PROBLEM", 119, 135], ["hsCRP", "TEST", 227, 232], ["antiinflammatory activity", "OBSERVATION", 172, 197]]], ["The mechanisms of the proinflammatory activity of ACE activation and its inhibition by ACE inhibitors have been extensively investigated.", [["ACE", "GENE_OR_GENE_PRODUCT", 50, 53], ["ACE", "GENE_OR_GENE_PRODUCT", 87, 90], ["ACE", "PROTEIN", 50, 53], ["ACE activation", "TREATMENT", 50, 64], ["its inhibition", "TREATMENT", 69, 83], ["ACE inhibitors", "TREATMENT", 87, 101], ["proinflammatory activity", "OBSERVATION", 22, 46]]], ["ACE stimulation enhances the expression of inducible NO synthase and COX-2 by NF-\u03baB activation (145) , also raising the production of reactive oxygen species and of proinflammatory T cells.", [["proinflammatory T cells", "ANATOMY", 165, 188], ["NO", "CHEMICAL", 53, 55], ["oxygen", "CHEMICAL", 143, 149], ["NO", "CHEMICAL", 53, 55], ["oxygen", "CHEMICAL", 143, 149], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["inducible NO synthase", "GENE_OR_GENE_PRODUCT", 43, 64], ["COX-2", "GENE_OR_GENE_PRODUCT", 69, 74], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 78, 83], ["reactive oxygen species", "SIMPLE_CHEMICAL", 134, 157], ["T cells", "CELL", 181, 188], ["ACE", "PROTEIN", 0, 3], ["NO synthase", "PROTEIN", 53, 64], ["COX-2", "PROTEIN", 69, 74], ["NF-\u03baB", "PROTEIN", 78, 83], ["proinflammatory T cells", "CELL_TYPE", 165, 188], ["ACE stimulation", "TREATMENT", 0, 15], ["COX", "TEST", 69, 72], ["NF", "TEST", 78, 80], ["reactive oxygen species", "PROBLEM", 134, 157], ["proinflammatory T cells", "PROBLEM", 165, 188], ["reactive", "OBSERVATION_MODIFIER", 134, 142], ["oxygen species", "OBSERVATION", 143, 157], ["proinflammatory T cells", "OBSERVATION", 165, 188]]], ["ACE-Inhibition suppresses Th17-and Th1-mediated autoimmunity, also promoting production of Treg, favorably modulating inflammation (146) .", [["Treg", "ANATOMY", 91, 95], ["autoimmunity", "DISEASE", 48, 60], ["inflammation", "DISEASE", 118, 130], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["Th17", "GENE_OR_GENE_PRODUCT", 26, 30], ["Th1", "GENE_OR_GENE_PRODUCT", 35, 38], ["Treg", "CELL", 91, 95], ["ACE", "PROTEIN", 0, 3], ["Treg", "CELL_TYPE", 91, 95], ["ACE", "TEST", 0, 3], ["Th17", "TEST", 26, 30], ["favorably modulating inflammation", "PROBLEM", 97, 130], ["production", "OBSERVATION_MODIFIER", 77, 87], ["Treg", "ANATOMY", 91, 95], ["inflammation", "OBSERVATION", 118, 130]]], ["Ang II may also activate the TLR4 signaling pathway, leading to inflammatory synergism.", [["Ang II", "CHEMICAL", 0, 6], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["TLR4", "GENE_OR_GENE_PRODUCT", 29, 33], ["Ang II", "PROTEIN", 0, 6], ["TLR4", "PROTEIN", 29, 33], ["inflammatory synergism", "PROBLEM", 64, 86], ["inflammatory", "OBSERVATION_MODIFIER", 64, 76]]], ["These proinflammatory cytokines enhance the abnormal serine phosphorylation of IRS-1, thus causing insulin resistance (147) .", [["serine", "CHEMICAL", 53, 59], ["serine", "AMINO_ACID", 53, 59], ["IRS-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["insulin", "GENE_OR_GENE_PRODUCT", 99, 106], ["proinflammatory cytokines", "PROTEIN", 6, 31], ["IRS-1", "PROTEIN", 79, 84], ["These proinflammatory cytokines", "TEST", 0, 31], ["the abnormal serine phosphorylation of IRS", "PROBLEM", 40, 82], ["insulin resistance", "PROBLEM", 99, 117], ["insulin resistance", "OBSERVATION", 99, 117]]], ["Treatment with ACE-inhibitors will rescue insulin-resistance and, in some cases even cause hypoglycemia (148).Sartans.Among sartans with apparent additional anti-inflammatory properties, telmisartan has received the largest attention.", [["ACE-inhibitors", "CHEMICAL", 15, 29], ["hypoglycemia", "DISEASE", 91, 103], ["sartans", "CHEMICAL", 124, 131], ["telmisartan", "CHEMICAL", 187, 198], ["sartans", "CHEMICAL", 124, 131], ["telmisartan", "CHEMICAL", 187, 198], ["ACE", "GENE_OR_GENE_PRODUCT", 15, 18], ["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["sartans", "SIMPLE_CHEMICAL", 124, 131], ["telmisartan", "SIMPLE_CHEMICAL", 187, 198], ["ACE-inhibitors", "TREATMENT", 15, 29], ["insulin", "TREATMENT", 42, 49], ["hypoglycemia", "PROBLEM", 91, 103], ["Sartans", "TREATMENT", 110, 117], ["apparent additional anti-inflammatory properties", "TREATMENT", 137, 185], ["telmisartan", "TREATMENT", 187, 198], ["anti-inflammatory properties", "OBSERVATION", 157, 185]]], ["This agent can reduce vascular SMC proliferation by a potentially additive mechanism to angiotensin receptor blockade and PPAR\uf067\uf020activation (149) .", [["vascular SMC", "ANATOMY", 22, 34], ["angiotensin", "CHEMICAL", 88, 99], ["vascular SMC", "CELL", 22, 34], ["angiotensin receptor", "GENE_OR_GENE_PRODUCT", 88, 108], ["PPAR\uf067", "GENE_OR_GENE_PRODUCT", 122, 127], ["SMC", "CELL_TYPE", 31, 34], ["angiotensin receptor", "PROTEIN", 88, 108], ["PPAR", "PROTEIN", 122, 126], ["vascular SMC proliferation", "PROBLEM", 22, 48], ["angiotensin receptor blockade", "TREATMENT", 88, 117], ["PPAR\uf067\uf020activation", "TREATMENT", 122, 138], ["vascular SMC", "ANATOMY", 22, 34], ["proliferation", "OBSERVATION", 35, 48]]], ["When given to HIV + patients with excess adiposity at 40mg/day treatment, a significant 5% visceral adipose tissue loss with raised urinary excretion of prostaglandin E2 were detected, supporting the conclusion that the anti-inflammatory activity may be linked to stimulated eicosanoid metabolism (150) .", [["visceral adipose tissue", "ANATOMY", 91, 114], ["urinary", "ANATOMY", 132, 139], ["prostaglandin E2", "CHEMICAL", 153, 169], ["prostaglandin E2", "CHEMICAL", 153, 169], ["eicosanoid", "CHEMICAL", 275, 285], ["HIV", "ORGANISM", 14, 17], ["patients", "ORGANISM", 20, 28], ["visceral adipose tissue", "TISSUE", 91, 114], ["urinary", "ORGANISM_SUBSTANCE", 132, 139], ["prostaglandin E2", "SIMPLE_CHEMICAL", 153, 169], ["eicosanoid", "SIMPLE_CHEMICAL", 275, 285], ["HIV", "SPECIES", 14, 17], ["patients", "SPECIES", 20, 28], ["HIV", "SPECIES", 14, 17], ["excess adiposity", "PROBLEM", 34, 50], ["treatment", "TREATMENT", 63, 72], ["a significant 5% visceral adipose tissue loss", "PROBLEM", 74, 119], ["raised urinary excretion of prostaglandin E2", "TREATMENT", 125, 169], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["visceral adipose", "ANATOMY", 91, 107], ["tissue loss", "OBSERVATION", 108, 119], ["prostaglandin E2", "OBSERVATION", 153, 169]]], ["It is of interest that candesartan, another angiotensin receptor blocker, may reduce TLR2, TLR4 and NFkB activation in monocytes, thus displaying a significant anti-inflammatory effect (151) .", [["monocytes", "ANATOMY", 119, 128], ["candesartan", "CHEMICAL", 23, 34], ["angiotensin", "CHEMICAL", 44, 55], ["candesartan", "CHEMICAL", 23, 34], ["candesartan", "SIMPLE_CHEMICAL", 23, 34], ["angiotensin receptor", "GENE_OR_GENE_PRODUCT", 44, 64], ["TLR2", "GENE_OR_GENE_PRODUCT", 85, 89], ["TLR4", "GENE_OR_GENE_PRODUCT", 91, 95], ["NFkB", "GENE_OR_GENE_PRODUCT", 100, 104], ["monocytes", "CELL", 119, 128], ["TLR2", "PROTEIN", 85, 89], ["TLR4", "PROTEIN", 91, 95], ["NFkB", "PROTEIN", 100, 104], ["monocytes", "CELL_TYPE", 119, 128], ["candesartan", "TREATMENT", 23, 34], ["another angiotensin receptor blocker", "TREATMENT", 36, 72], ["TLR2", "TEST", 85, 89], ["TLR4", "PROBLEM", 91, 95], ["monocytes", "TEST", 119, 128], ["a significant anti-inflammatory effect", "PROBLEM", 146, 184], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["anti-inflammatory", "OBSERVATION_MODIFIER", 160, 177]]], ["Significant differences can be found between the two classes of CCBs.", [["CCBs", "CHEMICAL", 64, 68], ["CCBs", "SIMPLE_CHEMICAL", 64, 68], ["CCBs", "TREATMENT", 64, 68], ["CCBs", "OBSERVATION", 64, 68]]], ["The dihydropyridine CCBs, nifedipine and amlodipine, antagonize L-type calcium channels and have antioxidant effects (155) .", [["dihydropyridine", "CHEMICAL", 4, 19], ["nifedipine", "CHEMICAL", 26, 36], ["amlodipine", "CHEMICAL", 41, 51], ["calcium", "CHEMICAL", 71, 78], ["dihydropyridine", "CHEMICAL", 4, 19], ["CCBs", "CHEMICAL", 20, 24], ["nifedipine", "CHEMICAL", 26, 36], ["amlodipine", "CHEMICAL", 41, 51], ["calcium", "CHEMICAL", 71, 78], ["dihydropyridine CCBs", "SIMPLE_CHEMICAL", 4, 24], ["nifedipine", "SIMPLE_CHEMICAL", 26, 36], ["amlodipine", "SIMPLE_CHEMICAL", 41, 51], ["L-type calcium", "SIMPLE_CHEMICAL", 64, 78], ["L-type calcium channels", "PROTEIN", 64, 87], ["The dihydropyridine CCBs", "TREATMENT", 0, 24], ["nifedipine", "TREATMENT", 26, 36], ["amlodipine", "TREATMENT", 41, 51], ["antagonize L-type calcium channels", "TREATMENT", 53, 87], ["antioxidant effects", "TREATMENT", 97, 116]]], ["The rate-limiting CCBs such as verapamil, may also improve endothelial function, indicating that the benefits of these agents may be related to an improved nitric oxide bioavailability (156) .", [["endothelial", "ANATOMY", 59, 70], ["verapamil", "CHEMICAL", 31, 40], ["nitric oxide", "CHEMICAL", 156, 168], ["verapamil", "CHEMICAL", 31, 40], ["nitric oxide", "CHEMICAL", 156, 168], ["CCBs", "SIMPLE_CHEMICAL", 18, 22], ["verapamil", "SIMPLE_CHEMICAL", 31, 40], ["endothelial", "CELL", 59, 70], ["nitric oxide", "SIMPLE_CHEMICAL", 156, 168], ["The rate", "TEST", 0, 8], ["limiting CCBs", "TREATMENT", 9, 22], ["verapamil", "TREATMENT", 31, 40], ["these agents", "TREATMENT", 113, 125], ["an improved nitric oxide bioavailability", "TREATMENT", 144, 184]]], ["In gluteal resistance arteries in hypertensive patients, treatment with the CCB nifedipine for 1 year improved vascular relaxation responses to acetylcholine, not observed with atenolol (157) .", [["gluteal resistance arteries", "ANATOMY", 3, 30], ["vascular", "ANATOMY", 111, 119], ["hypertensive", "DISEASE", 34, 46], ["CCB", "CHEMICAL", 76, 79], ["nifedipine", "CHEMICAL", 80, 90], ["acetylcholine", "CHEMICAL", 144, 157], ["atenolol", "CHEMICAL", 177, 185], ["nifedipine", "CHEMICAL", 80, 90], ["acetylcholine", "CHEMICAL", 144, 157], ["atenolol", "CHEMICAL", 177, 185], ["gluteal resistance arteries", "MULTI-TISSUE_STRUCTURE", 3, 30], ["patients", "ORGANISM", 47, 55], ["CCB", "SIMPLE_CHEMICAL", 76, 79], ["nifedipine", "SIMPLE_CHEMICAL", 80, 90], ["vascular", "MULTI-TISSUE_STRUCTURE", 111, 119], ["acetylcholine", "SIMPLE_CHEMICAL", 144, 157], ["atenolol", "SIMPLE_CHEMICAL", 177, 185], ["patients", "SPECIES", 47, 55], ["the CCB nifedipine", "TREATMENT", 72, 90], ["acetylcholine", "TREATMENT", 144, 157], ["atenolol", "TREATMENT", 177, 185], ["gluteal", "ANATOMY", 3, 10], ["resistance", "OBSERVATION", 11, 21], ["arteries", "ANATOMY", 22, 30], ["hypertensive", "OBSERVATION_MODIFIER", 34, 46], ["vascular", "ANATOMY", 111, 119]]], ["In the coronary vasculature, nicardipine can reverse endothelial dysfunction in non-stenotic segments from hypertensive patients and in stenotic segments from both normotensives and hypertensives (158) .", [["coronary vasculature", "ANATOMY", 7, 27], ["endothelial", "ANATOMY", 53, 64], ["nicardipine", "CHEMICAL", 29, 40], ["endothelial dysfunction", "DISEASE", 53, 76], ["hypertensive", "DISEASE", 107, 119], ["nicardipine", "CHEMICAL", 29, 40], ["coronary vasculature", "MULTI-TISSUE_STRUCTURE", 7, 27], ["nicardipine", "SIMPLE_CHEMICAL", 29, 40], ["endothelial", "CELL", 53, 64], ["patients", "ORGANISM", 120, 128], ["stenotic segments", "MULTI-TISSUE_STRUCTURE", 136, 153], ["patients", "SPECIES", 120, 128], ["nicardipine", "TREATMENT", 29, 40], ["reverse endothelial dysfunction in non-stenotic segments", "PROBLEM", 45, 101], ["hypertensive patients", "PROBLEM", 107, 128], ["normotensives", "TEST", 164, 177], ["hypertensives", "TEST", 182, 195], ["coronary vasculature", "ANATOMY", 7, 27], ["endothelial dysfunction", "OBSERVATION", 53, 76], ["segments", "ANATOMY_MODIFIER", 93, 101], ["hypertensive", "OBSERVATION_MODIFIER", 107, 119], ["stenotic", "OBSERVATION", 136, 144], ["segments", "ANATOMY_MODIFIER", 145, 153], ["both", "OBSERVATION_MODIFIER", 159, 163], ["normotensives", "OBSERVATION", 164, 177]]], ["Nicardipine has been shown to improve endothelium-dependent vasodilation in patients with essential hypertension (159) and to raise coronary vascular responses to acetylcholine.", [["endothelium", "ANATOMY", 38, 49], ["coronary vascular", "ANATOMY", 132, 149], ["Nicardipine", "CHEMICAL", 0, 11], ["essential hypertension", "DISEASE", 90, 112], ["acetylcholine", "CHEMICAL", 163, 176], ["Nicardipine", "CHEMICAL", 0, 11], ["acetylcholine", "CHEMICAL", 163, 176], ["Nicardipine", "SIMPLE_CHEMICAL", 0, 11], ["endothelium", "TISSUE", 38, 49], ["patients", "ORGANISM", 76, 84], ["coronary vascular", "MULTI-TISSUE_STRUCTURE", 132, 149], ["acetylcholine", "SIMPLE_CHEMICAL", 163, 176], ["patients", "SPECIES", 76, 84], ["Nicardipine", "TREATMENT", 0, 11], ["dependent vasodilation", "PROBLEM", 50, 72], ["essential hypertension", "PROBLEM", 90, 112], ["acetylcholine", "TREATMENT", 163, 176], ["dependent", "OBSERVATION_MODIFIER", 50, 59], ["vasodilation", "OBSERVATION", 60, 72], ["hypertension", "OBSERVATION", 100, 112], ["coronary vascular", "ANATOMY", 132, 149]]], ["Amlodipine increases basal NO release, whereas lacidipine enhanced the vasodilator responses to both acetylcholine and bradykinin within the forearm circulation of hypertensive patients (160).Diabetes and inflammationThe pattern of pathological responses characteristic of type 2 diabetes is dependent on the sensitivity of vessels to oxidative stress, hypertension, dyslipidemia and aging, all determining the risk of atherosclerosis progression and regression.", [["forearm", "ANATOMY", 141, 148], ["vessels", "ANATOMY", 324, 331], ["Amlodipine", "CHEMICAL", 0, 10], ["NO", "CHEMICAL", 27, 29], ["lacidipine", "CHEMICAL", 47, 57], ["acetylcholine", "CHEMICAL", 101, 114], ["bradykinin", "CHEMICAL", 119, 129], ["hypertensive", "DISEASE", 164, 176], ["Diabetes", "DISEASE", 192, 200], ["inflammation", "DISEASE", 205, 217], ["type 2 diabetes", "DISEASE", 273, 288], ["hypertension", "DISEASE", 353, 365], ["dyslipidemia", "DISEASE", 367, 379], ["atherosclerosis", "DISEASE", 419, 434], ["Amlodipine", "CHEMICAL", 0, 10], ["NO", "CHEMICAL", 27, 29], ["lacidipine", "CHEMICAL", 47, 57], ["acetylcholine", "CHEMICAL", 101, 114], ["bradykinin", "CHEMICAL", 119, 129], ["Amlodipine", "SIMPLE_CHEMICAL", 0, 10], ["NO", "SIMPLE_CHEMICAL", 27, 29], ["lacidipine", "SIMPLE_CHEMICAL", 47, 57], ["acetylcholine", "SIMPLE_CHEMICAL", 101, 114], ["bradykinin", "SIMPLE_CHEMICAL", 119, 129], ["forearm", "ORGANISM_SUBDIVISION", 141, 148], ["patients", "ORGANISM", 177, 185], ["vessels", "MULTI-TISSUE_STRUCTURE", 324, 331], ["patients", "SPECIES", 177, 185], ["Amlodipine", "TREATMENT", 0, 10], ["lacidipine", "TREATMENT", 47, 57], ["both acetylcholine", "TREATMENT", 96, 114], ["bradykinin", "TREATMENT", 119, 129], ["Diabetes", "PROBLEM", 192, 200], ["inflammation", "PROBLEM", 205, 217], ["type 2 diabetes", "PROBLEM", 273, 288], ["oxidative stress", "PROBLEM", 335, 351], ["hypertension", "PROBLEM", 353, 365], ["dyslipidemia", "PROBLEM", 367, 379], ["atherosclerosis progression", "PROBLEM", 419, 446], ["regression", "PROBLEM", 451, 461], ["forearm", "ANATOMY", 141, 148], ["hypertensive", "OBSERVATION", 164, 176], ["inflammation", "OBSERVATION", 205, 217], ["type 2", "OBSERVATION_MODIFIER", 273, 279], ["diabetes", "OBSERVATION", 280, 288], ["vessels", "ANATOMY", 324, 331], ["hypertension", "OBSERVATION", 353, 365], ["dyslipidemia", "OBSERVATION", 367, 379], ["atherosclerosis", "OBSERVATION", 419, 434]]], ["In diabetes, endothelial cell dysfunction is of frequent occurrence (161) .", [["endothelial cell", "ANATOMY", 13, 29], ["diabetes", "DISEASE", 3, 11], ["endothelial cell dysfunction", "DISEASE", 13, 41], ["endothelial cell", "CELL", 13, 29], ["diabetes", "PROBLEM", 3, 11], ["endothelial cell dysfunction", "PROBLEM", 13, 41], ["diabetes", "OBSERVATION", 3, 11], ["endothelial cell dysfunction", "OBSERVATION", 13, 41]]], ["It is characterized by raised production of cytokines and adhesion molecules: altogether they initiate the inflammatory driven responses including leukocyte recruitment and platelet activation.", [["leukocyte", "ANATOMY", 147, 156], ["platelet", "ANATOMY", 173, 181], ["leukocyte", "CELL", 147, 156], ["platelet", "CELL", 173, 181], ["cytokines", "PROTEIN", 44, 53], ["adhesion molecules", "PROTEIN", 58, 76], ["cytokines and adhesion molecules", "PROBLEM", 44, 76], ["the inflammatory driven responses", "PROBLEM", 103, 136], ["leukocyte recruitment", "TREATMENT", 147, 168], ["platelet activation", "TEST", 173, 192], ["cytokines", "OBSERVATION", 44, 53], ["inflammatory", "OBSERVATION", 107, 119], ["leukocyte recruitment", "OBSERVATION", 147, 168], ["platelet activation", "OBSERVATION", 173, 192]]], ["Characteristic of diabetes is, in particular, the activation of the proteolytic enzymes known as matrix metalloproteinases (MMPs).", [["diabetes", "DISEASE", 18, 26], ["matrix metalloproteinases", "GENE_OR_GENE_PRODUCT", 97, 122], ["MMPs", "GENE_OR_GENE_PRODUCT", 124, 128], ["proteolytic enzymes", "PROTEIN", 68, 87], ["matrix metalloproteinases", "PROTEIN", 97, 122], ["MMPs", "PROTEIN", 124, 128], ["diabetes", "PROBLEM", 18, 26], ["the proteolytic enzymes", "TEST", 64, 87], ["diabetes", "OBSERVATION", 18, 26]]], ["MMP activity is regulated by the endogenous tissue inhibitor of metalloproteinases (TIMP).", [["MMP", "GENE_OR_GENE_PRODUCT", 0, 3], ["tissue inhibitor of metalloproteinases", "GENE_OR_GENE_PRODUCT", 44, 82], ["TIMP", "GENE_OR_GENE_PRODUCT", 84, 88], ["MMP", "PROTEIN", 0, 3], ["endogenous tissue inhibitor of metalloproteinases", "PROTEIN", 33, 82], ["TIMP", "PROTEIN", 84, 88], ["MMP activity", "PROBLEM", 0, 12], ["endogenous tissue", "OBSERVATION", 33, 50]]], ["MMPs mediate the retinal neuropathy and vasculopathy that are associated with diabetes (162) .Diabetes and inflammationHyperglycemia and elevated FFAs may promote inflammation by stimulating glucose utilization with altered oxidative phosphorylation.", [["retinal", "ANATOMY", 17, 24], ["retinal neuropathy", "DISEASE", 17, 35], ["vasculopathy", "DISEASE", 40, 52], ["diabetes", "DISEASE", 78, 86], ["Diabetes", "DISEASE", 94, 102], ["inflammation", "DISEASE", 107, 119], ["Hyperglycemia", "DISEASE", 119, 132], ["FFAs", "CHEMICAL", 146, 150], ["inflammation", "DISEASE", 163, 175], ["glucose", "CHEMICAL", 191, 198], ["glucose", "CHEMICAL", 191, 198], ["MMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["retinal", "MULTI-TISSUE_STRUCTURE", 17, 24], ["FFAs", "SIMPLE_CHEMICAL", 146, 150], ["glucose", "SIMPLE_CHEMICAL", 191, 198], ["MMPs", "PROTEIN", 0, 4], ["MMPs", "PROBLEM", 0, 4], ["the retinal neuropathy", "PROBLEM", 13, 35], ["vasculopathy", "PROBLEM", 40, 52], ["diabetes", "PROBLEM", 78, 86], ["Diabetes", "PROBLEM", 94, 102], ["inflammationHyperglycemia", "PROBLEM", 107, 132], ["elevated FFAs", "PROBLEM", 137, 150], ["inflammation", "PROBLEM", 163, 175], ["stimulating glucose utilization", "TREATMENT", 179, 210], ["altered oxidative phosphorylation", "PROBLEM", 216, 249], ["retinal", "ANATOMY", 17, 24], ["neuropathy", "OBSERVATION", 25, 35], ["vasculopathy", "OBSERVATION", 40, 52], ["inflammation", "OBSERVATION", 107, 119], ["inflammation", "OBSERVATION", 163, 175], ["oxidative phosphorylation", "OBSERVATION", 224, 249]]], ["This will induce a proinflammatory trait in macrophages in the adipose tissue and other tissues, including the vasculature (163) .", [["macrophages", "ANATOMY", 44, 55], ["adipose tissue", "ANATOMY", 63, 77], ["tissues", "ANATOMY", 88, 95], ["vasculature", "ANATOMY", 111, 122], ["macrophages", "CELL", 44, 55], ["adipose tissue", "TISSUE", 63, 77], ["tissues", "TISSUE", 88, 95], ["vasculature", "MULTI-TISSUE_STRUCTURE", 111, 122], ["macrophages", "CELL_TYPE", 44, 55], ["a proinflammatory trait in macrophages", "PROBLEM", 17, 55], ["proinflammatory trait", "OBSERVATION", 19, 40], ["macrophages", "OBSERVATION", 44, 55], ["adipose tissue", "ANATOMY", 63, 77], ["other tissues", "ANATOMY", 82, 95], ["vasculature", "ANATOMY", 111, 122]]], ["Glucotoxicity Among the molecular mechanisms underlying diabetes related inflammation is the reduction of fatty acid synthase (FAS).", [["Glucotoxicity", "DISEASE", 0, 13], ["diabetes", "DISEASE", 56, 64], ["inflammation", "DISEASE", 73, 85], ["fatty acid", "CHEMICAL", 106, 116], ["fatty acid", "CHEMICAL", 106, 116], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 106, 125], ["FAS", "GENE_OR_GENE_PRODUCT", 127, 130], ["fatty acid synthase", "PROTEIN", 106, 125], ["FAS", "PROTEIN", 127, 130], ["Glucotoxicity", "TREATMENT", 0, 13], ["diabetes related inflammation", "PROBLEM", 56, 85], ["fatty acid synthase", "TREATMENT", 106, 125], ["diabetes", "OBSERVATION", 56, 64], ["inflammation", "OBSERVATION", 73, 85], ["fatty acid", "OBSERVATION", 106, 116]]], ["FAS, a large molecule producing mainly palmitate, as well as other mainly saturated FFAs, is reduced in many tissues in diabetic models.", [["tissues", "ANATOMY", 109, 116], ["palmitate", "CHEMICAL", 39, 48], ["FFAs", "CHEMICAL", 84, 88], ["diabetic", "DISEASE", 120, 128], ["palmitate", "CHEMICAL", 39, 48], ["FAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["palmitate", "SIMPLE_CHEMICAL", 39, 48], ["FFAs", "SIMPLE_CHEMICAL", 84, 88], ["tissues", "TISSUE", 109, 116], ["FAS", "PROTEIN", 0, 3], ["FAS", "TEST", 0, 3], ["a large molecule producing mainly palmitate", "PROBLEM", 5, 48], ["other mainly saturated FFAs", "PROBLEM", 61, 88], ["large", "OBSERVATION_MODIFIER", 7, 12], ["molecule", "OBSERVATION", 13, 21], ["mainly", "OBSERVATION_MODIFIER", 32, 38], ["palmitate", "OBSERVATION_MODIFIER", 39, 48], ["saturated", "OBSERVATION_MODIFIER", 74, 83], ["FFAs", "OBSERVATION", 84, 88], ["reduced", "OBSERVATION_MODIFIER", 93, 100], ["many tissues", "OBSERVATION_MODIFIER", 104, 116], ["diabetic models", "OBSERVATION", 120, 135]]], ["Liver specific inactivation of FAS leads to fatty liver, hypoglycemia and enhanced insulin sensitivity a picture not different from models of the deficiency of the nuclear receptor PPAR\uf061 (166) .", [["Liver", "ANATOMY", 0, 5], ["fatty liver", "ANATOMY", 44, 55], ["nuclear", "ANATOMY", 164, 171], ["fatty liver", "DISEASE", 44, 55], ["hypoglycemia", "DISEASE", 57, 69], ["Liver", "ORGAN", 0, 5], ["FAS", "GENE_OR_GENE_PRODUCT", 31, 34], ["liver", "ORGAN", 50, 55], ["insulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["PPAR\uf061 (166)", "GENE_OR_GENE_PRODUCT", 181, 192], ["FAS", "PROTEIN", 31, 34], ["nuclear receptor PPAR", "PROTEIN", 164, 185], ["fatty liver", "PROBLEM", 44, 55], ["hypoglycemia", "PROBLEM", 57, 69], ["enhanced insulin sensitivity", "PROBLEM", 74, 102], ["the deficiency", "PROBLEM", 142, 156], ["fatty", "OBSERVATION_MODIFIER", 44, 49], ["liver", "ANATOMY", 50, 55], ["hypoglycemia", "OBSERVATION", 57, 69]]], ["FAS deficiency, in contrast, leads to protection from insulin resistance and with disrupted function of Cdc42, a member the RhoGTPase family, coordinating macrophage activation in target tissues (167) .", [["macrophage", "ANATOMY", 155, 165], ["tissues", "ANATOMY", 187, 194], ["FAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["insulin", "GENE_OR_GENE_PRODUCT", 54, 61], ["Cdc42", "GENE_OR_GENE_PRODUCT", 104, 109], ["RhoGTPase", "GENE_OR_GENE_PRODUCT", 124, 133], ["macrophage", "CELL", 155, 165], ["tissues", "TISSUE", 187, 194], ["FAS", "PROTEIN", 0, 3], ["Cdc42", "PROTEIN", 104, 109], ["RhoGTPase family", "PROTEIN", 124, 140], ["FAS deficiency", "PROBLEM", 0, 14], ["insulin resistance", "TREATMENT", 54, 72], ["deficiency", "OBSERVATION", 4, 14], ["insulin resistance", "OBSERVATION", 54, 72], ["macrophage activation", "OBSERVATION", 155, 176]]], ["Reduced activation is associated with altered phospholipid and protein composition, responsible for the inflammatory signaling (170) and other mechanism of activation of inflammasomes in macrophages.", [["macrophages", "ANATOMY", 187, 198], ["phospholipid", "SIMPLE_CHEMICAL", 46, 58], ["macrophages", "CELL", 187, 198], ["inflammasomes", "PROTEIN", 170, 183], ["macrophages", "CELL_TYPE", 187, 198], ["Reduced activation", "PROBLEM", 0, 18], ["altered phospholipid and protein composition", "PROBLEM", 38, 82], ["the inflammatory signaling", "PROBLEM", 100, 126], ["activation of inflammasomes in macrophages", "PROBLEM", 156, 198], ["protein composition", "OBSERVATION", 63, 82], ["inflammatory", "OBSERVATION_MODIFIER", 104, 116], ["inflammasomes", "OBSERVATION", 170, 183], ["macrophages", "OBSERVATION", 187, 198]]], ["FAS inhibition thus may lead to reduced atherosclerosis, less adiposity and reduced blood glucose in skeletal muscle.", [["blood", "ANATOMY", 84, 89], ["skeletal muscle", "ANATOMY", 101, 116], ["atherosclerosis", "DISEASE", 40, 55], ["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["FAS", "GENE_OR_GENE_PRODUCT", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["skeletal muscle", "TISSUE", 101, 116], ["FAS", "PROTEIN", 0, 3], ["FAS inhibition", "PROBLEM", 0, 14], ["reduced atherosclerosis", "PROBLEM", 32, 55], ["less adiposity", "PROBLEM", 57, 71], ["reduced blood glucose in skeletal muscle", "PROBLEM", 76, 116], ["may lead to", "UNCERTAINTY", 20, 31], ["reduced", "OBSERVATION_MODIFIER", 32, 39], ["atherosclerosis", "OBSERVATION", 40, 55], ["less", "OBSERVATION_MODIFIER", 57, 61], ["adiposity", "OBSERVATION", 62, 71], ["reduced", "OBSERVATION_MODIFIER", 76, 83], ["blood glucose", "OBSERVATION", 84, 97], ["skeletal muscle", "ANATOMY", 101, 116]]], ["This basic knowledge allows the evaluation of potential links between inflammation and antidiabetic drugs, active not only on glucose, but also on different steps in the diabetes related inflammatory process.Metformin.This compound is the most widely used glucose lowering drug, whose effects are believed to be mediated by activation of AMPK, a key regulator of energy homeostasis (171) .Metformin.Metformin directly inhibits the production of reactive oxygen species from complex I (NADH: ubiquinone oxido-reductase) of the mitochondrial electron transport chain.", [["mitochondrial", "ANATOMY", 526, 539], ["inflammation", "DISEASE", 70, 82], ["glucose", "CHEMICAL", 126, 133], ["diabetes", "DISEASE", 170, 178], ["Metformin", "CHEMICAL", 208, 217], ["glucose", "CHEMICAL", 256, 263], ["Metformin", "CHEMICAL", 389, 398], ["Metformin", "CHEMICAL", 399, 408], ["oxygen", "CHEMICAL", 454, 460], ["NADH", "CHEMICAL", 485, 489], ["glucose", "CHEMICAL", 126, 133], ["Metformin", "CHEMICAL", 208, 217], ["glucose", "CHEMICAL", 256, 263], ["Metformin", "CHEMICAL", 389, 398], ["Metformin", "CHEMICAL", 399, 408], ["oxygen", "CHEMICAL", 454, 460], ["NADH", "CHEMICAL", 485, 489], ["ubiquinone", "CHEMICAL", 491, 501], ["glucose", "SIMPLE_CHEMICAL", 126, 133], ["Metformin", "SIMPLE_CHEMICAL", 208, 217], ["glucose", "SIMPLE_CHEMICAL", 256, 263], ["AMPK", "GENE_OR_GENE_PRODUCT", 338, 342], ["Metformin", "SIMPLE_CHEMICAL", 389, 398], ["Metformin", "SIMPLE_CHEMICAL", 399, 408], ["reactive oxygen species", "SIMPLE_CHEMICAL", 445, 468], ["complex I", "GENE_OR_GENE_PRODUCT", 474, 483], ["NADH", "SIMPLE_CHEMICAL", 485, 489], ["ubiquinone oxido-reductase", "GENE_OR_GENE_PRODUCT", 491, 517], ["mitochondrial", "CELLULAR_COMPONENT", 526, 539], ["AMPK", "PROTEIN", 338, 342], ["complex I", "PROTEIN", 474, 483], ["NADH: ubiquinone oxido-reductase", "PROTEIN", 485, 517], ["mitochondrial electron transport chain", "PROTEIN", 526, 564], ["the evaluation", "TEST", 28, 42], ["inflammation", "PROBLEM", 70, 82], ["antidiabetic drugs", "TREATMENT", 87, 105], ["glucose", "TEST", 126, 133], ["the diabetes related inflammatory process", "PROBLEM", 166, 207], ["Metformin", "TREATMENT", 208, 217], ["glucose lowering drug", "TREATMENT", 256, 277], ["Metformin", "TREATMENT", 389, 398], ["Metformin", "TREATMENT", 399, 408], ["reactive oxygen species", "PROBLEM", 445, 468], ["ubiquinone oxido-reductase", "TREATMENT", 491, 517], ["the mitochondrial electron transport chain", "TREATMENT", 522, 564], ["diabetes", "OBSERVATION", 170, 178], ["inflammatory", "OBSERVATION", 187, 199], ["most widely", "OBSERVATION_MODIFIER", 239, 250], ["reactive", "OBSERVATION_MODIFIER", 445, 453], ["oxygen species", "OBSERVATION", 454, 468]]], ["Metformin inhibits the pro-form of the IL-1\uf062\uf020\uf020in lipopolysaccharide (LPS) activated macrophages while stimulating induction of the anti-inflammatory cytokine IL-10 (172).Metformin.In vascular endothelium, metformin inhibits monocyte-to-macrophage differentiation (173) .Metformin.While these effects in rodents are well established, in particular by reducing the proinflammatory and proapoptotic protein TXNIP in \uf062-cells and hepatocytes (174) , data in humans are not well clarified.", [["macrophages", "ANATOMY", 84, 95], ["vascular endothelium", "ANATOMY", 183, 203], ["monocyte", "ANATOMY", 224, 232], ["macrophage", "ANATOMY", 236, 246], ["\uf062-cells", "ANATOMY", 413, 420], ["hepatocytes", "ANATOMY", 425, 436], ["Metformin", "CHEMICAL", 0, 9], ["lipopolysaccharide", "CHEMICAL", 49, 67], ["LPS", "CHEMICAL", 69, 72], ["Metformin", "CHEMICAL", 170, 179], ["metformin", "CHEMICAL", 205, 214], ["Metformin", "CHEMICAL", 270, 279], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 170, 179], ["metformin", "CHEMICAL", 205, 214], ["Metformin", "CHEMICAL", 270, 279], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["IL-1\uf062\uf020\uf020in lipopolysaccharide", "GENE_OR_GENE_PRODUCT", 39, 67], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["macrophages", "CELL", 84, 95], ["IL-10", "GENE_OR_GENE_PRODUCT", 158, 163], ["Metformin", "SIMPLE_CHEMICAL", 170, 179], ["vascular endothelium", "TISSUE", 183, 203], ["metformin", "SIMPLE_CHEMICAL", 205, 214], ["monocyte", "CELL", 224, 232], ["macrophage", "CELL", 236, 246], ["Metformin", "SIMPLE_CHEMICAL", 270, 279], ["TXNIP", "GENE_OR_GENE_PRODUCT", 404, 409], ["\uf062-cells", "CELL", 413, 420], ["hepatocytes", "CELL", 425, 436], ["humans", "ORGANISM", 453, 459], ["IL-1\uf062\uf020\uf020in lipopolysaccharide (LPS) activated macrophages", "CELL_LINE", 39, 95], ["anti-inflammatory cytokine", "PROTEIN", 131, 157], ["IL", "PROTEIN", 158, 160], ["proinflammatory and proapoptotic protein", "PROTEIN", 363, 403], ["TXNIP", "PROTEIN", 404, 409], ["\uf062-cells", "CELL_TYPE", 413, 420], ["hepatocytes", "CELL_TYPE", 425, 436], ["humans", "SPECIES", 453, 459], ["humans", "SPECIES", 453, 459], ["Metformin", "TREATMENT", 0, 9], ["the IL-1\uf062\uf020\uf020in lipopolysaccharide (LPS) activated macrophages", "TREATMENT", 35, 95], ["the anti-inflammatory cytokine IL", "TREATMENT", 127, 160], ["Metformin", "TREATMENT", 170, 179], ["metformin", "TREATMENT", 205, 214], ["monocyte", "TEST", 224, 232], ["Metformin", "TREATMENT", 270, 279], ["proapoptotic protein TXNIP", "TEST", 383, 409], ["hepatocytes", "TEST", 425, 436], ["vascular endothelium", "ANATOMY", 183, 203], ["proinflammatory", "OBSERVATION_MODIFIER", 363, 378], ["proapoptotic protein TXNIP", "OBSERVATION", 383, 409], ["hepatocytes", "ANATOMY", 425, 436]]], ["Metformin appeared to reduce hsCRP to a modest extent in patients in the US Diabetes J o u r n a l P r e -p r o o f Prevention Program (175) .", [["Metformin", "CHEMICAL", 0, 9], ["Diabetes", "DISEASE", 76, 84], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["hsCRP", "GENE_OR_GENE_PRODUCT", 29, 34], ["patients", "ORGANISM", 57, 65], ["hsCRP", "PROTEIN", 29, 34], ["patients", "SPECIES", 57, 65], ["Metformin", "TREATMENT", 0, 9], ["hsCRP", "TEST", 29, 34], ["modest", "OBSERVATION_MODIFIER", 40, 46], ["extent", "OBSERVATION_MODIFIER", 47, 53]]], ["In the LANCET Trial (Long acting Insulin Injections to Reduce C-Reactive Protein in Patients with Type 2 Diabetes), metformin did not modify inflammatory markers in patients with recent onset type 2 diabetes (176) .", [["Type 2 Diabetes", "DISEASE", 98, 113], ["metformin", "CHEMICAL", 116, 125], ["type 2 diabetes", "DISEASE", 192, 207], ["metformin", "CHEMICAL", 116, 125], ["Insulin", "GENE_OR_GENE_PRODUCT", 33, 40], ["Patients", "ORGANISM", 84, 92], ["metformin", "SIMPLE_CHEMICAL", 116, 125], ["patients", "ORGANISM", 165, 173], ["inflammatory markers", "PROTEIN", 141, 161], ["Patients", "SPECIES", 84, 92], ["patients", "SPECIES", 165, 173], ["the LANCET Trial (Long acting Insulin Injections", "TREATMENT", 3, 51], ["C-Reactive Protein", "TREATMENT", 62, 80], ["Type 2 Diabetes)", "PROBLEM", 98, 114], ["metformin", "TREATMENT", 116, 125], ["inflammatory markers", "PROBLEM", 141, 161], ["recent onset type 2 diabetes", "PROBLEM", 179, 207], ["diabetes", "OBSERVATION", 199, 207]]], ["In recent years, exciting news have been provided on the potential beneficial effects of metformin in chronic inflammatory disorders and cancer, also extending lifespan independent of glucose metabolism (177).Sulphonylureas and thiazolidinediones.While losing clinical interest because of their high potential to induce hypoglycemia, sulphonylureas have been shown to exert potentially significant anti-inflammatory effects.", [["cancer", "ANATOMY", 137, 143], ["metformin", "CHEMICAL", 89, 98], ["inflammatory disorders", "DISEASE", 110, 132], ["cancer", "DISEASE", 137, 143], ["glucose", "CHEMICAL", 184, 191], ["Sulphonylureas", "CHEMICAL", 209, 223], ["thiazolidinediones", "CHEMICAL", 228, 246], ["hypoglycemia", "DISEASE", 320, 332], ["sulphonylureas", "CHEMICAL", 334, 348], ["metformin", "CHEMICAL", 89, 98], ["glucose", "CHEMICAL", 184, 191], ["Sulphonylureas", "CHEMICAL", 209, 223], ["thiazolidinediones", "CHEMICAL", 228, 246], ["sulphonylureas", "CHEMICAL", 334, 348], ["metformin", "SIMPLE_CHEMICAL", 89, 98], ["cancer", "CANCER", 137, 143], ["glucose", "SIMPLE_CHEMICAL", 184, 191], ["Sulphonylureas", "SIMPLE_CHEMICAL", 209, 223], ["thiazolidinediones", "SIMPLE_CHEMICAL", 228, 246], ["sulphonylureas", "SIMPLE_CHEMICAL", 334, 348], ["metformin", "TREATMENT", 89, 98], ["chronic inflammatory disorders", "PROBLEM", 102, 132], ["cancer", "PROBLEM", 137, 143], ["glucose metabolism", "TEST", 184, 202], ["Sulphonylureas", "TREATMENT", 209, 223], ["thiazolidinediones", "TREATMENT", 228, 246], ["hypoglycemia", "PROBLEM", 320, 332], ["sulphonylureas", "TREATMENT", 334, 348], ["significant anti-inflammatory effects", "PROBLEM", 386, 423], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["inflammatory", "OBSERVATION", 110, 122], ["cancer", "OBSERVATION", 137, 143], ["anti-inflammatory effects", "OBSERVATION", 398, 423]]], ["Glyburide appears to inhibit the NLRP3 inflammasome and the subsequent IL-1\uf062\uf020activation in macrophages (178) .", [["macrophages", "ANATOMY", 91, 102], ["Glyburide", "CHEMICAL", 0, 9], ["Glyburide", "CHEMICAL", 0, 9], ["Glyburide", "SIMPLE_CHEMICAL", 0, 9], ["NLRP3", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL-1\uf062\uf020activation", "GENE_OR_GENE_PRODUCT", 71, 87], ["macrophages", "CELL", 91, 102], ["NLRP3", "PROTEIN", 33, 38], ["IL", "PROTEIN", 71, 73], ["macrophages", "CELL_TYPE", 91, 102], ["Glyburide", "TREATMENT", 0, 9], ["the NLRP3 inflammasome", "PROBLEM", 29, 51], ["the subsequent IL-1\uf062\uf020activation in macrophages", "TREATMENT", 56, 102], ["NLRP3 inflammasome", "OBSERVATION", 33, 51], ["macrophages", "ANATOMY", 91, 102]]], ["Gliclazide seems to exert a similar effect, i.e. reduced endothelial dysfunction in type 2 diabetes patients (179) .", [["endothelial", "ANATOMY", 57, 68], ["Gliclazide", "CHEMICAL", 0, 10], ["endothelial dysfunction", "DISEASE", 57, 80], ["type 2 diabetes", "DISEASE", 84, 99], ["Gliclazide", "CHEMICAL", 0, 10], ["Gliclazide", "SIMPLE_CHEMICAL", 0, 10], ["endothelial", "CELL", 57, 68], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["Gliclazide", "TREATMENT", 0, 10], ["reduced endothelial dysfunction", "PROBLEM", 49, 80], ["type 2 diabetes patients", "PROBLEM", 84, 108], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["endothelial dysfunction", "OBSERVATION", 57, 80]]], ["In clinical trials, however, sulphonylureas did not appear to exert a significant influence on hsCRP levels, whereas reductions were found after treatment with the thiazolidinediones (TZDs) (180) .Sulphonylureas and thiazolidinediones.TZDs are PPAR\uf067\uf020agonists that increase insulin sensitivity.", [["sulphonylureas", "CHEMICAL", 29, 43], ["TZDs", "CHEMICAL", 184, 188], ["Sulphonylureas", "CHEMICAL", 197, 211], ["thiazolidinediones", "CHEMICAL", 216, 234], ["TZDs", "CHEMICAL", 235, 239], ["sulphonylureas", "CHEMICAL", 29, 43], ["thiazolidinediones", "CHEMICAL", 164, 182], ["TZDs", "CHEMICAL", 184, 188], ["Sulphonylureas", "CHEMICAL", 197, 211], ["thiazolidinediones", "CHEMICAL", 216, 234], ["sulphonylureas", "SIMPLE_CHEMICAL", 29, 43], ["hsCRP", "GENE_OR_GENE_PRODUCT", 95, 100], ["thiazolidinediones", "SIMPLE_CHEMICAL", 164, 182], ["TZDs", "SIMPLE_CHEMICAL", 184, 188], ["Sulphonylureas", "SIMPLE_CHEMICAL", 197, 211], ["thiazolidinediones", "SIMPLE_CHEMICAL", 216, 234], ["TZDs", "SIMPLE_CHEMICAL", 235, 239], ["PPAR\uf067", "GENE_OR_GENE_PRODUCT", 244, 249], ["insulin", "GENE_OR_GENE_PRODUCT", 273, 280], ["hsCRP", "PROTEIN", 95, 100], ["PPAR", "PROTEIN", 244, 248], ["sulphonylureas", "TREATMENT", 29, 43], ["hsCRP levels", "TEST", 95, 107], ["the thiazolidinediones (TZDs", "TREATMENT", 160, 188], ["Sulphonylureas", "TREATMENT", 197, 211], ["thiazolidinediones", "TREATMENT", 216, 234], ["TZDs", "TEST", 235, 239], ["PPAR\uf067\uf020agonists", "TREATMENT", 244, 258], ["insulin sensitivity", "TEST", 273, 292], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["influence", "OBSERVATION", 82, 91]]], ["There is experimental evidence that PPAR\uf067\uf020and AMPK are both targets of TZD with consequent significant anti-inflammatory effects in liver and adipose tissue (181) .", [["liver", "ANATOMY", 132, 137], ["adipose tissue", "ANATOMY", 142, 156], ["TZD", "CHEMICAL", 71, 74], ["TZD", "CHEMICAL", 71, 74], ["PPAR\uf067\uf020and AMPK", "GENE_OR_GENE_PRODUCT", 36, 50], ["TZD", "SIMPLE_CHEMICAL", 71, 74], ["liver", "ORGAN", 132, 137], ["adipose tissue", "TISSUE", 142, 156], ["PPAR", "PROTEIN", 36, 40], ["AMPK", "PROTEIN", 46, 50], ["TZD", "TREATMENT", 71, 74], ["consequent significant anti-inflammatory effects in liver and adipose tissue", "PROBLEM", 80, 156], ["significant", "OBSERVATION_MODIFIER", 91, 102], ["anti-inflammatory effects", "OBSERVATION", 103, 128], ["liver", "ANATOMY", 132, 137], ["adipose tissue", "ANATOMY", 142, 156]]], ["Pioglitazone treatment may thus reduce infiltration of adipose tissue by proinflammatory macrophages, leading to improved hepatic and peripheral insulin sensitivity, potentially exerting an ameliorating effect on liver histology in patients with NASH (182) .Sulphonylureas and thiazolidinediones.Treatment with TZDs, in addition to improving endothelial function, can significant reduce hsCRP levels in people with and without diabetes irrespective of glycemic effects (183) .", [["adipose tissue", "ANATOMY", 55, 69], ["macrophages", "ANATOMY", 89, 100], ["hepatic", "ANATOMY", 122, 129], ["liver", "ANATOMY", 213, 218], ["endothelial", "ANATOMY", 342, 353], ["Pioglitazone", "CHEMICAL", 0, 12], ["NASH", "DISEASE", 246, 250], ["Sulphonylureas", "CHEMICAL", 258, 272], ["thiazolidinediones", "CHEMICAL", 277, 295], ["TZDs", "CHEMICAL", 311, 315], ["diabetes", "DISEASE", 427, 435], ["Pioglitazone", "CHEMICAL", 0, 12], ["Sulphonylureas", "CHEMICAL", 258, 272], ["thiazolidinediones", "CHEMICAL", 277, 295], ["Pioglitazone", "SIMPLE_CHEMICAL", 0, 12], ["adipose tissue", "TISSUE", 55, 69], ["macrophages", "CELL", 89, 100], ["hepatic", "MULTI-TISSUE_STRUCTURE", 122, 129], ["insulin", "GENE_OR_GENE_PRODUCT", 145, 152], ["liver", "ORGAN", 213, 218], ["patients", "ORGANISM", 232, 240], ["Sulphonylureas", "SIMPLE_CHEMICAL", 258, 272], ["thiazolidinediones", "SIMPLE_CHEMICAL", 277, 295], ["TZDs", "SIMPLE_CHEMICAL", 311, 315], ["endothelial", "CELL", 342, 353], ["hsCRP", "GENE_OR_GENE_PRODUCT", 387, 392], ["people", "ORGANISM", 403, 409], ["proinflammatory macrophages", "CELL_TYPE", 73, 100], ["hsCRP", "PROTEIN", 387, 392], ["patients", "SPECIES", 232, 240], ["people", "SPECIES", 403, 409], ["Pioglitazone treatment", "TREATMENT", 0, 22], ["infiltration of adipose tissue", "PROBLEM", 39, 69], ["proinflammatory macrophages", "PROBLEM", 73, 100], ["improved hepatic and peripheral insulin sensitivity", "PROBLEM", 113, 164], ["liver histology", "TEST", 213, 228], ["NASH", "PROBLEM", 246, 250], ["Sulphonylureas", "TREATMENT", 258, 272], ["thiazolidinediones", "TREATMENT", 277, 295], ["TZDs", "TREATMENT", 311, 315], ["improving endothelial function", "PROBLEM", 332, 362], ["hsCRP levels", "TEST", 387, 399], ["diabetes", "PROBLEM", 427, 435], ["glycemic effects", "PROBLEM", 452, 468], ["adipose tissue", "OBSERVATION", 55, 69], ["proinflammatory macrophages", "OBSERVATION", 73, 100], ["improved", "OBSERVATION_MODIFIER", 113, 121], ["hepatic", "ANATOMY", 122, 129], ["peripheral", "ANATOMY_MODIFIER", 134, 144], ["insulin sensitivity", "OBSERVATION", 145, 164], ["ameliorating", "OBSERVATION_MODIFIER", 190, 202], ["liver", "ANATOMY", 213, 218], ["histology", "OBSERVATION", 219, 228], ["NASH", "OBSERVATION", 246, 250]]], ["The apparent anti-inflammatory activity of PPAR\uf067\uf020agonists may be possibly related to the novel observation of their interaction with NLRC5, inhibiting vascular neointima formation (22).", [["vascular neointima", "ANATOMY", 151, 169], ["PPAR\uf067\uf020agonists", "GENE_OR_GENE_PRODUCT", 43, 57], ["NLRC5", "GENE_OR_GENE_PRODUCT", 133, 138], ["vascular neointima", "TISSUE", 151, 169], ["PPAR", "PROTEIN", 43, 47], ["NLRC5", "PROTEIN", 133, 138], ["NLRC5", "TREATMENT", 133, 138], ["inhibiting vascular neointima formation", "PROBLEM", 140, 179], ["anti-inflammatory activity", "OBSERVATION", 13, 39], ["may be possibly related to", "UNCERTAINTY", 58, 84], ["vascular neointima", "ANATOMY", 151, 169]]], ["The reduced hsCRP and increased HDL-C after pioglitazone treatment may explain the observed consequent reduction in CV morbidity (184).", [["pioglitazone", "CHEMICAL", 44, 56], ["pioglitazone", "CHEMICAL", 44, 56], ["hsCRP", "GENE_OR_GENE_PRODUCT", 12, 17], ["HDL-C", "SIMPLE_CHEMICAL", 32, 37], ["pioglitazone", "SIMPLE_CHEMICAL", 44, 56], ["hsCRP", "PROTEIN", 12, 17], ["HDL", "PROTEIN", 32, 35], ["The reduced hsCRP", "PROBLEM", 0, 17], ["increased HDL", "TREATMENT", 22, 35], ["pioglitazone treatment", "TREATMENT", 44, 66], ["consequent reduction in CV morbidity", "PROBLEM", 92, 128], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["hsCRP", "OBSERVATION", 12, 17], ["consequent", "OBSERVATION_MODIFIER", 92, 102], ["reduction", "OBSERVATION_MODIFIER", 103, 112], ["CV morbidity", "OBSERVATION", 116, 128]]], ["Both drug classes have given substantial evidence of improving a variety of CV risk factors as well as inflammation.", [["inflammation", "DISEASE", 103, 115], ["CV risk factors", "PROBLEM", 76, 91], ["inflammation", "PROBLEM", 103, 115], ["inflammation", "OBSERVATION", 103, 115]]], ["In particular DPP-IV inhibitors can suppress NLRP3, TLR4 and IL-1\uf062\uf020 expression in macrophages (189) .", [["macrophages", "ANATOMY", 82, 93], ["DPP-IV", "GENE_OR_GENE_PRODUCT", 14, 20], ["NLRP3", "GENE_OR_GENE_PRODUCT", 45, 50], ["TLR4", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-1\uf062\uf020", "GENE_OR_GENE_PRODUCT", 61, 67], ["macrophages", "CELL", 82, 93], ["NLRP3", "PROTEIN", 45, 50], ["TLR4", "PROTEIN", 52, 56], ["macrophages", "CELL_TYPE", 82, 93], ["IV inhibitors", "TREATMENT", 18, 31], ["NLRP3", "PROBLEM", 45, 50], ["TLR4", "TEST", 52, 56], ["IL", "TEST", 61, 63], ["macrophages", "ANATOMY", 82, 93]]], ["They can also reduce mRNA expression of CD26, TNF-\uf061, proinflammatory kinases, and chemokine receptor CCR2, as well as plasma hsCRP, IL-6 and FFA (190) .", [["plasma", "ANATOMY", 118, 124], ["CD26", "GENE_OR_GENE_PRODUCT", 40, 44], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 46, 51], ["CCR2", "GENE_OR_GENE_PRODUCT", 101, 105], ["plasma", "ORGANISM_SUBSTANCE", 118, 124], ["hsCRP", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-6", "GENE_OR_GENE_PRODUCT", 132, 136], ["FFA", "SIMPLE_CHEMICAL", 141, 144], ["CD26", "PROTEIN", 40, 44], ["TNF", "PROTEIN", 46, 49], ["proinflammatory kinases", "PROTEIN", 53, 76], ["chemokine receptor", "PROTEIN", 82, 100], ["CCR2", "PROTEIN", 101, 105], ["plasma hsCRP", "PROTEIN", 118, 130], ["IL", "PROTEIN", 132, 134], ["mRNA expression", "TEST", 21, 36], ["CD26", "TEST", 40, 44], ["TNF", "TEST", 46, 49], ["proinflammatory kinases", "TEST", 53, 76], ["chemokine receptor CCR2", "TEST", 82, 105], ["plasma hsCRP", "TEST", 118, 130], ["IL", "TEST", 132, 134], ["FFA", "TEST", 141, 144]]], ["In a clinical study evaluating endothelial dysfunction and inflammation in patients with type 2 diabetes treated with sitagliptin, there was clear evidence of reduced levels of markers including hsCRP, L-6, IL-1\uf062\uf020 phospholipase-A2, ICAM-1 and E selectin (191) .Incretins and incretin drugs.The case of GLP-1R agonists has provided somewhat similar findings in the lipid profile but also in statistically significant reductions of markers including hsCRP, brain natriuretic peptide and PAI-1 (192) .", [["endothelial", "ANATOMY", 31, 42], ["endothelial dysfunction", "DISEASE", 31, 54], ["inflammation", "DISEASE", 59, 71], ["type 2 diabetes", "DISEASE", 89, 104], ["sitagliptin", "CHEMICAL", 118, 129], ["Incretins", "CHEMICAL", 261, 270], ["sitagliptin", "CHEMICAL", 118, 129], ["Incretins", "CHEMICAL", 261, 270], ["endothelial", "CELL", 31, 42], ["patients", "ORGANISM", 75, 83], ["sitagliptin", "SIMPLE_CHEMICAL", 118, 129], ["hsCRP", "GENE_OR_GENE_PRODUCT", 195, 200], ["L-6", "GENE_OR_GENE_PRODUCT", 202, 205], ["IL-1", "GENE_OR_GENE_PRODUCT", 207, 211], ["phospholipase-A2", "GENE_OR_GENE_PRODUCT", 214, 230], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 232, 238], ["E selectin", "GENE_OR_GENE_PRODUCT", 243, 253], ["Incretins", "SIMPLE_CHEMICAL", 261, 270], ["incretin drugs", "SIMPLE_CHEMICAL", 275, 289], ["GLP-1R", "GENE_OR_GENE_PRODUCT", 302, 308], ["hsCRP", "GENE_OR_GENE_PRODUCT", 448, 453], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 455, 480], ["PAI-1", "GENE_OR_GENE_PRODUCT", 485, 490], ["hsCRP", "PROTEIN", 195, 200], ["L-6, IL-1\uf062\uf020 phospholipase-A2", "PROTEIN", 202, 230], ["ICAM", "PROTEIN", 232, 236], ["E selectin", "PROTEIN", 243, 253], ["hsCRP", "PROTEIN", 448, 453], ["patients", "SPECIES", 75, 83], ["a clinical study", "TEST", 3, 19], ["endothelial dysfunction", "PROBLEM", 31, 54], ["inflammation", "PROBLEM", 59, 71], ["type 2 diabetes", "PROBLEM", 89, 104], ["sitagliptin", "TREATMENT", 118, 129], ["reduced levels of markers", "PROBLEM", 159, 184], ["hsCRP", "TEST", 195, 200], ["L", "TEST", 202, 203], ["IL", "TEST", 207, 209], ["phospholipase", "TEST", 214, 227], ["ICAM", "TEST", 232, 236], ["E selectin", "TEST", 243, 253], ["Incretins and incretin drugs", "TREATMENT", 261, 289], ["the lipid profile", "TEST", 360, 377], ["hsCRP", "TEST", 448, 453], ["brain natriuretic peptide", "TEST", 455, 480], ["PAI", "TEST", 485, 488], ["inflammation", "OBSERVATION", 59, 71]]], ["Balestrieri et al. tested the anti-inflammatory activity in diabetic atherosclerotic plaques, reporting that plaques from incretin-treated type 2 diabetic patients are characterized by increased collagen content, raised sirtuin-6 expression and inhibited inflammatory response with reduced numbers of macrophages, T cells and lower expression of MMP-9 and TNF\uf061 (193) .Incretins and incretin drugs.Incretin drugs, particularly GLP-1RAs, although effective on glycemia and well tolerated, have not generally provided consistent reductions in CV events.", [["atherosclerotic plaques", "ANATOMY", 69, 92], ["plaques", "ANATOMY", 109, 116], ["macrophages", "ANATOMY", 301, 312], ["T cells", "ANATOMY", 314, 321], ["diabetic atherosclerotic plaques", "DISEASE", 60, 92], ["plaques", "DISEASE", 109, 116], ["diabetic", "DISEASE", 146, 154], ["Incretins", "CHEMICAL", 368, 377], ["Incretins", "CHEMICAL", 368, 377], ["atherosclerotic plaques", "PATHOLOGICAL_FORMATION", 69, 92], ["incretin", "SIMPLE_CHEMICAL", 122, 130], ["patients", "ORGANISM", 155, 163], ["collagen", "GENE_OR_GENE_PRODUCT", 195, 203], ["sirtuin-6", "GENE_OR_GENE_PRODUCT", 220, 229], ["macrophages", "CELL", 301, 312], ["T cells", "CELL", 314, 321], ["MMP-9", "GENE_OR_GENE_PRODUCT", 346, 351], ["TNF\uf061 (193)", "GENE_OR_GENE_PRODUCT", 356, 366], ["Incretins", "SIMPLE_CHEMICAL", 368, 377], ["incretin drugs", "SIMPLE_CHEMICAL", 382, 396], ["Incretin", "SIMPLE_CHEMICAL", 397, 405], ["GLP-1RAs", "GENE_OR_GENE_PRODUCT", 426, 434], ["collagen", "PROTEIN", 195, 203], ["sirtuin-6", "PROTEIN", 220, 229], ["macrophages", "CELL_TYPE", 301, 312], ["T cells", "CELL_TYPE", 314, 321], ["MMP-9", "PROTEIN", 346, 351], ["TNF", "PROTEIN", 356, 359], ["patients", "SPECIES", 155, 163], ["diabetic atherosclerotic plaques", "PROBLEM", 60, 92], ["plaques", "PROBLEM", 109, 116], ["incretin-treated type 2 diabetic patients", "PROBLEM", 122, 163], ["increased collagen content", "PROBLEM", 185, 211], ["inflammatory response", "PROBLEM", 255, 276], ["reduced numbers of macrophages", "PROBLEM", 282, 312], ["T cells", "PROBLEM", 314, 321], ["MMP", "TEST", 346, 349], ["TNF", "TEST", 356, 359], ["Incretins and incretin drugs", "TREATMENT", 368, 396], ["Incretin drugs", "TREATMENT", 397, 411], ["CV events", "PROBLEM", 540, 549], ["anti-inflammatory activity", "OBSERVATION", 30, 56], ["diabetic", "OBSERVATION_MODIFIER", 60, 68], ["atherosclerotic", "OBSERVATION_MODIFIER", 69, 84], ["plaques", "OBSERVATION", 85, 92], ["plaques", "OBSERVATION", 109, 116], ["increased", "OBSERVATION_MODIFIER", 185, 194], ["collagen content", "OBSERVATION", 195, 211], ["inflammatory", "OBSERVATION_MODIFIER", 255, 267]]], ["In the case of DPP-4 inhibitors outcome trials, the three-point MACE evaluation of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial with liraglutide reported significant reductions of events at all ages with somewhat reduced efficacy in individuals \uf0b3 60y (194) .", [["Cardiovascular", "ANATOMY", 152, 166], ["Liraglutide", "CHEMICAL", 95, 106], ["Diabetes", "DISEASE", 128, 136], ["liraglutide", "CHEMICAL", 195, 206], ["Liraglutide", "CHEMICAL", 95, 106], ["DPP-4", "GENE_OR_GENE_PRODUCT", 15, 20], ["liraglutide", "SIMPLE_CHEMICAL", 195, 206], ["DPP-4 inhibitors outcome trials", "TREATMENT", 15, 46], ["MACE evaluation", "TEST", 64, 79], ["the LEADER (Liraglutide Effect", "TREATMENT", 83, 113], ["liraglutide", "TREATMENT", 195, 206], ["significant reductions of events", "PROBLEM", 216, 248], ["somewhat reduced efficacy in individuals", "PROBLEM", 266, 306]]], ["The SUSTAIN trial with semaglutide with a similar design again resulted in a significant reduction of three-point MACEs with no differences between younger and older patients (195) .Sodium Glucose Cotransporter 2 Inhibitors (SLGT2).In all clinical trials, SGLT2 have consistently shown a CV benefit, both in younger and older individuals.", [["semaglutide", "CHEMICAL", 23, 34], ["Sodium Glucose", "CHEMICAL", 182, 196], ["semaglutide", "CHEMICAL", 23, 34], ["Sodium Glucose", "CHEMICAL", 182, 196], ["semaglutide", "SIMPLE_CHEMICAL", 23, 34], ["patients", "ORGANISM", 166, 174], ["Sodium Glucose Cotransporter 2", "GENE_OR_GENE_PRODUCT", 182, 212], ["SLGT2", "SIMPLE_CHEMICAL", 225, 230], ["SGLT2", "GENE_OR_GENE_PRODUCT", 256, 261], ["SGLT2", "PROTEIN", 256, 261], ["patients", "SPECIES", 166, 174], ["semaglutide", "TREATMENT", 23, 34], ["Sodium Glucose Cotransporter", "TREATMENT", 182, 210], ["Inhibitors (SLGT2)", "TREATMENT", 213, 231], ["SGLT2", "TEST", 256, 261], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["reduction", "OBSERVATION_MODIFIER", 89, 98], ["no", "UNCERTAINTY", 125, 127]]], ["Very interestingly, in the case of empagliflozin (EMPA-REG Trial) and canagliflozin (CANVAS Trial) (196, 197) , CV event reduction was not only of the ischemic type but, more frequently, consequent to reduced heart failure.", [["heart", "ANATOMY", 209, 214], ["empagliflozin", "CHEMICAL", 35, 48], ["EMPA", "CHEMICAL", 50, 54], ["canagliflozin", "CHEMICAL", 70, 83], ["heart failure", "DISEASE", 209, 222], ["empagliflozin", "CHEMICAL", 35, 48], ["EMPA", "CHEMICAL", 50, 54], ["canagliflozin", "CHEMICAL", 70, 83], ["empagliflozin", "SIMPLE_CHEMICAL", 35, 48], ["EMPA", "SIMPLE_CHEMICAL", 50, 54], ["canagliflozin", "SIMPLE_CHEMICAL", 70, 83], ["heart", "ORGAN", 209, 214], ["empagliflozin", "TREATMENT", 35, 48], ["EMPA-REG Trial)", "TREATMENT", 50, 65], ["canagliflozin", "TREATMENT", 70, 83], ["CV event reduction", "PROBLEM", 112, 130], ["the ischemic type", "PROBLEM", 147, 164], ["reduced heart failure", "PROBLEM", 201, 222], ["ischemic", "OBSERVATION", 151, 159], ["reduced", "OBSERVATION_MODIFIER", 201, 208], ["heart", "ANATOMY", 209, 214], ["failure", "OBSERVATION", 215, 222]]], ["These impressive results on heart failure are the object of intensive investigation and the recently J o u r n a l P r e -p r o o f completed DECLARE TIMI 58 with dapagliflozin confirmed the improvement of the heart failure endpoint but no clear benefit on MACE endpoints (198) .", [["heart", "ANATOMY", 28, 33], ["heart", "ANATOMY", 210, 215], ["heart failure", "DISEASE", 28, 41], ["dapagliflozin", "CHEMICAL", 163, 176], ["heart failure", "DISEASE", 210, 223], ["dapagliflozin", "CHEMICAL", 163, 176], ["heart", "ORGAN", 28, 33], ["dapagliflozin", "SIMPLE_CHEMICAL", 163, 176], ["heart", "ORGAN", 210, 215], ["heart failure", "PROBLEM", 28, 41], ["intensive investigation", "TEST", 60, 83], ["TIMI", "TEST", 150, 154], ["dapagliflozin", "TREATMENT", 163, 176], ["the heart failure endpoint", "PROBLEM", 206, 232], ["MACE endpoints", "TEST", 257, 271], ["heart", "ANATOMY", 28, 33], ["failure", "OBSERVATION", 34, 41], ["heart", "ANATOMY", 210, 215], ["failure", "OBSERVATION", 216, 223], ["no", "UNCERTAINTY", 237, 239]]], ["The significant reduction in hospitalizations for heart failure and progression of renal disease have not found a clear support from changes in the inflammatory profile in earlier studies with the SGLT inhibitor phlorizin in obese gerbils, where only decreased islet inflammation, possibly related to reduced glucose toxicity, was detected (199) .", [["heart", "ANATOMY", 50, 55], ["renal", "ANATOMY", 83, 88], ["islet", "ANATOMY", 261, 266], ["heart failure", "DISEASE", 50, 63], ["renal disease", "DISEASE", 83, 96], ["phlorizin", "CHEMICAL", 212, 221], ["islet inflammation", "DISEASE", 261, 279], ["glucose", "CHEMICAL", 309, 316], ["toxicity", "DISEASE", 317, 325], ["phlorizin", "CHEMICAL", 212, 221], ["glucose", "CHEMICAL", 309, 316], ["heart", "ORGAN", 50, 55], ["renal", "ORGAN", 83, 88], ["SGLT", "GENE_OR_GENE_PRODUCT", 197, 201], ["phlorizin", "SIMPLE_CHEMICAL", 212, 221], ["gerbils", "ORGANISM", 231, 238], ["islet", "MULTI-TISSUE_STRUCTURE", 261, 266], ["glucose", "SIMPLE_CHEMICAL", 309, 316], ["heart failure", "PROBLEM", 50, 63], ["renal disease", "PROBLEM", 83, 96], ["the inflammatory profile", "PROBLEM", 144, 168], ["earlier studies", "TEST", 172, 187], ["the SGLT inhibitor phlorizin", "TREATMENT", 193, 221], ["obese gerbils", "PROBLEM", 225, 238], ["decreased islet inflammation", "PROBLEM", 251, 279], ["reduced glucose toxicity", "PROBLEM", 301, 325], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["heart", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63], ["progression", "OBSERVATION_MODIFIER", 68, 79], ["renal", "ANATOMY", 83, 88], ["disease", "OBSERVATION", 89, 96], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["obese gerbils", "OBSERVATION", 225, 238], ["decreased", "OBSERVATION_MODIFIER", 251, 260], ["islet inflammation", "OBSERVATION", 261, 279], ["possibly related to", "UNCERTAINTY", 281, 300], ["reduced", "OBSERVATION_MODIFIER", 301, 308], ["glucose toxicity", "OBSERVATION", 309, 325]]], ["Similarly, in mice with type 2 diabetes, the SGLT2 inhibitor empaglifozin, in addition to positive changes in hyperglycemia and hyperlipidemia reduced markers of inflammation (IL-6, TNF-\uf061\uf02c MCP-1 and CRP levels) (200) .", [["type 2 diabetes", "DISEASE", 24, 39], ["empaglifozin", "CHEMICAL", 61, 73], ["hyperglycemia", "DISEASE", 110, 123], ["hyperlipidemia", "DISEASE", 128, 142], ["inflammation", "DISEASE", 162, 174], ["empaglifozin", "CHEMICAL", 61, 73], ["mice", "ORGANISM", 14, 18], ["SGLT2", "GENE_OR_GENE_PRODUCT", 45, 50], ["empaglifozin", "SIMPLE_CHEMICAL", 61, 73], ["IL-6", "GENE_OR_GENE_PRODUCT", 176, 180], ["TNF-\uf061\uf02c MCP-1", "GENE_OR_GENE_PRODUCT", 182, 194], ["CRP", "GENE_OR_GENE_PRODUCT", 199, 202], ["TNF", "PROTEIN", 182, 185], ["MCP", "PROTEIN", 189, 192], ["CRP", "PROTEIN", 199, 202], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["type 2 diabetes", "PROBLEM", 24, 39], ["the SGLT2 inhibitor empaglifozin", "TREATMENT", 41, 73], ["positive changes in hyperglycemia", "PROBLEM", 90, 123], ["hyperlipidemia", "PROBLEM", 128, 142], ["inflammation", "PROBLEM", 162, 174], ["IL", "TEST", 176, 178], ["TNF", "TEST", 182, 185], ["MCP", "TEST", 189, 192], ["CRP levels", "TEST", 199, 209], ["diabetes", "OBSERVATION", 31, 39], ["hyperglycemia", "OBSERVATION", 110, 123], ["hyperlipidemia", "OBSERVATION_MODIFIER", 128, 142], ["reduced", "OBSERVATION_MODIFIER", 143, 150], ["inflammation", "OBSERVATION_MODIFIER", 162, 174]]], ["In the same experimental model, no data on inflammation were reported with canagliflozin (201) .Sodium Glucose Cotransporter 2 Inhibitors (SLGT2).Data of this type have not been made available in the cardiovascular outcome trials with empaglifozin and canagliflozin (202) .", [["cardiovascular", "ANATOMY", 200, 214], ["inflammation", "DISEASE", 43, 55], ["canagliflozin", "CHEMICAL", 75, 88], ["Sodium Glucose", "CHEMICAL", 96, 110], ["empaglifozin", "CHEMICAL", 235, 247], ["canagliflozin", "CHEMICAL", 252, 265], ["canagliflozin", "CHEMICAL", 75, 88], ["Sodium Glucose", "CHEMICAL", 96, 110], ["empaglifozin", "CHEMICAL", 235, 247], ["canagliflozin", "CHEMICAL", 252, 265], ["canagliflozin", "SIMPLE_CHEMICAL", 75, 88], ["Sodium Glucose Cotransporter 2", "GENE_OR_GENE_PRODUCT", 96, 126], ["SLGT2", "SIMPLE_CHEMICAL", 139, 144], ["empaglifozin", "SIMPLE_CHEMICAL", 235, 247], ["canagliflozin", "SIMPLE_CHEMICAL", 252, 265], ["inflammation", "PROBLEM", 43, 55], ["canagliflozin", "TREATMENT", 75, 88], ["Sodium Glucose Cotransporter", "TREATMENT", 96, 124], ["Inhibitors (SLGT2)", "TREATMENT", 127, 145], ["empaglifozin", "TREATMENT", 235, 247], ["canagliflozin", "TREATMENT", 252, 265], ["no", "UNCERTAINTY", 32, 34], ["inflammation", "OBSERVATION", 43, 55]]], ["The DECLARE TIMI 58 study (198) with dapagliflozin did not provide data on inflammation.", [["dapagliflozin", "CHEMICAL", 37, 50], ["inflammation", "DISEASE", 75, 87], ["dapagliflozin", "CHEMICAL", 37, 50], ["dapagliflozin", "SIMPLE_CHEMICAL", 37, 50], ["TIMI 58 study", "TEST", 12, 25], ["dapagliflozin", "TREATMENT", 37, 50], ["inflammation", "PROBLEM", 75, 87], ["inflammation", "OBSERVATION", 75, 87]]], ["While expecting clinical data from the CREDENCE Study with canagliflozin (203) , attempting to establish inflammatory biomarker changes, a number of exploratory data have been provided with SLGT2 inhibitors mainly on short-term evaluations.Sodium Glucose Cotransporter 2 Inhibitors (SLGT2).Reduction in leptin levels and increased adiponectin are generally reported as well as modest reductions in hsCRP TNF-\uf061, IL-6 and IF\uf04e\uf067 with canagliflozin, dapagliflozin and empaglifozin, mainly not reaching statistical significance (202) .", [["canagliflozin", "CHEMICAL", 59, 72], ["Sodium Glucose", "CHEMICAL", 240, 254], ["canagliflozin", "CHEMICAL", 430, 443], ["dapagliflozin", "CHEMICAL", 445, 458], ["empaglifozin", "CHEMICAL", 463, 475], ["canagliflozin", "CHEMICAL", 59, 72], ["Sodium Glucose", "CHEMICAL", 240, 254], ["canagliflozin", "CHEMICAL", 430, 443], ["dapagliflozin", "CHEMICAL", 445, 458], ["empaglifozin", "CHEMICAL", 463, 475], ["canagliflozin", "SIMPLE_CHEMICAL", 59, 72], ["SLGT2", "SIMPLE_CHEMICAL", 190, 195], ["Sodium Glucose Cotransporter 2", "GENE_OR_GENE_PRODUCT", 240, 270], ["SLGT2", "SIMPLE_CHEMICAL", 283, 288], ["leptin", "GENE_OR_GENE_PRODUCT", 303, 309], ["adiponectin", "GENE_OR_GENE_PRODUCT", 331, 342], ["hsCRP", "GENE_OR_GENE_PRODUCT", 398, 403], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 404, 409], ["IL-6", "GENE_OR_GENE_PRODUCT", 411, 415], ["IF", "GENE_OR_GENE_PRODUCT", 420, 422], ["canagliflozin", "SIMPLE_CHEMICAL", 430, 443], ["dapagliflozin", "SIMPLE_CHEMICAL", 445, 458], ["empaglifozin", "SIMPLE_CHEMICAL", 463, 475], ["leptin", "PROTEIN", 303, 309], ["adiponectin", "PROTEIN", 331, 342], ["hsCRP", "PROTEIN", 398, 403], ["TNF", "PROTEIN", 404, 407], ["the CREDENCE Study", "TEST", 35, 53], ["canagliflozin", "TREATMENT", 59, 72], ["inflammatory biomarker changes", "PROBLEM", 105, 135], ["exploratory data", "TEST", 149, 165], ["SLGT2 inhibitors", "TREATMENT", 190, 206], ["short-term evaluations", "TEST", 217, 239], ["Sodium Glucose Cotransporter", "TREATMENT", 240, 268], ["Inhibitors (SLGT2)", "TREATMENT", 271, 289], ["Reduction in leptin levels", "TEST", 290, 316], ["increased adiponectin", "PROBLEM", 321, 342], ["hsCRP TNF", "TEST", 398, 407], ["IL", "TEST", 411, 413], ["canagliflozin", "TREATMENT", 430, 443], ["dapagliflozin", "TREATMENT", 445, 458], ["empaglifozin", "TREATMENT", 463, 475], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["leptin", "ANATOMY", 303, 309], ["increased", "OBSERVATION_MODIFIER", 321, 330], ["adiponectin", "OBSERVATION", 331, 342]]], ["In the CANTATA-SU Study (204) , with canagliflozin, there was a 22% reduction of IL-6 and a slight reduction of hsCRP (-4.4%).", [["canagliflozin", "CHEMICAL", 37, 50], ["canagliflozin", "CHEMICAL", 37, 50], ["canagliflozin", "SIMPLE_CHEMICAL", 37, 50], ["IL-6", "GENE_OR_GENE_PRODUCT", 81, 85], ["hsCRP", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL-6", "PROTEIN", 81, 85], ["hsCRP", "PROTEIN", 112, 117], ["canagliflozin", "TREATMENT", 37, 50], ["a 22% reduction of IL", "TREATMENT", 62, 83], ["hsCRP", "TEST", 112, 117], ["slight", "OBSERVATION_MODIFIER", 92, 98], ["reduction", "OBSERVATION_MODIFIER", 99, 108]]], ["Conversely, a 7% increase in TNF-\uf061\uf020was detected after canagliflozin vs glimepiride ( Table 4) .", [["canagliflozin", "CHEMICAL", 54, 67], ["glimepiride", "CHEMICAL", 71, 82], ["canagliflozin", "CHEMICAL", 54, 67], ["glimepiride", "CHEMICAL", 71, 82], ["TNF", "GENE_OR_GENE_PRODUCT", 29, 32], ["canagliflozin", "SIMPLE_CHEMICAL", 54, 67], ["glimepiride", "SIMPLE_CHEMICAL", 71, 82], ["TNF", "PROTEIN", 29, 32], ["a 7% increase in TNF", "PROBLEM", 12, 32], ["canagliflozin", "TREATMENT", 54, 67], ["glimepiride", "TREATMENT", 71, 82], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["Overall the effects on inflammatory markers are very modest and probably not contributing to the CV outcomes.Microbiome and inflammationThe trillions of microbes colonizing the human intestinal tract are of major importance for human development and physiology (205) .", [["intestinal tract", "ANATOMY", 183, 199], ["inflammation", "DISEASE", 124, 136], ["human", "ORGANISM", 177, 182], ["intestinal tract", "ORGAN", 183, 199], ["human", "ORGANISM", 228, 233], ["inflammatory markers", "PROTEIN", 23, 43], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 228, 233], ["inflammatory markers", "TEST", 23, 43], ["the CV outcomes", "PROBLEM", 93, 108], ["inflammation", "PROBLEM", 124, 136], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["probably not contributing", "UNCERTAINTY", 64, 89], ["inflammation", "OBSERVATION", 124, 136], ["microbes colonizing", "OBSERVATION", 153, 172], ["human", "ANATOMY_MODIFIER", 177, 182], ["intestinal tract", "ANATOMY", 183, 199]]], ["Alterations of the microbiome, however, may be associated with multiple disorders including a raised prevalence of atherosclerotic diseases (206) .Microbiome and inflammationAmong the best-studied mechanisms underlying this association is the increase of circulating trimethylamine oxide (TMAO) derived from the metabolism of choline and carnitine by gut microbiome (207) .", [["atherosclerotic", "ANATOMY", 115, 130], ["gut microbiome", "ANATOMY", 351, 365], ["atherosclerotic diseases", "DISEASE", 115, 139], ["inflammation", "DISEASE", 162, 174], ["trimethylamine oxide", "CHEMICAL", 267, 287], ["TMAO", "CHEMICAL", 289, 293], ["choline", "CHEMICAL", 326, 333], ["carnitine", "CHEMICAL", 338, 347], ["trimethylamine oxide", "CHEMICAL", 267, 287], ["TMAO", "CHEMICAL", 289, 293], ["choline", "CHEMICAL", 326, 333], ["carnitine", "CHEMICAL", 338, 347], ["trimethylamine oxide", "SIMPLE_CHEMICAL", 267, 287], ["TMAO", "SIMPLE_CHEMICAL", 289, 293], ["choline", "SIMPLE_CHEMICAL", 326, 333], ["carnitine", "SIMPLE_CHEMICAL", 338, 347], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 351, 365], ["multiple disorders", "PROBLEM", 63, 81], ["atherosclerotic diseases", "PROBLEM", 115, 139], ["inflammation", "PROBLEM", 162, 174], ["circulating trimethylamine oxide", "TREATMENT", 255, 287], ["carnitine", "TREATMENT", 338, 347], ["may be associated with", "UNCERTAINTY", 40, 62], ["atherosclerotic", "OBSERVATION_MODIFIER", 115, 130], ["diseases", "OBSERVATION", 131, 139], ["inflammation", "OBSERVATION", 162, 174]]], ["More recently the same authors indicated that the precursor trimethylysine is also associated with adverse cardiac risk and the two together provide the best risk estimate (208) .Microbiome and inflammationContrasting data have been reported in an animal model: in the apoE -/mice, Collins et al. (209) found that carnitine fed animals have raised TMAO levels but these are inversely related to aortic lesion formation.", [["cardiac", "ANATOMY", 107, 114], ["aortic lesion", "ANATOMY", 395, 408], ["trimethylysine", "CHEMICAL", 60, 74], ["inflammation", "DISEASE", 194, 206], ["carnitine", "CHEMICAL", 314, 323], ["TMAO", "CHEMICAL", 348, 352], ["aortic lesion", "DISEASE", 395, 408], ["trimethylysine", "CHEMICAL", 60, 74], ["carnitine", "CHEMICAL", 314, 323], ["TMAO", "CHEMICAL", 348, 352], ["trimethylysine", "SIMPLE_CHEMICAL", 60, 74], ["cardiac", "ORGAN", 107, 114], ["apoE", "GENE_OR_GENE_PRODUCT", 269, 273], ["carnitine", "SIMPLE_CHEMICAL", 314, 323], ["TMAO", "SIMPLE_CHEMICAL", 348, 352], ["aortic lesion", "PATHOLOGICAL_FORMATION", 395, 408], ["apoE", "PROTEIN", 269, 273], ["mice", "SPECIES", 276, 280], ["the precursor trimethylysine", "PROBLEM", 46, 74], ["adverse cardiac risk", "PROBLEM", 99, 119], ["inflammation", "PROBLEM", 194, 206], ["raised TMAO levels", "PROBLEM", 341, 359], ["aortic lesion formation", "PROBLEM", 395, 418], ["inflammation", "OBSERVATION", 194, 206], ["aortic", "ANATOMY", 395, 401], ["lesion", "OBSERVATION", 402, 408]]], ["In the same model, mice fed chow or Western diet and low or no choline There are limited data on the direct effect of microbial changes on, particularly, endothelial function and the endothelial inflammatory phenotype.", [["endothelial", "ANATOMY", 154, 165], ["endothelial", "ANATOMY", 183, 194], ["choline", "CHEMICAL", 63, 70], ["choline", "CHEMICAL", 63, 70], ["mice", "ORGANISM", 19, 23], ["choline", "SIMPLE_CHEMICAL", 63, 70], ["endothelial", "CELL", 154, 165], ["endothelial", "CELL", 183, 194], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["microbial changes", "PROBLEM", 118, 135], ["the endothelial inflammatory phenotype", "PROBLEM", 179, 217], ["endothelial", "ANATOMY", 154, 165], ["endothelial", "ANATOMY", 183, 194], ["inflammatory phenotype", "OBSERVATION", 195, 217]]], ["Limited information in rodent models has indicated that a major probiotic, Lactobacillus plantarum, may reduce myocardial infarct size in hypertensive rats (213) , as well as suppress LPS-mediated atherosclerotic plaque inflammation (214) .", [["myocardial", "ANATOMY", 111, 121], ["atherosclerotic plaque", "ANATOMY", 197, 219], ["Lactobacillus plantarum", "CHEMICAL", 75, 98], ["myocardial infarct", "DISEASE", 111, 129], ["hypertensive", "DISEASE", 138, 150], ["LPS", "CHEMICAL", 184, 187], ["atherosclerotic plaque inflammation", "DISEASE", 197, 232], ["Lactobacillus plantarum", "ORGANISM", 75, 98], ["myocardial infarct", "PATHOLOGICAL_FORMATION", 111, 129], ["rats", "ORGANISM", 151, 155], ["LPS", "SIMPLE_CHEMICAL", 184, 187], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 197, 219], ["Lactobacillus plantarum", "SPECIES", 75, 98], ["rats", "SPECIES", 151, 155], ["Lactobacillus plantarum", "SPECIES", 75, 98], ["a major probiotic", "TREATMENT", 56, 73], ["Lactobacillus plantarum", "TREATMENT", 75, 98], ["myocardial infarct size", "PROBLEM", 111, 134], ["hypertensive rats", "PROBLEM", 138, 155], ["mediated atherosclerotic plaque inflammation", "PROBLEM", 188, 232], ["myocardial", "ANATOMY", 111, 121], ["infarct", "OBSERVATION", 122, 129], ["size", "OBSERVATION_MODIFIER", 130, 134], ["hypertensive", "OBSERVATION_MODIFIER", 138, 150], ["atherosclerotic", "OBSERVATION_MODIFIER", 197, 212], ["plaque", "OBSERVATION_MODIFIER", 213, 219], ["inflammation", "OBSERVATION", 220, 232]]], ["The potential of Lactobacillus plantarum 299v (Ly299v) was evaluated by Malik et al (215) that directly tested in ASCVD patients the effects of oral Lp299v (20 billion-colony forming units (CFU) qd) for 6 weeks.", [["oral", "ANATOMY", 144, 148], ["Lactobacillus plantarum 299v", "CHEMICAL", 17, 45], ["Ly299v", "CHEMICAL", 47, 53], ["Lp299v", "CHEMICAL", 149, 155], ["Lp299v", "CHEMICAL", 149, 155], ["Lactobacillus plantarum 299v", "ORGANISM", 17, 45], ["Ly299v", "ORGANISM", 47, 53], ["patients", "ORGANISM", 120, 128], ["oral", "ORGANISM_SUBDIVISION", 144, 148], ["Lp299v", "SIMPLE_CHEMICAL", 149, 155], ["Lactobacillus plantarum", "SPECIES", 17, 40], ["patients", "SPECIES", 120, 128], ["Lactobacillus plantarum 299v (Ly299v", "SPECIES", 17, 53], ["Lactobacillus plantarum", "TREATMENT", 17, 40], ["oral Lp299v", "TREATMENT", 144, 155]]], ["Treatment did not change lipids, glucose or BMI, but improved flow-mediated dilation.", [["glucose", "CHEMICAL", 33, 40], ["glucose", "CHEMICAL", 33, 40], ["lipids", "SIMPLE_CHEMICAL", 25, 31], ["glucose", "SIMPLE_CHEMICAL", 33, 40], ["lipids", "TREATMENT", 25, 31], ["glucose", "TEST", 33, 40], ["BMI", "PROBLEM", 44, 47], ["mediated dilation", "PROBLEM", 67, 84], ["improved", "OBSERVATION_MODIFIER", 53, 61], ["flow", "OBSERVATION", 62, 66], ["dilation", "OBSERVATION", 76, 84]]], ["While TMAO levels were unchanged, significant reductions of IL-8 and IL-12 were recorded.Microbiome and inflammationResistance arteries isolated from patients after treatment and exposed to postbiotic plasma showed raised endothelium-dependent vasodilation.Microbiome and inflammationThe positive results of this last study suggested the experimental evaluation in a more frequent case of inflammation-mediated endothelial dysfunction and arterial stiffening, i.e. aging (216) .", [["inflammationResistance arteries", "ANATOMY", 104, 135], ["postbiotic plasma", "ANATOMY", 190, 207], ["endothelium", "ANATOMY", 222, 233], ["endothelial", "ANATOMY", 411, 422], ["arterial", "ANATOMY", 439, 447], ["TMAO", "CHEMICAL", 6, 10], ["inflammation", "DISEASE", 272, 284], ["inflammation", "DISEASE", 389, 401], ["TMAO", "CHEMICAL", 6, 10], ["TMAO", "SIMPLE_CHEMICAL", 6, 10], ["IL-8", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-12", "GENE_OR_GENE_PRODUCT", 69, 74], ["inflammationResistance arteries", "MULTI-TISSUE_STRUCTURE", 104, 135], ["patients", "ORGANISM", 150, 158], ["plasma", "ORGANISM_SUBSTANCE", 201, 207], ["endothelium", "TISSUE", 222, 233], ["endothelial", "TISSUE", 411, 422], ["arterial", "MULTI-TISSUE_STRUCTURE", 439, 447], ["IL-8", "PROTEIN", 60, 64], ["IL", "PROTEIN", 69, 71], ["patients", "SPECIES", 150, 158], ["TMAO levels", "TEST", 6, 17], ["IL", "TEST", 60, 62], ["IL", "TEST", 69, 71], ["inflammationResistance arteries", "PROBLEM", 104, 135], ["treatment", "TREATMENT", 165, 174], ["postbiotic plasma", "TEST", 190, 207], ["raised endothelium", "PROBLEM", 215, 233], ["dependent vasodilation", "PROBLEM", 234, 256], ["inflammation", "PROBLEM", 272, 284], ["this last study", "TEST", 308, 323], ["the experimental evaluation", "TEST", 334, 361], ["inflammation", "PROBLEM", 389, 401], ["mediated endothelial dysfunction", "PROBLEM", 402, 434], ["arterial stiffening", "PROBLEM", 439, 458], ["unchanged", "OBSERVATION_MODIFIER", 23, 32], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["reductions", "OBSERVATION_MODIFIER", 46, 56], ["arteries", "ANATOMY", 127, 135], ["endothelium", "OBSERVATION", 222, 233], ["dependent", "OBSERVATION_MODIFIER", 234, 243], ["vasodilation", "OBSERVATION", 244, 256], ["inflammation", "OBSERVATION", 272, 284], ["inflammation", "OBSERVATION", 389, 401], ["endothelial dysfunction", "OBSERVATION", 411, 434], ["arterial", "ANATOMY", 439, 447], ["stiffening", "OBSERVATION_MODIFIER", 448, 458]]], ["These Authors, by suppressing gut microbiota with antibiotic treatment in old mice noted reversed endothelial dysfunction and arterial stiffening, with attenuated vascular oxidative stress and inflammation.", [["gut microbiota", "ANATOMY", 30, 44], ["endothelial", "ANATOMY", 98, 109], ["arterial", "ANATOMY", 126, 134], ["vascular", "ANATOMY", 163, 171], ["endothelial dysfunction", "DISEASE", 98, 121], ["inflammation", "DISEASE", 193, 205], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 30, 44], ["mice", "ORGANISM", 78, 82], ["endothelial", "CELL", 98, 109], ["arterial", "MULTI-TISSUE_STRUCTURE", 126, 134], ["vascular", "MULTI-TISSUE_STRUCTURE", 163, 171], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["antibiotic treatment", "TREATMENT", 50, 70], ["endothelial dysfunction", "PROBLEM", 98, 121], ["arterial stiffening", "PROBLEM", 126, 145], ["attenuated vascular oxidative stress", "PROBLEM", 152, 188], ["inflammation", "PROBLEM", 193, 205], ["endothelial dysfunction", "OBSERVATION", 98, 121], ["arterial", "ANATOMY", 126, 134], ["stiffening", "OBSERVATION", 135, 145], ["attenuated", "OBSERVATION_MODIFIER", 152, 162], ["vascular", "ANATOMY", 163, 171], ["oxidative stress", "OBSERVATION", 172, 188], ["inflammation", "OBSERVATION", 193, 205]]], ["Plasma levels of TMAO were also suppressed by antibiotic treatment.", [["TMAO", "CHEMICAL", 17, 21], ["TMAO", "CHEMICAL", 17, 21], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["TMAO", "SIMPLE_CHEMICAL", 17, 21], ["Plasma levels", "TEST", 0, 13], ["TMAO", "TEST", 17, 21], ["antibiotic treatment", "TREATMENT", 46, 66]]], ["TheMicrobiome and inflammationAuthors noted an increase of the phylum Proteobacteria in antibiotic treated mice, almost entirely attributable to unclassified species within the Enterobacteriaceae.", [["mice", "ORGANISM", 107, 111], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["TheMicrobiome", "TREATMENT", 0, 13], ["inflammationAuthors", "PROBLEM", 18, 37], ["the phylum Proteobacteria", "PROBLEM", 59, 84], ["antibiotic", "TREATMENT", 88, 98], ["unclassified species within the Enterobacteriaceae", "PROBLEM", 145, 195], ["increase", "OBSERVATION_MODIFIER", 47, 55], ["phylum Proteobacteria", "OBSERVATION", 63, 84], ["unclassified", "OBSERVATION_MODIFIER", 145, 157], ["species", "OBSERVATION", 158, 165], ["Enterobacteriaceae", "OBSERVATION_MODIFIER", 177, 195]]], ["The issue of proinflammatory gut microbiota was examined by the use of caspase 1 -/mice with proinflammatory microbiota in LDLr -/mice (217) .", [["gut microbiota", "ANATOMY", 29, 43], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 29, 43], ["caspase 1", "GENE_OR_GENE_PRODUCT", 71, 80], ["mice", "ORGANISM", 83, 87], ["LDLr", "GENE_OR_GENE_PRODUCT", 123, 127], ["mice", "ORGANISM", 130, 134], ["caspase 1", "PROTEIN", 71, 80], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 130, 134], ["caspase", "TREATMENT", 71, 78], ["proinflammatory", "OBSERVATION_MODIFIER", 13, 28]]], ["When proinflammatory casp1 -/microbiota was introduced into LDLr -/mice a remarkable increase of systemic inflammation and atherogenesis was reported.Microbiome and inflammationThe aim of identifying enteral bacteria, possibly responsible for reducing inflammation and improve endothelial function, has called attention to the Akkermansia muciniphila, an enteral commensal anaerobe, postulated to exert potential anti-obesity effects, linked to reduced insulinresistance (218) .", [["endothelial", "ANATOMY", 277, 288], ["inflammation", "DISEASE", 106, 118], ["atherogenesis", "DISEASE", 123, 136], ["inflammation", "DISEASE", 165, 177], ["inflammation", "DISEASE", 252, 264], ["casp1", "GENE_OR_GENE_PRODUCT", 21, 26], ["LDLr", "GENE_OR_GENE_PRODUCT", 60, 64], ["endothelial", "CELL", 277, 288], ["Akkermansia muciniphila", "ORGANISM", 327, 350], ["proinflammatory casp1", "PROTEIN", 5, 26], ["LDLr", "PROTEIN", 60, 64], ["mice", "SPECIES", 67, 71], ["Akkermansia muciniphila", "SPECIES", 327, 350], ["mice", "SPECIES", 67, 71], ["Akkermansia muciniphila", "SPECIES", 327, 350], ["proinflammatory casp1 -/microbiota", "TREATMENT", 5, 39], ["systemic inflammation", "PROBLEM", 97, 118], ["atherogenesis", "PROBLEM", 123, 136], ["inflammation", "PROBLEM", 165, 177], ["enteral bacteria", "PROBLEM", 200, 216], ["reducing inflammation", "PROBLEM", 243, 264], ["the Akkermansia muciniphila", "PROBLEM", 323, 350], ["an enteral commensal anaerobe", "TREATMENT", 352, 381], ["reduced insulinresistance", "PROBLEM", 445, 470], ["remarkable", "OBSERVATION_MODIFIER", 74, 84], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["systemic", "OBSERVATION_MODIFIER", 97, 105], ["inflammation", "OBSERVATION", 106, 118], ["atherogenesis", "OBSERVATION", 123, 136], ["inflammation", "OBSERVATION", 165, 177], ["enteral bacteria", "OBSERVATION", 200, 216], ["possibly responsible for", "UNCERTAINTY", 218, 242], ["inflammation", "OBSERVATION", 252, 264], ["endothelial function", "OBSERVATION", 277, 297]]], ["Interestingly, beneficial properties appear to be improved by pasteurization (219) .J o u r n a l P r e -p r o o fThree-month supplementation of pasteurized A. muciniphila (1010 CFU daily) in insulin resistant volunteers reduced circulating LPS endotoxemia and white blood cells (220) .", [["white blood cells", "ANATOMY", 261, 278], ["insulin", "CHEMICAL", 192, 199], ["LPS", "CHEMICAL", 241, 244], ["A. muciniphila", "ORGANISM", 157, 171], ["insulin", "GENE_OR_GENE_PRODUCT", 192, 199], ["volunteers", "ORGANISM", 210, 220], ["LPS", "SIMPLE_CHEMICAL", 241, 244], ["white blood cells", "CELL", 261, 278], ["white blood cells", "CELL_TYPE", 261, 278], ["A. muciniphila", "SPECIES", 157, 171], ["A. muciniphila", "SPECIES", 157, 171], ["pasteurization", "TEST", 62, 76], ["fThree", "TEST", 113, 119], ["supplementation", "TREATMENT", 126, 141], ["muciniphila", "TEST", 160, 171], ["insulin resistant volunteers", "PROBLEM", 192, 220], ["circulating LPS endotoxemia", "PROBLEM", 229, 256], ["white blood cells", "TEST", 261, 278], ["LPS endotoxemia", "OBSERVATION", 241, 256]]], ["These findings support the hypothesis, now held by several Authors, that probiotic treatment with live bacteria may improve barrier function in the intestine, thus ameliorating both metabolic parameters as well inflammation (221) .", [["barrier", "ANATOMY", 124, 131], ["intestine", "ANATOMY", 148, 157], ["inflammation", "DISEASE", 211, 223], ["barrier", "TISSUE", 124, 131], ["intestine", "ORGAN", 148, 157], ["the hypothesis", "PROBLEM", 23, 37], ["probiotic treatment", "TREATMENT", 73, 92], ["live bacteria", "PROBLEM", 98, 111], ["inflammation", "PROBLEM", 211, 223], ["intestine", "ANATOMY", 148, 157]]], ["It may lead to improved vascular function in aging and vascular disease.NUTRACEUTICALSDiet, the most common variable for all individuals, may influence inflammation, in particular vascular inflammation, to a different extent according to general components, as well as to components with a drug-like activity, among these unsaturated fatty acids and commonly used nutraceuticals.Omega-6 fatty acids.Omega-6 fatty acids are a major component of the daily lipid intake.", [["vascular", "ANATOMY", 24, 32], ["vascular", "ANATOMY", 55, 63], ["vascular", "ANATOMY", 180, 188], ["vascular disease", "DISEASE", 55, 71], ["inflammation", "DISEASE", 152, 164], ["vascular inflammation", "DISEASE", 180, 201], ["fatty acids", "CHEMICAL", 334, 345], ["Omega-6 fatty acids", "CHEMICAL", 379, 398], ["Omega-6 fatty acids", "CHEMICAL", 399, 418], ["unsaturated fatty acids", "CHEMICAL", 322, 345], ["Omega-6 fatty acids", "CHEMICAL", 379, 398], ["Omega-6 fatty acids", "CHEMICAL", 399, 418], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["vascular", "MULTI-TISSUE_STRUCTURE", 55, 63], ["vascular", "MULTI-TISSUE_STRUCTURE", 180, 188], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 322, 345], ["Omega-6 fatty acids", "SIMPLE_CHEMICAL", 379, 398], ["Omega-6 fatty acids", "SIMPLE_CHEMICAL", 399, 418], ["lipid", "SIMPLE_CHEMICAL", 454, 459], ["vascular disease", "PROBLEM", 55, 71], ["influence inflammation", "PROBLEM", 142, 164], ["particular vascular inflammation", "PROBLEM", 169, 201], ["these unsaturated fatty acids", "TREATMENT", 316, 345], ["Omega-6 fatty acids", "TREATMENT", 379, 398], ["Omega-6 fatty acids", "TREATMENT", 399, 418], ["may lead to", "UNCERTAINTY", 3, 14], ["improved", "OBSERVATION_MODIFIER", 15, 23], ["vascular function", "OBSERVATION", 24, 41], ["vascular", "ANATOMY", 55, 63], ["disease", "OBSERVATION", 64, 71], ["most common", "OBSERVATION_MODIFIER", 96, 107], ["inflammation", "OBSERVATION", 152, 164], ["vascular", "ANATOMY", 180, 188], ["inflammation", "OBSERVATION", 189, 201], ["different extent", "OBSERVATION_MODIFIER", 208, 224]]], ["The most represented polyunsaturated fatty acid (PUFA) is linoleic acid (LA:18:2 n-6).", [["polyunsaturated fatty acid", "CHEMICAL", 21, 47], ["PUFA", "CHEMICAL", 49, 53], ["linoleic acid", "CHEMICAL", 58, 71], ["LA", "CHEMICAL", 73, 75], ["polyunsaturated fatty acid", "CHEMICAL", 21, 47], ["PUFA", "CHEMICAL", 49, 53], ["linoleic acid", "CHEMICAL", 58, 71], ["polyunsaturated fatty acid", "SIMPLE_CHEMICAL", 21, 47], ["PUFA", "SIMPLE_CHEMICAL", 49, 53], ["linoleic acid", "SIMPLE_CHEMICAL", 58, 71], ["LA", "SIMPLE_CHEMICAL", 73, 75], ["polyunsaturated fatty acid", "TEST", 21, 47], ["linoleic acid", "TEST", 58, 71], ["polyunsaturated", "OBSERVATION_MODIFIER", 21, 36], ["fatty acid", "OBSERVATION", 37, 47]]], ["A most recent assessment of omega-6 PUFA intake among adults in the UK was 10.9\uf0b14.7 g/day, most of which (at least 90%) would be LA, responsible for about 7% of daily energy.", [["omega-6 PUFA", "CHEMICAL", 28, 40], ["LA", "CHEMICAL", 129, 131], ["PUFA", "CHEMICAL", 36, 40], ["omega-6 PUFA", "SIMPLE_CHEMICAL", 28, 40]]], ["LA is converted after a series of steps to \uf067-linolenic acid, dihomo-\uf067-linolenic acid and arachidonic acid (ARA) (222) .", [["LA", "CHEMICAL", 0, 2], ["\uf067-linolenic acid", "CHEMICAL", 43, 59], ["dihomo-\uf067-linolenic acid", "CHEMICAL", 61, 84], ["arachidonic acid", "CHEMICAL", 89, 105], ["ARA", "CHEMICAL", 107, 110], ["\uf067-linolenic acid", "CHEMICAL", 43, 59], ["dihomo-\uf067-linolenic acid", "CHEMICAL", 61, 84], ["arachidonic acid", "CHEMICAL", 89, 105], ["ARA", "CHEMICAL", 107, 110], ["LA", "SIMPLE_CHEMICAL", 0, 2], ["\uf067-linolenic acid", "SIMPLE_CHEMICAL", 43, 59], ["dihomo-\uf067-linolenic acid", "SIMPLE_CHEMICAL", 61, 84], ["arachidonic acid", "SIMPLE_CHEMICAL", 89, 105], ["ARA", "SIMPLE_CHEMICAL", 107, 110], ["\uf067-linolenic acid", "TREATMENT", 43, 59], ["dihomo", "TREATMENT", 61, 67], ["\uf067-linolenic acid", "TREATMENT", 68, 84], ["arachidonic acid (ARA", "TREATMENT", 89, 110], ["arachidonic acid", "OBSERVATION", 89, 105]]], ["This last is the major precursor of eicosanoids, being converted by cyclooxygenase-1 (COX-1) to prostaglandins/thromboxanes.", [["prostaglandins", "CHEMICAL", 96, 110], ["eicosanoids", "CHEMICAL", 36, 47], ["prostaglandins", "CHEMICAL", 96, 110], ["thromboxanes", "CHEMICAL", 111, 123], ["eicosanoids", "SIMPLE_CHEMICAL", 36, 47], ["cyclooxygenase-1", "GENE_OR_GENE_PRODUCT", 68, 84], ["COX-1", "GENE_OR_GENE_PRODUCT", 86, 91], ["prostaglandins", "SIMPLE_CHEMICAL", 96, 110], ["thromboxanes", "SIMPLE_CHEMICAL", 111, 123], ["cyclooxygenase-1 (COX-1", "PROTEIN", 68, 91], ["cyclooxygenase", "TREATMENT", 68, 82], ["COX", "TEST", 86, 89], ["prostaglandins/thromboxanes", "TREATMENT", 96, 123], ["eicosanoids", "OBSERVATION", 36, 47]]], ["Concentrations of ARA-derived eicosanoids are elevated in inflammatory conditions.", [["ARA", "CHEMICAL", 18, 21], ["ARA", "CHEMICAL", 18, 21], ["eicosanoids", "CHEMICAL", 30, 41], ["ARA", "SIMPLE_CHEMICAL", 18, 21], ["ARA-derived eicosanoids", "TEST", 18, 41], ["elevated in inflammatory conditions", "PROBLEM", 46, 81], ["eicosanoids", "OBSERVATION_MODIFIER", 30, 41], ["elevated", "OBSERVATION_MODIFIER", 46, 54], ["inflammatory conditions", "OBSERVATION", 58, 81]]], ["Pathways to ARA synthesis from LA is generally saturated in the presence of a high LA intake in humans (likely to be around 10 g/d) and thus raised LA intake will have no further effect in promoting ARA synthesis.", [["ARA", "CHEMICAL", 12, 15], ["LA", "CHEMICAL", 31, 33], ["LA", "CHEMICAL", 83, 85], ["LA", "CHEMICAL", 148, 150], ["ARA", "CHEMICAL", 199, 202], ["ARA", "CHEMICAL", 12, 15], ["ARA", "CHEMICAL", 199, 202], ["ARA", "SIMPLE_CHEMICAL", 12, 15], ["LA", "SIMPLE_CHEMICAL", 31, 33], ["LA", "SIMPLE_CHEMICAL", 83, 85], ["humans", "ORGANISM", 96, 102], ["LA", "SIMPLE_CHEMICAL", 148, 150], ["ARA", "SIMPLE_CHEMICAL", 199, 202], ["humans", "SPECIES", 96, 102], ["humans", "SPECIES", 96, 102], ["ARA synthesis", "TEST", 12, 25], ["a high LA intake", "PROBLEM", 76, 92], ["promoting ARA synthesis", "TREATMENT", 189, 212], ["generally", "OBSERVATION_MODIFIER", 37, 46], ["saturated", "OBSERVATION", 47, 56], ["ARA synthesis", "OBSERVATION", 199, 212]]], ["This generally leads to unchanged levels of ARA in circulating mononuclear cells (MCs), and it is unlikely to see much of a change in inflammatory markers following raised dietary LA in individuals on a normal diet (223) .Omega-6 fatty acids.The major potential effect of LA itself on inflammation is its metabolism to lipoxygenase (LOX) derivatives such as the hydroxydecadienoic acids (HODEs) and further to oxo-HODEs and epoxy-HODEs, playing a role in inflammation and having been detected in colonic mucosal biopsies of patients with ulcerative colitis without, however, being significantly related to the degree of inflammation (224) .", [["mononuclear cells", "ANATOMY", 63, 80], ["MCs", "ANATOMY", 82, 85], ["colonic mucosal biopsies", "ANATOMY", 496, 520], ["ARA", "CHEMICAL", 44, 47], ["LA", "CHEMICAL", 180, 182], ["Omega-6 fatty acids", "CHEMICAL", 222, 241], ["LA", "CHEMICAL", 272, 274], ["inflammation", "DISEASE", 285, 297], ["hydroxydecadienoic acids", "CHEMICAL", 362, 386], ["HODEs", "CHEMICAL", 388, 393], ["oxo-HODEs", "CHEMICAL", 410, 419], ["epoxy-HODEs", "CHEMICAL", 424, 435], ["inflammation", "DISEASE", 455, 467], ["ulcerative colitis", "DISEASE", 538, 556], ["inflammation", "DISEASE", 620, 632], ["ARA", "CHEMICAL", 44, 47], ["Omega-6 fatty acids", "CHEMICAL", 222, 241], ["hydroxydecadienoic acids", "CHEMICAL", 362, 386], ["HODEs", "CHEMICAL", 388, 393], ["oxo-HODEs", "CHEMICAL", 410, 419], ["epoxy-HODEs", "CHEMICAL", 424, 435], ["ARA", "SIMPLE_CHEMICAL", 44, 47], ["circulating mononuclear cells", "CELL", 51, 80], ["MCs", "CELL", 82, 85], ["LA", "SIMPLE_CHEMICAL", 180, 182], ["Omega-6 fatty acids", "SIMPLE_CHEMICAL", 222, 241], ["LA", "SIMPLE_CHEMICAL", 272, 274], ["lipoxygenase", "SIMPLE_CHEMICAL", 319, 331], ["LOX", "GENE_OR_GENE_PRODUCT", 333, 336], ["hydroxydecadienoic acids", "SIMPLE_CHEMICAL", 362, 386], ["HODEs", "SIMPLE_CHEMICAL", 388, 393], ["oxo-HODEs", "SIMPLE_CHEMICAL", 410, 419], ["epoxy-HODEs", "SIMPLE_CHEMICAL", 424, 435], ["colonic mucosal biopsies", "TISSUE", 496, 520], ["patients", "ORGANISM", 524, 532], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 538, 556], ["circulating mononuclear cells", "CELL_TYPE", 51, 80], ["MCs", "CELL_TYPE", 82, 85], ["inflammatory markers", "PROTEIN", 134, 154], ["lipoxygenase", "PROTEIN", 319, 331], ["LOX", "PROTEIN", 333, 336], ["patients", "SPECIES", 524, 532], ["ARA in circulating mononuclear cells", "TREATMENT", 44, 80], ["a change in inflammatory markers", "PROBLEM", 122, 154], ["Omega-6 fatty acids", "TREATMENT", 222, 241], ["inflammation", "PROBLEM", 285, 297], ["lipoxygenase (LOX) derivatives", "TREATMENT", 319, 349], ["the hydroxydecadienoic acids (HODEs)", "TREATMENT", 358, 394], ["oxo-HODEs", "TREATMENT", 410, 419], ["epoxy-HODEs", "TREATMENT", 424, 435], ["inflammation", "PROBLEM", 455, 467], ["colonic mucosal biopsies", "TEST", 496, 520], ["ulcerative colitis", "PROBLEM", 538, 556], ["inflammation", "PROBLEM", 620, 632], ["unchanged", "OBSERVATION_MODIFIER", 24, 33], ["mononuclear cells", "OBSERVATION", 63, 80], ["change", "OBSERVATION_MODIFIER", 124, 130], ["inflammatory", "OBSERVATION", 134, 146], ["LA", "OBSERVATION", 272, 274], ["inflammation", "OBSERVATION", 285, 297], ["inflammation", "OBSERVATION", 455, 467], ["colonic mucosal", "ANATOMY", 496, 511], ["biopsies", "OBSERVATION", 512, 520], ["ulcerative", "OBSERVATION_MODIFIER", 538, 548], ["colitis", "OBSERVATION", 549, 556], ["inflammation", "OBSERVATION", 620, 632]]], ["Dietary LA intake was not associated with the inflammatory markers CRP, IL-6, soluble (s)TNF-R and sTNF-R2 (225, 226) .", [["LA", "CHEMICAL", 8, 10], ["LA", "SIMPLE_CHEMICAL", 8, 10], ["CRP", "GENE_OR_GENE_PRODUCT", 67, 70], ["IL-6", "GENE_OR_GENE_PRODUCT", 72, 76], ["TNF-R", "GENE_OR_GENE_PRODUCT", 89, 94], ["sTNF-R2", "GENE_OR_GENE_PRODUCT", 99, 106], ["inflammatory markers", "PROTEIN", 46, 66], ["CRP", "PROTEIN", 67, 70], ["IL-6", "PROTEIN", 72, 76], ["TNF", "PROTEIN", 89, 92], ["sTNF", "PROTEIN", 99, 103], ["the inflammatory markers", "TEST", 42, 66], ["CRP", "TEST", 67, 70], ["IL", "TEST", 72, 74], ["TNF", "TEST", 89, 92], ["sTNF", "TEST", 99, 103], ["inflammatory", "OBSERVATION_MODIFIER", 46, 58]]], ["Despite a long-held belief, available evidence does not support the conclusion that a high dietary intake or high plasma LA concentrations raise tissue ARA or change inflammatory marker concentrations in humans.J o u r n a l P r e -p r o o fThe lack of a significant anti-inflammatory effect of LA or in general omega-6 fatty acids in spite of the beneficial activity on CV prevention is well supported by the very recent novel Consortium Evaluation of 30 prospective observational studies from 13 countries (follow up ranging between 2.5 to 31.9 years) (227) .", [["plasma", "ANATOMY", 114, 120], ["tissue", "ANATOMY", 145, 151], ["LA", "CHEMICAL", 121, 123], ["ARA", "CHEMICAL", 152, 155], ["LA", "CHEMICAL", 295, 297], ["omega-6 fatty acids", "CHEMICAL", 312, 331], ["ARA", "CHEMICAL", 152, 155], ["omega-6 fatty acids", "CHEMICAL", 312, 331], ["plasma", "ORGANISM_SUBSTANCE", 114, 120], ["LA", "SIMPLE_CHEMICAL", 121, 123], ["tissue", "TISSUE", 145, 151], ["ARA", "SIMPLE_CHEMICAL", 152, 155], ["humans", "ORGANISM", 204, 210], ["LA", "SIMPLE_CHEMICAL", 295, 297], ["omega-6 fatty acids", "SIMPLE_CHEMICAL", 312, 331], ["humans", "SPECIES", 204, 210], ["humans", "SPECIES", 204, 210], ["a high dietary intake", "PROBLEM", 84, 105], ["high plasma LA concentrations", "TREATMENT", 109, 138], ["tissue ARA", "PROBLEM", 145, 155], ["change inflammatory marker concentrations in humans", "PROBLEM", 159, 210], ["a significant anti-inflammatory effect of LA", "PROBLEM", 253, 297], ["general omega-6 fatty acids", "TREATMENT", 304, 331], ["CV prevention", "TREATMENT", 371, 384], ["prospective observational studies", "TEST", 456, 489], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178], ["significant", "OBSERVATION_MODIFIER", 255, 266], ["anti-inflammatory", "OBSERVATION", 267, 284]]], ["High LA levels were associated with a lower risk of total CVD, CV mortality and ischemic stroke, with ratios between 0.93 and 0.88.", [["LA", "CHEMICAL", 5, 7], ["CVD", "DISEASE", 58, 61], ["ischemic stroke", "DISEASE", 80, 95], ["LA", "SIMPLE_CHEMICAL", 5, 7], ["High LA levels", "PROBLEM", 0, 14], ["total CVD", "PROBLEM", 52, 61], ["CV mortality", "PROBLEM", 63, 75], ["ischemic stroke", "PROBLEM", 80, 95], ["ratios", "TEST", 102, 108], ["total", "OBSERVATION_MODIFIER", 52, 57], ["CVD", "OBSERVATION", 58, 61], ["ischemic", "OBSERVATION_MODIFIER", 80, 88], ["stroke", "OBSERVATION", 89, 95]]], ["ARA levels were instead not associated with a high risk of CV outcomes.", [["ARA", "CHEMICAL", 0, 3], ["ARA", "CHEMICAL", 0, 3], ["ARA", "SIMPLE_CHEMICAL", 0, 3], ["ARA levels", "TEST", 0, 10], ["CV outcomes", "PROBLEM", 59, 70], ["CV outcomes", "OBSERVATION", 59, 70]]], ["Paradoxically, in extreme quintiles, higher ARA levels were linked to a lower risk of total CVD, thus supporting in general a favorable role for LA in CVD prevention.Omega-3 fatty acids.Dietary intake of omega-3 fatty acids is essential for health, since these PUFAs cannot be synthesized to a significant extent.", [["ARA", "CHEMICAL", 44, 47], ["CVD", "DISEASE", 92, 95], ["LA", "CHEMICAL", 145, 147], ["CVD", "DISEASE", 151, 154], ["Omega-3 fatty acids", "CHEMICAL", 166, 185], ["omega-3 fatty acids", "CHEMICAL", 204, 223], ["PUFAs", "CHEMICAL", 261, 266], ["ARA", "CHEMICAL", 44, 47], ["Omega-3 fatty acids", "CHEMICAL", 166, 185], ["omega-3 fatty acids", "CHEMICAL", 204, 223], ["PUFAs", "CHEMICAL", 261, 266], ["ARA", "SIMPLE_CHEMICAL", 44, 47], ["LA", "SIMPLE_CHEMICAL", 145, 147], ["Omega-3 fatty acids", "SIMPLE_CHEMICAL", 166, 185], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 204, 223], ["PUFAs", "SIMPLE_CHEMICAL", 261, 266], ["Paradoxically, in extreme quintiles", "PROBLEM", 0, 35], ["higher ARA levels", "PROBLEM", 37, 54], ["total CVD", "PROBLEM", 86, 95], ["LA in CVD prevention", "TREATMENT", 145, 165], ["Omega-3 fatty acids", "TREATMENT", 166, 185], ["omega-3 fatty acids", "TREATMENT", 204, 223], ["these PUFAs", "TREATMENT", 255, 266], ["total", "OBSERVATION_MODIFIER", 86, 91], ["CVD", "OBSERVATION", 92, 95], ["significant", "OBSERVATION_MODIFIER", 294, 305], ["extent", "OBSERVATION_MODIFIER", 306, 312]]], ["Omega-3 PUFAs are regarded as antiinflammatory, exerting their effects via multiple mechanisms (228) .", [["Omega-3 PUFAs", "CHEMICAL", 0, 13], ["Omega-3 PUFAs", "CHEMICAL", 0, 13], ["Omega-3 PUFAs", "SIMPLE_CHEMICAL", 0, 13], ["Omega-3 PUFAs", "TREATMENT", 0, 13], ["antiinflammatory", "TREATMENT", 30, 46]]], ["These include the partial inhibition of a number of steps of inflammation such as leukocyte chemotaxis, production of inflammatory cytokines, adhesion molecule expression, leukocyte-endothelial adhesive interactions, and Th1 lymphocyte reactivity (229) .", [["leukocyte", "ANATOMY", 82, 91], ["leukocyte", "ANATOMY", 172, 181], ["endothelial", "ANATOMY", 182, 193], ["Th1 lymphocyte", "ANATOMY", 221, 235], ["inflammation", "DISEASE", 61, 73], ["leukocyte", "CELL", 82, 91], ["leukocyte", "CELL", 172, 181], ["endothelial", "CELL", 182, 193], ["Th1 lymphocyte", "CELL", 221, 235], ["inflammatory cytokines", "PROTEIN", 118, 140], ["adhesion molecule", "PROTEIN", 142, 159], ["inflammation", "PROBLEM", 61, 73], ["leukocyte chemotaxis", "PROBLEM", 82, 102], ["inflammatory cytokines", "PROBLEM", 118, 140], ["adhesion molecule expression", "PROBLEM", 142, 170], ["leukocyte", "TEST", 172, 181], ["endothelial adhesive interactions", "PROBLEM", 182, 215], ["Th1 lymphocyte reactivity", "TEST", 221, 246], ["partial", "OBSERVATION_MODIFIER", 18, 25], ["inhibition", "OBSERVATION_MODIFIER", 26, 36], ["inflammation", "OBSERVATION", 61, 73], ["leukocyte chemotaxis", "OBSERVATION", 82, 102], ["inflammatory", "OBSERVATION_MODIFIER", 118, 130], ["adhesion molecule expression", "OBSERVATION", 142, 170], ["leukocyte", "OBSERVATION_MODIFIER", 172, 181], ["endothelial", "ANATOMY", 182, 193], ["adhesive interactions", "OBSERVATION", 194, 215], ["Th1 lymphocyte reactivity", "OBSERVATION", 221, 246]]], ["From the results of a number of randomized controlled trials, the anti-inflammatory effect of omega-3 PUFA was associated to a reduction of hsCRP, IL-6 and TNF (230) .", [["omega-3 PUFA", "CHEMICAL", 94, 106], ["omega-3 PUFA", "CHEMICAL", 94, 106], ["omega-3 PUFA", "SIMPLE_CHEMICAL", 94, 106], ["hsCRP", "GENE_OR_GENE_PRODUCT", 140, 145], ["IL-6", "GENE_OR_GENE_PRODUCT", 147, 151], ["TNF", "GENE_OR_GENE_PRODUCT", 156, 159], ["hsCRP", "PROTEIN", 140, 145], ["IL-6", "PROTEIN", 147, 151], ["TNF", "PROTEIN", 156, 159], ["randomized controlled trials", "TREATMENT", 32, 60], ["omega-3 PUFA", "TREATMENT", 94, 106], ["hsCRP", "TEST", 140, 145], ["IL", "TEST", 147, 149], ["anti-inflammatory", "OBSERVATION_MODIFIER", 66, 83]]], ["The basic mechanism is the incorporation of EPA and docosahexaenoic acid (DHA) into cell membranes at the expense of ARA, resulting in inhibited ARA metabolism and consequent decreased expression of the COX gene and, as a final consequence, reduction of ARA derived eicosanoids.Omega-3 fatty acids.More recently, a major advance in the field of PUFA and inflammation has been the discovery of the so called pro-resolving lipid mediators.", [["cell membranes", "ANATOMY", 84, 98], ["EPA", "CHEMICAL", 44, 47], ["docosahexaenoic acid", "CHEMICAL", 52, 72], ["DHA", "CHEMICAL", 74, 77], ["ARA", "CHEMICAL", 117, 120], ["ARA", "CHEMICAL", 145, 148], ["ARA", "CHEMICAL", 254, 257], ["Omega-3 fatty acids", "CHEMICAL", 278, 297], ["PUFA", "CHEMICAL", 345, 349], ["inflammation", "DISEASE", 354, 366], ["EPA", "CHEMICAL", 44, 47], ["docosahexaenoic acid", "CHEMICAL", 52, 72], ["DHA", "CHEMICAL", 74, 77], ["ARA", "CHEMICAL", 117, 120], ["ARA", "CHEMICAL", 145, 148], ["ARA", "CHEMICAL", 254, 257], ["eicosanoids", "CHEMICAL", 266, 277], ["Omega-3 fatty acids", "CHEMICAL", 278, 297], ["PUFA", "CHEMICAL", 345, 349], ["EPA", "SIMPLE_CHEMICAL", 44, 47], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 52, 72], ["DHA", "SIMPLE_CHEMICAL", 74, 77], ["cell membranes", "CELLULAR_COMPONENT", 84, 98], ["ARA", "SIMPLE_CHEMICAL", 117, 120], ["ARA", "SIMPLE_CHEMICAL", 145, 148], ["COX", "GENE_OR_GENE_PRODUCT", 203, 206], ["ARA", "SIMPLE_CHEMICAL", 254, 257], ["Omega-3 fatty acids", "SIMPLE_CHEMICAL", 278, 297], ["PUFA", "SIMPLE_CHEMICAL", 345, 349], ["COX gene", "DNA", 203, 211], ["pro-resolving lipid mediators", "PROTEIN", 407, 436], ["EPA and docosahexaenoic acid (DHA)", "TREATMENT", 44, 78], ["cell membranes", "TREATMENT", 84, 98], ["ARA", "TREATMENT", 117, 120], ["inhibited ARA metabolism", "PROBLEM", 135, 159], ["ARA derived eicosanoids", "TREATMENT", 254, 277], ["Omega-3 fatty acids", "TREATMENT", 278, 297], ["inflammation", "PROBLEM", 354, 366], ["pro-resolving lipid mediators", "TREATMENT", 407, 436], ["cell membranes", "OBSERVATION", 84, 98], ["ARA metabolism", "OBSERVATION", 145, 159], ["decreased", "OBSERVATION_MODIFIER", 175, 184], ["inflammation", "OBSERVATION", 354, 366]]], ["These mediators include resolvins from EPA (E-series) and DHA (D-series) and protectin and maresin from DHA.", [["resolvins", "CHEMICAL", 24, 33], ["EPA", "CHEMICAL", 39, 42], ["DHA", "CHEMICAL", 58, 61], ["D-series", "CHEMICAL", 63, 71], ["maresin", "CHEMICAL", 91, 98], ["DHA", "CHEMICAL", 104, 107], ["resolvins", "CHEMICAL", 24, 33], ["EPA", "CHEMICAL", 39, 42], ["DHA", "CHEMICAL", 58, 61], ["protectin", "CHEMICAL", 77, 86], ["maresin", "CHEMICAL", 91, 98], ["DHA", "CHEMICAL", 104, 107], ["resolvins", "SIMPLE_CHEMICAL", 24, 33], ["EPA", "SIMPLE_CHEMICAL", 39, 42], ["E-series", "SIMPLE_CHEMICAL", 44, 52], ["DHA", "SIMPLE_CHEMICAL", 58, 61], ["D-series", "SIMPLE_CHEMICAL", 63, 71], ["protectin", "SIMPLE_CHEMICAL", 77, 86], ["maresin", "SIMPLE_CHEMICAL", 91, 98], ["DHA", "SIMPLE_CHEMICAL", 104, 107], ["EPA (E-series", "TEST", 39, 52], ["DHA (D-series)", "TREATMENT", 58, 72], ["protectin", "TREATMENT", 77, 86], ["resolvins", "OBSERVATION_MODIFIER", 24, 33]]], ["Their synthesis involves the COX and LOX pathways operating in a transcellular manner (231) .", [["COX", "GENE_OR_GENE_PRODUCT", 29, 32], ["LOX", "GENE_OR_GENE_PRODUCT", 37, 40], ["COX", "PROTEIN", 29, 32], ["LOX", "PROTEIN", 37, 40]]], ["These compounds can be found in humans after EPA or DHA intake (232) and have shown anti-inflammatory benefits in vitro and in animal models of inflammation (233) .", [["EPA", "CHEMICAL", 45, 48], ["DHA", "CHEMICAL", 52, 55], ["inflammation", "DISEASE", 144, 156], ["EPA", "CHEMICAL", 45, 48], ["DHA", "CHEMICAL", 52, 55], ["humans", "ORGANISM", 32, 38], ["EPA", "SIMPLE_CHEMICAL", 45, 48], ["DHA", "SIMPLE_CHEMICAL", 52, 55], ["humans", "SPECIES", 32, 38], ["humans", "SPECIES", 32, 38], ["DHA intake", "TEST", 52, 62], ["inflammation", "PROBLEM", 144, 156], ["anti-inflammatory", "OBSERVATION_MODIFIER", 84, 101], ["inflammation", "OBSERVATION", 144, 156]]], ["By these mechanisms, omega-3 PUFA and especially DHA decrease expression of adhesion molecules such as ICAM-1 on the surface of endothelial cells and monocyte cultures, as well as of scavenger receptor A in rats fed a high fat fish oil diet (234) .Omega-3 fatty acids.The activity on NF-\uf06bB is probably exerted by reduced translocation of the NF-\uf06bB p503 and p-65 subunits to the nucleus where they bind omega-3 response elements, upregulating inflammatory gene expression.", [["surface", "ANATOMY", 117, 124], ["endothelial cells", "ANATOMY", 128, 145], ["monocyte cultures", "ANATOMY", 150, 167], ["nucleus", "ANATOMY", 378, 385], ["omega-3 PUFA", "CHEMICAL", 21, 33], ["DHA", "CHEMICAL", 49, 52], ["Omega-3 fatty acids", "CHEMICAL", 248, 267], ["PUFA", "CHEMICAL", 29, 33], ["DHA", "CHEMICAL", 49, 52], ["Omega-3 fatty acids", "CHEMICAL", 248, 267], ["omega-3 PUFA", "SIMPLE_CHEMICAL", 21, 33], ["DHA", "SIMPLE_CHEMICAL", 49, 52], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 103, 109], ["surface", "CELLULAR_COMPONENT", 117, 124], ["endothelial cells", "CELL", 128, 145], ["monocyte cultures", "CELL", 150, 167], ["scavenger receptor A", "GENE_OR_GENE_PRODUCT", 183, 203], ["rats", "ORGANISM", 207, 211], ["Omega-3 fatty acids", "SIMPLE_CHEMICAL", 248, 267], ["NF-\uf06bB", "GENE_OR_GENE_PRODUCT", 284, 289], ["NF-\uf06bB p503", "GENE_OR_GENE_PRODUCT", 342, 352], ["p-65", "GENE_OR_GENE_PRODUCT", 357, 361], ["nucleus", "CELLULAR_COMPONENT", 378, 385], ["omega-3", "GENE_OR_GENE_PRODUCT", 402, 409], ["adhesion molecules", "PROTEIN", 76, 94], ["ICAM-1", "PROTEIN", 103, 109], ["endothelial cells", "CELL_TYPE", 128, 145], ["monocyte cultures", "CELL_LINE", 150, 167], ["scavenger receptor A", "PROTEIN", 183, 203], ["NF-\uf06bB", "PROTEIN", 284, 289], ["NF-\uf06bB p503 and p-65 subunits", "PROTEIN", 342, 370], ["omega-3 response elements", "DNA", 402, 427], ["rats", "SPECIES", 207, 211], ["omega-3 PUFA", "TREATMENT", 21, 33], ["adhesion molecules", "PROBLEM", 76, 94], ["ICAM", "TEST", 103, 107], ["endothelial cells", "TEST", 128, 145], ["monocyte cultures", "TEST", 150, 167], ["a high fat fish oil diet", "TREATMENT", 216, 240], ["Omega-3 fatty acids", "TREATMENT", 248, 267], ["upregulating inflammatory gene expression", "PROBLEM", 429, 470], ["adhesion molecules", "OBSERVATION", 76, 94], ["endothelial", "ANATOMY", 128, 139], ["activity", "OBSERVATION_MODIFIER", 272, 280], ["probably", "UNCERTAINTY", 293, 301], ["nucleus", "ANATOMY", 378, 385], ["inflammatory", "OBSERVATION_MODIFIER", 442, 454]]], ["Exposure of macrophages to DHA inhibits the ability of LPS in TLR4 agonist to J o u r n a l P r e -p r o o f promote recruitment of co-stimulatory molecules, MHC class II and stimulate cytokine production (235) .Omega-3 fatty acids.In view of the relatively simple way of measuring circulating proinflammatory cytokines, a randomized controlled study in aging adults with chronic venous leg ulcers given EPA+DHA therapy In this study patients received 2 g bid of purified EPA vs placebo, resulting in a primary endpoint reduction of 25% (239) .", [["macrophages", "ANATOMY", 12, 23], ["venous leg ulcers", "ANATOMY", 380, 397], ["DHA", "CHEMICAL", 27, 30], ["LPS", "CHEMICAL", 55, 58], ["Omega-3 fatty acids", "CHEMICAL", 212, 231], ["chronic venous leg ulcers", "DISEASE", 372, 397], ["EPA", "CHEMICAL", 404, 407], ["DHA", "CHEMICAL", 408, 411], ["EPA", "CHEMICAL", 472, 475], ["DHA", "CHEMICAL", 27, 30], ["Omega-3 fatty acids", "CHEMICAL", 212, 231], ["EPA", "CHEMICAL", 404, 407], ["DHA", "CHEMICAL", 408, 411], ["EPA", "CHEMICAL", 472, 475], ["macrophages", "CELL", 12, 23], ["DHA", "SIMPLE_CHEMICAL", 27, 30], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["TLR4", "GENE_OR_GENE_PRODUCT", 62, 66], ["MHC class II", "GENE_OR_GENE_PRODUCT", 158, 170], ["Omega-3 fatty acids", "SIMPLE_CHEMICAL", 212, 231], ["venous leg", "ORGANISM_SUBDIVISION", 380, 390], ["EPA", "SIMPLE_CHEMICAL", 404, 407], ["DHA", "SIMPLE_CHEMICAL", 408, 411], ["patients", "ORGANISM", 434, 442], ["EPA", "SIMPLE_CHEMICAL", 472, 475], ["macrophages", "CELL_TYPE", 12, 23], ["TLR4", "PROTEIN", 62, 66], ["co-stimulatory molecules", "PROTEIN", 132, 156], ["MHC class II", "PROTEIN", 158, 170], ["cytokine", "PROTEIN", 185, 193], ["proinflammatory cytokines", "PROTEIN", 294, 319], ["patients", "SPECIES", 434, 442], ["LPS in TLR4 agonist", "TREATMENT", 55, 74], ["co-stimulatory molecules", "PROBLEM", 132, 156], ["Omega-3 fatty acids", "TREATMENT", 212, 231], ["measuring circulating proinflammatory cytokines", "PROBLEM", 272, 319], ["a randomized controlled study", "TEST", 321, 350], ["chronic venous leg ulcers", "PROBLEM", 372, 397], ["EPA", "TREATMENT", 404, 407], ["DHA therapy", "TREATMENT", 408, 419], ["this study", "TEST", 423, 433], ["purified EPA", "TREATMENT", 463, 475], ["placebo", "TREATMENT", 479, 486], ["a primary endpoint reduction", "TEST", 501, 529], ["macrophages", "OBSERVATION", 12, 23], ["proinflammatory cytokines", "OBSERVATION", 294, 319], ["chronic", "OBSERVATION_MODIFIER", 372, 379], ["venous", "ANATOMY", 380, 386], ["leg", "ANATOMY", 387, 390], ["ulcers", "OBSERVATION", 391, 397], ["DHA therapy", "OBSERVATION", 408, 419]]], ["Interestingly, at the last visit hsCRP levels were reduced by 23%, thus probably adding to the CV benefit of EPA intake.CONCLUSIONSThe clinician's approach to arterial disease is more and more frequently calling to action an inflammatory condition and the potentially use of agents affecting inflammation (240) .", [["arterial", "ANATOMY", 159, 167], ["EPA", "CHEMICAL", 109, 112], ["arterial disease", "DISEASE", 159, 175], ["inflammation", "DISEASE", 292, 304], ["EPA", "CHEMICAL", 109, 112], ["hsCRP", "GENE_OR_GENE_PRODUCT", 33, 38], ["EPA", "SIMPLE_CHEMICAL", 109, 112], ["arterial", "MULTI-TISSUE_STRUCTURE", 159, 167], ["hsCRP", "PROTEIN", 33, 38], ["hsCRP levels", "TEST", 33, 45], ["EPA intake", "TREATMENT", 109, 119], ["arterial disease", "PROBLEM", 159, 175], ["an inflammatory condition", "PROBLEM", 222, 247], ["inflammation", "PROBLEM", 292, 304], ["arterial", "ANATOMY", 159, 167], ["disease", "OBSERVATION", 168, 175], ["inflammatory", "OBSERVATION", 225, 237]]], ["This latter is certainly consequent to the presence of cholesterol crystals in the lesion, promoting plaque instability, but newer factors have come into play, in particular from an improved knowledge of myelopoiesis related mechanisms (9) .", [["lesion", "ANATOMY", 83, 89], ["plaque", "ANATOMY", 101, 107], ["cholesterol", "CHEMICAL", 55, 66], ["plaque instability", "DISEASE", 101, 119], ["cholesterol", "CHEMICAL", 55, 66], ["cholesterol", "SIMPLE_CHEMICAL", 55, 66], ["plaque", "PATHOLOGICAL_FORMATION", 101, 107], ["cholesterol crystals in the lesion", "PROBLEM", 55, 89], ["promoting plaque instability", "PROBLEM", 91, 119], ["myelopoiesis related mechanisms", "PROBLEM", 204, 235], ["cholesterol", "OBSERVATION_MODIFIER", 55, 66], ["crystals", "OBSERVATION_MODIFIER", 67, 75], ["lesion", "OBSERVATION", 83, 89], ["plaque", "OBSERVATION_MODIFIER", 101, 107], ["instability", "OBSERVATION", 108, 119], ["myelopoiesis", "OBSERVATION", 204, 216]]], ["Both raised progenitor cell recruitment after major CV events and clonal hematopoiesis related mechanisms, have provided crucial information on the inflammatory mechanisms underlying the ACS, also identifying potentially protective mechanisms such as the TET2 production (19) (Graphical abstract).CONCLUSIONSClinical diagnostics in CVD has instead mainly relied on circulating biomarkers, in particular the hsCRP, working as an acute marker and as an event predictor.", [["progenitor cell", "ANATOMY", 12, 27], ["ACS", "DISEASE", 187, 190], ["CVD", "DISEASE", 332, 335], ["progenitor cell", "CELL", 12, 27], ["TET2", "GENE_OR_GENE_PRODUCT", 255, 259], ["hsCRP", "GENE_OR_GENE_PRODUCT", 407, 412], ["TET2", "PROTEIN", 255, 259], ["hsCRP", "PROTEIN", 407, 412], ["progenitor cell recruitment", "TREATMENT", 12, 39], ["major CV events", "PROBLEM", 46, 61], ["clonal hematopoiesis", "PROBLEM", 66, 86], ["the inflammatory mechanisms", "PROBLEM", 144, 171], ["the ACS", "PROBLEM", 183, 190], ["the TET2 production", "PROBLEM", 251, 270], ["CVD", "PROBLEM", 332, 335], ["circulating biomarkers", "TEST", 365, 387], ["progenitor cell recruitment", "OBSERVATION", 12, 39], ["clonal hematopoiesis", "OBSERVATION", 66, 86]]], ["Agents affecting hsCRP levels, in particular canakinumab and, more recently, colchicine, both reduced hsCRP and inflammatory phenomena, leading to a reduced number of event relapses, independent of changes of other risk markers including lipids or hypertension (57, 63, 68) .J o u r n a l P r e -p r o o fAmong drug classes of common use in CVD treatment, variable effects have been shown on inflammatory biomarkers, in particular hsCRP (241) .", [["canakinumab", "CHEMICAL", 45, 56], ["colchicine", "CHEMICAL", 77, 87], ["hypertension", "DISEASE", 248, 260], ["CVD", "DISEASE", 341, 344], ["canakinumab", "CHEMICAL", 45, 56], ["colchicine", "CHEMICAL", 77, 87], ["hsCRP", "GENE_OR_GENE_PRODUCT", 17, 22], ["canakinumab", "SIMPLE_CHEMICAL", 45, 56], ["colchicine", "SIMPLE_CHEMICAL", 77, 87], ["hsCRP", "GENE_OR_GENE_PRODUCT", 102, 107], ["lipids", "SIMPLE_CHEMICAL", 238, 244], ["hsCRP", "GENE_OR_GENE_PRODUCT", 431, 436], ["hsCRP", "PROTEIN", 17, 22], ["hsCRP", "PROTEIN", 102, 107], ["hsCRP", "PROTEIN", 431, 436], ["hsCRP levels", "TEST", 17, 29], ["colchicine", "TREATMENT", 77, 87], ["both reduced hsCRP", "PROBLEM", 89, 107], ["inflammatory phenomena", "PROBLEM", 112, 134], ["lipids", "TREATMENT", 238, 244], ["hypertension", "PROBLEM", 248, 260], ["CVD treatment", "TREATMENT", 341, 354], ["inflammatory biomarkers", "TEST", 392, 415], ["inflammatory phenomena", "OBSERVATION", 112, 134], ["reduced", "OBSERVATION_MODIFIER", 149, 156], ["relapses", "OBSERVATION", 173, 181], ["hypertension", "OBSERVATION", 248, 260], ["inflammatory", "OBSERVATION_MODIFIER", 392, 404]]], ["In the case of lipid lowering agents, statins have provided the first evidence indicative of the CV benefit of the reduction of hsCRP in addition to that of LDL-C (242) .", [["statins", "CHEMICAL", 38, 45], ["LDL-C", "CHEMICAL", 157, 162], ["statins", "CHEMICAL", 38, 45], ["lipid", "SIMPLE_CHEMICAL", 15, 20], ["statins", "SIMPLE_CHEMICAL", 38, 45], ["hsCRP", "GENE_OR_GENE_PRODUCT", 128, 133], ["LDL-C", "SIMPLE_CHEMICAL", 157, 162], ["hsCRP", "PROTEIN", 128, 133], ["LDL", "PROTEIN", 157, 160], ["lipid lowering agents", "TREATMENT", 15, 36], ["statins", "TREATMENT", 38, 45], ["hsCRP", "TEST", 128, 133], ["LDL", "TEST", 157, 160]]], ["Fibrates have shown hsCRP reduction in the metabolic syndrome, whereas ezetimibe has modest effects, potentially additive to those of statins in drug combinations.", [["metabolic syndrome", "DISEASE", 43, 61], ["ezetimibe", "CHEMICAL", 71, 80], ["statins", "CHEMICAL", 134, 141], ["ezetimibe", "CHEMICAL", 71, 80], ["statins", "CHEMICAL", 134, 141], ["hsCRP", "GENE_OR_GENE_PRODUCT", 20, 25], ["ezetimibe", "SIMPLE_CHEMICAL", 71, 80], ["hsCRP", "PROTEIN", 20, 25], ["Fibrates", "TREATMENT", 0, 8], ["hsCRP reduction", "PROBLEM", 20, 35], ["the metabolic syndrome", "PROBLEM", 39, 61], ["ezetimibe", "TREATMENT", 71, 80], ["statins", "TREATMENT", 134, 141], ["drug combinations", "TREATMENT", 145, 162], ["hsCRP", "OBSERVATION_MODIFIER", 20, 25], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["metabolic syndrome", "OBSERVATION", 43, 61]]], ["Finally, among newer agents, bempedoic acid appears to provide the best combination of LDL-C and hsCRP reductions.", [["bempedoic acid", "CHEMICAL", 29, 43], ["bempedoic acid", "CHEMICAL", 29, 43], ["bempedoic acid", "SIMPLE_CHEMICAL", 29, 43], ["LDL-C", "SIMPLE_CHEMICAL", 87, 92], ["hsCRP", "GENE_OR_GENE_PRODUCT", 97, 102], ["LDL", "PROTEIN", 87, 90], ["hsCRP", "PROTEIN", 97, 102], ["bempedoic acid", "TREATMENT", 29, 43], ["LDL", "TEST", 87, 90], ["C and hsCRP reductions", "TREATMENT", 91, 113]]], ["The case of PCSK9 antagonist is more complex, since these agents do not directly reduce hsCRP levels (243) .", [["PCSK9", "GENE_OR_GENE_PRODUCT", 12, 17], ["hsCRP", "GENE_OR_GENE_PRODUCT", 88, 93], ["PCSK9", "PROTEIN", 12, 17], ["hsCRP", "PROTEIN", 88, 93], ["PCSK9 antagonist", "TREATMENT", 12, 28], ["hsCRP levels", "TEST", 88, 100]]], ["However, identification of patients with elevated hsCRP leads to the choice of individuals best responding to drug treatment (117) (Figure 2 ).J o u r n a l P r e -p r o o fAmong agents for blood pressure lowering, ACE inhibitors have an optimal antiinflammatory activity, potentially additive to that of sartans, somewhat less effective but exerting a stimulatory activity on eicosanoid metabolism.", [["blood", "ANATOMY", 190, 195], ["sartans", "CHEMICAL", 305, 312], ["eicosanoid", "CHEMICAL", 377, 387], ["patients", "ORGANISM", 27, 35], ["hsCRP", "GENE_OR_GENE_PRODUCT", 50, 55], ["o fAmong agents", "SIMPLE_CHEMICAL", 170, 185], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["ACE", "GENE_OR_GENE_PRODUCT", 215, 218], ["sartans", "SIMPLE_CHEMICAL", 305, 312], ["eicosanoid", "SIMPLE_CHEMICAL", 377, 387], ["hsCRP", "PROTEIN", 50, 55], ["patients", "SPECIES", 27, 35], ["elevated hsCRP", "PROBLEM", 41, 55], ["drug treatment", "TREATMENT", 110, 124], ["a l P r e -p r o o fAmong agents", "TREATMENT", 153, 185], ["blood pressure lowering", "TREATMENT", 190, 213], ["ACE inhibitors", "TREATMENT", 215, 229], ["an optimal antiinflammatory activity", "TREATMENT", 235, 271], ["sartans", "TREATMENT", 305, 312], ["eicosanoid metabolism", "TREATMENT", 377, 398], ["elevated", "OBSERVATION_MODIFIER", 41, 49], ["hsCRP", "OBSERVATION", 50, 55]]], ["Calcium channel blocker act by way of a CaSR, a cell surface coupled G protein receptor, regulating the NLRP3 inflammasome in the vascular area.J o u r n a l P r e -p r o o fThe diabetic condition is characterized by an increased inflammatory burden, with endothelial cell dysfunction and increased adhesion molecules.", [["cell surface", "ANATOMY", 48, 60], ["vascular area", "ANATOMY", 130, 143], ["endothelial cell", "ANATOMY", 256, 272], ["Calcium", "CHEMICAL", 0, 7], ["diabetic condition", "DISEASE", 178, 196], ["Calcium", "CHEMICAL", 0, 7], ["Calcium", "SIMPLE_CHEMICAL", 0, 7], ["CaSR", "GENE_OR_GENE_PRODUCT", 40, 44], ["cell", "CELL", 48, 52], ["G protein receptor", "GENE_OR_GENE_PRODUCT", 69, 87], ["NLRP3", "GENE_OR_GENE_PRODUCT", 104, 109], ["vascular area", "MULTI-TISSUE_STRUCTURE", 130, 143], ["endothelial cell", "CELL", 256, 272], ["CaSR", "PROTEIN", 40, 44], ["cell surface coupled G protein receptor", "PROTEIN", 48, 87], ["NLRP3", "PROTEIN", 104, 109], ["adhesion molecules", "PROTEIN", 299, 317], ["Calcium channel blocker", "TREATMENT", 0, 23], ["a CaSR", "TEST", 38, 44], ["a cell surface coupled G protein receptor", "TREATMENT", 46, 87], ["the NLRP3 inflammasome", "TREATMENT", 100, 122], ["The diabetic condition", "PROBLEM", 174, 196], ["an increased inflammatory burden", "PROBLEM", 217, 249], ["endothelial cell dysfunction", "PROBLEM", 256, 284], ["increased adhesion molecules", "PROBLEM", 289, 317], ["NLRP3 inflammasome", "OBSERVATION", 104, 122], ["vascular", "ANATOMY", 130, 138], ["area", "ANATOMY_MODIFIER", 139, 143], ["diabetic", "OBSERVATION", 178, 186], ["increased", "OBSERVATION_MODIFIER", 220, 229], ["inflammatory", "OBSERVATION_MODIFIER", 230, 242], ["endothelial cell dysfunction", "OBSERVATION", 256, 284], ["increased", "OBSERVATION_MODIFIER", 289, 298], ["adhesion molecules", "OBSERVATION", 299, 317]]], ["The novel antidiabetic agents, such as the incretin drugs, antagonizing glucagon secretion and delaying gastric emptying, reduce inflammatory mediators, including hsCRP, IL-6, IL1-\uf062 and ICAM-1.", [["gastric", "ANATOMY", 104, 111], ["glucagon", "GENE_OR_GENE_PRODUCT", 72, 80], ["gastric", "ORGAN", 104, 111], ["hsCRP", "GENE_OR_GENE_PRODUCT", 163, 168], ["IL-6", "GENE_OR_GENE_PRODUCT", 170, 174], ["IL1-\uf062", "GENE_OR_GENE_PRODUCT", 176, 181], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 186, 192], ["inflammatory mediators", "PROTEIN", 129, 151], ["hsCRP", "PROTEIN", 163, 168], ["IL-6", "PROTEIN", 170, 174], ["IL1", "PROTEIN", 176, 179], ["ICAM-1", "PROTEIN", 186, 192], ["The novel antidiabetic agents", "TREATMENT", 0, 29], ["the incretin drugs", "TREATMENT", 39, 57], ["antagonizing glucagon secretion", "TREATMENT", 59, 90], ["delaying gastric emptying", "PROBLEM", 95, 120], ["inflammatory mediators", "PROBLEM", 129, 151], ["hsCRP", "TEST", 163, 168], ["IL", "TEST", 170, 172], ["IL1", "TEST", 176, 179], ["ICAM", "TEST", 186, 190], ["gastric", "ANATOMY", 104, 111]]], ["The SLGT-2 inhibitors, instead, have in general shown impressive CV benefit, reduction of events being not only of the ischemic type but more frequently consequent to heart failure.", [["heart", "ANATOMY", 167, 172], ["heart failure", "DISEASE", 167, 180], ["SLGT-2", "GENE_OR_GENE_PRODUCT", 4, 10], ["heart", "ORGAN", 167, 172], ["The SLGT-2 inhibitors", "TREATMENT", 0, 21], ["impressive CV benefit", "PROBLEM", 54, 75], ["the ischemic type", "PROBLEM", 115, 132], ["heart failure", "PROBLEM", 167, 180], ["ischemic", "OBSERVATION", 119, 127], ["heart", "ANATOMY", 167, 172], ["failure", "OBSERVATION", 173, 180]]], ["The impressive clinical activity has, however, been associated with modest reductions in hsCRP, TNF-\uf061, and IL-6, thus suggesting that the antifailure activity may not be linked to an anti-inflammatory effect ( Figure 3 ).", [["hsCRP", "GENE_OR_GENE_PRODUCT", 89, 94], ["TNF-\uf061", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-6", "GENE_OR_GENE_PRODUCT", 107, 111], ["hsCRP", "PROTEIN", 89, 94], ["TNF", "PROTEIN", 96, 99], ["IL-6", "PROTEIN", 107, 111], ["modest reductions", "PROBLEM", 68, 85], ["hsCRP", "TEST", 89, 94], ["TNF", "TEST", 96, 99], ["IL", "TEST", 107, 109], ["the antifailure activity", "PROBLEM", 134, 158], ["impressive", "OBSERVATION_MODIFIER", 4, 14], ["modest", "OBSERVATION_MODIFIER", 68, 74], ["reductions", "OBSERVATION_MODIFIER", 75, 85]]], ["The overall evaluation of present knowledge on inflammation and CV risk points out, to specialists and non-specialists, the major role of evaluating the pro-and antiinflammatory profile of major agents used in therapy as well as the diagnostic criteria for establishing the most appropriate guidelines for prevention and treatment.", [["inflammation", "DISEASE", 47, 59], ["The overall evaluation", "TEST", 0, 22], ["inflammation", "PROBLEM", 47, 59], ["CV risk points", "PROBLEM", 64, 78], ["major agents", "TREATMENT", 189, 201], ["therapy", "TREATMENT", 210, 217], ["treatment", "TREATMENT", 321, 330]]], ["Table 4 Clinical study IL-6 hsCRP TNF-\uf061 Canagliflozin (259) CANTATA-SU -22% -4.4% +7%Conflict of interestEmpagliflozin (260) UMIN000021552 n/a +3.3% n/a Dapagliflozin (261) n/a From 0.26 (0.11-0-53) to (0.05-0.32) n/a", [["Canagliflozin", "CHEMICAL", 40, 53], ["interestEmpagliflozin", "CHEMICAL", 97, 118], ["UMIN000021552", "CHEMICAL", 125, 138], ["Dapagliflozin", "CHEMICAL", 153, 166], ["Canagliflozin", "CHEMICAL", 40, 53], ["interestEmpagliflozin", "CHEMICAL", 97, 118], ["Dapagliflozin", "CHEMICAL", 153, 166], ["IL-6", "GENE_OR_GENE_PRODUCT", 23, 27], ["TNF", "GENE_OR_GENE_PRODUCT", 34, 37], ["interestEmpagliflozin", "SIMPLE_CHEMICAL", 97, 118], ["TNF", "PROTEIN", 34, 37], ["Clinical study IL", "TEST", 8, 25], ["TNF", "TEST", 34, 37], ["Canagliflozin", "TEST", 40, 53], ["CANTATA", "TEST", 60, 67], ["a Dapagliflozin", "TREATMENT", 151, 166]]]], "abf7526308d07bb5fd96d27c8a21bdabf1622914": [["IntroductionThe emergence of new human viral diseases aff ecting the respiratory tract continues to threaten global public health security.", [["respiratory tract", "ANATOMY", 69, 86], ["viral diseases", "DISEASE", 39, 53], ["respiratory tract", "DISEASE", 69, 86], ["human", "ORGANISM", 33, 38], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["new human viral diseases", "PROBLEM", 29, 53], ["the respiratory tract", "PROBLEM", 65, 86], ["viral diseases", "OBSERVATION", 39, 53], ["respiratory tract", "ANATOMY", 69, 86]]], ["On March 12, 2003, WHO issued a global alert for an emerging and yet unknown illness that was subsequently known as severe acute respiratory syndrome (SARS) caused by a novel coronavirus (SARS-CoV).", [["acute respiratory syndrome", "DISEASE", 123, 149], ["SARS", "DISEASE", 151, 155], ["SARS", "DISEASE", 188, 192], ["coronavirus", "ORGANISM", 175, 186], ["SARS-CoV", "ORGANISM", 188, 196], ["SARS-CoV", "SPECIES", 188, 196], ["severe acute respiratory syndrome", "PROBLEM", 116, 149], ["SARS", "PROBLEM", 151, 155], ["a novel coronavirus", "PROBLEM", 167, 186], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["respiratory syndrome", "OBSERVATION", 129, 149]]], ["1 SARS-CoV caused more than 8000 cases and 800 deaths in over 30 countries with a substantial economic impact.", [["SARS", "DISEASE", 2, 6], ["deaths", "DISEASE", 47, 53], ["SARS-CoV", "ORGANISM", 2, 10], ["SARS-CoV", "SPECIES", 2, 10]]], ["2 Since then, several other viral respiratory pathogens (table 1) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] have emerged including avian infl uenza (H5N1, H7N9, H10N8), variant infl uenza A H3N2 virus, human adenovirus-14, and Middle East respiratory syndrome coronavirus (MERS-CoV).", [["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19", "CHEMICAL", 66, 142], ["Middle East respiratory syndrome coronavirus", "DISEASE", 263, 307], ["[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 66, 143], ["avian", "ORGANISM", 167, 172], ["infl uenza", "ORGANISM", 173, 183], ["H5N1", "ORGANISM", 185, 189], ["infl uenza A H3N2 virus", "ORGANISM", 213, 236], ["human adenovirus-14", "ORGANISM", 238, 257], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 263, 307], ["MERS-CoV", "ORGANISM", 309, 317], ["A H3N2 virus", "SPECIES", 224, 236], ["human", "SPECIES", 238, 243], ["infl uenza A H3N2 virus", "SPECIES", 213, 236], ["human adenovirus-14", "SPECIES", 238, 257], ["Middle East respiratory syndrome coronavirus", "SPECIES", 263, 307], ["MERS-CoV", "SPECIES", 309, 317], ["several other viral respiratory pathogens", "TEST", 14, 55], ["avian infl uenza", "TEST", 167, 183], ["H5N1", "TEST", 185, 189], ["H7N9", "TEST", 191, 195], ["H10N8", "TEST", 197, 202], ["variant infl", "TEST", 205, 217], ["A H3N2 virus", "PROBLEM", 224, 236], ["human adenovirus", "TEST", 238, 254], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 263, 307], ["H3N2 virus", "OBSERVATION", 226, 236], ["Middle", "ANATOMY_MODIFIER", 263, 269], ["respiratory syndrome", "OBSERVATION", 275, 295]]], ["Soon after the discovery of SARS, additional coronaviruses were also identifi ed: corona virus NL63 and coronavirus HKU1.", [["SARS", "DISEASE", 28, 32], ["coronaviruses", "ORGANISM", 45, 58], ["corona virus NL63", "ORGANISM", 82, 99], ["coronavirus HKU1", "ORGANISM", 104, 120], ["coronavirus HKU1", "PROTEIN", 104, 120], ["coronavirus", "SPECIES", 104, 115], ["SARS", "PROBLEM", 28, 32], ["additional coronaviruses", "PROBLEM", 34, 58], ["corona virus NL63", "PROBLEM", 82, 99], ["coronavirus HKU1", "PROBLEM", 104, 120]]], ["3, 4 Most infl uenza A epidemics occur in January, February, and March.", [["epidemics", "OBSERVATION", 23, 32]]], ["However, outbreaks of infl uenza A Beijing/32/92 H3N2 in 1993 and Fujian/411/2002 H3N2 in 2003 happened in November and December.", [["infl uenza A Beijing/32/92 H3N2", "ORGANISM", 22, 53], ["Fujian/411/2002 H3N2", "ORGANISM", 66, 86], ["infl uenza A Beijing/32/92 H3N2", "SPECIES", 22, 53], ["Fujian/411/2002 H3N2", "SPECIES", 66, 86], ["H3N2", "PROBLEM", 49, 53], ["H3N2", "PROBLEM", 82, 86]]], ["20 In an analysis of 335 emerging infectious diseases from 1940 to 2004, most (60%) were zoonoses and 25% were viruses, and the study showed an increase in events over time.", [["infectious diseases", "DISEASE", 34, 53], ["zoonoses", "DISEASE", 89, 97], ["an analysis", "TEST", 6, 17], ["the study", "TEST", 124, 133], ["an increase in events", "PROBLEM", 141, 162], ["infectious", "OBSERVATION", 34, 44], ["increase", "OBSERVATION_MODIFIER", 144, 152]]], ["21 In this Series paper, we review worldwide active surveillance systems for emerging and re-emerging respiratory viruses.", [["respiratory viruses", "DISEASE", 102, 121], ["surveillance systems", "TEST", 52, 72], ["re-emerging respiratory viruses", "PROBLEM", 90, 121], ["respiratory viruses", "OBSERVATION", 102, 121]]], ["We identify the rapid and early identifi cation systems to allow early control measures to be put in place to prevent the spread of these pathogens.", [["early identifi cation systems", "TREATMENT", 26, 55], ["early control measures", "TREATMENT", 65, 87], ["these pathogens", "PROBLEM", 132, 147], ["rapid", "OBSERVATION_MODIFIER", 16, 21], ["pathogens", "OBSERVATION", 138, 147]]], ["We also review the work of WHO Global Infl uenza Surveillance Network (GISN), Global Infl uenza Surveillance and Response System (GISRS), and the network of national infl uenza centres and laboratories.IntroductionSevere acute respiratory infection (SARI) is defi ned as fever of at least 100\u00baF (37\u00b78\u00b0C) or self-reported fever, and either a cough or a sore throat, and hospital admission.", [["respiratory", "ANATOMY", 227, 238], ["acute respiratory infection", "DISEASE", 221, 248], ["SARI", "DISEASE", 250, 254], ["fever", "DISEASE", 271, 276], ["fever", "DISEASE", 321, 326], ["cough", "DISEASE", 341, 346], ["sore throat", "DISEASE", 352, 363], ["acute respiratory infection", "PROBLEM", 221, 248], ["fever", "PROBLEM", 271, 276], ["fever", "PROBLEM", 321, 326], ["a cough", "PROBLEM", 339, 346], ["a sore throat", "PROBLEM", 350, 363], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["respiratory", "ANATOMY", 227, 238], ["infection", "OBSERVATION", 239, 248], ["cough", "OBSERVATION", 341, 346], ["sore throat", "ANATOMY", 352, 363]]], ["22 An infl uenza-like illness (ILI) is defi ned as acute illness with fever greater than 38\u00b0C, and cough or sore throat.", [["infl uenza-like illness", "DISEASE", 6, 29], ["ILI", "DISEASE", 31, 34], ["fever", "DISEASE", 70, 75], ["38\u00b0C", "DISEASE", 89, 93], ["cough", "DISEASE", 99, 104], ["sore throat", "DISEASE", 108, 119], ["acute illness", "PROBLEM", 51, 64], ["fever", "PROBLEM", 70, 75], ["cough", "PROBLEM", 99, 104], ["sore throat", "PROBLEM", 108, 119], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["illness", "OBSERVATION", 57, 64], ["sore throat", "ANATOMY", 108, 119]]], ["22Global surveillanceSurveillance of emerging and re-emerging respiratory viruses aims for rapid and early identifi cation andSurveillance goalsThe goals of surveillance are to monitor when the infl uenza season begins and ends, to characterise the types and subtypes of circulating strains, to monitor the clinical severity of illness, and to detect the emergence of any novel or reassortant viruses.", [["respiratory viruses", "DISEASE", 62, 81], ["illness", "DISEASE", 328, 335], ["re-emerging respiratory viruses", "PROBLEM", 50, 81], ["rapid and early identifi cation", "TREATMENT", 91, 122], ["circulating strains", "PROBLEM", 271, 290], ["illness", "PROBLEM", 328, 335], ["any novel or reassortant viruses", "PROBLEM", 368, 400], ["respiratory viruses", "OBSERVATION", 62, 81]]], ["This information also helps in selecting future vaccine strains.", [["future vaccine strains", "TREATMENT", 41, 63]]], ["The surveillance also monitors the emergence of any viral resistance.", [["The surveillance", "TEST", 0, 16], ["any viral resistance", "PROBLEM", 48, 68], ["viral resistance", "OBSERVATION", 52, 68]]], ["27 The basic goals of infl uenza surveillance include description of the epidemiology of seasonal infl uenza and burden of disease, provision of isolates for identifi cation of viruses and monitoring of resistance, and provision of country-specifi c data for programme planning and preparedness.", [["seasonal infl uenza", "PROBLEM", 89, 108], ["disease", "PROBLEM", 123, 130], ["isolates", "TREATMENT", 145, 153], ["identifi cation of viruses", "TREATMENT", 158, 184], ["programme planning", "TREATMENT", 259, 277], ["disease", "OBSERVATION", 123, 130]]], ["After the reemergence of highly-pathogenic infl uenza A H5N1 in 2004, another objective was to provide an early warning for outbreaks of novel infl uenza or agents of SARI in human beings or the circulation of a potentially new pandemic pathogen.", [["SARI", "CHEMICAL", 167, 171], ["infl uenza A H5N1", "ORGANISM", 43, 60], ["infl uenza", "ORGANISM", 143, 153], ["human", "ORGANISM", 175, 180], ["uenza A H5N1", "SPECIES", 48, 60], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["novel infl uenza", "TREATMENT", 137, 153], ["SARI", "PROBLEM", 167, 171], ["a potentially new pandemic pathogen", "PROBLEM", 210, 245]]], ["The main aim of pandemic surveillance is the early recognition of the emergence of a novel virus so that control measures can be instituted.", [["a novel virus", "TREATMENT", 83, 96], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pandemic", "OBSERVATION", 16, 24]]], ["However, once a pandemic has begun, surveillance should switch to monitoring of the epidemiology, the characteristics of the virus, the eff ect of prevention and control measures, and the progression of the pandemic.", [["surveillance", "TEST", 36, 48], ["the virus", "PROBLEM", 121, 130], ["the eff ect of prevention", "TREATMENT", 132, 157], ["control measures", "TREATMENT", 162, 178], ["the pandemic", "PROBLEM", 203, 215], ["progression", "OBSERVATION_MODIFIER", 188, 199], ["pandemic", "OBSERVATION_MODIFIER", 207, 215]]], ["28Early warning signs for pandemicOne of the objectives of surveillance for SARI and ILI caused by infl uenza is the detection of early warning signs for the emergence of any novel infl uenza virus or respiratory virus with pandemic potential in human beings.", [["SARI", "DISEASE", 76, 80], ["ILI", "DISEASE", 85, 88], ["respiratory virus", "DISEASE", 201, 218], ["infl uenza virus", "ORGANISM", 181, 197], ["respiratory virus", "ORGANISM", 201, 218], ["human", "ORGANISM", 246, 251], ["human", "SPECIES", 246, 251], ["infl uenza virus", "SPECIES", 181, 197], ["human", "SPECIES", 246, 251], ["SARI", "PROBLEM", 76, 80], ["ILI", "PROBLEM", 85, 88], ["early warning signs", "PROBLEM", 130, 149], ["any novel infl uenza virus", "PROBLEM", 171, 197], ["respiratory virus", "PROBLEM", 201, 218], ["respiratory virus", "OBSERVATION", 201, 218]]], ["The early warning system is built to detect events with potential public health threat across international borders, to verify detected events, to assess the risk that an event will have global eff ect, to report such risk within 48 h of the event determination according to the International Health Regulations, and to work with WHO to establish any public health emergency of international concern.", [["global eff ect", "PROBLEM", 187, 201]]], ["29 For early warning systems to work, specifi c triggers or signal criteria are needed for immediate reporting of possible occurrence of a single or multiple cases; such cases might be the initial indicators of the emergence of a novel respiratory virus with a pandemic potential such as H5N1 and Middle East respiratory syndrome coronavirus (MERS-CoV).", [["respiratory virus", "DISEASE", 236, 253], ["Middle East respiratory syndrome coronavirus", "DISEASE", 297, 341], ["specifi c", "GENE_OR_GENE_PRODUCT", 38, 47], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 297, 341], ["MERS-CoV", "ORGANISM", 343, 351], ["H5N1", "SPECIES", 288, 292], ["Middle East respiratory syndrome coronavirus", "SPECIES", 297, 341], ["MERS-CoV", "SPECIES", 343, 351], ["a single or multiple cases", "PROBLEM", 137, 163], ["a novel respiratory virus", "PROBLEM", 228, 253], ["H5N1", "PROBLEM", 288, 292], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 297, 341], ["Middle", "ANATOMY_MODIFIER", 297, 303], ["respiratory syndrome", "OBSERVATION", 309, 329]]], ["SARIs or pneumonia in health-care workers might serve as important signal events that the virus has acquired the ability to spread to human beings, as seen in the SARS epidemic.", [["SARIs", "CHEMICAL", 0, 5], ["pneumonia", "DISEASE", 9, 18], ["SARS", "DISEASE", 163, 167], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["pneumonia", "PROBLEM", 9, 18], ["the virus", "PROBLEM", 86, 95], ["pneumonia", "OBSERVATION", 9, 18]]], ["Examples of events that might signal human-to-human transmission of an emergingYear RegionHantavirus pulmonary syndrome, sin nombre virus 16 Series respiratory disease include clusters of SARI in people with social connections within a 2 week period, pneumonia in health-care workers, or people with a social or occupational connection.", [["RegionHantavirus pulmonary syndrome", "DISEASE", 84, 119], ["respiratory disease", "DISEASE", 148, 167], ["SARI", "DISEASE", 188, 192], ["pneumonia", "DISEASE", 251, 260], ["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 46, 51], ["pulmonary", "ORGAN", 101, 110], ["sin nombre virus", "ORGANISM", 121, 137], ["people", "ORGANISM", 196, 202], ["people", "ORGANISM", 288, 294], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["people", "SPECIES", 196, 202], ["people", "SPECIES", 288, 294], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["pulmonary syndrome", "PROBLEM", 101, 119], ["sin nombre virus", "PROBLEM", 121, 137], ["Series respiratory disease", "PROBLEM", 141, 167], ["SARI", "PROBLEM", 188, 192], ["pneumonia", "PROBLEM", 251, 260], ["pulmonary", "ANATOMY", 101, 110], ["syndrome", "OBSERVATION", 111, 119], ["pneumonia", "OBSERVATION", 251, 260], ["occupational connection", "OBSERVATION", 312, 335]]], ["In addition, any change in the epidemiology of SARI cases, with a shift in the age distribution, an increase in mortality, or an increase in the number of cases, might signal the circulation of a new respiratory pathogen.", [["SARI", "DISEASE", 47, 51], ["respiratory pathogen", "DISEASE", 200, 220], ["SARI cases", "PROBLEM", 47, 57], ["an increase in mortality", "PROBLEM", 97, 121], ["a new respiratory pathogen", "PROBLEM", 194, 220], ["change", "OBSERVATION_MODIFIER", 17, 23], ["increase", "OBSERVATION_MODIFIER", 100, 108], ["mortality", "OBSERVATION", 112, 121], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["new", "OBSERVATION_MODIFIER", 196, 199], ["respiratory pathogen", "OBSERVATION", 200, 220]]], ["30, 31 Monitoring for signals of increased activityYear RegionWhen the weekly infl uenza rates exceed the seasonal infl uenza threshold this increase would signal the start of a new infl uenza season.", [["increased activity", "PROBLEM", 33, 51], ["the weekly infl uenza rates", "TREATMENT", 67, 94], ["the seasonal infl uenza threshold", "TREATMENT", 102, 135], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["activity", "OBSERVATION_MODIFIER", 43, 51]]], ["32 For signal detection, the model built should have autoregressive components, seasonal trends, other trends, and covariates to predict the number of cases beyond expected for a specifi c day.", [["signal detection", "TEST", 7, 23], ["autoregressive components", "PROBLEM", 53, 78]]], ["However, monitoring of ILI and SARI should take into account the trends in any existing data and not wait to have a defi nite signal of increased activity.Year RegionThe adaptation of emerging respiratory viruses to human beings might occur suddenly with widespread infection or more gradually with infection of an at-risk population.", [["respiratory viruses", "DISEASE", 193, 212], ["infection", "DISEASE", 266, 275], ["infection", "DISEASE", 299, 308], ["human", "ORGANISM", 216, 221], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["ILI", "PROBLEM", 23, 26], ["SARI", "TREATMENT", 31, 35], ["increased activity", "PROBLEM", 136, 154], ["emerging respiratory viruses", "PROBLEM", 184, 212], ["widespread infection", "PROBLEM", 255, 275], ["infection", "PROBLEM", 299, 308], ["increased activity", "OBSERVATION", 136, 154], ["respiratory viruses", "OBSERVATION", 193, 212], ["widespread", "OBSERVATION_MODIFIER", 255, 265], ["infection", "OBSERVATION", 266, 275]]], ["The exposure of an at-risk population to a common source results in a spillover of viruses into people.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["an at-risk population", "PROBLEM", 16, 37]]], ["Once these viruses have gained a sustained transmission from human-to-human with an R 0 of 1 or more, in certain conditions an epidemic can result.", [["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 70, 75], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 70, 75], ["viruses", "OBSERVATION", 11, 18]]], ["33 Monitoring of the rate at which R 0 increases serves as a marker for impending epidemic.", [["the rate", "TEST", 17, 25], ["impending epidemic", "PROBLEM", 72, 90]]], ["34 -36 For accurate estimates of R 0 , a detailed outbreak and contact investigation is required.Early detectionFor early detection of new and emerging respiratory viruses, it is important to establish a programme and systems to detect the fi rst evidence of sustained human-to-human transmission of an emerging respiratory pathogen.", [["respiratory", "ANATOMY", 312, 323], ["respiratory viruses", "DISEASE", 152, 171], ["respiratory pathogen", "DISEASE", 312, 332], ["human", "ORGANISM", 269, 274], ["human", "ORGANISM", 278, 283], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 278, 283], ["contact investigation", "TEST", 63, 84], ["Early detection", "TEST", 97, 112], ["new and emerging respiratory viruses", "PROBLEM", 135, 171], ["an emerging respiratory pathogen", "PROBLEM", 300, 332], ["new", "OBSERVATION_MODIFIER", 135, 138], ["respiratory viruses", "OBSERVATION", 152, 171], ["respiratory pathogen", "OBSERVATION", 312, 332]]], ["37 The occurrence of clusters of SARI in a localised area, the occurrence of an increased mortality or a change in the aff ected age group, or high sales of specifi c therapies for upper respiratory tract infections can be evidence of new and emerging respiratory viruses.", [["upper respiratory tract", "ANATOMY", 181, 204], ["SARI", "DISEASE", 33, 37], ["respiratory tract infections", "DISEASE", 187, 215], ["respiratory viruses", "DISEASE", 252, 271], ["specifi c", "GENE_OR_GENE_PRODUCT", 157, 166], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 181, 204], ["SARI", "PROBLEM", 33, 37], ["an increased mortality", "PROBLEM", 77, 99], ["specifi c therapies", "TREATMENT", 157, 176], ["upper respiratory tract infections", "PROBLEM", 181, 215], ["new and emerging respiratory viruses", "PROBLEM", 235, 271], ["clusters", "OBSERVATION_MODIFIER", 21, 29], ["SARI", "OBSERVATION", 33, 37], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["mortality", "OBSERVATION", 90, 99], ["change", "OBSERVATION_MODIFIER", 105, 111], ["upper", "ANATOMY_MODIFIER", 181, 186], ["respiratory tract", "ANATOMY", 187, 204], ["infections", "OBSERVATION", 205, 215], ["new", "OBSERVATION_MODIFIER", 235, 238], ["respiratory viruses", "OBSERVATION", 252, 271]]], ["WHO, through a number of sentinel labs, monitors and coordinates the surveillance activities for any infl uenza outbreaks as indicated earlier.Syndromic surveillanceSyndromic surveillance combines cases into syndromes rather than specifi c diagnoses.", [["sentinel labs", "TEST", 25, 38], ["the surveillance activities", "TEST", 65, 92], ["any infl uenza outbreaks", "PROBLEM", 97, 121], ["syndromes", "PROBLEM", 208, 217]]], ["38 Such surveillance depends on the defi nitions of ILI and SARI that require clinical diagnoses but might not diff erentiate between diff erent etiological causes.", [["ILI", "DISEASE", 52, 55], ["SARI", "DISEASE", 60, 64], ["ILI", "PROBLEM", 52, 55], ["diff erent etiological causes", "PROBLEM", 134, 163]]], ["43, 44 The use of emergency-servicesbased surveillance is most sensitive for severe illness and for illnesses aff ecting elderly individuals.", [["severe illness", "PROBLEM", 77, 91], ["illnesses", "PROBLEM", 100, 109]]], ["41, 45, 46 A systematic analysis of syndromic surveillance for infl uenza and ILI in emergency departments showed that various data, such as primary complaint, discharge diagnosis, and free text analysis of the entire medical record, were used.", [["ILI", "DISEASE", 78, 81], ["A systematic analysis", "TEST", 11, 32], ["syndromic surveillance", "TEST", 36, 58], ["infl uenza", "TEST", 63, 73]]], ["47 Surveillance of paediatric cases with ILI might also facilitate detection of outbreaks 1-4 weeks before the peak of the disease onset.", [["ILI", "DISEASE", 41, 44], ["ILI", "PROBLEM", 41, 44], ["outbreaks", "PROBLEM", 80, 89], ["the disease onset", "PROBLEM", 119, 136], ["disease", "OBSERVATION", 123, 130]]], ["48 The largest surveillance networks are the USA DiSTRIBuTE network (no longer active) and the European triple \"S\" system (Syndromic Surveillance Systems in Europe), and these two systems collected large-scale emergency-department-based infl uenza and ILI syndromic surveillance data.", [["ILI syndromic surveillance data", "TEST", 252, 283], ["largest", "OBSERVATION_MODIFIER", 7, 14], ["no longer", "UNCERTAINTY", 69, 78]]], ["49, 50 Surveillance usually provides the fastest way to identify diseases and is an excellent approach to focus appropriate response measures to any outbreak.", [["diseases", "PROBLEM", 65, 73], ["diseases", "OBSERVATION", 65, 73]]], ["51, 52 Syndromic surveillance systems enable a rapid response to outbreak detection.", [["Syndromic surveillance systems", "TEST", 7, 37], ["outbreak detection", "TEST", 65, 83]]], ["53 The establishment of the Japanese non-governmental organisation Agency for Cooperation in International Health as a sentinel surveillance system for selected targets of infectious diseases in, Africa, Asia, and South America revealed unreported infectious diseases such as infl uenza.", [["infectious diseases", "DISEASE", 172, 191], ["infectious diseases", "DISEASE", 248, 267], ["infl uenza", "SPECIES", 276, 286], ["a sentinel surveillance system", "TEST", 117, 147], ["infectious diseases", "PROBLEM", 172, 191], ["unreported infectious diseases", "PROBLEM", 237, 267], ["infl uenza", "PROBLEM", 276, 286], ["infectious", "OBSERVATION", 172, 182], ["infectious", "OBSERVATION", 248, 258]]], ["54 Syndromic surveillance helps to detect the occurrence of signals of ILI that warrant further investigation.", [["ILI", "DISEASE", 71, 74], ["Syndromic surveillance", "TEST", 3, 25], ["ILI", "PROBLEM", 71, 74], ["further investigation", "TEST", 88, 109]]], ["In New York, a rise in the number of cases of respiratory syndrome and fever provided the earliest indication of the occurrence of community-wide infl uenza activity in 2001-02 seasons.", [["respiratory syndrome", "DISEASE", 46, 66], ["fever", "DISEASE", 71, 76], ["respiratory syndrome", "PROBLEM", 46, 66], ["fever", "PROBLEM", 71, 76], ["New", "OBSERVATION_MODIFIER", 3, 6], ["York", "OBSERVATION", 7, 11], ["rise", "OBSERVATION_MODIFIER", 15, 19], ["respiratory syndrome", "OBSERVATION", 46, 66]]], ["51 An advantage of sentinel syndromic surveillance is the early detection of syndromes before laboratory confi rmation.", [["sentinel syndromic surveillance", "TEST", 19, 50], ["syndromes", "PROBLEM", 77, 86], ["sentinel syndromic", "OBSERVATION", 19, 37]]], ["51 Syndromic surveillance could depend on the presence of specifi c symptoms of the ILI and SARI and could also depend on the chief or primary complaints of patients.", [["ILI", "DISEASE", 84, 87], ["SARI", "DISEASE", 92, 96], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["Syndromic surveillance", "TEST", 3, 25], ["specifi c symptoms", "PROBLEM", 58, 76], ["the ILI", "PROBLEM", 80, 87], ["SARI", "PROBLEM", 92, 96]]], ["The accuracy of chief complaint had a good agreement for the syndromes of respiratory infection in reference to discharge diagnosis.", [["respiratory", "ANATOMY", 74, 85], ["respiratory infection", "DISEASE", 74, 95], ["the syndromes", "PROBLEM", 57, 70], ["respiratory infection", "PROBLEM", 74, 95], ["respiratory", "ANATOMY", 74, 85], ["infection", "OBSERVATION", 86, 95]]], ["38, 51 Syndromic surveillance helped detect the 2009 pandemic infl uenza H1N1 outbreak in the USA 55 and was used in emergency departments in Canada to predict circulating respiratory viral disease such as infl uenza and respiratory syncytial virus.", [["infl uenza H1N1", "DISEASE", 62, 77], ["respiratory viral disease", "DISEASE", 172, 197], ["respiratory syncytial virus", "DISEASE", 221, 248], ["infl uenza", "ORGANISM", 206, 216], ["respiratory syncytial virus", "ORGANISM", 221, 248], ["respiratory syncytial virus", "SPECIES", 221, 248], ["respiratory syncytial virus", "SPECIES", 221, 248], ["Syndromic surveillance", "TEST", 7, 29], ["circulating respiratory viral disease", "PROBLEM", 160, 197], ["infl uenza", "TREATMENT", 206, 216], ["respiratory syncytial virus", "PROBLEM", 221, 248], ["respiratory viral disease", "OBSERVATION", 172, 197], ["respiratory", "ANATOMY", 221, 232], ["syncytial virus", "OBSERVATION", 233, 248]]], ["56 One study compared the Geographic Utilization of Artifi cial Intelligence in Real-time for Disease Identifi cation and Alert Notifi cation (GUARDIAN) system with the Complaint Coder (CoCo) of the Real-time Outbreak Detection System (RODS), the Symptom Coder (SyCo) of RODS, and an electronic medical record (EMR) system.", [["One study", "TEST", 3, 12]]], ["57 The study showed that the GUARDIAN surveillance system was more robust in performance compared with standard EMR-based reports and the RODS systems in detection of ILI.", [["ILI", "DISEASE", 167, 170], ["The study", "TEST", 3, 12], ["the GUARDIAN surveillance system", "TEST", 25, 57], ["standard EMR", "TEST", 103, 115], ["the RODS systems", "TEST", 134, 150], ["ILI", "PROBLEM", 167, 170], ["ILI", "OBSERVATION", 167, 170]]], ["57 Emergency department discharge diagnoses increased Series surveillance validity for automated and drop-in syndromic surveillance.", [["surveillance validity", "TEST", 61, 82], ["syndromic surveillance", "TEST", 109, 131]]], ["58 The advantages and disadvantages of syndromic surveillance of ILI were discussed by the Provincial Infectious Diseases Advisory Committee.", [["ILI", "DISEASE", 65, 68], ["Infectious Diseases", "DISEASE", 102, 121], ["syndromic surveillance", "TEST", 39, 61], ["ILI", "PROBLEM", 65, 68]]], ["59 The main disadvantages were that not all patients visit an emergency department as their fi rst step towards treatment, free text entry of data reduces automation of data, and start-up costs are substantial.Surveillance in emergency departmentsChief-complaint-based emergency department surveillance systems are being used for surveillance of infl uenza.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["infl uenza", "SPECIES", 346, 356], ["treatment", "TREATMENT", 112, 121], ["surveillance systems", "TEST", 290, 310], ["surveillance of infl uenza", "TREATMENT", 330, 356], ["main", "OBSERVATION_MODIFIER", 7, 11], ["substantial", "OBSERVATION_MODIFIER", 198, 209]]], ["During the 2009 H1N1 pandemic, infl uenza activity in emergency departments increased 2 weeks before it did in outpatient sentinel clinics.", [["H1N1", "DISEASE", 16, 20], ["infl uenza", "ORGANISM", 31, 41]]], ["60 The use of physician diagnosis in emergency departments proved superior to chief-complaints surveillance in the same setting.", [["surveillance", "TEST", 95, 107]]], ["62 By contrast, another study showed that self-reporting by patients was better than chiefcomplaint surveillance for prediction of the diagnosis.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["another study", "TEST", 16, 29]]], ["63 In emergency departments, increased infl uenza activity could be assessed by triage nurses recording complaints by categories, 64 syndromic analysis of patients' chief complaints, 39 and patient-based free text grouped into diagnostic groups.", [["infl uenza", "GENE_OR_GENE_PRODUCT", 39, 49], ["patients", "ORGANISM", 155, 163], ["patient", "ORGANISM", 190, 197], ["patients", "SPECIES", 155, 163], ["patient", "SPECIES", 190, 197], ["increased infl uenza activity", "PROBLEM", 29, 58]]], ["65, 66 Similarly, syndromic surveillance is being used in the Hajj pilgrimage for detection of any outbreaks.", [["syndromic surveillance", "TEST", 18, 40], ["any outbreaks", "PROBLEM", 95, 108]]], ["67 Patients' chief-complaint and triage data proved to be a good indicator of respiratory complaints.", [["respiratory", "ANATOMY", 78, 89], ["respiratory complaints", "DISEASE", 78, 100], ["Patients", "ORGANISM", 3, 11], ["Patients", "SPECIES", 3, 11], ["triage data", "TEST", 33, 44], ["respiratory complaints", "PROBLEM", 78, 100]]], ["38 Information on initial patients' complaint and triage data were used in a few surveillance programmes.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["triage data", "TEST", 50, 61]]], ["[68] [69] [70] A computerised triage log was eff ective in the identifi cation of infl uenza outbreaks in the fi rst week.", [["A computerised triage log", "TEST", 15, 40]]], ["71 In a study from England and Wales, surveillance of infl uenza based on deaths, sickness-benefi t claims (SBC), laboratory reports, and observations from general practitioners showed that general practitioners' statistics and respiratory deathsHospitalisation and laboratory surveillance of respiratory virusesIn addition to syndromic surveillance, laboratoryconfi rmed infl uenza hospitalisations and laboratory surveillance depend on identifi cation of the specifi c cause of respiratory infection; they also rely on good laboratory support for the identifi cation of the causative agent.", [["respiratory", "ANATOMY", 480, 491], ["deaths", "DISEASE", 74, 80], ["respiratory deaths", "DISEASE", 228, 246], ["respiratory viruses", "DISEASE", 293, 312], ["respiratory infection", "DISEASE", 480, 501], ["specifi c", "GENE_OR_GENE_PRODUCT", 461, 470], ["cation", "SIMPLE_CHEMICAL", 562, 568], ["a study", "TEST", 6, 13], ["sickness", "PROBLEM", 82, 90], ["respiratory deathsHospitalisation", "PROBLEM", 228, 261], ["laboratory surveillance", "TEST", 266, 289], ["respiratory viruses", "PROBLEM", 293, 312], ["syndromic surveillance", "TEST", 327, 349], ["laboratoryconfi", "TEST", 351, 366], ["laboratory surveillance", "TEST", 404, 427], ["identifi cation", "TREATMENT", 438, 453], ["respiratory infection", "PROBLEM", 480, 501], ["the identifi cation", "TREATMENT", 549, 568], ["respiratory viruses", "OBSERVATION", 293, 312], ["respiratory", "ANATOMY", 480, 491], ["infection", "OBSERVATION", 492, 501]]], ["This conventional disease surveillance that relies on passive reporting of confi rmed cases might be slow and insensitive for rapid detection of largescale infectious disease outbreaks.", [["infectious disease", "DISEASE", 156, 174], ["This conventional disease surveillance", "TEST", 0, 38], ["confi rmed cases", "PROBLEM", 75, 91], ["largescale infectious disease outbreaks", "PROBLEM", 145, 184], ["disease", "OBSERVATION", 18, 25], ["infectious", "OBSERVATION_MODIFIER", 156, 166]]], ["73 The goals of the laboratory surveillance are provision of information on geographic distribution and secular patterns of circulating viruses, monitoring of antigenic changes in the viruses for vaccine strain selection, monitoring of antiviral resistance, and detection of novel infl uenza subtypes of possible pandemic potential.Surveillance of infl uenza through drug salesThere are mixed results from studies looking at sales of over-the-counter drugs as an indicator of infl uenza activity.", [["pandemic", "DISEASE", 313, 321], ["infl uenza", "ORGANISM", 281, 291], ["infl uenza", "GENE_OR_GENE_PRODUCT", 476, 486], ["the laboratory surveillance", "TEST", 16, 43], ["circulating viruses", "PROBLEM", 124, 143], ["antigenic changes in the viruses", "PROBLEM", 159, 191], ["vaccine strain selection", "TREATMENT", 196, 220], ["antiviral resistance", "TREATMENT", 236, 256], ["novel infl uenza subtypes", "PROBLEM", 275, 300], ["studies", "TEST", 406, 413], ["drugs", "TREATMENT", 451, 456], ["infl uenza activity", "PROBLEM", 476, 495], ["circulating viruses", "OBSERVATION", 124, 143], ["antiviral resistance", "OBSERVATION", 236, 256], ["possible", "UNCERTAINTY", 304, 312], ["pandemic", "OBSERVATION", 313, 321], ["mixed", "OBSERVATION_MODIFIER", 387, 392]]], ["The earliest assessment of this indicator of infl uenza activity dates back to 1979.", [["The earliest assessment", "TEST", 0, 23], ["infl uenza activity", "PROBLEM", 45, 64]]], ["74 An increase in sales of these drugs occurred 4 weeks after the fi rst infl uenza B isolate and 1 week before peak infl uenza activity.", [["these drugs", "TREATMENT", 27, 38], ["increase", "OBSERVATION_MODIFIER", 6, 14]]], ["74 Another study assessed the sale of nonprescription drugs for three consecutive winters 1998-99, 1999-2000, and 2000-01 and did not show any correlation with increased infl uenza activity nationally.", [["Another study", "TEST", 3, 16], ["nonprescription drugs", "TREATMENT", 38, 59]]], ["75 Similarly, in a study from Japan, over-thecounter drug sales did not collate with real-time detection systems for infl uenza epidemics.", [["a study", "TEST", 17, 24], ["infl uenza epidemics", "PROBLEM", 117, 137]]], ["76 In a study from New York, USA, ILI over-the-counter drug sales increased during infl uenza epidemics and during spring and fall allergy seasons, a fi nding that was similar to trends in emergency departments for fever and infl uenza syndrome.", [["allergy", "DISEASE", 131, 138], ["fever", "DISEASE", 215, 220], ["infl uenza syndrome", "DISEASE", 225, 244], ["fall allergy seasons", "PROBLEM", 126, 146], ["fever", "PROBLEM", 215, 220], ["infl uenza syndrome", "PROBLEM", 225, 244], ["uenza syndrome", "OBSERVATION", 230, 244]]], ["77 In two other studies from France and Slovenia, drug sales correlated with infl uenza activity.", [["infl uenza", "GENE_OR_GENE_PRODUCT", 77, 87]]], ["78,79Self-reporting participatory systemsNew surveillance systems such as Infl uenzanet, Flu Near You, FluTracking, and Go Viral are a new frontier in the collection of population symptom data ( This network obtains information about ILI directly from volunteers from the diff erent countries who enter data in a web-based interphase.", [["interphase", "CELLULAR_COMPONENT", 323, 333], ["New surveillance systems", "TEST", 41, 65], ["Flu", "PROBLEM", 89, 92], ["population symptom data", "PROBLEM", 169, 192]]], ["44, [80] [81] [82] Flu Near You is a website-based survey about symptoms of ILI that can be completed by anyone older than 13 years of age.", [["ILI", "DISEASE", 76, 79], ["symptoms", "PROBLEM", 64, 72], ["ILI", "PROBLEM", 76, 79]]], ["In Australia, FluTracking is an online health surveillance system for the detection of infl uenza.", [["infl uenza", "SPECIES", 87, 97], ["infl uenza", "PROBLEM", 87, 97]]], ["In addition to reporting symptoms of infl uenza, specifi c websites also provide participants with kits including the sample collection materials so that participants can provide a nasal swab and saliva sample for infl uenza testing.Self-reporting participatory systemsOne of the challenges in the case of outbreaks is the high demand for specifi c supplies such as beds, storage areas, haemodynamic monitors, mechanical ventilators, and specialised personnel.", [["nasal swab", "ANATOMY", 181, 191], ["sample", "ANATOMY", 203, 209], ["participants", "ORGANISM", 154, 166], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 181, 191], ["saliva", "ORGANISM_SUBSTANCE", 196, 202], ["participants", "SPECIES", 81, 93], ["participants", "SPECIES", 154, 166], ["symptoms", "PROBLEM", 25, 33], ["infl uenza", "PROBLEM", 37, 47], ["the sample collection materials", "TREATMENT", 114, 145], ["a nasal swab", "TEST", 179, 191], ["saliva sample", "TEST", 196, 209], ["infl uenza testing", "TEST", 214, 232], ["specifi c supplies", "TREATMENT", 339, 357], ["haemodynamic monitors", "TEST", 387, 408], ["mechanical ventilators", "TREATMENT", 410, 432]]], ["83 An online cumulative-sumbased model named Overcrowd-Severe-Respiratory-Disease-Index was based on the Modifi ed Overcrowd Index.", [["Respiratory-Disease", "PROBLEM", 62, 81], ["Severe", "OBSERVATION_MODIFIER", 55, 61], ["Respiratory", "ANATOMY", 62, 73], ["Disease", "OBSERVATION", 74, 81]]], ["The model simultaneously monitors and informs the demand of required supplies and personnel and generates early warnings of severe respiratory disease epidemic outbreaks through the interpretation of such variables.", [["respiratory", "ANATOMY", 131, 142], ["respiratory disease", "DISEASE", 131, 150], ["severe respiratory disease epidemic outbreaks", "PROBLEM", 124, 169], ["severe", "OBSERVATION_MODIFIER", 124, 130], ["respiratory disease", "OBSERVATION", 131, 150]]], ["83 BioDiaspora is an easy-to-use, customisable, intelligent web application that predicts the eff ect of infectious diseases worldwide by integration of data on outbreaks, human populations, animal and insect populations, environmental and climatic conditions, and commercial air travel.", [["BioDiaspora", "CHEMICAL", 3, 14], ["infectious diseases", "DISEASE", 105, 124], ["human", "ORGANISM", 172, 177], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["infectious diseases", "PROBLEM", 105, 124], ["human populations", "PROBLEM", 172, 189], ["infectious", "OBSERVATION_MODIFIER", 105, 115], ["air travel", "OBSERVATION", 276, 286]]], ["BioDiaspora has an easy-to-access, web-based, global information system solution that can generate and communicate intelligence about global infectious disease threats in real time and that integrates global epidemic intelligence from HealthMap.", [["BioDiaspora", "CHEMICAL", 0, 11], ["global information system solution", "TREATMENT", 46, 80], ["global infectious disease threats", "PROBLEM", 134, 167], ["infectious", "OBSERVATION", 141, 151]]], ["84Informal surveillance and epidemic intelligenceEpidemic intelligence is a key component of modern surveillance of emerging infectious diseases.", [["infectious diseases", "DISEASE", 125, 144], ["surveillance", "TEST", 11, 23], ["epidemic intelligence", "PROBLEM", 28, 49], ["Epidemic intelligence", "PROBLEM", 49, 70], ["emerging infectious diseases", "PROBLEM", 116, 144], ["infectious", "OBSERVATION", 125, 135]]], ["Epidemic intelligence is an ad-hoc detection and analysis of unstructured information available on the internet.", [["Epidemic intelligence", "PROBLEM", 0, 21]]], ["Epidemic intelligence was developed in the 1990s after the development of the internet, 85 and several systems exist (tables 2 and 3).", [["Epidemic intelligence", "PROBLEM", 0, 21]]], ["[85] [86] [87] [88] [89] [90] [91] [92] [93] The Program for Monitoring Emerging Diseases (ProMED) mail is an internet-based reporting system designed for rapid distribution of Description Syndromic surveillance 38-42, 45-47, 58, 68-70 The following clinical data was used: chief complaint and presentation, discharge diagnosis, free text analysis of the entire medical record, calls to triage and help lines, ambulance dispatch calls, discharge diagnosis, ambulance dispatch data that successfully identifi ed the expected annual epidemics of infl uenza Laboratory surveillance 73 Slow and insensitive in rapid detection a large-scale infectious disease outbreakInformal surveillance and epidemic intelligenceMedication sales [74] [75] [76] [77] [78] [79] Over-the-counter drug sales correlated with infl uenza activity Self-reporting participatory systems [81] [82] [83] Online-based surveillance system relying on voluntary participationInformal surveillance and epidemic intelligenceInformal surveillance and epidemic intelligence [85] [86] [87] [88] [89] [90] [91] [92] [93] 94 Detect relevant information from the internet, nationally and internationally Series information on infectious disease outbreaks.", [["infectious disease outbreaks", "DISEASE", 1183, 1211], ["[85] [86] [87] [88] [89] [90]", "CHEMICAL", 0, 29], ["[85] [86] [87] [88] [89] [90] [91] [92", "SIMPLE_CHEMICAL", 0, 38], ["Syndromic surveillance", "TEST", 189, 211], ["Laboratory surveillance", "TEST", 555, 578], ["rapid detection", "TEST", 606, 621], ["a large-scale infectious disease outbreak", "PROBLEM", 622, 663], ["infectious disease outbreaks", "PROBLEM", 1183, 1211], ["large", "OBSERVATION_MODIFIER", 624, 629], ["-scale", "OBSERVATION_MODIFIER", 629, 635], ["infectious", "OBSERVATION", 636, 646], ["infectious", "OBSERVATION_MODIFIER", 1183, 1193]]], ["ProMED mail was started in August, 1994, to monitor emerging infectious diseases worldwide.", [["infectious diseases", "DISEASE", 61, 80], ["infectious", "OBSERVATION", 61, 71]]], ["95 This epidemic became known as SARS.", [["SARS", "DISEASE", 33, 37], ["SARS", "PROBLEM", 33, 37]]], ["On Sept 20, 2012, ProMED-mail reported the identifi cation of a novel coronavirus (nCoV), later known as MERS-CoV, from a fatal case of severe respiratory illness with renal failure.", [["respiratory", "ANATOMY", 143, 154], ["renal", "ANATOMY", 168, 173], ["respiratory illness", "DISEASE", 143, 162], ["renal failure", "DISEASE", 168, 181], ["coronavirus", "ORGANISM", 70, 81], ["nCoV", "CANCER", 83, 87], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["renal", "ORGAN", 168, 173], ["MERS-CoV", "SPECIES", 105, 113], ["a novel coronavirus", "PROBLEM", 62, 81], ["severe respiratory illness", "PROBLEM", 136, 162], ["renal failure", "PROBLEM", 168, 181], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["respiratory illness", "OBSERVATION", 143, 162], ["renal", "ANATOMY", 168, 173], ["failure", "OBSERVATION", 174, 181]]], ["5, 96, 97 A team of researchers, epidemiologists, and software developers at Boston Children's Hospital founded HealthMap in 2006.", [["Children", "SPECIES", 84, 92]]], ["This web-based approach provides informal sources for disease outbreak monitoring and real-time surveillance of emerging public health threats.", [["disease outbreak monitoring", "TEST", 54, 81]]], ["HealthMap is available as a website, and as a mobile app, Outbreaks Near Me, and both deliver realtime intelligence on a broad range of emerging infectious diseases for a diverse audience, including libraries, local health departments, governments, and international travellers.Informal surveillance and epidemic intelligenceThe Global Public Health Intelligence Network (GPHIN) is a Canadian initiative that draws on the capacity of the internet and worldwide news coverage of health events.", [["infectious diseases", "DISEASE", 145, 164], ["emerging infectious diseases", "PROBLEM", 136, 164], ["Informal surveillance", "TEST", 278, 299], ["infectious", "OBSERVATION", 145, 155], ["Global", "OBSERVATION_MODIFIER", 329, 335]]], ["93 GPHIN creates an early warning of outbreaks by monitoring internet media, including news wires and websites, to detect and report disease outbreaks.", [["news wires", "TREATMENT", 87, 97], ["disease outbreaks", "PROBLEM", 133, 150]]], ["94 Google Flu Trend is a web-based site that estimates ILI incidence on the basis of infl uenza-related queries made by millions of users around the world online in search for health data related to infl uenza.", [["ILI", "DISEASE", 55, 58], ["infl uenza", "PROBLEM", 199, 209]]], ["98 Use of Google Flu Trend in emergency departments predicted the 2009 H1N1 outbreak in Manitoba, 99 other emergency rooms, 100 and South Korea.", [["H1N1", "DISEASE", 71, 75]]], ["101 Google Flu Trend results strongly correlated with ILI data from the USA, 98, 102, 103 Australia, 104 Canada, 99 and China 105 and Google Flu Trend was the only external information system to provided the most accurate infl uenza predictions with diff erent prediction models.", [["ILI data", "TEST", 54, 62], ["the USA", "TEST", 68, 75], ["Canada", "TEST", 105, 111], ["Google Flu", "TEST", 134, 144], ["diff erent prediction models", "PROBLEM", 250, 278]]], ["106 Google Flu Trend results were less reliable during the 2009 infl uenza H1N1 pandemic in many countries including New Zealand, Singapore, and the USA.", [["H1N1", "DISEASE", 75, 79], ["uenza H1N1 pandemic", "SPECIES", 69, 88], ["Google Flu", "TEST", 4, 14]]], ["[107] [108] [109] Such inconsistency might result from a change in internet search behaviour and the change in age-related internet use.", [["a change in internet search behaviour", "PROBLEM", 55, 92]]], ["110-112 Google Flu Trend might not provide reliable surveillance for seasonal or pandemic infl uenza, and the result obtained from this surveillance method should be interpreted with caution.", [["seasonal or pandemic infl uenza", "PROBLEM", 69, 100], ["this surveillance method", "TEST", 131, 155]]], ["113 Google Flu Trend also performed poorly compared with laboratory-confi rmed infl uenza.", [["Google Flu Trend", "TEST", 4, 20], ["laboratory", "TEST", 57, 67]]], ["115Infl uenza in AfricaThe exact epidemiology of ILI and SARI is not well known in Africa and the Middle East.", [["ILI", "DISEASE", 49, 52], ["SARI", "DISEASE", 57, 61], ["ILI", "PROBLEM", 49, 52], ["SARI", "PROBLEM", 57, 61], ["Middle", "ANATOMY_MODIFIER", 98, 104]]], ["In a study from several countries, from Madagascar to Senegal, the epidemiology and virology of infl uenza viruses showed variation in relation to spatiotemporal circulation of the diff erent virus types, subtypes, and strains.", [["infl uenza viruses", "ORGANISM", 96, 114], ["infl uenza viruses", "SPECIES", 96, 114], ["diff erent virus", "SPECIES", 181, 197], ["a study", "TEST", 3, 10], ["infl uenza viruses", "PROBLEM", 96, 114], ["the diff erent virus types", "PROBLEM", 177, 203], ["strains", "PROBLEM", 219, 226], ["spatiotemporal circulation", "OBSERVATION", 147, 173], ["diff", "OBSERVATION", 181, 185]]], ["116 In 2008, the sentinel surveillance system in Madagascar showed that of 26 669 fever cases, 11\u00b71% were ILI.", [["fever", "DISEASE", 82, 87], ["ILI", "DISEASE", 106, 109], ["the sentinel surveillance system", "TEST", 13, 45], ["fever cases", "TEST", 82, 93], ["ILI", "PROBLEM", 106, 109]]], ["117 The availability of seasonal infl uenza vaccine in Africa was reported to be 45% of 31 countries who responded to the questionnaire sent by the investigators in one study, and that vaccine coverage data were available for four of 14 countries that reported availability of seasonal infl uenza vaccine.", [["infl uenza", "ORGANISM", 33, 43], ["infl uenza", "ORGANISM", 286, 296], ["seasonal infl uenza vaccine", "TREATMENT", 24, 51], ["one study", "TEST", 165, 174], ["vaccine coverage data", "TREATMENT", 185, 206], ["seasonal infl uenza vaccine", "TREATMENT", 277, 304]]], ["118 The importance of having laboratory infl uenza virus surveillance was highlighted in a study from west Africa where genetic sequencing of 2009 pandemic infl uenza A H1N1 viruses during 2009-13 showed persistence of two viral lineages.", [["infl uenza virus", "ORGANISM", 40, 56], ["infl uenza A H1N1 viruses", "ORGANISM", 156, 181], ["A H1N1 viruses", "SPECIES", 167, 181], ["infl uenza virus", "SPECIES", 40, 56], ["A H1N1 viruses", "SPECIES", 167, 181], ["laboratory infl uenza virus surveillance", "TEST", 29, 69], ["a study", "TEST", 89, 96], ["genetic sequencing", "TEST", 120, 138], ["A H1N1 viruses", "PROBLEM", 167, 181], ["two viral lineages", "PROBLEM", 219, 237], ["viral lineages", "OBSERVATION", 223, 237]]], ["119Challenges for emerging respiratory viruses surveillanceThe challenges for the surveillance of any emerging respiratory viruses, especially at the beginning of any outbreak, are the diffi culties in the identifi cation of the causative agent and the large number of samples received.", [["samples", "ANATOMY", 269, 276], ["respiratory viruses", "DISEASE", 27, 46], ["respiratory viruses", "DISEASE", 111, 130], ["samples", "CANCER", 269, 276], ["emerging respiratory viruses", "PROBLEM", 18, 46], ["any emerging respiratory viruses", "PROBLEM", 98, 130], ["the causative agent", "TREATMENT", 225, 244], ["respiratory viruses", "OBSERVATION", 27, 46], ["respiratory viruses", "OBSERVATION", 111, 130], ["large", "OBSERVATION_MODIFIER", 253, 258]]], ["Ideally, routine cultures might provide the answer for any emerging virus identifi cation; such techniques would require additional safety measures.", [["cation", "SIMPLE_CHEMICAL", 83, 89], ["routine cultures", "TEST", 9, 25], ["virus identifi cation", "TREATMENT", 68, 89], ["such techniques", "TREATMENT", 91, 106], ["additional safety measures", "TREATMENT", 121, 147]]], ["Comprehensive multiplexed PCR reactions might help in the identifi cation of various agents without the use of biosafety level 3 laboratories.", [["Comprehensive multiplexed PCR reactions", "PROBLEM", 0, 39], ["various agents", "TREATMENT", 77, 91]]], ["120 The combined use of culture, rapid antigen detection assays, and molecular assays are often eff ective.", [["culture", "TEST", 24, 31], ["rapid antigen detection assays", "TEST", 33, 63], ["molecular assays", "TEST", 69, 85]]], ["121, 122 The use of a combination of these techniques will decrease the number of samples from patients being tested at one time.", [["samples", "ANATOMY", 82, 89], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["these techniques", "TREATMENT", 37, 53]]], ["123 Further improvement of surveillance systems to cover diverse areas of the world including developed and developing countries is clearly needed.", [["surveillance systems", "TEST", 27, 47], ["improvement", "OBSERVATION_MODIFIER", 12, 23]]], ["Such anSearch strategy and selection criteriaWe did a literature search of the electronic database PubMed and Google Scholar (1980-2014) with the following search terms: \"surveillance AND infl uenza\", \"infl uenza\", \"infl uenzalike illness\", \"surveillance\" \"internet-based surveillance\" \"syndromic surveillance\", \"respiratory\" \"viruses\" and \"emerging\".", [["respiratory", "ANATOMY", 313, 324], ["infl uenzalike illness", "DISEASE", 216, 238]]], ["We complemented the search with publications from WHO, Centre for Disease Control and Prevention, and Google Scholar.", [["Disease Control", "TREATMENT", 66, 81]]], ["We included only studies in human beings and in the English language.Search strategy and selection criteriaFor more on HealthMap see http://healthmap.org/en/ objective could be accomplished by capacity building.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33]]], ["124 There was a clear coordination and collaboration between multisector interests such as human and animal health, the Govern ment of Laos, and the international partner community through the Lao National Avian and Human Infl uenza Coordinating Offi ce (NAHICO) resulting in the translation of experience into practical steps to deal with emerging viral infections.", [["viral infections", "DISEASE", 349, 365], ["human", "ORGANISM", 91, 96], ["Human", "ORGANISM", 216, 221], ["human", "SPECIES", 91, 96], ["Human", "SPECIES", 216, 221], ["human", "SPECIES", 91, 96], ["emerging viral infections", "PROBLEM", 340, 365], ["clear coordination", "OBSERVATION", 16, 34], ["viral infections", "OBSERVATION", 349, 365]]], ["124 The collateral impact of the infl uenza investment in advance of overall public health capacity in Laos has been pronounced, and this could also happen to other resource-limited countries.", [["the infl uenza investment", "TREATMENT", 29, 54], ["collateral", "OBSERVATION_MODIFIER", 8, 18], ["impact", "OBSERVATION_MODIFIER", 19, 25], ["pronounced", "OBSERVATION_MODIFIER", 117, 127]]], ["The immediate availability of data would help healthcare policy makers in the preparation for any epidemics.ContributorsZAM and AZ initiated The Lancet Infectious Diseases respiratory tract infections series.", [["ContributorsZAM", "CHEMICAL", 108, 123], ["AZ", "CHEMICAL", 128, 130], ["Infectious Diseases respiratory tract infections", "DISEASE", 152, 200], ["AZ", "SIMPLE_CHEMICAL", 128, 130], ["any epidemics", "PROBLEM", 94, 107], ["ContributorsZAM", "TREATMENT", 108, 123], ["AZ", "TREATMENT", 128, 130], ["The Lancet Infectious Diseases respiratory tract infections series", "PROBLEM", 141, 207], ["respiratory tract", "ANATOMY", 172, 189]]], ["ZAM, AZ, DH, and JAA-T developed the series articles outlines and assigned lead authors.", [["AZ", "SIMPLE_CHEMICAL", 5, 7]]], ["ZAM and JAA-T coordinated the writing of this Series paper and wrote the draft outline, subsequent and fi nal drafts of the manuscript.", [["JAA-T", "CELL", 8, 13]]]], "PMC6371441": [["IntroductionInfectious bronchitis (IB) is an acute, highly contagious viral disease of chickens.", [["IntroductionInfectious bronchitis (IB)", "DISEASE", 0, 38], ["viral disease", "DISEASE", 70, 83], ["chickens", "ORGANISM", 87, 95], ["chickens", "SPECIES", 87, 95], ["chickens", "SPECIES", 87, 95], ["IntroductionInfectious bronchitis (IB)", "PROBLEM", 0, 38], ["an acute, highly contagious viral disease of chickens", "PROBLEM", 42, 95], ["bronchitis", "OBSERVATION", 23, 33], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["highly", "OBSERVATION_MODIFIER", 52, 58], ["contagious", "OBSERVATION_MODIFIER", 59, 69], ["viral disease", "OBSERVATION", 70, 83]]], ["IB affects chickens of all ages and based on the organ system affected the disease is manifested in three major clinical forms\u2014respiratory, renal and reproductive.", [["organ system", "ANATOMY", 49, 61], ["forms\u2014respiratory", "ANATOMY", 121, 138], ["renal", "ANATOMY", 140, 145], ["chickens", "ORGANISM", 11, 19], ["organ", "ORGAN", 49, 54], ["renal", "CANCER", 140, 145], ["chickens", "SPECIES", 11, 19], ["chickens", "SPECIES", 11, 19], ["the disease", "PROBLEM", 71, 82], ["all ages", "OBSERVATION_MODIFIER", 23, 31], ["disease", "OBSERVATION", 75, 82], ["renal", "ANATOMY", 140, 145]]], ["IB causes great economic losses in the poultry industry worldwide [1, 2].", [["great economic losses", "PROBLEM", 10, 31], ["great", "OBSERVATION_MODIFIER", 10, 15], ["economic losses", "OBSERVATION", 16, 31]]], ["Infectious bronchitis virus (IBV) is a member of the genus Gammacoronavirus in the family Coronaviridae.", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 59, 75], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["Infectious bronchitis virus", "PROBLEM", 0, 27]]], ["The viral genome is a single-stranded, positive-sense RNA of about 27.6 Kb in length [3].", [["viral genome", "DNA", 4, 16], ["positive-sense RNA", "RNA", 39, 57], ["The viral genome", "TEST", 0, 16], ["viral genome", "OBSERVATION", 4, 16]]], ["The 5\u2032-two-third of the viral genome codes for the non-structural proteins responsible for RNA replication and transcription.", [["5\u2032-two-third of the viral genome", "DNA", 4, 36], ["non-structural proteins", "PROTEIN", 51, 74], ["the non-structural proteins", "PROBLEM", 47, 74], ["RNA replication", "TREATMENT", 91, 106], ["viral genome", "OBSERVATION", 24, 36], ["RNA replication", "OBSERVATION", 91, 106]]], ["The 3\u2032-one-third of the viral genome codes for four structural proteins, namely, spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, in addition to several non-structural proteins [3].IntroductionThe S protein of IBV is heavily glycosylated and plays a major role in eliciting protective immune responses.", [["membrane", "ANATOMY", 106, 114], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 81, 104], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["nucleocapsid (N) proteins", "GENE_OR_GENE_PRODUCT", 123, 148], ["IBV", "ORGANISM", 230, 233], ["3\u2032-one-third of the viral genome", "DNA", 4, 36], ["structural proteins", "PROTEIN", 52, 71], ["spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins", "PROTEIN", 81, 148], ["non-structural proteins", "PROTEIN", 173, 196], ["S protein", "PROTEIN", 217, 226], ["IBV", "SPECIES", 230, 233], ["four structural proteins", "TEST", 47, 71], ["spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins", "PROBLEM", 81, 148], ["several non-structural proteins", "PROBLEM", 165, 196], ["heavily glycosylated", "PROBLEM", 237, 257], ["viral genome", "OBSERVATION", 24, 36]]], ["It is present as trimers on the surface of the virion and contains conformation dependent epitopes [4].", [["surface", "ANATOMY", 32, 39], ["virion", "ANATOMY", 47, 53], ["surface", "CELLULAR_COMPONENT", 32, 39], ["virion", "CELLULAR_COMPONENT", 47, 53], ["epitopes", "PROTEIN", 90, 98], ["conformation dependent epitopes", "PROBLEM", 67, 98]]], ["The S protein is cleaved post-translationally by host cell proteases into S1 (N-terminal, globular head domain) and S2 (C-terminal, stalk domain) subunits [5\u20137].", [["cell", "ANATOMY", 54, 58], ["N", "CHEMICAL", 78, 79], ["C", "CHEMICAL", 120, 121], ["host cell proteases", "GENE_OR_GENE_PRODUCT", 49, 68], ["S2", "GENE_OR_GENE_PRODUCT", 116, 118], ["S protein", "PROTEIN", 4, 13], ["host cell proteases", "PROTEIN", 49, 68], ["S1", "PROTEIN", 74, 76], ["N-terminal", "PROTEIN", 78, 88], ["globular head domain", "PROTEIN", 90, 110], ["S2", "PROTEIN", 116, 118], ["C-terminal, stalk domain) subunits", "PROTEIN", 120, 154], ["5\u20137", "PROTEIN", 156, 159], ["The S protein", "TEST", 0, 13], ["S1", "TEST", 74, 76], ["S2 (C-terminal, stalk domain) subunits", "TREATMENT", 116, 154], ["host cell", "OBSERVATION", 49, 58], ["S1", "ANATOMY", 74, 76]]], ["The S1 subunit is the most variable subunit that harbors the major neutralizing epitopes [8, 9] and the receptor binding domain (RBD) responsible for viral attachment and tissue tropism [5].", [["tissue", "ANATOMY", 171, 177], ["S1", "GENE_OR_GENE_PRODUCT", 4, 6], ["tissue", "TISSUE", 171, 177], ["S1 subunit", "PROTEIN", 4, 14], ["major neutralizing epitopes [8, 9", "PROTEIN", 61, 94], ["receptor binding domain", "PROTEIN", 104, 127], ["RBD", "PROTEIN", 129, 132], ["the receptor binding domain (RBD)", "PROBLEM", 100, 133], ["viral attachment and tissue tropism", "PROBLEM", 150, 185], ["most variable", "OBSERVATION_MODIFIER", 22, 35], ["major", "OBSERVATION_MODIFIER", 61, 66], ["neutralizing", "OBSERVATION", 67, 79], ["responsible for", "UNCERTAINTY", 134, 149], ["viral attachment", "OBSERVATION", 150, 166]]], ["The S2 subunit is the most conserved subunit and is involved in mediating membrane fusion and viral entry [5].", [["membrane", "ANATOMY", 74, 82], ["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["membrane", "CELLULAR_COMPONENT", 74, 82], ["S2 subunit", "PROTEIN", 4, 14], ["mediating membrane fusion", "TREATMENT", 64, 89], ["membrane fusion", "OBSERVATION", 74, 89]]], ["The S2 protein also contains minor neutralizing epitopes and contributes to the avidity of S1 protein [10].", [["S2", "GENE_OR_GENE_PRODUCT", 4, 6], ["S1", "GENE_OR_GENE_PRODUCT", 91, 93], ["S2 protein", "PROTEIN", 4, 14], ["neutralizing epitopes", "PROTEIN", 35, 56], ["S1 protein", "PROTEIN", 91, 101], ["minor neutralizing epitopes", "PROBLEM", 29, 56], ["minor", "OBSERVATION_MODIFIER", 29, 34], ["neutralizing epitopes", "OBSERVATION", 35, 56]]], ["It has been shown that a tyrosine motif located in the cytoplasmic tail of the S protein is responsible for the intracellular retention [11].", [["cytoplasmic tail", "ANATOMY", 55, 71], ["intracellular", "ANATOMY", 112, 125], ["tyrosine", "CHEMICAL", 25, 33], ["tyrosine", "CHEMICAL", 25, 33], ["tyrosine", "AMINO_ACID", 25, 33], ["cytoplasmic", "ORGANISM_SUBSTANCE", 55, 66], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["tyrosine motif", "PROTEIN", 25, 39], ["cytoplasmic tail", "PROTEIN", 55, 71], ["S protein", "PROTEIN", 79, 88], ["a tyrosine motif", "TREATMENT", 23, 39], ["the S protein", "TEST", 75, 88], ["the intracellular retention", "PROBLEM", 108, 135], ["cytoplasmic", "OBSERVATION_MODIFIER", 55, 66], ["tail", "OBSERVATION_MODIFIER", 67, 71], ["responsible for", "UNCERTAINTY", 92, 107], ["intracellular retention", "OBSERVATION", 112, 135]]], ["This tyrosine residue is essential for productive virus infection [12].", [["tyrosine", "CHEMICAL", 5, 13], ["infection", "DISEASE", 56, 65], ["tyrosine", "CHEMICAL", 5, 13], ["tyrosine", "AMINO_ACID", 5, 13], ["This tyrosine residue", "PROBLEM", 0, 21], ["productive virus infection", "PROBLEM", 39, 65]]], ["However, the role of this tyrosine residue on induction of protective immune response by IBV S protein has not been studied.IntroductionMany different IBV serotypes and genotypes circulate worldwide [2, 6, 13].", [["tyrosine", "CHEMICAL", 26, 34], ["tyrosine", "CHEMICAL", 26, 34], ["tyrosine", "AMINO_ACID", 26, 34], ["IBV S protein", "GENE_OR_GENE_PRODUCT", 89, 102], ["IBV", "ORGANISM", 151, 154], ["IBV S protein", "PROTEIN", 89, 102], ["IBV", "SPECIES", 89, 92], ["IBV", "SPECIES", 151, 154], ["this tyrosine residue", "PROBLEM", 21, 42], ["protective immune response", "TREATMENT", 59, 85], ["IBV S protein", "TEST", 89, 102], ["IntroductionMany different IBV serotypes", "TREATMENT", 124, 164], ["IBV serotypes", "OBSERVATION", 151, 164]]], ["These serotypes arise due to high frequency of mutations and/or recombination events [14, 15].", [["These serotypes", "PROBLEM", 0, 15], ["high frequency of mutations", "PROBLEM", 29, 56]]], ["Cross-protection between different serotypes is variable or poor [16].IntroductionIn Egypt, classical and variant strains of IBV co-circulate causing frequent disease outbreaks [17, 18].", [["IBV", "ORGANISM", 125, 128], ["IBV", "SPECIES", 125, 128], ["Cross-protection between different serotypes", "TREATMENT", 0, 44], ["IBV", "PROBLEM", 125, 128], ["frequent disease outbreaks", "PROBLEM", 150, 176]]], ["The majority of IBV variant strains reported in Egypt belong to GI-23 lineage [19].", [["IBV", "ORGANISM", 16, 19], ["GI-23 lineage", "CELL", 64, 77], ["IBV", "SPECIES", 16, 19], ["IBV variant strains", "PROBLEM", 16, 35], ["GI", "TEST", 64, 66], ["GI", "ANATOMY", 64, 66]]], ["The Egyptian variant strains are mostly related to strains IS/885/00 and IS/1494/06, also known as Israeli Variant II [17, 18].", [["strains IS/885/00 and IS/1494/06", "SPECIES", 51, 83], ["The Egyptian variant strains", "PROBLEM", 0, 28]]], ["Israeli Variant II-related serotypes have also been reported in many countries in the Middle East and North Africa [20] and recently, in Poland [21] and Turkey [22].IntroductionLive-attenuated vaccines have been highly successful in controlling IB in the field [23, 24].", [["IntroductionLive-attenuated vaccines", "TREATMENT", 165, 201], ["successful", "OBSERVATION_MODIFIER", 219, 229]]], ["However, live-attenuated vaccines provide cross-protection against some of the IBV variants but not all [24\u201326].", [["IBV", "ORGANISM", 79, 82], ["IBV", "SPECIES", 79, 82], ["live-attenuated vaccines", "TREATMENT", 9, 33], ["cross-protection", "TREATMENT", 42, 58], ["the IBV variants", "PROBLEM", 75, 91]]], ["Furthermore, use of live-attenuated IBV vaccines can lead to production of variant IBV strains by mutations and/or recombination [27, 28].IntroductionIn Egypt, classical and variant live-attenuated vaccine strains, mainly H120 and 793B, are used to control IB.", [["IBV", "ORGANISM", 36, 39], ["IBV", "ORGANISM", 83, 86], ["IBV", "SPECIES", 36, 39], ["IBV", "SPECIES", 83, 86], ["live-attenuated IBV vaccines", "TREATMENT", 20, 48], ["variant IBV strains", "PROBLEM", 75, 94], ["attenuated vaccine strains", "TREATMENT", 187, 213]]], ["Although these vaccines provide good protection against some of the variant viruses, they provide poor protection against the prevalent variant field viruses belonging to GI-23 lineage.", [["GI-23 lineage", "ANATOMY", 171, 184], ["GI-23 lineage", "CELL", 171, 184], ["GI-23 lineage", "CELL_LINE", 171, 184], ["these vaccines", "TREATMENT", 9, 23], ["the variant viruses", "PROBLEM", 64, 83], ["GI", "TEST", 171, 173], ["viruses", "OBSERVATION", 76, 83]]], ["These live-attenuated vaccines are also a source for generation of new variant viruses [27, 29, 30].", [["These live-attenuated vaccines", "TREATMENT", 0, 30], ["new variant viruses", "PROBLEM", 67, 86]]], ["Therefore, an alternative vaccine strategy will be beneficial to control IB outbreaks in Egypt.IntroductionViral vectored vaccines provide an alternative approach to live-attenuated IBV vaccines.", [["IBV", "ORGANISM", 182, 185], ["IBV", "SPECIES", 182, 185], ["an alternative vaccine strategy", "TREATMENT", 11, 42], ["IntroductionViral vectored vaccines", "TREATMENT", 95, 130], ["an alternative approach", "TREATMENT", 139, 162], ["IBV vaccines", "TREATMENT", 182, 194]]], ["A vectored vaccine expressing the protective antigen of IBV will not lead to creation of variant viruses.", [["IBV", "ORGANISM", 56, 59], ["IBV", "SPECIES", 56, 59], ["A vectored vaccine", "TREATMENT", 0, 18], ["IBV", "TREATMENT", 56, 59], ["variant viruses", "PROBLEM", 89, 104], ["variant viruses", "OBSERVATION", 89, 104]]], ["Attempts have been made to express S1 or S2 subunits of S protein using fowl pox virus, herpes virus and adenovirus vectors [31\u201334].", [["S1", "GENE_OR_GENE_PRODUCT", 35, 37], ["S2", "GENE_OR_GENE_PRODUCT", 41, 43], ["S protein", "GENE_OR_GENE_PRODUCT", 56, 65], ["fowl pox virus", "ORGANISM", 72, 86], ["herpes virus", "ORGANISM", 88, 100], ["adenovirus", "ORGANISM", 105, 115], ["S1", "PROTEIN", 35, 37], ["S2 subunits", "PROTEIN", 41, 52], ["S protein", "PROTEIN", 56, 65], ["fowl pox virus", "SPECIES", 72, 86], ["herpes virus", "SPECIES", 88, 100], ["fowl pox virus", "SPECIES", 72, 86], ["herpes virus", "SPECIES", 88, 100], ["S protein", "TEST", 56, 65], ["fowl pox virus", "PROBLEM", 72, 86], ["herpes virus and adenovirus vectors", "PROBLEM", 88, 123]]], ["However, none of these vaccines are effective in providing complete protection against IBV, suggesting the need for new vaccine vectors.IntroductionUse of Newcastle disease virus (NDV) as a vaccine vector for IBV holds great promise.", [["Newcastle disease", "DISEASE", 155, 172], ["IBV", "ORGANISM", 87, 90], ["Newcastle disease virus", "ORGANISM", 155, 178], ["NDV", "ORGANISM", 180, 183], ["IBV", "ORGANISM", 209, 212], ["IBV", "SPECIES", 87, 90], ["Newcastle disease virus", "SPECIES", 155, 178], ["NDV", "SPECIES", 180, 183], ["IBV", "SPECIES", 209, 212], ["these vaccines", "TREATMENT", 17, 31], ["IBV", "PROBLEM", 87, 90], ["new vaccine vectors", "TREATMENT", 116, 135], ["Newcastle disease virus (NDV", "TREATMENT", 155, 183], ["a vaccine vector", "TREATMENT", 188, 204], ["IBV holds great promise", "TREATMENT", 209, 232], ["Newcastle disease", "OBSERVATION", 155, 172]]], ["NDV is a member of the genus Avulavirus in the family Paramyxoviridae [35].", [["NDV", "ORGANISM", 0, 3], ["Avulavirus", "GENE_OR_GENE_PRODUCT", 29, 39], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV", "PROBLEM", 0, 3]]], ["NDV causes a highly contagious disease with substantial mortality in chickens [36].", [["NDV", "DISEASE", 0, 3], ["NDV", "ORGANISM", 0, 3], ["chickens", "ORGANISM", 69, 77], ["NDV", "SPECIES", 0, 3], ["chickens", "SPECIES", 69, 77], ["NDV", "SPECIES", 0, 3], ["chickens", "SPECIES", 69, 77], ["NDV", "PROBLEM", 0, 3], ["a highly contagious disease", "PROBLEM", 11, 38], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["contagious", "OBSERVATION_MODIFIER", 20, 30], ["substantial", "OBSERVATION_MODIFIER", 44, 55], ["mortality", "OBSERVATION_MODIFIER", 56, 65]]], ["The natural avirulent NDV strain LaSota is widely used as a live NDV vaccine in chickens for more than 60 years with a good record of safety and stability.", [["LaSota", "CHEMICAL", 33, 39], ["NDV strain LaSota", "ORGANISM", 22, 39], ["NDV", "ORGANISM", 65, 68], ["chickens", "ORGANISM", 80, 88], ["NDV", "SPECIES", 22, 25], ["chickens", "SPECIES", 80, 88], ["NDV", "SPECIES", 22, 25], ["NDV", "SPECIES", 65, 68], ["chickens", "SPECIES", 80, 88], ["The natural avirulent NDV strain LaSota", "TREATMENT", 0, 39], ["a live NDV vaccine", "TREATMENT", 58, 76], ["avirulent", "OBSERVATION_MODIFIER", 12, 21], ["NDV", "OBSERVATION", 22, 25]]], ["NDV replicates efficiently in the respiratory tract of chickens inducing mucosal immunity at the site of IBV entry and it also elicits strong humoral and cell-mediated immune responses crucial for clearance of IBV [37].", [["respiratory tract", "ANATOMY", 34, 51], ["mucosal", "ANATOMY", 73, 80], ["cell", "ANATOMY", 154, 158], ["NDV", "ORGANISM", 0, 3], ["respiratory tract", "ORGANISM_SUBDIVISION", 34, 51], ["chickens", "ORGANISM", 55, 63], ["mucosal", "ANATOMICAL_SYSTEM", 73, 80], ["IBV", "ORGANISM", 105, 108], ["cell", "CELL", 154, 158], ["IBV", "ORGANISM", 210, 213], ["chickens", "SPECIES", 55, 63], ["NDV", "SPECIES", 0, 3], ["chickens", "SPECIES", 55, 63], ["IBV", "SPECIES", 105, 108], ["IBV", "SPECIES", 210, 213], ["NDV", "PROBLEM", 0, 3], ["mucosal immunity", "PROBLEM", 73, 89], ["respiratory tract", "ANATOMY", 34, 51], ["mucosal immunity", "OBSERVATION", 73, 89]]], ["Moreover, it can be used as a dual vaccine against IBV and NDV.IntroductionRecombinant NDV (rNDV) has been used previously as a vaccine vector to evaluate the protective efficacy of S1, S2 and S proteins of IBV [38\u201340].", [["IBV", "ORGANISM", 51, 54], ["NDV", "ORGANISM", 59, 62], ["NDV", "ORGANISM", 87, 90], ["rNDV", "ORGANISM", 92, 96], ["S1", "GENE_OR_GENE_PRODUCT", 182, 184], ["S2", "GENE_OR_GENE_PRODUCT", 186, 188], ["IBV", "ORGANISM", 207, 210], ["S1, S2 and S proteins", "PROTEIN", 182, 203], ["NDV", "SPECIES", 59, 62], ["IBV", "SPECIES", 51, 54], ["NDV", "SPECIES", 59, 62], ["NDV", "SPECIES", 87, 90], ["NDV", "SPECIES", 93, 96], ["IBV", "SPECIES", 207, 210], ["a dual vaccine", "TREATMENT", 28, 42], ["IBV", "PROBLEM", 51, 54], ["NDV", "PROBLEM", 59, 62], ["IntroductionRecombinant NDV (rNDV", "TREATMENT", 63, 96], ["a vaccine vector", "TREATMENT", 126, 142], ["IBV", "TEST", 207, 210], ["NDV", "OBSERVATION", 59, 62], ["S2", "ANATOMY", 186, 188]]], ["It was reported that rNDV expressing the S2 protein provided only partial protection against virulent IBV challenge [39]. rNDV expressing the IBV S1 protein provided partial protection after a single vaccination and better protection was observed after a booster vaccination [38].", [["rNDV", "GENE_OR_GENE_PRODUCT", 21, 25], ["S2", "GENE_OR_GENE_PRODUCT", 41, 43], ["IBV", "ORGANISM", 102, 105], ["rNDV", "GENE_OR_GENE_PRODUCT", 122, 126], ["IBV S1", "ORGANISM", 142, 148], ["rNDV", "PROTEIN", 21, 25], ["S2 protein", "PROTEIN", 41, 51], ["rNDV", "PROTEIN", 122, 126], ["IBV S1 protein", "PROTEIN", 142, 156], ["rNDV", "SPECIES", 21, 25], ["IBV", "SPECIES", 102, 105], ["rNDV", "SPECIES", 122, 126], ["IBV", "SPECIES", 142, 145], ["virulent IBV challenge", "TREATMENT", 93, 115], ["the IBV S1 protein", "TREATMENT", 138, 156], ["partial protection", "TREATMENT", 166, 184], ["a single vaccination", "TREATMENT", 191, 211], ["a booster vaccination", "TREATMENT", 253, 274]]], ["Recently, it was shown that the rNDV expressing the whole S protein of classical IBV M41 strain provided better protection than the rNDVs expressing S1 or S2 protein of IBV [40].IntroductionThe goal of this study was to evaluate the protective efficacies of three forms of the S protein of Egyptian IBV GI-23 lineage variant strain IBV/Ck/EG/CU/4/2014 using NDV as a vaccine vector.", [["rNDV", "GENE_OR_GENE_PRODUCT", 32, 36], ["IBV M41 strain", "ORGANISM", 81, 95], ["rNDVs", "GENE_OR_GENE_PRODUCT", 132, 137], ["S1", "GENE_OR_GENE_PRODUCT", 149, 151], ["S2", "GENE_OR_GENE_PRODUCT", 155, 157], ["IBV [40", "ORGANISM", 169, 176], ["IBV GI-23 lineage", "ORGANISM", 299, 316], ["IBV", "ORGANISM", 332, 335], ["Ck/EG/CU/4/2014", "ORGANISM", 336, 351], ["NDV", "ORGANISM", 358, 361], ["rNDV", "PROTEIN", 32, 36], ["S protein", "PROTEIN", 58, 67], ["rNDVs", "PROTEIN", 132, 137], ["S1", "PROTEIN", 149, 151], ["S2 protein", "PROTEIN", 155, 165], ["S protein", "PROTEIN", 277, 286], ["IBV M41", "SPECIES", 81, 88], ["IBV", "SPECIES", 169, 172], ["Egyptian IBV GI-23 lineage variant strain IBV/Ck/EG/CU/4/2014", "SPECIES", 290, 351], ["NDV", "SPECIES", 358, 361], ["classical IBV M41 strain", "TREATMENT", 71, 95], ["this study", "TEST", 202, 212], ["the S protein", "TEST", 273, 286], ["Egyptian IBV GI", "TEST", 290, 305], ["Ck", "TEST", 336, 338], ["NDV", "TREATMENT", 358, 361], ["a vaccine vector", "TREATMENT", 365, 381]]], ["In addition to the expression of wild type S protein, a second S protein was expressed in which the tyrosine residue in the cytoplasmic tail was mutated to alanine, and the modified S protein was fused to the last 12 amino acids of NDF F protein.", [["cytoplasmic tail", "ANATOMY", 124, 140], ["tyrosine", "CHEMICAL", 100, 108], ["alanine", "CHEMICAL", 156, 163], ["amino acids", "CHEMICAL", 217, 228], ["tyrosine", "CHEMICAL", 100, 108], ["alanine", "CHEMICAL", 156, 163], ["amino acids", "CHEMICAL", 217, 228], ["type S protein", "GENE_OR_GENE_PRODUCT", 38, 52], ["tyrosine", "AMINO_ACID", 100, 108], ["cytoplasmic", "ORGANISM_SUBSTANCE", 124, 135], ["tail", "ORGANISM_SUBSTANCE", 136, 140], ["alanine", "AMINO_ACID", 156, 163], ["amino acids", "AMINO_ACID", 217, 228], ["NDF F", "GENE_OR_GENE_PRODUCT", 232, 237], ["wild type S protein", "PROTEIN", 33, 52], ["S protein", "PROTEIN", 63, 72], ["cytoplasmic tail", "PROTEIN", 124, 140], ["S protein", "PROTEIN", 182, 191], ["last 12 amino acids", "PROTEIN", 209, 228], ["NDF F protein", "PROTEIN", 232, 245], ["wild type S protein", "PROBLEM", 33, 52], ["a second S protein", "TEST", 54, 72], ["the tyrosine residue in the cytoplasmic tail", "PROBLEM", 96, 140], ["alanine", "TEST", 156, 163], ["the modified S protein", "TREATMENT", 169, 191], ["tyrosine residue", "OBSERVATION", 100, 116], ["cytoplasmic tail", "OBSERVATION", 124, 140]]], ["A third S protein was expressed in which only the cytoplasmic tail (CT) of S protein was replaced with last 12 amino acids of NDV F protein CT.", [["cytoplasmic tail", "ANATOMY", 50, 66], ["amino acids", "CHEMICAL", 111, 122], ["amino acids", "CHEMICAL", 111, 122], ["cytoplasmic tail", "CELLULAR_COMPONENT", 50, 66], ["S protein", "GENE_OR_GENE_PRODUCT", 75, 84], ["amino acids", "AMINO_ACID", 111, 122], ["S protein", "PROTEIN", 8, 17], ["cytoplasmic tail", "PROTEIN", 50, 66], ["CT", "PROTEIN", 68, 70], ["S protein", "PROTEIN", 75, 84], ["NDV F protein CT", "PROTEIN", 126, 142], ["NDV", "SPECIES", 126, 129], ["A third S protein", "TEST", 0, 17], ["the cytoplasmic tail", "TEST", 46, 66], ["S protein", "TEST", 75, 84], ["last 12 amino acids", "TREATMENT", 103, 122], ["NDV F protein CT", "TEST", 126, 142]]], ["The CT modification was done to enhance incorporation of IBV S protein into NDV envelope.", [["IBV", "ORGANISM", 57, 60], ["NDV", "ORGANISM", 76, 79], ["IBV S protein", "PROTEIN", 57, 70], ["IBV", "SPECIES", 57, 60], ["NDV", "SPECIES", 76, 79], ["The CT modification", "TEST", 0, 19], ["IBV S protein", "TREATMENT", 57, 70]]], ["The protective efficacies of the three IBV S proteins were evaluated by homologous challenge with the Egyptian strain IBV/Ck/EG/CU/4/2014.Cells and viruses ::: Materials and methodsHuman epidermoid carcinoma (HEp-2) and chicken embryo fibroblast (DF-1) cell lines were cultured in Dulbecco\u2019s minimal essential medium (DMEM) with 10% fetal bovine serum.", [["Cells", "ANATOMY", 138, 143], ["epidermoid carcinoma", "ANATOMY", 187, 207], ["HEp-2", "ANATOMY", 209, 214], ["embryo fibroblast (DF-1) cell lines", "ANATOMY", 228, 263], ["fetal bovine serum", "ANATOMY", 333, 351], ["epidermoid carcinoma", "DISEASE", 187, 207], ["IBV", "ORGANISM", 39, 42], ["IBV", "ORGANISM", 118, 121], ["Cells", "CELL", 138, 143], ["Human", "ORGANISM", 181, 186], ["epidermoid carcinoma", "CANCER", 187, 207], ["HEp-2", "CELL", 209, 214], ["chicken", "ORGANISM", 220, 227], ["embryo fibroblast", "CELL", 228, 245], ["DF-1) cell lines", "CELL", 247, 263], ["bovine", "ORGANISM", 339, 345], ["serum", "ORGANISM_SUBSTANCE", 346, 351], ["IBV S proteins", "PROTEIN", 39, 53], ["chicken embryo fibroblast (DF-1) cell lines", "CELL_LINE", 220, 263], ["Human", "SPECIES", 181, 186], ["chicken", "SPECIES", 220, 227], ["bovine", "SPECIES", 339, 345], ["IBV", "SPECIES", 39, 42], ["Egyptian strain IBV/Ck/EG/CU/4/2014", "SPECIES", 102, 137], ["chicken", "SPECIES", 220, 227], ["bovine", "SPECIES", 339, 345], ["the three IBV S proteins", "TEST", 29, 53], ["the Egyptian strain IBV", "TREATMENT", 98, 121], ["methodsHuman epidermoid carcinoma", "PROBLEM", 174, 207], ["HEp", "TEST", 209, 212], ["chicken embryo fibroblast (DF", "PROBLEM", 220, 249], ["cell lines", "TREATMENT", 253, 263], ["Dulbecco", "TEST", 281, 289], ["10% fetal bovine serum", "TEST", 329, 351], ["viruses", "OBSERVATION", 148, 155], ["epidermoid carcinoma", "OBSERVATION", 187, 207], ["embryo fibroblast", "OBSERVATION", 228, 245], ["cell lines", "OBSERVATION", 253, 263], ["minimal", "OBSERVATION_MODIFIER", 292, 299], ["essential", "OBSERVATION_MODIFIER", 300, 309], ["medium", "OBSERVATION_MODIFIER", 310, 316]]], ["Specific pathogen free (SPF) embryonated chicken eggs (ECE) were obtained from Charles River Laboratories, Manassas, VA, USA.", [["eggs", "ANATOMY", 49, 53], ["ECE", "ANATOMY", 55, 58], ["chicken", "ORGANISM", 41, 48], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 49, 53], ["chicken", "SPECIES", 41, 48], ["chicken", "SPECIES", 41, 48], ["Manassas", "SPECIES", 107, 115], ["Specific pathogen free (SPF) embryonated chicken eggs", "PROBLEM", 0, 53]]], ["The Egyptian IBV strain IBV/Ck/EG/CU/4/2014 belonging to GI-23 lineage (GenBank accession number: KY805846) [27], NDV strain LaSota, virulent NDV strain Texas GB (GenBank accession number: GU978777.1) and modified vaccinia strain Ankara expressing T7 polymerase (MVA-T7), a kind gift from Dr Bernard Moss, were used in this study.", [["Egyptian", "ORGANISM", 4, 12], ["IBV strain IBV", "ORGANISM", 13, 27], ["Ck/EG/CU/4", "ORGANISM", 28, 38], ["GI-23", "ORGANISM", 57, 62], ["KY805846", "ORGANISM", 98, 106], ["NDV strain LaSota", "ORGANISM", 114, 131], ["NDV strain", "ORGANISM", 142, 152], ["Texas GB", "ORGANISM", 153, 161], ["vaccinia strain Ankara", "ORGANISM", 214, 236], ["T7 polymerase", "GENE_OR_GENE_PRODUCT", 248, 261], ["MVA-T7", "ORGANISM", 263, 269], ["T7 polymerase", "PROTEIN", 248, 261], ["NDV", "SPECIES", 114, 117], ["NDV", "SPECIES", 142, 145], ["Egyptian IBV strain IBV/Ck/EG/CU/4/2014", "SPECIES", 4, 43], ["NDV", "SPECIES", 114, 117], ["NDV", "SPECIES", 142, 145], ["The Egyptian IBV strain IBV", "TEST", 0, 27], ["Ck", "TEST", 28, 30], ["GI", "TEST", 57, 59], ["NDV strain LaSota", "TEST", 114, 131], ["GU", "TEST", 189, 191], ["modified vaccinia strain", "TREATMENT", 205, 229], ["this study", "TEST", 319, 329], ["GI", "ANATOMY", 57, 59], ["T7", "ANATOMY", 267, 269]]], ["All work related to virulent NDV was performed in our USDA certified enhanced animal biosafety level 3 (ABSL-3+) facility.Construction of recombinant NDV-vectored IBV vaccine candidates ::: Materials and methodsThree different forms of chicken-codon-optimized S gene of the Egyptian IBV strain IBV/Ck/EG/CU/4/2014 were inserted individually between phosphoprotein (P) and matrix (M) protein genes in the LaSota antigenomic cDNA backbone using PmeI site [41] to generate three different recombinant NDV vectored IBV vaccine candidates (Figure 1).", [["NDV", "ORGANISM", 29, 32], ["NDV", "ORGANISM", 150, 153], ["IBV", "ORGANISM", 163, 166], ["chicken", "ORGANISM", 236, 243], ["Egyptian", "ORGANISM", 274, 282], ["IBV strain IBV", "ORGANISM", 283, 297], ["Ck/EG/CU/4", "ORGANISM", 298, 308], ["matrix", "CELLULAR_COMPONENT", 372, 378], ["NDV", "ORGANISM", 498, 501], ["IBV", "ORGANISM", 511, 514], ["chicken-codon", "DNA", 236, 249], ["S gene", "DNA", 260, 266], ["EG/CU/4/2014", "DNA", 301, 313], ["phosphoprotein (P) and matrix (M) protein genes", "DNA", 349, 396], ["LaSota antigenomic cDNA backbone", "DNA", 404, 436], ["PmeI site", "DNA", 443, 452], ["chicken", "SPECIES", 236, 243], ["IBV strain IBV", "SPECIES", 283, 297], ["NDV", "SPECIES", 29, 32], ["NDV-vectored IBV", "SPECIES", 150, 166], ["chicken", "SPECIES", 236, 243], ["Egyptian IBV strain IBV/Ck/EG/CU/4/2014", "SPECIES", 274, 313], ["NDV vectored IBV", "SPECIES", 498, 514], ["virulent NDV", "PROBLEM", 20, 32], ["ABSL", "TEST", 104, 108], ["recombinant NDV", "TREATMENT", 138, 153], ["chicken-codon", "TREATMENT", 236, 249], ["the Egyptian IBV strain IBV", "TEST", 270, 297], ["Ck/EG", "TEST", 298, 303], ["phosphoprotein (P) and matrix (M) protein genes", "TREATMENT", 349, 396], ["the LaSota antigenomic cDNA backbone", "TREATMENT", 400, 436], ["PmeI site", "TREATMENT", 443, 452], ["three different recombinant NDV vectored IBV vaccine candidates", "TREATMENT", 470, 533]]], ["In the first recombinant, rLaSota/wt.S, the full chicken-codon-optimized sequence of the IBV S gene without any modification was inserted.", [["rLaSota", "GENE_OR_GENE_PRODUCT", 26, 33], ["chicken", "ORGANISM", 49, 56], ["IBV", "ORGANISM", 89, 92], ["rLaSota", "PROTEIN", 26, 33], ["chicken-codon-optimized sequence", "DNA", 49, 81], ["IBV S gene", "DNA", 89, 99], ["chicken", "SPECIES", 49, 56], ["chicken", "SPECIES", 49, 56], ["IBV", "SPECIES", 89, 92], ["the full chicken-codon", "TREATMENT", 40, 62], ["the IBV S gene", "TREATMENT", 85, 99], ["any modification", "TREATMENT", 108, 124]]], ["In the second recombinant, rLaSota/S(Y1145A) + Fct12, the tyrosine residue present at position 1145 of the IBV S protein was mutated to Alanine (Y1145A) by PCR mutagenesis and the modified S gene was fused to the last 12 amino acids of NDV fusion (F) protein cytoplasmic domain using overlap PCR.", [["cytoplasmic", "ANATOMY", 259, 270], ["tyrosine", "CHEMICAL", 58, 66], ["Alanine", "CHEMICAL", 136, 143], ["amino acids", "CHEMICAL", 221, 232], ["tyrosine", "CHEMICAL", 58, 66], ["Alanine", "CHEMICAL", 136, 143], ["amino acids", "CHEMICAL", 221, 232], ["rLaSota/S(Y1145A)", "GENE_OR_GENE_PRODUCT", 27, 44], ["tyrosine", "AMINO_ACID", 58, 66], ["IBV S protein", "GENE_OR_GENE_PRODUCT", 107, 120], ["Alanine", "AMINO_ACID", 136, 143], ["amino acids", "AMINO_ACID", 221, 232], ["NDV fusion (F)", "GENE_OR_GENE_PRODUCT", 236, 250], ["cytoplasmic", "ORGANISM_SUBSTANCE", 259, 270], ["rLaSota", "PROTEIN", 27, 34], ["S(Y1145A)", "PROTEIN", 35, 44], ["Fct12", "PROTEIN", 47, 52], ["position 1145", "PROTEIN", 86, 99], ["IBV S protein", "PROTEIN", 107, 120], ["modified S gene", "DNA", 180, 195], ["NDV fusion (F) protein cytoplasmic domain", "PROTEIN", 236, 277], ["IBV", "SPECIES", 107, 110], ["NDV", "SPECIES", 236, 239], ["the tyrosine residue", "PROBLEM", 54, 74], ["the IBV S protein", "TEST", 103, 120], ["Alanine (Y1145A", "TREATMENT", 136, 151], ["PCR mutagenesis", "TEST", 156, 171], ["the modified S gene", "TREATMENT", 176, 195], ["the last 12 amino acids", "TREATMENT", 209, 232], ["NDV fusion (F) protein cytoplasmic domain", "TREATMENT", 236, 277], ["overlap PCR", "TEST", 284, 295]]], ["In the third recombinant, rLaSota/S\u0394ct + Fct12, the cytoplasmic tail of the IBV S gene was replaced by the last 12 amino acids of NDV fusion protein using fusion PCR technique.", [["cytoplasmic tail", "ANATOMY", 52, 68], ["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 115, 126], ["rLaSota", "GENE_OR_GENE_PRODUCT", 26, 33], ["S\u0394ct", "GENE_OR_GENE_PRODUCT", 34, 38], ["Fct12", "GENE_OR_GENE_PRODUCT", 41, 46], ["cytoplasmic", "ORGANISM_SUBSTANCE", 52, 63], ["tail", "MULTI-TISSUE_STRUCTURE", 64, 68], ["IBV S", "GENE_OR_GENE_PRODUCT", 76, 81], ["amino acids", "AMINO_ACID", 115, 126], ["NDV", "ORGANISM", 130, 133], ["rLaSota", "PROTEIN", 26, 33], ["S\u0394ct", "PROTEIN", 34, 38], ["Fct12", "PROTEIN", 41, 46], ["cytoplasmic tail", "PROTEIN", 52, 68], ["IBV S gene", "DNA", 76, 86], ["NDV fusion protein", "PROTEIN", 130, 148], ["IBV", "SPECIES", 76, 79], ["NDV", "SPECIES", 130, 133], ["the IBV S gene", "TREATMENT", 72, 86], ["the last 12 amino acids", "TREATMENT", 103, 126], ["NDV fusion protein", "TREATMENT", 130, 148], ["fusion PCR technique", "TREATMENT", 155, 175]]], ["All the three forms of the IBV S gene were inserted as an independent transcription cassette flanked by the gene-start (GS) and gene-end (GE) sequences of the NDV and the \u201crule of six\u201d was ensured in the final length of the recombinant NDV genome for efficient replication [42].", [["IBV S", "GENE_OR_GENE_PRODUCT", 27, 32], ["NDV", "ORGANISM", 159, 162], ["NDV", "ORGANISM", 236, 239], ["IBV S gene", "DNA", 27, 37], ["transcription cassette", "DNA", 70, 92], ["gene-start (GS) and gene-end (GE) sequences", "DNA", 108, 151], ["recombinant NDV genome", "DNA", 224, 246], ["NDV", "SPECIES", 159, 162], ["IBV", "SPECIES", 27, 30], ["NDV", "SPECIES", 159, 162], ["NDV", "SPECIES", 236, 239], ["the IBV S gene", "TREATMENT", 23, 37], ["gene-end (GE) sequences", "TREATMENT", 128, 151], ["the NDV", "TREATMENT", 155, 162], ["the recombinant NDV genome", "TREATMENT", 220, 246]]], ["Briefly, the codon-optimized IBV S gene\u2014preceded with GE, intergenic sequence (IGS), GS and Kozak sequences, and flanked by PmeI sites\u2014was synthesized and cloned in pUC57 (pUC57-CO.S) by GenScript\u00ae (Additional file 1A).", [["codon-optimized IBV S", "DNA", 13, 34], ["GE, intergenic sequence", "DNA", 54, 77], ["IGS", "DNA", 79, 82], ["GS", "DNA", 85, 87], ["Kozak sequences", "DNA", 92, 107], ["PmeI sites\u2014was", "DNA", 124, 138], ["pUC57", "DNA", 165, 170], ["pUC57", "DNA", 172, 177], ["GS and Kozak sequences", "TEST", 85, 107]]], ["To construct rLaSota/wt.S, pUC57-CO.S was digested with PmeI (NEB), and the released insert was gel purified and ligated into full-length rLaSota clone which was predigested by PmeI and dephosphorylated by thermostable shrimp alkaline phosphatase (TSAP) (Promega).", [["rLaSota", "GENE_OR_GENE_PRODUCT", 13, 20], ["pUC57-CO.S", "SIMPLE_CHEMICAL", 27, 37], ["PmeI", "SIMPLE_CHEMICAL", 56, 60], ["NEB", "GENE_OR_GENE_PRODUCT", 62, 65], ["rLaSota clone", "CELL", 138, 151], ["PmeI", "GENE_OR_GENE_PRODUCT", 177, 181], ["shrimp alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 219, 246], ["rLaSota", "PROTEIN", 13, 20], ["pUC57", "DNA", 27, 32], ["CO.S", "DNA", 33, 37], ["PmeI", "PROTEIN", 56, 60], ["NEB", "PROTEIN", 62, 65], ["rLaSota clone", "CELL_LINE", 138, 151], ["PmeI", "PROTEIN", 177, 181], ["thermostable shrimp alkaline phosphatase", "PROTEIN", 206, 246], ["TSAP", "PROTEIN", 248, 252], ["pUC57", "TEST", 27, 32], ["PmeI (NEB", "TREATMENT", 56, 65], ["the released insert", "TREATMENT", 72, 91], ["full-length rLaSota clone", "TREATMENT", 126, 151], ["thermostable shrimp alkaline phosphatase", "TEST", 206, 246], ["TSAP", "TEST", 248, 252]]], ["To construct rLaSota/S(Y1145A) + Fct12, primer sets (1 and 2) and (3 and 4) were used to induce the \u201cY1145A-mutation\u201d and add the last 12 aa of NDV F protein using pUC57-CO.S as template (Table 1).", [["CO", "CHEMICAL", 170, 172], ["rLaSota", "GENE_OR_GENE_PRODUCT", 13, 20], ["rLaSota", "PROTEIN", 13, 20], ["S(Y1145A)", "DNA", 21, 30], ["Fct12", "DNA", 33, 38], ["primer sets", "DNA", 40, 51], ["NDV F protein", "PROTEIN", 144, 157], ["pUC57", "PROTEIN", 164, 169], ["CO", "PROTEIN", 170, 172], ["NDV", "SPECIES", 144, 147], ["primer sets", "TEST", 40, 51], ["NDV F protein", "TEST", 144, 157], ["pUC57", "TEST", 164, 169]]], ["The two PCR products were then fused using primers (1 and 4) by fusion PCR.", [["PCR products", "DNA", 8, 20], ["The two PCR products", "TREATMENT", 0, 20], ["primers", "TEST", 43, 50], ["fusion PCR", "TEST", 64, 74]]], ["The fused PCR product was then digested by SmaI and StuI (NEB), and ligated into pUC57-CO.S which was predigested by SmaI and by StuI, its sequence is naturally present downstream to the S gene, to create pUC57-CO.S(Y1145A) + Fct12 (Additional file 1B).", [["CO", "CHEMICAL", 87, 89], ["CO", "CHEMICAL", 211, 213], ["SmaI", "GENE_OR_GENE_PRODUCT", 43, 47], ["StuI", "GENE_OR_GENE_PRODUCT", 52, 56], ["NEB", "GENE_OR_GENE_PRODUCT", 58, 61], ["pUC57-CO", "GENE_OR_GENE_PRODUCT", 81, 89], ["SmaI", "GENE_OR_GENE_PRODUCT", 117, 121], ["StuI", "GENE_OR_GENE_PRODUCT", 129, 133], ["pUC57-CO", "GENE_OR_GENE_PRODUCT", 205, 213], ["Additional file 1B", "GENE_OR_GENE_PRODUCT", 233, 251], ["SmaI", "PROTEIN", 43, 47], ["StuI", "PROTEIN", 52, 56], ["NEB", "PROTEIN", 58, 61], ["pUC57", "DNA", 81, 86], ["CO", "PROTEIN", 87, 89], ["SmaI", "DNA", 117, 121], ["StuI", "DNA", 129, 133], ["S gene", "DNA", 187, 193], ["pUC57", "DNA", 205, 210], ["CO", "PROTEIN", 211, 213], ["The fused PCR product", "TREATMENT", 0, 21], ["StuI (NEB", "TREATMENT", 52, 61]]], ["To construct rLaSota/S\u0394ct + Fct12, primer set (1 and 5) was used to replace the cytoplasmic tail of IBV S protein by the last 12 aa of NDV F protein using pUC57-CO.S as template.", [["cytoplasmic tail", "ANATOMY", 80, 96], ["CO", "CHEMICAL", 161, 163], ["rLaSota", "GENE_OR_GENE_PRODUCT", 13, 20], ["S\u0394ct", "GENE_OR_GENE_PRODUCT", 21, 25], ["cytoplasmic", "ORGANISM_SUBSTANCE", 80, 91], ["IBV S protein", "GENE_OR_GENE_PRODUCT", 100, 113], ["NDV", "ORGANISM", 135, 138], ["rLaSota", "PROTEIN", 13, 20], ["S\u0394ct", "DNA", 21, 25], ["Fct12", "DNA", 28, 33], ["primer set", "DNA", 35, 45], ["cytoplasmic tail", "PROTEIN", 80, 96], ["IBV S protein", "PROTEIN", 100, 113], ["NDV F protein", "PROTEIN", 135, 148], ["pUC57", "PROTEIN", 155, 160], ["CO", "PROTEIN", 161, 163], ["IBV", "SPECIES", 100, 103], ["NDV", "SPECIES", 135, 138], ["IBV S protein", "TREATMENT", 100, 113], ["NDV F protein", "TREATMENT", 135, 148]]], ["The PCR product was then digested by SmaI and StuI and ligated into pUC57-CO.S which is predigested by SmaI and StuI to create pUC57-CO.S\u0394ct + Fct12 (Additional file 1C).", [["pUC57-CO.", "CHEMICAL", 127, 136], ["CO", "CHEMICAL", 74, 76], ["SmaI", "GENE_OR_GENE_PRODUCT", 37, 41], ["StuI", "GENE_OR_GENE_PRODUCT", 46, 50], ["SmaI", "GENE_OR_GENE_PRODUCT", 103, 107], ["StuI", "GENE_OR_GENE_PRODUCT", 112, 116], ["SmaI", "DNA", 37, 41], ["StuI", "DNA", 46, 50], ["pUC57", "DNA", 68, 73], ["SmaI", "DNA", 103, 107], ["StuI", "PROTEIN", 112, 116], ["pUC57", "DNA", 127, 132], ["S\u0394ct", "PROTEIN", 136, 140], ["Fct12", "PROTEIN", 143, 148], ["The PCR product", "TEST", 0, 15]]], ["The newly formed pUC57-CO.S(Y1145A) + Fct12 and pUC57-CO.S\u0394ct + Fct12 were then digested with PmeI and the released inserts were ligated individually into full-length rLaSota clone which was predigested by PmeI and dephosphorylated by TSAP to construct rLaSota/S(Y1145A) + Fct12 and rLaSota/S\u0394ct + Fct12, respectively.", [["CO", "CHEMICAL", 23, 25], ["pUC57-CO", "SIMPLE_CHEMICAL", 17, 25], ["S\u0394ct", "GENE_OR_GENE_PRODUCT", 57, 61], ["Fct12", "GENE_OR_GENE_PRODUCT", 64, 69], ["PmeI", "GENE_OR_GENE_PRODUCT", 94, 98], ["rLaSota clone", "CELL", 167, 180], ["PmeI", "GENE_OR_GENE_PRODUCT", 206, 210], ["TSAP", "GENE_OR_GENE_PRODUCT", 235, 239], ["rLaSota", "GENE_OR_GENE_PRODUCT", 253, 260], ["rLaSota", "GENE_OR_GENE_PRODUCT", 283, 290], ["pUC57", "PROTEIN", 17, 22], ["CO", "PROTEIN", 23, 25], ["S\u0394ct", "PROTEIN", 57, 61], ["Fct12", "PROTEIN", 64, 69], ["PmeI", "DNA", 94, 98], ["released inserts", "DNA", 107, 123], ["full-length rLaSota clone", "DNA", 155, 180], ["PmeI", "PROTEIN", 206, 210], ["TSAP", "PROTEIN", 235, 239], ["rLaSota", "PROTEIN", 253, 260], ["Fct12", "PROTEIN", 273, 278], ["rLaSota", "PROTEIN", 283, 290], ["S\u0394ct", "DNA", 291, 295], ["Fct12", "DNA", 298, 303], ["Fct12", "TEST", 38, 43], ["pUC57", "TEST", 48, 53], ["PmeI", "TREATMENT", 94, 98], ["the released inserts", "TREATMENT", 103, 123], ["full-length rLaSota clone", "TREATMENT", 155, 180], ["Fct12", "TEST", 273, 278], ["rLaSota", "TEST", 283, 290]]], ["The sequences of all inserts were confirmed by DNA nucleotide sequencing.", [["nucleotide", "CHEMICAL", 51, 61], ["nucleotide", "CHEMICAL", 51, 61], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["all inserts", "TREATMENT", 17, 28], ["DNA nucleotide sequencing", "TEST", 47, 72]]], ["The recombinant viruses were rescued using the reverse genetic technique as previously described [43].", [["The recombinant viruses", "PROBLEM", 0, 23], ["viruses", "OBSERVATION", 16, 23]]], ["Rescued recombinant viruses were plaque purified and propagated in 10-day-old SPF ECE.", [["plaque", "ANATOMY", 33, 39], ["SPF", "ORGANISM", 78, 81], ["Rescued recombinant viruses", "PROBLEM", 0, 27], ["plaque", "PROBLEM", 33, 39], ["viruses", "OBSERVATION", 20, 27], ["plaque", "OBSERVATION", 33, 39]]], ["The infective allantoic fluids were harvested, aliquoted and stored at \u221270 \u00b0C for further work.", [["allantoic fluids", "ANATOMY", 14, 30], ["allantoic fluids", "ORGANISM_SUBSTANCE", 14, 30], ["The infective allantoic fluids", "TREATMENT", 0, 30], ["infective", "OBSERVATION_MODIFIER", 4, 13], ["allantoic fluids", "OBSERVATION", 14, 30]]], ["The insertion of the different forms of IBV S genes were detected by RT-PCR using LaSota specific primers flanking the PmeI site and confirmed by nucleotide sequencing.", [["nucleotide", "CHEMICAL", 146, 156], ["nucleotide", "CHEMICAL", 146, 156], ["IBV S", "GENE_OR_GENE_PRODUCT", 40, 45], ["PmeI", "GENE_OR_GENE_PRODUCT", 119, 123], ["IBV S genes", "DNA", 40, 51], ["LaSota specific primers", "DNA", 82, 105], ["PmeI site", "DNA", 119, 128], ["IBV", "SPECIES", 40, 43], ["IBV S genes", "PROBLEM", 40, 51], ["RT-PCR", "TREATMENT", 69, 75], ["LaSota specific primers", "TREATMENT", 82, 105], ["nucleotide sequencing", "TEST", 146, 167], ["insertion", "OBSERVATION_MODIFIER", 4, 13], ["IBV", "OBSERVATION", 40, 43]]]], "767a9bf1aa5eb98311a9c72fedf28415f6ad4c6a": [["I. INTRODUCTIONRapid identification of infectious agents (viruses, bacteria, and fungi) is critical for the diagnosis and effective treatment of diseases.", [["infectious agents", "TREATMENT", 39, 56], ["viruses", "PROBLEM", 58, 65], ["bacteria", "PROBLEM", 67, 75], ["diseases", "PROBLEM", 145, 153], ["infectious", "OBSERVATION", 39, 49]]], ["The monitoring of biohazards in the environment and the detection of pathogens in foodstuffs are also crucial to protect human health.", [["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["biohazards", "TREATMENT", 18, 28], ["pathogens in foodstuffs", "PROBLEM", 69, 92]]], ["Various procedures have traditionally been used to collect, isolate, and identify pathogens from different specimens and samples.", [["specimens", "ANATOMY", 107, 116], ["samples", "ANATOMY", 121, 128], ["Various procedures", "TREATMENT", 0, 18], ["pathogens", "PROBLEM", 82, 91], ["different specimens", "TEST", 97, 116]]], ["In general, culture methods using differential and selective media are employed for isolation and identification.", [["culture methods", "TEST", 12, 27], ["selective media", "TREATMENT", 51, 66], ["isolation", "TREATMENT", 84, 93], ["identification", "TEST", 98, 112]]], ["The identification is based on microscopic observation, colonial morphology, and phenotypic characteristics on isolation medium.", [["microscopic observation", "TEST", 31, 54], ["colonial morphology", "TEST", 56, 75], ["isolation medium", "TREATMENT", 111, 127]]], ["Further, biochemical, serological, and molecular biology methods are employed for the definitive identification of microbial isolates.", [["biochemical, serological", "TEST", 9, 33], ["microbial isolates", "TREATMENT", 115, 133]]], ["These established methods are often timeconsuming and labor-intensive.", [["labor", "PROBLEM", 54, 59]]], ["For instance, cultivation on differential media and selective media might take days to weeks.", [["differential media", "TREATMENT", 29, 47], ["selective media", "TREATMENT", 52, 67]]], ["Differentiation of clinical microorganisms to the species level might require as many as 20 biochemical tests.", [["clinical microorganisms", "PROBLEM", 19, 42], ["the species level", "PROBLEM", 46, 63], ["biochemical tests", "TEST", 92, 109]]], ["Consequently, the need for alternative procedures that allow the rapid and reliable identification of microorganisms is increasing.", [["alternative procedures", "TREATMENT", 27, 49], ["microorganisms", "PROBLEM", 102, 116], ["microorganisms", "OBSERVATION", 102, 116]]], ["Mass spectrometry (MS) is a powerful tool in biological research, and represents an attractive alternative to classical biochemical methods, especially for the accurate identification and classification of microbial species (Anhalt & Fenselau, 1975; Cain, Lubman, & Weber, 1994; Lay, 2001; Demirev & Fenselau, 2008a) .I. INTRODUCTIONThere are challenges associated with identification of various types of pathogens from wide range of samples.", [["samples", "ANATOMY", 434, 441], ["samples", "CANCER", 434, 441], ["Anhalt & Fenselau, 1975; Cain, Lubman, & Weber, 1994; Lay, 2001; Demirev & Fenselau", "SPECIES", 225, 308], ["Mass spectrometry", "PROBLEM", 0, 17], ["microbial species", "PROBLEM", 206, 223], ["pathogens", "PROBLEM", 405, 414]]], ["Viruses are ultramicroscopic and they must be cultivated within a susceptible cell.", [["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["Viruses", "PROBLEM", 0, 7], ["ultramicroscopic", "TREATMENT", 12, 28], ["a susceptible cell", "PROBLEM", 64, 82], ["susceptible cell", "OBSERVATION", 66, 82]]], ["Unlike bacterial proteomes, viral proteomes are relatively small.", [["bacterial proteomes", "PROBLEM", 7, 26], ["viral proteomes", "PROBLEM", 28, 43], ["bacterial proteomes", "OBSERVATION", 7, 26], ["viral proteomes", "OBSERVATION", 28, 43], ["relatively", "OBSERVATION_MODIFIER", 48, 58], ["small", "OBSERVATION_MODIFIER", 59, 64]]], ["Therefore, available biomarkers might be limited.", [["available biomarkers", "TEST", 11, 31]]], ["The cell wall of Gram-positive bacteria is more difficult to disrupt than that of Gram-negative bacteria.", [["cell wall", "ANATOMY", 4, 13], ["cell wall", "MULTI-TISSUE_STRUCTURE", 4, 13], ["Gram", "GENE_OR_GENE_PRODUCT", 17, 21], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 82, 104], ["The cell wall of Gram", "TEST", 0, 21], ["positive bacteria", "PROBLEM", 22, 39], ["Gram", "TEST", 82, 86], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["wall", "OBSERVATION_MODIFIER", 9, 13], ["positive bacteria", "OBSERVATION_MODIFIER", 22, 39], ["negative bacteria", "OBSERVATION", 87, 104]]], ["Because of the resistance of spores, methods to identify them require germination and cultivation of the resulting vegetative cells.", [["spores", "ANATOMY", 29, 35], ["vegetative cells", "ANATOMY", 115, 131], ["vegetative cells", "CELL", 115, 131], ["vegetative cells", "CELL_TYPE", 115, 131], ["the resistance of spores", "PROBLEM", 11, 35], ["methods", "TREATMENT", 37, 44], ["germination", "TREATMENT", 70, 81], ["cultivation", "TREATMENT", 86, 97], ["the resulting vegetative cells", "PROBLEM", 101, 131], ["vegetative cells", "OBSERVATION", 115, 131]]], ["Microbiological analysis of a variety of samples generally requires specific approaches, as a first step, to isolate and culture the microorganisms.", [["samples", "ANATOMY", 41, 48], ["Microbiological analysis", "TEST", 0, 24], ["a variety of samples", "PROBLEM", 28, 48], ["culture the microorganisms", "TEST", 121, 147]]], ["Liquid samples such as milk and body fluids might be directly cultured in media.", [["Liquid samples", "ANATOMY", 0, 14], ["milk", "ANATOMY", 23, 27], ["body fluids", "ANATOMY", 32, 43], ["milk", "ORGANISM_SUBSTANCE", 23, 27], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["fluids", "ORGANISM_SUBSTANCE", 37, 43], ["Liquid samples", "TEST", 0, 14], ["milk and body fluids", "TREATMENT", 23, 43]]], ["Solid samples such as food are blended and diluted before culturing.", [["Solid samples", "ANATOMY", 0, 13], ["Solid samples", "CANCER", 0, 13], ["Solid samples", "PROBLEM", 0, 13], ["culturing", "TEST", 58, 67]]], ["Airborne pathogens should be sampled with an air sampler before further analysis.I. INTRODUCTIONThe applicability of MS to the analysis of complex biomolecules has been greatly improved by the introduction of two softionization techniques-electrospray ionization (ESI) and matrixassisted laser desorption/ionization (MALDI) MS. These two soft-ionization methods ionize large molecules with little or no fragmentation, and therefore have been applied to analyze various biomolecules such as carbohydrates, proteins and peptides, DNA and RNA, and synthetic polymers.", [["carbohydrates", "CHEMICAL", 490, 503], ["carbohydrates", "SIMPLE_CHEMICAL", 490, 503], ["DNA", "CELLULAR_COMPONENT", 528, 531], ["Airborne pathogens", "PROBLEM", 0, 18], ["an air sampler", "TEST", 42, 56], ["further analysis", "TEST", 64, 80], ["complex biomolecules", "PROBLEM", 139, 159], ["two softionization techniques", "TREATMENT", 209, 238], ["electrospray ionization (ESI)", "TREATMENT", 239, 268], ["matrixassisted laser desorption/ionization (MALDI)", "TREATMENT", 273, 323], ["soft-ionization methods", "TREATMENT", 338, 361], ["large molecules", "PROBLEM", 369, 384], ["fragmentation", "PROBLEM", 403, 416], ["carbohydrates, proteins", "TREATMENT", 490, 513], ["peptides", "TREATMENT", 518, 526], ["DNA and RNA", "TREATMENT", 528, 539], ["synthetic polymers", "TREATMENT", 545, 563], ["soft", "OBSERVATION_MODIFIER", 338, 342], ["large", "OBSERVATION_MODIFIER", 369, 374], ["molecules", "OBSERVATION", 375, 384], ["no", "UNCERTAINTY", 400, 402], ["fragmentation", "OBSERVATION", 403, 416]]], ["MALDI and ESI have both been effectively used for the accurate analysis of peptides and the determination of peptide sequences to identify and characterize proteins in microorganisms (Yao, Demirev, & Fenselau, 2002; Dworzanski et al., 2004) .", [["ESI", "TREATMENT", 10, 13], ["the accurate analysis", "TEST", 50, 71], ["the determination of peptide sequences", "TEST", 88, 126], ["proteins in microorganisms", "PROBLEM", 156, 182]]], ["These methods can be easily implemented in a straightforward diagnostic procedure to identify reliably the genus, species and, in some cases, subspecies of bacteria.I. INTRODUCTIONMicrobial samples can be analyzed with MS by using a culture or a non-culture approach.", [["samples", "ANATOMY", 190, 197], ["a straightforward diagnostic procedure", "TREATMENT", 43, 81], ["bacteria", "PROBLEM", 156, 164], ["a culture", "TEST", 231, 240], ["a non-culture approach", "TREATMENT", 244, 266], ["bacteria", "OBSERVATION", 156, 164]]], ["Figure 1 presents an overview of MS-based approaches to identify and characterize microorganisms.", [["microorganisms", "PROBLEM", 82, 96]]], ["In culture approaches, potential biomarkers are analyzed directly with MALDI-MS or extracted/digested, separated by chromatography, and identified with MS. In non-culture approaches, cell enrichment (with affinity methods) is performed with physical, chemical, or biochemical interactions with target cells, followed by MS analysis.", [["cell", "ANATOMY", 183, 187], ["cells", "ANATOMY", 301, 306], ["cell", "CELL", 183, 187], ["cells", "CELL", 301, 306], ["target cells", "CELL_TYPE", 294, 306], ["culture approaches", "TEST", 3, 21], ["potential biomarkers", "TEST", 23, 43], ["MS analysis", "TEST", 320, 331], ["cell enrichment", "OBSERVATION", 183, 198]]], ["The coupling of air sampling and polymerase chain reaction (PCR) amplification to MS has also been developed to detect microorganisms.", [["air sampling", "PROBLEM", 16, 28], ["polymerase chain reaction", "PROBLEM", 33, 58], ["PCR", "TEST", 60, 63], ["microorganisms", "PROBLEM", 119, 133], ["air sampling", "OBSERVATION", 16, 28]]], ["Finally, unknown microorganisms are identified with a database search and/or a computer algorithm.I. INTRODUCTIONMass spectrometry (MS) analysis of microorganisms present in complex biological samples obtained from food, water, and clinical specimens must often be preceded by purification and concentration.", [["samples", "ANATOMY", 193, 200], ["specimens", "ANATOMY", 241, 250], ["unknown microorganisms", "PROBLEM", 9, 31], ["a database search", "TEST", 52, 69], ["a computer algorithm", "TEST", 77, 97], ["microorganisms", "PROBLEM", 148, 162], ["clinical specimens", "TEST", 232, 250], ["microorganisms", "OBSERVATION", 17, 31]]], ["Affinity extraction can effectively clean up, enrich, and probe analytes of interest from complex biological mixtures.", [["Affinity extraction", "TREATMENT", 0, 19]]], ["Nanostructures have many characteristics that favor their use as selective extraction agents, and their small size makes them inherently effective as concentration agents.", [["selective extraction agents", "TREATMENT", 65, 92], ["concentration agents", "TREATMENT", 150, 170], ["small", "OBSERVATION_MODIFIER", 104, 109], ["size", "OBSERVATION_MODIFIER", 110, 114]]], ["The field of nanotechnology has seen explosive growth in recent years, primarily because of the availability of new strategies for the synthesis of nanomaterials and new tools for characterization and manipulation (Curtis & Wilkinson, 2001; Levy et al., 2002) .", [["new strategies", "TREATMENT", 112, 126], ["the synthesis of nanomaterials", "PROBLEM", 131, 161], ["explosive", "OBSERVATION_MODIFIER", 37, 46], ["growth", "OBSERVATION_MODIFIER", 47, 53]]], ["Generally, biological molecules such as proteins/enzymes, antigens/antibodies, and DNA/oligonucleotides have been immobilized on the surfaces of nanoparticles with supports of organic/inorganic and polymer matrices.", [["DNA", "CELLULAR_COMPONENT", 83, 86], ["inorganic", "SIMPLE_CHEMICAL", 184, 193], ["enzymes", "PROTEIN", 49, 56], ["antigens", "PROTEIN", 58, 66], ["antibodies", "PROTEIN", 67, 77], ["proteins/enzymes", "TEST", 40, 56], ["antigens/antibodies", "TEST", 58, 77], ["DNA/oligonucleotides", "PROBLEM", 83, 103], ["organic/inorganic and polymer matrices", "TREATMENT", 176, 214], ["polymer matrices", "OBSERVATION", 198, 214]]], ["Sample concentration techniques that are based on nanotechnology have potential applications to detect pathogens in complex samples.I. INTRODUCTIONThe complexity of microbial biomarkers might be reduced with various chromatography-based methods.", [["samples", "ANATOMY", 124, 131], ["Sample concentration techniques", "TREATMENT", 0, 31], ["pathogens in complex samples", "PROBLEM", 103, 131], ["microbial biomarkers", "TEST", 165, 185], ["various chromatography", "TEST", 208, 230], ["reduced", "OBSERVATION_MODIFIER", 195, 202]]], ["However, sample preparation and fractionation tend to slow down measurements.", [["sample", "ANATOMY", 9, 15], ["sample preparation", "TEST", 9, 27], ["fractionation", "TEST", 32, 45]]], ["Efficient separation approaches should be considered to achieve a fast and high-throughput analysis.", [["Efficient separation approaches", "TREATMENT", 0, 31]]], ["Various techniques, such as liquid chromatography (LC), capillary electrophoresis (CE), two-dimensional gel electrophoresis (2DGE), protein precipitation, membrane-based methods (dialysis, ultrafiltration), supercritical fluid extraction, and solid-phase microextraction have been developed for sample pretreatment (Wang & Hanash, 2005; Bodzon-Kulakowska et al., 2007) .", [["membrane", "ANATOMY", 155, 163], ["sample", "ANATOMY", 295, 301], ["capillary", "TISSUE", 56, 65], ["membrane", "CELLULAR_COMPONENT", 155, 163], ["Various techniques", "TREATMENT", 0, 18], ["liquid chromatography", "TEST", 28, 49], ["capillary electrophoresis", "TEST", 56, 81], ["two-dimensional gel electrophoresis (2DGE)", "TREATMENT", 88, 130], ["protein precipitation", "TREATMENT", 132, 153], ["membrane-based methods (dialysis", "TREATMENT", 155, 187], ["ultrafiltration", "TREATMENT", 189, 204], ["supercritical fluid extraction", "TREATMENT", 207, 237], ["solid-phase microextraction", "TREATMENT", 243, 270]]], ["This article focuses only on sample fractionation methods that are used to identify microorganisms.", [["sample fractionation methods", "TEST", 29, 57], ["microorganisms", "PROBLEM", 84, 98]]], ["MS analysis of various classes of biomolecules (peptides, proteins, nucleic acids, oligosaccharides, and lipids) with hyphenated MS techniques, including gas chromatography (GC), CE, and LC, are described.", [["nucleic acids", "CHEMICAL", 68, 81], ["nucleic acids", "SIMPLE_CHEMICAL", 68, 81], ["lipids", "SIMPLE_CHEMICAL", 105, 111], ["MS analysis", "TEST", 0, 11], ["various classes of biomolecules (peptides", "PROBLEM", 15, 56], ["nucleic acids", "TEST", 68, 81], ["oligosaccharides", "TEST", 83, 99], ["lipids", "TEST", 105, 111], ["hyphenated MS techniques", "TEST", 118, 142], ["gas chromatography", "TEST", 154, 172], ["GC", "TEST", 174, 176], ["CE", "TEST", 179, 181], ["LC", "ANATOMY", 187, 189]]], ["The direct analysis of pathogens with MALDI-MS has several advantages, such as rapidity and simplicity.", [["The direct analysis", "TEST", 0, 19], ["pathogens", "PROBLEM", 23, 32], ["MALDI", "TEST", 38, 43]]], ["This review also describes direct methods, such as bioaerosol mass spectrometry (BAMS) and affinity methods, such as surface-enhanced laser desorption/ionization (SELDI).I. INTRODUCTIONVarious research groups have developed ambient ionization techniques, including desorption electrospray ionization (DESI) (Takats et al., 2004) , direct analysis in real time (DART) (Cody, Laramee, & Durst, 2005) , and electrospray-assisted laser desorption ionization mass spectrometry (ELDI) (Shiea et al., 2005) .", [["direct methods", "TEST", 27, 41], ["bioaerosol mass spectrometry", "TEST", 51, 79], ["affinity methods", "TEST", 91, 107], ["surface-enhanced laser desorption/ionization (SELDI)", "TREATMENT", 117, 169], ["ambient ionization techniques", "TREATMENT", 224, 253], ["desorption electrospray ionization", "TREATMENT", 265, 299], ["direct analysis", "TEST", 331, 346], ["electrospray-assisted laser desorption ionization mass spectrometry", "TREATMENT", 404, 471]]], ["Some of these techniques have been applied to examine bacterial samples without prior sample preparation, and enabled researchers to collect fingerprint-spectra of bacteria in less than a minute with a mass spectrometer (Takats et al., 2004) .", [["samples", "ANATOMY", 64, 71], ["sample", "ANATOMY", 86, 92], ["bacterial samples", "TEST", 54, 71], ["prior sample preparation", "TREATMENT", 80, 104], ["bacteria", "PROBLEM", 164, 172], ["a mass spectrometer", "PROBLEM", 200, 219]]], ["The review will briefly describe recent progress in microbial analysis with DESI, DART, and other techniques, such as inductively coupled plasma mass spectrometry (ICP-MS) and secondary ion mass spectrometry (SIMS).I. INTRODUCTIONGenotypic methods such as PCR and nucleotide sequence analysis might be used as diagnostic tools to identify pathogens.", [["nucleotide", "CHEMICAL", 264, 274], ["microbial analysis", "TEST", 52, 70], ["inductively coupled plasma mass spectrometry", "PROBLEM", 118, 162], ["ICP", "TEST", 164, 167], ["secondary ion mass spectrometry", "PROBLEM", 176, 207], ["INTRODUCTIONGenotypic methods", "TREATMENT", 218, 247], ["PCR", "TEST", 256, 259], ["nucleotide sequence analysis", "TEST", 264, 292], ["diagnostic tools", "TEST", 310, 326], ["pathogens", "PROBLEM", 339, 348]]], ["PCR methods are particularly promising because of their high specificity and sensitivity.", [["PCR methods", "TEST", 0, 11]]], ["Although PCR methods are quite useful to identify microbial species, they cannot be used for classification, especially when the microbial identities are unknown.", [["PCR methods", "TEST", 9, 20], ["microbial species", "PROBLEM", 50, 67]]], ["The combination of PCR and MS is an even more powerful tool for microbial identification; in some cases, it yields additional information that cannot be obtained from either technique alone (Sampath et al., 2007b) .", [["PCR", "TEST", 19, 22], ["MS", "PROBLEM", 27, 29], ["microbial identification", "TEST", 64, 88]]], ["The ESI-based detection of PCR products and MALDI-based resequencing provide detailed genomic information that is useful in the rapid identification of microorganisms (Sauer & Kliem, 2010) .", [["PCR products", "DNA", 27, 39], ["The ESI", "TEST", 0, 7], ["PCR products", "TREATMENT", 27, 39], ["MALDI", "TEST", 44, 49], ["microorganisms", "PROBLEM", 152, 166]]], ["LC-ESI-MS has been successfully used to make mass measurements of bacterial PCR amplicons (Mayr et al., 2005) .", [["LC", "TEST", 0, 2], ["MS", "PROBLEM", 7, 9], ["bacterial PCR amplicons", "PROBLEM", 66, 89]]], ["Ion-pair reversed-phase highperformance LC with monolithic capillary columns has been employed for the rapid and efficient on-line purification of DNA fragments amplified by PCR because it can be fully automated with a high throughput (Oberacher et al., 2000; Berger et al., 2002) .I. INTRODUCTIONThe utility of MS as an analytical tool for pathogens depends on the availability of a variety of MS methods and instruments that each provides particular pieces of information regarding the identity of the sample.", [["DNA", "CELLULAR_COMPONENT", 147, 150], ["DNA fragments", "DNA", 147, 160], ["Ion-pair", "TEST", 0, 8], ["monolithic capillary columns", "TREATMENT", 48, 76], ["-line purification", "TREATMENT", 125, 143], ["DNA fragments", "PROBLEM", 147, 160], ["pathogens", "PROBLEM", 341, 350], ["a variety of MS methods", "TREATMENT", 382, 405], ["instruments", "TREATMENT", 410, 421], ["capillary columns", "OBSERVATION", 59, 76]]], ["The complexity of the relevant experimental data has led to the development of many dedicated algorithms to extract and interpret useful information.", [["complexity", "OBSERVATION_MODIFIER", 4, 14]]], ["The review will also introduce methods of data analysis, including library searches and statistical approaches, to differentiate among pathogens and conclude with selected examples of applications of microbial analysis.", [["data analysis", "TEST", 42, 55], ["library searches", "TEST", 67, 83], ["microbial analysis", "TEST", 200, 218]]], ["The review is intended to cover most current MS techniques of microbial analysis.", [["microbial analysis", "TEST", 62, 80]]], ["Clearly, although not all of the recently published literature will be referred to, representative studies will be described.A. Nanotechnologies to Concentrate SamplesMicrobial biomarkers might be suppressed by the ions that are formed from complex matrices during MS analysis.", [["representative studies", "TEST", 84, 106], ["Concentrate SamplesMicrobial biomarkers", "TEST", 148, 187], ["MS analysis", "TEST", 265, 276]]], ["Various affinity probes have been used to concentrate and purify the bacteria of interest.", [["Various affinity probes", "TREATMENT", 0, 23]]], ["Fenselau and co-workers described the detection of bacteria from complex biological mixtures using affinity capture coupled with MALDI-MS.", [["bacteria", "PROBLEM", 51, 59], ["complex biological mixtures", "TREATMENT", 65, 92]]], ["They proposed an affinity method to trap traces of bacterial cells from complex biological mixtures with a lectin-immobilized substrate.", [["cells", "ANATOMY", 61, 66], ["bacterial cells", "CELL", 51, 66], ["lectin", "GENE_OR_GENE_PRODUCT", 107, 113], ["bacterial cells", "CELL_TYPE", 51, 66], ["lectin", "PROTEIN", 107, 113], ["bacterial cells", "PROBLEM", 51, 66], ["a lectin-immobilized substrate", "TREATMENT", 105, 135], ["bacterial cells", "OBSERVATION", 51, 66]]], ["This technique offers a broad range with less-selective recovery because many bacteria have lectin on their cell surfaces (Bundy & Fenselau, 1999; Bundy & Fenselau, 2001; Afonso & Fenselau, 2003) .", [["cell", "ANATOMY", 108, 112], ["lectin", "GENE_OR_GENE_PRODUCT", 92, 98], ["cell", "CELL", 108, 112], ["lectin", "PROTEIN", 92, 98], ["many bacteria", "PROBLEM", 73, 86], ["their cell surfaces", "TEST", 102, 121], ["bacteria", "OBSERVATION", 78, 86]]], ["Recently, affinity surfaces modified with immunoglobulin G (IgG) or small peptides that were selected from phage libraries were used to isolate protein A from Staphylococcus aureus.", [["Staphylococcus aureus", "DISEASE", 159, 180], ["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 42, 58], ["IgG", "GENE_OR_GENE_PRODUCT", 60, 63], ["Staphylococcus aureus", "ORGANISM", 159, 180], ["immunoglobulin G", "PROTEIN", 42, 58], ["IgG", "PROTEIN", 60, 63], ["protein A", "PROTEIN", 144, 153], ["Staphylococcus aureus", "SPECIES", 159, 180], ["Staphylococcus aureus", "SPECIES", 159, 180], ["immunoglobulin G (IgG)", "TREATMENT", 42, 64], ["small peptides", "PROBLEM", 68, 82], ["phage libraries", "TREATMENT", 107, 122], ["Staphylococcus aureus", "PROBLEM", 159, 180], ["Staphylococcus aureus", "OBSERVATION", 159, 180]]], ["The structure of protein A was identified with MALDI-MS (Johnson et al., 2009) .", [["protein A", "GENE_OR_GENE_PRODUCT", 17, 26], ["protein A", "PROTEIN", 17, 26]]], ["Over the past decade, a number of biomedical applications of magnetic micro-and nanoparticles of various sizes, shapes, and compositions have emerged (Berry & Curtis, 2003) .", [["magnetic micro", "TEST", 61, 75], ["various", "OBSERVATION_MODIFIER", 97, 104], ["sizes", "OBSERVATION_MODIFIER", 105, 110], ["shapes", "OBSERVATION_MODIFIER", 112, 118]]], ["Immunomagnetic separation has been widely used to reduce the detection time/suppression effect, and to improve detection sensitivity.", [["Immunomagnetic separation", "TREATMENT", 0, 25], ["detection sensitivity", "TEST", 111, 132]]], ["Magnetic particles conjugated with a specific antibody can selectively separate a target pathogen from complex samples (Ochoa & Harrington, 2005) .", [["samples", "ANATOMY", 111, 118], ["Magnetic particles", "TEST", 0, 18], ["a specific antibody", "PROBLEM", 35, 54]]], ["Voorhees et al. proposed an approach that used affinity-capture techniques, such as immunomagnetic separation, to concentrate and isolate bacteria from complex sample solutions, which was followed with a MALDI-MS analysis (Madonna et al., 2001; Madonna, Van Cuyk, & Voorhees, 2003a) .", [["an approach", "TREATMENT", 25, 36], ["affinity-capture techniques", "TREATMENT", 47, 74], ["immunomagnetic separation", "TREATMENT", 84, 109], ["isolate bacteria", "PROBLEM", 130, 146], ["a MALDI", "TEST", 202, 209]]], ["The method involved microsized magnetic beads immobilized with affinity-purified antibodies.", [["affinity-purified antibodies", "PROTEIN", 63, 91], ["microsized magnetic beads", "TREATMENT", 20, 45], ["affinity", "TEST", 63, 71]]], ["The immuno-captured bacterium was further infected with a bacteriophage (a lytic virus).", [["The immuno", "TEST", 0, 10], ["captured bacterium", "PROBLEM", 11, 29], ["a bacteriophage", "PROBLEM", 56, 71], ["a lytic virus", "PROBLEM", 73, 86]]], ["Phage amplification occurred within the living bacterial cell and induced cell lysis.", [["cell", "ANATOMY", 57, 61], ["cell", "ANATOMY", 74, 78], ["bacterial cell", "CELL", 47, 61], ["cell", "CELL", 74, 78], ["Phage amplification", "TREATMENT", 0, 19], ["the living bacterial cell", "TREATMENT", 36, 61], ["induced cell lysis", "TREATMENT", 66, 84], ["bacterial cell", "OBSERVATION", 47, 61], ["induced cell lysis", "OBSERVATION", 66, 84]]], ["Many phage progeny released into the sample medium and detection of the phage capsid proteins from the medium indicated the presence of the bacterium.", [["phage capsid proteins", "PROTEIN", 72, 93], ["the phage capsid proteins", "TEST", 68, 93], ["the bacterium", "PROBLEM", 136, 149], ["bacterium", "OBSERVATION", 140, 149]]], ["The detectable concentration was improved to $5.0 \u00c2 10 4 cells/mL and the analysis could be finished within 2 hr.", [["cells", "ANATOMY", 57, 62], ["cells", "CELL", 57, 62], ["the analysis", "TEST", 70, 82], ["detectable", "OBSERVATION_MODIFIER", 4, 14], ["concentration", "OBSERVATION_MODIFIER", 15, 28], ["improved", "OBSERVATION_MODIFIER", 33, 41]]], ["Because many antibodies and bacteriophages are commercially available, the approach has the potential to analyze speciesor even strain-specific bacteria and to improve their detection limit.A. Nanotechnologies to Concentrate SamplesThe rapid and sensitive detection of microorganisms at low concentrations is a challenging task.", [["antibodies", "PROTEIN", 13, 23], ["many antibodies and bacteriophages", "PROBLEM", 8, 42], ["strain", "PROBLEM", 128, 134], ["specific bacteria", "PROBLEM", 135, 152], ["Concentrate Samples", "TEST", 213, 232], ["microorganisms at low concentrations", "PROBLEM", 269, 305]]], ["Functionalized magnetic nanoparticles very efficiently concentrate pathogens from large sample volumes into much smaller volumes.", [["sample", "ANATOMY", 88, 94], ["Functionalized magnetic nanoparticles", "TREATMENT", 0, 37], ["large sample volumes", "TEST", 82, 102], ["large", "OBSERVATION_MODIFIER", 82, 87], ["smaller", "OBSERVATION_MODIFIER", 113, 120], ["volumes", "OBSERVATION_MODIFIER", 121, 128]]], ["A minimum capture efficiency of 94% for E. coli O157:H7 at concentrations from 1.6 \u00c2 10 1 to 7.2 \u00c2 10 7 colony forming unit (CFU)/mL with magnetic nanoparticle-anti-E. coli conjugates has been reported (Varshney et al., 2005) .", [["O157:H7", "CHEMICAL", 48, 55], ["E. coli", "ORGANISM", 40, 47], ["O157:H7", "ORGANISM", 48, 55], ["E. coli", "ORGANISM", 165, 172], ["E. coli O157", "SPECIES", 40, 52], ["E. coli", "SPECIES", 165, 172], ["E. coli O157:H7", "SPECIES", 40, 55], ["E. coli", "SPECIES", 165, 172], ["A minimum capture efficiency", "TEST", 0, 28], ["E. coli", "PROBLEM", 40, 47], ["magnetic nanoparticle", "TEST", 138, 159], ["anti-E. coli conjugates", "TREATMENT", 160, 183]]], ["Various carbohydrates have been recognized as receptors for the attachment of pathogens to epithelial cells of E. coli (Sharon, 2006) .", [["epithelial cells", "ANATOMY", 91, 107], ["carbohydrates", "CHEMICAL", 8, 21], ["epithelial cells", "CELL", 91, 107], ["E. coli", "ORGANISM", 111, 118], ["epithelial cells", "CELL_TYPE", 91, 107], ["E. coli", "SPECIES", 111, 118], ["E. coli", "SPECIES", 111, 118], ["Various carbohydrates", "TREATMENT", 0, 21], ["pathogens", "PROBLEM", 78, 87], ["E. coli", "PROBLEM", 111, 118], ["epithelial cells", "OBSERVATION", 91, 107], ["E. coli", "OBSERVATION", 111, 118]]], ["For example, mannose-encapsulated gold nanoparticles have been used to observe the specific binding to a FimH protein of bacterial type 1 pili E. coli (Lin et al., 2002) .", [["mannose", "CHEMICAL", 13, 20], ["mannose", "CHEMICAL", 13, 20], ["mannose-encapsulated gold nanoparticles", "SIMPLE_CHEMICAL", 13, 52], ["FimH", "GENE_OR_GENE_PRODUCT", 105, 109], ["E. coli", "ORGANISM", 143, 150], ["FimH protein", "PROTEIN", 105, 117], ["E. coli", "SPECIES", 143, 150], ["E. coli", "SPECIES", 143, 150], ["mannose-encapsulated gold nanoparticles", "TREATMENT", 13, 52]]], ["The covalent binding between nanoparticles and targets is easily achieved with the self-assembly of thiolated molecules on the nanoparticles (thiol-metal interactions).", [["thiol", "CHEMICAL", 142, 147], ["thiol", "CHEMICAL", 142, 147], ["nanoparticles", "SIMPLE_CHEMICAL", 29, 42], ["thiolated molecules", "SIMPLE_CHEMICAL", 100, 119], ["nanoparticles", "SIMPLE_CHEMICAL", 127, 140], ["thiol", "SIMPLE_CHEMICAL", 142, 147], ["The covalent binding between nanoparticles", "TREATMENT", 0, 42], ["the nanoparticles (thiol-metal interactions", "TREATMENT", 123, 166], ["covalent binding", "OBSERVATION", 4, 20]]], ["Gu et al. developed a strategy that used vancomycin-conjugated Fe-Pt nanoparticles to capture and detect pathogens such as vancomycin-resistant enterococci and other Gram-positive bacteria or -negative bacteria at exceptionally low concentrations (Gu et al., 2003a (Gu et al., ,b, 2006 .", [["vancomycin", "CHEMICAL", 41, 51], ["Fe-Pt", "CHEMICAL", 63, 68], ["vancomycin", "CHEMICAL", 123, 133], ["vancomycin", "CHEMICAL", 41, 51], ["Fe", "CHEMICAL", 63, 65], ["Pt", "CHEMICAL", 66, 68], ["vancomycin", "CHEMICAL", 123, 133], ["vancomycin", "SIMPLE_CHEMICAL", 41, 51], ["Fe-Pt nanoparticles", "SIMPLE_CHEMICAL", 63, 82], ["vancomycin", "SIMPLE_CHEMICAL", 123, 133], ["enterococci", "CANCER", 144, 155], ["Gram", "GENE_OR_GENE_PRODUCT", 166, 170], ["a strategy", "TREATMENT", 20, 30], ["vancomycin", "TREATMENT", 41, 51], ["conjugated Fe", "TREATMENT", 52, 65], ["Pt nanoparticles", "TREATMENT", 66, 82], ["pathogens", "PROBLEM", 105, 114], ["vancomycin", "TEST", 123, 133], ["resistant enterococci", "PROBLEM", 134, 155], ["other Gram", "TEST", 160, 170], ["positive bacteria", "PROBLEM", 171, 188], ["negative bacteria at exceptionally low concentrations", "PROBLEM", 193, 246], ["et al", "OBSERVATION", 3, 8], ["positive bacteria", "OBSERVATION_MODIFIER", 171, 188], ["negative bacteria", "OBSERVATION_MODIFIER", 193, 210]]], ["They used optical and scanning electron microscopy to observe the captured bacteria.", [["scanning electron microscopy", "TEST", 22, 50], ["the captured bacteria", "PROBLEM", 62, 83]]], ["The thiol-metal binding protocol enabled the detection of bacteria from the samples within 1 hr, and had a detection limit of 10 CFU/mL (Gu et al., 2003a) .A. Nanotechnologies to Concentrate SamplesSeveral research groups have investigated nanoparticles as extraction/concentration agents for coupling with MS. Figure 2 shows the experimental procedure for the selective extraction and concentration of microorganisms with functionalized magnetic nanoparticles, followed by detection with MALDI-MS.", [["samples", "ANATOMY", 76, 83], ["thiol", "CHEMICAL", 4, 9], ["thiol", "CHEMICAL", 4, 9], ["thiol", "SIMPLE_CHEMICAL", 4, 9], ["The thiol-metal binding protocol", "TREATMENT", 0, 32], ["bacteria", "PROBLEM", 58, 66], ["Nanotechnologies", "TREATMENT", 159, 175], ["Concentrate SamplesSeveral research groups", "TREATMENT", 179, 221], ["nanoparticles", "TREATMENT", 240, 253], ["extraction/concentration agents", "TREATMENT", 257, 288], ["the experimental procedure", "TREATMENT", 326, 352], ["the selective extraction", "TREATMENT", 357, 381], ["microorganisms", "PROBLEM", 403, 417], ["functionalized magnetic nanoparticles", "TREATMENT", 423, 460]]], ["After functionalized magnetic nanoparticles are added to an Eppendorf tube that contains microbial cells, the suspension is incubated under gentle vortexing.", [["cells", "ANATOMY", 99, 104], ["magnetic nanoparticles", "SIMPLE_CHEMICAL", 21, 43], ["microbial cells", "CELL", 89, 104], ["microbial cells", "CELL_TYPE", 89, 104], ["functionalized magnetic nanoparticles", "TREATMENT", 6, 43], ["an Eppendorf tube", "TREATMENT", 57, 74], ["microbial cells", "TREATMENT", 89, 104], ["the suspension", "TREATMENT", 106, 120], ["Eppendorf tube", "OBSERVATION", 60, 74], ["microbial cells", "OBSERVATION", 89, 104], ["gentle vortexing", "OBSERVATION", 140, 156]]], ["The magnetic nanoparticles interact with the pathogens, and efficiently attach to them.", [["The magnetic nanoparticles", "TREATMENT", 0, 26]]], ["The nanoparticle-microbial cell conjugates are isolated by magnetic separation, and are deposited on a MALDI target for MS analysis.", [["cell", "ANATOMY", 27, 31], ["nanoparticle", "CHEMICAL", 4, 16], ["The nanoparticle-microbial cell conjugates", "TREATMENT", 0, 42], ["MS analysis", "TEST", 120, 131], ["microbial cell conjugates", "OBSERVATION", 17, 42], ["magnetic separation", "OBSERVATION_MODIFIER", 59, 78]]], ["Chen's research group used functionalized nanoparticles to probe pathogenic bacteria .", [["functionalized nanoparticles", "TREATMENT", 27, 55], ["pathogenic bacteria", "PROBLEM", 65, 84]]], ["They proposed a simple method to fabricate IgG functionalized gold nanoparticles as useful probes of the electrostatic interactions between IgG and pathogens (Ho et al., 2004) .", [["IgG functionalized gold nanoparticles", "SIMPLE_CHEMICAL", 43, 80], ["IgG", "GENE_OR_GENE_PRODUCT", 140, 143], ["IgG", "PROTEIN", 43, 46], ["IgG", "PROTEIN", 140, 143], ["a simple method", "TREATMENT", 14, 29], ["IgG functionalized gold nanoparticles", "TREATMENT", 43, 80]]], ["The IgG-modified magnetic nanoparticles, which bind selectively to IgG-binding sites on the cell walls of pathogens, serve as affinity probes to capture targeted bacteria from sample solutions.", [["cell walls", "ANATOMY", 92, 102], ["IgG", "GENE_OR_GENE_PRODUCT", 4, 7], ["magnetic nanoparticles", "SIMPLE_CHEMICAL", 17, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 67, 70], ["cell", "CELLULAR_COMPONENT", 92, 96], ["IgG", "PROTEIN", 4, 7], ["IgG", "PROTEIN", 67, 70], ["The IgG", "TREATMENT", 0, 7], ["modified magnetic nanoparticles", "TREATMENT", 8, 39], ["pathogens", "PROBLEM", 106, 115], ["affinity probes", "TEST", 126, 141], ["targeted bacteria from sample solutions", "PROBLEM", 153, 192]]], ["The optimal detectable cell concentration of bacteria in aqueous sample solutions (Staphylococcus saprophyticus and S. aureus, 0.5 mL) and in urine samples (S. saprophyticus, 0.5 mL) was $3 \u00c2 10 5 and $3 \u00c2 10 7 CFU/mL, respectively (Ho et al., 2004) .", [["cell", "ANATOMY", 23, 27], ["aqueous sample", "ANATOMY", 57, 71], ["urine samples", "ANATOMY", 142, 155], ["cell", "CELL", 23, 27], ["aqueous", "ORGANISM_SUBSTANCE", 57, 64], ["Staphylococcus saprophyticus", "ORGANISM", 83, 111], ["S. aureus", "ORGANISM", 116, 125], ["urine samples", "ORGANISM_SUBSTANCE", 142, 155], ["S. saprophyticus", "ORGANISM", 157, 173], ["Staphylococcus saprophyticus", "SPECIES", 83, 111], ["S. aureus", "SPECIES", 116, 125], ["S. saprophyticus", "SPECIES", 157, 173], ["Staphylococcus saprophyticus", "SPECIES", 83, 111], ["S. aureus", "SPECIES", 116, 125], ["S. saprophyticus", "SPECIES", 157, 173], ["bacteria", "PROBLEM", 45, 53], ["aqueous sample solutions", "TEST", 57, 81], ["Staphylococcus saprophyticus", "PROBLEM", 83, 111], ["S. aureus", "PROBLEM", 116, 125], ["urine samples", "TEST", 142, 155], ["detectable cell", "OBSERVATION", 12, 27], ["concentration", "OBSERVATION_MODIFIER", 28, 41], ["bacteria", "OBSERVATION_MODIFIER", 45, 53]]], ["The same group used the IgG-Fe 3 O 4 2 magnetic nanoparticles as IDENTIFICATION OF PATHOGENS BY MASS SPECTROMETRY & photokilling agents that exhibit antimicrobial activity against pathogenic bacteria under UV irradiation .", [["Fe", "CHEMICAL", 28, 30], ["UV", "CHEMICAL", 206, 208], ["Fe 3 O 4", "CHEMICAL", 28, 36], ["IgG-Fe 3 O 4 2 magnetic nanoparticles", "SIMPLE_CHEMICAL", 24, 61], ["IgG", "PROTEIN", 24, 27], ["MASS SPECTROMETRY", "TEST", 96, 113], ["photokilling agents", "TREATMENT", 116, 135], ["antimicrobial activity", "TREATMENT", 149, 171], ["pathogenic bacteria", "PROBLEM", 180, 199], ["UV irradiation", "TREATMENT", 206, 220], ["UV irradiation", "OBSERVATION", 206, 220]]], ["They also employed vancomycin-modified magnetic nanoparticles for the selective isolation of Gram-positive pathogens (S. saprophyticus, S. aureus, and E. faecalis) from sample solutions.", [["sample", "ANATOMY", 169, 175], ["vancomycin", "CHEMICAL", 19, 29], ["Gram-", "CHEMICAL", 93, 98], ["vancomycin", "CHEMICAL", 19, 29], ["vancomycin", "SIMPLE_CHEMICAL", 19, 29], ["magnetic nanoparticles", "SIMPLE_CHEMICAL", 39, 61], ["Gram-", "GENE_OR_GENE_PRODUCT", 93, 98], ["S. saprophyticus", "ORGANISM", 118, 134], ["S. aureus", "ORGANISM", 136, 145], ["E. faecalis", "ORGANISM", 151, 162], ["S. saprophyticus", "SPECIES", 118, 134], ["S. aureus", "SPECIES", 136, 145], ["E. faecalis", "SPECIES", 151, 162], ["S. saprophyticus", "SPECIES", 118, 134], ["S. aureus", "SPECIES", 136, 145], ["E. faecalis", "SPECIES", 151, 162], ["vancomycin", "TREATMENT", 19, 29], ["modified magnetic nanoparticles", "TREATMENT", 30, 61], ["Gram-positive pathogens", "PROBLEM", 93, 116], ["S. saprophyticus", "PROBLEM", 118, 134], ["S. aureus", "PROBLEM", 136, 145], ["E. faecalis", "PROBLEM", 151, 162], ["positive pathogens", "OBSERVATION", 98, 116]]], ["The optimal detectable concentration of S. saprophyticus and S. aureus spiked in a urine sample was $7 \u00c2 10 4 CFU/mL .", [["urine sample", "ANATOMY", 83, 95], ["S. saprophyticus", "ORGANISM", 40, 56], ["S. aureus", "ORGANISM", 61, 70], ["urine", "ORGANISM_SUBSTANCE", 83, 88], ["S. saprophyticus", "SPECIES", 40, 56], ["S. aureus", "SPECIES", 61, 70], ["S. saprophyticus", "SPECIES", 40, 56], ["S. aureus", "SPECIES", 61, 70], ["S. saprophyticus", "PROBLEM", 40, 56], ["S. aureus", "PROBLEM", 61, 70], ["a urine sample", "TEST", 81, 95]]], ["Recently, pigeon ovalbumin-bound Fe 3 O 4 2 O 3 magnetic nanoparticles have been used as affinity probes to trap selectively uropathogenic P fimbriated E. coli from bacteria-spiked urine samples (Liu et al., 2008) and Pseudomonas aeruginosa ) from clinical urine samples through disaccharide-protein interactions.", [["urine samples", "ANATOMY", 181, 194], ["urine samples", "ANATOMY", 257, 270], ["Fe", "CHEMICAL", 33, 35], ["Fe 3 O 4 2 O 3", "CHEMICAL", 33, 47], ["disaccharide", "CHEMICAL", 279, 291], ["pigeon ovalbumin", "ORGANISM", 10, 26], ["Fe 3 O 4 2 O 3 magnetic nanoparticles", "SIMPLE_CHEMICAL", 33, 70], ["E. coli", "ORGANISM", 152, 159], ["urine samples", "ORGANISM_SUBSTANCE", 181, 194], ["Pseudomonas aeruginosa", "ORGANISM", 218, 240], ["urine samples", "ORGANISM_SUBSTANCE", 257, 270], ["disaccharide", "SIMPLE_CHEMICAL", 279, 291], ["pigeon", "SPECIES", 10, 16], ["E. coli", "SPECIES", 152, 159], ["Pseudomonas aeruginosa", "SPECIES", 218, 240], ["pigeon", "SPECIES", 10, 16], ["E. coli", "SPECIES", 152, 159], ["Pseudomonas aeruginosa", "SPECIES", 218, 240], ["pigeon ovalbumin-bound Fe", "TREATMENT", 10, 35], ["magnetic nanoparticles", "TREATMENT", 48, 70], ["uropathogenic P fimbriated E. coli from bacteria", "PROBLEM", 125, 173], ["urine samples", "TEST", 181, 194], ["Liu et al.", "TEST", 196, 206], ["Pseudomonas aeruginosa", "PROBLEM", 218, 240], ["clinical urine samples", "TEST", 248, 270], ["disaccharide", "TEST", 279, 291]]], ["They have been able to detect peptide signal from 250 mL of samples at a concentration as low as 4 \u00c2 10 4 cells/mL, corresponding to 10 2 cells deposited on the MALDI plate.", [["samples", "ANATOMY", 60, 67], ["cells", "ANATOMY", 106, 111], ["cells", "ANATOMY", 138, 143], ["cells", "CELL", 138, 143], ["peptide signal", "TEST", 30, 44], ["MALDI plate", "ANATOMY", 161, 172]]], ["Guo and coworkers utilized anion-exchange/cation-exchange magnetic nanoparticles as affinity probes to separate bacteria from water .", [["anion", "CHEMICAL", 27, 32], ["anion", "SIMPLE_CHEMICAL", 27, 32], ["cation", "SIMPLE_CHEMICAL", 42, 48], ["magnetic nanoparticles", "SIMPLE_CHEMICAL", 58, 80], ["water", "SIMPLE_CHEMICAL", 126, 131], ["anion-exchange/cation", "TREATMENT", 27, 48], ["exchange magnetic nanoparticles", "TREATMENT", 49, 80], ["bacteria", "OBSERVATION", 112, 120]]], ["The positively charged nanoparticles interacted with bacteria (generally carrying negative charges).", [["bacteria", "PROBLEM", 53, 61]]], ["This approach was used to analyze various bacteria spiked in tap water and reservoir water with a detection limit of 1 \u00c2 10 3 CFU/mL in 2 hr.", [["This approach", "TREATMENT", 0, 13], ["various bacteria", "PROBLEM", 34, 50]]], ["Although most of the above affinity methods employ MALDI-MS for microbial analysis, LC-ESI-MS should be in principle as feasible as MALDI-MS.A. Nanotechnologies to Concentrate SamplesThe most important advantage of affinity-based nanotechnology is its ability to concentrate and purify microbial cells from complex samples such as urine.", [["cells", "ANATOMY", 296, 301], ["samples", "ANATOMY", 315, 322], ["urine", "ANATOMY", 331, 336], ["microbial cells", "CELL", 286, 301], ["urine", "ORGANISM_SUBSTANCE", 331, 336], ["microbial cells", "CELL_TYPE", 286, 301], ["MALDI", "TEST", 51, 56], ["microbial analysis", "TEST", 64, 82], ["LC", "TEST", 84, 86], ["complex samples", "TEST", 307, 322], ["urine", "TEST", 331, 336]]], ["Microorganisms might be identified directly with MALDI-MS without microbial culturing.", [["Microorganisms", "PROBLEM", 0, 14], ["MALDI", "TEST", 49, 54], ["microbial culturing", "TEST", 66, 85]]], ["Direct MALDI analysis of microorganisms in urine samples would be hindered by the high amounts of salts without the affinity-enrichment step (Liu et al., 2008) .", [["urine samples", "ANATOMY", 43, 56], ["salts", "CHEMICAL", 98, 103], ["urine samples", "ORGANISM_SUBSTANCE", 43, 56], ["salts", "SIMPLE_CHEMICAL", 98, 103], ["Direct MALDI analysis", "TEST", 0, 21], ["microorganisms", "PROBLEM", 25, 39], ["urine samples", "TEST", 43, 56]]], ["Notably, different cell counting methods are used among various labs and absolute cell number or CFU per volume are reported in literatures.", [["cell", "ANATOMY", 19, 23], ["cell", "ANATOMY", 82, 86], ["cell", "CELL", 19, 23], ["cell", "CELL", 82, 86], ["various labs", "TEST", 56, 68], ["different", "OBSERVATION_MODIFIER", 9, 18], ["cell counting", "OBSERVATION", 19, 32]]], ["Although CFU reflects the viable cell number, absolute cell number is likely higher than those indicated by the CFU value.", [["cell", "ANATOMY", 33, 37], ["cell", "ANATOMY", 55, 59], ["cell", "CELL", 33, 37], ["cell", "CELL", 55, 59], ["absolute cell number", "TEST", 46, 66], ["the CFU value", "TEST", 108, 121], ["viable cell", "OBSERVATION", 26, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["absolute cell number", "OBSERVATION", 46, 66], ["likely", "UNCERTAINTY", 70, 76], ["higher", "OBSERVATION_MODIFIER", 77, 83]]], ["Limits of detection given in these two units should be compared carefully.B. ESI-MSWhen a large set of digested peptides that are obtained from a complex microorganism are analyzed, MALDI-MS yields spectra that are too complicated to be interpreted.", [["B. ESI", "TEST", 74, 80], ["a large set of digested peptides", "PROBLEM", 88, 120], ["a complex microorganism", "PROBLEM", 144, 167], ["large", "OBSERVATION_MODIFIER", 90, 95]]], ["Moreover, MALDI-MS is relatively difficult to couple on-line with sample pretreatment and separation methods, and cannot easily be automated.", [["sample", "ANATOMY", 66, 72], ["sample pretreatment", "TREATMENT", 66, 85], ["separation methods", "TEST", 90, 108]]], ["ESI-MS, however, allows on-line detection to be combined with sample purification, concentration, and separation techniques, such as microdialysis, solid phase extraction, LC, and CE.", [["sample", "ANATOMY", 62, 68], ["sample purification", "TREATMENT", 62, 81], ["separation techniques", "TREATMENT", 102, 123], ["microdialysis, solid phase extraction", "TEST", 133, 170], ["LC", "TEST", 172, 174]]], ["Goodacre, Heald, and Kell (1999) applied ESI-MS to characterize strains of intact Gram-negative and Gram-positive bacteria.", [["Gram-", "GENE_OR_GENE_PRODUCT", 82, 87], ["Gram-", "GENE_OR_GENE_PRODUCT", 100, 105], ["ESI", "TEST", 41, 44], ["strains", "PROBLEM", 64, 71], ["Gram-positive bacteria", "PROBLEM", 100, 122], ["positive bacteria", "OBSERVATION", 105, 122]]], ["The bacteria were suspended in 50% acetonitrile/water (1%, v/v, formic acid) for positive ESI and the samples were analyzed in 50% isopropanol/water for negative ESI.", [["samples", "ANATOMY", 102, 109], ["acetonitrile", "CHEMICAL", 35, 47], ["formic acid", "CHEMICAL", 64, 75], ["isopropanol", "CHEMICAL", 131, 142], ["acetonitrile", "CHEMICAL", 35, 47], ["formic acid", "CHEMICAL", 64, 75], ["isopropanol", "CHEMICAL", 131, 142], ["formic acid", "SIMPLE_CHEMICAL", 64, 75], ["isopropanol", "SIMPLE_CHEMICAL", 131, 142], ["The bacteria", "PROBLEM", 0, 12], ["v/v, formic acid", "TREATMENT", 59, 75], ["positive ESI", "PROBLEM", 81, 93], ["the samples", "TEST", 98, 109], ["bacteria", "OBSERVATION_MODIFIER", 4, 12]]], ["This approach produces the information-rich spectra, in both the positive and negative ion modes, from whole bacterial suspensions, but requires the cells to be suspended in solvent before analysis.", [["cells", "ANATOMY", 149, 154], ["cells", "CELL", 149, 154], ["whole bacterial suspensions", "TREATMENT", 103, 130], ["the cells", "TREATMENT", 145, 154], ["ion modes", "OBSERVATION_MODIFIER", 87, 96]]], ["Further, Xiang et al. (2000) employed ESI-MS/MS to identify bacteria by analyzing cell lysates.", [["cell lysates", "ANATOMY", 82, 94], ["cell lysates", "CELL", 82, 94], ["MS", "PROBLEM", 45, 47], ["bacteria", "PROBLEM", 60, 68], ["cell lysates", "OBSERVATION", 82, 94]]], ["Vaidyanathan et al. also investigated the effectiveness of direct ESI-MS of bacterial cell lysates/extracts without prior chromatographic separation (Vaidyanathan, Kell, & Goodacre, 2002; Vaidyanathan et al., 2001; Vaidyanathan, O'Hagan, & Goodacre, 2006) .", [["cell lysates", "ANATOMY", 86, 98], ["extracts", "ANATOMY", 99, 107], ["cell lysates", "ORGANISM_SUBSTANCE", 86, 98], ["extracts", "ORGANISM_SUBSTANCE", 99, 107], ["direct ESI", "TEST", 59, 69], ["bacterial cell lysates", "PROBLEM", 76, 98], ["prior chromatographic separation", "TREATMENT", 116, 148], ["bacterial cell lysates", "OBSERVATION", 76, 98]]], ["This approach yields informative mass spectra from microbial cells and crude cell extracts that are used in microbial characterizations.LC-MSThe combination of MS with LC is one of the most important analytical methods to separate and identify a wide variety of biological samples (Banoub et al., 2005) .", [["cells", "ANATOMY", 61, 66], ["cell extracts", "ANATOMY", 77, 90], ["microbial cells", "CELL", 51, 66], ["cell extracts", "ORGANISM_SUBSTANCE", 77, 90], ["microbial cells", "CELL_TYPE", 51, 66], ["informative mass spectra from microbial cells", "PROBLEM", 21, 66], ["crude cell extracts", "TREATMENT", 71, 90], ["microbial characterizations", "TEST", 108, 135], ["mass", "OBSERVATION", 33, 37], ["microbial cells", "OBSERVATION", 51, 66], ["crude cell extracts", "OBSERVATION", 71, 90]]], ["LC-MS is rapidly being developed as a tool in proteomics to deal with the inherent complexity of a biological system, and to complement conventional approaches that are based on 2DGE (Delahunty & Yates, 2005) .", [["MS", "OBSERVATION", 3, 5]]], ["Furthermore, LC-MS has greatly facilitated the determination of the molecular weights of proteins from complicated mixtures.", [["complicated mixtures", "PROBLEM", 103, 123]]], ["Krishnamurthy et al. (1999) used LC-ESI-MS to identify protein biomarkers specific to individual organisms present in crude bacterial mixtures.", [["LC", "TEST", 33, 35], ["protein biomarkers", "TEST", 55, 73], ["individual organisms", "PROBLEM", 86, 106], ["crude bacterial mixtures", "PROBLEM", 118, 142], ["bacterial mixtures", "OBSERVATION", 124, 142]]], ["Lyophilized intact bacterial cells were suspended in 0.1% aqueous TFA (containing 0-20% acetonitrile) to lyse the cells and release cellular proteins or metabolites specific to an individual microorganism.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 114, 119], ["cellular", "ANATOMY", 132, 140], ["TFA", "CHEMICAL", 66, 69], ["acetonitrile", "CHEMICAL", 88, 100], ["TFA", "CHEMICAL", 66, 69], ["acetonitrile", "CHEMICAL", 88, 100], ["bacterial cells", "CELL", 19, 34], ["TFA", "SIMPLE_CHEMICAL", 66, 69], ["acetonitrile", "SIMPLE_CHEMICAL", 88, 100], ["cells", "CELL", 114, 119], ["cellular", "CELL", 132, 140], ["bacterial cells", "CELL_TYPE", 19, 34], ["cellular proteins", "PROTEIN", 132, 149], ["Lyophilized intact bacterial cells", "PROBLEM", 0, 34], ["cellular proteins", "TEST", 132, 149], ["an individual microorganism", "PROBLEM", 177, 204], ["bacterial cells", "OBSERVATION", 19, 34]]], ["Biomarker proteins and peptides were separated with reversed-phase HPLC and a chromatogram of biomarker signals was used to distinguish bacteria.", [["Biomarker proteins", "PROTEIN", 0, 18], ["Biomarker proteins", "TEST", 0, 18], ["peptides", "TEST", 23, 31], ["phase HPLC", "TEST", 61, 71], ["a chromatogram of biomarker signals", "TEST", 76, 111], ["bacteria", "PROBLEM", 136, 144]]], ["A solution to this problem was reported by Williams and colleagues with an automated data handling algorithm that provided sequential scanning, centroiding, and deconvolution of multiply charged proteins present in successive scans of the LC-MS analysis (Williams, Leopold, & Musser, 2002) .", [["multiply charged proteins", "PROTEIN", 178, 203], ["A solution", "TREATMENT", 0, 10], ["sequential scanning", "TEST", 123, 142], ["multiply charged proteins", "PROBLEM", 178, 203], ["successive scans of the LC", "TEST", 215, 241], ["MS analysis", "TEST", 242, 253], ["LC", "ANATOMY", 239, 241]]], ["This approach has proven useful for identifying protein biomarkers of Vibrio parahaemolyticus (Williams et al., 2004) .", [["Vibrio parahaemolyticus", "DISEASE", 70, 93], ["Vibrio parahaemolyticus", "ORGANISM", 70, 93], ["Vibrio parahaemolyticus", "SPECIES", 70, 93], ["Vibrio parahaemolyticus", "SPECIES", 70, 93], ["protein biomarkers", "TEST", 48, 66], ["Vibrio parahaemolyticus", "PROBLEM", 70, 93]]], ["The same group demonstrated a method in which LC-MS was used to identify unique proteins that can be sequenced, identified, and reverse engineered into PCR primers that are specific to a desired phenotypic trait, thermal tolerance (Williams et al., 2005) .", [["PCR primers", "DNA", 152, 163], ["a method", "TEST", 28, 36], ["unique proteins", "PROBLEM", 73, 88], ["reverse engineered into PCR primers", "PROBLEM", 128, 163], ["a desired phenotypic trait", "PROBLEM", 185, 211]]], ["Because the genome for Enterobacter sakazakii was not sequenced by that time, this methodology provided a unique, independent means to identify genetic differences among closely related strains of this species, without the need for any prior sequencing of the genome.", [["genome", "CELLULAR_COMPONENT", 12, 18], ["Enterobacter sakazakii", "ORGANISM", 23, 45], ["Enterobacter sakazakii", "SPECIES", 23, 45], ["Enterobacter sakazakii", "SPECIES", 23, 45], ["Enterobacter sakazakii", "PROBLEM", 23, 45], ["genetic differences", "PROBLEM", 144, 163], ["this species", "PROBLEM", 197, 209]]], ["Recently, Everley et al. discovered reproducible intact protein biomarkers with an LC-ESI-MS approach to differentiate and correctly identify unknown pathogens at the species (Everley et al., 2008) and strain level (Everley et al., 2009 ).", [["an LC", "TEST", 80, 85], ["unknown pathogens", "PROBLEM", 142, 159], ["strain level", "TEST", 202, 214], ["reproducible", "OBSERVATION_MODIFIER", 36, 48], ["intact", "OBSERVATION", 49, 55]]], ["The organism Bacillus anthracis was identified with the MS/MS analysis of an antigenic protein biomarker EA1 isolated with affinity chromatography and a monoclonal antibody (Krishnamurthy et al., 2006) .", [["Bacillus anthracis", "ORGANISM", 13, 31], ["EA1", "SIMPLE_CHEMICAL", 105, 108], ["EA1", "PROTEIN", 105, 108], ["monoclonal antibody", "PROTEIN", 153, 172], ["Bacillus anthracis", "SPECIES", 13, 31], ["Bacillus anthracis", "SPECIES", 13, 31], ["The organism Bacillus anthracis", "PROBLEM", 0, 31], ["the MS", "TEST", 52, 58], ["MS analysis", "TEST", 59, 70], ["an antigenic protein biomarker EA1", "TEST", 74, 108], ["affinity chromatography", "TEST", 123, 146], ["a monoclonal antibody", "TEST", 151, 172]]], ["Multi-dimensional protein identification has been used to identify B. anthracis strains (Krishnamurthy et al., 2007) .", [["B. anthracis", "ORGANISM", 67, 79], ["B. anthracis", "SPECIES", 67, 79], ["B. anthracis", "SPECIES", 67, 79], ["Multi-dimensional protein identification", "TEST", 0, 40], ["B. anthracis strains", "PROBLEM", 67, 87]]], ["Ho and Hsu (2002) investigated with LC-ESI-MS the effect of variations in the protein patterns obtained from E. coli in bacterial identification.LC-MSBotulinum toxin (BTx) and tetanus toxin (TTx) both belong to a family of potent bacterial neurotoxins, and might be used as biological warfare agents. van Baar et al. noted that protein toxins can be unambiguously identified with MS, and they exploited this fact in analyses of tetanus (van Baar et al., 2002b) and botulinum (van Baar et al., 2002a (van Baar et al., , 2004 toxins.", [["BTx", "CHEMICAL", 167, 170], ["TTx", "CHEMICAL", 191, 194], ["tetanus", "DISEASE", 428, 435], ["E. coli", "ORGANISM", 109, 116], ["LC-MSBotulinum toxin", "GENE_OR_GENE_PRODUCT", 145, 165], ["BTx", "SIMPLE_CHEMICAL", 167, 170], ["tetanus toxin", "SIMPLE_CHEMICAL", 176, 189], ["TTx", "SIMPLE_CHEMICAL", 191, 194], ["BTx", "PROTEIN", 167, 170], ["tetanus toxin", "PROTEIN", 176, 189], ["TTx", "PROTEIN", 191, 194], ["E. coli", "SPECIES", 109, 116], ["E. coli", "SPECIES", 109, 116], ["LC", "TEST", 36, 38], ["the protein patterns", "TEST", 74, 94], ["E. coli in bacterial identification", "PROBLEM", 109, 144], ["LC", "TEST", 145, 147], ["MSBotulinum toxin", "PROBLEM", 148, 165], ["BTx", "TEST", 167, 170], ["tetanus toxin", "PROBLEM", 176, 189], ["potent bacterial neurotoxins", "PROBLEM", 223, 251], ["biological warfare agents", "TREATMENT", 274, 299], ["protein toxins", "PROBLEM", 328, 342], ["MS", "PROBLEM", 380, 382], ["bacterial identification", "OBSERVATION", 120, 144]]], ["LC-MS/MS of selected precursor ions from trypsin digest fragments yielded specific sequence data for the identification of the protein toxins.", [["trypsin digest fragments", "DNA", 41, 65], ["protein toxins", "PROTEIN", 127, 141], ["LC", "TEST", 0, 2], ["selected precursor ions", "PROBLEM", 12, 35], ["trypsin digest fragments", "PROBLEM", 41, 65], ["specific sequence data", "TEST", 74, 96], ["the protein toxins", "PROBLEM", 123, 141]]], ["The authors showed that accurate strain assignments were possible when genetic sequences were available.LC-MSMass spectrometry (MS) analysis of bacterial proteins or digests of protein extracts (Zhou et al., 2001) , followed by statistical matching of protein/peptide masses that were detected in an unknown sample to those in a proteome database, has been developed as a useful tool for bacterial identification Tao et al., 2004) .", [["extracts", "ANATOMY", 185, 193], ["extracts", "ORGANISM_SUBSTANCE", 185, 193], ["bacterial proteins", "PROTEIN", 144, 162], ["accurate strain assignments", "PROBLEM", 24, 51], ["genetic sequences", "TEST", 71, 88], ["LC", "TEST", 104, 106], ["MSMass spectrometry", "TEST", 107, 126], ["bacterial proteins", "PROBLEM", 144, 162], ["digests of protein extracts", "PROBLEM", 166, 193], ["protein/peptide masses", "PROBLEM", 252, 274], ["bacterial proteins", "OBSERVATION", 144, 162], ["masses", "OBSERVATION", 268, 274]]], ["Figure 3 schematically depicts a proteomic approach to identify microorganisms based on MS/MS analysis.", [["a proteomic approach", "TREATMENT", 31, 51], ["microorganisms", "PROBLEM", 64, 78], ["MS/MS analysis", "TEST", 88, 102]]], ["Microbial proteins are extracted from a cell lysate and digested.", [["cell lysate", "ANATOMY", 40, 51], ["cell lysate", "ORGANISM_SUBSTANCE", 40, 51], ["Microbial proteins", "PROTEIN", 0, 18], ["Microbial proteins", "TEST", 0, 18], ["a cell lysate", "TREATMENT", 38, 51], ["proteins", "OBSERVATION", 10, 18], ["cell lysate", "OBSERVATION", 40, 51]]], ["The peptide digests are LC-separated, and are analyzed with MS/MS. The MS/MS spectra are checked against a proteome database to identify the proteins, and to deduce the source of the microorganism.", [["The peptide digests", "TEST", 0, 19], ["LC", "TEST", 24, 26], ["The MS/MS spectra", "TEST", 67, 84], ["a proteome database", "TEST", 105, 124], ["the proteins", "TEST", 137, 149], ["the microorganism", "PROBLEM", 179, 196], ["LC", "OBSERVATION_MODIFIER", 24, 26], ["microorganism", "OBSERVATION", 183, 196]]], ["Demirev et al. (1999) was the first to propose this method.", [["this method", "TREATMENT", 47, 58]]], ["Mathematical methods might be applied to evaluate the search results.", [["Mathematical methods", "TREATMENT", 0, 20]]], ["Hu et al. proposed a method that used LCselective proteotypic peptide analysis (LC-SPA) to identify the bacterial species in a complex mixture.", [["a method", "TREATMENT", 19, 27], ["LCselective proteotypic peptide analysis", "TEST", 38, 78], ["the bacterial species", "PROBLEM", 100, 121], ["bacterial species", "OBSERVATION", 104, 121]]], ["Many pathogens were simultaneously identified from a series of selective MS/MS analyses of marker peptides in the appropriate elution time windows for the specific peptides.", [["Many pathogens", "PROBLEM", 0, 14], ["marker peptides", "TREATMENT", 91, 106], ["pathogens", "OBSERVATION", 5, 14]]], ["The SEQUEST application was used to check all of the tandem mass spectra of the peptides against the NCBInr protein database.", [["NCBInr", "GENE_OR_GENE_PRODUCT", 101, 107], ["NCBInr protein database", "PROTEIN", 101, 124], ["The SEQUEST application", "TREATMENT", 0, 23], ["the NCBInr protein database", "TEST", 97, 124]]], ["This method successfully identified eight pathogens present in a microbial mixture (Lo, Hu, & Ho, 2006) .", [["eight", "OBSERVATION_MODIFIER", 36, 41], ["pathogens", "OBSERVATION", 42, 51]]], ["Dworzanski et al. (2004) developed a method to identify microorganisms or protein toxins based on the LC-MS/ MS analysis of peptides derived from bacterial proteins.", [["bacterial proteins", "PROTEIN", 146, 164], ["microorganisms", "PROBLEM", 56, 70], ["protein toxins", "PROBLEM", 74, 88], ["the LC", "TEST", 98, 104], ["MS", "PROBLEM", 105, 107], ["MS analysis", "TEST", 109, 120], ["peptides", "PROBLEM", 124, 132], ["bacterial proteins", "PROBLEM", 146, 164], ["bacterial proteins", "OBSERVATION", 146, 164]]], ["In their research, product-ion mass spectra of peptides that were generated from a microbial protein digest were checked against the prototype proteome database (87 bacterial genomes) with SEQUEST, and the results of the search of the database were subjected to discriminant function analysis.", [["ion mass spectra of peptides", "PROBLEM", 27, 55], ["a microbial protein digest", "TEST", 81, 107], ["the database", "TEST", 231, 243], ["discriminant function analysis", "TEST", 262, 292]]], ["Instead of matching peptide sequences to a microbial source in the database, Dworzanski et al. (2006) employed multivariate statistical methods, such as principal component analysis (PCA) and cluster analysis, to determine the peptide-sequence similarities between the unknown species and a database of bacteria, grouped by their established taxonomic position.", [["matching peptide sequences", "TREATMENT", 11, 37], ["multivariate statistical methods", "TEST", 111, 143], ["principal component analysis", "TEST", 153, 181], ["cluster analysis", "TEST", 192, 208], ["the peptide", "TEST", 223, 234], ["the unknown species", "PROBLEM", 265, 284], ["bacteria", "PROBLEM", 303, 311], ["taxonomic position", "OBSERVATION", 342, 360]]], ["They classified bacterial species into corresponding taxons based on similarities.", [["bacterial species", "PROBLEM", 16, 33], ["bacterial species", "OBSERVATION", 16, 33]]], ["More recently, the same group reported on the classification/identification and genotyping of B. anthracis, B. cereus, and B. thuringiensis strains based on the LC-MS/MS analysis of whole-cell protein digests (Dworzanski et al., 2010) .LC-MSLipid biomarkers have also been used extensively to characterize complex microorganisms from various environments with LC-MS or MS/MS analysis (Jelinek et al., 2006; Zhang et al., 2007) .", [["cell", "ANATOMY", 188, 192], ["B. anthracis", "ORGANISM", 94, 106], ["B. cereus", "ORGANISM", 108, 117], ["B. thuringiensis strains", "ORGANISM", 123, 147], ["B. anthracis", "SPECIES", 94, 106], ["B. cereus", "SPECIES", 108, 117], ["B. thuringiensis", "SPECIES", 123, 139], ["B. anthracis", "SPECIES", 94, 106], ["B. cereus", "SPECIES", 108, 117], ["B. thuringiensis", "SPECIES", 123, 139], ["B. anthracis", "PROBLEM", 94, 106], ["B. cereus", "PROBLEM", 108, 117], ["B. thuringiensis strains", "PROBLEM", 123, 147], ["the LC", "TEST", 157, 163], ["MS", "TEST", 164, 166], ["MS analysis", "TEST", 167, 178], [".LC", "TEST", 235, 238], ["MSLipid biomarkers", "TEST", 239, 257], ["complex microorganisms", "PROBLEM", 306, 328], ["LC", "TEST", 360, 362], ["MS", "PROBLEM", 363, 365], ["MS", "PROBLEM", 369, 371], ["MS analysis", "TEST", 372, 383]]], ["The collision-induced dissociation of lipid biomarkers produces arrays of fragment ions that reveal structural information about bacteria (Moe et al., 2005) .", [["lipid biomarkers", "TEST", 38, 54], ["fragment ions", "PROBLEM", 74, 87], ["bacteria", "PROBLEM", 129, 137], ["collision", "OBSERVATION", 4, 13]]], ["Similarly, polar phospholipids can be used as a biomarker of bacterial presence.", [["polar phospholipids", "SIMPLE_CHEMICAL", 11, 30], ["polar phospholipids", "TREATMENT", 11, 30], ["bacterial presence", "PROBLEM", 61, 79], ["bacterial", "OBSERVATION", 61, 70]]], ["Mazzella et al. (2004) separated and identified with LC-MS most of the phospholipid species (phosphatidylglycerol, phosphatidylinositol, diphosphatidylglycerol, and a unique lipid compound, acyl phosphatidylglycerol) of a Gram-positive bacterium (Corynebacterium species strain 8).", [["phosphatidylglycerol", "CHEMICAL", 93, 113], ["phosphatidylinositol", "CHEMICAL", 115, 135], ["diphosphatidylglycerol", "CHEMICAL", 137, 159], ["acyl phosphatidylglycerol", "CHEMICAL", 190, 215], ["phosphatidylglycerol", "CHEMICAL", 93, 113], ["phosphatidylinositol", "CHEMICAL", 115, 135], ["diphosphatidylglycerol", "CHEMICAL", 137, 159], ["acyl phosphatidylglycerol", "CHEMICAL", 190, 215], ["phospholipid species", "SIMPLE_CHEMICAL", 71, 91], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 93, 113], ["phosphatidylinositol", "SIMPLE_CHEMICAL", 115, 135], ["diphosphatidylglycerol", "SIMPLE_CHEMICAL", 137, 159], ["lipid compound", "SIMPLE_CHEMICAL", 174, 188], ["acyl phosphatidylglycerol", "SIMPLE_CHEMICAL", 190, 215], ["Gram-", "GENE_OR_GENE_PRODUCT", 222, 227], ["Corynebacterium species strain 8", "ORGANISM", 247, 279], ["LC", "TEST", 53, 55], ["the phospholipid species (phosphatidylglycerol", "TREATMENT", 67, 113], ["phosphatidylinositol", "TREATMENT", 115, 135], ["diphosphatidylglycerol", "TREATMENT", 137, 159], ["a unique lipid compound", "TREATMENT", 165, 188], ["acyl phosphatidylglycerol", "TREATMENT", 190, 215], ["a Gram-positive bacterium", "PROBLEM", 220, 245], ["Corynebacterium species strain", "PROBLEM", 247, 277]]], ["The same group proposed fragmentation pathways and identified the diagnostic ions of two common bacterial phospholipid classes, phosphatidylglycerol and phosphatidylethanolamine.", [["phosphatidylglycerol", "CHEMICAL", 128, 148], ["phosphatidylethanolamine", "CHEMICAL", 153, 177], ["phosphatidylglycerol", "CHEMICAL", 128, 148], ["phosphatidylethanolamine", "CHEMICAL", 153, 177], ["phospholipid", "SIMPLE_CHEMICAL", 106, 118], ["phosphatidylglycerol", "SIMPLE_CHEMICAL", 128, 148], ["phosphatidylethanolamine", "SIMPLE_CHEMICAL", 153, 177], ["two common bacterial phospholipid classes", "TREATMENT", 85, 126], ["phosphatidylglycerol", "TREATMENT", 128, 148], ["phosphatidylethanolamine", "TREATMENT", 153, 177], ["fragmentation", "OBSERVATION", 24, 37], ["bacterial phospholipid classes", "OBSERVATION", 96, 126]]], ["They used LC-MS and MS/ MS methods to determine the structures of intact phospholipids from the two bacterial strains Pseudomonas nautica IP 617 and Marinobacter hydrocarbonoclasticus, cultured on either ammonium acetate or crude oil (Mazzella et al., 2005) .LC-MSWhite et al. have developed a rapid method to extract and detect the bacterial biomarker 2,6-dipicolinic acid, from Gram-negative bacteria.", [["ammonium acetate", "CHEMICAL", 204, 220], ["2,6-dipicolinic acid", "CHEMICAL", 353, 373], ["ammonium acetate", "CHEMICAL", 204, 220], ["2,6-dipicolinic acid", "CHEMICAL", 353, 373], ["phospholipids", "SIMPLE_CHEMICAL", 73, 86], ["Pseudomonas nautica IP 617", "ORGANISM", 118, 144], ["Marinobacter hydrocarbonoclasticus", "ORGANISM", 149, 183], ["ammonium acetate", "SIMPLE_CHEMICAL", 204, 220], ["oil", "ORGANISM_SUBSTANCE", 230, 233], ["2,6-dipicolinic acid", "SIMPLE_CHEMICAL", 353, 373], ["Pseudomonas nautica", "SPECIES", 118, 137], ["Marinobacter hydrocarbonoclasticus", "SPECIES", 149, 183], ["Pseudomonas nautica IP 617", "SPECIES", 118, 144], ["Marinobacter hydrocarbonoclasticus", "SPECIES", 149, 183], ["MS", "PROBLEM", 13, 15], ["MS/ MS methods", "TREATMENT", 20, 34], ["intact phospholipids", "PROBLEM", 66, 86], ["the two bacterial strains Pseudomonas nautica IP", "PROBLEM", 92, 140], ["Marinobacter hydrocarbonoclasticus", "PROBLEM", 149, 183], ["ammonium acetate", "TREATMENT", 204, 220], ["a rapid method to extract", "PROBLEM", 292, 317], ["the bacterial biomarker", "TEST", 329, 352], ["dipicolinic acid", "TEST", 357, 373], ["Gram", "TEST", 380, 384], ["Marinobacter hydrocarbonoclasticus", "OBSERVATION", 149, 183], ["negative bacteria", "OBSERVATION", 385, 402]]], ["Specific lipid components can also provide insights into the viability and potential infectivity of the pathogens detected in the samples (White et al., 2002) .", [["samples", "ANATOMY", 130, 137], ["Specific lipid components", "TREATMENT", 0, 25], ["the pathogens", "PROBLEM", 100, 113]]], ["Bacteriohopanoids or bacteriohopanepolyols (BHPs) are good biomarkers for bacteria separation and identification.", [["Bacteriohopanoids", "CHEMICAL", 0, 17], ["bacteriohopanepolyols", "CHEMICAL", 21, 42], ["BHPs", "CHEMICAL", 44, 48], ["Bacteriohopanoids", "CHEMICAL", 0, 17], ["bacteriohopanepolyols", "CHEMICAL", 21, 42], ["Bacteriohopanoids", "SIMPLE_CHEMICAL", 0, 17], ["bacteriohopanepolyols", "SIMPLE_CHEMICAL", 21, 42], ["BHPs", "SIMPLE_CHEMICAL", 44, 48], ["Bacteriohopanoids", "PROBLEM", 0, 17], ["bacteriohopanepolyols", "PROBLEM", 21, 42], ["bacteria separation", "PROBLEM", 74, 93]]], ["Many bacterial species are known to produce various BHPs with specific modifications in the side-chain and ring-structure.", [["BHPs", "SIMPLE_CHEMICAL", 52, 56], ["BHPs", "PROTEIN", 52, 56], ["Many bacterial species", "PROBLEM", 0, 22], ["various BHPs", "PROBLEM", 44, 56], ["bacterial species", "OBSERVATION", 5, 22], ["chain", "ANATOMY_MODIFIER", 97, 102], ["ring", "OBSERVATION_MODIFIER", 107, 111]]], ["Intact BHPs have been directly detected from bacterial isolates with LC-MS/ MS (Talbot et al., 2003a,b; Talbot, Rohmer, & Farrimond, 2007a,b) .", [["BHPs", "GENE_OR_GENE_PRODUCT", 7, 11], ["BHPs", "PROTEIN", 7, 11]]], ["Although lipid markers have been proven to be useful for microbial identification, the dependence of lipid profiles on growth conditions might complicate identification results.CE-MSCapillary electrophoresis allows the rapid and efficient separation of biological molecules with the least consumption of sample and reagents.", [["sample", "ANATOMY", 304, 310], ["CE", "CHEMICAL", 177, 179], ["lipid", "SIMPLE_CHEMICAL", 101, 106], ["lipid markers", "TEST", 9, 22], ["microbial identification", "TEST", 57, 81], ["the dependence of lipid profiles on growth conditions", "PROBLEM", 83, 136], ["CE", "TEST", 177, 179], ["MSCapillary electrophoresis", "TEST", 180, 207]]], ["CE coupled to MS has been established as a method for the fast separation and identification of microorganisms (Kolch et al., 2005) .", [["CE", "CHEMICAL", 0, 2], ["CE", "TEST", 0, 2], ["the fast separation", "PROBLEM", 54, 73], ["microorganisms", "PROBLEM", 96, 110]]], ["A limited number of articles have described the use of CE-MS to identify microorganisms (Chong et al., 2000; Hu, Tsai, & Ho, 2005; Lo, Hu, & Ho, 2006; Hu et al., 2007; Petr et al., 2009 ).", [["CE", "CHEMICAL", 55, 57], ["CE", "TEST", 55, 57], ["microorganisms", "PROBLEM", 73, 87]]], ["Hu et al. applied CE-MS/MS to selected proteotypic peptide ions to obtain partial sequences of protein biomarkers.", [["CE", "CHEMICAL", 18, 20], ["CE", "TEST", 18, 20], ["MS", "PROBLEM", 24, 26], ["selected proteotypic peptide ions", "TREATMENT", 30, 63], ["protein biomarkers", "TEST", 95, 113]]], ["Proteotypic peptides refer to those experimentally observable peptides that identify specific proteins.", [["Proteotypic peptides", "TREATMENT", 0, 20]]], ["They performed a preliminary analysis with CE-MS/MS of the proteolytic digests of cell extracts from pure pathogens, and carried out subsequent database searches to select abundant peptide ions that were specific to the pathogens of interest.", [["cell extracts", "ANATOMY", 82, 95], ["CE", "CHEMICAL", 43, 45], ["cell extracts", "ORGANISM_SUBSTANCE", 82, 95], ["a preliminary analysis", "TEST", 15, 37], ["CE", "TEST", 43, 45], ["MS", "PROBLEM", 46, 48], ["MS", "PROBLEM", 49, 51], ["cell extracts", "PROBLEM", 82, 95], ["pure pathogens", "PROBLEM", 101, 115], ["abundant peptide ions", "PROBLEM", 172, 193]]], ["Minor bacterial species present in the complex mixture at even 1% relative abundance were identified with high confidence.", [["Minor bacterial species", "PROBLEM", 0, 23], ["bacterial species", "OBSERVATION", 6, 23], ["complex", "OBSERVATION_MODIFIER", 39, 46], ["mixture", "OBSERVATION_MODIFIER", 47, 54]]], ["They also applied this method to identify pathogens present in a saliva sample that had been spiked with bacterial mixtures.", [["sample", "ANATOMY", 72, 78], ["saliva", "ORGANISM_SUBSTANCE", 65, 71], ["this method", "TREATMENT", 18, 29], ["pathogens", "PROBLEM", 42, 51], ["a saliva sample", "TEST", 63, 78], ["bacterial mixtures", "TREATMENT", 105, 123]]], ["Further, the speed of data analysis was greatly improved because only selected markers, instead of whole-protein digests, were analyzed.", [["data analysis", "TEST", 22, 35], ["whole-protein digests", "TREATMENT", 99, 120]]], ["CE-MS/MS analysis of proteolytic digests of microbial cell extracts has been combined with SEQUEST searching and a new empirical scoring system to identify bacterial species in microbial mixtures (Hu et al., 2007) .", [["cell extracts", "ANATOMY", 54, 67], ["CE", "CHEMICAL", 0, 2], ["cell extracts", "ORGANISM_SUBSTANCE", 54, 67], ["CE", "TEST", 0, 2], ["MS", "TEST", 3, 5], ["MS analysis", "TEST", 6, 17], ["proteolytic digests", "PROBLEM", 21, 40], ["microbial cell extracts", "PROBLEM", 44, 67], ["a new empirical scoring system", "TEST", 113, 143], ["bacterial species in microbial mixtures", "PROBLEM", 156, 195], ["microbial cell", "OBSERVATION", 44, 58], ["bacterial species", "OBSERVATION", 156, 173]]], ["The search results for 19 samples of bacterial mixtures revealed that the empirical Z-scoring function improved the identification of bacteria in the mixtures.", [["samples", "ANATOMY", 26, 33], ["bacterial mixtures", "TEST", 37, 55], ["the empirical Z", "TEST", 70, 85], ["bacteria in the mixtures", "PROBLEM", 134, 158], ["bacteria", "OBSERVATION", 134, 142]]], ["Petr et al. (2009) combined CE separation with the off-line MS identification of microorganisms.", [["combined CE separation", "TREATMENT", 19, 41], ["microorganisms", "PROBLEM", 81, 95]]], ["They separated the model microorganisms E. coli and Saccharomyces cerevisiae, and cultivated them after the fractions were collected.", [["E. coli", "ORGANISM", 40, 47], ["Saccharomyces cerevisiae", "ORGANISM", 52, 76], ["E. coli", "SPECIES", 40, 47], ["Saccharomyces cerevisiae", "SPECIES", 52, 76], ["E. coli", "SPECIES", 40, 47], ["Saccharomyces cerevisiae", "SPECIES", 52, 76], ["Saccharomyces cerevisiae", "TREATMENT", 52, 76], ["the fractions", "TEST", 104, 117], ["Saccharomyces cerevisiae", "OBSERVATION", 52, 76]]], ["After cultivation, DESI-MS was used for further identification.Protein FingerprintingMatrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) allows the fast and accurate identification and subtyping of bacterial species (Seng et al., 2009; Stevenson, Drake, & Murray, 2010) , fungi (Marinach-Patrice et al., 2009 , 2010 Santos et al., 2010) , and viruses Franco et al., 2010) .", [["DESI", "CHEMICAL", 19, 23], ["further identification", "TEST", 40, 62], ["Protein FingerprintingMatrix", "TREATMENT", 63, 91], ["assisted laser desorption/ionization", "TREATMENT", 92, 128], ["mass spectrometry", "PROBLEM", 129, 146], ["bacterial species", "PROBLEM", 219, 236], ["bacterial species", "OBSERVATION", 219, 236]]], ["Currently, most published studies of the direct mass spectrometric analysis of microorganisms are based on MALDI techniques (Demirev & Fenselau, 2008a,b) .", [["the direct mass spectrometric analysis", "TEST", 37, 75], ["microorganisms", "PROBLEM", 79, 93], ["MALDI techniques", "TEST", 107, 123]]], ["Direct bacterial profiling with MALDI-TOFMS is based mainly on a comparison of specific mass spectra of the proteins, peptides, and other cellular components that are obtained from microbial cells.", [["cellular", "ANATOMY", 138, 146], ["cells", "ANATOMY", 191, 196], ["cellular", "CELL", 138, 146], ["microbial cells", "CELL", 181, 196], ["microbial cells", "CELL_TYPE", 181, 196], ["Direct bacterial profiling", "TEST", 0, 26], ["MALDI", "TEST", 32, 37], ["the proteins", "TEST", 104, 116], ["other cellular components", "PROBLEM", 132, 157], ["bacterial", "OBSERVATION_MODIFIER", 7, 16], ["mass", "OBSERVATION", 88, 92], ["cellular components", "OBSERVATION", 138, 157], ["microbial cells", "OBSERVATION", 181, 196]]], ["One of the first studies using this approach was based on the protein profiles of microorganisms (Cain, Lubman, & Weber, 1994) .", [["the first studies", "TEST", 7, 24], ["this approach", "TREATMENT", 31, 44], ["the protein profiles", "TEST", 58, 78], ["microorganisms", "PROBLEM", 82, 96]]], ["Although sample preparation is crucial to MALDI analysis of microbial markers, there is no universal sample preparation and measurement protocol.", [["sample", "ANATOMY", 9, 15], ["microbial markers", "TEST", 60, 77], ["universal sample preparation", "TREATMENT", 91, 119], ["measurement protocol", "TEST", 124, 144], ["no", "UNCERTAINTY", 88, 90]]], ["Many methods have been described since the method for direct MALDI analysis of bacteria was proposed.", [["direct MALDI analysis", "TEST", 54, 75], ["bacteria", "PROBLEM", 79, 87]]], ["The experimental parameters studied include cultivation conditions, matrices, solvents, cell-lysis, and matrix-spotting methods.", [["cell", "ANATOMY", 88, 92], ["cell", "CELL", 88, 92], ["The experimental parameters", "TEST", 0, 27], ["cultivation conditions", "TREATMENT", 44, 66], ["solvents", "TREATMENT", 78, 86], ["cell-lysis", "TREATMENT", 88, 98], ["matrix-spotting methods", "TREATMENT", 104, 127]]], ["Microbial cells are generally obtained from a purified liquid culture or a single colony.", [["cells", "ANATOMY", 10, 15], ["colony", "ANATOMY", 82, 88], ["Microbial cells", "CELL", 0, 15], ["Microbial cells", "PROBLEM", 0, 15], ["a purified liquid culture", "TEST", 44, 69], ["a single colony", "PROBLEM", 73, 88]]], ["Samples are analyzed by direct deposition of intact cells on the sample plate or using various ways of biomarker extraction.", [["Samples", "ANATOMY", 0, 7], ["cells", "ANATOMY", 52, 57], ["cells", "CELL", 52, 57], ["intact cells", "CELL_TYPE", 45, 57], ["Samples", "TEST", 0, 7], ["the sample plate", "TREATMENT", 61, 77], ["biomarker extraction", "TREATMENT", 103, 123], ["intact cells", "OBSERVATION", 45, 57]]], ["The MALDI matrices that most often used are a-cyano-4-hydroxycinnamic acid (HCCA), ferulic acid (FA), and sinapinic acid (SA).", [["a-cyano-4-hydroxycinnamic acid", "CHEMICAL", 44, 74], ["HCCA", "CHEMICAL", 76, 80], ["ferulic acid", "CHEMICAL", 83, 95], ["FA", "CHEMICAL", 97, 99], ["sinapinic acid", "CHEMICAL", 106, 120], ["SA", "CHEMICAL", 122, 124], ["a-cyano-4-hydroxycinnamic acid", "CHEMICAL", 44, 74], ["HCCA", "CHEMICAL", 76, 80], ["ferulic acid", "CHEMICAL", 83, 95], ["sinapinic acid", "CHEMICAL", 106, 120], ["a-cyano-4-hydroxycinnamic acid", "SIMPLE_CHEMICAL", 44, 74], ["HCCA", "SIMPLE_CHEMICAL", 76, 80], ["ferulic acid", "SIMPLE_CHEMICAL", 83, 95], ["FA", "SIMPLE_CHEMICAL", 97, 99], ["sinapinic acid", "SIMPLE_CHEMICAL", 106, 120], ["SA", "SIMPLE_CHEMICAL", 122, 124], ["The MALDI matrices", "TREATMENT", 0, 18], ["a-cyano", "TEST", 44, 51], ["hydroxycinnamic acid (HCCA", "TREATMENT", 54, 80], ["ferulic acid", "TEST", 83, 95]]], ["HCCA provides better signal-to-noise ratio than FA and SA.", [["FA", "SIMPLE_CHEMICAL", 48, 50]]], ["FA is suitable for the detection of high-mass ions above 15 kDa.", [["FA", "CHEMICAL", 0, 2], ["FA", "SIMPLE_CHEMICAL", 0, 2], ["the detection", "TEST", 19, 32], ["high-mass ions", "PROBLEM", 36, 50], ["mass", "OBSERVATION", 41, 45]]], ["A UV laser is often used as an irradiation source.", [["A UV laser", "TREATMENT", 0, 10], ["an irradiation source", "TREATMENT", 28, 49], ["UV", "OBSERVATION_MODIFIER", 2, 4], ["laser", "OBSERVATION", 5, 10]]], ["IR-MALDI is rarely used to analyze microorganisms because of its somewhat lower sensitivity compared to UV-MALDI.", [["MALDI", "TREATMENT", 3, 8], ["microorganisms", "PROBLEM", 35, 49], ["its somewhat lower sensitivity", "PROBLEM", 61, 91]]], ["Although 5 \u00c2 10 3 -10 4 intact cells deposited on the MALDI plate were sufficient to obtain useful biomarker signals, the detected biomarkers were low-mass ions (less than 1,000 Da).", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["the MALDI plate", "TEST", 50, 65], ["biomarker signals", "TEST", 99, 116], ["the detected biomarkers", "TEST", 118, 141], ["mass ions", "PROBLEM", 151, 160], ["mass", "OBSERVATION", 151, 155]]], ["It has been reported that 10 6 cells yielded the most good-quality and reproducible spectra for protein fingerprinting (Mazzeo et al., 2006) .", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["protein fingerprinting", "TEST", 96, 118]]], ["Current protein fingerprinting methods still require culturing of the microbial cells to obtain detectable signals.", [["cells", "ANATOMY", 80, 85], ["microbial cells", "CELL", 70, 85], ["microbial cells", "CELL_TYPE", 70, 85], ["Current protein fingerprinting methods", "TEST", 0, 38], ["the microbial cells", "TEST", 66, 85]]], ["Analysis of non-culturable microorganism remains a challenge.Protein FingerprintingRecent studies on MALDI analysis of microorganisms have been focused on development of standardized analytical protocols (Vargha et al., 2006; Ilina et al., 2009 ) and high throughput analysis of pathogenic bacteria (Donohue et al., 2006; Rajakaruna et al., 2009) .", [["non-culturable microorganism", "PROBLEM", 12, 40], ["Protein Fingerprinting", "TEST", 61, 83], ["MALDI analysis", "TEST", 101, 115], ["microorganisms", "PROBLEM", 119, 133], ["standardized analytical protocols", "TEST", 170, 203], ["pathogenic bacteria", "PROBLEM", 279, 298], ["non-culturable microorganism", "OBSERVATION", 12, 40]]], ["Perhaps a universal protocol for sample preparation and analysis will not be obtained, due to the complex nature of MALDI experiments.", [["sample", "ANATOMY", 33, 39], ["a universal protocol", "TREATMENT", 8, 28], ["sample preparation", "TEST", 33, 51], ["analysis", "TEST", 56, 64]]], ["Careful control of the sample preparation and measurement parameters is the key to the success of the fingerprinting approaches.", [["sample", "ANATOMY", 23, 29], ["the sample preparation", "TREATMENT", 19, 41], ["measurement parameters", "TEST", 46, 68], ["the fingerprinting approaches", "TREATMENT", 98, 127]]], ["The MALDI-MS fingerprinting approach has been applied to analyze Bacillus spores (Dickinson et al., 2004) , Campylobacter (Mandrell et al., 2005) , Salmonella (Leuschner, Beresford-Jones, & Robinson, 2004) , Aeromonas (Donohue et al., 2006) , Clostridium (Grosse-Herrenthey et al., 2008) , Streptococcus (Williamson et al., 2008) , non-fermenting bacteria (Pseudomonas cepacia) (Mellmann et al., 2008) , Staphylococcus (Rajakaruna et al., 2009) , Neisseria , and Helicobacter (Ilina et al., 2010) .", [["Aeromonas", "ORGANISM", 208, 217], ["Pseudomonas cepacia", "ORGANISM", 357, 376], ["Helicobacter", "ORGANISM", 463, 475], ["Pseudomonas cepacia", "SPECIES", 357, 376], ["Pseudomonas cepacia", "SPECIES", 357, 376], ["The MALDI-MS fingerprinting approach", "TREATMENT", 0, 36], ["analyze Bacillus spores", "TEST", 57, 80], ["Dickinson et al.", "TEST", 82, 98], ["Campylobacter (Mandrell et al.", "TEST", 108, 138], ["Salmonella", "PROBLEM", 148, 158], ["Leuschner", "TEST", 160, 169], ["Aeromonas", "PROBLEM", 208, 217], ["Clostridium", "TEST", 243, 254], ["Streptococcus (Williamson et al.", "TEST", 290, 322], ["non-fermenting bacteria (Pseudomonas cepacia", "PROBLEM", 332, 376], ["Staphylococcus", "PROBLEM", 404, 418], ["Neisseria", "PROBLEM", 447, 456], ["Helicobacter", "ANATOMY", 463, 475]]], ["The approach has such advantages as being able to detect intact biomarkers, simplicity of sample preparation, broad-band identification, and high throughput.Protein FingerprintingMatrix-assisted laser desorption/ionization (MALDI) mass spectra might vary with growth media and growth stage Wunschel et al., 2005) .", [["sample", "ANATOMY", 90, 96], ["sample preparation", "TEST", 90, 108], ["broad-band identification", "TEST", 110, 135], ["Protein FingerprintingMatrix-assisted laser desorption/ionization (MALDI) mass spectra", "TREATMENT", 157, 243], ["high", "OBSERVATION_MODIFIER", 141, 145]]], ["The intra-and inter-laboratory reproducibility of whole-cell MS, and the effect of culture media on the spectral profiles, have been investigated (Walker et al., 2002) .", [["whole-cell", "ANATOMY", 50, 60], ["whole-cell", "CELL", 50, 60], ["whole-cell MS", "PROBLEM", 50, 63], ["culture media", "TEST", 83, 96], ["the spectral profiles", "TEST", 100, 121], ["reproducibility", "OBSERVATION_MODIFIER", 31, 46], ["whole-cell MS", "OBSERVATION", 50, 63]]], ["Williams et al. (2003) discussed the experimental factors that affect the quality and reproducibility of bacterial analysis with MALDI-TOFMS.Protein FingerprintingThe cell walls of Gram-positive bacteria are usually more difficult to analyze with MALDI-MS than those of Gram-negative bacteria.", [["cell walls", "ANATOMY", 167, 177], ["cell", "CELL", 167, 171], ["Gram", "GENE_OR_GENE_PRODUCT", 181, 185], ["Gram-negative bacteria", "GENE_OR_GENE_PRODUCT", 270, 292], ["the experimental factors", "PROBLEM", 33, 57], ["bacterial analysis", "TEST", 105, 123], ["Protein Fingerprinting", "TEST", 141, 163], ["The cell walls", "TEST", 163, 177], ["Gram", "TEST", 181, 185], ["positive bacteria", "PROBLEM", 186, 203], ["MALDI", "TEST", 247, 252], ["Gram-negative bacteria", "PROBLEM", 270, 292], ["cell", "OBSERVATION_MODIFIER", 167, 171], ["walls", "OBSERVATION_MODIFIER", 172, 177], ["Gram", "OBSERVATION_MODIFIER", 181, 185], ["positive bacteria", "OBSERVATION", 186, 203], ["negative bacteria", "OBSERVATION", 275, 292]]], ["Therefore, analysis of Gram-positive bacteria yields spectra with fewer peaks, lower intensities, and a smaller mass range than the spectra of Gram-negative bacteria.", [["Gram", "GENE_OR_GENE_PRODUCT", 23, 27], ["analysis", "TEST", 11, 19], ["Gram", "TEST", 23, 27], ["positive bacteria yields spectra with fewer peaks, lower intensities", "PROBLEM", 28, 96], ["a smaller mass range", "PROBLEM", 102, 122], ["Gram-negative bacteria", "PROBLEM", 143, 165], ["positive bacteria", "OBSERVATION_MODIFIER", 28, 45], ["fewer peaks", "OBSERVATION", 66, 77], ["lower intensities", "OBSERVATION_MODIFIER", 79, 96], ["smaller", "OBSERVATION_MODIFIER", 104, 111], ["mass", "OBSERVATION", 112, 116], ["negative bacteria", "OBSERVATION", 148, 165]]], ["Several methods have been suggested to overcome these difficulties, including disruption of the cell wall with enzymatic or chemical cleavage (Smole et al., 2002; Williams et al., 2003) .", [["cell wall", "ANATOMY", 96, 105], ["cell wall", "CELLULAR_COMPONENT", 96, 105], ["these difficulties", "PROBLEM", 48, 66], ["disruption of the cell wall", "PROBLEM", 78, 105], ["cell", "ANATOMY", 96, 100], ["wall", "ANATOMY_MODIFIER", 101, 105], ["chemical cleavage", "OBSERVATION", 124, 141]]], ["Smole et al. (2002) developed a method to prepare samples of whole-cell Gram-positive bacteria for analysis.", [["samples", "ANATOMY", 50, 57], ["cell", "CELL", 67, 71], ["a method", "TREATMENT", 30, 38], ["whole-cell Gram", "TEST", 61, 76], ["positive bacteria", "PROBLEM", 77, 94], ["analysis", "TEST", 99, 107], ["positive bacteria", "OBSERVATION", 77, 94]]], ["They found that lysozyme treatment of Gram-positive bacteria increased the spectral range to levels close to those of Gram-negative bacteria from the Enterobacteriaceae family.", [["lysozyme", "GENE_OR_GENE_PRODUCT", 16, 24], ["lysozyme", "PROTEIN", 16, 24], ["lysozyme treatment", "TREATMENT", 16, 34], ["Gram", "TEST", 38, 42], ["positive bacteria", "PROBLEM", 43, 60], ["Gram", "TEST", 118, 122], ["negative bacteria", "OBSERVATION", 123, 140]]], ["Not only were intact cells analyzed, but also four cell-lysis methods-mechanical, enzymatic, chemical, and heat treatment-were compared (Smole et al., 2002; Williams et al., 2003) and optimized to increase the complexity of the biomarker profile to develop bacterial species-specific fingerprints.", [["cells", "ANATOMY", 21, 26], ["cell", "ANATOMY", 51, 55], ["cells", "CELL", 21, 26], ["cell", "CELL", 51, 55], ["lysis methods", "TREATMENT", 56, 69], ["heat treatment", "TREATMENT", 107, 121], ["the biomarker profile", "TEST", 224, 245], ["bacterial species", "PROBLEM", 257, 274], ["intact cells", "OBSERVATION", 14, 26], ["bacterial species", "OBSERVATION", 257, 274]]], ["Vargha et al. (2006) optimized the experimental parameters of MALDI-TOFMS analysis to differentiate among Arthrobacter isolates at the strain level.", [["MALDI-TOFMS analysis", "TEST", 62, 82], ["Arthrobacter isolates", "PROBLEM", 106, 127]]], ["Liu et al. evaluated a universal sample-preparation protocol to analyze Gram-positive bacteria (B. anthracis and S. aureus) and Gram-negative bacteria (Yersinia pestis, E. coli, and B. cepacia) that have high extracellular polysaccharide contents.", [["extracellular", "ANATOMY", 209, 222], ["Gram-", "GENE_OR_GENE_PRODUCT", 72, 77], ["B. anthracis", "ORGANISM", 96, 108], ["S. aureus", "ORGANISM", 113, 122], ["Gram", "GENE_OR_GENE_PRODUCT", 128, 132], ["Yersinia pestis", "ORGANISM", 152, 167], ["E. coli", "ORGANISM", 169, 176], ["B. cepacia", "ORGANISM", 182, 192], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 209, 222], ["polysaccharide", "SIMPLE_CHEMICAL", 223, 237], ["B. anthracis", "SPECIES", 96, 108], ["S. aureus", "SPECIES", 113, 122], ["Yersinia pestis", "SPECIES", 152, 167], ["E. coli", "SPECIES", 169, 176], ["B. cepacia", "SPECIES", 182, 192], ["B. anthracis", "SPECIES", 96, 108], ["S. aureus", "SPECIES", 113, 122], ["Yersinia pestis", "SPECIES", 152, 167], ["E. coli", "SPECIES", 169, 176], ["B. cepacia", "SPECIES", 182, 192], ["a universal sample-preparation protocol", "TEST", 21, 60], ["Gram-positive bacteria", "PROBLEM", 72, 94], ["B. anthracis", "TEST", 96, 108], ["S. aureus", "TEST", 113, 122], ["Gram-negative bacteria", "PROBLEM", 128, 150], ["Yersinia pestis", "PROBLEM", 152, 167], ["E. coli", "PROBLEM", 169, 176], ["B. cepacia", "PROBLEM", 182, 192], ["high extracellular polysaccharide contents", "PROBLEM", 204, 246], ["negative bacteria", "OBSERVATION_MODIFIER", 133, 150], ["E. coli", "OBSERVATION_MODIFIER", 169, 176], ["high", "OBSERVATION_MODIFIER", 204, 208], ["extracellular", "OBSERVATION_MODIFIER", 209, 222], ["polysaccharide contents", "OBSERVATION", 223, 246]]], ["In their study, three samplepreparation methods (direct analysis, solvent treatment, and enzyme treatment) were tested for the direct analysis of bacteria with MALDI-TOFMS .Protein FingerprintingB. anthracis is the etiological agent of anthrax in humans/ animals, and is recognized to be a potential biological-threat agent that could be used in biological warfare or by terrorists (Demirev & Fenselau, 2008b; Lasch et al., 2009) .", [["anthrax", "DISEASE", 236, 243], ["anthracis", "ORGANISM", 198, 207], ["anthrax", "ORGANISM", 236, 243], ["humans", "ORGANISM", 247, 253], ["anthracis", "SPECIES", 198, 207], ["humans", "SPECIES", 247, 253], ["anthracis", "SPECIES", 198, 207], ["humans", "SPECIES", 247, 253], ["their study", "TEST", 3, 14], ["three samplepreparation methods", "TEST", 16, 47], ["direct analysis", "TEST", 49, 64], ["solvent treatment", "TREATMENT", 66, 83], ["enzyme treatment", "TREATMENT", 89, 105], ["the direct analysis", "TEST", 123, 142], ["bacteria", "PROBLEM", 146, 154], ["MALDI-TOFMS", "TEST", 160, 171], ["Protein FingerprintingB", "TEST", 173, 196], ["anthracis", "PROBLEM", 198, 207]]], ["Numerous lowmolecular-weight proteins can be readily extracted from the spores of B. anthracis and related species.", [["B. anthracis", "ORGANISM", 82, 94], ["lowmolecular-weight proteins", "PROTEIN", 9, 37], ["B. anthracis", "SPECIES", 82, 94], ["B. anthracis", "SPECIES", 82, 94], ["Numerous lowmolecular-weight proteins", "PROBLEM", 0, 37], ["B. anthracis", "PROBLEM", 82, 94], ["related species", "PROBLEM", 99, 114], ["lowmolecular", "OBSERVATION_MODIFIER", 9, 21], ["species", "OBSERVATION_MODIFIER", 107, 114]]], ["Many of these proteins have been identified as small acid-soluble spore proteins (SASPs) with various solvents including 10% TFA, 30% acetonitrile and 40% formic acid, 50% acetic acid, and acetonitrile-5% TFA (70:30, vol/vol) (Hathout et al., 2003; Dickinson et al., 2004; Castanha et al., 2007; Fenselau et al., 2007) , whereas others have been identified as cyclic lipopeptides (Madonna et al., 2003b) .", [["TFA", "CHEMICAL", 125, 128], ["acetonitrile", "CHEMICAL", 134, 146], ["formic acid", "CHEMICAL", 155, 166], ["acetic acid", "CHEMICAL", 172, 183], ["acetonitrile", "CHEMICAL", 189, 201], ["TFA", "CHEMICAL", 205, 208], ["TFA", "CHEMICAL", 125, 128], ["acetonitrile", "CHEMICAL", 134, 146], ["formic acid", "CHEMICAL", 155, 166], ["acetic acid", "CHEMICAL", 172, 183], ["acetonitrile", "CHEMICAL", 189, 201], ["TFA", "CHEMICAL", 205, 208], ["SASPs", "SIMPLE_CHEMICAL", 82, 87], ["TFA", "SIMPLE_CHEMICAL", 125, 128], ["acetonitrile", "SIMPLE_CHEMICAL", 134, 146], ["formic acid", "SIMPLE_CHEMICAL", 155, 166], ["acetic acid", "SIMPLE_CHEMICAL", 172, 183], ["acetonitrile", "SIMPLE_CHEMICAL", 189, 201], ["TFA", "SIMPLE_CHEMICAL", 205, 208], ["small acid-soluble spore proteins", "PROTEIN", 47, 80], ["SASPs", "PROTEIN", 82, 87], ["these proteins", "PROBLEM", 8, 22], ["small acid-soluble spore proteins", "PROBLEM", 47, 80], ["various solvents", "TREATMENT", 94, 110], ["10% TFA", "TREATMENT", 121, 128], ["30% acetonitrile", "TREATMENT", 130, 146], ["formic acid", "TREATMENT", 155, 166], ["acetic acid", "TREATMENT", 172, 183], ["acetonitrile", "TREATMENT", 189, 201], ["cyclic lipopeptides", "TREATMENT", 360, 379], ["small", "OBSERVATION_MODIFIER", 47, 52], ["acid-soluble", "OBSERVATION_MODIFIER", 53, 65], ["spore proteins", "OBSERVATION", 66, 80]]], ["Coxiella burnetii, the causative agent of Q fever, has been identified from its proteins, extracted with acetonitrile and trichloroacetic acid (Hernychova et al., 2008) , and characterized with MALDI-TOFMS.Protein FingerprintingSeveral groups have focused on identifying fungal cells (Valentine et al., 2002) and fungal spores (Li, Liu, & Chen, 2000; Kemptner et al., 2009a,b) with MALDI-TOFMS.", [["cells", "ANATOMY", 278, 283], ["Coxiella burnetii", "DISEASE", 0, 17], ["Q fever", "DISEASE", 42, 49], ["acetonitrile", "CHEMICAL", 105, 117], ["trichloroacetic acid", "CHEMICAL", 122, 142], ["acetonitrile", "CHEMICAL", 105, 117], ["trichloroacetic acid", "CHEMICAL", 122, 142], ["Coxiella burnetii", "ORGANISM", 0, 17], ["acetonitrile", "SIMPLE_CHEMICAL", 105, 117], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 122, 142], ["fungal cells", "CELL", 271, 283], ["fungal spores", "CELL", 313, 326], ["fungal cells", "CELL_TYPE", 271, 283], ["Coxiella burnetii", "SPECIES", 0, 17], ["Coxiella burnetii", "SPECIES", 0, 17], ["Coxiella burnetii", "PROBLEM", 0, 17], ["Q fever", "PROBLEM", 42, 49], ["acetonitrile and trichloroacetic acid", "TREATMENT", 105, 142], ["Protein Fingerprinting", "TEST", 206, 228], ["fungal cells", "PROBLEM", 271, 283], ["burnetii", "OBSERVATION", 9, 17], ["fungal cells", "OBSERVATION", 271, 283]]], ["Welham et al. (2000) presented the first article on the use of MALDI-TOFMS with different matrices to characterize various fungal spores.", [["spores", "ANATOMY", 130, 136], ["MALDI-TOFMS", "TREATMENT", 63, 74], ["different matrices", "TREATMENT", 80, 98], ["various fungal spores", "PROBLEM", 115, 136], ["various", "OBSERVATION_MODIFIER", 115, 122], ["fungal spores", "OBSERVATION", 123, 136]]], ["MALDI-MS has been used to desorb protein biomarkers from intact fungi, and to generate highly reproducible mass spectra for Penicillium species (Hettick et al., 2008b) , 12 species of Aspergillus, and five strains of A. flavus (Hettick et al., 2008a) .", [["A. flavus", "ORGANISM", 217, 226], ["A. flavus", "SPECIES", 217, 226], ["A. flavus", "SPECIES", 217, 226], ["MS", "PROBLEM", 6, 8], ["protein biomarkers", "TEST", 33, 51], ["intact fungi", "PROBLEM", 57, 69], ["highly reproducible mass spectra", "PROBLEM", 87, 119], ["Penicillium species", "PROBLEM", 124, 143], ["Hettick et al.", "TEST", 145, 159], ["Aspergillus", "PROBLEM", 184, 195], ["A. flavus", "PROBLEM", 217, 226], ["mass", "OBSERVATION", 107, 111], ["flavus", "OBSERVATION", 220, 226]]], ["These results indicate that MALDI-TOFMS data might be used to identify fungi unambiguously at the species and strain levels.", [["MALDI-TOFMS data", "TEST", 28, 44], ["fungi", "PROBLEM", 71, 76]]], ["Qian et al. (2008) investigated MALDI-TOF mass signatures for the accurate identification and differentiation of pathogenic Candida species (C. albicans, C. glabrata, C. krusei, C. kefyr), Aspergillus species (A. terreus, A. fumigatus, A. syndowii), and other yeast genera (Cryptococcus neoformans, S. cerevisiae, and Rhodotorula spp.).", [["Cryptococcus neoformans", "DISEASE", 274, 297], ["Candida species", "ORGANISM", 124, 139], ["C. albicans", "ORGANISM", 141, 152], ["C. glabrata", "ORGANISM", 154, 165], ["C. krusei", "ORGANISM", 167, 176], ["C. kefyr", "ORGANISM", 178, 186], ["Aspergillus species", "ORGANISM", 189, 208], ["A. terreus", "ORGANISM", 210, 220], ["A. fumigatus", "ORGANISM", 222, 234], ["A. syndowii", "ORGANISM", 236, 247], ["yeast genera", "ORGANISM", 260, 272], ["Cryptococcus neoformans", "ORGANISM", 274, 297], ["S. cerevisiae", "ORGANISM", 299, 312], ["Rhodotorula spp.", "ORGANISM", 318, 334], ["C. albicans", "SPECIES", 141, 152], ["C. glabrata", "SPECIES", 154, 165], ["C. krusei", "SPECIES", 167, 176], ["C. kefyr", "SPECIES", 178, 186], ["A. terreus", "SPECIES", 210, 220], ["A. fumigatus", "SPECIES", 222, 234], ["A. syndowii", "SPECIES", 236, 247], ["yeast", "SPECIES", 260, 265], ["Cryptococcus neoformans", "SPECIES", 274, 297], ["S. cerevisiae", "SPECIES", 299, 312], ["Rhodotorula spp.", "SPECIES", 318, 334], ["C. albicans", "SPECIES", 141, 152], ["C. glabrata", "SPECIES", 154, 165], ["C. krusei", "SPECIES", 167, 176], ["C. kefyr", "SPECIES", 178, 186], ["A. terreus", "SPECIES", 210, 220], ["A. fumigatus", "SPECIES", 222, 234], ["A. syndowii", "SPECIES", 236, 247], ["yeast", "SPECIES", 260, 265], ["Cryptococcus neoformans", "SPECIES", 274, 297], ["S. cerevisiae", "SPECIES", 299, 312], ["Rhodotorula spp.", "SPECIES", 318, 334], ["MALDI", "TEST", 32, 37], ["TOF mass signatures", "PROBLEM", 38, 57], ["the accurate identification", "TEST", 62, 89], ["pathogenic Candida species", "PROBLEM", 113, 139], ["C. albicans", "PROBLEM", 141, 152], ["C. glabrata", "TREATMENT", 154, 165], ["C. krusei", "PROBLEM", 167, 176], ["Aspergillus species", "PROBLEM", 189, 208], ["A. fumigatus", "PROBLEM", 222, 234], ["other yeast genera", "PROBLEM", 254, 272], ["Cryptococcus neoformans", "PROBLEM", 274, 297], ["pathogenic", "OBSERVATION_MODIFIER", 113, 123], ["Candida species", "OBSERVATION", 124, 139], ["yeast genera", "OBSERVATION", 260, 272]]], ["Marinach-Patrice et al. (2009) identified 62 clinical Fusarium isolates of nine Fusarium species with partial TEF1 gene sequencing and MALDI-TOF analysis.", [["TEF1 gene", "DNA", 110, 119], ["clinical Fusarium isolates", "TEST", 45, 71], ["nine Fusarium species", "PROBLEM", 75, 96], ["partial TEF1 gene sequencing", "TREATMENT", 102, 130], ["MALDI", "TEST", 135, 140], ["TOF analysis", "TEST", 141, 153]]], ["Recently, Marklein et al. (2009) demonstrated the identification of more than 250 clinical yeasts and yeast-like fungi (Candida, Cryptococcus, Saccharomyces, Trichosporon, Geotrichum, Pichia, and Blastoschizomyces spp.) with MALDI-TOFMS.", [["yeast-like fungi", "ORGANISM", 102, 118], ["Candida, Cryptococcus, Saccharomyces", "ORGANISM", 120, 156], ["Trichosporon, Geotrichum", "ORGANISM", 158, 182], ["Pichia", "GENE_OR_GENE_PRODUCT", 184, 190], ["Blastoschizomyces spp.", "ORGANISM", 196, 218], ["yeast", "SPECIES", 102, 107], ["Saccharomyces", "SPECIES", 143, 156], ["Blastoschizomyces spp.", "SPECIES", 196, 218], ["yeast", "SPECIES", 102, 107], ["Blastoschizomyces spp.", "SPECIES", 196, 218], ["clinical yeasts", "PROBLEM", 82, 97], ["yeast-like fungi", "PROBLEM", 102, 118], ["Candida", "TEST", 120, 127], ["Cryptococcus", "PROBLEM", 129, 141], ["Saccharomyces", "TEST", 143, 156], ["Trichosporon", "TEST", 158, 170], ["Geotrichum", "TEST", 172, 182], ["Pichia", "TEST", 184, 190]]], ["Cyclic lipopeptides are potential biomarker molecules that can differentiate some microorganisms at the species and even at the subspecies levels (Jegorov et al., 2006; Price et al., 2007) .Protein FingerprintingThe challenge in the above approach is that culture conditions and instrumental parameters can significantly influence the spectral reproducibility.", [["Cyclic lipopeptides", "SIMPLE_CHEMICAL", 0, 19], ["Cyclic lipopeptides", "TREATMENT", 0, 19], ["potential biomarker molecules", "PROBLEM", 24, 53], ["some microorganisms at the species", "PROBLEM", 77, 111], ["Protein Fingerprinting", "TEST", 190, 212], ["The challenge", "TREATMENT", 212, 225], ["the above approach", "TREATMENT", 229, 247], ["culture conditions", "TEST", 256, 274], ["instrumental parameters", "TEST", 279, 302], ["spectral reproducibility", "OBSERVATION", 335, 359]]], ["Because of the complexity of mass spectral data, many statistical algorithms have been developed to match acquired spectra to reference spectra, or to generate fingerprints for microbial differentiation.", [["mass spectral data", "PROBLEM", 29, 47], ["many statistical algorithms", "PROBLEM", 49, 76], ["mass", "OBSERVATION", 29, 33]]], ["The linear correlation of analyzed spectra and library spectra has been performed to differentiate among protein profiles from Bacillus spores (Dickinson et al., 2004) .", [["library spectra", "TEST", 47, 62], ["linear", "OBSERVATION_MODIFIER", 4, 10]]], ["A fingerprint-selection algorithm that is similar to a statistical test of significance has been used to extract key biomarkers from spectra.", [["A fingerprint-selection algorithm", "TEST", 0, 33], ["a statistical test", "TEST", 53, 71]]], ["The constructed fingerprint IDENTIFICATION OF PATHOGENS BY MASS SPECTROMETRY & library has been used to identify bacterial samples from three different laboratories .", [["samples", "ANATOMY", 123, 130], ["PATHOGENS BY MASS SPECTROMETRY & library", "DNA", 46, 86], ["MASS SPECTROMETRY", "TEST", 59, 76], ["bacterial samples", "TEST", 113, 130]]], ["Keys et al. (2004) compiled a MALDI mass spectral database of over 100 genera and 350 species to characterize bacteria that are associated with human infectious diseases.", [["infectious diseases", "DISEASE", 150, 169], ["human", "ORGANISM", 144, 149], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["a MALDI mass", "PROBLEM", 28, 40], ["bacteria", "PROBLEM", 110, 118], ["human infectious diseases", "PROBLEM", 144, 169], ["bacteria", "OBSERVATION", 110, 118], ["infectious", "OBSERVATION", 150, 160]]], ["Species-or subspecies-specific markers in the spectra were sometimes difficult to identify because the number of overlapping signals increased with the number of strains in the database.", [["Species", "TEST", 0, 7], ["subspecies", "PROBLEM", 11, 21], ["overlapping signals", "PROBLEM", 113, 132], ["strains", "PROBLEM", 162, 169], ["increased", "OBSERVATION_MODIFIER", 133, 142]]], ["Many multivariate analytical (MVA) techniques, including PCA, cluster analysis, and factor analysis, have been applied to analyze the protein profiles of bacterial samples (Chen, Lu, & Harrington, 2008) .", [["samples", "ANATOMY", 164, 171], ["Many multivariate analytical (MVA) techniques", "TREATMENT", 0, 45], ["PCA", "TREATMENT", 57, 60], ["cluster analysis", "TEST", 62, 78], ["factor analysis", "TEST", 84, 99]]], ["MVA is based on multivariate statistics, and involves the analysis of several statistical variables (m/z herein) simultaneously.", [["MVA", "PROBLEM", 0, 3], ["the analysis", "TEST", 54, 66]]], ["Parisi et al. (2008) demonstrated the PCA classification of two pathogens and the linear discriminant analysis of MALDI-MS spectra.", [["two pathogens", "PROBLEM", 60, 73]]], ["Hsieh et al. (2008) identified six human pathogens with cluster analysis and genetic algorithms.", [["human", "ORGANISM", 35, 40], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["cluster analysis", "TEST", 56, 72], ["genetic algorithms", "TEST", 77, 95]]], ["Ilina et al. (2009) reported on the direct bacterial profiling of two human pathogens, N. meningitidis and N. gonorrboeae.", [["human", "ORGANISM", 70, 75], ["N. meningitidis", "ORGANISM", 87, 102], ["N. gonorrboeae", "ORGANISM", 107, 121], ["human", "SPECIES", 70, 75], ["N. meningitidis", "SPECIES", 87, 102], ["N. gonorrboeae", "SPECIES", 107, 121], ["human", "SPECIES", 70, 75], ["N. meningitidis", "SPECIES", 87, 102], ["N. gonorrboeae", "SPECIES", 107, 121], ["two human pathogens", "PROBLEM", 66, 85], ["meningitidis", "PROBLEM", 90, 102], ["meningitidis", "OBSERVATION", 90, 102]]], ["Cluster analysis successfully separated mass spectra of pathogenic and non-pathogenic Neisseria isolates.", [["Neisseria isolates", "ORGANISM", 86, 104], ["Cluster analysis", "TEST", 0, 16], ["pathogenic and non-pathogenic Neisseria isolates", "PROBLEM", 56, 104], ["mass", "OBSERVATION", 40, 44], ["non-pathogenic", "OBSERVATION_MODIFIER", 71, 85], ["Neisseria isolates", "OBSERVATION", 86, 104]]], ["Discussion of various mathematic methods used in data analysis has been described elsewhere (Ho & Reddy, 2010) .Protein/Peptide IdentificationThe top-down proteomics method identifies intact proteins without the need for prior proteolytic digestion of the sample.", [["data analysis", "TEST", 49, 62], ["Protein/Peptide Identification", "TEST", 112, 142], ["intact proteins", "PROBLEM", 184, 199], ["prior proteolytic digestion", "TREATMENT", 221, 248], ["top", "OBSERVATION_MODIFIER", 146, 149]]], ["The method has been used successfully for microbial proteomics in the analysis of Bacillus spores.", [["Bacillus spores", "ORGANISM", 82, 97], ["The method", "TREATMENT", 0, 10], ["microbial proteomics", "TEST", 42, 62], ["the analysis", "TEST", 66, 78], ["Bacillus spores", "PROBLEM", 82, 97], ["Bacillus", "ANATOMY", 82, 90]]], ["Demirev et al. presented results obtained with a top-down proteomics approach that exploited MALDI-TOF/TOFMS of protein biomarkers to identify directly and rapidly individual Bacillus spore species, whether they are present alone or in a mixture Wynne et al., 2009) .", [["MALDI", "TEST", 93, 98], ["protein biomarkers", "TEST", 112, 130], ["rapidly individual Bacillus spore species", "PROBLEM", 156, 197]]], ["A major advantage of this method is that the MS/MS spectra of biomarkers are obtained without the need for biomarker prefractionation, digestion, separation, or cleanup.", [["the MS/MS spectra of biomarkers", "TEST", 41, 72], ["biomarker prefractionation", "TEST", 107, 133], ["digestion", "PROBLEM", 135, 144]]], ["The MALDI tandem mass spectra of intact biomarkers are fairly reproducible, and library fingerprint matching of such tandem mass spectra can be exploited to identify intact microorganisms.", [["The MALDI tandem mass", "PROBLEM", 0, 21], ["library fingerprint", "TEST", 80, 99], ["such tandem mass spectra", "PROBLEM", 112, 136], ["tandem", "OBSERVATION_MODIFIER", 10, 16], ["mass", "OBSERVATION", 17, 21], ["intact", "OBSERVATION_MODIFIER", 33, 39], ["biomarkers", "OBSERVATION", 40, 50], ["fairly", "OBSERVATION_MODIFIER", 55, 61], ["reproducible", "OBSERVATION_MODIFIER", 62, 74]]], ["Top-down proteomics has been applied to distinguish the pathogenic E. coli strain from the non-pathogenic strain (Fagerquist et al., 2010) .", [["E. coli", "ORGANISM", 67, 74], ["E. coli", "SPECIES", 67, 74], ["E. coli", "SPECIES", 67, 74], ["Top-down proteomics", "TREATMENT", 0, 19], ["the pathogenic E. coli strain", "PROBLEM", 52, 81], ["the non-pathogenic strain", "PROBLEM", 87, 112], ["pathogenic", "OBSERVATION_MODIFIER", 56, 66], ["E. coli strain", "OBSERVATION", 67, 81], ["non-pathogenic", "OBSERVATION_MODIFIER", 91, 105], ["strain", "OBSERVATION_MODIFIER", 106, 112]]], ["Figure 4 displays an MS/MS spectrum of a protein marker at m/z 7705.6.", [["an MS", "PROBLEM", 18, 23], ["a protein marker", "TEST", 39, 55]]], ["The protein was identified from its sequence-specific fragment ions by checking against a database of theoretical fragment ions derived from bacterial proteomes.", [["The protein", "TEST", 0, 11], ["specific fragment ions", "PROBLEM", 45, 67], ["theoretical fragment ions", "PROBLEM", 102, 127], ["bacterial proteomes", "PROBLEM", 141, 160], ["fragment", "OBSERVATION", 114, 122], ["bacterial proteomes", "OBSERVATION", 141, 160]]], ["The protein sequences associated with the identified pathogenic strain and the non-pathogenic strain differ by only one amino acid (1 Da).", [["amino acid", "CHEMICAL", 120, 130], ["amino acid", "CHEMICAL", 120, 130], ["amino acid", "AMINO_ACID", 120, 130], ["The protein sequences", "TEST", 0, 21], ["pathogenic strain", "PROBLEM", 53, 70], ["the non-pathogenic strain", "PROBLEM", 75, 100], ["pathogenic strain", "OBSERVATION", 53, 70]]], ["The 1 Da difference in protein mass would be difficult to detect with protein fingerprinting.Protein/Peptide IdentificationIn bottom-up proteomics, proteins from lysed cells are cleaved to form peptides, which are fragmented in a MS/MS experiment.", [["cells", "ANATOMY", 168, 173], ["cells", "CELL", 168, 173], ["lysed cells", "CELL_TYPE", 162, 173], ["protein mass", "PROBLEM", 23, 35], ["protein fingerprinting", "PROBLEM", 70, 92], ["Protein", "TEST", 93, 100], ["Peptide IdentificationIn bottom", "TEST", 101, 132], ["proteins from lysed cells", "PROBLEM", 148, 173], ["a MS/MS experiment", "PROBLEM", 228, 246], ["mass", "OBSERVATION", 31, 35], ["lysed cells", "OBSERVATION", 162, 173], ["fragmented", "OBSERVATION_MODIFIER", 214, 224]]], ["The protein/peptide identification approach overcomes the challenges of identifying components of mixtures of microorganisms .", [["The protein/peptide identification approach", "TREATMENT", 0, 43], ["microorganisms", "PROBLEM", 110, 124]]], ["Warscheid et al. found that proteolytic digests are generated in situ from SASPs to enable microorganisms to be identified with microsequencing and a database search (English et al., 2003; .", [["SASPs", "GENE_OR_GENE_PRODUCT", 75, 80], ["proteolytic digests", "PROBLEM", 28, 47]]], ["SASPs are reliable biomarkers for spore-forming microorganisms, such as Bacillus and Clostridium species, and allow the identification and FIGURE 4.", [["SASPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["Clostridium species", "ORGANISM", 85, 104], ["SASPs", "TEST", 0, 5], ["spore-forming microorganisms", "PROBLEM", 34, 62], ["Bacillus", "PROBLEM", 72, 80], ["Clostridium species", "PROBLEM", 85, 104]]], ["Tandem mass spectrum of a protein marker observed at m/z 7705.6, obtained from the extracted cell lysate of a pathogenic E. coli O157:H7 strain.", [["cell lysate", "ANATOMY", 93, 104], ["cell", "CELL", 93, 97], ["E. coli", "ORGANISM", 121, 128], ["O157:H7", "ORGANISM", 129, 136], ["strain", "ORGANISM", 137, 143], ["E. coli O157", "SPECIES", 121, 133], ["E. coli O157:H7", "SPECIES", 121, 136], ["Tandem mass", "PROBLEM", 0, 11], ["a protein marker", "TEST", 24, 40], ["a pathogenic E. coli", "PROBLEM", 108, 128], ["H7 strain", "PROBLEM", 134, 143], ["mass", "OBSERVATION", 7, 11], ["E. coli", "OBSERVATION", 121, 128]]], ["Many of the fragment ions correspond to backbone cleavage adjacent to aspartic acid (D) and/or glutamic acid (E) residues.", [["aspartic acid", "CHEMICAL", 70, 83], ["glutamic acid", "CHEMICAL", 95, 108], ["aspartic acid", "CHEMICAL", 70, 83], ["glutamic acid", "CHEMICAL", 95, 108], ["aspartic acid", "SIMPLE_CHEMICAL", 70, 83], ["D", "SIMPLE_CHEMICAL", 85, 86], ["glutamic acid", "SIMPLE_CHEMICAL", 95, 108], ["the fragment ions", "PROBLEM", 8, 25], ["backbone cleavage", "PROBLEM", 40, 57], ["aspartic acid (D)", "TREATMENT", 70, 87], ["glutamic acid (E) residues", "TREATMENT", 95, 121], ["fragment", "OBSERVATION", 12, 20], ["backbone cleavage", "OBSERVATION", 40, 57]]], ["The identified protein sequence and the sequence of the nonpathogenic E. coli K-12 strain are shown with the spectrum.", [["K", "CHEMICAL", 78, 79], ["E. coli", "ORGANISM", 70, 77], ["K-12", "GENE_OR_GENE_PRODUCT", 78, 82], ["E. coli", "SPECIES", 70, 77], ["E. coli", "SPECIES", 70, 77], ["The identified protein sequence", "TEST", 0, 31], ["the sequence", "TEST", 36, 48], ["the nonpathogenic E. coli K", "TEST", 52, 79]]], ["The two sequences differ by only one amino acid (in bold; aspartic acid vs. asparagine) and, therefore, by only 1 Da in molecular weight.", [["amino acid", "CHEMICAL", 37, 47], ["aspartic acid", "CHEMICAL", 58, 71], ["asparagine", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 37, 47], ["aspartic acid", "CHEMICAL", 58, 71], ["asparagine", "CHEMICAL", 76, 86], ["amino acid", "AMINO_ACID", 37, 47], ["aspartic acid", "AMINO_ACID", 58, 71], ["asparagine", "AMINO_ACID", 76, 86], ["one amino acid", "TEST", 33, 47], ["aspartic acid", "TEST", 58, 71]]], ["The top-down proteomics approach can distinguish E. coli O157:H7 from E. coli K-12.", [["E. coli", "ORGANISM", 49, 56], ["O157:H7", "ORGANISM", 57, 64], ["E. coli", "ORGANISM", 70, 77], ["K-12", "GENE_OR_GENE_PRODUCT", 78, 82], ["E. coli O157", "SPECIES", 49, 61], ["E. coli", "SPECIES", 70, 77], ["E. coli O157:H7", "SPECIES", 49, 64], ["E. coli", "SPECIES", 70, 77], ["The top", "TEST", 0, 7], ["E. coli O157", "PROBLEM", 49, 61], ["E. coli K", "TEST", 70, 79]]], ["Reprinted and modified with permission from Fagerquist et al. (2010) , copyright 2010 American Chemical Society. differentiation of closely related species (Hathout et al., 2003; .", [["closely related species", "PROBLEM", 132, 155]]], ["The same group obtained the complete sequences of the three most-abundant SASPs from B. globigii with MS. They used a combination of MS/MS, chemical derivatization, ladder sequencing, and checking against a database to determine peptide sequences and to construct entire protein sequences (Whiteaker et al., 2004) .", [["MS", "DISEASE", 102, 104], ["SASPs", "GENE_OR_GENE_PRODUCT", 74, 79], ["B. globigii", "ORGANISM", 85, 96], ["SASPs", "PROTEIN", 74, 79], ["B. globigii", "SPECIES", 85, 96], ["B. globigii", "SPECIES", 85, 96], ["MS/MS", "TREATMENT", 133, 138], ["chemical derivatization", "TREATMENT", 140, 163], ["ladder sequencing", "TREATMENT", 165, 182], ["a database", "TEST", 205, 215], ["peptide sequences", "TEST", 229, 246]]], ["Unfortunately, several of the identified peptides are common to more than one species of Bacillus, and make difficult the determination of their origin .", [["Bacillus", "PROBLEM", 89, 97], ["peptides", "OBSERVATION", 41, 49], ["Bacillus", "OBSERVATION", 89, 97], ["origin", "ANATOMY_MODIFIER", 145, 151]]], ["This difficulty applies particularly when closely related members of the cereus group (B. anthracis, B. cereus, B. mycoides, and B. thuringiensis) are involved.", [["cereus group", "ORGANISM", 73, 85], ["B. anthracis", "ORGANISM", 87, 99], ["B. cereus", "ORGANISM", 101, 110], ["B. mycoides", "ORGANISM", 112, 123], ["B. thuringiensis", "ORGANISM", 129, 145], ["cereus group", "SPECIES", 73, 85], ["B. anthracis", "SPECIES", 87, 99], ["B. cereus", "SPECIES", 101, 110], ["B. mycoides", "SPECIES", 112, 123], ["B. thuringiensis", "SPECIES", 129, 145], ["B. anthracis", "SPECIES", 87, 99], ["B. cereus", "SPECIES", 101, 110], ["B. mycoides", "SPECIES", 112, 123], ["B. thuringiensis", "SPECIES", 129, 145]]], ["Furthermore, the determined major SASPs of B. globigii and B. stearothermophilus are almost identical (Whiteaker et al., 2004) .", [["SASPs", "GENE_OR_GENE_PRODUCT", 34, 39], ["B. globigii", "ORGANISM", 43, 54], ["B. stearothermophilus", "ORGANISM", 59, 80], ["B. globigii", "SPECIES", 43, 54], ["B. stearothermophilus", "SPECIES", 59, 80], ["B. globigii", "SPECIES", 43, 54], ["B. stearothermophilus", "SPECIES", 59, 80], ["B. globigii and B. stearothermophilus", "PROBLEM", 43, 80]]], ["Focusing directly on the identification of species-unique peptide sequences with MALDI-MS and MS/MS analysis can help to achieve more rapid and automatable species differentiation.", [["MALDI", "TEST", 81, 86], ["MS", "PROBLEM", 87, 89], ["MS", "PROBLEM", 94, 96], ["MS analysis", "PROBLEM", 97, 108], ["more rapid and automatable species differentiation", "PROBLEM", 129, 179]]], ["Pribil et al. (2005) used the direct scanning of speciesunique SASP tryptic peptides and modified SASP extraction procedures to discriminate between B. anthracis and B. cereus with either MS or MS/MS analysis.", [["SASP", "SIMPLE_CHEMICAL", 98, 102], ["B. anthracis", "ORGANISM", 149, 161], ["B. cereus", "ORGANISM", 166, 175], ["B. anthracis", "SPECIES", 149, 161], ["B. cereus", "SPECIES", 166, 175], ["B. anthracis", "SPECIES", 149, 161], ["B. cereus", "SPECIES", 166, 175], ["the direct scanning", "TEST", 26, 45], ["speciesunique SASP tryptic peptides", "TREATMENT", 49, 84], ["modified SASP extraction procedures", "TREATMENT", 89, 124], ["B. anthracis", "PROBLEM", 149, 161], ["B. cereus", "PROBLEM", 166, 175], ["MS", "PROBLEM", 188, 190], ["MS/MS analysis", "TEST", 194, 208]]], ["In protein-/peptide-identification approaches, spectral reproducibility is not critical as long as the observed spectra of the product ions are consistent with the protein/peptides sequences in the database.", [["spectral reproducibility", "TEST", 47, 71], ["the protein/peptides sequences", "PROBLEM", 160, 190], ["consistent with", "UNCERTAINTY", 144, 159]]], ["Positive identification will be hindered if the protein database of the analyzed microorganism does not exist, unless the protein/peptide databases can be constructed from experimental data (Yao, Demirev, & Fenselau, 2002) .Other BiomarkersCurrently, proteins are the most used and accessible biomarkers for microbial identification because of their high-abundances and gene-related characteristics.", [["the protein database", "TEST", 44, 64], ["the analyzed microorganism", "PROBLEM", 68, 94], ["the protein/peptide databases", "TEST", 118, 147], ["accessible biomarkers", "TEST", 282, 303], ["microbial identification", "TEST", 308, 332]]], ["MALDI analysis of biomarkers other than proteins has also been reported.", [["MALDI analysis", "TEST", 0, 14], ["biomarkers", "TEST", 18, 28]]], ["Ishida et al. applied an on-probe sample pretreatment protocol for the MALDI-MS measurement of phospholipids in growing bacterial colonies, obtained directly from culture dishes.", [["colonies", "ANATOMY", 130, 138], ["phospholipids", "SIMPLE_CHEMICAL", 95, 108], ["growing bacterial colonies", "CELL_LINE", 112, 138], ["an on-probe sample pretreatment protocol", "TREATMENT", 22, 62], ["the MALDI", "TEST", 67, 76], ["phospholipids", "PROBLEM", 95, 108], ["bacterial colonies", "PROBLEM", 120, 138], ["bacterial colonies", "OBSERVATION", 120, 138]]], ["They successfully observed a series of ions derived from phospholipids in Gramnegative bacteria (Enterobacteriaceae family) (Ishida et al., 2002) .", [["phospholipids", "SIMPLE_CHEMICAL", 57, 70]]], ["However, the spectra of Gram-positive bacteria did not include any lipid-related peaks, presumably because these bacteria have a thicker peptidoglycan layer.", [["lipid", "SIMPLE_CHEMICAL", 67, 72], ["Gram", "TEST", 24, 28], ["positive bacteria", "PROBLEM", 29, 46], ["any lipid-related peaks", "PROBLEM", 63, 86], ["these bacteria", "PROBLEM", 107, 121], ["a thicker peptidoglycan layer", "PROBLEM", 127, 156], ["thicker", "OBSERVATION_MODIFIER", 129, 136], ["peptidoglycan layer", "OBSERVATION", 137, 156]]], ["Therefore, Ishida et al. (2005) developed a new method for the direct detection of phospholipids in Gram-positive bacteria (B. subtilis) with MALDI-MS combined with on-probe sample pretreatment with trifluoroacetic acid as an additional reagent.", [["trifluoroacetic acid", "CHEMICAL", 199, 219], ["trifluoroacetic acid", "CHEMICAL", 199, 219], ["phospholipids", "SIMPLE_CHEMICAL", 83, 96], ["B. subtilis", "ORGANISM", 124, 135], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 199, 219], ["B. subtilis", "SPECIES", 124, 135], ["B. subtilis", "SPECIES", 124, 135], ["the direct detection", "TEST", 59, 79], ["phospholipids", "TEST", 83, 96], ["Gram-positive bacteria", "PROBLEM", 100, 122], ["MS", "PROBLEM", 148, 150], ["trifluoroacetic acid", "TREATMENT", 199, 219], ["an additional reagent", "TREATMENT", 223, 244], ["positive bacteria", "OBSERVATION", 105, 122]]], ["They also characterized the phospholipids in whole bacteria with solid-sampling MALDI-MS (Ohtani & Ishida, 2007) .", [["phospholipids", "SIMPLE_CHEMICAL", 28, 41], ["the phospholipids", "TEST", 24, 41], ["whole bacteria", "PROBLEM", 45, 59], ["sampling MALDI", "TEST", 71, 85], ["MS", "PROBLEM", 86, 88]]], ["With MALDI-FTMS, Jones et al. (2003) investigated E. coli lipids in the low-mass region (m/z 100-1,000).", [["E. coli", "ORGANISM", 50, 57], ["E. coli", "SPECIES", 50, 57], ["E. coli", "SPECIES", 50, 57], ["MALDI", "TEST", 5, 10], ["E. coli lipids", "TEST", 50, 64], ["low", "OBSERVATION_MODIFIER", 72, 75], ["mass", "OBSERVATION", 76, 80]]], ["They identified two major components, phosphatidyl ethanolamine and triglycerides, that are generally found in prokaryotic membranes.", [["membranes", "ANATOMY", 123, 132], ["phosphatidyl ethanolamine", "CHEMICAL", 38, 63], ["triglycerides", "CHEMICAL", 68, 81], ["phosphatidyl ethanolamine", "CHEMICAL", 38, 63], ["triglycerides", "CHEMICAL", 68, 81], ["phosphatidyl ethanolamine", "SIMPLE_CHEMICAL", 38, 63], ["triglycerides", "SIMPLE_CHEMICAL", 68, 81], ["prokaryotic membranes", "CELLULAR_COMPONENT", 111, 132], ["phosphatidyl ethanolamine", "TREATMENT", 38, 63], ["triglycerides", "TEST", 68, 81], ["prokaryotic membranes", "OBSERVATION", 111, 132]]], ["The same group described methods for the lipid analysis of S. cerevisiae with conventional MALDI-FTMS .Other BiomarkersLipopolysaccharides (LPSs), broadly known as endotoxins, are essential components of the outer membrane of all Gramnegative bacteria.", [["outer membrane", "ANATOMY", 208, 222], ["Lipopolysaccharides", "CHEMICAL", 119, 138], ["S. cerevisiae", "ORGANISM", 59, 72], ["Lipopolysaccharides", "GENE_OR_GENE_PRODUCT", 119, 138], ["outer membrane", "CELLULAR_COMPONENT", 208, 222], ["S. cerevisiae", "SPECIES", 59, 72], ["S. cerevisiae", "SPECIES", 59, 72], ["the lipid analysis", "TEST", 37, 55], ["conventional MALDI", "TREATMENT", 78, 96], ["Other BiomarkersLipopolysaccharides", "TEST", 103, 138], ["LPSs", "TEST", 140, 144], ["endotoxins", "PROBLEM", 164, 174], ["all Gramnegative bacteria", "PROBLEM", 226, 251], ["endotoxins", "OBSERVATION", 164, 174], ["outer membrane", "ANATOMY", 208, 222], ["Gramnegative bacteria", "OBSERVATION", 230, 251]]], ["Bacterial LPSs are dimeric molecules that comprise a polysaccharide moiety linked to a lipid core, termed lipid A, which is anchored within the cell membrane.", [["cell membrane", "ANATOMY", 144, 157], ["lipid A", "SIMPLE_CHEMICAL", 106, 113], ["cell membrane", "CELLULAR_COMPONENT", 144, 157], ["dimeric molecules", "PROTEIN", 19, 36], ["Bacterial LPSs", "TEST", 0, 14], ["dimeric molecules", "PROBLEM", 19, 36], ["a polysaccharide moiety", "PROBLEM", 51, 74], ["LPSs", "OBSERVATION_MODIFIER", 10, 14], ["dimeric molecules", "OBSERVATION", 19, 36], ["polysaccharide moiety", "OBSERVATION_MODIFIER", 53, 74], ["lipid core", "OBSERVATION_MODIFIER", 87, 97], ["lipid", "OBSERVATION_MODIFIER", 106, 111], ["cell membrane", "OBSERVATION", 144, 157]]], ["Therisod, Labas, and Caroff (2001) reported a method for the direct selective extraction and separation of LPSs from bacterial cells with thin-layer chromatography followed by MALDI-MS analysis.", [["cells", "ANATOMY", 127, 132], ["LPSs", "SIMPLE_CHEMICAL", 107, 111], ["cells", "CELL", 127, 132], ["bacterial cells", "CELL_TYPE", 117, 132], ["Labas", "TEST", 10, 15], ["the direct selective extraction", "TREATMENT", 57, 88], ["LPSs", "PROBLEM", 107, 111], ["bacterial cells", "PROBLEM", 117, 132], ["thin-layer chromatography", "TEST", 138, 163], ["MALDI-MS analysis", "TEST", 176, 193], ["Labas", "ANATOMY", 10, 15], ["bacterial cells", "OBSERVATION", 117, 132]]], ["This method can be used for the direct MS analysis of heterogeneous LPS and lipid A preparations (E. coli lipid A and Bordetella LPSs were used).", [["LPS", "CHEMICAL", 68, 71], ["LPS", "SIMPLE_CHEMICAL", 68, 71], ["lipid A", "SIMPLE_CHEMICAL", 76, 83], ["E. coli", "ORGANISM", 98, 105], ["lipid A", "GENE_OR_GENE_PRODUCT", 106, 113], ["Bordetella LPSs", "GENE_OR_GENE_PRODUCT", 118, 133], ["E. coli", "SPECIES", 98, 105], ["E. coli", "SPECIES", 98, 105], ["This method", "TREATMENT", 0, 11], ["the direct MS analysis", "TEST", 28, 50], ["heterogeneous LPS", "PROBLEM", 54, 71], ["lipid A preparations", "TREATMENT", 76, 96], ["E. coli lipid A and Bordetella LPSs", "TREATMENT", 98, 133]]], ["Tirsoaga et al. (2007) characterized the lipids A from three Citrobacter and two Bordetella strains with a procedure that involved direct extraction from cells followed by MALDI-MS.", [["cells", "ANATOMY", 154, 159], ["Citrobacter", "SIMPLE_CHEMICAL", 61, 72], ["cells", "CELL", 154, 159], ["Citrobacter", "PROBLEM", 61, 72], ["two Bordetella strains", "PROBLEM", 77, 99], ["a procedure", "TREATMENT", 105, 116], ["direct extraction", "TREATMENT", 131, 148]]], ["This method is especially convenient when only small amounts of bacteria, LPS, or lipid A are available.", [["LPS", "CHEMICAL", 74, 77], ["LPS", "SIMPLE_CHEMICAL", 74, 77], ["lipid A", "SIMPLE_CHEMICAL", 82, 89], ["bacteria", "PROBLEM", 64, 72], ["LPS", "TEST", 74, 77], ["bacteria", "OBSERVATION", 64, 72]]], ["Schilling et al. (2007) investigated low-abundance lipid A species from LPS, obtained from Francisella tularensis, F. novicida, and F. philomiragia grown in vitro with a MALDI-linear ion-trap mass spectrometer.BAMSBioaerosol mass spectrometry (BAMS) has been used to identify bacteria, spores, and viruses without consuming any reagent (Fergenson et al., 2004; Adams et al., 2008; Russell, 2009 ).", [["spores", "ANATOMY", 286, 292], ["LPS", "CHEMICAL", 72, 75], ["lipid A species", "SIMPLE_CHEMICAL", 51, 66], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["Francisella tularensis", "ORGANISM", 91, 113], ["F. novicida", "ORGANISM", 115, 126], ["F. philomiragia", "ORGANISM", 132, 147], ["BAMSBioaerosol", "SIMPLE_CHEMICAL", 210, 224], ["Francisella tularensis", "SPECIES", 91, 113], ["F. novicida", "SPECIES", 115, 126], ["F. philomiragia", "SPECIES", 132, 147], ["Francisella tularensis", "SPECIES", 91, 113], ["F. novicida", "SPECIES", 115, 126], ["F. philomiragia", "SPECIES", 132, 147], ["LPS", "PROBLEM", 72, 75], ["a MALDI", "TEST", 168, 175], ["linear ion-trap mass spectrometer", "PROBLEM", 176, 209], ["BAMSBioaerosol mass spectrometry", "PROBLEM", 210, 242], ["bacteria", "PROBLEM", 276, 284], ["spores", "PROBLEM", 286, 292], ["viruses", "PROBLEM", 298, 305]]], ["The first attempt at species-level identification with reagentless BAMS was that of Fergenson et al. This technique has been used to distinguish aerosolized spores of B. thuringiensis and B. atrophaeus from a variety of background mixtures of powders, soil, and fungal spores, by matching the mass spectra with fingerprints of pure samples (Fergenson et al., 2004) .", [["spores", "ANATOMY", 269, 275], ["B. thuringiensis", "ORGANISM", 167, 183], ["B. atrophaeus", "ORGANISM", 188, 201], ["B. thuringiensis", "SPECIES", 167, 183], ["B. atrophaeus", "SPECIES", 188, 201], ["B. thuringiensis", "SPECIES", 167, 183], ["B. atrophaeus", "SPECIES", 188, 201], ["reagentless BAMS", "TEST", 55, 71], ["This technique", "TREATMENT", 101, 115], ["aerosolized spores", "PROBLEM", 145, 163], ["B. thuringiensis", "PROBLEM", 167, 183], ["B. atrophaeus", "PROBLEM", 188, 201], ["background mixtures of powders", "TREATMENT", 220, 250], ["fungal spores", "PROBLEM", 262, 275], ["fungal spores", "OBSERVATION", 262, 275], ["mass", "OBSERVATION", 293, 297]]], ["A pulse laser at 226 nm was used to desorb and ionize chemicals from the aerosolized particles.", [["A pulse laser", "TREATMENT", 0, 13], ["aerosolized particles", "OBSERVATION", 73, 94]]], ["They demonstrated that chemical components of the two Bacillus spore species were consistently and easily laser desorbed and detected in seconds.", [["the two Bacillus spore species", "PROBLEM", 46, 76], ["Bacillus", "OBSERVATION_MODIFIER", 54, 62], ["spore species", "OBSERVATION", 63, 76]]], ["Furthermore, BAMS has been applied to detect Mycobacterium tuberculosis, M. smegmatis , and the biochemical and morphological changes of B. atrophaeus cells during the sporulation process (Tobias et al., 2006) .", [["cells", "ANATOMY", 151, 156], ["BAMS", "CHEMICAL", 13, 17], ["Mycobacterium tuberculosis", "DISEASE", 45, 71], ["Mycobacterium tuberculosis", "ORGANISM", 45, 71], ["M. smegmatis", "ORGANISM", 73, 85], ["B. atrophaeus cells", "CELL", 137, 156], ["BAMS", "PROTEIN", 13, 17], ["B. atrophaeus cells", "CELL_TYPE", 137, 156], ["Mycobacterium tuberculosis", "SPECIES", 45, 71], ["M. smegmatis", "SPECIES", 73, 85], ["B. atrophaeus", "SPECIES", 137, 150], ["Mycobacterium tuberculosis", "SPECIES", 45, 71], ["M. smegmatis", "SPECIES", 73, 85], ["B. atrophaeus", "SPECIES", 137, 150], ["BAMS", "TEST", 13, 17], ["Mycobacterium tuberculosis", "PROBLEM", 45, 71], ["M. smegmatis", "PROBLEM", 73, 85], ["the biochemical", "PROBLEM", 92, 107], ["B. atrophaeus cells", "PROBLEM", 137, 156], ["the sporulation process", "PROBLEM", 164, 187], ["Mycobacterium tuberculosis", "OBSERVATION", 45, 71], ["M. smegmatis", "OBSERVATION", 73, 85], ["atrophaeus cells", "OBSERVATION", 140, 156]]], ["Although no sample preparation such as matrix addition was required, the reagentless BAMS mass spectra of microbial cells were limited to signals under m/z 300.", [["matrix", "ANATOMY", 39, 45], ["cells", "ANATOMY", 116, 121], ["matrix", "CELLULAR_COMPONENT", 39, 45], ["BAMS", "SIMPLE_CHEMICAL", 85, 89], ["microbial cells", "CELL", 106, 121], ["microbial cells", "CELL_TYPE", 106, 121], ["sample preparation", "TREATMENT", 12, 30], ["the reagentless BAMS mass spectra of microbial cells", "PROBLEM", 69, 121], ["no", "UNCERTAINTY", 9, 11], ["microbial cells", "OBSERVATION", 106, 121]]], ["Low-mass biomarkers for B. atrophaeus have also been identified with isotope incorporation and BAMS Srivastava et al., 2005) .BAMSStowers et al. reported on the real-time and high-mass detection of individual airborne pathogens with MALDI aerosol TOFMS (Stowers et al., 2000; van Wuijckhuijse et al., 2005) .", [["B. atrophaeus", "ORGANISM", 24, 37], ["B. atrophaeus", "SPECIES", 24, 37], ["B. atrophaeus", "SPECIES", 24, 37], ["Low-mass biomarkers", "PROBLEM", 0, 19], ["B. atrophaeus", "PROBLEM", 24, 37], ["isotope incorporation", "TREATMENT", 69, 90], ["individual airborne pathogens", "PROBLEM", 198, 227], ["MALDI aerosol TOFMS", "TREATMENT", 233, 252], ["mass", "OBSERVATION", 4, 8], ["mass", "OBSERVATION", 180, 184], ["airborne pathogens", "OBSERVATION", 209, 227]]], ["Aerosol MALDI-MS can help detect high-mass biomolecules and identify bacteria or other biological microparticles from their fingerprints.", [["Aerosol MALDI", "TREATMENT", 0, 13], ["high-mass biomolecules", "PROBLEM", 33, 55], ["bacteria", "PROBLEM", 69, 77], ["other biological microparticles", "PROBLEM", 81, 112]]], ["In aerosol MALDI, the matrix is introduced via either condensation or deposition on a matrix-coated target (Noble & Prather, 2000) .", [["matrix", "ANATOMY", 22, 28], ["matrix", "CELLULAR_COMPONENT", 22, 28], ["matrix", "CELLULAR_COMPONENT", 86, 92], ["aerosol MALDI", "TREATMENT", 3, 16]]], ["Aerosol MALDI differs from classical MALDI in a number of important ways (The differences include optimal laser fluence, matrix-to-analyte molar ratio, and choice of matrix.), and not just in the analytes (McJimpsey et al., 2008) .", [["matrix", "CELLULAR_COMPONENT", 166, 172], ["Aerosol MALDI", "TREATMENT", 0, 13], ["optimal laser fluence, matrix-to-analyte molar ratio", "TREATMENT", 98, 150]]], ["Stowers et al. described the analysis of biological aerosol particles with MALDI-TOFMS, and applied this method to B. subtilis spores.", [["spores", "ANATOMY", 127, 133], ["B. subtilis spores", "ORGANISM", 115, 133], ["B. subtilis", "SPECIES", 115, 126], ["B. subtilis", "SPECIES", 115, 126], ["biological aerosol particles", "TREATMENT", 41, 69], ["MALDI-TOFMS", "TREATMENT", 75, 86], ["this method", "TREATMENT", 100, 111]]], ["They observed a single biomarker ion at ca. m/z 1225 that was attributed to a peptidoglycan (Stowers et al., 2000) .", [["a single biomarker ion at ca", "PROBLEM", 14, 42]]], ["A new aerosol TOFMS instrument, which is used with laser-induced fluorescence selection and MALDI, has been developed for the real-time analysis of single bioaerosol particles.", [["A new aerosol TOFMS instrument", "TREATMENT", 0, 30], ["laser-induced fluorescence selection", "TREATMENT", 51, 87], ["MALDI", "TREATMENT", 92, 97], ["single bioaerosol particles", "TREATMENT", 148, 175], ["new", "OBSERVATION_MODIFIER", 2, 5], ["aerosol", "OBSERVATION", 6, 13]]], ["MALDI ionization is triggered when fluorescent emission from microorganisms is observed.", [["MALDI ionization", "TEST", 0, 16], ["fluorescent emission", "TEST", 35, 55], ["microorganisms", "PROBLEM", 61, 75]]], ["The instrument can be used to measure the molecular masses of biomarker ions of bacteria and aerosolized proteinaceous materials up to 20 kDa IDENTIFICATION OF PATHOGENS BY MASS SPECTROMETRY & (van Wuijckhuijse et al., 2005) .", [["The instrument", "TREATMENT", 0, 14], ["the molecular masses", "PROBLEM", 38, 58], ["biomarker ions of bacteria", "PROBLEM", 62, 88], ["aerosolized proteinaceous materials", "PROBLEM", 93, 128], ["masses", "OBSERVATION", 52, 58]]], ["In more recent studies, Kleefsman et al. used single-particle MALDI to detect E. coli (Kleefsman et al., 2008) and Erwinia herbicola cells (Kleefsman et al., 2007) .", [["Erwinia herbicola cells", "ANATOMY", 115, 138], ["E. coli", "ORGANISM", 78, 85], ["Erwinia herbicola cells", "CELL", 115, 138], ["Erwinia herbicola cells", "CELL_LINE", 115, 138], ["E. coli", "SPECIES", 78, 85], ["Erwinia herbicola", "SPECIES", 115, 132], ["E. coli", "SPECIES", 78, 85], ["Erwinia herbicola", "SPECIES", 115, 132], ["recent studies", "TEST", 8, 22], ["single-particle MALDI", "TREATMENT", 46, 67], ["E. coli", "PROBLEM", 78, 85], ["Erwinia herbicola cells", "PROBLEM", 115, 138], ["herbicola cells", "OBSERVATION", 123, 138]]], ["They stated that the instrument efficiency could be improved by the selective ionization of biological particles, following the observation of single-particle fluorescence (Stowers et al., 2006; Kleefsman et al., 2007) .", [["the instrument efficiency", "PROBLEM", 17, 42]]], ["Although useful spectra of a few thousands of particles containing bacteria such as E. herbicola have been obtained (Kleefsman et al., 2007) , improvements in detection limit are still required for the analysis of real-world samples.SELDI-MSSurface-enhanced laser desorption/ionization (SELDI), a modified version of MALDI-TOFMS, has been successfully used for biomarker discovery and protein fingerprinting of bacterial species (Barzaghi et al., 2004; Lancashire et al., 2005; Lundquist et al., 2005; Schmid et al., 2005; Al Dahouk et al., 2006) .", [["E. herbicola", "ORGANISM", 84, 96], ["E. herbicola", "SPECIES", 84, 96], ["E. herbicola", "SPECIES", 84, 96], ["a few thousands of particles containing bacteria", "PROBLEM", 27, 75], ["E. herbicola", "PROBLEM", 84, 96], ["the analysis", "TEST", 198, 210], ["SELDI", "TEST", 233, 238], ["enhanced laser desorption/ionization (SELDI)", "TREATMENT", 249, 293], ["a modified version of MALDI", "TREATMENT", 295, 322], ["biomarker discovery", "TEST", 361, 380], ["bacterial species", "PROBLEM", 411, 428], ["bacterial species", "OBSERVATION", 411, 428]]], ["SELDI-MS provided protein expression patterns from hundreds of samples in a single experiment (Thulasiraman et al., 2000; Diamond et al., 2003; Barzaghi et al., 2004) .", [["samples", "ANATOMY", 63, 70]]], ["It is an affinity-based MS method in which proteins are selectively adsorbed onto a chemically or biochemically modified surface.", [["surface", "ANATOMY", 121, 128], ["surface", "CELLULAR_COMPONENT", 121, 128], ["an affinity-based MS method", "PROBLEM", 6, 33], ["affinity", "OBSERVATION_MODIFIER", 9, 17], ["surface", "OBSERVATION_MODIFIER", 121, 128]]], ["Seo, Kim, and Chai (2004) studied the protein-expression profile in human macrophages that were infected by B. anthracis spores with SELDI-TOFMS.", [["macrophages", "ANATOMY", 74, 85], ["human", "ORGANISM", 68, 73], ["macrophages", "CELL", 74, 85], ["B. anthracis", "ORGANISM", 108, 120], ["human macrophages", "CELL_TYPE", 68, 85], ["human", "SPECIES", 68, 73], ["B. anthracis", "SPECIES", 108, 120], ["human", "SPECIES", 68, 73], ["B. anthracis", "SPECIES", 108, 120], ["the protein", "TEST", 34, 45], ["expression profile in human macrophages", "PROBLEM", 46, 85], ["human macrophages", "OBSERVATION", 68, 85]]], ["Lundquist et al. (2005) demonstrated that SELDI-TOFMS can generate unique and reproducible protein profiles for F. tularensis subspecies, to allow its subspecies to be distinguished from each other.", [["F. tularensis", "ORGANISM", 112, 125], ["subspecies", "ORGANISM", 126, 136], ["F. tularensis", "SPECIES", 112, 125], ["F. tularensis", "SPECIES", 112, 125], ["F. tularensis subspecies", "PROBLEM", 112, 136]]], ["Similarly, Seibold et al. (2007) identified single strains of the subspecies F. tularensis with SELDI-MS.", [["F. tularensis", "ORGANISM", 77, 90], ["F. tularensis", "SPECIES", 77, 90], ["F. tularensis", "SPECIES", 77, 90]]], ["Huang and co-workers proposed a method based on SELDI-MS to identify Klebsiella pneumoniae and other related microorganisms by directly analyzing bacterial colonies without any protein extraction .SELDI-MSBecause SELDI might yield many ion signals per bacterial sample, computer algorithms used in MALDI protein fingerprinting are also employed to identify useful biomarkers for bacterial identification.", [["colonies", "ANATOMY", 156, 164], ["sample", "ANATOMY", 262, 268], ["Klebsiella pneumoniae", "ORGANISM", 69, 90], ["Klebsiella pneumoniae", "SPECIES", 69, 90], ["Klebsiella pneumoniae", "SPECIES", 69, 90], ["a method", "TREATMENT", 30, 38], ["Klebsiella pneumoniae", "PROBLEM", 69, 90], ["other related microorganisms", "PROBLEM", 95, 123], ["directly analyzing bacterial colonies", "PROBLEM", 127, 164], ["any protein extraction", "TREATMENT", 173, 195], ["bacterial sample", "TEST", 252, 268], ["computer algorithms", "TEST", 270, 289], ["MALDI protein fingerprinting", "TEST", 298, 326], ["bacterial identification", "TEST", 379, 403], ["Klebsiella pneumoniae", "OBSERVATION", 69, 90], ["bacterial colonies", "OBSERVATION", 146, 164]]], ["Seibold et al. (2007) differentiated single strains within the subspecies F. tularensis by combining SELDI-TOFMS with cluster analysis and PCA.", [["F. tularensis", "ORGANISM", 74, 87], ["F. tularensis", "SPECIES", 74, 87], ["F. tularensis", "SPECIES", 74, 87], ["single strains", "PROBLEM", 37, 51], ["cluster analysis", "TEST", 118, 134], ["PCA", "TREATMENT", 139, 142], ["PCA", "ANATOMY", 139, 142]]], ["The artificial neural network (ANN) algorithm has been combined with SELDI-MS to identify N. meningitides Schmid et al., 2005) and Neisseria gonorrhoeae .", [["Neisseria gonorrhoeae", "DISEASE", 131, 152], ["neural network", "MULTI-TISSUE_STRUCTURE", 15, 29], ["Neisseria gonorrhoeae", "ORGANISM", 131, 152], ["N. meningitides", "SPECIES", 90, 105], ["Neisseria gonorrhoeae", "SPECIES", 131, 152], ["N. meningitides", "SPECIES", 90, 105], ["Neisseria gonorrhoeae", "SPECIES", 131, 152], ["Neisseria gonorrhoeae", "PROBLEM", 131, 152], ["artificial neural", "OBSERVATION", 4, 21], ["gonorrhoeae", "OBSERVATION", 141, 152]]], ["Schmid et al. analyzed over 350 strains of N. gonorrhoeae, other neisseriae, and closely related species such as Kingella denitrificans and Moraxella osloensis.", [["N. gonorrhoeae", "ORGANISM", 43, 57], ["Kingella denitrificans", "ORGANISM", 113, 135], ["Moraxella osloensis", "ORGANISM", 140, 159], ["N. gonorrhoeae", "SPECIES", 43, 57], ["Kingella denitrificans", "SPECIES", 113, 135], ["Moraxella osloensis", "SPECIES", 140, 159], ["N. gonorrhoeae", "SPECIES", 43, 57], ["Kingella denitrificans", "SPECIES", 113, 135], ["Moraxella osloensis", "SPECIES", 140, 159], ["N. gonorrhoeae", "PROBLEM", 43, 57], ["closely related species", "PROBLEM", 81, 104], ["Kingella denitrificans", "PROBLEM", 113, 135], ["Moraxella osloensis", "PROBLEM", 140, 159], ["Moraxella osloensis", "OBSERVATION", 140, 159]]], ["They performed comparative 16S rDNA sequence analysis and standard biochemical tests to establish the identity of the strains prior to SELDI-MS analysis .", [["16S rDNA sequence", "DNA", 27, 44], ["comparative 16S rDNA sequence analysis", "TEST", 15, 53], ["standard biochemical tests", "TEST", 58, 84], ["the strains", "PROBLEM", 114, 125], ["SELDI-MS analysis", "TEST", 135, 152]]], ["ANN is an algorithm for machine learning, and represents a mathematical method that is not based on multivariate statistics.", [["a mathematical method", "TREATMENT", 57, 78]]], ["The model is trained, tested, and validated with bacterial samples.", [["samples", "ANATOMY", 59, 66], ["bacterial samples", "TEST", 49, 66]]], ["This approach has been applied to a blind dataset of 188 samples, and correctly identified 184 out of 188 samples .", [["samples", "ANATOMY", 57, 64], ["samples", "ANATOMY", 106, 113], ["samples", "CANCER", 57, 64], ["This approach", "TREATMENT", 0, 13]]], ["Yates et al. analyzed the volatile compounds of pathogens with quadrupole MS. Radial-basis function neural networks successfully identified the unknown bacterial samples .", [["neural networks", "ANATOMY", 100, 115], ["samples", "ANATOMY", 162, 169], ["neural networks", "MULTI-TISSUE_STRUCTURE", 100, 115], ["pathogens", "PROBLEM", 48, 57], ["the unknown bacterial samples", "PROBLEM", 140, 169], ["volatile compounds", "OBSERVATION_MODIFIER", 26, 44], ["bacterial samples", "OBSERVATION", 152, 169]]], ["SELDI-MS allows more selective analysis of protein profiles than does direct MALDI-MS.", [["protein profiles", "TEST", 43, 59]]], ["Useful markers might be selectively extracted and analyzed.", [["Useful markers", "TREATMENT", 0, 14]]], ["The surface capacity of a SELDI probe plays an important role in the detection of markers.", [["surface", "ANATOMY", 4, 11], ["a SELDI probe", "TREATMENT", 24, 37], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["capacity", "OBSERVATION_MODIFIER", 12, 20]]], ["The capacity depends on the number of interacting groups and even the size of the markers.", [["capacity", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["The markers that the SELDI surface captures are usually the abundant ones possessing specific interacting functional groups.", [["surface", "ANATOMY", 27, 34]]], ["Further, the ionization efficiencies of various molecules also determine the molecules detected in a mass spectrum.", [["the ionization efficiencies of various molecules", "TREATMENT", 9, 57], ["a mass spectrum", "PROBLEM", 99, 114], ["mass", "OBSERVATION", 101, 105]]], ["In microbial analysis, because SELDI is generally used to obtain proteomic fingerprints from microbial samples, the fingerprint data are useful as long as they are reproducible.", [["samples", "ANATOMY", 103, 110], ["microbial analysis", "TEST", 3, 21], ["proteomic fingerprints", "TEST", 65, 87], ["microbial samples", "TEST", 93, 110], ["the fingerprint data", "TEST", 112, 132]]], ["However, just as for MALDI analysis, spectral reproducibility remains a key challenge in this approach.Ambient Mass Spectrometric MethodsAmbient mass spectrometric methods such as DESI (Takats et al., 2004) and DART (Cody, Laramee, & Durst, 2005) have recently been applied to examine microbial samples with little or no sample preparation in an attempt accurately and rapidly to type closely related strains of bacteria.", [["samples", "ANATOMY", 295, 302], ["MALDI analysis", "TEST", 21, 35], ["spectral reproducibility", "TEST", 37, 61], ["Ambient Mass Spectrometric MethodsAmbient mass spectrometric methods", "TREATMENT", 103, 171], ["microbial samples", "TEST", 285, 302], ["sample preparation", "TREATMENT", 321, 339], ["bacteria", "PROBLEM", 412, 420]]], ["DART-MS has been successfully applied to the analysis of fatty-acid methyl ester profiles from bacterial cells (Pierce et al., 2007) .", [["cells", "ANATOMY", 105, 110], ["fatty-acid methyl ester", "CHEMICAL", 57, 80], ["fatty-acid methyl ester", "CHEMICAL", 57, 80], ["fatty-acid methyl ester", "SIMPLE_CHEMICAL", 57, 80], ["bacterial cells", "CELL", 95, 110], ["bacterial cells", "CELL_TYPE", 95, 110], ["MS", "PROBLEM", 5, 7], ["the analysis", "TEST", 41, 53], ["fatty-acid methyl ester profiles", "TREATMENT", 57, 89], ["bacterial cells", "PROBLEM", 95, 110], ["bacterial cells", "OBSERVATION", 95, 110]]], ["The ionization process involves an interaction between electronically excited atoms or vibronically excited molecules and the analytes that are obtained by the thermal hydrolysis and methylation of bacterial lipids.", [["vibronically excited molecules", "PROTEIN", 87, 117], ["The ionization process", "PROBLEM", 0, 22], ["the analytes", "TEST", 122, 134], ["the thermal hydrolysis", "TREATMENT", 156, 178], ["bacterial lipids", "TREATMENT", 198, 214], ["ionization process", "OBSERVATION", 4, 22]]], ["Takats et al. used the DESI method to identify microorganisms by spraying microbial samples with electrosprayed solvent droplets.", [["samples", "ANATOMY", 84, 91], ["the DESI method", "TREATMENT", 19, 34], ["microorganisms", "PROBLEM", 47, 61], ["electrosprayed solvent droplets", "TREATMENT", 97, 128]]], ["This technique has been used to differentiate among several bacteria species based on their DESI-mass spectral profiles (Meetani et al., 2007; Song et al., 2009 ).", [["This technique", "TREATMENT", 0, 14], ["several bacteria species", "PROBLEM", 52, 76]]], ["The bacteria include E. coli, S. aureus, Enterococcus sp., Bordetella bronchiseptica, B. thuringiensis, B. subtilis, and Salmonella typhimurium.", [["Bordetella bronchiseptica", "DISEASE", 59, 84], ["E. coli", "ORGANISM", 21, 28], ["S. aureus", "ORGANISM", 30, 39], ["Enterococcus sp.", "ORGANISM", 41, 57], ["Bordetella bronchiseptica", "ORGANISM", 59, 84], ["B. thuringiensis", "ORGANISM", 86, 102], ["B. subtilis", "ORGANISM", 104, 115], ["Salmonella typhimurium", "ORGANISM", 121, 143], ["E. coli", "SPECIES", 21, 28], ["S. aureus", "SPECIES", 30, 39], ["Enterococcus sp.", "SPECIES", 41, 57], ["Bordetella bronchiseptica", "SPECIES", 59, 84], ["B. thuringiensis", "SPECIES", 86, 102], ["B. subtilis", "SPECIES", 104, 115], ["Salmonella typhimurium", "SPECIES", 121, 143], ["E. coli", "SPECIES", 21, 28], ["S. aureus", "SPECIES", 30, 39], ["Enterococcus sp.", "SPECIES", 41, 57], ["Bordetella bronchiseptica", "SPECIES", 59, 84], ["B. thuringiensis", "SPECIES", 86, 102], ["B. subtilis", "SPECIES", 104, 115], ["Salmonella typhimurium", "SPECIES", 121, 143], ["The bacteria", "PROBLEM", 0, 12], ["E. coli", "PROBLEM", 21, 28], ["S. aureus", "PROBLEM", 30, 39], ["Enterococcus sp.", "PROBLEM", 41, 57], ["Bordetella bronchiseptica", "PROBLEM", 59, 84], ["B. thuringiensis", "PROBLEM", 86, 102], ["B. subtilis", "PROBLEM", 104, 115], ["Salmonella typhimurium", "PROBLEM", 121, 143], ["bacteria", "OBSERVATION", 4, 12], ["E. coli", "OBSERVATION", 21, 28], ["aureus", "OBSERVATION", 33, 39], ["Enterococcus sp.", "OBSERVATION", 41, 57]]], ["Highquality mass spectra have been obtained in positive-and negative-ion modes when whole bacteria were subjected to DESI (Meetani et al., 2007) .", [["Highquality mass spectra", "PROBLEM", 0, 24], ["whole bacteria", "PROBLEM", 84, 98], ["mass", "OBSERVATION", 12, 16]]], ["The same approach has also been applied to the phospholipid profiling of intact bacteria (Song et al., 2007) .", [["phospholipid", "SIMPLE_CHEMICAL", 47, 59], ["The same approach", "TREATMENT", 0, 17], ["intact bacteria", "PROBLEM", 73, 88], ["intact bacteria", "OBSERVATION_MODIFIER", 73, 88]]], ["Recently, Song et al. (2009) applied DESI-MS to the analysis of untreated B. subtilis in an in vivo experiment.Pyrolysis-GC-MSPyrolysis mass spectrometry (Py-MS) analyzes microorganisms from their pyrolysate fingerprint after decomposition of their biochemical components by heating to high temperature (Wilkes et al., 2005) .", [["B. subtilis", "ORGANISM", 74, 85], ["B. subtilis", "SPECIES", 74, 85], ["B. subtilis", "SPECIES", 74, 85], ["untreated B. subtilis", "PROBLEM", 64, 85], ["Pyrolysis", "TEST", 111, 120], ["GC", "TEST", 121, 123], ["MSPyrolysis mass spectrometry", "PROBLEM", 124, 153], ["microorganisms", "PROBLEM", 171, 185], ["their pyrolysate fingerprint", "TREATMENT", 191, 219], ["their biochemical components", "PROBLEM", 243, 271]]], ["In Curie point pyrolysis, pure microbial cultures are dried in a suitable alloy foil and heated rapidly to the Curie point of the foil.", [["pure microbial cultures", "CELL_LINE", 26, 49], ["pure microbial cultures", "TEST", 26, 49], ["a suitable alloy foil", "TREATMENT", 63, 84]]], ["The pyrolysates are immediately swept into a mass spectrometer and identified based on their m/z ratio.", [["pyrolysates", "SIMPLE_CHEMICAL", 4, 15], ["a mass spectrometer", "PROBLEM", 43, 62], ["their m/z ratio", "TEST", 87, 102], ["mass", "OBSERVATION", 45, 49]]], ["Then, the fingerprint or chemical profile of the pyrolysis mass spectrum is analyzed by suitable mathematic methods to differentiate pathogens.", [["the fingerprint", "TEST", 6, 21], ["the pyrolysis mass spectrum", "PROBLEM", 45, 72], ["pathogens", "PROBLEM", 133, 142]]], ["The first automated Curie-point Py-MS was developed by Meuzelaar et al. specifically for fingerprinting complex non-volatile biological samples such as bacteria (Meuzelaar & Kistemaker, 1973; Meuzelaar et al., 1976) .", [["samples", "ANATOMY", 136, 143], ["MS", "PROBLEM", 35, 37], ["fingerprinting complex non-volatile biological samples", "PROBLEM", 89, 143], ["bacteria", "PROBLEM", 152, 160]]], ["The mass spectra of pyrolysates are usually complicated because many large biomolecules decompose into small fragments.Pyrolysis-GC-MSThe cell envelopes of many bacteria have been analyzed, and various separation methods, such as HPLC, GC, and thin layer chromatography, have been developed for use with Py-MS.", [["fragments", "ANATOMY", 109, 118], ["cell", "ANATOMY", 138, 142], ["pyrolysates", "SIMPLE_CHEMICAL", 20, 31], ["The mass spectra of pyrolysates", "PROBLEM", 0, 31], ["many large biomolecules decompose into small fragments", "PROBLEM", 64, 118], ["Pyrolysis", "TEST", 119, 128], ["GC", "TEST", 129, 131], ["MSThe cell envelopes", "PROBLEM", 132, 152], ["many bacteria", "PROBLEM", 156, 169], ["HPLC", "TEST", 230, 234], ["thin layer chromatography", "TEST", 244, 269], ["mass", "OBSERVATION", 4, 8], ["large", "OBSERVATION_MODIFIER", 69, 74], ["biomolecules", "OBSERVATION", 75, 87], ["small", "OBSERVATION_MODIFIER", 103, 108], ["fragments", "OBSERVATION", 109, 118], ["many", "OBSERVATION_MODIFIER", 156, 160], ["bacteria", "OBSERVATION", 161, 169]]], ["Py-GC and Py-GC-MS techniques allow for rapid volatilization, separation, and identification of pyrolysis products Sobeih, Baron, & Gonzalez-Rodriguez, 2008) .", [["Py", "TEST", 0, 2], ["GC", "TEST", 3, 5], ["Py", "TEST", 10, 12], ["rapid volatilization", "TREATMENT", 40, 60], ["separation", "TREATMENT", 62, 72], ["pyrolysis products", "TREATMENT", 96, 114]]], ["In Py-GC and Py-GC-MS, high-resolution gas-chromatographic separation is carried out in a capillary column, and mass spectrometric identification can be improved with either soft-ionization methods or tandem MS (Sobeih, Baron, & Gonzalez-Rodriguez, 2008) .Pyrolysis-GC-MSPyrolysis products that derive from carbohydrates (Abbas-Hawks, Voorhees, & Miketova, 2006) , lipids (Voorhees et al., 2006b) , nucleic acids (Abbas-Hawks, Voorhees, & Miketova, 2006) , proteins (Voorhees, Abbas-Hawks, & Miketova, 2006a) , and other components, such as dipicolinic or poly(3-hydroxyalkanoic) acids, have been utilized to differentiate bacteria.", [["capillary column", "ANATOMY", 90, 106], ["Py-GC", "CHEMICAL", 3, 8], ["Py", "CHEMICAL", 13, 15], ["nucleic acids", "CHEMICAL", 399, 412], ["dipicolinic", "CHEMICAL", 541, 552], ["poly(3-hydroxyalkanoic) acids", "CHEMICAL", 556, 585], ["carbohydrates", "CHEMICAL", 307, 320], ["dipicolinic or poly(3-hydroxyalkanoic) acids", "CHEMICAL", 541, 585], ["Py-GC", "SIMPLE_CHEMICAL", 3, 8], ["Py", "SIMPLE_CHEMICAL", 13, 15], ["capillary", "TISSUE", 90, 99], ["carbohydrates", "SIMPLE_CHEMICAL", 307, 320], ["lipids", "SIMPLE_CHEMICAL", 365, 371], ["nucleic acids", "SIMPLE_CHEMICAL", 399, 412], ["dipicolinic", "SIMPLE_CHEMICAL", 541, 552], ["poly(3-hydroxyalkanoic) acids", "SIMPLE_CHEMICAL", 556, 585], ["MS", "TEST", 19, 21], ["high-resolution gas-chromatographic separation", "PROBLEM", 23, 69], ["a capillary column", "TEST", 88, 106], ["mass spectrometric identification", "PROBLEM", 112, 145], ["soft-ionization methods", "TREATMENT", 174, 197], ["Pyrolysis", "TEST", 256, 265], ["MSPyrolysis products", "TREATMENT", 269, 289], ["carbohydrates", "TEST", 307, 320], ["Abbas", "TEST", 322, 327], ["Voorhees", "TEST", 335, 343], ["lipids", "TEST", 365, 371], ["nucleic acids", "TEST", 399, 412], ["Abbas", "TEST", 414, 419], ["Voorhees", "TEST", 427, 435], ["proteins", "TEST", 457, 465], ["Voorhees", "TEST", 467, 475], ["Abbas", "TEST", 477, 482], ["dipicolinic or poly(3-hydroxyalkanoic) acids", "TREATMENT", 541, 585], ["bacteria", "PROBLEM", 623, 631], ["capillary column", "ANATOMY", 90, 106], ["mass", "OBSERVATION", 112, 116]]], ["Goodacre et al. (2000) detected the dipicolinic acid biomarker in 36 Bacillus species with Py-MS.", [["dipicolinic acid", "CHEMICAL", 36, 52], ["dipicolinic acid", "CHEMICAL", 36, 52], ["dipicolinic acid", "SIMPLE_CHEMICAL", 36, 52], ["the dipicolinic acid biomarker", "TEST", 32, 62], ["Bacillus species", "PROBLEM", 69, 85]]], ["An ion-mobility spectrometer (IMS) has been employed as a detector in the Py-GC analysis of bacteria in the on-site monitoring of transient plumes of aerosols that contain B. subtilis .", [["B. subtilis", "ORGANISM", 172, 183], ["B. subtilis", "SPECIES", 172, 183], ["B. subtilis", "SPECIES", 172, 183], ["GC analysis", "TEST", 77, 88], ["bacteria", "PROBLEM", 92, 100], ["transient plumes of aerosols", "PROBLEM", 130, 158], ["B. subtilis", "OBSERVATION", 172, 183]]], ["Dworzanski et al. (2005) reported on the use of the Py-GC-IMS system to identify Gram-negative Pantoea agglomerans and Gram-positive B. anthracis strain Texas and B. atrophaeus.", [["Gram", "GENE_OR_GENE_PRODUCT", 81, 85], ["Pantoea agglomerans", "ORGANISM", 95, 114], ["Gram-positive", "ORGANISM", 119, 132], ["B. anthracis strain", "ORGANISM", 133, 152], ["Texas", "ORGANISM", 153, 158], ["B. atrophaeus", "ORGANISM", 163, 176], ["Pantoea agglomerans", "SPECIES", 95, 114], ["B. anthracis", "SPECIES", 133, 145], ["B. atrophaeus", "SPECIES", 163, 176], ["Pantoea agglomerans", "SPECIES", 95, 114], ["B. anthracis", "SPECIES", 133, 145], ["B. atrophaeus", "SPECIES", 163, 176], ["Gram", "TEST", 81, 85], ["negative Pantoea agglomerans", "PROBLEM", 86, 114], ["Gram-positive B. anthracis strain Texas and B. atrophaeus", "PROBLEM", 119, 176]]], ["They identified pyridine-2-carboxamide (2-picolinamide) from the cell walls of Gram-positive bacteria.", [["cell walls", "ANATOMY", 65, 75], ["pyridine-2-carboxamide", "CHEMICAL", 16, 38], ["2-picolinamide", "CHEMICAL", 40, 54], ["pyridine-2-carboxamide", "CHEMICAL", 16, 38], ["2-picolinamide", "CHEMICAL", 40, 54], ["pyridine-2-carboxamide", "SIMPLE_CHEMICAL", 16, 38], ["2-picolinamide", "SIMPLE_CHEMICAL", 40, 54], ["cell", "CELL", 65, 69], ["Gram", "GENE_OR_GENE_PRODUCT", 79, 83], ["pyridine", "TREATMENT", 16, 24], ["carboxamide", "TREATMENT", 27, 38], ["Gram", "TEST", 79, 83], ["positive bacteria", "PROBLEM", 84, 101], ["positive bacteria", "OBSERVATION", 84, 101]]], ["They characterized the envelopes of Gram-negative bacteria by the presence of a second membrane, with the outer leaflet composed mainly of LPS molecules anchored with a lipid A moiety.", [["membrane", "ANATOMY", 87, 95], ["outer leaflet", "ANATOMY", 106, 119], ["LPS", "CHEMICAL", 139, 142], ["Gram", "GENE_OR_GENE_PRODUCT", 36, 40], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["outer leaflet", "CELLULAR_COMPONENT", 106, 119], ["LPS", "SIMPLE_CHEMICAL", 139, 142], ["lipid A moiety", "SIMPLE_CHEMICAL", 169, 183], ["LPS molecules", "PROTEIN", 139, 152], ["Gram-negative bacteria", "PROBLEM", 36, 58], ["the outer leaflet", "TREATMENT", 102, 119], ["LPS molecules", "PROBLEM", 139, 152], ["a lipid A moiety", "TREATMENT", 167, 183], ["negative bacteria", "OBSERVATION", 41, 58], ["second membrane", "ANATOMY_MODIFIER", 80, 95], ["outer", "ANATOMY_MODIFIER", 106, 111], ["leaflet", "ANATOMY_MODIFIER", 112, 119], ["LPS molecules", "OBSERVATION", 139, 152]]], ["These biomarkers include pyrolysis products of the 3-hydroxymyristate fatty-acid residues, such as 1-tridecene, dodecanal, and methylundecylketone.", [["3-hydroxymyristate fatty-acid", "CHEMICAL", 51, 80], ["1-tridecene", "CHEMICAL", 99, 110], ["dodecanal", "CHEMICAL", 112, 121], ["methylundecylketone", "CHEMICAL", 127, 146], ["3-hydroxymyristate fatty-acid", "CHEMICAL", 51, 80], ["1-tridecene", "CHEMICAL", 99, 110], ["dodecanal", "CHEMICAL", 112, 121], ["methylundecylketone", "CHEMICAL", 127, 146], ["3-hydroxymyristate fatty-acid", "SIMPLE_CHEMICAL", 51, 80], ["1-tridecene", "SIMPLE_CHEMICAL", 99, 110], ["dodecanal", "SIMPLE_CHEMICAL", 112, 121], ["methylundecylketone", "SIMPLE_CHEMICAL", 127, 146], ["These biomarkers", "TEST", 0, 16], ["pyrolysis products", "TREATMENT", 25, 43], ["methylundecylketone", "TREATMENT", 127, 146], ["pyrolysis products", "OBSERVATION", 25, 43]]], ["The same group detected and classified deliberately released bioaerosols (Gram-positive and -negative bacteria) in outdoor-field scenarios.", [["bioaerosols", "SIMPLE_CHEMICAL", 61, 72], ["Gram-positive", "GENE_OR_GENE_PRODUCT", 74, 87], ["Gram-positive and -negative bacteria", "PROBLEM", 74, 110], ["negative bacteria", "OBSERVATION_MODIFIER", 93, 110]]], ["They identified 2-pyridinecarboxamide in Bacillus samples, including B. anthracis, whose origin was traced to the peptidoglycan macromolecule in the cell wall.", [["samples", "ANATOMY", 50, 57], ["cell wall", "ANATOMY", 149, 158], ["2-pyridinecarboxamide", "CHEMICAL", 16, 37], ["2-pyridinecarboxamide", "CHEMICAL", 16, 37], ["2-pyridinecarboxamide", "SIMPLE_CHEMICAL", 16, 37], ["Bacillus samples", "ORGANISM", 41, 57], ["B. anthracis", "ORGANISM", 69, 81], ["cell wall", "CELLULAR_COMPONENT", 149, 158], ["B. anthracis", "SPECIES", 69, 81], ["B. anthracis", "SPECIES", 69, 81], ["2-pyridinecarboxamide in Bacillus samples", "TREATMENT", 16, 57], ["B. anthracis", "PROBLEM", 69, 81], ["peptidoglycan macromolecule", "OBSERVATION", 114, 141], ["cell", "ANATOMY_MODIFIER", 149, 153], ["wall", "ANATOMY_MODIFIER", 154, 158]]], ["Py-GC-MS analyses of Gram-negative E. coli revealed significant amounts of 3-hydroxymyristic acid derivatives and degradation products .", [["3-hydroxymyristic acid", "CHEMICAL", 75, 97], ["3-hydroxymyristic acid", "CHEMICAL", 75, 97], ["E. coli", "ORGANISM", 35, 42], ["3-hydroxymyristic acid derivatives", "SIMPLE_CHEMICAL", 75, 109], ["E. coli", "SPECIES", 35, 42], ["E. coli", "SPECIES", 35, 42], ["Py", "TEST", 0, 2], ["GC", "TEST", 3, 5], ["MS analyses", "TEST", 6, 17], ["Gram", "TEST", 21, 25], ["E. coli", "TEST", 35, 42], ["hydroxymyristic acid derivatives", "TREATMENT", 77, 109], ["degradation products", "TREATMENT", 114, 134], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["amounts", "OBSERVATION_MODIFIER", 64, 71]]], ["Voorhees et al. used high-resolution Py-MS to identify different Gram-type whole-cell microorganisms.", [["cell", "ANATOMY", 81, 85], ["different Gram", "TEST", 55, 69], ["cell microorganisms", "OBSERVATION", 81, 100]]], ["Twelve bacterial species were analyzed in triplicate.", [["Twelve bacterial species", "PROBLEM", 0, 24], ["bacterial species", "OBSERVATION", 7, 24]]], ["Grampositive bacteria (B. cereus, B. subtilis, B. anthracis, E. faecalis, S. epidermidis, and S. pyogenes) were identified mainly by their carbohydrate biomarker peaks, whereas Gram-negative bacteria (E. aerogenes, Proteus mirabilis, P. aeruginosa, Serratia marcescens, Brucella neotomae, and F. tularensis) yielded mainly lipid-biomarker peaks (Miketova et al., 2003) .", [["carbohydrate", "CHEMICAL", 139, 151], ["B. cereus", "ORGANISM", 23, 32], ["B. subtilis", "ORGANISM", 34, 45], ["B. anthracis", "ORGANISM", 47, 59], ["E. faecalis", "ORGANISM", 61, 72], ["S. epidermidis", "ORGANISM", 74, 88], ["S. pyogenes", "ORGANISM", 94, 105], ["Gram", "GENE_OR_GENE_PRODUCT", 177, 181], ["E. aerogenes", "ORGANISM", 201, 213], ["Proteus mirabilis", "ORGANISM", 215, 232], ["P. aeruginosa", "ORGANISM", 234, 247], ["Serratia marcescens", "ORGANISM", 249, 268], ["Brucella neotomae", "ORGANISM", 270, 287], ["F. tularensis", "ORGANISM", 293, 306], ["lipid", "SIMPLE_CHEMICAL", 323, 328], ["B. cereus", "SPECIES", 23, 32], ["B. subtilis", "SPECIES", 34, 45], ["B. anthracis", "SPECIES", 47, 59], ["E. faecalis", "SPECIES", 61, 72], ["S. epidermidis", "SPECIES", 74, 88], ["S. pyogenes", "SPECIES", 94, 105], ["E. aerogenes", "SPECIES", 201, 213], ["Proteus mirabilis", "SPECIES", 215, 232], ["P. aeruginosa", "SPECIES", 234, 247], ["Serratia marcescens", "SPECIES", 249, 268], ["Brucella neotomae", "SPECIES", 270, 287], ["F. tularensis", "SPECIES", 293, 306], ["B. cereus", "SPECIES", 23, 32], ["B. subtilis", "SPECIES", 34, 45], ["B. anthracis", "SPECIES", 47, 59], ["E. faecalis", "SPECIES", 61, 72], ["S. epidermidis", "SPECIES", 74, 88], ["S. pyogenes", "SPECIES", 94, 105], ["E. aerogenes", "SPECIES", 201, 213], ["Proteus mirabilis", "SPECIES", 215, 232], ["P. aeruginosa", "SPECIES", 234, 247], ["Serratia marcescens", "SPECIES", 249, 268], ["Brucella neotomae", "SPECIES", 270, 287], ["F. tularensis", "SPECIES", 293, 306], ["Grampositive bacteria (B. cereus, B. subtilis, B. anthracis", "PROBLEM", 0, 59], ["E. faecalis", "PROBLEM", 61, 72], ["S. epidermidis", "PROBLEM", 74, 88], ["S. pyogenes", "PROBLEM", 94, 105], ["their carbohydrate biomarker peaks", "TEST", 133, 167], ["Gram", "TEST", 177, 181], ["bacteria", "TEST", 191, 199], ["E. aerogenes", "TEST", 201, 213], ["Proteus mirabilis", "TEST", 215, 232], ["P. aeruginosa", "PROBLEM", 234, 247], ["Serratia marcescens", "PROBLEM", 249, 268], ["Brucella neotomae", "TEST", 270, 287], ["B. cereus", "OBSERVATION_MODIFIER", 23, 32], ["epidermidis", "OBSERVATION", 77, 88]]], ["In many of the studies referred to above, multivariate statistics were used to analyze the pyrolysis mass spectra.", [["the studies", "TEST", 11, 22], ["multivariate statistics", "TEST", 42, 65]]], ["For instance, PCA has been applied to differentiate Salmonella and Vibrio species from their pyrolysis mass spectra (Wilkes et al., 2006) .Pyrolysis-GC-MSPyrolysis methods, such as thermally assisted hydrolysis and methylation (THM) in the presence of tetramethylammonium hydroxide [TMAH; (CH 3 ) 4 NOH], have been widely used in the direct analysis of fatty-acid components of lipids in whole-bacterial cells (David, Tienpont, & Sandra, 2008; Cha et al., 2009) .", [["cells", "ANATOMY", 404, 409], ["THM", "CHEMICAL", 228, 231], ["tetramethylammonium hydroxide", "CHEMICAL", 252, 281], ["TMAH", "CHEMICAL", 283, 287], ["NOH", "CHEMICAL", 299, 302], ["fatty-acid", "CHEMICAL", 353, 363], ["tetramethylammonium hydroxide", "CHEMICAL", 252, 281], ["TMAH", "CHEMICAL", 283, 287], ["(CH 3 ) 4 NOH", "CHEMICAL", 289, 302], ["fatty-acid", "CHEMICAL", 353, 363], ["tetramethylammonium hydroxide", "SIMPLE_CHEMICAL", 252, 281], ["(CH 3 ) 4 NOH", "SIMPLE_CHEMICAL", 289, 302], ["fatty-acid", "SIMPLE_CHEMICAL", 353, 363], ["lipids", "SIMPLE_CHEMICAL", 378, 384], ["whole-bacterial cells", "CELL", 388, 409], ["whole-bacterial cells", "CELL_TYPE", 388, 409], ["Salmonella", "SPECIES", 52, 62], ["PCA", "TREATMENT", 14, 17], ["Salmonella", "PROBLEM", 52, 62], ["Vibrio species", "PROBLEM", 67, 81], ["Pyrolysis", "TEST", 139, 148], ["GC-MSPyrolysis methods", "PROBLEM", 149, 171], ["thermally assisted hydrolysis", "TREATMENT", 181, 210], ["methylation (THM", "TREATMENT", 215, 231], ["tetramethylammonium hydroxide [TMAH", "TREATMENT", 252, 287], ["fatty-acid components", "TREATMENT", 353, 374], ["lipids", "TREATMENT", 378, 384]]], ["Recently, phospholipids were directly identified on whole cells of E. coli with THM-GC in the presence of TMAH and MALDI-MS, with on-probe sample pretreatment without the need for any tedious sample preparation (Ishida et al., 2006) .ICP-MS/SIMSInductively coupled plasma mass spectrometry (ICP-MS) has been used in the chemical characterization of trace and ultratrace elements in biological materials, such as bacteria, fungi, and viruses Gikunju et al., 2004; Jackson, Ranville, & Neal, 2005; Li, Armstrong, & Houk, 2005; Beauchemin, 2006) .", [["whole cells", "ANATOMY", 52, 63], ["sample", "ANATOMY", 192, 198], ["THM", "CHEMICAL", 80, 83], ["TMAH", "CHEMICAL", 106, 110], ["THM-GC", "CHEMICAL", 80, 86], ["phospholipids", "SIMPLE_CHEMICAL", 10, 23], ["cells", "CELL", 58, 63], ["E. coli", "ORGANISM", 67, 74], ["THM-GC", "CELL", 80, 86], ["TMAH", "SIMPLE_CHEMICAL", 106, 110], ["E. coli", "SPECIES", 67, 74], ["E. coli", "SPECIES", 67, 74], ["phospholipids", "TEST", 10, 23], ["E. coli", "PROBLEM", 67, 74], ["THM", "TEST", 80, 83], ["TMAH", "PROBLEM", 106, 110], ["MALDI", "TEST", 115, 120], ["MS", "PROBLEM", 121, 123], ["any tedious sample preparation", "TREATMENT", 180, 210], ["ICP", "TEST", 234, 237], ["MS", "PROBLEM", 238, 240], ["SIMSInductively", "PROBLEM", 241, 256], ["plasma mass spectrometry", "TEST", 265, 289], ["ICP", "TEST", 291, 294], ["trace and ultratrace elements in biological materials", "PROBLEM", 349, 402], ["bacteria", "PROBLEM", 412, 420], ["fungi", "PROBLEM", 422, 427], ["E. coli", "OBSERVATION_MODIFIER", 67, 74], ["trace", "OBSERVATION", 349, 354], ["ultratrace elements", "OBSERVATION", 359, 378]]], ["Knowledge of the amounts of these trace elements and their speciation is important to understand the toxicological behavior of organisms.", [["these trace elements", "PROBLEM", 28, 48]]], ["ICP-MS has several attractive features for trace element studies, including rapid multielement analysis and very good detection limits of bacteria in suspension (Gikunju et al., 2004) .", [["ICP", "TEST", 0, 3], ["trace element studies", "PROBLEM", 43, 64], ["rapid multielement analysis", "TEST", 76, 103], ["bacteria", "PROBLEM", 138, 146]]], ["The detection and identification of B. subtilis spores, B. subtilis vegetative cells, and B. thuringiensis with an inorganic-chemical fingerprint obtained with direct injection ICP-MS might be useful to detect biologicalwarfare agents (Gikunju et al., 2004) .", [["vegetative cells", "ANATOMY", 68, 84], ["B. subtilis spores", "ORGANISM", 36, 54], ["B. subtilis", "ORGANISM", 56, 67], ["vegetative cells", "CELL", 68, 84], ["B. thuringiensis", "ORGANISM", 90, 106], ["B. subtilis vegetative cells", "CELL_LINE", 56, 84], ["B. subtilis", "SPECIES", 36, 47], ["B. subtilis", "SPECIES", 56, 67], ["B. thuringiensis", "SPECIES", 90, 106], ["B. subtilis", "SPECIES", 36, 47], ["B. subtilis", "SPECIES", 56, 67], ["B. thuringiensis", "SPECIES", 90, 106], ["The detection", "TEST", 0, 13], ["B. subtilis spores", "PROBLEM", 36, 54], ["B. subtilis vegetative cells", "PROBLEM", 56, 84], ["B. thuringiensis", "PROBLEM", 90, 106], ["direct injection ICP", "TREATMENT", 160, 180], ["vegetative cells", "OBSERVATION", 68, 84]]], ["This method reveals unique chemical signatures that reflect the processing history of each Bacillus organism.ICP-MS/SIMSCliff et al. demonstrated the use of TOF secondary-ion mass spectrometry (SIMS) to identify B. subtilis spores that were grown in various media, based on their elemental signatures.", [["spores", "ANATOMY", 224, 230], ["Bacillus organism", "ORGANISM", 91, 108], ["B. subtilis", "ORGANISM", 212, 223], ["B. subtilis", "SPECIES", 212, 223], ["B. subtilis", "SPECIES", 212, 223], ["This method", "TEST", 0, 11], ["unique chemical signatures", "PROBLEM", 20, 46], ["each Bacillus organism", "PROBLEM", 86, 108], ["ICP", "TEST", 109, 112], ["TOF", "TREATMENT", 157, 160], ["ion mass spectrometry", "PROBLEM", 171, 192], ["B. subtilis spores", "PROBLEM", 212, 230], ["Bacillus organism", "OBSERVATION", 91, 108]]], ["The TOF-SIMS signatures consist of 16 elemental intensities (Cliff et al., 2005) .", [["The TOF", "TEST", 0, 7], ["SIMS signatures", "TEST", 8, 23]]], ["Thompson et al. used TOF-SIMS to distinguish between spores and vegetative bacterial cells of B. megaterium.", [["spores", "ANATOMY", 53, 59], ["cells", "ANATOMY", 85, 90], ["vegetative bacterial cells", "CELL", 64, 90], ["B. megaterium", "ORGANISM", 94, 107], ["vegetative bacterial cells", "CELL_TYPE", 64, 90], ["B. megaterium", "SPECIES", 94, 107], ["B. megaterium", "SPECIES", 94, 107], ["TOF", "TEST", 21, 24], ["spores", "PROBLEM", 53, 59], ["vegetative bacterial cells of B. megaterium", "PROBLEM", 64, 107], ["vegetative bacterial cells", "OBSERVATION", 64, 90]]], ["The differentiation was based on the surfacelipid profiles (Thompson et al., 2004) .E. MS of Nucleic AcidsNucleic acid-based techniques for microbial analysis rely on the genetic conservation within a species and genetic variability among species.", [["AcidsNucleic acid", "CHEMICAL", 101, 118], ["Nucleic AcidsNucleic acid", "SIMPLE_CHEMICAL", 93, 118], ["Nucleic AcidsNucleic acid", "TEST", 93, 118], ["microbial analysis", "TEST", 140, 158], ["a species", "TEST", 199, 208], ["genetic variability among species", "PROBLEM", 213, 246]]], ["Although conventional biochemical analysis remains an important method in clinical microbiology laboratories, nucleic acid-based methods have become popular in diagnostic microbiology.", [["nucleic acid", "CHEMICAL", 110, 122], ["nucleic acid", "SIMPLE_CHEMICAL", 110, 122], ["conventional biochemical analysis", "TEST", 9, 42], ["nucleic acid", "TEST", 110, 122]]], ["Genotyping methods to analyze nucleic acids might involve hybridization, primer extension, ligation, and cleavage, or a combination thereof (Monis & Giglio, 2006; Mothershed & Whitney, 2006; Klouche & Schroder, 2008) .", [["nucleic acids", "CHEMICAL", 30, 43], ["Genotyping methods", "TREATMENT", 0, 18], ["nucleic acids", "TREATMENT", 30, 43], ["ligation", "TREATMENT", 91, 99], ["ligation", "OBSERVATION", 91, 99]]], ["The device to read out the measurements can be a gel reader, a plate reader, or an array reader, among others.", [["The device", "TREATMENT", 0, 10], ["a plate reader", "TREATMENT", 61, 75]]], ["MALDI-MS is considered to be an alternative tool to sequence DNA.", [["DNA", "CELLULAR_COMPONENT", 61, 64]]], ["However, some technical problems, such as adduct formation and limited sequence length, have led to the use of MS primarily to analyze DNA fragment profiles or single nucleotide polymorphisms (SNPs).", [["DNA", "CELLULAR_COMPONENT", 135, 138], ["some technical problems", "PROBLEM", 9, 32], ["adduct formation", "PROBLEM", 42, 58], ["MS", "TREATMENT", 111, 113], ["DNA fragment profiles", "PROBLEM", 135, 156], ["single nucleotide polymorphisms (SNPs)", "PROBLEM", 160, 198]]], ["ESI-MS can detect large and multiply charged PCR products (Mayr et al., 2005) .", [["ESI", "TEST", 0, 3], ["large", "OBSERVATION_MODIFIER", 18, 23]]], ["Therefore, accurate masses of the PCR products, obtained with high-resolution ESI-MS, have been used to determine their base compositions .", [["the PCR products", "TEST", 30, 46], ["accurate", "OBSERVATION_MODIFIER", 11, 19], ["masses", "OBSERVATION", 20, 26]]], ["Generally, the mass spectra of nucleic acid products or their fragments are matched with theoretical ones in nucleic acid sequence databases to identify the species.", [["nucleic acid", "CHEMICAL", 31, 43], ["nucleic acid", "CHEMICAL", 109, 121], ["nucleic acid products", "PROTEIN", 31, 52], ["the mass spectra of nucleic acid products", "PROBLEM", 11, 52], ["their fragments", "PROBLEM", 56, 71], ["nucleic acid sequence databases", "TEST", 109, 140], ["mass", "OBSERVATION", 15, 19], ["nucleic acid", "OBSERVATION", 31, 43], ["fragments", "OBSERVATION_MODIFIER", 62, 71]]], ["The advantage and disadvantages of genotyping methods have been reviewed elsewhere (Sobrino, Brion, & Carracedo, 2005) .", [["genotyping methods", "TREATMENT", 35, 53]]], ["PCR-amplification methods are able to detect a few tens of microbial cells and might be applied to the analysis of non-culturable microorganisms.", [["cells", "ANATOMY", 69, 74], ["microbial cells", "CELL", 59, 74], ["microbial cells", "CELL_TYPE", 59, 74], ["PCR", "TEST", 0, 3], ["amplification methods", "TEST", 4, 25], ["microbial cells", "PROBLEM", 59, 74], ["the analysis", "TEST", 99, 111], ["non-culturable microorganisms", "PROBLEM", 115, 144], ["microbial cells", "OBSERVATION", 59, 74]]], ["The major procedures for microbial analysis include cell lysis, DNA extraction, amplification, and PCR-product analysis.", [["cell", "ANATOMY", 52, 56], ["cell", "CELL", 52, 56], ["DNA", "CELLULAR_COMPONENT", 64, 67], ["microbial analysis", "TEST", 25, 43], ["cell lysis", "TREATMENT", 52, 62], ["DNA extraction", "TREATMENT", 64, 78], ["amplification", "TEST", 80, 93], ["PCR-product analysis", "TEST", 99, 119], ["cell lysis", "OBSERVATION", 52, 62]]], ["The sample IDENTIFICATION OF PATHOGENS BY MASS SPECTROMETRY & workup time may be less than that for conventional culturing methods.", [["MASS SPECTROMETRY", "TEST", 42, 59], ["workup", "TEST", 62, 68], ["conventional culturing methods", "TEST", 100, 130]]], ["Notably, some procedures are labor-intensive and the PCR techniques might require additional steps to remove potential inhibitors from samples.", [["samples", "ANATOMY", 135, 142], ["labor", "PROBLEM", 29, 34], ["the PCR techniques", "TEST", 49, 67], ["additional steps", "TREATMENT", 82, 98], ["potential inhibitors", "TREATMENT", 109, 129]]], ["The major advantage of using a mass spectrometer as a read-out device, in addition to the speed of analysis, is its ability to measure masses of oligonucleotides.", [["a mass spectrometer", "TREATMENT", 29, 48], ["device", "TREATMENT", 63, 69], ["masses of oligonucleotides", "PROBLEM", 135, 161], ["masses", "OBSERVATION", 135, 141]]], ["The molecular mass that is directly related to the nucleotide composition is more accurate than other sequence-related parameters such as migration times.E. MS of Nucleic AcidsBecause the 16 S rRNA gene is universally distributed and highly conserved, it has been widely used to differentiate microbial species.", [["nucleotide", "CHEMICAL", 51, 61], ["nucleotide", "CHEMICAL", 51, 61], ["16 S rRNA gene", "DNA", 188, 202], ["The molecular mass", "PROBLEM", 0, 18], ["Nucleic AcidsBecause", "TEST", 163, 183], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["microbial species", "OBSERVATION", 293, 310]]], ["Restriction-fragment patterns are obtained from digestion of the PCR products with restriction enzymes.", [["restriction enzymes", "PROTEIN", 83, 102], ["Restriction-fragment patterns", "PROBLEM", 0, 29], ["the PCR products", "TREATMENT", 61, 77], ["restriction enzymes", "TEST", 83, 102], ["fragment patterns", "OBSERVATION_MODIFIER", 12, 29]]], ["The reduced size of the digested PCR products also favors ionization and mass analysis.", [["digested PCR products", "PROTEIN", 24, 45], ["the digested PCR products", "TREATMENT", 20, 45], ["mass analysis", "TEST", 73, 86], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16], ["mass", "OBSERVATION", 73, 77]]], ["MALDI-MS has been successfully applied to differentiate microbial species by profiling the restriction digests of DNA (Taranenko et al., 2002) .", [["DNA", "CELLULAR_COMPONENT", 114, 117], ["MS", "PROBLEM", 6, 8], ["microbial species", "PROBLEM", 56, 73]]], ["This method can detect hepatitis B and C viruses (HBVand HCV) in human-serum samples (Hong et al., 2004; Kim et al., 2005; Oh et al., 2008) .", [["serum samples", "ANATOMY", 71, 84], ["hepatitis B", "DISEASE", 23, 34], ["hepatitis B and C viruses", "ORGANISM", 23, 48], ["HBVand HCV", "ORGANISM", 50, 60], ["human", "ORGANISM", 65, 70], ["serum samples", "ORGANISM_SUBSTANCE", 71, 84], ["human", "SPECIES", 65, 70], ["hepatitis B", "SPECIES", 23, 34], ["HBVand", "SPECIES", 50, 56], ["HCV", "SPECIES", 57, 60], ["human", "SPECIES", 65, 70], ["This method", "TEST", 0, 11], ["hepatitis B and C viruses (HBVand HCV", "PROBLEM", 23, 60], ["serum samples", "TEST", 71, 84]]], ["It has been used to analyze as few as 100 copies of hepatitis B virus gene per milliliter of serum and differentiated among wild-type and variant viruses (Ho et al., 2004) .", [["serum", "ANATOMY", 93, 98], ["hepatitis B", "DISEASE", 52, 63], ["hepatitis B virus", "ORGANISM", 52, 69], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["hepatitis B virus gene", "DNA", 52, 74], ["hepatitis B virus", "SPECIES", 52, 69], ["hepatitis B virus", "SPECIES", 52, 69], ["hepatitis B virus gene", "TREATMENT", 52, 74], ["serum", "TEST", 93, 98]]], ["The limitation of these approaches in accurate microbial identification is the resolution of length heterogeneities of marker genes among species. von Wintzingerode et al. (2002) developed a method of microbial identification with the base-specific cleavage of PCR products.", [["marker genes", "DNA", 119, 131], ["PCR products", "PROTEIN", 261, 273], ["length heterogeneities of marker genes among species", "PROBLEM", 93, 145], ["PCR products", "TREATMENT", 261, 273], ["length", "OBSERVATION_MODIFIER", 93, 99]]], ["Amplification of 16S rDNA marker sequences was followed by enzyme-mediated fragmentation at T-specific sites.", [["16S", "GENE_OR_GENE_PRODUCT", 17, 20], ["rDNA", "CELLULAR_COMPONENT", 21, 25], ["16S rDNA marker sequences", "DNA", 17, 42], ["enzyme", "PROTEIN", 59, 65], ["T-specific sites", "DNA", 92, 108], ["16S rDNA marker sequences", "TEST", 17, 42], ["enzyme-mediated fragmentation", "PROBLEM", 59, 88], ["fragmentation", "OBSERVATION", 75, 88]]], ["The basespecific cleavage yielded useful species-specific fragments, and allowed differentiation of several cultured Bordetella species and as-yet-uncultured bacteria.", [["fragments", "ANATOMY", 58, 67], ["Bordetella species", "ORGANISM", 117, 135], ["The basespecific cleavage", "PROBLEM", 0, 25], ["useful species", "PROBLEM", 34, 48], ["specific fragments", "PROBLEM", 49, 67], ["several cultured Bordetella species", "TEST", 100, 135], ["uncultured bacteria", "PROBLEM", 147, 166], ["specific", "OBSERVATION_MODIFIER", 49, 57], ["fragments", "OBSERVATION", 58, 67]]], ["Another comparative-sequencing method, multilocus sequence typing (MLST), was used to analyze N. meningitides by comparing the MALDI spectra of MLST loci to reference sequences in the public MLST database (Honisch et al., 2007) .", [["N. meningitides", "ORGANISM", 94, 109], ["MLST loci", "DNA", 144, 153], ["N. meningitides", "SPECIES", 94, 109], ["N. meningitides", "SPECIES", 94, 109], ["Another comparative-sequencing method", "TEST", 0, 37], ["multilocus sequence typing", "TEST", 39, 65]]], ["This method is based on PCR of several housekeeping genes.", [["housekeeping genes", "DNA", 39, 57], ["PCR", "TEST", 24, 27]]], ["The variations in the sequences of multiple loci that are derived from base-specific RNA cleavage support the identification of pathogens.E. MS of Nucleic AcidsThe homogeneous base-specific cleavage of PCR-amplified and transcribed 16S rRNA gene was analyzed with MALDI-MS to identify mycobacteria at the species level (Lefmann et al., 2004) .", [["Nucleic Acids", "SIMPLE_CHEMICAL", 147, 160], ["16S", "GENE_OR_GENE_PRODUCT", 232, 235], ["rRNA", "CELLULAR_COMPONENT", 236, 240], ["16S rRNA gene", "DNA", 232, 245], ["multiple loci", "PROBLEM", 35, 48], ["pathogens", "PROBLEM", 128, 137], ["Nucleic Acids", "TEST", 147, 160], ["PCR", "TEST", 202, 205], ["MALDI", "TEST", 264, 269], ["mycobacteria", "PROBLEM", 285, 297], ["pathogens", "OBSERVATION", 128, 137], ["mycobacteria", "OBSERVATION", 285, 297]]], ["The MALDI-MS analysis of RNA is superior to that of DNA because RNA that is transcribed from DNA is more stable.", [["DNA", "CELLULAR_COMPONENT", 52, 55], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["The MALDI", "TREATMENT", 0, 9], ["MS analysis of RNA", "PROBLEM", 10, 28], ["RNA", "PROBLEM", 64, 67], ["stable", "OBSERVATION_MODIFIER", 105, 111]]], ["The 2 0 OH group on the sugar ring reduces N-glycosylic bond fragmentation (Tang, Zhu, & Smith, 1997; Tost & Gut, 2006) .E. MS of Nucleic AcidsSingle nucleotide polymorphisms (SNPs) represent single base changes that occur at a specific position in a genome.", [["OH", "CHEMICAL", 8, 10], ["N-glycosylic", "CHEMICAL", 43, 55], ["OH", "CHEMICAL", 8, 10], ["sugar", "CHEMICAL", 24, 29], ["N-glycosylic", "CHEMICAL", 43, 55], ["2 0 OH", "SIMPLE_CHEMICAL", 4, 10], ["sugar ring", "SIMPLE_CHEMICAL", 24, 34], ["Nucleic AcidsSingle nucleotide", "GENE_OR_GENE_PRODUCT", 130, 160], ["the sugar ring", "TREATMENT", 20, 34], ["glycosylic bond fragmentation", "PROBLEM", 45, 74], ["Nucleic AcidsSingle nucleotide polymorphisms (SNPs)", "TREATMENT", 130, 181], ["single base changes", "PROBLEM", 192, 211], ["Gut", "ANATOMY", 109, 112]]], ["The MALDI mass spectra obtained from eight SNPs in the precore/ basal core promoter of HBV were used to differentiate wild-type and mutant samples (Lau et al., 2007) .", [["samples", "ANATOMY", 139, 146], ["HBV", "ORGANISM", 87, 90], ["precore/ basal core promoter", "DNA", 55, 83], ["HBV", "SPECIES", 87, 90], ["The MALDI mass spectra", "PROBLEM", 0, 22], ["eight SNPs", "TEST", 37, 47], ["the precore/ basal core promoter", "TREATMENT", 51, 83], ["HBV", "PROBLEM", 87, 90], ["mass", "OBSERVATION", 10, 14], ["basal", "ANATOMY_MODIFIER", 64, 69], ["HBV", "OBSERVATION", 87, 90]]], ["The PCR extension of primers that were designed to be annealed at the polymorphic site yielded distinguishable genotype-specific SNPs, even though their mass differences were in a narrow range of 9-24 Da.", [["polymorphic site", "DNA", 70, 86], ["genotype-specific SNPs", "DNA", 111, 133], ["The PCR extension of primers", "PROBLEM", 0, 28], ["distinguishable genotype-specific SNPs", "PROBLEM", 95, 133], ["their mass differences", "PROBLEM", 147, 169], ["genotype-specific SNPs", "OBSERVATION", 111, 133], ["mass", "OBSERVATION", 153, 157]]], ["An SNP within the fumC gene was found to differentiate between the hypervirulent ET-15 strain and other ET-37 complex strains of N. meningitidis (Lowe, Diggle, & Clarke, 2004) .", [["SNP", "CHEMICAL", 3, 6], ["fumC", "GENE_OR_GENE_PRODUCT", 18, 22], ["ET-15 strain", "ORGANISM", 81, 93], ["ET-37 complex", "ORGANISM", 104, 117], ["N. meningitidis", "ORGANISM", 129, 144], ["fumC gene", "DNA", 18, 27], ["N. meningitidis", "SPECIES", 129, 144], ["hypervirulent ET-15", "SPECIES", 67, 86], ["N. meningitidis", "SPECIES", 129, 144], ["An SNP", "TEST", 0, 6], ["the hypervirulent ET-15 strain", "PROBLEM", 63, 93], ["N. meningitidis", "PROBLEM", 129, 144], ["hypervirulent", "OBSERVATION", 67, 80], ["meningitidis", "OBSERVATION", 132, 144]]], ["Ilina et al. (2005) employed a similar MALDI-MS approach to genotype HCV from HCV-positive blood sera or plasma.", [["blood sera", "ANATOMY", 91, 101], ["plasma", "ANATOMY", 105, 111], ["HCV", "ORGANISM", 69, 72], ["HCV", "ORGANISM", 78, 81], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["sera", "ORGANISM_SUBSTANCE", 97, 101], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["HCV", "SPECIES", 69, 72], ["HCV", "SPECIES", 78, 81], ["a similar MALDI", "TREATMENT", 29, 44], ["genotype HCV", "PROBLEM", 60, 72], ["HCV", "PROBLEM", 78, 81], ["blood sera", "TEST", 91, 101]]], ["They designed three oligonucleotide primers to detect two sets of genotypespecific SNPs.", [["genotypespecific SNPs", "DNA", 66, 87], ["three oligonucleotide primers", "TREATMENT", 14, 43], ["genotypespecific SNPs", "PROBLEM", 66, 87]]], ["The proposed method was an accurate and efficient method for HCV genotyping based on minisequencing.", [["HCV", "SPECIES", 61, 64], ["HCV genotyping", "TREATMENT", 61, 75]]], ["Although the occurrence of novel mutations limits the use of genotypic methods based on single nucleotide differences between strains, genotypic assays with base-specific cleavage strategies detect new strains.E. MS of Nucleic AcidsA method called Triangulation Identification for the Genetic Evaluation of Risks (TIGER), to analyze microbial mixtures, has been proposed .", [["novel mutations", "PROBLEM", 27, 42], ["genotypic methods", "TREATMENT", 61, 78], ["single nucleotide differences between strains", "PROBLEM", 88, 133], ["genotypic assays", "TEST", 135, 151], ["base-specific cleavage strategies", "TREATMENT", 157, 190], ["new strains", "PROBLEM", 198, 209], ["the Genetic Evaluation", "TEST", 281, 303]]], ["The bacterium B. anthracis, the Poxyviridae family, Alphaviruses , Acinetobacter species , adenovirus (Russell et al., 2006) , Campylobacter species (Hannis et al., 2008) , and the Enterobacteriaceae family (Baldwin et al., 2009) were successfully identified with this approach.", [["Campylobacter species", "DISEASE", 127, 148], ["bacterium", "ORGANISM", 4, 13], ["B. anthracis", "ORGANISM", 14, 26], ["Poxyviridae", "GENE_OR_GENE_PRODUCT", 32, 43], ["Alphaviruses", "GENE_OR_GENE_PRODUCT", 52, 64], ["Acinetobacter species", "ORGANISM", 67, 88], ["adenovirus", "ORGANISM", 91, 101], ["Campylobacter species", "ORGANISM", 127, 148], ["B. anthracis", "SPECIES", 14, 26], ["B. anthracis", "SPECIES", 14, 26], ["The bacterium B. anthracis", "PROBLEM", 0, 26], ["Alphaviruses", "PROBLEM", 52, 64], ["Acinetobacter species", "PROBLEM", 67, 88], ["adenovirus", "PROBLEM", 91, 101], ["Campylobacter species", "PROBLEM", 127, 148], ["this approach", "TREATMENT", 264, 277]]], ["It uses high-resolution ESI-FT-ICR/-TOF MS to analyze multiple PCR products to allow the base compositions (A, T, G, and C, base counts) obtained from multiple primer pairs to be accurately deduced.", [["multiple PCR products", "TREATMENT", 54, 75], ["the base compositions", "TEST", 85, 106], ["A, T, G", "TEST", 108, 115], ["base counts", "TEST", 124, 135], ["multiple primer pairs", "PROBLEM", 151, 172]]], ["The first step involves extraction of all nucleic acids that are present in a sample.", [["all nucleic acids", "PROBLEM", 38, 55], ["nucleic acids", "OBSERVATION", 42, 55]]], ["Aliquots of the nucleic-acid solution are amplified with various primers.", [["Aliquots", "ANATOMY", 0, 8], ["nucleic-acid", "CHEMICAL", 16, 28], ["the nucleic-acid solution", "TREATMENT", 12, 37], ["various primers", "TREATMENT", 57, 72]]], ["The PCR primers target universally distributed and highly conserved regions of microbial genes (such as 16S and 23S DNA).", [["DNA", "CELLULAR_COMPONENT", 116, 119], ["PCR primers", "DNA", 4, 15], ["microbial genes", "DNA", 79, 94], ["16S", "DNA", 104, 107], ["23S DNA", "DNA", 112, 119], ["The PCR primers", "TEST", 0, 15], ["microbial genes (such as 16S and 23S DNA", "PROBLEM", 79, 119], ["microbial genes", "OBSERVATION", 79, 94]]], ["The second step is to use MS to measure accurately the masses of the PCR products in a size range of around 100 bp (and a mass of ca.", [["the PCR products", "TREATMENT", 65, 81], ["bp", "TEST", 112, 114], ["a mass of ca", "PROBLEM", 120, 132], ["masses", "OBSERVATION", 55, 61], ["size", "OBSERVATION_MODIFIER", 87, 91], ["mass", "OBSERVATION", 122, 126], ["ca", "OBSERVATION", 130, 132]]], ["These base compositions are employed to ''triangulate'' the identities of most pathogens.", [["These base compositions", "TREATMENT", 0, 23], ["most pathogens", "PROBLEM", 74, 88], ["most", "OBSERVATION_MODIFIER", 74, 78], ["pathogens", "OBSERVATION", 79, 88]]], ["Additional primers that are targeted to variable regions of specific microbial genomes are used in the highresolution genotyping of specific species.", [["microbial genomes", "DNA", 69, 86], ["Additional primers", "TREATMENT", 0, 18], ["specific microbial genomes", "PROBLEM", 60, 86], ["specific", "OBSERVATION_MODIFIER", 60, 68], ["microbial genomes", "OBSERVATION", 69, 86], ["specific species", "OBSERVATION", 132, 148]]], ["To deduce the base compositions based on the mass of PCR products, use of mass spectrometers with high mass accuracy is a must.E. MS of Nucleic AcidsThis PCR-ESI-MS approach has also been used to detect and type the strains of S. aureus isolates Wolk et al., 2009 ), a diverse collection of human and avian influenza viruses (Sampath et al., 2007b) , orthopoxviruses , and more recently, Ehrlichia species from patients suspected of having ehrlichiosis (Eshoo et al., 2010) .III. APPLICATIONSMass spectrometry (MS) is poised to take an increasingly important role in clinical chemistry (Ho & Reddy, 2010; Marvin, Roberts, & Fay, 2003) , environmental monitoring, and biodefense (Demirev & Fenselau, 2008b) .", [["avian influenza viruses", "DISEASE", 301, 324], ["Ehrlichia species", "DISEASE", 388, 405], ["ehrlichiosis", "DISEASE", 440, 452], ["S. aureus", "ORGANISM", 227, 236], ["human", "ORGANISM", 291, 296], ["avian influenza viruses", "ORGANISM", 301, 324], ["Ehrlichia", "ORGANISM", 388, 397], ["patients", "ORGANISM", 411, 419], ["ehrlichiosis", "ORGANISM", 440, 452], ["S. aureus", "SPECIES", 227, 236], ["human", "SPECIES", 291, 296], ["avian influenza viruses", "SPECIES", 301, 324], ["patients", "SPECIES", 411, 419], ["S. aureus", "SPECIES", 227, 236], ["human", "SPECIES", 291, 296], ["the base compositions", "TREATMENT", 10, 31], ["PCR products", "TREATMENT", 53, 65], ["mass spectrometers", "PROBLEM", 74, 92], ["high mass accuracy", "PROBLEM", 98, 116], ["Nucleic Acids", "TEST", 136, 149], ["This PCR", "TEST", 149, 157], ["ESI", "TEST", 158, 161], ["S. aureus isolates", "PROBLEM", 227, 245], ["a diverse collection of human and avian influenza viruses", "PROBLEM", 267, 324], ["orthopoxviruses", "PROBLEM", 351, 366], ["Ehrlichia species", "PROBLEM", 388, 405], ["ehrlichiosis", "PROBLEM", 440, 452], ["environmental monitoring", "TEST", 637, 661], ["base", "ANATOMY_MODIFIER", 14, 18], ["mass", "OBSERVATION", 45, 49], ["high", "OBSERVATION_MODIFIER", 98, 102], ["mass", "OBSERVATION", 103, 107], ["influenza viruses", "OBSERVATION", 307, 324], ["ehrlichiosis", "OBSERVATION", 440, 452]]], ["Because mass analyzers provide flexibility, sensitivity, specificity, and rich information (qualitative/quantitative), various MS-based methods have been used for accurate microbial identification.", [["mass analyzers", "PROBLEM", 8, 22], ["sensitivity", "TEST", 44, 55], ["various MS-based methods", "TREATMENT", 119, 143], ["accurate microbial identification", "TEST", 163, 196]]], ["As mentioned above, each method has its strength and weaknesses.", [["weaknesses", "PROBLEM", 53, 63]]], ["MALDI-MS is a rapid, sensitive, simple method.", [["a rapid, sensitive, simple method", "PROBLEM", 12, 45]]], ["Therefore, it is very suitable for direct biomarker profiling of microorganisms.", [["direct biomarker profiling", "TEST", 35, 61], ["microorganisms", "PROBLEM", 65, 79]]], ["MALDI-MS/MS (top-down or bottom-up approaches) might avoid the reproducibility problems by analyzing sequence information of specific biomarkers.", [["MALDI", "TEST", 0, 5], ["MS", "PROBLEM", 9, 11], ["the reproducibility problems", "PROBLEM", 59, 87], ["specific biomarkers", "TEST", 125, 144]]], ["LC (CE)-MS/MS separates and analyzes biomarkers such as proteins or peptides belonging to a microorganism and provides accuracy and selectivity.", [["CE", "CHEMICAL", 4, 6], ["LC (CE", "TEST", 0, 6], ["MS/MS separates", "PROBLEM", 8, 23], ["analyzes biomarkers", "TEST", 28, 47], ["proteins or peptides", "PROBLEM", 56, 76], ["a microorganism", "PROBLEM", 90, 105]]], ["Although the speed of analysis is reduced, microbial mixtures can be analyzed without culture isolation.", [["the speed of analysis", "TEST", 9, 30], ["microbial mixtures", "TREATMENT", 43, 61], ["culture isolation", "TREATMENT", 86, 103]]], ["PCR-MS provides the best detection limit and might indentify non-culturable microorganisms.", [["PCR", "TEST", 0, 3], ["non-culturable microorganisms", "PROBLEM", 61, 90]]], ["However, designing primers requires knowledge of target nucleic acid sequences and the sample workup steps can be labor-intensive.", [["nucleic acid", "CHEMICAL", 56, 68], ["target nucleic acid sequences", "PROBLEM", 49, 78], ["the sample workup steps", "TEST", 83, 106], ["labor", "PROBLEM", 114, 119]]], ["In general, the MS-based approaches require less time for microbial analysis than most conventional methods.", [["microbial analysis", "TEST", 58, 76]]], ["This section provides some examples of MS application.III. APPLICATIONSDirect MALDI-TOFMS analysis of intact bacteria cells might differentiate different bacterial species or subspecies in many clinical-microbiology laboratories (Carbonnelle et al., 2007; Eigner et al., 2009; Reich et al., 2009) .", [["cells", "ANATOMY", 118, 123], ["bacteria cells", "CELL", 109, 123], ["This section", "TREATMENT", 0, 12], ["MS application", "TREATMENT", 39, 53], ["APPLICATIONSDirect MALDI", "TEST", 59, 83], ["intact bacteria cells", "PROBLEM", 102, 123], ["different bacterial species", "PROBLEM", 144, 171], ["bacteria cells", "OBSERVATION", 109, 123], ["bacterial species", "OBSERVATION", 154, 171], ["subspecies", "OBSERVATION_MODIFIER", 175, 185]]], ["Degand et al. (2008) identified non-fermenting bacilli that were recovered from cystic-fibrosis patients with protein fingerprinting.", [["cystic-fibrosis", "DISEASE", 80, 95], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["non-fermenting bacilli", "PROBLEM", 32, 54], ["cystic-fibrosis", "PROBLEM", 80, 95], ["protein fingerprinting", "PROBLEM", 110, 132], ["bacilli", "OBSERVATION", 47, 54], ["cystic", "OBSERVATION_MODIFIER", 80, 86], ["fibrosis", "OBSERVATION", 87, 95], ["protein fingerprinting", "OBSERVATION", 110, 132]]], ["MALDI-MS protein profiles obtained have been used to differentiate methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA), which are responsible for various hospital-acquired infections (Edwards-Jones et al., 2000; Du et al., 2002) .", [["methicillin", "CHEMICAL", 67, 78], ["methicillin", "CHEMICAL", 110, 121], ["infections", "DISEASE", 204, 214], ["methicillin", "CHEMICAL", 67, 78], ["methicillin", "CHEMICAL", 110, 121], ["methicillin-resistant S. aureus", "ORGANISM", 67, 98], ["MRSA", "ORGANISM", 100, 104], ["methicillin-susceptible S. aureus", "ORGANISM", 110, 143], ["MSSA", "CANCER", 145, 149], ["S. aureus", "SPECIES", 89, 98], ["MRSA", "SPECIES", 100, 104], ["S. aureus", "SPECIES", 134, 143], ["S. aureus", "SPECIES", 89, 98], ["MRSA", "SPECIES", 100, 104], ["S. aureus", "SPECIES", 134, 143], ["MSSA", "SPECIES", 145, 149], ["MALDI-MS protein profiles", "TEST", 0, 25], ["methicillin", "TEST", 67, 78], ["resistant S. aureus", "PROBLEM", 79, 98], ["MRSA", "PROBLEM", 100, 104], ["methicillin-susceptible S. aureus", "PROBLEM", 110, 143], ["MSSA", "PROBLEM", 145, 149], ["aureus", "OBSERVATION", 92, 98], ["aureus", "OBSERVATION", 137, 143], ["MSSA", "OBSERVATION", 145, 149]]], ["The strain-specific MALDI-TOFMS differentiation has been demonstrated with intact cells from 20 Staphylococcal isolates, to rapidly distinguish between the MRSA and MSSA and, therefore, to support the proper treatment of S. aureus infections in light of their resistance to antibiotics (Edwards-Jones et al., 2000) .", [["cells", "ANATOMY", 82, 87], ["MRSA", "DISEASE", 156, 160], ["S. aureus infections", "DISEASE", 221, 241], ["cells", "CELL", 82, 87], ["MSSA", "CANCER", 165, 169], ["S. aureus", "ORGANISM", 221, 230], ["MRSA", "SPECIES", 156, 160], ["S. aureus", "SPECIES", 221, 230], ["MRSA", "SPECIES", 156, 160], ["MSSA", "SPECIES", 165, 169], ["S. aureus", "SPECIES", 221, 230], ["The strain", "TEST", 0, 10], ["intact cells", "PROBLEM", 75, 87], ["20 Staphylococcal isolates", "PROBLEM", 93, 119], ["the MRSA", "PROBLEM", 152, 160], ["MSSA", "PROBLEM", 165, 169], ["S. aureus infections", "PROBLEM", 221, 241], ["antibiotics", "TREATMENT", 274, 285], ["intact cells", "OBSERVATION_MODIFIER", 75, 87], ["MRSA", "OBSERVATION", 156, 160], ["MSSA", "OBSERVATION", 165, 169], ["aureus", "OBSERVATION_MODIFIER", 224, 230], ["infections", "OBSERVATION", 231, 241]]], ["The direct MALDI-MS analysis of bacterial colonies has been used for the routine identification of 1,660 bacterial isolates collected from clinical specimens.", [["colonies", "ANATOMY", 42, 50], ["specimens", "ANATOMY", 148, 157], ["bacterial colonies", "CELL_LINE", 32, 50], ["The direct MALDI", "TEST", 0, 16], ["bacterial colonies", "PROBLEM", 32, 50], ["the routine identification", "TEST", 69, 95], ["bacterial isolates", "TEST", 105, 123], ["clinical specimens", "TEST", 139, 157], ["bacterial colonies", "OBSERVATION", 32, 50]]], ["Identification was quick; 95.4% of isolates were correctly identified with MALDI-TOFMS; 84.1% were identified at the species level, and 11.3% were identified at the genus level.", [["Identification", "TEST", 0, 14], ["isolates", "TEST", 35, 43], ["MALDI", "TEST", 75, 80], ["TOFMS", "TEST", 81, 86], ["genus", "ANATOMY", 165, 170]]], ["The average delay and cost of MALDI-MS identification for routine use in clinics have been evaluated in detail (Seng et al., 2009 ).", [["average", "OBSERVATION_MODIFIER", 4, 11], ["delay", "OBSERVATION_MODIFIER", 12, 17]]], ["Fenselau et al. (2008) detected beta-lactamase in antibioticresistant strain B. cereus spores with MALDI-TOFMS.", [["spores", "ANATOMY", 87, 93], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 32, 46], ["B. cereus", "ORGANISM", 77, 86], ["B. cereus", "SPECIES", 77, 86], ["B. cereus", "SPECIES", 77, 86], ["beta-lactamase", "PROBLEM", 32, 46]]], ["This protein marker might be used for the rapid preliminary detection of the resistance of B. cereus spores to antibiotics.", [["B. cereus", "ORGANISM", 91, 100], ["B. cereus", "SPECIES", 91, 100], ["B. cereus", "SPECIES", 91, 100], ["This protein marker", "TEST", 0, 19], ["B. cereus spores", "PROBLEM", 91, 107], ["antibiotics", "TREATMENT", 111, 122]]], ["Demirev et al. (2001) obtained positive-and negative-ion spectra of proteins that were desorbed from Helicobacter pylori 26995 cells, a strain of bacteria that has been implicated in the development of gastrointestinal ulcers.", [["26995 cells", "ANATOMY", 121, 132], ["gastrointestinal ulcers", "ANATOMY", 202, 225], ["gastrointestinal ulcers", "DISEASE", 202, 225], ["Helicobacter pylori", "ORGANISM", 101, 120], ["26995 cells", "CELL", 121, 132], ["gastrointestinal ulcers", "PATHOLOGICAL_FORMATION", 202, 225], ["Helicobacter pylori 26995 cells", "CELL_LINE", 101, 132], ["Helicobacter pylori", "SPECIES", 101, 120], ["Helicobacter pylori", "SPECIES", 101, 120], ["ion spectra of proteins", "PROBLEM", 53, 76], ["Helicobacter pylori", "PROBLEM", 101, 120], ["a strain of bacteria", "PROBLEM", 134, 154], ["gastrointestinal ulcers", "PROBLEM", 202, 225], ["gastrointestinal", "ANATOMY", 202, 218], ["ulcers", "OBSERVATION", 219, 225]]], ["Seventeen clinical and two laboratory strains of H. pylori have been analyzed from the direct protein-fingerprinting method for quick species identification (Ilina et al., 2010) .", [["H. pylori", "ORGANISM", 49, 58], ["H. pylori", "SPECIES", 49, 58], ["H. pylori", "SPECIES", 49, 58], ["H. pylori", "PROBLEM", 49, 58], ["the direct protein", "TEST", 83, 101], ["quick species identification", "PROBLEM", 128, 156]]], ["MALDI-TOFMS has also been used to detect and identify Legionella species (which cause Legionellosis disease) (Pennanec et al., 2010) and human pathogens such as Bacteroides fragilis, which is frequently misidentified with phenotypical identification procedures (Nagy et al., 2009) .", [["Legionellosis disease", "DISEASE", 86, 107], ["human", "ORGANISM", 137, 142], ["Bacteroides fragilis", "ORGANISM", 161, 181], ["human", "SPECIES", 137, 142], ["Bacteroides fragilis", "SPECIES", 161, 181], ["human", "SPECIES", 137, 142], ["Bacteroides fragilis", "SPECIES", 161, 181], ["MALDI", "TEST", 0, 5], ["Legionella species", "PROBLEM", 54, 72], ["Legionellosis disease", "PROBLEM", 86, 107], ["human pathogens", "PROBLEM", 137, 152], ["Bacteroides fragilis", "PROBLEM", 161, 181], ["Legionella species", "OBSERVATION", 54, 72]]], ["SELDI-TOF MS has been used to analyze 273 strains of staphylococci and other species isolated in a clinical-microbiology laboratory .", [["staphylococci", "ANATOMY", 53, 66], ["staphylococci", "DISEASE", 53, 66], ["staphylococci", "CANCER", 53, 66], ["staphylococci", "PROBLEM", 53, 66], ["other species", "PROBLEM", 71, 84]]], ["The authors demonstrated that SELDI-TOFMS protein profiles of microorganisms include protein peaks that can be used to identify bacteria.", [["SELDI", "TEST", 30, 35], ["microorganisms", "PROBLEM", 62, 76], ["protein peaks", "PROBLEM", 85, 98], ["bacteria", "PROBLEM", 128, 136]]], ["Laser desorption ionization (LDI) MS has been applied to the detection of Plasmodium falciparum in blood samples from pregnant women (Nyunt et al., 2005) .", [["blood samples", "ANATOMY", 99, 112], ["Plasmodium falciparum", "DISEASE", 74, 95], ["Plasmodium", "ORGANISM", 74, 84], ["falciparum", "ORGANISM", 85, 95], ["blood samples", "ORGANISM_SUBSTANCE", 99, 112], ["women", "ORGANISM", 127, 132], ["Plasmodium falciparum", "SPECIES", 74, 95], ["women", "SPECIES", 127, 132], ["Plasmodium falciparum", "SPECIES", 74, 95], ["Laser desorption ionization (LDI) MS", "TREATMENT", 0, 36], ["Plasmodium falciparum", "PROBLEM", 74, 95], ["blood samples", "TEST", 99, 112]]], ["P. falciparum is a malaria-causing protozoan.", [["P. falciparum", "DISEASE", 0, 13], ["malaria-causing protozoan", "DISEASE", 19, 44], ["P. falciparum", "ORGANISM", 0, 13], ["P. falciparum", "SPECIES", 0, 13], ["P. falciparum", "SPECIES", 0, 13], ["falciparum", "PROBLEM", 3, 13], ["a malaria", "PROBLEM", 17, 26], ["protozoan", "PROBLEM", 35, 44], ["falciparum", "OBSERVATION", 3, 13], ["malaria", "OBSERVATION", 19, 26]]], ["LDI of hemozoin inside the parasites generated heme ion and FIGURE 5.", [["hemozoin", "CHEMICAL", 7, 15], ["heme", "CHEMICAL", 47, 51], ["hemozoin", "SIMPLE_CHEMICAL", 7, 15], ["heme ion", "SIMPLE_CHEMICAL", 47, 55], ["LDI of hemozoin", "TEST", 0, 15], ["hemozoin", "OBSERVATION", 7, 15], ["parasites", "OBSERVATION_MODIFIER", 27, 36], ["heme ion", "OBSERVATION", 47, 55]]], ["PCR-MS approach-TIGER: Aliquots of nucleic acids present in a sample are deposited into wells of a micro-titer plate to begin PCR.", [["sample", "ANATOMY", 62, 68], ["nucleic acids", "CHEMICAL", 35, 48], ["nucleic acids", "SIMPLE_CHEMICAL", 35, 48], ["PCR", "TEST", 0, 3], ["nucleic acids", "TREATMENT", 35, 48], ["a micro-titer plate", "TREATMENT", 97, 116], ["PCR", "TEST", 126, 129]]], ["Each well contains a pair of broad-range primers that target a selected domain of microorganisms.", [["broad-range primers", "TREATMENT", 29, 48], ["a selected domain of microorganisms", "PROBLEM", 61, 96]]], ["PCR products are desalted and electrosprayed into a high-resolution mass spectrometer to determine their base compositions.", [["PCR products", "TEST", 0, 12], ["a high-resolution mass spectrometer", "TREATMENT", 50, 85]]], ["The combined base compositions from multiple PCR reactions (multiple primer sets) support the identification of microorganisms in a sample.", [["The combined base compositions", "PROBLEM", 0, 30], ["multiple PCR reactions", "PROBLEM", 36, 58], ["multiple primer sets", "TREATMENT", 60, 80], ["microorganisms", "PROBLEM", 112, 126], ["a sample", "TEST", 130, 138], ["base", "OBSERVATION_MODIFIER", 13, 17], ["compositions", "OBSERVATION_MODIFIER", 18, 30], ["multiple", "OBSERVATION_MODIFIER", 36, 44]]], ["[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com] IDENTIFICATION OF PATHOGENS BY MASS SPECTROMETRY & its fragment ions.", [["PATHOGENS", "PROBLEM", 113, 122], ["MASS SPECTROMETRY", "PROBLEM", 126, 143], ["its fragment ions", "PROBLEM", 146, 163], ["PATHOGENS", "OBSERVATION_MODIFIER", 113, 122], ["MASS", "OBSERVATION", 126, 130], ["fragment", "OBSERVATION_MODIFIER", 150, 158]]], ["MS detection of these marker ions represents malaria infection Demirev, 2004; Scholl et al., 2004) .", [["malaria infection", "DISEASE", 45, 62], ["MS detection", "TEST", 0, 12], ["malaria infection", "PROBLEM", 45, 62]]], ["Tuberculosis (TB) is an infectious disease that is caused by the Gram-positive bacteria M. tuberculosis.", [["Tuberculosis", "DISEASE", 0, 12], ["TB", "DISEASE", 14, 16], ["tuberculosis", "DISEASE", 91, 103], ["Gram-", "GENE_OR_GENE_PRODUCT", 65, 70], ["M. tuberculosis", "ORGANISM", 88, 103], ["M. tuberculosis", "SPECIES", 88, 103], ["M. tuberculosis", "SPECIES", 88, 103], ["Tuberculosis (TB", "PROBLEM", 0, 16], ["an infectious disease", "PROBLEM", 21, 42], ["the Gram-positive bacteria M. tuberculosis", "PROBLEM", 61, 103], ["infectious", "OBSERVATION_MODIFIER", 24, 34], ["positive", "OBSERVATION_MODIFIER", 70, 78], ["bacteria", "OBSERVATION_MODIFIER", 79, 87], ["M. tuberculosis", "OBSERVATION", 88, 103]]], ["M. tuberculosis is often associated with the human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS), which has led to the increased prevalence of pulmonary TB worldwide.", [["pulmonary", "ANATOMY", 172, 181], ["tuberculosis", "DISEASE", 3, 15], ["human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome", "DISEASE", 45, 118], ["AIDS", "DISEASE", 120, 124], ["pulmonary TB", "DISEASE", 172, 184], ["M. tuberculosis", "ORGANISM", 0, 15], ["human immunodeficiency virus", "ORGANISM", 45, 73], ["pulmonary", "ORGAN", 172, 181], ["M. tuberculosis", "SPECIES", 0, 15], ["human immunodeficiency virus (HIV", "SPECIES", 45, 78], ["M. tuberculosis", "SPECIES", 0, 15], ["human immunodeficiency virus", "SPECIES", 45, 73], ["HIV", "SPECIES", 75, 78], ["M. tuberculosis", "PROBLEM", 0, 15], ["the human immunodeficiency virus", "PROBLEM", 41, 73], ["HIV", "PROBLEM", 75, 78], ["acquired immunodeficiency syndrome", "PROBLEM", 84, 118], ["pulmonary TB worldwide", "PROBLEM", 172, 194], ["tuberculosis", "OBSERVATION", 3, 15], ["immunodeficiency syndrome", "OBSERVATION", 93, 118], ["increased", "OBSERVATION_MODIFIER", 148, 157], ["pulmonary", "ANATOMY", 172, 181], ["TB", "OBSERVATION", 182, 184]]], ["Recently, GC-MS analysis of derivatized fatty acids obtained from microbial cells has been used for the rapid diagnosis of pulmonary TB in clinical-microbiology laboratories (Stopforth et al., 2005; Cha et al., 2009) .", [["cells", "ANATOMY", 76, 81], ["pulmonary", "ANATOMY", 123, 132], ["fatty acids", "CHEMICAL", 40, 51], ["pulmonary TB", "DISEASE", 123, 135], ["fatty acids", "CHEMICAL", 40, 51], ["derivatized fatty acids", "SIMPLE_CHEMICAL", 28, 51], ["microbial cells", "CELL", 66, 81], ["pulmonary", "ORGAN", 123, 132], ["microbial cells", "CELL_TYPE", 66, 81], ["GC-MS analysis", "TEST", 10, 24], ["derivatized fatty acids", "PROBLEM", 28, 51], ["microbial cells", "PROBLEM", 66, 81], ["pulmonary TB", "PROBLEM", 123, 135], ["pulmonary", "ANATOMY", 123, 132], ["TB", "OBSERVATION", 133, 135]]], ["GC-MS has also been used for the fast and accurate identification of M. tuberculosis in cultures and sputum samples that were collected from patients who were suspected to be suffering from TB (Cha et al., 2009; Kaal et al., 2009) .", [["cultures", "ANATOMY", 88, 96], ["sputum samples", "ANATOMY", 101, 115], ["tuberculosis", "DISEASE", 72, 84], ["TB", "DISEASE", 190, 192], ["M. tuberculosis", "ORGANISM", 69, 84], ["cultures", "CELL", 88, 96], ["sputum samples", "ORGANISM_SUBSTANCE", 101, 115], ["patients", "ORGANISM", 141, 149], ["M. tuberculosis", "SPECIES", 69, 84], ["patients", "SPECIES", 141, 149], ["M. tuberculosis", "SPECIES", 69, 84], ["GC", "TEST", 0, 2], ["M. tuberculosis", "PROBLEM", 69, 84], ["cultures", "TEST", 88, 96], ["sputum samples", "TEST", 101, 115], ["TB", "PROBLEM", 190, 192], ["tuberculosis", "OBSERVATION", 72, 84]]], ["The results show that tuberculosis stearic acid was detected only in the sputum specimens from patients who were clinically diagnosed with TB.", [["sputum specimens", "ANATOMY", 73, 89], ["tuberculosis stearic acid", "CHEMICAL", 22, 47], ["TB", "DISEASE", 139, 141], ["stearic acid", "CHEMICAL", 35, 47], ["tuberculosis stearic acid", "SIMPLE_CHEMICAL", 22, 47], ["sputum specimens", "ORGANISM_SUBSTANCE", 73, 89], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["tuberculosis stearic acid", "PROBLEM", 22, 47], ["the sputum specimens", "TEST", 69, 89], ["TB", "PROBLEM", 139, 141], ["tuberculosis", "OBSERVATION_MODIFIER", 22, 34], ["stearic acid", "OBSERVATION", 35, 47]]], ["Hu et al. applied selective CE-MS/MS to identify specific pathogens in clinical specimens that had been collected from pus, wound, sputum, and urine samples.", [["specimens", "ANATOMY", 80, 89], ["pus", "ANATOMY", 119, 122], ["wound", "ANATOMY", 124, 129], ["sputum", "ANATOMY", 131, 137], ["urine samples", "ANATOMY", 143, 156], ["CE", "CHEMICAL", 28, 30], ["pus", "ORGANISM_SUBSTANCE", 119, 122], ["wound", "PATHOLOGICAL_FORMATION", 124, 129], ["urine samples", "ORGANISM_SUBSTANCE", 143, 156], ["selective CE", "TEST", 18, 30], ["MS", "PROBLEM", 34, 36], ["specific pathogens", "PROBLEM", 49, 67], ["clinical specimens", "TEST", 71, 89], ["pus", "PROBLEM", 119, 122], ["wound, sputum, and urine samples", "TEST", 124, 156], ["pus", "OBSERVATION", 119, 122], ["wound", "ANATOMY", 124, 129]]], ["The bacteria in these clinical specimens were cultivated directly, without prior isolation of a pure colony, before the selective MS/MS analyses were performed.", [["specimens", "ANATOMY", 31, 40], ["colony", "ANATOMY", 101, 107], ["The bacteria", "PROBLEM", 0, 12], ["these clinical specimens", "TEST", 16, 40], ["a pure colony", "PROBLEM", 94, 107], ["the selective MS/MS analyses", "TEST", 116, 144], ["bacteria", "OBSERVATION_MODIFIER", 4, 12]]], ["The total time taken to perform the analysis, including fast protein digestion and MS analysis, was 30 min, and the cultivation time was 6 hr.", [["the analysis", "TEST", 32, 44], ["fast protein digestion", "PROBLEM", 56, 78], ["MS analysis", "TEST", 83, 94]]], ["The identified pathogens included many species such as P. aeruginosa, S. aureus, and S. agalactiae .III. APPLICATIONSPolymerase chain reaction-mass spectrometry (PCR-MS) has been used to detect/identify infectious pathogens (Fox, 2006; Sampath et al., 2007a; Eshoo et al., 2010; Fabris, 2010) .", [["P. aeruginosa", "ORGANISM", 55, 68], ["S. aureus", "ORGANISM", 70, 79], ["S. agalactiae", "ORGANISM", 85, 98], ["P. aeruginosa", "SPECIES", 55, 68], ["S. aureus", "SPECIES", 70, 79], ["S. agalactiae", "SPECIES", 85, 98], ["P. aeruginosa", "SPECIES", 55, 68], ["S. aureus", "SPECIES", 70, 79], ["S. agalactiae", "SPECIES", 85, 98], ["The identified pathogens", "PROBLEM", 0, 24], ["many species", "PROBLEM", 34, 46], ["P. aeruginosa", "PROBLEM", 55, 68], ["S. aureus", "PROBLEM", 70, 79], ["S. agalactiae", "PROBLEM", 85, 98], ["APPLICATIONSPolymerase chain reaction", "PROBLEM", 105, 142], ["mass spectrometry", "PROBLEM", 143, 160], ["PCR", "TEST", 162, 165], ["pathogens", "OBSERVATION", 15, 24], ["aureus", "OBSERVATION", 73, 79], ["agalactiae", "OBSERVATION", 88, 98], ["infectious", "OBSERVATION_MODIFIER", 203, 213]]], ["The detection of SNPs with a MALDI-MS-based minisequencing method has been used to identify hepatitis B virus in HBsAgpositive patients with chronic hepatitis B and to detect drug resistance-related mutations in N. gonorrhoeae (Vereshchagin et al., 2005) and M. tuberculosis (Ikryannikova et al., 2007) .", [["hepatitis B", "DISEASE", 92, 103], ["chronic hepatitis B", "DISEASE", 141, 160], ["N. gonorrhoeae", "DISEASE", 212, 226], ["M. tuberculosis", "DISEASE", 259, 274], ["hepatitis B virus", "ORGANISM", 92, 109], ["patients", "ORGANISM", 127, 135], ["N. gonorrhoeae", "ORGANISM", 212, 226], ["M. tuberculosis", "ORGANISM", 259, 274], ["SNPs", "DNA", 17, 21], ["hepatitis B virus", "SPECIES", 92, 109], ["patients", "SPECIES", 127, 135], ["N. gonorrhoeae", "SPECIES", 212, 226], ["M. tuberculosis", "SPECIES", 259, 274], ["hepatitis B virus", "SPECIES", 92, 109], ["N. gonorrhoeae", "SPECIES", 212, 226], ["M. tuberculosis", "SPECIES", 259, 274], ["SNPs", "PROBLEM", 17, 21], ["a MALDI", "TEST", 27, 34], ["based minisequencing method", "TREATMENT", 38, 65], ["hepatitis B virus", "PROBLEM", 92, 109], ["chronic hepatitis B", "PROBLEM", 141, 160], ["drug resistance", "PROBLEM", 175, 190], ["related mutations", "PROBLEM", 191, 208], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["hepatitis", "OBSERVATION", 149, 158], ["tuberculosis", "OBSERVATION", 262, 274]]], ["The same method has been successfully applied to the rapid detection of clinically significant TEM-type extended-spectrum beta-lactamases in clinical strains of E. coli and Klebsiella pneumonia (Ikryannikova et al., 2008) .", [["Klebsiella pneumonia", "DISEASE", 173, 193], ["E. coli", "ORGANISM", 161, 168], ["Klebsiella pneumonia", "ORGANISM", 173, 193], ["E. coli", "SPECIES", 161, 168], ["E. coli", "SPECIES", 161, 168], ["Klebsiella pneumonia", "SPECIES", 173, 193], ["The same method", "TREATMENT", 0, 15], ["the rapid detection", "TEST", 49, 68], ["type extended-spectrum beta-lactamases", "PROBLEM", 99, 137], ["E. coli", "PROBLEM", 161, 168], ["Klebsiella pneumonia", "PROBLEM", 173, 193], ["E. coli", "OBSERVATION", 161, 168], ["Klebsiella", "OBSERVATION_MODIFIER", 173, 183], ["pneumonia", "OBSERVATION", 184, 193]]], ["Faix, Sherman, and Waterman (2009) used PCR and ESI-MS to classify swine-origin influenza A (H1N1) viruses (S-OIV).", [["swine-origin", "ORGANISM", 67, 79], ["influenza A (H1N1) viruses", "ORGANISM", 80, 106], ["swine", "SPECIES", 67, 72], ["influenza A (H1N1", "SPECIES", 80, 97], ["swine-origin influenza A (H1N1) viruses", "SPECIES", 67, 106], ["PCR", "TEST", 40, 43], ["ESI", "TEST", 48, 51], ["influenza", "PROBLEM", 80, 89]]], ["Data from numerous outbreak sites indicate that the novel influenza A/H1N1 virus is currently the dominant influenza strain in most parts of the world.III. APPLICATIONSEcker's research group identified the genotypes of bacteria in complex mixtures of clinical samples, by performing a basecomposition analysis of PCR-amplification products with highresolution ESI-MS.", [["samples", "ANATOMY", 260, 267], ["influenza A/H1N1 virus", "ORGANISM", 58, 80], ["influenza A/H1N1 virus", "SPECIES", 58, 80], ["A/H1N1 virus", "SPECIES", 68, 80], ["the novel influenza A/H1N1 virus", "PROBLEM", 48, 80], ["the dominant influenza strain", "PROBLEM", 94, 123], ["bacteria", "PROBLEM", 219, 227], ["a basecomposition analysis", "TEST", 283, 309], ["PCR", "TEST", 313, 316], ["dominant", "OBSERVATION_MODIFIER", 98, 106], ["influenza", "OBSERVATION", 107, 116]]], ["They employed this approach to identify quinolone resistance in Acinetobacter spp., whose quinolone resistance is mediated by mutations in the quinolone resistance-determining DNA sequences of two essential housekeeping genes (Hujer et al., 2009) .", [["quinolone", "CHEMICAL", 40, 49], ["Acinetobacter spp.", "DISEASE", 64, 82], ["quinolone", "CHEMICAL", 90, 99], ["quinolone", "CHEMICAL", 143, 152], ["quinolone", "CHEMICAL", 40, 49], ["quinolone", "CHEMICAL", 90, 99], ["quinolone", "CHEMICAL", 143, 152], ["quinolone", "SIMPLE_CHEMICAL", 40, 49], ["Acinetobacter spp.", "ORGANISM", 64, 82], ["quinolone", "SIMPLE_CHEMICAL", 90, 99], ["quinolone", "SIMPLE_CHEMICAL", 143, 152], ["DNA", "CELLULAR_COMPONENT", 176, 179], ["quinolone resistance-determining DNA sequences", "DNA", 143, 189], ["housekeeping genes", "DNA", 207, 225], ["Acinetobacter spp.", "SPECIES", 64, 82], ["Acinetobacter spp.", "SPECIES", 64, 82], ["quinolone resistance in Acinetobacter spp.", "PROBLEM", 40, 82], ["whose quinolone resistance", "TREATMENT", 84, 110], ["the quinolone resistance", "TREATMENT", 139, 163], ["DNA sequences", "TEST", 176, 189]]], ["The results provide important information for the therapeutic treatment of Acinetobacter spp. infection.", [["Acinetobacter spp.", "CHEMICAL", 75, 93], ["infection", "DISEASE", 94, 103], ["Acinetobacter spp.", "ORGANISM", 75, 93], ["Acinetobacter spp.", "SPECIES", 75, 93], ["the therapeutic treatment", "TREATMENT", 46, 71], ["Acinetobacter spp.", "PROBLEM", 75, 93], ["infection", "PROBLEM", 94, 103]]], ["Analysis of respiratory samples collected during respiratory disease outbreaks revealed high concentrations of pathogenic respiratory species, including Haemophilus influenzae, N. meningitidis, and S. pyogenes .", [["respiratory samples", "ANATOMY", 12, 31], ["respiratory", "ANATOMY", 49, 60], ["respiratory disease", "DISEASE", 49, 68], ["Haemophilus influenzae", "DISEASE", 153, 175], ["Haemophilus influenzae", "ORGANISM", 153, 175], ["N. meningitidis", "ORGANISM", 177, 192], ["S. pyogenes", "ORGANISM", 198, 209], ["Haemophilus influenzae", "SPECIES", 153, 175], ["N. meningitidis", "SPECIES", 177, 192], ["S. pyogenes", "SPECIES", 198, 209], ["Haemophilus influenzae", "SPECIES", 153, 175], ["N. meningitidis", "SPECIES", 177, 192], ["S. pyogenes", "SPECIES", 198, 209], ["Analysis of respiratory samples", "TEST", 0, 31], ["respiratory disease outbreaks", "PROBLEM", 49, 78], ["pathogenic respiratory species", "PROBLEM", 111, 141], ["Haemophilus influenzae", "PROBLEM", 153, 175], ["meningitidis", "PROBLEM", 180, 192], ["S. pyogenes", "PROBLEM", 198, 209], ["respiratory", "ANATOMY", 12, 23], ["high concentrations", "OBSERVATION_MODIFIER", 88, 107], ["pathogenic", "OBSERVATION_MODIFIER", 111, 121], ["respiratory species", "OBSERVATION", 122, 141], ["Haemophilus influenzae", "OBSERVATION", 153, 175], ["meningitidis", "OBSERVATION", 180, 192]]], ["This approach has been used to identify 14 isolates of nine diverse Coronavirus spp., including the severe acute respiratory syndrome (SARS)-associated coronavirus.", [["Coronavirus spp.", "DISEASE", 68, 84], ["acute respiratory syndrome (SARS)-associated coronavirus", "DISEASE", 107, 163], ["Coronavirus spp.", "ORGANISM", 68, 84], ["coronavirus", "ORGANISM", 152, 163], ["Coronavirus spp.", "SPECIES", 68, 84], ["coronavirus", "SPECIES", 152, 163], ["Coronavirus spp.", "SPECIES", 68, 84], ["nine diverse Coronavirus spp.", "PROBLEM", 55, 84], ["the severe acute respiratory syndrome", "PROBLEM", 96, 133], ["SARS", "PROBLEM", 135, 139], ["coronavirus", "PROBLEM", 152, 163], ["Coronavirus spp.", "OBSERVATION", 68, 84], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory syndrome", "OBSERVATION", 113, 133], ["coronavirus", "OBSERVATION", 152, 163]]], ["The detection limit was one plaque-forming-unit per mL of human serum .IV. CONCLUSIONSRecent outbreaks, including the SARS outbreak that was caused by coronavirus and the H1N1 flu outbreak that was caused by a novel influenza A virus, as well as some biothreat incidents, reveal the importance to develop more rapid, sensitive, and accurate real-time detection methods.", [["plaque", "ANATOMY", 28, 34], ["serum", "ANATOMY", 64, 69], ["SARS", "DISEASE", 118, 122], ["coronavirus", "DISEASE", 151, 162], ["flu", "DISEASE", 176, 179], ["influenza A virus", "DISEASE", 216, 233], ["human", "ORGANISM", 58, 63], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["coronavirus", "ORGANISM", 151, 162], ["influenza A virus", "ORGANISM", 216, 233], ["human", "SPECIES", 58, 63], ["coronavirus", "SPECIES", 151, 162], ["H1N1 flu", "SPECIES", 171, 179], ["influenza A virus", "SPECIES", 216, 233], ["human", "SPECIES", 58, 63], ["H1N1 flu", "SPECIES", 171, 179], ["influenza A virus", "SPECIES", 216, 233], ["human serum", "TEST", 58, 69], ["IV", "TREATMENT", 71, 73], ["CONCLUSIONSRecent outbreaks", "PROBLEM", 75, 102], ["the SARS outbreak", "PROBLEM", 114, 131], ["coronavirus", "PROBLEM", 151, 162], ["the H1N1 flu outbreak", "PROBLEM", 167, 188], ["a novel influenza A virus", "PROBLEM", 208, 233]]], ["MS has been successfully applied to the analysis of biomarkers from microbial samples.", [["samples", "ANATOMY", 78, 85], ["the analysis", "TEST", 36, 48], ["biomarkers", "TEST", 52, 62], ["microbial samples", "TEST", 68, 85]]], ["Many advanced methods for microbial analysis have been proposed.", [["microbial analysis", "TEST", 26, 44]]], ["The MALDI-MS fingerprinting of microorganisms has a number of advantages, including rapidity and ease of implementation.", [["The MALDI", "TEST", 0, 9]]], ["Construction of a large reference spectral library and the use of a fingerprint-selection algorithm are critical to the success of the fingerprinting approach because of the complexity and the lack of reproducibility of microbial mass spectra obtained from real-world samples.", [["a fingerprint-selection algorithm", "TREATMENT", 66, 99], ["the fingerprinting approach", "TREATMENT", 131, 158], ["microbial mass spectra", "PROBLEM", 220, 242], ["microbial", "OBSERVATION_MODIFIER", 220, 229], ["mass", "OBSERVATION", 230, 234]]], ["Identification of microorganisms through the sequence analysis of peptide or proteins markers might solve the problems associated with spectral reproducibility.", [["microorganisms", "PROBLEM", 18, 32], ["the sequence analysis", "TEST", 41, 62], ["peptide or proteins markers", "PROBLEM", 66, 93], ["the problems", "PROBLEM", 106, 118], ["spectral reproducibility", "PROBLEM", 135, 159], ["microorganisms", "OBSERVATION", 18, 32], ["spectral reproducibility", "OBSERVATION", 135, 159]]], ["Although the proteomic methods are limited by the number of available proteome databases, more and more microbial proteomes have been revealed and should broaden the applicability of these approaches in microbial analysis.", [["the proteomic methods", "TEST", 9, 30], ["available proteome databases", "TEST", 60, 88], ["microbial analysis", "TEST", 203, 221]]], ["In bottom-up approaches, the complexity of microbial biomarkers might be simplified with various chromatography-based methods; although separation processes reduce the speed of identification, they provide significantly improved accuracy and selectivity.", [["microbial biomarkers", "TEST", 43, 63], ["various chromatography", "TEST", 89, 111], ["bottom", "OBSERVATION_MODIFIER", 3, 9]]], ["Furthermore, because the dynamic range is also increased, even a small amount of microorganisms in complex sample matrices can be identified.", [["a small amount of microorganisms in complex sample matrices", "PROBLEM", 63, 122], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["small", "OBSERVATION_MODIFIER", 65, 70], ["amount", "OBSERVATION_MODIFIER", 71, 77], ["microorganisms", "OBSERVATION_MODIFIER", 81, 95], ["complex", "OBSERVATION_MODIFIER", 99, 106], ["sample matrices", "OBSERVATION", 107, 122]]], ["Most current microbial analysis methods require the culturing of the target cells to obtain detectable signals.", [["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81], ["target cells", "CELL_TYPE", 69, 81], ["the culturing", "TEST", 48, 61]]], ["The culturing time is by far the rate-limiting step in rapid microbial identification.", [["The culturing time", "TEST", 0, 18], ["the rate", "TEST", 29, 37]]], ["Reducing the detection threshold for microbial cells will be one of the major challenges in the future.", [["cells", "ANATOMY", 47, 52], ["microbial cells", "CELL", 37, 52], ["microbial cells", "CELL_TYPE", 37, 52], ["microbial cells", "TREATMENT", 37, 52]]], ["Methods and instrumentation must both be improved to reach this goal.", [["Methods", "TREATMENT", 0, 7], ["instrumentation", "TREATMENT", 12, 27]]], ["Cell enrichment through affinity techniques will also be important.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell enrichment through affinity techniques", "TREATMENT", 0, 43]]], ["Selective biomarker analysis with multiple reaction monitoring approaches coupled with affinity techniques will enhance the sensitivity and accuracy of microbial identification.", [["Selective biomarker analysis", "TEST", 0, 28], ["multiple reaction monitoring approaches", "TREATMENT", 34, 73], ["affinity techniques", "TREATMENT", 87, 106], ["the sensitivity", "TEST", 120, 135], ["microbial identification", "TEST", 152, 176]]], ["The MS detection of PCR products from microbial genes might be an alternative means to improve the detection limit, especially in analyses of non-culturable microorganisms.", [["PCR products", "DNA", 20, 32], ["microbial genes", "DNA", 38, 53], ["The MS detection", "TEST", 0, 16], ["PCR products", "TREATMENT", 20, 32], ["microbial genes", "PROBLEM", 38, 53], ["the detection limit", "TEST", 95, 114], ["non-culturable microorganisms", "PROBLEM", 142, 171]]], ["Advances in MS instrumentation and methods shall support a simple and accurate means of pathogen identification for environmental monitoring and clinical diagnosis.ACKNOWLEDGMENTSWe thank the National Science Council of the Republic of China for financially supporting part of the work mentioned in this review.", [["MS instrumentation", "TREATMENT", 12, 30], ["methods", "TREATMENT", 35, 42], ["pathogen identification", "TEST", 88, 111], ["environmental monitoring", "TEST", 116, 140]]]], "PMC7332273": [], "PMC4642273": [["Homogenisation with ceramic beads reduces number of viral particles ::: ResultsTo obtain reproducible results a proper homogenisation of biological samples (such as tissue or faecal samples) is crucial and minimises subsequent filter clogging23.", [["samples", "ANATOMY", 148, 155], ["tissue", "ANATOMY", 165, 171], ["faecal samples", "ANATOMY", 175, 189], ["tissue", "TISSUE", 165, 171], ["faecal samples", "MULTI-TISSUE_STRUCTURE", 175, 189], ["Homogenisation with ceramic beads", "TREATMENT", 0, 33], ["biological samples", "TEST", 137, 155], ["faecal samples", "TEST", 175, 189], ["subsequent filter clogging", "TREATMENT", 216, 242], ["ceramic beads", "OBSERVATION", 20, 33], ["viral particles", "OBSERVATION", 52, 67], ["filter clogging", "OBSERVATION", 227, 242]]], ["As benchtop vortexers do not provide a standardised approach for sample homogenisation, a tissue homogeniser was used.", [["tissue", "ANATOMY", 90, 96], ["tissue", "TISSUE", 90, 96], ["a standardised approach", "TREATMENT", 37, 60], ["sample homogenisation", "PROBLEM", 65, 86], ["a tissue homogeniser", "TEST", 88, 108]]], ["The mock-virome and bacterial mock-community were subjected to homogenisation at different speeds (3000 and 5000 rpm) and with or without beads of different sizes (\u00d80.1 and \u00d82.8 mm) and compared to a non-homogenised control (Fig. 2).", [["a non-homogenised control", "TREATMENT", 198, 223], ["sizes", "OBSERVATION_MODIFIER", 157, 162]]], ["Homogenisation with \u00d82.8 mm beads led to a destruction of viral particles irrespective of homogenisation speed.", [["Homogenisation", "PROBLEM", 0, 14], ["\u00d82.8 mm beads", "TREATMENT", 20, 33], ["a destruction of viral particles", "PROBLEM", 41, 73], ["\u00d82.8 mm", "OBSERVATION_MODIFIER", 20, 27], ["destruction", "OBSERVATION", 43, 54], ["viral particles", "OBSERVATION", 58, 73], ["homogenisation speed", "OBSERVATION", 90, 110]]], ["The reduction was largest for coronavirus (99.5% and 99.6% and Ct differences of 8.5 and 8.9 for 5000 and 3000 rpm, respectively) and mimivirus (96.0% and 97.7% and Ct differences of 6.0 and 6.3 for 5000 and 3000 rpm, respectively).", [["coronavirus", "ORGANISM", 30, 41], ["The reduction", "TREATMENT", 0, 13], ["coronavirus", "PROBLEM", 30, 41], ["Ct differences", "TEST", 63, 77], ["mimivirus", "TEST", 134, 143], ["Ct differences", "TEST", 165, 179], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["largest", "OBSERVATION_MODIFIER", 18, 25]]], ["In addition, \u00d82.8 mm beads led to a 316% and 350% increase in the detection of 16S rRNA at 5000 and 3000 rpm, respectively (Ct difference 2.3 and 2.4, respectively).", [["16S rRNA", "DNA", 79, 87], ["the detection", "TEST", 62, 75], ["16S rRNA", "TEST", 79, 87], ["Ct difference", "TEST", 124, 137], ["increase", "OBSERVATION_MODIFIER", 50, 58]]], ["For the bacteria, \u00d82.8 mm beads also showed increases ranging from 612% (3.2Ct decrease) for the Bacteroides to 6184% for the E.coli (6.1Ct decrease).", [["the bacteria", "TEST", 4, 16], ["mm beads", "TEST", 23, 31], ["the Bacteroides", "TEST", 93, 108], ["the E.coli", "PROBLEM", 122, 132], ["bacteria", "OBSERVATION", 8, 16], ["increases", "OBSERVATION_MODIFIER", 44, 53], ["ranging", "OBSERVATION_MODIFIER", 54, 61], ["E.coli", "OBSERVATION", 126, 132]]], ["Homogenisation at 5000 rpm (without beads or with \u00d80.1 mm beads) showed a larger reduction in viral particles than homogenisation at 3000 rpm.", [["beads", "TREATMENT", 36, 41], ["\u00d80.1 mm beads", "TREATMENT", 50, 63], ["a larger reduction in viral particles", "PROBLEM", 72, 109], ["larger", "OBSERVATION_MODIFIER", 74, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["viral particles", "OBSERVATION", 94, 109]]], ["Reduction of viral particles was lowest using 3000 rpm homogenisation without beads (the maximum percentage of reduction was 59.6% for the pepino mosaic virus, 1.07Ct), and did not increase the amount of bacterial DNA/rRNA.", [["pepino mosaic virus", "ORGANISM", 139, 158], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["rRNA", "CELLULAR_COMPONENT", 218, 222], ["bacterial DNA/rRNA", "DNA", 204, 222], ["pepino mosaic virus", "SPECIES", 139, 158], ["pepino mosaic virus", "SPECIES", 139, 158], ["viral particles", "PROBLEM", 13, 28], ["reduction", "TEST", 111, 120], ["the pepino mosaic virus", "PROBLEM", 135, 158], ["bacterial DNA/rRNA", "PROBLEM", 204, 222], ["viral particles", "OBSERVATION", 13, 28], ["bacterial DNA", "OBSERVATION", 204, 217]]], ["All conditions resulted in well-homogenised suspensions suitable for subsequent filtration experiments (data not shown).Centrifugation conditions strongly influence the reduction in bacterial and viral particles ::: ResultsCentrifugation is commonly used to precipitate larger particles, such as cells and cellular debris, while viruses remain in solution.", [["cells", "ANATOMY", 296, 301], ["cellular debris", "ANATOMY", 306, 321], ["cells", "CELL", 296, 301], ["cellular", "CELL", 306, 314], ["subsequent filtration experiments", "TEST", 69, 102], ["Centrifugation conditions", "PROBLEM", 120, 145], ["the reduction in bacterial and viral particles", "PROBLEM", 165, 211], ["larger particles", "PROBLEM", 270, 286], ["cellular debris", "PROBLEM", 306, 321], ["viruses", "PROBLEM", 329, 336], ["reduction", "OBSERVATION_MODIFIER", 169, 178], ["bacterial", "OBSERVATION", 182, 191], ["viral particles", "OBSERVATION", 196, 211], ["larger", "OBSERVATION_MODIFIER", 270, 276], ["particles", "OBSERVATION", 277, 286], ["cellular", "OBSERVATION_MODIFIER", 306, 314], ["debris", "OBSERVATION", 315, 321]]], ["Since this step differs greatly among studies242526, we decided to test a mild and medium centrifugal force (100 g and 17000 g, respectively) as well as short (3 min) and medium (30 min) centrifugation times on our mock-communities (Fig. 3).", [["a mild and medium centrifugal force", "PROBLEM", 72, 107], ["mild", "OBSERVATION_MODIFIER", 74, 78]]], ["Higher g-forces or longer centrifugation times were not tested as this would result in even higher viral losses.", [["Higher g-forces or longer centrifugation", "TREATMENT", 0, 40], ["higher viral losses", "PROBLEM", 92, 111], ["viral losses", "OBSERVATION", 99, 111]]], ["Centrifugation at 100 g for 3 min showed limited differences compared to the control for viruses, bacteria and rRNA.", [["rRNA", "CELLULAR_COMPONENT", 111, 115], ["Centrifugation", "TREATMENT", 0, 14], ["limited differences", "PROBLEM", 41, 60], ["viruses", "PROBLEM", 89, 96], ["bacteria", "PROBLEM", 98, 106], ["rRNA", "PROBLEM", 111, 115]]], ["Only for Lactobacillus a reduction of more than 1 Ct was observed (68.6%; 1.8Ct increase).", [["Lactobacillus", "CHEMICAL", 9, 22], ["Lactobacillus", "PROBLEM", 9, 22], ["1 Ct", "TEST", 48, 52], ["Ct", "TEST", 77, 79], ["reduction", "OBSERVATION_MODIFIER", 25, 34]]], ["Centrifugation for 30 min at 100 g, resulted in an increased reduction of mimivirus (94.6%; 4.5Ct).", [["Centrifugation", "TREATMENT", 0, 14], ["an increased reduction of mimivirus", "PROBLEM", 48, 83], ["Ct", "TEST", 95, 97], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["reduction", "OBSERVATION_MODIFIER", 61, 70]]], ["For the bacteria, the highest reductions were observed for the Lactobacillus (99.0%; 7Ct) and Bifidobacterium (96.0%; 5Ct), whereas E.coli and Bacteroides showed less pronounced reductions (80.6% or 2.4 Ct and 48% or 0.95 Ct, respectively).", [["Lactobacillus", "CHEMICAL", 63, 76], ["Bifidobacterium", "CHEMICAL", 94, 109], ["Bacteroides", "CHEMICAL", 143, 154], ["Bacteroides", "SIMPLE_CHEMICAL", 143, 154], ["E.coli", "SPECIES", 132, 138], ["the bacteria", "PROBLEM", 4, 16], ["the highest reductions", "TEST", 18, 40], ["the Lactobacillus", "TEST", 59, 76], ["Bifidobacterium", "TEST", 94, 109], ["E.coli", "TEST", 132, 138], ["Bacteroides", "PROBLEM", 143, 154], ["less pronounced reductions", "PROBLEM", 162, 188], ["Ct", "TEST", 203, 205], ["Ct", "TEST", 222, 224], ["bacteria", "OBSERVATION", 8, 16], ["less", "OBSERVATION_MODIFIER", 162, 166], ["pronounced", "OBSERVATION_MODIFIER", 167, 177], ["reductions", "OBSERVATION_MODIFIER", 178, 188]]], ["Centrifugation at 17000 g for both 3 and 30 min resulted in more than 99.99% reductions for Bifidobacterium, E.coli and Bacteroides.", [["Bifidobacterium", "CHEMICAL", 92, 107], ["Bifidobacterium", "SIMPLE_CHEMICAL", 92, 107], ["E.coli", "SPECIES", 109, 115], ["Centrifugation", "TREATMENT", 0, 14], ["Bifidobacterium", "PROBLEM", 92, 107], ["E.coli", "PROBLEM", 109, 115], ["Bacteroides", "PROBLEM", 120, 131], ["E.coli", "OBSERVATION", 109, 115], ["Bacteroides", "OBSERVATION", 120, 131]]], ["The reduction in Lactobacillus was slightly lower (99.7%\u201399.8%), whereas the reduction in the rRNA was 98.5\u201399.4%.", [["Lactobacillus", "SIMPLE_CHEMICAL", 17, 30], ["rRNA", "CELLULAR_COMPONENT", 94, 98], ["The reduction in Lactobacillus", "TEST", 0, 30], ["the rRNA", "TEST", 90, 98], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["Lactobacillus", "OBSERVATION_MODIFIER", 17, 30], ["slightly", "OBSERVATION_MODIFIER", 35, 43], ["lower", "OBSERVATION_MODIFIER", 44, 49], ["reduction", "OBSERVATION_MODIFIER", 77, 86]]], ["For 3 minutes at 17000 g the losses for viruses were negligible, except for polyomavirus (43.3% loss, 1.2Ct), herpesvirus (65.3% loss, 1.3Ct), and especially mimivirus (96.9% loss, 5.4Ct).", [["polyomavirus", "DISEASE", 76, 88], ["herpesvirus", "DISEASE", 110, 121], ["herpesvirus", "ORGANISM", 110, 121], ["viruses", "PROBLEM", 40, 47], ["polyomavirus", "PROBLEM", 76, 88], ["herpesvirus", "TEST", 110, 121], ["mimivirus", "TEST", 158, 167], ["polyomavirus", "OBSERVATION", 76, 88]]], ["Surprisingly, more than 90% reduction was observed for polyomavirus, coronavirus and herpesvirus, and 99.9% for mimivirus.", [["polyomavirus, coronavirus and herpesvirus", "DISEASE", 55, 96], ["polyomavirus", "ORGANISM", 55, 67], ["coronavirus", "ORGANISM", 69, 80], ["herpesvirus", "ORGANISM", 85, 96], ["mimivirus", "CANCER", 112, 121], ["coronavirus", "SPECIES", 69, 80], ["polyomavirus", "PROBLEM", 55, 67], ["coronavirus", "PROBLEM", 69, 80], ["herpesvirus", "TEST", 85, 96], ["mimivirus", "PROBLEM", 112, 121]]], ["Although the samples where thoroughly homogenised, it cannot be excluded that this observation is due to viral aggregates still present in the sample.Filtration: keep the viruses or get rid of bacteria? ::: ResultsFiltration is an efficient and widely used method to enrich viral particles by removing bacterial and host cells (human/animal/plant).", [["samples", "ANATOMY", 13, 20], ["sample", "ANATOMY", 143, 149], ["cells", "ANATOMY", 321, 326], ["ResultsFiltration", "CHEMICAL", 207, 224], ["host cells", "CELL", 316, 326], ["human", "ORGANISM", 328, 333], ["bacterial and host cells", "CELL_TYPE", 302, 326], ["human", "SPECIES", 328, 333], ["human", "SPECIES", 328, 333], ["the samples", "TEST", 9, 20], ["this observation", "TEST", 78, 94], ["viral aggregates", "PROBLEM", 105, 121], ["Filtration", "TREATMENT", 150, 160], ["the viruses", "PROBLEM", 167, 178], ["bacteria", "PROBLEM", 193, 201], ["viral particles", "PROBLEM", 274, 289], ["bacterial and host cells", "TREATMENT", 302, 326], ["host cells", "OBSERVATION", 316, 326]]], ["Therefore, the mock-virome and bacterial mock-community were filtered with a 0.8-\u03bcm centrifugal filter (PES), a 0.8-\u03bcm polycarbonate filter (PC), a 0.45-\u03bcm centrifugal filter (PVDF) or a 0.22-\u03bcm centrifugal filter (PVDF) and compared with an unfiltered control (Fig. 4).", [["polycarbonate", "CHEMICAL", 119, 132], ["PVDF", "CHEMICAL", 176, 180], ["PVDF", "CHEMICAL", 215, 219], ["a 0.8-\u03bcm centrifugal filter (PES", "TREATMENT", 75, 107], ["a 0.8-\u03bcm polycarbonate filter (PC", "TREATMENT", 110, 143], ["a 0.45-\u03bcm centrifugal filter (PVDF", "TREATMENT", 146, 180], ["a 0.22-\u03bcm centrifugal filter (PVDF", "TREATMENT", 185, 219], ["centrifugal filter", "OBSERVATION", 156, 174], ["centrifugal filter", "OBSERVATION", 195, 213]]], ["Filtration with the two 0.8-\u03bcm and 0.45-\u03bcm filters showed limited effects on most of the viruses in the mock-virome, except for mimivirus, the largest virus in the mock-virome, for which a 81.7% (3.8Ct increase), a 95.9% (6.8Ct) and a 99.0% (9.9Ct) reduction was observed for the 0.8-\u03bcm PES, the 0.8-\u03bcm PC and 0.45-\u03bcm filters, respectively.", [["Filtration", "TREATMENT", 0, 10], ["0.45-\u03bcm filters", "TREATMENT", 35, 50], ["limited effects", "PROBLEM", 58, 73], ["the viruses", "PROBLEM", 85, 96], ["mimivirus", "PROBLEM", 128, 137], ["the largest virus", "PROBLEM", 139, 156], ["Ct", "TEST", 199, 201], ["the 0.8-\u03bcm PC", "TREATMENT", 292, 305], ["0.45-\u03bcm filters", "TREATMENT", 310, 325], ["viruses", "OBSERVATION", 89, 96], ["largest", "OBSERVATION_MODIFIER", 143, 150], ["virus", "OBSERVATION", 151, 156]]], ["The least mimivirus was recovered using the 0.22-\u03bcm filter (99.90% reduction, 13.95Ct), and also 82.0% (4.1Ct) reduction was observed for herpesvirus using the 0.22-\u03bcm filter.", [["herpesvirus", "ORGANISM", 138, 149], ["the 0.22-\u03bcm filter", "TREATMENT", 40, 58], ["4.1Ct) reduction", "TREATMENT", 104, 120], ["herpesvirus", "PROBLEM", 138, 149], ["the 0.22-\u03bcm filter", "TREATMENT", 156, 174], ["least", "OBSERVATION_MODIFIER", 4, 9], ["mimivirus", "OBSERVATION", 10, 19]]], ["The use of the 0.8-\u03bcm PC filter resulted in a reduction of 99.1% (7.5Ct) and 99.2% (7.9Ct) for Lactobacillus and Bifidobacterium, respectively, whereas E.coli (80.7%, 2.5Ct) and Bacteroides (50.1%, 1.04Ct) showed modest reductions.", [["Lactobacillus", "CHEMICAL", 95, 108], ["Bacteroides", "CHEMICAL", 178, 189], ["E.coli", "SPECIES", 152, 158], ["the 0.8-\u03bcm PC filter", "TREATMENT", 11, 31], ["a reduction", "TEST", 44, 55], ["Lactobacillus", "TEST", 95, 108], ["Bifidobacterium", "TEST", 113, 128], ["E.coli", "TEST", 152, 158], ["Bacteroides", "TEST", 178, 189], ["Ct)", "TEST", 202, 205], ["modest reductions", "PROBLEM", 213, 230], ["reduction", "OBSERVATION_MODIFIER", 46, 55], ["modest", "OBSERVATION_MODIFIER", 213, 219], ["reductions", "OBSERVATION_MODIFIER", 220, 230]]], ["A much more efficient removal of bacteria was obtained with the 0.8-\u03bcm PES, 0.45-\u03bcm and 0.22-\u03bcm filters, removing 99.5% to 99.90% of all bacteria present in the bacterial mock-community.", [["bacteria", "PROBLEM", 33, 41], ["the 0.8-\u03bcm PES", "TREATMENT", 60, 74], ["0.22-\u03bcm filters", "TREATMENT", 88, 103], ["all bacteria", "PROBLEM", 133, 145], ["bacteria", "OBSERVATION", 33, 41], ["bacteria", "OBSERVATION", 137, 145], ["bacterial mock", "OBSERVATION", 161, 175]]], ["Independent of the filter used, rRNA was less efficiently removed than bacteria (30\u201375% reduction; 0.7\u20132.4Ct).Chloroform treatment efficiently removes bacteria but alters viral abundances ::: ResultsChloroform disrupts lipid membranes and is often used to remove bacteria.", [["lipid membranes", "ANATOMY", 219, 234], ["Chloroform", "CHEMICAL", 110, 120], ["Chloroform", "CHEMICAL", 199, 209], ["Chloroform", "CHEMICAL", 110, 120], ["Chloroform", "CHEMICAL", 199, 209], ["rRNA", "CELLULAR_COMPONENT", 32, 36], ["Chloroform", "SIMPLE_CHEMICAL", 110, 120], ["Chloroform", "SIMPLE_CHEMICAL", 199, 209], ["lipid membranes", "CELLULAR_COMPONENT", 219, 234], ["rRNA", "DNA", 32, 36], ["the filter", "TREATMENT", 15, 25], ["rRNA", "PROBLEM", 32, 36], ["bacteria", "TEST", 71, 79], ["Chloroform treatment", "TREATMENT", 110, 130], ["bacteria", "PROBLEM", 151, 159], ["Chloroform disrupts lipid membranes", "TREATMENT", 199, 234], ["bacteria", "PROBLEM", 263, 271], ["lipid membranes", "OBSERVATION", 219, 234]]], ["However, some viruses are enveloped, and their capsid can become unstable after envelope removal.", [["some viruses", "PROBLEM", 9, 21], ["envelope removal", "TREATMENT", 80, 96], ["some", "OBSERVATION_MODIFIER", 9, 13], ["viruses", "OBSERVATION", 14, 21]]], ["To determine the effects of chloroform, the mock-virome as well as the bacterial mock-community were incubated in the presence of 1%, 5%, 10% and 20% chloroform and compared with a non-chloroform exposed control sample.", [["chloroform", "CHEMICAL", 28, 38], ["chloroform", "CHEMICAL", 150, 160], ["chloroform", "CHEMICAL", 28, 38], ["chloroform", "CHEMICAL", 150, 160], ["chloroform", "SIMPLE_CHEMICAL", 28, 38], ["chloroform", "SIMPLE_CHEMICAL", 150, 160], ["chloroform", "TREATMENT", 28, 38], ["the mock-virome", "TREATMENT", 40, 55], ["20% chloroform", "TREATMENT", 146, 160], ["a non-chloroform exposed control sample", "TREATMENT", 179, 218]]], ["Incubation in 1% chloroform resulted in a reduction less than 1 Ct for all the enveloped and non-enveloped viruses, except for mimivirus showing a moderate loss of 53.2% (1.3Ct increase) (Fig. 5A).", [["chloroform", "CHEMICAL", 17, 27], ["chloroform", "CHEMICAL", 17, 27], ["chloroform", "SIMPLE_CHEMICAL", 17, 27], ["Incubation", "TREATMENT", 0, 10], ["1% chloroform", "TREATMENT", 14, 27], ["a reduction", "TREATMENT", 40, 51], ["1 Ct", "TEST", 62, 66], ["non-enveloped viruses", "PROBLEM", 93, 114], ["mimivirus", "PROBLEM", 127, 136], ["a moderate loss", "PROBLEM", 145, 160], ["viruses", "OBSERVATION", 107, 114], ["moderate", "OBSERVATION_MODIFIER", 147, 155], ["loss", "OBSERVATION_MODIFIER", 156, 160]]], ["When incubating with higher percentages of chloroform (5\u201320%), no or very limited losses for circovirus, parvovirus, pepino mosaic virus and LIMEstone virus were observed.", [["chloroform", "CHEMICAL", 43, 53], ["chloroform", "CHEMICAL", 43, 53], ["chloroform", "SIMPLE_CHEMICAL", 43, 53], ["circovirus", "ORGANISM", 93, 103], ["parvovirus", "ORGANISM", 105, 115], ["pepino mosaic virus", "ORGANISM", 117, 136], ["LIMEstone virus", "ORGANISM", 141, 156], ["pepino mosaic virus", "SPECIES", 117, 136], ["pepino mosaic virus", "SPECIES", 117, 136], ["LIMEstone virus", "SPECIES", 141, 156], ["chloroform", "TREATMENT", 43, 53], ["very limited losses", "PROBLEM", 69, 88], ["circovirus", "PROBLEM", 93, 103], ["parvovirus", "PROBLEM", 105, 115], ["pepino mosaic virus", "PROBLEM", 117, 136], ["LIMEstone virus", "PROBLEM", 141, 156], ["LIMEstone virus", "OBSERVATION", 141, 156]]], ["The highest reductions were observed for the enveloped coronavirus (range of reduction: 81.4\u201389.9%; 2.6\u20132.8Ct) and mimivirus (61.4\u201377%; 1.6\u20132.5Ct), and as well as for the non-enveloped rotavirus (range of reduction: 74\u201377%; 2.3\u20132.5Ct).", [["rotavirus", "DISEASE", 185, 194], ["coronavirus", "ORGANISM", 55, 66], ["rotavirus", "ORGANISM", 185, 194], ["The highest reductions", "PROBLEM", 0, 22], ["the enveloped coronavirus", "PROBLEM", 41, 66], ["reduction", "TEST", 77, 86], ["mimivirus", "TEST", 115, 124], ["the non-enveloped rotavirus", "PROBLEM", 167, 194], ["reduction", "TEST", 205, 214]]], ["In contrast, for the enveloped herpesvirus only 18.8\u201331.2% (0.38\u20130.69Ct) reduction was observed.", [["herpesvirus", "DISEASE", 31, 42], ["herpesvirus", "ORGANISM", 31, 42], ["the enveloped herpesvirus", "TEST", 17, 42], ["\u20130.69Ct) reduction", "TREATMENT", 64, 82]]], ["Gram-positive bacteria were sensitive to 1% chloroform, resulting in a decrease of 97.6\u201399.4% (6.1\u20137.9Ct) for Bifidobacterium and Lactobacillus, respectively, whereas Gram-negative bacteria were less affected with reductions below 90% (Fig. 5B).", [["chloroform", "CHEMICAL", 44, 54], ["Lactobacillus", "CHEMICAL", 130, 143], ["chloroform", "CHEMICAL", 44, 54], ["chloroform", "SIMPLE_CHEMICAL", 44, 54], ["Bifidobacterium", "SIMPLE_CHEMICAL", 110, 125], ["Lactobacillus", "SIMPLE_CHEMICAL", 130, 143], ["Gram-positive bacteria", "PROBLEM", 0, 22], ["1% chloroform", "TREATMENT", 41, 54], ["Bifidobacterium", "TEST", 110, 125], ["Lactobacillus", "TEST", 130, 143], ["Gram", "TEST", 167, 171], ["negative bacteria", "PROBLEM", 172, 189], ["bacteria", "OBSERVATION", 14, 22], ["decrease", "OBSERVATION_MODIFIER", 71, 79], ["negative bacteria", "OBSERVATION_MODIFIER", 172, 189]]], ["However, high concentrations of chloroform (10\u201320%) resulted in a substantial reduction of all bacterial species (99.6\u201399.999%; 8.8\u201317.6Ct).", [["chloroform", "CHEMICAL", 32, 42], ["chloroform", "CHEMICAL", 32, 42], ["chloroform", "SIMPLE_CHEMICAL", 32, 42], ["high concentrations of chloroform", "TREATMENT", 9, 42], ["all bacterial species", "PROBLEM", 91, 112], ["high", "OBSERVATION_MODIFIER", 9, 13], ["concentrations", "OBSERVATION_MODIFIER", 14, 28], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["reduction", "OBSERVATION_MODIFIER", 78, 87], ["bacterial species", "OBSERVATION", 95, 112]]], ["Finally, rRNA was reduced by 83.5\u201394.9% (2.9\u20134.8Ct), and only a limited effect was observed when the percentage of chloroform was changed (Fig. 5B).Random amplification: the necessary bias that amplifies all viruses ::: ResultsTo sequence viral RNA genomes, a reverse transcription step is required to convert RNA to DNA and all single-stranded genomes to double-stranded.", [["chloroform", "CHEMICAL", 115, 125], ["chloroform", "CHEMICAL", 115, 125], ["rRNA", "CELLULAR_COMPONENT", 9, 13], ["chloroform", "SIMPLE_CHEMICAL", 115, 125], ["DNA", "CELLULAR_COMPONENT", 317, 320], ["viral RNA genomes", "DNA", 239, 256], ["single-stranded genomes", "DNA", 329, 352], ["rRNA", "TEST", 9, 13], ["chloroform", "TREATMENT", 115, 125], ["viral RNA genomes", "OBSERVATION", 239, 256]]], ["Furthermore, the low amount of genetic material from a sample often requires an amplification step.", [["the low amount of genetic material", "PROBLEM", 13, 47], ["an amplification step", "TREATMENT", 77, 98], ["low amount", "OBSERVATION_MODIFIER", 17, 27], ["genetic material", "OBSERVATION", 31, 47]]], ["Amplification was performed using an adapted version of the Whole Transcriptome Amplification Kit 2 (WTA2) to amplify both DNA and RNA.", [["WTA2", "GENE_OR_GENE_PRODUCT", 101, 105], ["DNA", "CELLULAR_COMPONENT", 123, 126], ["the Whole Transcriptome Amplification Kit", "TREATMENT", 56, 97]]], ["To determine bias introduced by amplification, the number of cycles was varied with 5-step intervals between 7 and 22 and compared with a non-amplified control.", [["a non-amplified control", "TREATMENT", 136, 159]]], ["At 7 amplification cycles an increase of at least 374% (3.7-fold) was observed for all viruses in the mock-virome.", [["all viruses", "PROBLEM", 83, 94], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["viruses", "OBSERVATION", 87, 94]]], ["A strong increase in the concentration of all viruses was observed at 12 (range 26\u2013808 fold increase) and 17 cycles (range 170\u20136466 fold increase), whereas at 22 cycles, 3 out of 9 viruses in the mock-virome showed lower yields than at 17 cycles.", [["A strong increase", "PROBLEM", 0, 17], ["all viruses", "PROBLEM", 42, 53], ["strong", "OBSERVATION_MODIFIER", 2, 8], ["increase", "OBSERVATION_MODIFIER", 9, 17], ["concentration", "OBSERVATION_MODIFIER", 25, 38], ["all", "OBSERVATION_MODIFIER", 42, 45], ["viruses", "OBSERVATION", 46, 53]]], ["The same procedure was followed for the bacterial mock-community and bacterial amplification after 7 cycles for Lactobacillus, E.coli and Bacteroides ranged between 1061\u20132033%, and increased 5611% for rRNA (Fig. 6).", [["Lactobacillus", "CHEMICAL", 112, 125], ["Bacteroides", "CHEMICAL", 138, 149], ["The same procedure", "TREATMENT", 0, 18], ["the bacterial mock", "TEST", 36, 54], ["bacterial amplification", "TREATMENT", 69, 92], ["Lactobacillus", "TEST", 112, 125], ["E.coli", "PROBLEM", 127, 133], ["Bacteroides", "TEST", 138, 149]]], ["An increase between 7844% and 19088% was observed for 12 amplification cycles, whereas rRNA increased to 14920%.", [["rRNA", "CELLULAR_COMPONENT", 87, 91], ["rRNA", "TEST", 87, 91], ["increase", "OBSERVATION_MODIFIER", 3, 11]]], ["For 17 and 22 cycles, the median amplification decreased, and for 22 cycles amplification pattern was similar to 7 cycles.", [["the median amplification", "TREATMENT", 22, 46], ["22 cycles amplification pattern", "TREATMENT", 66, 97], ["decreased", "OBSERVATION_MODIFIER", 47, 56]]], ["No amplification was observed for the Bifidobacterium for 7, 17 and 22 cycles and very limited amplification (7.5%) for 12 cycles.The percentage of sequencing reads correlates with number of viral genome copies after amplification ::: ResultsBased on all results above, seven different work-flows were selected including homogenisation at 3000 rpm without beads and 17 amplification cycles, in combination with different conditions of filtration (0.8 PC/PES, 0.45 and 0.22-\u03bcm) and/or centrifugation (3 min at 17000 g).", [["Bifidobacterium", "CHEMICAL", 38, 53], ["viral genome copies", "DNA", 191, 210], ["the Bifidobacterium", "TEST", 34, 53], ["beads", "TREATMENT", 356, 361], ["filtration", "TEST", 435, 445], ["PC/PES", "TREATMENT", 451, 457]]], ["A combined artificial community of viruses and bacteria was subjected to the selected conditions and sequenced using an Illumina HiSeq2500\u2122.", [["Illumina HiSeq2500\u2122", "DNA", 120, 139], ["A combined artificial community of viruses", "PROBLEM", 0, 42], ["bacteria", "PROBLEM", 47, 55], ["viruses", "OBSERVATION", 35, 42]]], ["In the control sample sequencing data, 47.6%, 43.2% and 1.6% of the reads were attributed to bacteria, viruses and rRNA, respectively (Fig. 7A and Table S4).", [["sequencing data", "TEST", 22, 37], ["bacteria", "PROBLEM", 93, 101], ["viruses", "PROBLEM", 103, 110], ["rRNA", "TEST", 115, 119], ["bacteria", "OBSERVATION", 93, 101]]], ["The unmapped reads obtained were attributed to residual host and bacterial DNA derived from the preparation of viral stocks, such as Dickeya solani and Chlamydiales.", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["Dickeya solani", "ORGANISM", 133, 147], ["bacterial DNA", "DNA", 65, 78], ["Dickeya solani", "SPECIES", 133, 147], ["Dickeya solani", "SPECIES", 133, 147], ["The unmapped reads", "TEST", 0, 18], ["residual host", "PROBLEM", 47, 60], ["bacterial DNA", "PROBLEM", 65, 78], ["viral stocks", "TREATMENT", 111, 123], ["Dickeya solani and Chlamydiales", "PROBLEM", 133, 164], ["residual host", "OBSERVATION", 47, 60], ["bacterial DNA", "OBSERVATION", 65, 78], ["viral stocks", "OBSERVATION", 111, 123]]], ["The use of the 0.8-\u03bcm PC filter resulted only in minor reduction in the percentage of reads mapping to bacteria (47.3%).", [["the 0.8-\u03bcm PC filter", "TREATMENT", 11, 31], ["minor reduction", "TREATMENT", 49, 64], ["bacteria", "TEST", 103, 111], ["minor", "OBSERVATION_MODIFIER", 49, 54], ["reduction", "OBSERVATION_MODIFIER", 55, 64]]], ["The remaining filtering and/or centrifugation conditions resulted in a dramatic reduction in the percentage reads that mapped to bacteria (ranging from 0.39% to 0.71%), while the number of viral reads increased to 88.8\u201396.7%.", [["centrifugation conditions", "TREATMENT", 31, 56], ["a dramatic reduction", "PROBLEM", 69, 89], ["bacteria", "PROBLEM", 129, 137], ["viral reads", "TEST", 189, 200], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["filtering", "OBSERVATION", 14, 23], ["dramatic", "OBSERVATION_MODIFIER", 71, 79], ["reduction", "OBSERVATION_MODIFIER", 80, 89]]], ["The 0.8-\u03bcm PES filter plus centrifugation condition yielded the highest percentage of viral reads, of which most were attributed to pepino mosaic virus (33.9%), LIMEstone virus (32.9%) and rotavirus (20.6%) (Fig. 7B).", [["pepino mosaic virus", "DISEASE", 132, 151], ["rotavirus", "DISEASE", 189, 198], ["pepino mosaic virus", "ORGANISM", 132, 151], ["LIMEstone virus", "ORGANISM", 161, 176], ["pepino mosaic virus", "SPECIES", 132, 151], ["pepino mosaic virus", "SPECIES", 132, 151], ["LIMEstone virus", "SPECIES", 161, 176], ["The 0.8-\u03bcm PES filter plus centrifugation condition", "TREATMENT", 0, 51], ["pepino mosaic virus", "PROBLEM", 132, 151], ["LIMEstone virus", "TEST", 161, 176], ["rotavirus", "TEST", 189, 198], ["viral reads", "OBSERVATION", 86, 97]]], ["When comparing the distribution of the viral reads of the control, the four protocols without centrifugation showed an expansion of the LIMEstone virus reads, mainly at the expense of rotavirus and pepino mosaic virus reads.", [["rotavirus", "ORGANISM", 184, 193], ["pepino mosaic virus", "ORGANISM", 198, 217], ["LIMEstone virus", "SPECIES", 136, 151], ["rotavirus", "SPECIES", 184, 193], ["pepino mosaic virus", "SPECIES", 198, 217], ["an expansion of the LIMEstone virus reads", "PROBLEM", 116, 157], ["rotavirus", "PROBLEM", 184, 193], ["pepino mosaic virus reads", "PROBLEM", 198, 223], ["expansion", "OBSERVATION", 119, 128], ["LIMEstone virus reads", "OBSERVATION", 136, 157], ["rotavirus", "OBSERVATION", 184, 193], ["mosaic virus", "OBSERVATION", 205, 217]]], ["Also, the combination of centrifugation with filtration showed a minimal increase of LIMEstone virus and pepino mosaic virus reads, but at the expense of parvovirus, polyomavirus and circovirus reads.", [["LIMEstone virus", "ORGANISM", 85, 100], ["pepino mosaic virus", "ORGANISM", 105, 124], ["parvovirus", "ORGANISM", 154, 164], ["polyomavirus", "ORGANISM", 166, 178], ["circovirus", "ORGANISM", 183, 193], ["circovirus", "SPECIES", 183, 193], ["LIMEstone virus", "SPECIES", 85, 100], ["pepino mosaic virus", "SPECIES", 105, 124], ["circovirus", "SPECIES", 183, 193], ["centrifugation", "TREATMENT", 25, 39], ["filtration", "TREATMENT", 45, 55], ["LIMEstone virus", "PROBLEM", 85, 100], ["pepino mosaic virus reads", "PROBLEM", 105, 130], ["parvovirus", "PROBLEM", 154, 164], ["polyomavirus", "PROBLEM", 166, 178], ["minimal", "OBSERVATION_MODIFIER", 65, 72], ["increase", "OBSERVATION_MODIFIER", 73, 81], ["LIMEstone virus", "OBSERVATION", 85, 100], ["mosaic virus reads", "OBSERVATION", 112, 130], ["parvovirus", "OBSERVATION", 154, 164], ["circovirus reads", "OBSERVATION", 183, 199]]], ["The percentage of herpesvirus reads in the control was low (0.11%) and slightly increased with centrifugation plus 0.8-\u03bcm PES filter (0.18%).", [["herpesvirus", "ORGANISM", 18, 29], ["centrifugation", "TEST", 95, 109], ["0.8-\u03bcm PES filter", "TREATMENT", 115, 132], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["herpesvirus reads", "OBSERVATION", 18, 35], ["slightly", "OBSERVATION_MODIFIER", 71, 79], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["PES filter", "OBSERVATION", 122, 132]]], ["For the remaining conditions, herpesvirus reads ranged from 0.04% to 0.24%.", [["herpesvirus", "ORGANISM", 30, 41], ["the remaining conditions", "PROBLEM", 4, 28], ["herpesvirus reads", "TEST", 30, 47]]], ["The mimivirus viral reads in the control (0.91%) could only be increased when filtering with 0.8-\u03bcm PC filter (2.2%), but were strongly reduced when using the other protocols (0.011%\u20130.034%).", [["mimivirus viral reads", "DNA", 4, 25], ["The mimivirus viral reads", "TREATMENT", 0, 25], ["0.8-\u03bcm PC filter", "TREATMENT", 93, 109], ["the other protocols", "TREATMENT", 155, 174], ["mimivirus", "OBSERVATION", 4, 13], ["viral reads", "OBSERVATION", 14, 25], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["Although nearly all bacteria were removed, the distribution of remaining bacterial sequence reads was dominated by Bacteroides in the control and 0.8-\u03bcm PC filter (41.3% and 43.5% of total reads, respectively), whereas in the remaining conditions E.coli was the most abundant (0.14\u20130.40%) (Fig. 7C and Table S4).", [["Bacteroides", "CHEMICAL", 115, 126], ["E.coli", "SPECIES", 247, 253], ["nearly all bacteria", "PROBLEM", 9, 28], ["remaining bacterial sequence reads", "PROBLEM", 63, 97], ["Bacteroides", "PROBLEM", 115, 126], ["\u03bcm PC filter", "TREATMENT", 150, 162], ["the remaining conditions E.coli", "PROBLEM", 222, 253], ["all", "OBSERVATION_MODIFIER", 16, 19], ["bacteria", "OBSERVATION", 20, 28], ["E.coli", "OBSERVATION", 247, 253]]], ["The rRNA obtained reads were low for the control (1.59%) and reduced to 0.2%\u20130.004% for the treated conditions.", [["rRNA", "CELLULAR_COMPONENT", 4, 8], ["The rRNA", "TEST", 0, 8]]], ["Overall, a good correlation was observed between the number of viral copies as determined by qPCR and the percentage of mapped reads (R2 = 0.91).", [["viral copies", "TEST", 63, 75], ["qPCR", "TEST", 93, 97], ["R2", "TEST", 134, 136]]], ["For most viruses a high correlation between 0.88 and 0.97 was observed, only for circovirus and herpesvirus the correlation was slightly lower (R2 = 0.75 and 0.63, respectively) (Fig. 7D).", [["circovirus", "ORGANISM", 81, 91], ["herpesvirus", "ORGANISM", 96, 107], ["circovirus", "PROBLEM", 81, 91], ["R2", "TEST", 144, 146]]], ["For parvovirus no correlation was observed (R2 = 0.16).", [["parvovirus", "ORGANISM", 4, 14], ["parvovirus", "PROBLEM", 4, 14], ["R2", "TEST", 44, 46]]], ["No correlation for bacteria was calculated as the qPCR measurements for the bacteria after treatment were often below the detection limits of the used assays.The percentage of sequencing reads correlates with number of viral genome copies after amplification ::: ResultsTaking into account the sequencing results, a favoured protocol named NetoVIR (Novel enrichment technique of VIRomes) was selected.", [["viral genome copies", "DNA", 219, 238], ["bacteria", "PROBLEM", 19, 27], ["the qPCR measurements", "TEST", 46, 67], ["the bacteria", "PROBLEM", 72, 84], ["treatment", "TREATMENT", 91, 100], ["a favoured protocol", "TREATMENT", 314, 333], ["NetoVIR (Novel enrichment technique of VIRomes)", "TREATMENT", 340, 387]]], ["NetoVIR consisted of homogenisation at 3000 rpm for 1 min without beads, centrifugation for 3 min at 17000 g plus 0.8-\u03bcm PES filter filtration and 17 amplification cycles (Fig. 1), and was further tested for reproducibility.", [["NetoVIR", "TREATMENT", 0, 7], ["0.8-\u03bcm PES filter filtration", "TREATMENT", 114, 142], ["reproducibility", "TEST", 208, 223], ["filter filtration", "OBSERVATION", 125, 142]]], ["Two replicates were processed in parallel and evaluated before and after the procedure (Fig. S1 and Table S5).", [["S1", "GENE_OR_GENE_PRODUCT", 93, 95], ["Table S5", "GENE_OR_GENE_PRODUCT", 100, 108], ["S1", "PROTEIN", 93, 95], ["the procedure", "TREATMENT", 73, 86]]], ["Before the procedure, standard deviations ranged from 3% for the LIMEstone virus to 19% for the polyomavirus.", [["LIMEstone", "DISEASE", 65, 74], ["polyomavirus", "DISEASE", 96, 108], ["polyomavirus", "ORGANISM", 96, 108], ["LIMEstone virus", "SPECIES", 65, 80], ["the procedure", "TREATMENT", 7, 20], ["standard deviations", "TEST", 22, 41], ["the LIMEstone virus", "TREATMENT", 61, 80], ["the polyomavirus", "PROBLEM", 92, 108], ["polyomavirus", "OBSERVATION", 96, 108]]], ["After treatment, standard deviations ranged from 3% for the coronavirus to 24% of the circovirus.", [["coronavirus", "DISEASE", 60, 71], ["coronavirus", "ORGANISM", 60, 71], ["circovirus", "ORGANISM", 86, 96], ["treatment", "TREATMENT", 6, 15], ["standard deviations", "TEST", 17, 36], ["the coronavirus", "PROBLEM", 56, 71], ["the circovirus", "PROBLEM", 82, 96], ["circovirus", "OBSERVATION", 86, 96]]], ["As a result of a low viral copy number after centrifugation and filtration, a slightly higher standard deviation was observed for mimivirus (38%).", [["filtration", "TREATMENT", 64, 74], ["a slightly higher standard deviation", "PROBLEM", 76, 112], ["mimivirus", "PROBLEM", 130, 139], ["slightly", "OBSERVATION_MODIFIER", 78, 86], ["higher", "OBSERVATION_MODIFIER", 87, 93]]], ["Overall, the standard deviation was comparably low before and after the procedure (Fig. S1 and Table S5).DiscussionAberrations of the human virome have been implicated in acute and chronic diseases.", [["S1", "GENE_OR_GENE_PRODUCT", 88, 90], ["Table S5", "GENE_OR_GENE_PRODUCT", 95, 103], ["human", "ORGANISM", 134, 139], ["virome", "CANCER", 140, 146], ["S1", "PROTEIN", 88, 90], ["human", "SPECIES", 134, 139], ["human", "SPECIES", 134, 139], ["the procedure", "TREATMENT", 68, 81], ["the human virome", "PROBLEM", 130, 146], ["acute and chronic diseases", "PROBLEM", 171, 197], ["low", "OBSERVATION_MODIFIER", 47, 50], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["chronic", "OBSERVATION_MODIFIER", 181, 188], ["diseases", "OBSERVATION", 189, 197]]], ["In order to systematically investigate virome-disease relationships, reproducible, inexpensive and high-throughput virome methods are urgently needed.", [["virome-disease relationships", "PROBLEM", 39, 67], ["inexpensive and high-throughput virome methods", "PROBLEM", 83, 129]]], ["In this study we investigated bias that can be introduced during various sample treatment procedures commonly used in viral metagenomics studies on artificial, well-characterised communities of viruses and bacteria.", [["sample", "ANATOMY", 73, 79], ["communities", "ANATOMY", 179, 190], ["this study", "TEST", 3, 13], ["various sample treatment procedures", "TREATMENT", 65, 100], ["viral metagenomics studies", "TEST", 118, 144], ["viruses", "PROBLEM", 194, 201], ["bacteria", "PROBLEM", 206, 214], ["viruses", "OBSERVATION", 194, 201]]], ["With the results obtained we established a protocol for viral metagenomics that maximises removal of non-viral nucleic acids, while minimising disturbances in viral relative abundances.DiscussionA homogeneous solution is crucial for optimal and reproducible viral particle purification from most biological or environmental sample.", [["nucleic acids", "CHEMICAL", 111, 124], ["a protocol", "TREATMENT", 41, 51], ["viral metagenomics", "PROBLEM", 56, 74], ["removal", "TREATMENT", 90, 97], ["non-viral nucleic acids", "TREATMENT", 101, 124], ["minimising disturbances in viral relative abundances", "PROBLEM", 132, 184], ["reproducible viral particle purification", "PROBLEM", 245, 285], ["nucleic acids", "OBSERVATION", 111, 124]]], ["No or limited homogenisation might be needed for cell culture supernatants, water or blood/serum samples.", [["cell", "ANATOMY", 49, 53], ["supernatants", "ANATOMY", 62, 74], ["blood", "ANATOMY", 85, 90], ["serum samples", "ANATOMY", 91, 104], ["cell", "CELL", 49, 53], ["water", "SIMPLE_CHEMICAL", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["serum samples", "ORGANISM_SUBSTANCE", 91, 104], ["limited homogenisation", "PROBLEM", 6, 28], ["cell culture supernatants", "TEST", 49, 74], ["blood/serum samples", "TEST", 85, 104]]], ["Faeces, respiratory or soil samples may benefit from a proper homogenisation, whereas tissue samples cannot proceed without a thorough homogenisation for virus release, often using beads of varying sizes.", [["Faeces", "ANATOMY", 0, 6], ["respiratory", "ANATOMY", 8, 19], ["soil samples", "ANATOMY", 23, 35], ["tissue samples", "ANATOMY", 86, 100], ["tissue samples", "TISSUE", 86, 100], ["respiratory or soil samples", "PROBLEM", 8, 35], ["virus release", "TREATMENT", 154, 167], ["respiratory", "ANATOMY", 8, 19], ["varying", "OBSERVATION_MODIFIER", 190, 197], ["sizes", "OBSERVATION_MODIFIER", 198, 203]]], ["In this study we evaluated the effect of several homogenisation conditions on our artificial communities.", [["this study", "TEST", 3, 13], ["several homogenisation conditions", "PROBLEM", 41, 74]]], ["Homogenisation with 2.8 mm beads resulted in severe loss of coronavirus and mimivirus, and particularly in a strong increase of bacteria and bacterial rRNA.", [["loss of coronavirus and mimivirus", "DISEASE", 52, 85], ["coronavirus", "ORGANISM", 60, 71], ["bacterial rRNA", "RNA", 141, 155], ["Homogenisation", "TEST", 0, 14], ["2.8 mm beads", "PROBLEM", 20, 32], ["severe loss of coronavirus", "PROBLEM", 45, 71], ["mimivirus", "PROBLEM", 76, 85], ["bacteria", "PROBLEM", 128, 136], ["bacterial rRNA", "PROBLEM", 141, 155], ["2.8 mm", "OBSERVATION_MODIFIER", 20, 26], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["loss", "OBSERVATION", 52, 56], ["coronavirus", "OBSERVATION", 60, 71], ["strong", "OBSERVATION_MODIFIER", 109, 115], ["increase", "OBSERVATION_MODIFIER", 116, 124], ["bacteria", "OBSERVATION", 128, 136], ["bacterial rRNA", "OBSERVATION", 141, 155]]], ["Since the nucleic acids extraction kit used in this study was not optimised to extract bacterial DNA, extraction efficiency might be enhanced when homogenising with 2.8 mm beads by severely impairing bacterial cell walls.", [["cell walls", "ANATOMY", 210, 220], ["nucleic acids", "CHEMICAL", 10, 23], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["cell", "CELL", 210, 214], ["the nucleic acids extraction", "TREATMENT", 6, 34], ["this study", "TEST", 47, 57], ["bacterial DNA", "PROBLEM", 87, 100], ["extraction efficiency", "PROBLEM", 102, 123], ["severely impairing bacterial cell walls", "PROBLEM", 181, 220], ["bacterial DNA", "OBSERVATION", 87, 100], ["severely", "OBSERVATION_MODIFIER", 181, 189], ["impairing", "OBSERVATION_MODIFIER", 190, 199], ["bacterial cell walls", "OBSERVATION", 200, 220]]], ["For any virome study this seems to be highly undesirable and should therefore be avoided.", [["any virome study", "TEST", 4, 20]]], ["If unavoidable, viral losses have to be considered when interpreting the obtained results.", [["unavoidable", "PROBLEM", 3, 14], ["viral losses", "PROBLEM", 16, 28]]], ["The same effect was not observed when 0.1 mm beads were used, suggesting that a bigger mechanical force is necessary to increase extraction efficiency.", [["a bigger mechanical force", "TREATMENT", 78, 103], ["extraction efficiency", "TREATMENT", 129, 150]]], ["Overall, the smallest effects on viral losses were observed using the lowest homogenisation speed without beads.", [["viral losses", "PROBLEM", 33, 45], ["smallest", "OBSERVATION_MODIFIER", 13, 21], ["effects", "OBSERVATION_MODIFIER", 22, 29], ["viral losses", "OBSERVATION", 33, 45]]], ["In our experience, a proper homogenisation without beads is sufficient to destroy faecal aggregates and obtain a workable suspension.DiscussionCentrifugation, filtration and chloroform treatment are commonly used methods to enrich samples for viral particles.", [["faecal aggregates", "ANATOMY", 82, 99], ["samples", "ANATOMY", 231, 238], ["chloroform", "CHEMICAL", 174, 184], ["chloroform", "CHEMICAL", 174, 184], ["chloroform", "SIMPLE_CHEMICAL", 174, 184], ["a proper homogenisation without beads", "TREATMENT", 19, 56], ["a workable suspension", "TREATMENT", 111, 132], ["DiscussionCentrifugation", "TREATMENT", 133, 157], ["filtration", "TREATMENT", 159, 169], ["chloroform treatment", "TREATMENT", 174, 194], ["viral particles", "PROBLEM", 243, 258]]], ["The increasing number of reports on giant viruses, which have similar physical dimensions as small bacteria makes this challenging272829.", [["giant viruses", "PROBLEM", 36, 49], ["small bacteria", "PROBLEM", 93, 107], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["number", "OBSERVATION_MODIFIER", 15, 21], ["giant", "OBSERVATION_MODIFIER", 36, 41], ["viruses", "OBSERVATION", 42, 49], ["physical dimensions", "OBSERVATION_MODIFIER", 70, 89], ["small", "OBSERVATION_MODIFIER", 93, 98], ["bacteria", "OBSERVATION", 99, 107]]], ["Centrifugation is widely used in virome studies prior to filtration131426, but effects on the virome have been quantitated poorly.", [["Centrifugation", "TREATMENT", 0, 14], ["virome studies", "TEST", 33, 47], ["filtration", "TREATMENT", 57, 67], ["widely", "OBSERVATION_MODIFIER", 18, 24]]], ["Centrifugation for 3 min at 17000 g resulted in the removal of almost all bacteria, but unfortunately a significant reduction of mimivirus was also observed (Fig. 3).", [["mimivirus", "CANCER", 129, 138], ["Centrifugation", "TREATMENT", 0, 14], ["the removal", "TREATMENT", 48, 59], ["almost all bacteria", "PROBLEM", 63, 82], ["a significant reduction of mimivirus", "PROBLEM", 102, 138], ["bacteria", "OBSERVATION", 74, 82], ["significant", "OBSERVATION_MODIFIER", 104, 115], ["reduction", "OBSERVATION_MODIFIER", 116, 125], ["mimivirus", "OBSERVATION", 129, 138]]], ["Interestingly, centrifugation at 17000 g also resulted in a decrease around 99% in rRNA despite the fact that ribosomes have a size (20\u201330 nm) similar to those of many other viruses in our mock-virome (Table 1).", [["ribosomes", "ANATOMY", 110, 119], ["rRNA", "CELLULAR_COMPONENT", 83, 87], ["ribosomes", "CELLULAR_COMPONENT", 110, 119], ["a decrease", "PROBLEM", 58, 68], ["decrease", "OBSERVATION_MODIFIER", 60, 68], ["size", "OBSERVATION_MODIFIER", 127, 131], ["viruses", "OBSERVATION", 174, 181]]], ["However, the higher density of ribosomes (more than 1.6 g/cm230) in comparison to viral particles may have led to their more efficient precipitation (Table 1).", [["ribosomes", "ANATOMY", 31, 40], ["ribosomes", "CELLULAR_COMPONENT", 31, 40], ["the higher density of ribosomes", "PROBLEM", 9, 40], ["higher", "OBSERVATION_MODIFIER", 13, 19], ["density", "OBSERVATION_MODIFIER", 20, 27], ["ribosomes", "OBSERVATION_MODIFIER", 31, 40], ["viral particles", "OBSERVATION_MODIFIER", 82, 97]]], ["Alternatively this observation may be partially explained by the fact that some of the ribosomes may still have been attached to larger bacterial cellular components.DiscussionFiltration is probably the most used procedure to separate viral from bacterial/host cells during virome studies.", [["ribosomes", "ANATOMY", 87, 96], ["cellular", "ANATOMY", 146, 154], ["cells", "ANATOMY", 261, 266], ["ribosomes", "CELLULAR_COMPONENT", 87, 96], ["cellular", "CELL", 146, 154], ["host cells", "CELL", 256, 266], ["bacterial/host cells", "CELL_TYPE", 246, 266], ["larger bacterial cellular components", "PROBLEM", 129, 165], ["procedure", "TREATMENT", 213, 222], ["bacterial/host cells", "PROBLEM", 246, 266], ["virome studies", "TEST", 274, 288], ["may be partially explained", "UNCERTAINTY", 31, 57], ["larger", "OBSERVATION_MODIFIER", 129, 135], ["bacterial", "OBSERVATION_MODIFIER", 136, 145], ["cellular components", "OBSERVATION", 146, 165], ["host cells", "OBSERVATION", 256, 266]]], ["The most popular filters for viral metagenomics studies contain 0.45-\u03bcm or 0.22-\u03bcm pore sizes17.", [["viral metagenomics studies", "TEST", 29, 55]]], ["Our results showed that the majority (>99.5%) of bacteria in our mock-community were efficiently removed using filtration.", [["bacteria", "PROBLEM", 49, 57], ["filtration", "TREATMENT", 111, 121], ["bacteria", "OBSERVATION_MODIFIER", 49, 57]]], ["Only the 0.8-\u03bcm PC filter had a relatively low filter efficiency (from 50% to 99.2%).", [["\u03bcm PC filter", "TREATMENT", 13, 25], ["a relatively low filter efficiency", "PROBLEM", 30, 64], ["relatively", "OBSERVATION_MODIFIER", 32, 42], ["low filter efficiency", "OBSERVATION", 43, 64]]], ["Unfortunately, filters efficiently removing bacteria also removed more than 99% of mimivirus (Fig. 4A).", [["bacteria", "PROBLEM", 44, 52]]], ["Not unexpectedly, more than 90% of the herpesviruses were lost with the 0.22-\u03bcm filter, alongside unexpected losses of several smaller viruses.", [["herpesviruses", "ORGANISM", 39, 52], ["the herpesviruses", "PROBLEM", 35, 52], ["the 0.22-\u03bcm filter", "TREATMENT", 68, 86], ["several smaller viruses", "PROBLEM", 119, 142], ["herpesviruses", "OBSERVATION", 39, 52], ["losses", "OBSERVATION_MODIFIER", 109, 115], ["several", "OBSERVATION_MODIFIER", 119, 126], ["smaller", "OBSERVATION_MODIFIER", 127, 134], ["viruses", "OBSERVATION", 135, 142]]], ["Free floating ribosomes (20\u201330 nm) were not efficiently removed by filtration regardless of the pore size.", [["ribosomes", "ANATOMY", 14, 23], ["pore", "ANATOMY", 96, 100], ["ribosomes", "CELLULAR_COMPONENT", 14, 23], ["pore", "CELLULAR_COMPONENT", 96, 100], ["Free floating ribosomes", "TREATMENT", 0, 23], ["floating ribosomes", "OBSERVATION", 5, 23], ["pore", "OBSERVATION_MODIFIER", 96, 100], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["Our findings suggest that besides the pore size, also the filter material highly influences filter efficiency.", [["pore", "ANATOMY", 38, 42], ["the filter material", "TREATMENT", 54, 73], ["pore", "OBSERVATION_MODIFIER", 38, 42], ["size", "OBSERVATION_MODIFIER", 43, 47], ["filter", "OBSERVATION", 58, 64], ["filter efficiency", "OBSERVATION", 92, 109]]], ["This was prominently observed between 0.8-\u03bcm PC and PES filters.", [["PES filters", "TREATMENT", 52, 63], ["PES filters", "OBSERVATION", 52, 63]]], ["Polycarbonate filters have pores precisely cylindrical and narrowly distributed across a thin polycarbonate sheet, whereas the centrifugal PES filter is a 3D polymer network, resulting in much higher filtering efficiency for bacteria and mimivirus (Fig. 4).", [["Polycarbonate", "CHEMICAL", 0, 13], ["polycarbonate", "CHEMICAL", 94, 107], ["Polycarbonate", "SIMPLE_CHEMICAL", 0, 13], ["Polycarbonate filters", "TREATMENT", 0, 21], ["a thin polycarbonate sheet", "TREATMENT", 87, 113], ["the centrifugal PES filter", "TREATMENT", 123, 149], ["a 3D polymer network", "TREATMENT", 153, 173], ["much higher filtering efficiency", "PROBLEM", 188, 220], ["bacteria", "PROBLEM", 225, 233], ["mimivirus", "PROBLEM", 238, 247], ["cylindrical", "OBSERVATION_MODIFIER", 43, 54], ["narrowly", "OBSERVATION_MODIFIER", 59, 67], ["centrifugal", "OBSERVATION_MODIFIER", 127, 138], ["PES filter", "OBSERVATION", 139, 149], ["higher", "OBSERVATION_MODIFIER", 193, 199], ["filtering efficiency", "OBSERVATION", 200, 220]]], ["A limitation of our study is that no representatives of very small bacteria were included, however a great majority of small bacteria are obligate intracellular (e.g. Chlamydiales, Mycoplasmatales) and therefore removed together with their host during centrifugation and filtration.DiscussionChloroform destabilises lipid membranes, disrupting the bacterial structural integrity after which bacterial nucleic acids become available for nucleases.", [["intracellular", "ANATOMY", 147, 160], ["lipid membranes", "ANATOMY", 316, 331], ["Chloroform", "CHEMICAL", 292, 302], ["nucleic acids", "CHEMICAL", 401, 414], ["Chloroform", "CHEMICAL", 292, 302], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 147, 160], ["Chloroform", "SIMPLE_CHEMICAL", 292, 302], ["lipid membranes", "CELLULAR_COMPONENT", 316, 331], ["nucleases", "PROTEIN", 436, 445], ["our study", "TEST", 16, 25], ["very small bacteria", "PROBLEM", 56, 75], ["small bacteria", "PROBLEM", 119, 133], ["filtration", "TREATMENT", 271, 281], ["Chloroform destabilises lipid membranes", "TREATMENT", 292, 331], ["bacterial nucleic acids", "TEST", 391, 414], ["nucleases", "PROBLEM", 436, 445], ["very", "OBSERVATION_MODIFIER", 56, 60], ["small", "OBSERVATION_MODIFIER", 61, 66], ["bacteria", "OBSERVATION", 67, 75], ["great", "OBSERVATION_MODIFIER", 101, 106], ["small", "OBSERVATION_MODIFIER", 119, 124], ["bacteria", "OBSERVATION", 125, 133], ["lipid membranes", "OBSERVATION", 316, 331], ["bacterial structural integrity", "OBSERVATION", 348, 378]]], ["According to our findings, chloroform concentration highly correlated with bacterial removal.", [["chloroform", "CHEMICAL", 27, 37], ["chloroform", "CHEMICAL", 27, 37], ["chloroform", "SIMPLE_CHEMICAL", 27, 37], ["chloroform concentration", "TREATMENT", 27, 51], ["bacterial removal", "TREATMENT", 75, 92], ["bacterial removal", "OBSERVATION", 75, 92]]], ["However, enveloped viruses, especially coronavirus and mimivirus, also lost stability after the removal of the envelope.", [["enveloped viruses", "ORGANISM", 9, 26], ["coronavirus", "ORGANISM", 39, 50], ["coronavirus", "SPECIES", 39, 50], ["enveloped viruses", "PROBLEM", 9, 26], ["coronavirus", "PROBLEM", 39, 50], ["mimivirus", "PROBLEM", 55, 64], ["the removal of the envelope", "TREATMENT", 92, 119], ["enveloped", "OBSERVATION_MODIFIER", 9, 18], ["viruses", "OBSERVATION", 19, 26], ["stability", "OBSERVATION_MODIFIER", 76, 85]]], ["Interestingly, some non-enveloped viruses were also susceptible to chloroform, especially rotavirus and polyomavirus.", [["chloroform", "CHEMICAL", 67, 77], ["chloroform", "CHEMICAL", 67, 77], ["chloroform", "SIMPLE_CHEMICAL", 67, 77], ["rotavirus", "ORGANISM", 90, 99], ["polyomavirus", "ORGANISM", 104, 116], ["some non-enveloped viruses", "PROBLEM", 15, 41], ["chloroform", "TREATMENT", 67, 77], ["rotavirus", "PROBLEM", 90, 99], ["polyomavirus", "PROBLEM", 104, 116], ["non-enveloped", "OBSERVATION_MODIFIER", 20, 33], ["viruses", "OBSERVATION", 34, 41]]], ["It is also known that other non-enveloped phages belonging to the Corticoviridae, Plasmaviridae or Inoviridae are susceptible to chloroform31.", [["Plasmaviridae", "CHEMICAL", 82, 95], ["chloroform", "CHEMICAL", 129, 139], ["chloroform", "CHEMICAL", 129, 139], ["Corticoviridae", "GENE_OR_GENE_PRODUCT", 66, 80], ["Plasmaviridae", "GENE_OR_GENE_PRODUCT", 82, 95], ["Inoviridae", "GENE_OR_GENE_PRODUCT", 99, 109], ["chloroform31", "SIMPLE_CHEMICAL", 129, 141], ["the Corticoviridae", "TREATMENT", 62, 80], ["Plasmaviridae", "TREATMENT", 82, 95], ["Inoviridae", "TREATMENT", 99, 109], ["chloroform", "TREATMENT", 129, 139]]], ["The effect of chloroform seems highly virus-specific and therefore chloroform might not be a preferred approach for virome studies.DiscussionRandom amplification of viral genetic material is crucial in viral metagenomics to obtain sufficient input material for sequencing.", [["chloroform", "CHEMICAL", 14, 24], ["chloroform", "CHEMICAL", 67, 77], ["chloroform", "CHEMICAL", 14, 24], ["chloroform", "CHEMICAL", 67, 77], ["chloroform", "SIMPLE_CHEMICAL", 14, 24], ["chloroform", "SIMPLE_CHEMICAL", 67, 77], ["chloroform", "TREATMENT", 14, 24], ["highly virus", "PROBLEM", 31, 43], ["chloroform", "TREATMENT", 67, 77], ["virome studies", "TEST", 116, 130], ["viral genetic material", "PROBLEM", 165, 187], ["crucial in viral metagenomics", "PROBLEM", 191, 220]]], ["Of note, when using the WTA2 kit (ligating an oligonucleotide to either sides of the PCR products before amplification), we strongly recommend using the Nextera XT library preparation kit to avoid cluster-calling problems during Illumina sequencing.", [["WTA2", "GENE_OR_GENE_PRODUCT", 24, 28], ["WTA2 kit", "PROTEIN", 24, 32], ["PCR products", "DNA", 85, 97], ["the WTA2 kit", "TREATMENT", 20, 32], ["ligating an oligonucleotide", "TREATMENT", 34, 61], ["the PCR products", "TREATMENT", 81, 97], ["the Nextera XT library preparation kit", "TREATMENT", 149, 187], ["cluster-calling problems", "PROBLEM", 197, 221], ["Illumina sequencing", "TEST", 229, 248]]], ["A limited disadvantage of using the Nextera XT library preparation kit is that the ends of viral genomes are underrepresented in the obtained reads due to the transposon technology use by this kit.DiscussionKohl and colleagues showed that random amplification using a random primer with a universal 5\u2032 end and a degenerate 3\u2032 end was preferred to amplify viruses20.", [["viral genomes", "DNA", 91, 104], ["5\u2032 end", "DNA", 299, 305], ["degenerate 3\u2032 end", "DNA", 312, 329], ["the Nextera XT library preparation kit", "TREATMENT", 32, 70], ["viral genomes", "PROBLEM", 91, 104], ["viral genomes", "OBSERVATION", 91, 104]]], ["WTA2 utilises a similar approach and was modified to amplify both RNA and DNA.", [["WTA2", "SIMPLE_CHEMICAL", 0, 4], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["WTA2", "PROTEIN", 0, 4]]], ["Although 17 amplification cycles are recommended by the manufacturer for transcriptome amplification, our findings indicate that all viruses could be amplified, independently of the number of cycles.", [["transcriptome amplification", "TREATMENT", 73, 100], ["all viruses", "PROBLEM", 129, 140], ["viruses", "OBSERVATION", 133, 140]]], ["However, the amplification efficiency differed between viruses, which could not be unambiguously explained by genome type (ssDNA, dsDNA, ssRNA, dsRNA), length or composition (linear, circular, segmented).", [["ssDNA", "CELLULAR_COMPONENT", 123, 128], ["dsDNA", "CELLULAR_COMPONENT", 130, 135], ["genome type", "DNA", 110, 121], ["ssDNA", "DNA", 123, 128], ["dsDNA", "DNA", 130, 135], ["ssRNA", "DNA", 137, 142], ["dsRNA", "DNA", 144, 149], ["the amplification efficiency", "PROBLEM", 9, 37], ["viruses", "PROBLEM", 55, 62], ["genome type (ssDNA", "PROBLEM", 110, 128], ["dsDNA", "PROBLEM", 130, 135], ["ssRNA", "PROBLEM", 137, 142], ["dsRNA", "PROBLEM", 144, 149], ["length or composition (linear, circular, segmented)", "PROBLEM", 152, 203], ["circular", "OBSERVATION_MODIFIER", 183, 191]]], ["In previous reports it was shown that multiple displacement amplification preferentially amplified (single-stranded) circular genomes, which was not observed in this study using WTA23233.", [["WTA23233", "CHEMICAL", 178, 186], ["WTA23233", "CHEMICAL", 178, 186], ["WTA23233", "SIMPLE_CHEMICAL", 178, 186], ["circular genomes", "DNA", 117, 133], ["multiple displacement amplification", "PROBLEM", 38, 73], ["single-stranded) circular genomes", "PROBLEM", 100, 133], ["this study", "TEST", 161, 171], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["displacement", "OBSERVATION_MODIFIER", 47, 59]]], ["Depending on the viral load in a sample, less than 17 amplification cycles can be sufficient, however, in our experience 17 amplification cycles produce reliable and reproducible results in various sample types with a wide range of virus concentrations.", [["sample", "ANATOMY", 198, 204], ["the viral load", "TEST", 13, 27], ["a sample", "TEST", 31, 39], ["a wide range of virus concentrations", "TREATMENT", 216, 252], ["viral load", "OBSERVATION", 17, 27]]], ["Nevertheless, in our protocol viral genome amplification introduced the most substantial bias, which was independent of the number of amplification cycles.DiscussionIndependent of viral enrichment procedures, all viruses could be detected using the Illumina HiSeq2500\u2122.", [["viral genome", "DNA", 30, 42], ["Illumina HiSeq2500\u2122", "DNA", 249, 268], ["viral genome amplification", "TREATMENT", 30, 56], ["amplification cycles", "TREATMENT", 134, 154], ["viral enrichment procedures", "TREATMENT", 180, 207], ["all viruses", "PROBLEM", 209, 220]]], ["The combination of centrifugation followed by filtration (0.8-\u03bcm PES) led to the highest number of viral reads (96.7%) and lowest percentage of bacterial and rRNA reads (0.19% and 0.003%; Fig. 7A).", [["viral reads", "RNA", 99, 110], ["centrifugation", "TREATMENT", 19, 33], ["filtration", "TEST", 46, 56], ["viral reads", "TEST", 99, 110], ["bacterial and rRNA reads", "PROBLEM", 144, 168], ["centrifugation", "OBSERVATION", 19, 33], ["bacterial", "OBSERVATION_MODIFIER", 144, 153]]], ["In other viral metagenomics studies a combination of more stringent centrifugation conditions and filtration, typically carried out using 0.45-\u03bcm or 0.22-\u03bcm pore sizes, have been applied152425263435, which according to our results will lead to a dramatic reduction of larger viruses in a sample.", [["pore", "ANATOMY", 157, 161], ["more stringent centrifugation conditions", "PROBLEM", 53, 93], ["filtration", "TREATMENT", 98, 108], ["0.22-\u03bcm pore sizes", "TREATMENT", 149, 167], ["a dramatic reduction of larger viruses", "PROBLEM", 244, 282], ["viral metagenomics", "OBSERVATION", 9, 27], ["centrifugation conditions", "OBSERVATION", 68, 93], ["larger", "OBSERVATION_MODIFIER", 268, 274], ["viruses", "OBSERVATION", 275, 282]]], ["Nevertheless, as with every viral enrichment protocol, including the one described in this study, the recovery of large viruses has to be balanced with the removal of bacterial/host genetic material, suggesting that bigger viruses (giant viruses, poxviruses, herpesviruses, etc.) might have been largely overlooked in past virome studies28.DiscussionRosseel and colleagues22 showed that significant differences in sequence depth can be obtained when viral genomes are subjected to sequence independent amplification and Illumina sequencing, which could influence the relationship between qPCR results and read numbers.", [["giant viruses", "DISEASE", 232, 245], ["giant viruses", "ORGANISM", 232, 245], ["viral genomes", "DNA", 450, 463], ["every viral enrichment protocol", "TEST", 22, 53], ["this study", "TEST", 86, 96], ["large viruses", "PROBLEM", 114, 127], ["the removal", "TREATMENT", 152, 163], ["bacterial/host genetic material", "PROBLEM", 167, 198], ["bigger viruses (giant viruses", "PROBLEM", 216, 245], ["poxviruses", "PROBLEM", 247, 257], ["herpesviruses", "PROBLEM", 259, 272], ["virome studies", "TEST", 323, 337], ["significant differences in sequence depth", "PROBLEM", 387, 428], ["viral genomes", "PROBLEM", 450, 463], ["Illumina sequencing", "TEST", 520, 539], ["large", "OBSERVATION_MODIFIER", 114, 119], ["viruses", "OBSERVATION", 120, 127], ["host genetic material", "OBSERVATION", 177, 198], ["bigger viruses", "OBSERVATION", 216, 230], ["giant viruses", "OBSERVATION", 232, 245], ["significant", "OBSERVATION_MODIFIER", 387, 398]]], ["However, except for parvovirus, all viruses showed a high correlation between the number of viral genome copies measured by qPCR after amplification and the number of mapped NGS reads (R2=0.91).", [["viral genome copies", "DNA", 92, 111], ["NGS reads", "DNA", 174, 183], ["parvovirus", "PROBLEM", 20, 30], ["all viruses", "PROBLEM", 32, 43], ["viral genome copies", "PROBLEM", 92, 111], ["R2", "TEST", 185, 187], ["parvovirus", "OBSERVATION", 20, 30], ["viral genome", "OBSERVATION", 92, 104]]], ["The aberrant behaviour of the parvovirus remains unexplained, but is unlikely to be an experimental error as good correlations between qPCR assays and NGS reads were obtained for the remaining viruses.", [["parvovirus", "DISEASE", 30, 40], ["parvovirus", "ORGANISM", 30, 40], ["the parvovirus", "PROBLEM", 26, 40], ["an experimental error", "PROBLEM", 84, 105], ["qPCR assays", "TEST", 135, 146], ["NGS reads", "TEST", 151, 160], ["the remaining viruses", "PROBLEM", 179, 200], ["aberrant", "OBSERVATION_MODIFIER", 4, 12], ["behaviour", "OBSERVATION_MODIFIER", 13, 22], ["parvovirus", "OBSERVATION", 30, 40], ["unlikely to be", "UNCERTAINTY", 69, 83], ["viruses", "OBSERVATION", 193, 200]]], ["Overall, this suggests that no additional strong bias are introduced after amplification.", [["strong", "OBSERVATION_MODIFIER", 42, 48], ["bias", "OBSERVATION", 49, 53]]], ["To extend this further, high reproducibility was shown for our preferred viral enrichment procedure (Fig. S1), which is crucial for comparison of viral abundancies from samples in large-scale studies.DiscussionThe main aim of our study was to obtain a reproducible protocol which could be easily upscaled for high-throughput virome studies.", [["samples", "ANATOMY", 169, 176], ["viral enrichment procedure", "TREATMENT", 73, 99], ["viral abundancies", "PROBLEM", 146, 163], ["large-scale studies", "TEST", 180, 199], ["our study", "TEST", 226, 235], ["a reproducible protocol", "TEST", 250, 273], ["high-throughput virome studies", "PROBLEM", 309, 339]]], ["CsCl ultracentrifugation poses difficulties with respect to reproducibility and automation, as discussed by Kleiner and colleagues21, and therefore was not investigated in this study.", [["CsCl", "CHEMICAL", 0, 4], ["CsCl", "CHEMICAL", 0, 4], ["CsCl", "SIMPLE_CHEMICAL", 0, 4], ["CsCl ultracentrifugation", "TREATMENT", 0, 24], ["automation", "TEST", 80, 90], ["this study", "TEST", 172, 182]]], ["In addition, some viral families and genera are known to be unstable in CsCl, such as the Guttaviridae, Orthomyxoviridae and Nanovirus31.", [["CsCl", "CHEMICAL", 72, 76], ["CsCl", "SIMPLE_CHEMICAL", 72, 76], ["Guttaviridae", "GENE_OR_GENE_PRODUCT", 90, 102], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 104, 120], ["Nanovirus31", "GENE_OR_GENE_PRODUCT", 125, 136], ["some viral families and genera", "PROBLEM", 13, 43], ["the Guttaviridae", "TREATMENT", 86, 102], ["Orthomyxoviridae", "TREATMENT", 104, 120], ["Nanovirus31", "TREATMENT", 125, 136]]], ["Furthermore a more recent study reported a strong loss of specific phages (\u03d5VPE25 and T7) tested when using a CsCl method21.", [["CsCl", "CHEMICAL", 110, 114], ["CsCl", "CHEMICAL", 110, 114], ["T7", "DNA", 86, 88], ["a more recent study", "TEST", 12, 31], ["a strong loss of specific phages", "PROBLEM", 41, 73], ["a CsCl method21", "TREATMENT", 108, 123]]], ["For samples with high volume and low viral load (e.g. ocean waters, urine), an additional concentration step may be required.", [["samples", "ANATOMY", 4, 11], ["urine", "ANATOMY", 68, 73], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["samples", "TEST", 4, 11], ["high volume", "PROBLEM", 17, 28], ["low viral load", "PROBLEM", 33, 47], ["urine", "TEST", 68, 73], ["an additional concentration step", "TREATMENT", 76, 108], ["high volume", "OBSERVATION_MODIFIER", 17, 28], ["low viral load", "OBSERVATION", 33, 47]]], ["Approaches using FeCl3 or PEG precipitation have been shown very useful363738.", [["FeCl3", "CHEMICAL", 17, 22], ["PEG", "CHEMICAL", 26, 29], ["FeCl3", "CHEMICAL", 17, 22], ["PEG", "CHEMICAL", 26, 29], ["FeCl3", "SIMPLE_CHEMICAL", 17, 22], ["PEG", "SIMPLE_CHEMICAL", 26, 29], ["FeCl3 or PEG precipitation", "TREATMENT", 17, 43]]], ["The quantitative effect of these procedures on each member of the viral community has not been studied.", [["these procedures", "TREATMENT", 27, 43], ["quantitative", "OBSERVATION_MODIFIER", 4, 16], ["effect", "OBSERVATION_MODIFIER", 17, 23]]], ["However, the use of a pre-filtration step with 0.2-\u03bcm, as often used for these methods, will lead to the removal of larger viruses (Fig. 4), which could be overcome by using a 0.8-\u03bcm filter instead.DiscussionIn our method, only a single nucleic acids extraction method was tested.", [["nucleic acids", "CHEMICAL", 237, 250], ["a pre-filtration step", "TREATMENT", 20, 41], ["these methods", "TREATMENT", 73, 86], ["the removal of larger viruses", "TREATMENT", 101, 130], ["a 0.8-\u03bcm filter", "TREATMENT", 174, 189], ["a single nucleic acids extraction method", "TREATMENT", 228, 268], ["larger", "OBSERVATION_MODIFIER", 116, 122], ["viruses", "OBSERVATION", 123, 130]]], ["The QIAamp Viral RNA mini kit is a rapid method to extract viral nucleic acids, and has shown consistently good performance in previous virome studies1920.", [["nucleic acids", "CHEMICAL", 65, 78], ["The QIAamp", "TEST", 0, 10], ["a rapid method", "PROBLEM", 33, 47], ["viral nucleic acids", "TEST", 59, 78], ["previous virome studies", "TEST", 127, 150], ["nucleic acids", "OBSERVATION", 65, 78], ["good", "OBSERVATION_MODIFIER", 107, 111]]], ["Nevertheless, non-column based extraction methods might be considered to avoid silica contaminants39, but can be too time-consuming for large scale studies.DiscussionAlthough our optimisation was performed with mock communities containing high concentrations of viruses, NetoVIR has been successfully applied on a number of biological samples such as faeces (both of human and animal origin), clinical respiratory samples, serum samples and even homogenised insects.", [["samples", "ANATOMY", 335, 342], ["faeces", "ANATOMY", 351, 357], ["respiratory samples", "ANATOMY", 402, 421], ["serum samples", "ANATOMY", 423, 436], ["NetoVIR", "CHEMICAL", 271, 278], ["silica", "CHEMICAL", 79, 85], ["faeces", "ORGANISM_SUBSTANCE", 351, 357], ["human", "ORGANISM", 367, 372], ["serum samples", "ORGANISM_SUBSTANCE", 423, 436], ["NetoVIR", "PROTEIN", 271, 278], ["human", "SPECIES", 367, 372], ["human", "SPECIES", 367, 372], ["non-column based extraction methods", "TREATMENT", 14, 49], ["silica contaminants", "PROBLEM", 79, 98], ["large scale studies", "TEST", 136, 155], ["high concentrations of viruses", "PROBLEM", 239, 269], ["NetoVIR", "TREATMENT", 271, 278], ["clinical respiratory samples", "TEST", 393, 421], ["serum samples", "TEST", 423, 436], ["viruses", "OBSERVATION", 262, 269]]], ["For all these samples a variety of known and unknown viruses could be identified.DiscussionTo our knowledge this is the first modular VLP purification approach which provides virologists the information to adapt their procedures according to their particular needs.", [["samples", "ANATOMY", 14, 21], ["unknown viruses", "PROBLEM", 45, 60], ["the first modular VLP purification approach", "TREATMENT", 116, 159], ["their procedures", "TREATMENT", 212, 228], ["viruses", "OBSERVATION", 53, 60]]], ["For virome studies in faecal samples we provide an overview and detailed explanation of NetoVIR (Fig. 1 and Protocol S1), which is suitable for large-scale studies and provided the best obtainable viral/bacterial ratio.Design of the mock-virome ::: Material and MethodsThe mock-virome consists of known concentrations (ranging from 107 to 1010 genome copies per mL) of nine viruses (Table 1).", [["faecal samples", "ANATOMY", 22, 36], ["faecal samples", "CANCER", 22, 36], ["virome studies", "TEST", 4, 18], ["faecal samples", "TEST", 22, 36], ["large-scale studies", "TEST", 144, 163], ["known concentrations", "PROBLEM", 297, 317]]], ["These viruses were selected as representatives of a very wide range of physical virus characteristics, such as a distinct virus architecture (spherical, rod-shaped, head-tail structure), different virion sizes (ranging from 17 nm to 700 nm), presence or absence of an envelope, different genome lengths (ranging from 1.8 kb to 1180 kb) different genome types (dsDNA, dsRNA, ssDNA, ssRNA) and different genome compositions (linear, circular, segmented).", [["head-tail structure", "ANATOMY", 165, 184], ["virion", "ANATOMY", 197, 203], ["head", "ORGANISM_SUBDIVISION", 165, 169], ["ssDNA", "CELLULAR_COMPONENT", 374, 379], ["dsDNA", "DNA", 360, 365], ["dsRNA", "DNA", 367, 372], ["ssDNA", "DNA", 374, 379], ["ssRNA", "DNA", 381, 386], ["These viruses", "PROBLEM", 0, 13], ["a very wide range of physical virus characteristics", "PROBLEM", 50, 101], ["a distinct virus architecture (spherical, rod-shaped, head-tail structure", "PROBLEM", 111, 184], ["different virion sizes", "PROBLEM", 187, 209], ["an envelope", "PROBLEM", 265, 276], ["different genome types (dsDNA", "PROBLEM", 336, 365], ["dsRNA", "PROBLEM", 367, 372], ["ssDNA", "PROBLEM", 374, 379], ["ssRNA", "PROBLEM", 381, 386], ["viruses", "OBSERVATION", 6, 13], ["physical virus", "OBSERVATION", 71, 85], ["distinct", "OBSERVATION_MODIFIER", 113, 121], ["virus", "OBSERVATION", 122, 127], ["spherical", "OBSERVATION_MODIFIER", 142, 151], ["rod", "OBSERVATION_MODIFIER", 153, 156], ["shaped", "OBSERVATION_MODIFIER", 157, 163], ["head", "ANATOMY", 165, 169], ["tail", "ANATOMY_MODIFIER", 170, 174], ["different", "OBSERVATION_MODIFIER", 187, 196], ["virion", "OBSERVATION_MODIFIER", 197, 203], ["sizes", "OBSERVATION_MODIFIER", 204, 209], ["envelope", "OBSERVATION_MODIFIER", 268, 276], ["lengths", "OBSERVATION_MODIFIER", 295, 302], ["linear", "OBSERVATION_MODIFIER", 423, 429], ["circular", "OBSERVATION_MODIFIER", 431, 439]]], ["The largest amount of the above diversity has been observed for eukaryotic viruses, explaining why only a single bacteriophage was included in our mock virome.", [["eukaryotic viruses", "PROBLEM", 64, 82], ["a single bacteriophage", "PROBLEM", 104, 126], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["above diversity", "OBSERVATION", 26, 41], ["viruses", "OBSERVATION", 75, 82], ["mock virome", "OBSERVATION", 147, 158]]], ["Moreover, no (-)ssRNA virus was included as there is no reason to expect a different behaviour than any other ssRNA virus in any step of our procedure.", [["(-)ssRNA virus", "PROBLEM", 13, 27], ["a different behaviour", "PROBLEM", 73, 94], ["any other ssRNA virus", "PROBLEM", 100, 121], ["our procedure", "TREATMENT", 137, 150], ["no reason", "UNCERTAINTY", 53, 62]]], ["We believe that the morphological and physicochemical properties of all know bacteriophages are covered by the nine viruses selected.", [["the morphological and physicochemical properties of all know bacteriophages", "PROBLEM", 16, 91], ["bacteriophages", "OBSERVATION", 77, 91]]], ["Porcine circovirus 2, feline panleukopenia virus, feline infectious peritonitis virus and bovine herpesvirus were kindly provided by Sebastiaan Theuns and Hans Nauwynck (University of Ghent).", [["feline panleukopenia", "DISEASE", 22, 42], ["feline infectious peritonitis", "DISEASE", 50, 79], ["Porcine circovirus 2", "ORGANISM", 0, 20], ["feline panleukopenia virus", "ORGANISM", 22, 48], ["feline infectious peritonitis virus", "ORGANISM", 50, 85], ["bovine", "ORGANISM", 90, 96], ["herpesvirus", "ORGANISM", 97, 108], ["Porcine circovirus", "SPECIES", 0, 18], ["feline panleukopenia virus", "SPECIES", 22, 48], ["feline infectious peritonitis virus", "SPECIES", 50, 85], ["bovine", "SPECIES", 90, 96], ["herpesvirus", "SPECIES", 97, 108], ["Porcine circovirus 2", "SPECIES", 0, 20], ["feline panleukopenia virus", "SPECIES", 22, 48], ["feline infectious peritonitis virus", "SPECIES", 50, 85], ["bovine", "SPECIES", 90, 96], ["Porcine circovirus", "PROBLEM", 0, 18], ["feline panleukopenia virus", "PROBLEM", 22, 48], ["feline infectious peritonitis virus", "PROBLEM", 50, 85], ["bovine herpesvirus", "PROBLEM", 90, 108], ["circovirus", "OBSERVATION", 8, 18], ["infectious", "OBSERVATION_MODIFIER", 57, 67], ["peritonitis", "OBSERVATION", 68, 79], ["bovine herpesvirus", "OBSERVATION", 90, 108]]], ["The mimivirus was provided by Didier Raoult (Universit\u00e9 de la M\u00e9diterran\u00e9e).", [["mimivirus", "CANCER", 4, 13], ["mimivirus", "OBSERVATION", 4, 13]]], ["Inge Hanssen from Scientia Terrae VZW provided the pepino mosaic virus.", [["Scientia Terrae VZW", "ORGANISM", 18, 37], ["pepino mosaic virus", "ORGANISM", 51, 70], ["pepino mosaic virus", "SPECIES", 51, 70], ["the pepino mosaic virus", "PROBLEM", 47, 70]]], ["The BK polyomavirus was provided by Robert Snoeck and Dimitrios Topalis (KU Leuven).", [["BK polyomavirus", "ORGANISM", 4, 19], ["The BK polyomavirus", "TREATMENT", 0, 19], ["BK", "ANATOMY", 4, 6], ["polyomavirus", "OBSERVATION", 7, 19]]], ["The LIMEstone virus was obtained from Rob Lavigne (KU Leuven).", [["LIMEstone virus", "ORGANISM", 4, 19], ["LIMEstone virus", "SPECIES", 4, 19], ["The LIMEstone virus", "PROBLEM", 0, 19], ["LIMEstone virus", "OBSERVATION", 4, 19]]], ["Timo Vesikari (University of Tampere) provided the WC3 rotavirus.", [["WC3 rotavirus", "ORGANISM", 51, 64], ["WC3 rotavirus", "SPECIES", 51, 64], ["the WC3 rotavirus", "PROBLEM", 47, 64]]], ["Except for the LIMEstone virus (arrived at 4 \u00b0C) all virus stocks were frozen upon arrival and were then thawn for q(RT)PCR quantification.", [["LIMEstone virus", "ORGANISM", 15, 30], ["LIMEstone virus", "SPECIES", 15, 30], ["the LIMEstone virus", "PROBLEM", 11, 30], ["all virus stocks", "TREATMENT", 49, 65], ["PCR quantification", "TEST", 120, 138], ["LIMEstone virus", "OBSERVATION", 15, 30]]], ["Preparation of the mock communities was done with their original cell culture media, followed by aliquotation and freezing again at \u221280 \u00b0C before final use.", [["cell", "ANATOMY", 65, 69], ["cell", "CELL", 65, 69]]], ["For all the viruses, specific q(RT)-PCR assays and standards were either developed or retrieved from literature404142 (Table S1).Design of the bacterial mock-community ::: Material and MethodsThe bacterial mock-community consists of known concentrations of four different bacteria representative for the majority of bacterial phyla in the gut (Table S2).", [["gut", "ANATOMY", 339, 342], ["gut", "ORGANISM_SUBDIVISION", 339, 342], ["all the viruses", "PROBLEM", 4, 19], ["PCR assays", "TEST", 36, 46], ["The bacterial mock", "TEST", 192, 210], ["known concentrations", "PROBLEM", 233, 253], ["four different bacteria", "PROBLEM", 257, 280], ["bacterial phyla", "PROBLEM", 316, 331], ["viruses", "OBSERVATION", 12, 19], ["bacterial mock", "OBSERVATION", 143, 157], ["bacterial mock", "OBSERVATION", 196, 210], ["concentrations", "OBSERVATION_MODIFIER", 239, 253], ["four different", "OBSERVATION_MODIFIER", 257, 271], ["bacteria", "OBSERVATION", 272, 280], ["bacterial phyla", "OBSERVATION", 316, 331], ["gut", "ANATOMY", 339, 342]]], ["Lactobacillus acidophilus (Firmicutes) and Bifidobacterium animalis are Gram-positive (Actinobacteria), whereas Escherichia coli (Proteobacteria) and Bacteroides thetaiotaomicron (Bacteroidetes) are Gram-negative.", [["Lactobacillus acidophilus", "CHEMICAL", 0, 25], ["Lactobacillus acidophilus", "ORGANISM", 0, 25], ["Firmicutes", "SIMPLE_CHEMICAL", 27, 37], ["Bifidobacterium animalis", "ORGANISM", 43, 67], ["Gram-", "GENE_OR_GENE_PRODUCT", 72, 77], ["Escherichia coli", "ORGANISM", 112, 128], ["Bacteroides thetaiotaomicron", "ORGANISM", 150, 178], ["Gram-", "GENE_OR_GENE_PRODUCT", 199, 204], ["Lactobacillus acidophilus", "SPECIES", 0, 25], ["Bifidobacterium animalis", "SPECIES", 43, 67], ["Escherichia coli", "SPECIES", 112, 128], ["Bacteroides thetaiotaomicron", "SPECIES", 150, 178], ["Lactobacillus acidophilus", "SPECIES", 0, 25], ["Bifidobacterium animalis", "SPECIES", 43, 67], ["Escherichia coli", "SPECIES", 112, 128], ["Bacteroides thetaiotaomicron", "SPECIES", 150, 178], ["Lactobacillus acidophilus", "TREATMENT", 0, 25], ["Firmicutes", "TEST", 27, 37], ["Bifidobacterium animalis", "TEST", 43, 67], ["Gram-positive (Actinobacteria)", "PROBLEM", 72, 102], ["Escherichia coli", "PROBLEM", 112, 128], ["Proteobacteria", "TEST", 130, 144], ["Bacteroides thetaiotaomicron (Bacteroidetes", "TEST", 150, 193], ["Gram-", "TEST", 199, 204], ["Escherichia coli", "OBSERVATION", 112, 128]]], ["For each member in our mock-community, a qPCR assay targeting a unique and specific region was developed or retrieved from literature43.", [["literature43", "DNA", 123, 135], ["a qPCR assay", "TEST", 39, 51]]], ["In addition, to quantify the number of 16S rRNA copies of the Bacteroides genus an additional qPCR assay was used (Table S3).", [["16S rRNA copies", "DNA", 39, 54], ["the Bacteroides genus", "TEST", 58, 79], ["an additional qPCR assay", "TEST", 80, 104]]], ["The number of 16S copies for the other bacterial species was not determined because the structure of ribosomes is highly conserved among bacterial species, and were therefore not expected to behave differently in our experiments.", [["ribosomes", "ANATOMY", 101, 110], ["ribosomes", "CELLULAR_COMPONENT", 101, 110], ["16S copies", "DNA", 14, 24], ["the other bacterial species", "PROBLEM", 29, 56], ["bacterial species", "PROBLEM", 137, 154], ["bacterial species", "OBSERVATION", 137, 154]]], ["All bacterial strains were acquired from the Belgian Co-ordinated Collection of Micro-organisms (BCCM) in their growing medium with the following LGM accession numbers: 13550 (Lactobacillus acidophilus), 2092 (Escherichia coli), 18906 (Bifidobacterium animalis) and 11262 (Bacteroides thetaiotaomicron).", [["Lactobacillus acidophilus", "ORGANISM", 176, 201], ["Escherichia coli", "ORGANISM", 210, 226], ["Bifidobacterium animalis", "ORGANISM", 236, 260], ["Bacteroides thetaiotaomicron", "ORGANISM", 273, 301], ["Lactobacillus acidophilus", "SPECIES", 176, 201], ["Escherichia coli", "SPECIES", 210, 226], ["Bifidobacterium animalis", "SPECIES", 236, 260], ["Bacteroides thetaiotaomicron", "SPECIES", 273, 301], ["Lactobacillus acidophilus", "SPECIES", 176, 201], ["Escherichia coli", "SPECIES", 210, 226], ["Bifidobacterium animalis", "SPECIES", 236, 260], ["Bacteroides thetaiotaomicron", "SPECIES", 273, 301], ["All bacterial strains", "PROBLEM", 0, 21], ["Micro-organisms", "PROBLEM", 80, 95], ["LGM accession numbers", "TEST", 146, 167], ["Lactobacillus acidophilus", "TEST", 176, 201], ["Escherichia coli", "TEST", 210, 226], ["Bifidobacterium animalis", "TEST", 236, 260], ["Bacteroides thetaiotaomicron", "TREATMENT", 273, 301], ["bacterial strains", "OBSERVATION", 4, 21], ["Micro-organisms", "OBSERVATION", 80, 95]]], ["The bacterial mock-community was assembled from its original growing stocks and no buffers/medium were added and aliquots were made and preserved at \u221280 \u00b0C to ensure one freeze-thaw cycle.Real time (RT)-PCR assays ::: Material and MethodsAll qPCR assays for DNA viruses and bacteria were carried out using the TaqMan\u00ae Universal PCR Master Mix (Applied Biosystems) with the following conditions: 2 min at 50 \u00b0C, 10 min at 95 \u00b0C and 45 cycles of 15 sec at 95 \u00b0C and 1 min at 60 \u00b0C. RNA viruses and rRNA qRT-PCR were carried out with the One step qRT-PCR MasterMix Low Rox (Eurogentec) using the following conditions: 30 min at 48 \u00b0C followed by 10 min at 95 \u00b0C and 45 cycles of 15 sec at 95 \u00b0C and 1 min at 60 \u00b0C. qPCRs were performed on an ABI 7500 Real-Time PCR System (Applied Biosystems).Homogenisation ::: Material and MethodsMock-virome and bacterial mock-community were homogenised using a tissue homogeniser (MINILYS, Bertin technologies).", [["tissue", "ANATOMY", 895, 901], ["DNA", "CELLULAR_COMPONENT", 258, 261], ["tissue", "TISSUE", 895, 901], ["The bacterial mock", "TEST", 0, 18], ["buffers/medium", "TREATMENT", 83, 97], ["Real time (RT)-PCR assays", "TEST", 188, 213], ["Methods", "TEST", 231, 238], ["All qPCR assays", "TEST", 238, 253], ["DNA viruses", "PROBLEM", 258, 269], ["bacteria", "PROBLEM", 274, 282], ["the TaqMan\u00ae Universal PCR Master Mix", "TREATMENT", 306, 342], ["RNA viruses", "TEST", 480, 491], ["rRNA qRT", "TEST", 496, 504], ["PCR", "TEST", 505, 508], ["an ABI", "TEST", 736, 742], ["a tissue homogeniser", "TREATMENT", 893, 913], ["bacterial mock", "OBSERVATION", 4, 18], ["viruses", "OBSERVATION", 484, 491]]], ["A 200 \u03bcL stock of mock-virome or bacterial mock-community were subjected to different homogenisation speeds (3000 rpm or 5000 rpm) with or without the presence of ceramic beads (\u00d80.1 mm (CK01\u20132 ml, Precellys) or \u00d82.8 mm (CK28\u20132 ml, Precellys)).", [["ceramic beads", "TREATMENT", 163, 176], ["Precellys", "TEST", 198, 207], ["ceramic beads", "OBSERVATION", 163, 176]]], ["All samples were homogenised for 1 min.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11]]], ["After homogenisation, samples were treated for 2 hours at 37 \u00b0C with a cocktail of 1 \u03bcl microccocal nuclease (NEB) and 2 \u03bcl of benzonase (Millipore) and 7 \u03bcl of homemade buffer (1M Tris, 100 mM CaCl2 and 30 mM MgCl2, pH 8) and extracted with the QIAamp Viral RNA Mini Kit (Qiagen) without carrier RNA.Centrifugation ::: Material and MethodsSamples were centrifuged using a bench top centrifuge (Heraeus pico 17, Thermoscientific).", [["samples", "ANATOMY", 22, 29], ["benzonase", "CHEMICAL", 127, 136], ["CaCl2", "CHEMICAL", 194, 199], ["benzonase", "CHEMICAL", 127, 136], ["CaCl2", "CHEMICAL", 194, 199], ["MgCl2", "CHEMICAL", 210, 215], ["benzonase", "SIMPLE_CHEMICAL", 127, 136], ["carrier RNA", "RNA", 289, 300], ["a cocktail", "TREATMENT", 69, 79], ["benzonase (Millipore", "TREATMENT", 127, 147], ["homemade buffer (1M Tris", "TREATMENT", 161, 185], ["100 mM CaCl2", "TREATMENT", 187, 199], ["30 mM MgCl2", "TREATMENT", 204, 215], ["pH", "TEST", 217, 219], ["the QIAamp Viral RNA Mini Kit (Qiagen)", "TREATMENT", 242, 280], ["carrier RNA", "PROBLEM", 289, 300], ["MethodsSamples", "TREATMENT", 333, 347], ["a bench top centrifuge (Heraeus pico", "TREATMENT", 371, 407]]], ["Two-hundred \u03bcl of mock-virome or bacterial mock-community was centrifuged at 100 g or 17000 g for 3 min or 30 min.", [["bacterial mock", "TREATMENT", 33, 47]]], ["Subsequently, samples underwent nuclease treatment, nucleic acids extraction and qPCR assays as described above.Filtration ::: Material and MethodsAliquots of 1000 \u03bcl containing mock-virome or bacterial mock-community were filtered through a 0.8-\u03bcm centrifugal (PES) filter (VK01P042, Sartorius), a 0.8-\u03bcm polycarbonate (PC) filter (ATTP14250, Millipore), a 0.45-\u03bcm centrifugal filter (UFC40HV00, Millipore) or a 0.22-\u03bcm centrifugal filter (UFC40GV00, Millipore).", [["samples", "ANATOMY", 14, 21], ["nucleic acids", "CHEMICAL", 52, 65], ["polycarbonate", "CHEMICAL", 306, 319], ["nucleic acids", "SIMPLE_CHEMICAL", 52, 65], ["nuclease", "PROTEIN", 32, 40], ["nuclease treatment", "TREATMENT", 32, 50], ["nucleic acids extraction", "TREATMENT", 52, 76], ["qPCR assays", "TEST", 81, 92], ["MethodsAliquots", "TREATMENT", 140, 155], ["a 0.8-\u03bcm centrifugal (PES) filter", "TREATMENT", 240, 273], ["a 0.8-\u03bcm polycarbonate (PC) filter", "TREATMENT", 297, 331], ["a 0.45-\u03bcm centrifugal filter (UFC40HV00, Millipore", "TREATMENT", 356, 406], ["a 0.22-\u03bcm centrifugal filter (UFC40GV00, Millipore", "TREATMENT", 411, 461], ["Sartorius", "ANATOMY", 285, 294], ["centrifugal filter", "OBSERVATION", 366, 384], ["centrifugal filter", "OBSERVATION", 421, 439]]], ["The 0.8-\u03bcm PC filter was pre-wetted with nuclease-free water prior to filtration to enhance performance.", [["nuclease", "PROTEIN", 41, 49], ["\u03bcm PC filter", "TREATMENT", 8, 20], ["nuclease", "TREATMENT", 41, 49], ["filtration", "TREATMENT", 70, 80]]], ["After filtration, samples underwent a nuclease treatment, nucleic acids extraction and qPCR assays as described above.Chloroform treatment ::: Material and MethodsMock-virome or bacterial mock-community (150 \u03bcl) were incubated with 1%, 5%, 10% and 20% (%v/v) of chloroform and incubated for 60 min in a ferris wheel at 10 rpm (model L23, Labinco BV).", [["samples", "ANATOMY", 18, 25], ["nucleic acids", "CHEMICAL", 58, 71], ["Chloroform", "CHEMICAL", 118, 128], ["chloroform", "CHEMICAL", 262, 272], ["Chloroform", "CHEMICAL", 118, 128], ["chloroform", "CHEMICAL", 262, 272], ["nucleic acids", "SIMPLE_CHEMICAL", 58, 71], ["Chloroform", "SIMPLE_CHEMICAL", 118, 128], ["chloroform", "SIMPLE_CHEMICAL", 262, 272], ["nuclease", "PROTEIN", 38, 46], ["filtration", "TREATMENT", 6, 16], ["a nuclease treatment", "TREATMENT", 36, 56], ["nucleic acids extraction", "TREATMENT", 58, 82], ["qPCR assays", "TEST", 87, 98], ["Chloroform treatment", "TREATMENT", 118, 138], ["chloroform", "TREATMENT", 262, 272]]], ["After the chloroform treatment, samples underwent a nuclease treatment, nucleic acids extraction and qPCR assays as described above.Random amplification ::: Material and MethodsRandom amplification of nucleic acids was performed using the Whole Transcriptome Amplification Kit 2 (WTA2, Sigma Aldrich) according to manufacturer\u2019s instructions with the exception of the initial denaturation step which was performed at 95 \u00b0C instead of 70 \u00b0C in order to also denature double-stranded DNA or RNA to make it available for the amplification.", [["samples", "ANATOMY", 32, 39], ["chloroform", "CHEMICAL", 10, 20], ["nucleic acids", "CHEMICAL", 72, 85], ["nucleic acids", "CHEMICAL", 201, 214], ["chloroform", "CHEMICAL", 10, 20], ["chloroform", "SIMPLE_CHEMICAL", 10, 20], ["nucleic acids", "SIMPLE_CHEMICAL", 72, 85], ["DNA", "CELLULAR_COMPONENT", 482, 485], ["nuclease", "PROTEIN", 52, 60], ["the chloroform treatment", "TREATMENT", 6, 30], ["a nuclease treatment", "TREATMENT", 50, 70], ["nucleic acids extraction", "TREATMENT", 72, 96], ["qPCR assays", "TEST", 101, 112], ["nucleic acids", "TREATMENT", 201, 214], ["the Whole Transcriptome Amplification Kit", "TREATMENT", 235, 276], ["Sigma Aldrich)", "TREATMENT", 286, 300], ["the initial denaturation step", "TREATMENT", 364, 393], ["double-stranded DNA or RNA", "TREATMENT", 466, 492], ["the amplification", "TREATMENT", 518, 535]]], ["In addition, the number of amplification cycles was varied between 7, 12, 17 and 22.", [["amplification cycles", "TEST", 27, 47]]], ["WTA2 products were purified with the QIAquick PCR Purification Kit (Qiagen) according to the manufacturer\u2019s instructions and amplification efficiency was determined for every virus and bacteria using qPCR assays as described above.Illumina sequencing ::: Material and MethodsMock-virome and bacterial mock-community were pooled in 1:1 ratio to a total of 1.5 mL and homogenised for 1 min at 3000 rpm with a MINILYS homogeniser.", [["WTA2", "GENE_OR_GENE_PRODUCT", 0, 4], ["WTA2 products", "PROTEIN", 0, 13], ["WTA2 products", "TREATMENT", 0, 13], ["the QIAquick PCR Purification Kit (Qiagen)", "TREATMENT", 33, 75], ["amplification efficiency", "PROBLEM", 125, 149], ["every virus", "PROBLEM", 169, 180], ["bacteria", "PROBLEM", 185, 193], ["qPCR assays", "TEST", 200, 211], ["MethodsMock", "TEST", 268, 279], ["bacterial mock", "TEST", 291, 305], ["a MINILYS homogeniser", "TREATMENT", 405, 426]]], ["Aliquots of the pooled sample were then centrifuged for 3 min at 17000 g, and/or filtered through 0.8 (PES/PC) \u03bcm or 0.45-\u03bcm/0.22-\u03bcm filter.", [["Aliquots", "ANATOMY", 0, 8], ["sample", "ANATOMY", 23, 29], ["PES/PC) \u03bcm", "TREATMENT", 103, 113], ["\u03bcm filter", "TREATMENT", 130, 139], ["\u03bcm filter", "OBSERVATION", 130, 139]]], ["Samples underwent a nuclease treatment, nucleic acids, extraction and random amplification as previously described. qPCR assays were performed for the mock-virome and the bacterial mock communities\u2019 amplified WTA product.", [["Samples", "ANATOMY", 0, 7], ["communities", "ANATOMY", 186, 197], ["nucleic acids", "CHEMICAL", 40, 53], ["nucleic acids", "SIMPLE_CHEMICAL", 40, 53], ["nuclease", "PROTEIN", 20, 28], ["amplified WTA product", "PROTEIN", 199, 220], ["a nuclease treatment", "TREATMENT", 18, 38], ["nucleic acids", "TREATMENT", 40, 53], ["extraction", "TREATMENT", 55, 65], ["random amplification", "TREATMENT", 70, 90], ["qPCR assays", "TEST", 116, 127]]], ["An NGS library preparation was performed using the Nextera XT DNA Library Preparation kit (Illumina) according to the manufacter\u2019s instructions except that 1) the tagmentation time was decreased to 4 min, 2) input DNA was increased to 1.2 ng/\u03bcl and 3) reagents\u2019 quantities were halved to increase the average size of the DNA fragments.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNA", "CELLULAR_COMPONENT", 214, 217], ["DNA", "CELLULAR_COMPONENT", 321, 324], ["DNA fragments", "DNA", 321, 334], ["An NGS library preparation", "TREATMENT", 0, 26], ["the Nextera XT DNA Library Preparation kit (Illumina)", "TREATMENT", 47, 100], ["DNA", "TEST", 214, 217], ["the DNA fragments", "PROBLEM", 317, 334], ["increase", "OBSERVATION_MODIFIER", 288, 296], ["average", "OBSERVATION_MODIFIER", 301, 308], ["size", "OBSERVATION_MODIFIER", 309, 313], ["DNA fragments", "OBSERVATION", 321, 334]]], ["Fragment sizes were determined using a High Sensitivity DNA Kit (Agilent) and run in a Bioanalyzer 2100 (Agilent).", [["Fragment sizes", "PROBLEM", 0, 14], ["sizes", "OBSERVATION_MODIFIER", 9, 14]]], ["Libraries were quantified with the KAPA Library Quantification kit (Kapa Biosystems) and sequencing was performed on a HiSeq\u2122 2500 platform (Illumina) for 2 \u00d7 150 cycles.", [["HiSeq\u2122 2500 platform", "DNA", 119, 139], ["Libraries", "TREATMENT", 0, 9], ["the KAPA Library Quantification kit (Kapa Biosystems", "TREATMENT", 31, 83], ["a HiSeq\u2122 2500 platform (Illumina)", "TREATMENT", 117, 150]]], ["Each sample was attributed a total of 10 million paired end reads.Illumina sequencing ::: Material and MethodsThe obtained sequence reads were subjected to a bioinformatics pipeline comprising deduplication (FastUniq)44, quality and adapter trimming (Trimmomatic)45, and subsequently mapped with Burrows-Wheeler Aligner (BWA)46 against reference genomes of all viruses, bacteria and 16S rRNA present in the mock-virome and bacterial mix.", [["FastUniq", "DNA", 208, 216], ["Burrows-Wheeler Aligner (BWA)46", "DNA", 296, 327], ["adapter trimming (Trimmomatic)", "TREATMENT", 233, 263], ["all viruses", "PROBLEM", 357, 368], ["bacteria", "PROBLEM", 370, 378], ["16S rRNA", "TEST", 383, 391], ["bacterial mix", "TREATMENT", 423, 436], ["bacterial mix", "OBSERVATION", 423, 436]]], ["The number of mapped reads for each genome was obtained with Samtools47 and the percentage of mapped reads was calculated as the number of mapped reads divided by the total number of reads after trimming.", [["Samtools47", "DNA", 61, 71]]], ["For every virus, the correlation between the qPCR results and the percentage of mapped reads was determined based on all viral enrichment conditions.", [["every virus", "PROBLEM", 4, 15], ["the qPCR", "TEST", 41, 49], ["all viral enrichment conditions", "PROBLEM", 117, 148], ["viral", "OBSERVATION", 121, 126], ["enrichment conditions", "OBSERVATION", 127, 148]]], ["Normalisation of the number of reads to the genome length allows for a proper comparison with qPCR results.Method validation: reproducibility ::: Material and MethodsMock-virome and bacterial mock-community were pooled in 1:1 ratio, and split into two aliquots.", [["qPCR results", "TEST", 94, 106], ["bacterial mock", "TEST", 182, 196]]], ["From both aliquots a part was kept for qPCR before treatment and underwent a nuclease treatment and nucleic acids extraction.", [["nucleic acids", "CHEMICAL", 100, 113], ["nucleic acids", "SIMPLE_CHEMICAL", 100, 113], ["nuclease", "PROTEIN", 77, 85], ["qPCR", "TEST", 39, 43], ["treatment", "TREATMENT", 51, 60], ["a nuclease treatment", "TREATMENT", 75, 95], ["nucleic acids extraction", "TREATMENT", 100, 124]]], ["The rest of the mock-virome and bacterial mock-community were treated as follows: homogenisation was performed for 1 min (3000 rpm), followed by centrifugation for 3 min at 17000 g, then filtration with the 0.8-\u03bcm PES.", [["the 0.8-\u03bcm PES", "TREATMENT", 203, 217]]], ["Samples underwent a nuclease treatment, nucleic acids extraction and a random amplification was performed and qPCR assays were done as described above.Additional InformationHow to cite this article: Concei\u00e7\u00e3o-Neto, N. et al. Modular approach to customise sample preparation procedures for viral metagenomics: a reproducible protocol for virome analysis.", [["Samples", "ANATOMY", 0, 7], ["sample", "ANATOMY", 255, 261], ["nucleic acids", "CHEMICAL", 40, 53], ["nucleic acids", "SIMPLE_CHEMICAL", 40, 53], ["nuclease", "PROTEIN", 20, 28], ["a nuclease treatment", "TREATMENT", 18, 38], ["nucleic acids extraction", "TREATMENT", 40, 64], ["a random amplification", "TEST", 69, 91], ["qPCR assays", "TEST", 110, 121], ["Modular approach", "TREATMENT", 225, 241], ["customise sample preparation procedures", "TREATMENT", 245, 284], ["a reproducible protocol", "TREATMENT", 309, 332], ["virome analysis", "TEST", 337, 352]]], ["Rep.5, 16532; doi: 10.1038/srep16532 (2015).", [["Rep.5, 16532", "CHEMICAL", 0, 12]]]], "6fd54268496636686088811988ba120f2a86c795": [["produce a large number of mRNA isoforms through alternative splicing of pre-mRNA [5] .", [["mRNA isoforms", "RNA", 26, 39], ["mRNA isoforms", "TREATMENT", 26, 39], ["large", "OBSERVATION_MODIFIER", 10, 15]]], ["Alternative splicing actually regulates gene expression at the intron/exon level [6] [7] [8] .", [["intron", "DNA", 63, 69], ["Alternative splicing", "PROBLEM", 0, 20], ["the intron/exon level", "TEST", 59, 80]]], ["In addition, alternative splicing causes the premature occurrence of termination codon in mRNA, which degrades immediately upon discovery to prevent its translation [9] .", [["mRNA", "RNA", 90, 94], ["alternative splicing", "TREATMENT", 13, 33], ["termination codon in mRNA", "PROBLEM", 69, 94], ["premature", "OBSERVATION_MODIFIER", 45, 54], ["termination codon", "OBSERVATION", 69, 86]]], ["Therefore, alternative splicing is a key biological process in cells, and different mRNA splicing isoforms make the final protein products perform different functions.", [["cells", "ANATOMY", 63, 68], ["cells", "CELL", 63, 68], ["protein products", "PROTEIN", 122, 138], ["a key biological process in cells", "PROBLEM", 35, 68], ["different mRNA splicing isoforms", "PROBLEM", 74, 106], ["the final protein products", "TREATMENT", 112, 138]]]], "PMC7120170": [["This scheme was devised to facilitate families with immediate members (spouses and children) residing on the mainland to be reunited in Hong Kong.", [["children", "ORGANISM", 83, 91], ["children", "SPECIES", 83, 91]]], ["The numbers of children settled in Hong Kong increased too, rising from 30% to 40% of the total influx (Lin 1998).1980s: One-Way Permit Quota System and Social Adjustment Policies ::: Changing PerspectivesThe colonial government maintained its minimal interventionist policy towards Chinese migrants.", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["numbers", "OBSERVATION_MODIFIER", 4, 11], ["colonial", "OBSERVATION_MODIFIER", 209, 217], ["minimal", "OBSERVATION_MODIFIER", 244, 251]]], ["This quantitative research identified the social, economic and psychological problems faced by the migrants in the adaptation process and highlighted the urgent needs of migrants in four aspects: housing, medical, employment and education.1980s: One-Way Permit Quota System and Social Adjustment Policies ::: Changing PerspectivesThe study was a landmark in Chinese migrant research.", [["The study", "TEST", 330, 339]]], ["It had tremendous influence on subsequent research in the early 1990s.", [["tremendous", "OBSERVATION_MODIFIER", 7, 17], ["influence", "OBSERVATION_MODIFIER", 18, 27]]], ["The colonial policy was to \u201cmaintain the Chinese tradition\u201d which treated poverty as a personal matter which should be dealt with within the family system (Lee and Edwards 1998, p.", [["colonial", "OBSERVATION_MODIFIER", 4, 12]]], ["Underpinning this model also lies the value of economic rationality that welfare expenditures should fall within the confines of economic growth.Early 1990s\u2013Mid-1990s: Split Family Phenomenon ::: Changing PerspectivesThe daily quota for one-way permit was 75 in 1983, but it increased to 105 in 1993 and 150 in 1995.", [["economic growth", "PROBLEM", 129, 144]]], ["From 1997 to 2001, mainland new arrivals under this scheme were equivalent to 93% of the population growth in the host society (SOCO 2003).Early 1990s\u2013Mid-1990s: Split Family Phenomenon ::: Changing PerspectivesThe negative impact of the quota system gradually emerged in the early 1990s.", [["this scheme", "TREATMENT", 47, 58], ["the quota system", "TEST", 234, 250], ["negative", "OBSERVATION", 215, 223], ["impact", "OBSERVATION_MODIFIER", 224, 230]]], ["Because of the quota, children and spouses are separated under the one-way permit scheme, and the discrepancy in the times of arrival in Hong Kong between mainland children and their parents gave rise to separated families.", [["children", "ORGANISM", 22, 30], ["children", "ORGANISM", 164, 172], ["children", "SPECIES", 22, 30], ["children", "SPECIES", 164, 172]]]]}